

ISHLT SAN DIEGO

FINAL PROGRAM

34th Annual Meeting
and Scientific Sessions
April 10 – 13, 2014

MANCHESTER GRAND HYATT SAN DIEGO



International Society for Heart and Lung Transplantation

Gilead is committed

to expanding healthcare
options for individuals living with
cardiovascular and pulmonary diseases
through innovative research, access,
and education programs.



INTERNATIONAL SOCIETY FOR HEART AND LUNG TRANSPLANTATION

FINAL PROGRAM

**34th ANNUAL MEETING
and SCIENTIFIC SESSIONS
April 10 – 13, 2014**

TABLE OF CONTENTS

About ISHLT	2
Board of Directors	4
Scientific Program Committee	6
Abstract Reviewers	8
Committees	17
Scientific Councils	25
Past Presidents	32
Daily Schedule Foldouts	between 34-47
Award Recipients	35
Continuing Medical Education	46
Annual Meeting Scientific Session Highlights	49
Manchester Grand Hyatt Floor Plans	64
Annual Meeting Schedule At a Glance	67
Corporate Partners	78
Annual Meeting Scientific Program and Schedule	79
Exhibit Hall Floor Plan	278
List of Exhibitors	280



ABOUT ISH-I.T



THE INTERNATIONAL SOCIETY FOR HEART AND LUNG TRANSPLANTATION (ISHLT) is a not-for-profit, multidisciplinary, professional organization dedicated to improving the care of patients with advanced heart or lung disease through transplantation, mechanical support and innovative therapies via research, education and advocacy.

ISHLT was created in 1981 at a small gathering of about 15 cardiologists and cardiac surgeons. Today we have over 2700 members from over 45 countries, representing over 15 different professional disciplines involved in the management and treatment of end-stage heart and lung disease. This multinational, multidisciplinary mix is one of the biggest strengths of the Society. It brings greater breadth and depth to our educational offerings and provides an exceptional environment for networking and exchanging information on an informal basis.

Our members include anesthesiologists, basic scientists, cardiologists, cardiothoracic surgeons, ethicists, immunologists, nurses, pathologists, perfusionists, pharmacists, pulmonologists, tissue engineers, transplant coordinators and infectious disease specialists. Despite their differing specializations, all ISHLT members share a common dedication to the advancement of the science and treatment of end-stage heart and lung disease.

The Purposes of the Society are:

- 1.** To associate persons interested in the fields of heart and lung transplantation, end-stage heart and lung disease and related sciences.
- 2.** To encourage and stimulate basic and clinical research in these disciplines and to promote new therapeutic strategies.
- 3.** To hold scientific meetings featuring presentations and discussions relevant to these disciplines.
- 4.** To sponsor a scientific journal for the publication of manuscripts related to these disciplines.
- 5.** To establish and maintain an international registry for heart and lung transplantation.
- 6.** To award research grants and establish endowments for the study of these disciplines.



ISHLT 2013-2014 BOARD OF DIRECTORS

Officers

Allan R. Glanville, MD, FRACP, President

Hermann Reichenspurner, MD, PhD, President-Elect

David O. Taylor, MD, Past-President

Stuart C. Sweet, MD, PhD, Secretary-Treasurer

Directors

Lara Danziger-Isakov, MD, MPH, Director

Andrew J. Fisher, FRCP, PhD, Director

Daniel R. Goldstein, MD, Director

Maryl R. Johnson, MD, Director

Richard Kirk, MA FRCP FRCPCH, Director

Bronwyn J. Levvey, RN, Grad Dip Clin Ep, Director

Francis D. Pagani, MD, PhD, Director

Myung H. Park, MD, Director

Joseph G. Rogers, MD, Director

Martin Strueber, MD, Director

George M. Wieselthaler, MD, Director

Ex Officio Board Members

Mandeep R. Mehra, MD, Editor-in-Chief

Journal of Heart and Lung Transplantation

Josef Stehlik, MD, MPH,

Transplant Registry Medical Director

Lori J. West, MD, DPhil,

Development Committee Chair

Christopher H. Wigfield, MD FRCS (C/Th),

Director of Educational Affairs

Amanda W. Rowe, ISHLT Executive Director



Staff

Amanda W. Rowe
Executive Director

Phyllis Glenn
Director of
Membership Services

Lisa Edwards
Director of Meetings

Lee Ann Mills
Director of Operations

Susie Newton
Communications Manager



14673 Midway Road
Suite 200

Addison, TX 75001

Phone: 972-490-9495

Fax: 972-490-9499

www.ishlt.org

ANNUAL MEETING SCIENTIFIC PROGRAM COMMITTEE

◆ ★ Symposium Planning Committee

★ Abstract Selection Committee

- ◆ ★ **Jason Christie, MD, MS**, University of Pennsylvania, Philadelphia, PA, USA, 2014 Program Chair
- ◆ ★ **Allan R. Glanville, MD, FRACP**, St. Vincent's Hospital, Sydney, Australia, 2013 President and Past Program Chair
- ◆ ★ **Samantha Anthony, PhD, MSW**, Hospital for Sick Children, Toronto, Canada
- ◆ ★ **John A. Belperio, MD**, University of California, Los Angeles, CA, USA
- ◆ ★ **Christian Benden, MD**, University Hospital, Zurich, Switzerland
- ◆ ★ **Gerald J. Berry, MD**, Stanford University, Stanford, CA, USA
- ◆ ★ **Emma Birks, MBBS, PhD, BSc, FRCP**, University of Louisville, Louisville, KY, USA
- ◆ ★ **Kevin Carney, RN, CCTC**, Hospital of the University of Pennsylvania, Philadelphia, PA, USA
- ◆ ★ **Daniel Chambers, MBBS, MD**, The Prince Charles Hospital, Brisbane, Australia
- ◆ ★ **Tamara E. Claridge, PharmD**, Hospital of the University of Pennsylvania, Philadelphia, PA, USA
- ◆ ★ **Paul A. Corris, MB, FRCP**, Freeman Hospital, Newcastle upon Tyne, UK
- ◆ ★ **Jennifer Cowger, MD, MS**, St. Vincent Heart Center, Indianapolis, IN, USA
- ◆ ★ **Maria G. Crespo-Leiro, MD**, Hospital Universitario a Coruña, La Coruña, Spain
- ◆ ★ **Goran Dellgren, MD**, Sahlgrenska University Hospital, Goteborg, Sweden
- ★ **Marc De Perrot, MD, MSc**, Toronto General Hospital, Toronto, ON, Canada
- ◆ ★ **Tobias Deuse, MD, PhD**, University Heart Center, Hamburg, Germany
- ◆ ★ **Esmé Dijke, PhD**, University of Alberta, Edmonton, Canada
- ◆ ★ **Fabienne Dobbels, MSc, PhD**, Leuven, Belgium
- ◆ ★ **Howard J. Eisen, MD**, Drexel University College of Medicine and Hahnemann University Hospital, Philadelphia, PA, USA
- ◆ ★ **David S. Feldman, MD, PhD**, Minneapolis Heart Institute, Minneapolis, MN, USA

- ★ **Cynthia Gries, MD, MSc**, University of Pittsburgh Medical Center, Pittsburgh, PA, USA
- ◆ ★ **Denis Hadjiliadis, MD**, University of Pennsylvania, Philadelphia, PA, USA
- ◆ ★ **David Lederer, MD, MS**, Columbia University Medical Center, New York, NY, USA
- ◆ ★ **Stanley I. Martin, MD**, Ohio State University Medical Center, Columbus, OH, USA
- ◆ ★ **Mandeep R. Mehra, MD, MBBS, FACC, FACP**, Brigham & Women's Hospital, Boston, MA, USA
- ◆ ★ **Myung H. Park, MD**, University of Maryland School of Medicine, Baltimore, MD, USA
- ◆ ★ **Ashish S. Shah, MD**, Johns Hopkins Hospital, Baltimore, MD, USA
- ★ **Pali D. Shah, MD**, Johns Hopkins Hospital, Baltimore, MD, USA
- ◆ ★ **Tajinder P. Singh, MD**, Children's Hospital Boston, Boston, MA, USA
- ◆ ★ **Amparo Sole, MD, PhD**, University Hospital la Fe Valencia, Valencia, Spain
- ◆ ★ **Martin Strueber, MD**, University Heart Center, Leipzig, Germany
- ◆ ★ **Josef Stehlik, MD, PhD**, University of Utah, Salt Lake City, UT, USA
- ★ **Carmela D. Tan**, Cleveland Clinic Foundation, Cleveland, OH, USA
- ◆ ★ **Fernando Torres, MD**, UT Southwestern Medical Center, Dallas, TX, USA
- ◆ ★ **Walter Uber, PharmD**, Medical University of South Carolina, Charleston, SC, USA
- ★ **Geert M. Verleden, MD, PhD**, University Hospital Gasthuisberg, Leuven, Belgium
- ★ **Richard D. Weisel, MD, FRSCS**, Toronto General Hospital, Toronto, Canada
- ◆ ★ **Lori J. West, MD, DPhil**, University of Alberta, Edmonton, Canada
- ◆ ★ **Christopher H. Wigfield, MD, FRCS(C/Th)**, University of Chicago Medicine & Biological Sciences, Chicago, IL, USA
- ◆ ★ **Michal Zakliczynski, MD**, Slaskie Centrum Chorb Serca, Zabrze, Poland
- ◆ ★ **Martin R. Zamora, MD**, Aurora, Co, Colorado University Health Science Center, Aurora, CO, USA
- ◆ ★ **Marian Zembala, MD, PhD**, Silesian University Center Heart Disease, Tarnowskie Góry, Poland
- ◆ ★ **Andreas O. Zuckermann, MD**, Medical University of Vienna, Vienna, Austria

ABSTRACT REVIEWERS

Clemens Aigner, MD, Medical University of Vienna, Vienna, Austria

Annalisa Angelini, MD, University of Padua, Padua, Italy

Francisco Arabia, MD, MBA, Cedars-Sinai Medical Center,
Los Angeles, CA, USA

Abbas Ardehali, MD, UCLA Medical Center, Los Angeles, CA, USA

Saima Aslam, MD, MS, University of California, San Diego,
San Diego, CA, USA

David Baran, MD, Newark Beth Israel Medical Center,
Newark, NJ, USA

Mark Barr, MD, University of Southern California,
Los Angeles, CA, USA

Raymond Benza, MD, Allegheny General Hospital,
Pittsburgh, PA, USA

Lut Berben, PhD, University of Basel, Basel, Switzerland

Marius Berman, MD, Papworth Hospital, Cambridge,
United Kingdom

Geetha Bhat, MD, PhD, Advocate Christ Medical Center,
Oak Lawn, IL, USA

Tara Bolden, RN, University Health Network, Toronto, ON, Canada

Robert Bourge, MD, University of Alabama at Birmingham,
Birmingham, AL, USA

Andrew Boyle, MD, Cleveland Clinic Florida, Weston, FL, USA

Patrick Bruneval, MD, University Paris Descartes, Paris, France

Marie Budev, DO, MPH, The Cleveland Clinic, Cleveland, OH, USA

Michael Burch, MD, Great Ormond Street Hospital, London,
United Kingdom

Margaret Burke, MB FRCPATH, Harefield Hospital, Royal Brompton
& Harefield NHS Trust, London, United Kingdom

Fiorella Calabrese, MD, University of Padova, Padova, Italy

Lilibeth Carlos, B. Pharm (Hons), St. Vincent's Hospital,
Sydney, Australia

Chesney Castleberry, MD, Cincinnati Children's Hospital Medical
Center, Cincinnati, OH, USA

Murali Chakinala, MD, Washington University, St. Louis, MO, USA

Cecilia Chaparro, MD, Toronto General Hospital, Toronto,
ON, Canada

Adam Cochrane, PharmD, Inova Fairfax, Falls Church, VA, USA

Carol Conrad, MD, Stanford University, Palo Alto, CA, USA

Jennifer Conway, MD, Stollery Children's Hospital, Edmonton,
AB, Canada

Hannah Copeland, MD, Loma Linda University, Loma Linda,
CA, USA

Marcelo Cypel, MD, University of Toronto, Toronto, ON, Canada

Barbara Czerska, MD, Florida Hospital, Orlando, FL, USA

David D'Allesandro, MD, Montefiore Medical Center/Albert
Einstein College of Medicine, New York, NY, USA



Lara Danziger-Isakov, MD, MPH, Cincinnati Children's Hospital Medical Center, Cincinnati, OH, USA

John Dark, MB FRCS, Newcastle University, Newcastle upon Tyne, United Kingdom

Alexey Dashkevich, MD, University of Helsinki, Finland

Kyle Dawson, PharmD, Houston Methodist, Houston, TX, USA

Sabina De Geest, PhD, Institute of Nursing Science, Basel, Switzerland

Teresa De Marco, MD, University of California, San Francisco, San Francisco, CA, USA

Juan Delgado, PhD, 12 de Octubre University Hospital, Madrid, Spain

Eugene DePasquale, MD, UCLA, Los Angeles, CA, USA

Mary Amanda Dew, PhD, University of Pittsburgh School of Medicine and Medical Center, Pittsburgh, PA, USA

Joshua Diamond, MD, University of Pennsylvania, Philadelphia, PA, USA

Mirta Diez, MD, Instituto Cardiovascular de Buenos Aires, Ciudad Autonoma de Buenos Aires, Argentina

Debra Dodd, MD, Vanderbilt Children's Hospital, Nashville, TN, USA

Stavros Drakos, MD, PhD, University of Utah, Sandy, UT, USA

Nathalie Duernickx, MSN, KU Leuven, Leuven, Belgium

Jean-Paul Duong-van-Huyen, MD PhD, Hôpital Necker Enfants Malades, Paris, France

David Brad Dyke, MD, University of Michigan, Ann Arbor, MI, USA

Peter Eckman, MD, University of Minnesota, Minneapolis, MN, USA

Jeff Edelman, MD, University of Washington, Seattle, WA, USA

Jay Eidem, PharmD, Abbott Northwestern Hospital, Minneapolis, MN, USA

Sandra Eifert, MD, PhD, Herzzentrum Leipzig, Leipzig, Germany

Hans Eiskjaer, PhD, Aarhus University Hospital, Skejby, Aarhus, Denmark

Stephan Ensminger, MD PhD, Heart and Diabetes Center NRW, Ruhr University Bochum, Bad Oeynhausen, Germany

Christopher Ensor, PharmD, University of Pittsburgh Medical Center, Pittsburgh, PA, USA

Eric Epailly, MD, Les Hôpitaux Universitaires de Strasbourg, Strasbourg, France

Michele Estabrook, MD, St Louis Children's Hospital, St Louis, MO, USA

Roger Evans, PhD, United Network for the Recruitment of Transplantation Professionals, Rochester, MN, USA

ABSTRACT REVIEWERS

- Melanie Everitt, MD**, Primary Children's Medical Center,
Salt Lake City, UT, USA
- Gregory Ewald, MD**, Washington University School of Medicine,
St. Louis, MO, USA
- Harrison Farber, MD**, Boston University School of Medicine,
Boston, MA, USA
- Albert Faro, MD**, Washington University in St. Louis,
St. Louis, MO, USA
- Carol Farver, MD**, Cleveland Clinic, Cleveland, OH, USA
- Paul Fedak, MD, PhD FRCSC**, University of Calgary,
Calgary, AB, Canada
- Brian Feingold, MD MS**, Children's Hospital of Pittsburgh
of UPMC, Pittsburgh, PA, USA
- Roberto Fiocchi, MD, PhD**, Ospedale Papa Giovanni XXIII,
Bergamo, Italy
- Ashraf Firouzi, MSc, PGC, BSc**, Royal Brompton & Harefield NHS
Foundation Trust, London, United Kingdom
- Michael Fishbein, MD**, David Geffen School of Medicine
at UCLA, Los Angeles, CA, USA
- Andrew Fisher, FRCP PhD**, Newcastle University, Newcastle
upon Tyne, United Kingdom
- Iris Fontanilla, MSc(Hons)**, Auckland City Hospital, ADHB,
Auckland City, New Zealand
- Katrina Ford, BPharm MSc**, Great Ormond Street NHS Hospital,
London, United Kingdom
- Jason Fritz, MD**, Perelman School of Medicine at the University
of Pennsylvania, Philadelphia, PA, USA
- Adaani Frost, MD**, Baylor College of Medicine, Houston, TX, USA
- Louise Fuller, BA**, The Alfred, Melbourne, Australia
- Kim Gandy, MD, PhD**, University of Missouri-Kansas City,
Kansas City, MO, USA
- Rochelle Gellatly, PharmD**, The Alfred Hospital,
Melbourne, Victoria, Australia
- Patricia Ging, MSc BPharm**, Mater Misericordiae University
Hospital, Dublin, Ireland
- Lee Goldberg, MD, MPH**, University of Pennsylvania,
Philadelphia, PA, USA
- Daniel J. Goldstein, MD**, Montefiore Medical Center, Bronx, NY, USA
- Mardi Gomberg-Maitland, MD, MSc**, University of Chicago,
Chicago, IL, USA
- Eva Goncalvesova, MD, PhD**, Nat Cardiovasc Institute,
Bratislava, Slovakia
- Francisco Gonzalez-Vilchez, MD, PhD**, Hospital Marques
de Valdecilla, Santander, Spain
- Robert Gordon, MD, PharmD**, Northwestern Medicine,
Chicago, IL, USA
- Jens Gottlieb, MD**, Hannover Medical School, Hannover, Germany
- John Granton, MD FRCPC**, University Health Network, Toronto,
ON, Canada
- Aric Gregson, MD**, UCLA, Los Angeles, CA, USA
- Paolo Grossi, MD, PhD**, University of Insubria, Varese, Italy



Marcin Gruchala, Prof, Medical University of Gdansk,
Gdansk, Poland

Einar Gude, MD, Oslo University Hospital Rikshospitalet,
Oslo, Norway

Lars Gullestad, MD, PhD, Oslo University Hospital, Oslo, Norway

Finn Gustafsson, MD, PhD, Rigshospitalet, Copenhagen, Denmark

Jonathan Haft, MD, University of Michigan, Ann Arbor, MI, USA

Marc Halushka, MD, PhD, Johns Hopkins, Baltimore, MD, USA

Margaret Hannan, MD, Mater Misericordiae University
Hospital, Dublin, Ireland

Asif Hasan, CTh, Freeman Hospital, Newcastle upon Tyne,
United Kingdom

Nicola Hiemann, MD, Deutsches Herzzentrum Berlin,
Berlin, Germany

Zsuzsanna Hollander, PhD, PROOF Centre of Excellence,
Vancouver, BC, Canada

William Holman, MD, University of Alabama at Birmingham,
Birmingham, AL, USA

Charles Hoopes, MD, University of Kentucky, Lexington, KY, USA

Peter Hopkins, MBBS FRACP, The Prince Charles Hospital,
Brisbane, Australia

Douglas Horstmanshof, MD, INTEGRIS Baptist Medical Center,
Oklahoma City, OK, USA

Laila Hubbert, MD, PhD, University Hospital, Linköping, Sweden

Lars Huber, MD, University Hospital Zurich, Zurich, Switzerland

Sharon Hunt, MD, Stanford University, Palo Alto, CA, USA

Shahid Husain, MD, MS, University of Toronto, Toronto,
ON, Canada

David Hwang, MD, PhD, FRCPC, University Health Network,
Toronto, ON, Canada

John Ikonmidis, MD PhD, Medical University of South Carolina,
Charleston, SC, USA

Ilhan Inci, MD, University Hospital, Zurich, Switzerland

Claire Irving, MD, Freeman Hospital, Newcastle upon Tyne,
United Kingdom

Martin Iversen, MD, DMSc, Rigshospitalet, Copenhagen University
Hospital, Copenhagen, Denmark

Val Jeevanandam, MD, University of Chicago Medical Center,
Chicago, IL, USA

David Jenkins, FRCS, Papworth Hospital, Cambridge,
United Kingdom

Ranjit John, MD, University of Minnesota, Minneapolis, MN, USA

Maryl Johnson, MD, University of Wisconsin, Madison, WI, USA

ABSTRACT REVIEWERS

- Jonathan Johnson, MD**, Mayo Clinic, Rochester, MN, USA
- Ulrich Jorde, MD**, Columbia University, New York, NY, USA
- Manreet Kanwar, MD, FACC**, Allegheny General Hospital,
Pittsburgh, PA, USA
- Kristjan Karason, MD, PHD**, Sahlgrenska University Hospital,
Gothenburg, Sweden
- Jason Katz, MD, MHS**, University of North Carolina,
Chapel Hill, NC, USA
- Aditya Kaza, MD**, Children's Hospital Boston, Boston, MA, USA
- Mary Keebler, MD**, Vanderbilt University Medical Center,
Nashville, TN, USA
- Anne Keogh, MBBS MD**, St Vincent's Hospital, Victoria St,
Darlinghurst, Australia
- Kiran Khush, MD, MAS**, Stanford University, Palo Alto, CA, USA
- Jun Sung Kim, MD**, Seoul National University Bundang
Hospital, Seongnam, Korea
- Soichiro Kitamura, MD**, National Cerebral and Cardiovascular
Center, Suita, Osaka, Japan
- Walter Klepetko, MD**, Medical University of Vienna, Vienna,
Austria
- Jolanda Kluin, MD, PhD**, UMC Utrecht, Utrecht, Netherlands
- Christiane Knoop, MD, PhD**, Erasme University Hospital,
Brussels, Belgium
- Jon Kobashigawa, MD**, Cedars-Sinai Heart Institute,
Los Angeles, CA, USA
- Christiane Kugler, PhD**, Witten University, Witten, Germany
- Yuk Law, MD**, Seattle Children's Hospital, Seattle, WA, USA
- Lori Leard, MD**, University of California San Francisco,
San Francisco, CA, USA
- Erika Lease, MD**, University of Washington, Seattle, WA, USA
- Sangjin Lee, MD, MSc**, Cleveland Clinic, Cleveland, OH, USA
- James C. Lee, MD**, University of Pennsylvania,
Philadelphia, PA, USA
- Sven Lehmann, MD, PhD**, Heartcenter Leipzig, Leipzig, Germany
- Karl Lemstrom, MD**, University of Helsinki, Helsinki, Finland
- Debbie Levine, MD**, University of Texas Health Science Center
San Antonio Texas, San Antonio, TX, USA
- Robert D. Levy, MD**, University of British Columbia,
Vancouver, BC, Canada
- Mathias Loebe, MD, PHD**, Houston Methodist, Houston, TX, USA
- Louis Benton Louis, MD**, Minneapolis Heart Institute, Minneapolis,
MN, USA
- Erin Lowery, MD, MS**, Loyola University Medical Center,
Maywood, IL, USA
- Lars Lund, MD, PhD**, Karolinska Institutet and University
Hospital, Stockholm, Sweden
- Me-linh Luong, MD**, Montreal University, Montreal, QC, Canada
- Haifa Lyster, BPharm(Hons), MSc**, Royal Brompton & Harefield
NHS Foundation Trust, London, United Kingdom



- Peter Macdonald, MBBS PHD MD**, St. Vincent's Hospital, Sydney, Australia
- Guy MacGowan, MD**, Freeman Hospital, Newcastle upon Tyne, United Kingdom
- Joseph Maleszewski, MD**, Mayo Clinic, Rochester, MN, USA
- Hari Mallidi, MD**, Texas Heart Institute/Baylor College of Medicine, Houston, TX, USA
- Simon Maltais, MD, PhD**, Vanderbilt University, Nashville, TN, USA
- Megan Maltby, MSW**, VCU Medical Center, Richmond, VA, USA
- Pradeep Mammen, MD**, UT Southwestern Medical Center, Dallas, TX, USA
- Nicolas Manito, MD**, Hospital Universitario de Bellvitge/ L'Hospitalet del Llobregat, Barcelona, Spain
- Charles Marboe, MD**, Columbia University, New York, NY, USA
- Kathy Martin, Master of Nursing**, The Hospital for Sick Children, Toronto, ON, Canada
- Tereza Martinu, MD**, Duke University, Durham, NC, USA
- David Mason, MD**, Cleveland Clinic, Cleveland, OH, USA
- Oliver Mauthner, RN, BScN, MN**, University of Toronto, Toronto, ON, Canada
- Kelly McCants, MD**, University of Louisville/Kentucky One Health, Louisville, KY, USA
- Stephen McKellar, MD**, University of Utah, Salt Lake City, UT, USA
- David McMullan, MD**, Seattle Children's Hospital, Seattle, WA, USA
- Tanya McWilliams, MD, PhD, FRACP**, Auckland City Hospital, Auckland, New Zealand
- Gerard Meachery, MB BCh MRCP**, Freeman Hospital, Newcastle Upon Tyne, United Kingdom
- Benjamin Medalion, MD**, Rabin Medical Center, Beilinson Campus, Petach Tiqva, Israel
- Bruno Meiser, MD, PhD**, University of Munich Medical Center, Munich, Germany
- Anna Meyer, MD**, Heart Center Leipzig, Leipzig, Germany
- Deborah Meyers, MD FRACP FACC**, Texas Heart Institute, Houston, TX, USA
- Dylan Miller, MD, UTAH** Cardiac Transplant, Salt Lake City, UT, USA
- Elina Minami, MD**, The Everett Clinic, Everett, WA, USA
- Nader Moazami, MD**, Cleveland Clinic, Cleveland, OH, USA
- Paul Mohacsi, MD, MBA**, University Hospital Bern, Bern, Switzerland
- Martha Mooney, MD, FACP**, Sentara Norfolk Transplant Center/Eastern Virginia Medical School, Norfolk, VA, USA

ABSTRACT REVIEWERS

- David Morales, MD**, Cincinnati Children's Hospital
Medical Center, Cincinnati, OH, USA
- Antonio Moreno, MD, PhD**, Hospital Universitari Vall d'Hebron,
Barcelona, Spain
- Orla Morrissey, MD**, Alfred Health, Melbourne, Australia
- Michael Mulligan, MD**, University of Washington School
of Medicine, Seattle, WA, USA
- Kavitha Muthiah, MBChB, FRACP**, St. Vincent's Hospital,
Sydney, United Kingdom
- Jayan Nagendran, MD, PhD**, University of Alberta,
Edmonton, AB, Canada
- Desley Neil, FRCPath**, Queen Elizabeth Hospital Birmingham,
Birmingham, United Kingdom
- Mark Nicolls, MD**, VA Palo Alto/Stanford University,
Palo Alto, CA, USA
- Johan Nilsson, MD, PhD**, Lund University and Skane
University Hospital, Lund, Sweden
- Yishay Orr, MBBS BSc(med) PhD FRACS**, Texas Children's
Hospital, Houston, TX, USA
- Robert Padera, MD, PhD**, Brigham and Women's Hospital,
Boston, MA, USA
- Francis Pagani, MD PhD**, University of Michigan, Ann Arbor, MI, USA
- Scott Palmer, MD, MHS**, Duke University, Durham, NC, USA
- Salpy Pamboukian, MD MSPH**, University of Alabama at
Birmingham, Birmingham, AL, USA
- Jignesh Patel, MD PhD**, Cedars-Sinai, Los Angeles, CA, USA
- Michael Petty, PhD, RN**, University of Minnesota Medical Center,
Fairview, Minneapolis, MN, USA
- Charles Poirier, MD**, Montreal University, Montreal, QC, Canada
- Luciano Potena, MD PhD**, University of Bologna, Bologna, Italy
- Ioana Preston, MD**, Tufts Medical Center, Boston, MA, USA
- Piotr Przybylowski, MD, PhD**, Jagiellonian University,
Medical College, Krakow, Poland
- Aaron Ranasinghe, MD FRCS CTh**, University Hospitals
Birmingham, Birmingham, United Kingdom
- Hermann Reichenspurner, MD, PhD**, University Heart Center
Hamburg, Hamburg, Germany
- Alex Reyentovich, MD**, New York University School of
Medicine, New York, NY, USA
- Debbie Rinde-Hoffman, MD**, Tampa General Medical Group,
Tampa, FL, USA
- Desiree Robson, RN, BSc (Hons)**, St Vincent's Hospital,
Sydney, Australia
- E Rene Rodriguez, MD**, Cleveland Clinic, Cleveland, OH, USA
- Joseph Rogers, MD**, Duke University, Durham, NC, USA
- Eulalia Roig, MD**, Hospital de la Santa Creu i Sant Pau,
Barcelona, Spain
- David Rosenthal, MD**, Stanford University, Palo Alto, CA, USA
- Heather Ross, MD, MHSc, FRCPC**, Toronto General Hospital,
Toronto, ON, Canada
- Stuart Russell, MD**, Johns Hopkins Hospital, Baltimore, MD, USA



Zeenat Safdar, MD, Baylor College of Medicine, Houston, TX, USA

Christopher T. Salerno, MD, St. Vincent Heart Center of Indiana, Indianapolis, IN, USA

Gian Lucas Santise, MD, ISMETT, Palermo, Italy

Murat Sargin, MD, Siyami Ersek Thoracic and Cardiovascular Surgery, Istanbul, Turkey

Sonja Schrepfer, MD, PhD, Stanford University/University Heart Center Hamburg, Germany

Stephan Schueler, MD, PhD, FRCS, Freeman Hospital, Newcastle upon Tyne, United Kingdom

Uwe Schulz, MD, Heart and Diabetes Center NRW, Bad Oeynhausen, Germany

Mace Schuurmans, MD, Zurich University Hospital, Zurich, Switzerland

Martin Schweiger, MD, Children's Hospital, Zurich, Switzerland

Nicolaus Schwerk, MD, Hannover Medical School, Hannover, Germany

Javier Segovia, MD, PhD, Hospital Puerta de Hierro Majadahonda, Madrid, Spain

Nedim Selimovic, MD, PhD, King Faisal Specialist Hospital & Research Centre, Riyadh, Saudi Arabia

Craig Selzman, MD, University of Utah, Salt Lake City, UT, USA

Keyur Shah, MD, Virginia Commonwealth University, Richmond, VA, USA

Mike Shullo, PharmD, University of Pittsburgh Medical Center, Pittsburgh, PA, USA

Fernanda Silveira, MD, University of Pittsburgh Medical Center, Pittsburgh, PA, USA

Scott Silvestry, MD, Washington University School of Medicine, St. Louis, MO, USA

Lianne Singer, MD, University of Toronto, Toronto, ON, Canada

Gregory Snell, MBBS, FRACP, MD, Alfred Hospital, Melbourne, Australia

Behzad Soleimani, MD, MRCP, FRCS(C-Th), Penn State Hershey Medical Center, Hershey, PA, USA

Heike Spaderna, PhD, Bergische Universität Wuppertal, Wuppertal, Germany

Randall Starling, MD MPH, Cleveland Clinic, Cleveland, OH, USA


Marc Stern, MD, Hopital Foch, Suresnes, France

Emily Stimpson, RN, BSN, CCTC, Cedars Sinai Medical Center, Los Angeles, CA, USA

Jose Tallaj, MD, University of Alabama at Birmingham, Birmingham, AL, USA

ABSTRACT REVIEWERS

- Anthony Tatoes, MD**, Advocate Christ Medical Center, Oak Lawn, IL, USA
- David Taylor, MD**, Cleveland Clinic, Cleveland, OH, USA
- Ryan Tedford, MD**, Johns Hopkins School of Medicine, Baltimore, MD, USA
- Jeffrey Teuteberg, MD**, University of Pittsburgh, Pittsburgh, PA, USA
- Mitesh Thakrar, MD**, University of Calgary, Calgary, AB, Canada
- Keri Townsend, PharmD**, Brigham & Women's Hospital, Boston, MA, USA
- Yoshiya Toyoda, MD, PhD**, Temple University School of Medicine, Philadelphia, PA, USA
- Steven Tsui, MD FRCS(C-Th)**, Papworth Hospital, Cambridge, United Kingdom
- Patricia Uber, PharmD**, University of Maryland, Baltimore, MD, USA
- Simon Urschel, MD**, University of Alberta, Edmonton, AB, Canada
- Jean-Luc Vachieri, MD**, Erasme University Hospital, Brussels, Belgium
- Dirk Van Raemdonck, MD, PHD**, University Hospitals Leuven, Leuven, Belgium
- Bart Vanaudenaerde, PhD**, KU Leuven, Leuven, Belgium
- Corey Ventetuolo, MD, MS**, Alpert Medical School of Brown University, Rhode Island Hospital, Providence, RI, USA
- Stijn Verleden, PhD**, KU Leuven, Leuven, Belgium
- C. Dario Vizza, MD**, Sapienza University of Roma, Rome, Italy
- Ludwig Von Segesser, MD**, CHUV, Lausanne, Switzerland
- Robin Vos, MD, PhD**, UZ Leuven, Leuven, Belgium
- Bojan Vrtovec, MD, PhD**, UMC Ljubljana, Ljubljana, Slovenia
- W. Dean Wallace, MD**, David Geffen School of Medicine at UCLA, Los Angeles, CA, USA
- Sam Weigt, MD, MS**, David Geffen School of Medicine at UCLA, Los Angeles, CA, USA
- David Weill, MD**, Stanford University, Stanford, CA, USA
- Glen Westall, MD, FRACP**, Alfred Hospital, Melbourne, Australia
- Timothy Whelan, MD**, Medical University of South Carolina, Charleston, SC, USA
- Helen Whitford, MBBS FRACP**, Alfred Hospital, Melbourne, Australia
- Glenn Whitman, MD**, Johns Hopkins Hospital, Baltimore, MD, USA
- Keith Wille, MD, MSPH**, University of Alabama at Birmingham, Birmingham, AL, USA
- Trevor Williams, MB BS MD FRACP**, Alfred Hospital/Monash University, Melbourne, Australia
- Jeremy Wrobel, MBBS(hons), FRACP, MPH**, Royal Perth Hospital, Perth, Australia
- Stephanie Yerkovich, BSc (Hons) PhD**, The Prince Charles Hospital, Brisbane, Australia
- Roger Yusen, MD, MPH**, Washington University School of Medicine, St. Louis, MO, USA



ISHLT COMMITTEES

DEVELOPMENT COMMITTEE

Lori J. West, MD, DPhil, Chair

Allan R. Glanville, MBBS, MD, FRACP, ISHLT President

Hermann Reichenspurner, MD, PhD, President-Elect

Amanda W. Rowe, ISHLT Executive Director

Stephan M. Ensminger, MD, PhD, Basic Science & Translational
Research Council Workforce Leader

Robert C. Bourge, MD, Heart Failure and Transplant Medicine
Council Workforce Leader

Arezu Z. Aliabadi, MD, Junior Faculty & Trainees Council
Workforce Leader

Mario C. Deng, MD, Mechanical Circulatory Support Council
Workforce Leader

Gerald J. Berry, MD, Pathology Council Workforce Leader

Robert L. Page, II, PharmD, MSPH, Pharmacy & Pharmacology
Council Workforce Leader

Evelyn Horn, MD, Pulmonary Hypertension Council
Workforce Leader

Glen P. Westall, FRACP, PhD, Pulmonary Transplantation
Council Workforce Leader

EDUCATION COMMITTEE

Christopher H. Wigfield, MD, FRCS(C/Th), Director of Educational Affairs

Jason D. Christie, MD, MS, 2014 Scientific Program Chair

Andreas Zuckermann, MD, 2015 Scientific Program Chair

Lori J. West, MD, DPhil, Development Committee Chair

Marilia Cascalho, MD, PhD, Basic Science & Translational Research Council Workforce Leader

David Baran, MD, Heart Failure and Transplant Medicine Council Workforce Leader

Me-Linh Luong, MD, Infectious Diseases Council Workforce Leader

Jonathan N. Johnson, MD, Junior Faculty and Trainees Council Workforce Leader

Salpy V. Pamboukian, MD, MSPH, Mechanical Circulatory Support Council Workforce Leader

Michael Petty, PhD, RN, CCNS, ACNS-BC, Nursing, Health Sciences & Allied Health Council Workforce Leader

Debra A. Dodd, MD, Pediatric Transplantation Council Workforce Leader

Haifa Lyster, MSc, Pharmacy & Pharmacology Council Workforce Leader

Dana McGlothlin, MD, Pulmonary Hypertension Council Workforce Leader

Kevin M. Chan, MD, Pulmonary Transplantation Council Workforce Leader

Esme Dijke, PhD, Taskforce Member

Andrew J. Fisher, FRCP, PhD, Taskforce Member

Peter M. Hopkins, FRACP, Taskforce Member

Jon A. Kobashigawa, MD, Taskforce Member

Jeffrey J. Teutenberg, MD, Taskforce Member

Andreas Zuckermann, MD, Taskforce Member

GRANTS AND AWARDS COMMITTEE

Daniel R. Goldstein, MD, Co-Chair

Andrew J. Fisher, FRCP, PhD, Co-Chair

Stephan Ensminger, MD, DPhil

Andrew E. Gelman, PhD

Mark S. Slaughter, MD

Laurie D. Snyder, MD

Dirk Van Raemdonck, MD, PhD

John Dark, MB, FRCS

Lut Berben, PhD

Josef Stehlik, MD, MPH

INTERNATIONAL AND INTER-SOCIETY COORDINATION COMMITTEE (I2C2)

Stephen C. Clark, MD, Co-Chair

Andreas Zuckermann, MD, Co-Chair

Lori J. West, MD, DPhil

Maria G. Crespo-Leiro, MD, Core Leader

Diego H. Delgado, MD, MSc, Core Leader

Allan R. Glanville, MBBS, MD, FRACP, Core Leader

James Kirkpatrick, MD, Core Leader

Jacob Lavee, MD, Core Leader

**Heather J. Ross, MD, MHSc, FRCP(c), Development
Committee Chair**

Josef Stehlik, MD, MPH, Registry Medical Director

Geert M. Verleden, MD, PhD, Board of Directors Liaison

Georg M. Wieselthaler, MD, Board of Directors Liaison

**Christopher H. Wigfield, MD, FRCS(C/Th), Director of
Educational Affairs**

**Howard J. Eisen, MD, FAHA, FACC, FACP, Basic Science and
Translational Research Council Representative**

**Deborah E. Meyers, MD, FRACP, FACC, Heart Failure &
Transplant Medicine Council Representative**

**Martha L. Mooney, MD, FACP, Infectious Diseases Council
Representative**

**Reema Hasan, MD, Junior Faculty and Trainees Council
Representative**

**Sean P. Pinney, MD, Mechanical Circulatory Support Council
Representative**

**Michael G. Petty, PhD, RN, CCNS, CNS, Nursing, Health
Sciences and Allied Health Council Representative**

Margaret M. Burke, FRCPATH, Pathology Council Representative

**Anne I. Dipchand, MD, Pediatric Transplantation Council
Representative**

**Patricia A. Uber, PharmD, Pharmacy and Pharmacology
Council Representative**

John Granton, MD, Pulmonary Hypertension Council Representative

**Lianne G. Singer, MD, FRCPC, Pulmonary Transplantation
Council Representative**

**Naveen Pereira, MD, Standards & Guidelines Committee
Representative**

Maryl R. Johnson, MD, Communications Liaison

Keith McNeil, FRACP (Australia), Ambassador

Fernando A. Figueira, MD (Brazil), Ambassador

Pablo F. Castro, MD (Chile), Ambassador

Anantharam V. Kalya, MD (India/USA), Ambassador

Hamidreza Abtahi, MD (Iran), Ambassador

Tuvia Ben Gal, MD (Israel), Ambassador

Cumara C. Sivathanan, MBBS FRCS (Singapore), Ambassador

Graham A. Cassel, MD (South Africa), Ambassador

ISHLT MECHANICALLY ASSISTED CIRCULATORY SUPPORT (IMACS) REGISTRY COMMITTEE

James K. Kirklin, MD, Chair

S. Craig Collum, MPH, Administrator

Nicholas Banner, MD, United Kingdom

Elizabeth Blume, MD, USA

Eric A. Chen, MS, USA

Anne I. Dipchand, MD, Canada

Margaret M. Hannan, MD, Ireland

Anchal Kaushiva, MS, USA

Richard Kirk, MA FRCP FRCPCH, United Kingdom

Robert L. Kormos, MD, USA

Jaap Lahpor, MD, PhD, The Netherlands

Pascal Leprince, MD, PhD, France

Lars H. Lund, MD, PhD, Sweden

Mandeep R. Mehra, MD MBBS FACC FACP, USA

Marissa Miller, DVM, MPH, USA

David C. Naftel, PhD, USA

Takeshi Nakatani, MD, PhD, Japan

Francis D. Pagani, MD, PhD, USA

Heather J. Ross, MD, MHSc, FRCP(c), Canada

Stephan Schueler, MD, PhD, United Kingdom

Martin Strueber, MD, Germany

Steven Tsui, MD, FRCS, United Kingdom

George M. Wieselthaler, MD, USA

Amanda Rowe – Ex Officio

Allan R. Glanville, MD, FRACP

JHLT EDITORIAL BOARD

Mandeep R. Mehra, MBBS, FACC, FACP, Editor-in-Chief

Patricia A. Uber, PharmD, Executive Editor

Erica M. Bartmanis, Journal Office Manager

Maria Rosa Costanzo, MD, Consulting Editor,
Editor Emeritus 1995-1999

James K. Kirklin, MD, Consulting Editor,
Editor Emeritus 2000-2009

James F. George, PhD, Editorial Office Consultant

Jonathan B. Orens, MD, Editorial Office Consultant

Jayan Parameshwar, FRCP, Editorial Office Consultant

Richard N. Pierson, III, MD, Editorial Office Consultant

Hector O. Ventura, MD, Editorial Office Consultant

Claus B. Andersen, MD, DMSc (Denmark), Editorial Board Consultant

Annalisa Angelini, MD (Italy), Editorial Board Consultant

Robert M. Aris, MD (USA), Editorial Board Consultant
Marcelo Cantarovich, MD (Canada), Editorial Board Consultant
Charles E. Canter, MD (USA), Editorial Board Consultant
Pablo F. Castro, MD (Chile), Editorial Board Consultant
John V. Conte, MD (USA), Editorial Board Consultant
Paul A. Corris, MB FRCP (UK), Editorial Board Consultant
John Dark, MB FRCS (UK), Editorial Board Consultant
R. Duane Davis, MD (USA), Editorial Board Consultant
Mary Amanda Dew, PhD (USA), Editorial Board Consultant
Fabienne Dobbels, PhD (Belgium), Editorial Board Consultant
Howard J. Eisen, MD (USA), Editorial Board Consultant
Roger W. Evans, PhD (USA), Editorial Board Consultant
Michael C. Fishbein, MD (USA), Editorial Board Consultant
Edward R. Garrity, Jr. MD (USA), Editorial Board Consultant
Allan R. Glanville, MBBS, MD, FRACP (Australia),
Editorial Board Consultant
Kate Gould, FRCPath (UK), Editorial Board Consultant
Margaret M. Hannan, MD (Ireland), Editorial Board Consultant
Shahid Husain, MD MS (Canada), Editorial Board Consultant
Valluvan Jeevanandam, MD (USA), Editorial Board Consultant
Maryl R. Johnson, MD (USA), Editorial Board Consultant
Shaf Keshavjee, MD (Canada), Editorial Board Consultant
Richard Kirk, MA FRCP FRCPC (UK), Editorial Board Consultant
Jon Kobashigawa, MD (USA), Editorial Board Consultant
JoAnn Lindenfeld, MD (USA), Editorial Board Consultant
Bruce McManus, MD, PhD, FRSC, FCAHS (Canada),
Editorial Board Consultant
Bruno M. Meiser, MD (Germany), Editorial Board Consultant
Martha L. Mooney, MD, FACP (USA), Editorial Board Consultant
Jonah Odum, MD (USA), Editorial Board Consultant
Francesco Parisi, MD (Italy), Editorial Board Consultant
Myung H. Park, MD (USA), Editorial Board Consultant
Evgenij V. Potapov, MD, PhD (Germany), Editorial Board Consultant
Luciano Potena, MD, PhD (Italy), Editorial Board Consultant
Joseph G. Rogers, MD (USA), Editorial Board Consultant
Heather J. Ross, MD, MHSc, FRCP(c) (Canada),
Editorial Board Consultant
Lewis J. Rubin, MD (USA), Editorial Board Consultant
Stephan Schueler, MD, PhD (UK), Editorial Board Consultant
Keyur B. Shah, MD (USA), Editorial Board Consultant
Mark S. Slaughter, MD (USA), Editorial Board Consultant
Randall C. Starling, MD (USA), Editorial Board Consultant
Stuart C. Sweet, MD, PhD (USA), Editorial Board Consultant
Geert M. Verleden, MD, PhD (Belgium), Editorial Board Consultant
Aaron B. Waxman, MD, PhD (USA), Editorial Board Consultant

ISHLT COMMITTEES

Steven A. Webber, MBChB (USA), Editorial Board Consultant

Lori J. West, MD, DPhil, FRACP (Canada),
Editorial Board Consultant

Michal Zakliczynski, MD (Poland), Editorial Board Consultant

NOMINATING COMMITTEE

David O. Taylor, MD, Chair

Allan Glanville, MBBS, MD, FRACP, President

Lori J. West, MD, DPhil, FRCPC, Past President

John Dark, MB, FRCS, ISHLT Past President

James K. Kirklin, MD, ISHLT Past President

Lara Danziger-Isakov, MD, MPH, Member Board of Directors

Daniel R. Goldstein, MD, Member Board of Directors

PROFESSIONAL STANDARDS AND GUIDELINES COMMITTEE

James K. Kirklin, MD, Chair

Roland G. Nador, MD, Basic Science & Translational
Research Council Workforce Leader

Naveen Pereira, MD, Heart Failure & Transplant Medicine
Council Workforce Leader

Stanley I. Martin, MD, Infectious Diseases Council
Workforce Leader

Steven Kindel, MD, Junior Faculty and Trainees Council
Workforce Leader

David S. Feldman, MD, PhD, FACC, FAHA, Mechanical
Circulatory Support Council Workforce Leader

Connie White-Williams, PhD, RN, FAAN, Nursing, Health
Sciences & Allied Health Council Workforce Leader

Joseph J. Maleszewski, MD, Pathology Council
Workforce Leader

Robert J. Boucek, Jr., MD, Pediatric Transplantation
Council Workforce Leader

Adam B. Cochrane, PharmD, Pharmacy & Pharmacology
Council Workforce Leader

Teresa De Marco, MD, FACC, Pulmonary Hypertension
Council Workforce Leader

Peter M. Hopkins, FRACP, Pulmonary Transplantation
Council Workforce Leader

Diego H. Delgado, MD, MSc, At Large Member

Maria G. Crespo-Leiro, MD, At Large Member

Daniela Pini, MD, At Large Member

James F. George, PhD, At Large Member

REGISTRIES AND DATABASES COMMITTEE

Josef Stehlik, MD, MPH, Chair

Octavio E. Pajaro, MD, PhD, Basic Science & Translational Research Council Workforce Leader

TBA, Heart Failure Transplant Medicine Council Workforce Co-Leader

Denis Hadjiliadis, MD, Infectious Diseases Council Workforce Co-Leader

Keyur B. Shah, MD, Junior Faculty and Trainees Council Workforce Leader

Vivek Rao, MD, PhD, Mechanical Circulatory Support Council Workforce Leader

Sharon A. Beer, RN, MSc, Nursing, Health Sciences & Allied Health Council Workforce Leader

Robert F. Padera, MD, PhD, Pathology Council Workforce Leader

Scott R. Auerbach, MD, Pediatric Transplantation Council Workforce Leader

Tam Khuu, PharmD, BCPS, Pharmacy & Pharmacology Council Workforce Leader

Ivan Robbins, MD, Pulmonary Hypertension Council Workforce Co-Leader

Roger D. Yusen, MD, MPH, Pulmonary Transplantation Council Workforce Leader

Maria G. Crespo-Leiro, MD, Outcomes Specialist

Leah Edwards, PhD, Biostatistics

Jaime Williamson, SAS Analyst

Kathryn A. Philibin, RN, TII Liaison

HEART AND LUNG TRANSPLANT REGISTRY STEERING COMMITTEE

Josef Stehlik, MD, MPH, Medical Director

Lars H. Lund, MD, PhD, Associate Medical Director Adult Heart

Roger D. Yusen, MD, MPH, Associate Medical Director Adult Lung

Anne I. Dipchand, MD, Associate Medical Director Assistant Pediatric Heart

Christian Benden, MD, Associate Medical Director Pediatric Lung

Samuel B. Goldfarb, MD, Associate Medical Director Pediatric Lung

Fabienne Dobbels, PhD, Outcomes

Bronwyn J. Levvey, RN, Grad Dip Clin Ep, Outcomes

Axel Rahmel, MD, Associate Medical Director OEO Relations

Leah Edwards, PhD, Associate Medical Director Biostatistics

Jaime Williams, SAS Analyst

Kathryn A. Philibin, RN, TII Liaison

Anna Kucheryavaya, MS, Assistant Biostatistician

LINKS NEWSLETTER EDITORIAL STAFF

Vincent G. Valentine, MD, Editor-in-Chief

Paul Corris, Senior Associate Editor

John Dark, MB FRCS, Senior Associate Editor

Roger W. Evans, PhD, Senior Associate Editor

Allan R. Glanville, MBBS, MD, FRACP, Senior Associate Editor

Maryl R. Johnson, MD, Senior Associate Editor

Lori J. West, MD, DPhil, FRACP, Senior Associate Editor

Emma Birks, FRCP, PhD, Associate Editor Cardiology

Stavros G. Drakos, MD, PhD, Associate Editor Cardiology

Daniel Dilling, MD, Associate Editor Junior Faculty & Trainees

Stanley I. Martin, MD, Associate Editor Infectious Diseases

Christian Benden, MD, Associate Editor Pediatrics

Tereza Martinu, MD, Associate Editor Pulmonary Transplant

Susie Newton, Managing Editor

Javier Carbone, MD, PhD (Spain), International
Correspondents Board

Takeshi Nakatani, MD, PhD (Japan), International
Correspondents Board

Luciano Potena, MD, PhD (Italy), International
Correspondents Board

Andreas Zuckermann, MD (Austria), International
Correspondents Board

Howard J. Eisen, MD, FAHA, FACC, FACP, Basic Science &
Translational Research Council Communications Liaison

David P. Nelson, MD, Heart Failure & Transplant Medicine
Council Communications Liaison

Michele Estabrook, MD, Infectious Diseases Council
Communications Co-Liaison

Macé Schuurmans, MD, Infectious Diseases Council
Communications Co-Liaison

Christina Migliore, MD, Junior Faculty & Trainees Council
Communications Liaison

Evgenij V. Potapov, MD, Mechanical Circulatory Support
Council Communications Liaison


Emily Stimpson, RN, BSN, CCTC, Nursing, Health Sciences and
Allied Health Council Communications Liaison

Kimberly L. Gandy, MD, Pediatric Council Communications Liaison

Ed Horn, PharmD, Pharmacy & Pharmacology Council
Communications Liaison

Veronica Franco, MD, Pulmonary Hypertension Council
Communications Liaison

Tereza Martinu, MD, Pulmonary Transplantation Council
Communications Liaison



SCIENTIFIC COUNCIL OPERATING BOARDS

BASIC SCIENCE AND TRANSLATIONAL RESEARCH

Kimberly L. Gandy, MD, PhD, Chair

Sonja Schrepfer, MD, PhD, Vice Chair

Doris A. Taylor, PhD, Senior Advisor

Jeffrey L. Platt, MD, Senior Advisor

John A. Belperio, MD, Annual Program Committee Representative

Esme Dijke, PhD, Annual Program Committee Representative

Daniel C. Chambers, MBBS, MD, Annual Program Committee Representative

Lori J. West, MD, DPhil, FRCPC, Annual Program Committee Representative

Stephan M. Ensminger, MD, PhD, Development Committee Representative

Marilia Cascalho, MD, PhD, Education Committee Representative

Howard J. Eisen, MD, FAHA, FACC, FACP, I2C2 Committee and Communications Representative

Octavio E. Pajaro, MD, PhD, Registries & Databases Committee Representative

COUNCIL OPERATING BOARDS

Roland G. Nador, MD, Standards & Guidelines Committee Representative

Daniel R. Goldstein, MD, Board of Directors Co-Liaison

Howard J. Eisen, MD, FAHA, FACC, FACP, Links Communications

Pradeep P. A. Mammen, MD, FACC, FAHA, Heart Failure & Transplant Medicine Co-Liaison

Uwe Schulz, MD, Heart Failure & Transplant Medicine Co-Liaison

Orla Morrissey, MD, Infectious Diseases Council Liaison

Zsuzsanna Hollander, MSc, Junior Faculty and Trainees Council Co-Liaison

Esme Dijke, PhD, Junior Faculty and Trainees Council Co-Liaison

J. Michael DiMaio, MD, Mechanical Circulatory Support Liaison

Bernice L. Coleman, PhD, RN, Nursing, Health Sciences and Allied Health Co-Liaison

Judy A. Currey, PhD, Nursing, Health Sciences and Allied Health Co-Liaison

Annalisa Angelini, MD, Pathology Council Liaison

Carol K. Conrad, MD, Pediatric Transplantation Council Liaison

Paul E Nolan, Jr, PharmD, Pharmacy & Pharmacology Council Liaison

James D. West, PhD, Pulmonary Hypertension Council Liaison

Daniel C. Chambers, MBBS, MD, Pulmonary Transplantation Council Liaison

HEART FAILURE & TRANSPLANT MEDICINE

José Tallaj, MD, Chair

Monica M. Colvin-Adams, MD, Vice Chair

David Brad Dyke, MD, Past Chair

Maria G. Crespo-Leiro, MD, Annual Meeting Program Committee Co-Representative

Goran Dellgren, MD, Annual Meeting Program Committee Co-Representative

Howard J. Eisen, MD, FAHA, FACC, FACP, Annual Meeting Program Committee Co-Representative

David S. Feldman, MD, PhD, Annual Meeting Program Committee Co-Representative

Ashish S. Shah, MD, Annual Meeting Program Committee Co-Representative

Michal Zakliczynski, MD, 2013 Annual Meeting Program Committee Co-Representative

Robert C. Bourge, MD, Development Committee Representative

David A. Baran, MD, Education Committee Representative

Deborah E. Meyers, MD, FRACP, FACC, I2C2 Committee Representative

Naveen Pereira, MD, Standards & Guidelines Committee Representative

Maryl R. Johnson, MD, Board of Directors Co-Liaison

David O. Taylor, MD, Board of Directors Co-Liaison
David P. Nelson, MD, Links Communications Liaison
Pradeep P.A. Mammen, MD, FACC, FAHA, Basic Science & Translational Research Council Co-Liaison
Uwe Schulz, MD, Basic Science & Translational Research Council Co-Liaison
Hannah Copeland, MD, Junior Faculty & Trainee Liaison

INFECTIOUS DISEASES

Fernanda Silveira, MD, Chair
Paolo A. Grossi, MD, PhD, Vice Chair
Lara Danziger-Isakov, MD, MPH, Past Chair
Stanley I. Martin, MD, Annual Meeting Program Committee Co-Representative
Amparo Solé, MD, PhD, Annual Meeting Program Committee Co-Representative
Me-Linh Luong, MD, Education Committee Representative
Martha L. Mooney, MD, FACP, I2C2 Committee Representative
Margaret M. Hannan, MD, IMACS Committee Representative
Denis Hadjiliadis, MD, Registries & Databases Committee Co-Representative
Stanley I. Martin, MD, Standards & Guidelines Committee Representative
Lara Danziger-Isakov, MD, MPH, Board of Directors Liaison
Orla Morrissey, MD, Basic Science and Translational Research Council Liaison
Saima Aslam, MD, MS, Junior Faculty and Trainees Council Liaison
Stanley I. Martin, MD, Links Communications Co-Liaison
Michele Estabrook, MD, Links Communications Co-Liaison
Macé M. Schuurmans, MD, Links Communications Co-Liaison

JUNIOR FACULTY AND TRAINEES

Jennifer Ann Cowger, MD, MS, Chair and Annual Meeting Program Committee Co-Representative
Manreet Kanwar, MD, Vice Chair
Eugene C. DePasquale, MD, Secretary/Vice Chair
Pali D. Shah, MD, Past Chair
Esme Dijke, PhD, Annual Meeting Program Committee Co-Representative
Arezu Z. Aliabadi, MD, Development Committee Representative
Jonathan N. Johnson, MD, Education Committee Representative
Reema Hasan, MD, I2C2 Committee Representative
Keyur B. Shah, MD, Registries & Databases Committee Representative
Steven Kindel, MD, Standards & Guidelines Committee Representative

COUNCIL OPERATING BOARDS

David O. Taylor, MD, Board of Directors Co-Liaison

Zsuzsanna Hollander, MSc, Basic Science and Translational Research Council Co-Liaison

Esme Dijke, PhD, Basic Science and Translational Research Council Co-Liaison

Dan Dilling, MD, Links Communications Liaison

Christina Migliore, MD, Communications Liaison

Hannah Copeland, MD, Heart Failure and Transplant Medicine Council Liaison

Saima Aslam, MD, MS, Infectious Diseases Council Liaison

Palak Shah, MD, MS, Mechanical Circulatory Support Council Liaison

Chesney Castleberry, MD, Pediatric Transplantation Council Liaison

Robin Vos, MD, PhD, Pulmonary Transplantation Council Liaison

MECHANICAL CIRCULATORY SUPPORT

Daniel J. Goldstein, MD, Chair

Ulrich P. Jorde, MD, Vice Chair

Jeffrey J. Teuteberg, MD, Past Chair

Emma J. Birks, MBBS, PhD, BSc, FRCP, Annual Meeting Program Committee Representative

Jennifer Ann Cowger, MD, MS, Annual Meeting Program Committee Representative

Josef Stehlik, MD, PhD, Annual Meeting Program Committee Representative

Martin Strueber, MD, Annual Meeting Program Committee Representative

Marian Zembala, MD, PhD, Annual Meeting Program Committee Representative

Andreas Zuckermann, MD, Annual Meeting Program Committee Representative

Mario C. Deng, MD, Development Committee Representative

Salpy V. Pamboukian, MD, MSPH, Education Committee Representative

Sean P. Pinney, MD, I2C2 Committee Representative

Vivek Rao, MD, PhD, Registries & Databases Committee Representative

David S. Feldman, MD, PhD, FACC, FAHA, Standards & Guidelines Committee Representative

Francis D. Pagani, MD, PhD, Board of Directors Co-Liaison

Martin Strueber, MD, Board of Directors Co-Liaison

Evgenij V. Potapov, MD, Links Communications Liaison

Dawn M. Christensen, MS, CRNP, VAD Coordinator Liaison

J. Michael DiMaio, MD, Basic Science and Translational Research Council Liaison

Palak Shah, MD, MS, Junior Faculty & Trainee Council Liaison

NURSING, HEALTH SCIENCES AND ALLIED HEALTH

Masina Scavuzzo, RN, Chair

Samantha J. Anthony, PhD, MSW, Vice Chair and Annual Meeting Program Committee Co-Representative

Annemarie Kaan, MCN, RN, Past Chair

Kevin Carney, RN, CCTC, Annual Meeting Program Committee Co-Representative

Michael G. Petty, PhD, RN, CCNS, CNS, Education Committee and I2C2 Committee Representative

Lut Berben, PhD, RN, Grants & Awards Committee Representative

Sharon A. Beer, RN, MSc, Registries & Databases Committee Representative

Connie White-Williams, PhD, RN, Standards & Guidelines Committee Representative

Bronwyn J. Levvey, RN, Grad Dip Clin Ep, Board of Directors Liaison

Bernice L. Coleman, PhD, RN, Basic Science and Translational Research Council Co-Liaison

Judy A. Currey, PhD, Basic Science and Translational Research Council Co-Liaison

Emily Stimpson, RN, BSN, CCTC, Links Communications Liaison

PATHOLOGY

Dylan V. Miller, MD, Chair

Carmela D. Tan, MD, Vice Chair

Patrick Bruneval, MD, Past Chair

Gerald J. Berry, MD, Development Committee Representative and Annual Meeting Program Committee Representative

Margaret M. Burke, FRCPath, I2C2 Committee Representative

Robert F. Padera, MD, PhD, Registries & Databases Committee Representative

Joseph J. Maleszewski, MD, Standards & Guidelines Committee Representative

Daniel R. Goldstein, MD, Board of Directors Liaison

Annalisa Angelini, MD, Basic Science and Translational Research Council Liaison

PEDIATRIC TRANSPLANTATION

Marc G. Schecter, MD, Chair

Janet N. Scheel, MD, Vice Chair

Melanie Everitt, MD, Past Chair

Christian Benden, MD, Annual Meeting Program Committee Co-Representative

Tajinder P. Singh, MD, Annual Meeting Program Committee Co-Representative

Debra A. Dodd, MD, Education Committee Representative

COUNCIL OPERATING BOARDS

Anne I. Dipchand, MD, I2C2 Committee Representative

Scott R. Auerbach, MD, Registries & Databases
Committee Representative

Robert J. Boucek, Jr., MD, Standards & Guidelines
Committee Representative

Richard Kirk, MA FRCP FRCPC, Board of Directors Liaison

Carol K. Conrad, MD, Basic Science and Translational
Research Council Liaison

Chesney Castleberry, MD, Junior Faculty and Trainee Council

Christian Benden, MD, Communications Liaison

Yuk M. Law, MD, Pediatric Heart Failure Workforce Leader

PHARMACY AND PHARMACOLOGY

Michael A. Shullo, BS, PharmD, Chair

Tamara E. Claridge, PharmD, Vice Chair and Annual
Meeting Program Committee

Christopher R. Ensor, PharmD, BCPS-CV, Past Chair

Walter Uber, PharmD, Annual Meeting Program
Committee Co-Representative

Robert L. Page, II, PharmD, MSPH, Development
Committee Representative

Haifa Lyster, BPharm(Hons), MSc, Education Committee
Representative

Patricia A. Uber, PharmD, I2C2 Committee Representative

Tam Khuu, PharmD, BCPS, Registries & Databases
Committee Representative

Adam B. Cochrane, PharmD, BCPS, Standards & Guidelines
Committee Representative

Joseph G. Rogers, MD, Board of Directors Liaison

Paul E. Nolan, PharmD, FCCP, FASHP, Basic Science and
Translational Research Council Liaison

Edward Horn, PharmD, BCPS, Links Communications Liaison

PULMONARY HYPERTENSION

Robert P. Frantz, MD, Chair

Mardi Gomberg-Maitland, MD, MSc, Vice Chair

Myung H. Park, MD, FACC, Past Chair

Paul A. Corris, Annual Meeting Program Committee
Representative

Marc de Perrot, MD, 2013 Annual Meeting Program
Committee Representative

Mandeep R. Mehra, MD, MBBS, FACC, FACP, Annual Meeting
Program Committee Representative

Myung H. Park, MD, Annual Meeting Program
Committee Representative

Fernando Torres, MD, Annual Meeting Program
Committee Representative

Evelyn Horn, MD, Development Committee Representative
Dana P. McGlothlin, MD, Education Committee Representative
John Granton, MD, I2C2 Committee Representative
Ivan Robbins, MD, Registries & Databases Committee Representative
Teresa De Marco, MD, FACC, Standards & Guidelines Committee Representative
Myung H. Park, MD, Board of Directors Liaison
James D. West, PhD, Basic Science and Translational Research Council Liaison
Veronica Franco, MD, Communications Liaison

PULMONARY TRANSPLANTATION

David Weill, MD, Chair
Michael Mulligan, Vice Chair
Lianne G. Singer, MD, FRCPC, Past Chair and I2C2 Committee Representative
Tobias Deuse, MD, PhD, Annual Meeting Program Committee Representative
Allan R. Glanville, MD, FRACP, Board of Directors Liaison and Annual Meeting Program Committee Representative
Denis Hadjiliadis, MD, Annual Meeting Program Committee Representative
David Lederer, MD, MS, Annual Meeting Program Committee Representative
Christopher H. Wigfield, MD FRCS(C/Th), Annual Meeting Program Committee Representative
Martin R. Zamora, MD, Annual Meeting Program Committee Representative
Glen P. Westall, FRACP, PhD, Development Committee Representative
Kevin M. Chan, MD, Education Committee Representative
Roger D. Yusen, MD, MPH, Registries & Databases Committee Representative
Peter M. Hopkins, FRACP, Standards & Guidelines Committee Representative
Daniel C. Chambers, MBBS, MD, Basic Science and Translational Research Council Liaison
Robin Vos, MD, PhD, Junior Faculty and Trainee Council Liaison
Tereza Martinu, MD, Communications Liaison
Jonathan P. Singer, MD MS, Quality of Life Workforce Leader

PAST PRESIDENTS

1981-1982	Michael Hess, MD
1982-1984	Jack Copeland, MD
1984-1986	Terence English, FRCS
1986-1988	Stuart Jamieson, MD
1988-1990	Bruno Reichart, MD
1990-1991	Margaret Billingham, MD
1991-1992	Christian Cabrol, MD
1992-1993	John O'Connell, MD
1993-1994	Eric Rose, MD
1994-1995	John Wallwork, FRCS
1995-1996	Sharon Hunt, MD
1996-1997	William Baumgartner, MD
1997-1998	Leslie Miller, MD
1998-1999	Alan Menkis, MD, FRCS(C)
1999-2000	Robert L. Kormos, MD
2000-2001	Anne Keogh, MBBS, MD
2001-2002	James B. Young, MD
2002-2003	Stephan Schueler, MD
2003-2004	Jon Kobashigawa, MD
2004-2005	Alec Patterson, MD
2005-2006	Mark L. Barr, MD
2006-2007	Robert C. Robbins, MD
2007-2008	Paul A. Corris, MB FRCP
2008-2009	Mandeep R. Mehra, MD
2009-2010	James K. Kirklin, MD
2010-2011	John Dark, MB, FRCS
2011-2012	Lori J. West, MD, DPhil
2012-2013	David O. Taylor, MD

PAST SCIENTIFIC PROGRAM CHAIRS

1981	San Francisco, CA	Edward B. Stinson, MD and Michael L. Hess, MD
1982	Phoenix, AZ	Michael Kaye and Bernard Gersh
1983	New Orleans, LA	Stuart W. Jamieson, MD and Mark E. Thompson, MD
1984	New York, NY	Randall B. Grieppe, MD
1985	Anaheim, CA	Terence A. H. English and Hillel Laks
1986	New York, NY	
1987	New Orleans, LA	
1988	Los Angeles, CA	John C. Baldwin, MD
1989	Munich, Germany	Bruno Reichart, MD
1990	San Diego, CA	D. Glenn Pennington, MD
1991	Paris, France	John B. O'Connell, MD
1992	San Diego, CA	Eric A. Rose, MD
1993	Boca Raton, FL	Maria Rosa Costanzo, MD
1994	Venice, Italy	John Wallwork, MBChB, FRCS
1995	San Francisco, CA	Leslie W. Miller, MD
1996	New York, NY	William A. Baumgartner, MD
1997	London, England	Stephan Schueler, MD
1998	Chicago, IL	James B. Young, MD
1999	San Francisco, CA	Mark L. Barr, MD
2000	Osaka, Japan	Jon Kobashigawa, MD
2001	Vancouver, Canada	David O. Taylor, MD
2002	Washington, DC	Robert C. Robbins, MD
2003	Vienna, Austria	Bruce R. Rosengard, MD
2004	San Francisco, CA	Mandeep R. Mehra, MD
2005	Philadelphia, PA	Shaf Keshavjee, MD
2006	Madrid, Spain	John Dark, MB, FRCS
2007	San Francisco, CA	Duane Davis, MD
2008	Boston, MA	Lori J. West, MD, DPhil
2009	Paris, France	Randall C. Starling, MD, MPH
2010	Chicago, IL	Hermann Reichenspurner, MD, PhD
2011	San Diego, CA	Richard N. Pierson, III, MD
2012	Prague, Czech Republic	Stuart C. Sweet, MD, PhD
2013	Montreal, Canada	Allan R. Glanville, MBBS, MD, FRACP

EDITORS:

LINKS NEWSLETTER

2008-2011 David S. Feldman, MD, PhD
2011-Present Vincent G. Valentine, MD

JOURNAL OF HEART AND LUNG TRANSPLANTATION

1981-1985 Jacques G. Losman, MD
1986-1994 Michael P. Kaye, MD
1995-1999 Maria Rosa Costanzo, MD
2000-2009 James K. Kirklin, MD
2010-Present Mandeep R. Mehra, MD

MEDICAL DIRECTORS: THORACIC ORGAN TRANSPLANT REGISTRY

1987-1993 Michael P. Kaye, MD
1993-2001 Jeffrey D. Hosenpud, MD
2001-2012 Marshall I. Hertz, MD
2012-Present Josef Stehlik, MD, PhD

ISHLT AWARD RECIPIENTS

LIFETIME ACHIEVEMENT AWARD

- 1996 Norman Shumway, MD
- 1999 Keith Reemtsma, MD
- 2004 Sir Magdi Yacoub, MD
- 2010 Margaret Billingham, MD
- 2012 Sharon Hunt, MD

LIFETIME SERVICE AWARD

- 1996 Michael P. Kaye, MD
- 1997 Jacques G. Losman, MD

PIONEERS IN TRANSPLANTATION LECTURE

- 2000 Christiaan Barnard, MD
Joel D. Cooper, MD
Norman E. Shumway, MD
- 2002 Michael DeBakey, MD
Bruce A. Reitz, MD
- 2006 Leonard L. Bailey, MD
- 2008 Richard E. Lower, MD
- 2009 Christian E. A. Cabrol, MD
- 2011 Elizabeth Hammond, MD
- 2013 Jack G. Copeland, MD

ISHLT AWARD RECIPIENTS

NORMAN E. SHUMWAY ISHLT CAREER DEVELOPMENT AWARD

- 2000 Gordon D. Wu, MD *(supported by Roche)*
- 2002 Anthony Azakie, MD *(supported by Roche)*
- 2004 Allan M. Ramirez, MD *(supported by Novartis Pharma)*
- 2006 Dennis W. Wigle, MD, PhD
(supported by Astellas Pharma)
- 2008 Glen Westall, MD, PhD *(supported by Roche)*
- 2010 Sonja Schrepfer, MD, PhD *(supported by Astellas)*
- 2012 Tereza Martinu, MD, PhD

ISHLT RESEARCH FELLOWSHIP GRANT

- 1995 Frances L. Johnson, MD *(supported by Ortho-Biotech)*
- 1996 Tuija S. Ikonen, MD *(supported by Roche)*
Andrew F. Pierre, MD *(supported by Ortho-Biotech)*
- 1997 Jonathan Chen, MD *(supported by Roche)*
Alyssa M. Krasinskas, MD *(supported by Astellas)*
Owen T. Lawrence, MD *(supported by Ortho-Biotech)*
Anne K. Raisanen-Sokolowski, MD
(supported by Roche)
- 1998 Kelly S.A. Blair, MD *(supported by Roche)*
A.M. El Gamel, MD *(supported by Roche)*
Christine L. Lau, MD *(supported by Wyeth-Ayerst)*
Scott D. Ross, MD
Margaret L. Schwarze, MD *(supported by Novartis)*
- 1999 George Juang, MD *(supported by Novartis)*
Sivasai Krovvidi, PhD *(supported by Roche)*
Satoshi Saito, MD *(supported by Novartis)*
Donald Wong, PhD *(supported by Roche)*
- 2000 Richard S. Lee, MD *(supported by Novartis)*
Christopher H. Wigfield, FRCS *(supported by Roche)*
- 2001 Arnar Geirsson, MD *(supported by Roche)*
Matteo Vatta, PhD *(supported by Roche)*
- 2002 Ruediger Hoebelt, MD *(supported by Roche)*
- 2003 Ewout J. van den Bos, MD *(supported by Astellas)*
Felix Fernandez, MD *(supported by Roche)*

- 2004 **Christian A. Gleissner, MD** (supported by Astellas)
Tsuyoshi Shoji, MD, PhD (supported by Actelion)
Kendra N. Taylor, PhD (supported by Roche)
Monica Zwierzchonieuska, MD (supported by XDx)
- 2005 **Ryan C. Fields, MD** (supported by Chiron)
Arne Neyrinck, MD (supported by Astellas)
Ahmad Saad, MD (supported by Roche)
- 2006 **Rachel L. Anderson, MBBS** (supported by Roche)
Zhaohui Li, PhD (supported by Transmedics)
Heather E. Merry, MD (supported by Encysive)
Edward N. Seung, PhD (supported by XDx)
Matthew J. Weiss, MD (supported by Novartis)
- 2007 **J. Raymond Fitzpatrick, III, MD** (supported by Encysive)
Howard J. Huang, MD (supported by Transmedics)
Mylvganam Jeyakanthan, MD (supported by XDx)
Timothy M. Millington, MD (supported by Novartis)
Satish N. Nadig, MD (supported by Roche)
Takeshi Oyaizu, MD, PhD (supported by Actelion)
Sonja Schrepfer, MD (supported by Astellas)
- 2008 **Jonathan Choy, PhD** (supported by XDx)
Satoshi Itoh, MD (supported by Transmedics)
Tereza Martinu, MD (supported by Novartis)
Deepti Saini, PhD (supported by Gilead)
Atsushi Shiozaki, MD, PhD (supported by Astellas)
Seiichiro Sugimoto, MD, PhD (supported by Roche)
- 2009 **Hua Shen, MD, PhD** (supported by Astellas)
Tobias Deuse, MD, PhD (supported by Novartis)
Masahiro Miyajima, MD, PhD (supported by XDx)
Shin Hirayama, MD, PhD (supported by Gilead)
- 2010 **Esme Dijke, PhD** (supported by Novartis)
Smita Sihag, MD (supported by Genentech)
Sumiharu Yamamoto, MD (supported by Gilead)
Khurram Shahzad, MD
(supported by United Therapeutics)
Nina Pilat, MSc, PhD (supported by XDx)
- 2011 **Alejandro Bribriescio, MD** (supported by Astellas)
Alexey Dashkevich, MD (supported by XDx)
Patricia E. de Almeida, DVM, MS, PhD
Tiago Machuca, MD, PhD
- 2012 **Stephen C. Juvet, MD, FRCPC**
Maria Lucia L. Madariga, MD
Jessica H. Spahn, PhD
Konstantinos Malliaras, PhD
- 2013 **Nikolaos Diakos, MD**
Raymond Givens, MD, PhD
Pablo Sanchez, MD, PhD

ISHLT AWARD RECIPIENTS

ISHLT TRANSPLANT REGISTRY EARLY CAREER AWARD (FORMERLY JUNIOR FACULTY AWARD)

- 2007 Beth D. Kaufman, MD
- 2008 Cynthia Gries, MD, MSc
Scott Halpern, MD, PhD
Josef Stehlik, MD, MPH
- 2010 Jennifer Conway, MD, FRCPC
Kiran K. Khush, MD, MAS
- 2011 Jose Nativi, MD
- 2012 Erin M. Lowery, MD
Omar E. Wever-Pinzon, MD
- 2013 Chesney Castleberry, MD
Eugene DePasquale, MD
Aaron Healy, MD

ISHLT NURSING AND SOCIAL SCIENCES RESEARCH GRANT

- 1997 Eileen Collins, RN, PhD
- 1998 Katherine St. Clair, RN, MSN
- 1999 Jeanne Salyer, PhD
- 2000 Nancy M. Albert, MSN, RN
- 2001 Lynn Doering, RN, DNSc
- 2002 Annette J. De Vito Dabbs, RN, MN, PhD
- 2003 Diane H. Leloudis, RN, MSN
Janet E. Madill, PhD
- 2004 Deidre E. Logan, PhD
- 2005 Annemarie F. Kaan, MCN
- 2006 Thierry Troosters, PhD
- 2007 Mi-Kyung Song, PhD
- 2008 Stacey M. Pollock-BarZiv, PhD
- 2009 Jane MacIver, RN, MSc
- 2010 Heike Spaderna, PhD
Gerdi Weidner, PhD

- 2011 **Christiane Kugler, PhD** *(supported by CSL Behring)*
Hilde Bollen, RN
- 2012 **Lut Berben, PhD, RN** *(supported by CSL Behring)*
Connie White-Williams, PhD, RN, FAAN
- 2013 **Jo Wray, PhD**
Jane Haines, DNP, RN, CMSRN

ISHLT BRANISLAV RADOVANCEVIC MEMORIAL FELLOWSHIP GRANT

- 2009 **Sasa D. Borovic, MD** *(supported by Thoratec)*
- 2010 **Iki Adachi, MD** *(supported by Thoratec)*
- 2012 **Antigone Koliopoulou, MD** *(supported by Thoratec)*
- 2013 **Leonardo Salazar, MD** *(supported by Thoratec)*

ISHLT AWARD RECIPIENTS

PHILIP K. CAVES AWARD

1983	Robbin G. Cohen, MD
1984	Hermann Reichenspurner, MD
1985	Michael A. Breda, MD
1986	Stuart J. Knechtle, MD
1987	Wim Van Der Bij, MD
1988	Charles D. Fraser, Jr., MD
1989	A.M. Wood, MD
1990	Andres J. Duncan, MD
1991	A. Jiminez, MD
1992	David P. Kapelanski, MD
1993	David Marshman, MD
1994	Jobst Winter, MD Alain Chapelier, MD
1995	Elizabeth A. Davis, MD
1996	Moninder S. Bhabra, MD
1997	Simon D. Eiref, MD
1998	Carla C. Baan, MD
1999	Joerg Koglin, MD
2000	Michael P. Fischbein, MD
2001	Alexander S. Krupnick, MD
2002	Peter Blaha, MD
2003	Sigrid Sandner, MD
2004	M.D. Peterson, MD
2005	Sigrid Sandner, MD Frank D'Ovidio, MD
2006	Gregor Warnecke, MD
2007	Heather E. Merry, MD
2008	Satish N. Nadig, MD
2009	Howard Huang, MD
2010	Tobias Deuse, MD, PhD
2011	Ankit Bharat, MD
2012	Simo Syrjälä, MD
2013	Alexey Dashkevich, MD

NURSING AND SOCIAL SCIENCES EXCELLENCE IN RESEARCH AWARD

- 2005 Mary Amanda Dew, PhD
- 2006 Kathleen L. Grady, PhD, RN
- 2007 Christianne Kugler, PhD
- 2008 Annette DeVito Dabbs, RN, PhD
- 2009 Connie White-Williams, MSN
- 2010 Bronwyn Levvey, RN
- 2011 Samantha J. Anthony, PhD, MSW
- 2012 Kate Hayes, MPhysio (Cardio)
- 2013 Jane Haines, DNP, RN, CMSRN

ISHLT BRANISLAV RADOVANCEVIC MEMORIAL BEST MCSD PAPER AWARD

- 2009 Nishant Shah, MD *(supported by Thoratec)*
- 2010 Jose N. Nativi, MD *(supported by Thoratec)*
- 2011 Dan Spiegelstein, MD *(supported by Thoratec)*
- 2012 Arun Raghav Mahankali Sridhar, MD, MPH
(supported by Thoratec)
- 2013 Claire Watkins, MD *(supported by Thoratec)*

ISHLT AWARD RECIPIENTS

ISHLT INTERNATIONAL TRAVELING SCHOLARSHIP RECIPIENTS

- 2011 Stephanie T. Yerkovich, PhD
 Sarah E. Gilpin, PhD
 Kimberly M. Derkatz, BNSc
 Jennifer Conway, MD, FRCPC
- 2012 Ramin E. Beygui, MD
 Kevin C. Carney, MSN
 Alexandre Souza Cauduro, MD
 Esme Dijke, PhD
 Ana Belen Mendez, MD
 David Schibilsky, MD
 Aleem Siddique, MBBS
 Amparo Solé, MD, PhD
 Manon Huibers, MSc
 Daniel R. Goldstein, MD
 Laveena Munshi, MD, FRCPC
 Marco Masetti, MD
 Rochelle M. Gellatly, PScPharm, ACPR, PharmD
- 2013 Alison Gareau, MSc
 Erin Schumer, MD, MS
 Bojan Vrtovec, MD, PhD
 Marsha Renikunta, PhD (student)
 Katie Morley, BA(Hons), RCN, MA
 Ali Yeginsu, MD
 Fabrizio Gandolfo, MD
 Marian Urban, MD
 Alexander Bernhardt, MD
 Victor Rossel, MD
 Mohammed Quader, MD

ISHLT AWARD RECIPIENTS

ISHLT LEACH- ABRAMSON-IMHOFF LINKS TRAVEL AWARDS

- 2012 **Tereza Martinu, MD**, Writer of the Year
Stanley I. Martin, MD, First Runner-Up
Luciano Potena, MD, PhD, First Runner-Up
Nancy P. Blumenthal, CRNP, Honorable Mention
Bronwyn J. Levvey, RN, Honorable Mention
Javier Carbone, MD, PhD, Honorable Mention
Stavros G. Drakos, MD, Honorable Mention
Daniel F. Dilling, MD, Honorable Mention
- 2013 **Michele Estabrook, MD**, Writer of the Year
Melanie Everitt, MD, First Runner-Up
Christina Migliore, MD, First Runner-Up
Veronica Franco, MD, Honorable Mention
Manreet Kanwar, MD, Honorable Mention
Luciano Potena, MD, PhD, Honorable Mention
Macé Schuurmans, MD, Honorable Mention
Jeffrey J. Teuteberg, MD, Honorable Mention

JFTC CLINICAL CASE DILEMMAS IN THORACIC TRANSPLANTATION BEST PRESENTATION AWARD

- 2011 **Michelle M. Kittleson, MD, PhD**
- 2012 **Erin Albers, MD**
- 2013 **Mustafa Ahmed, MD**

APRIL 10	PLENARY	CONCURRENT	CONCURRENT	CONCURRENT
Thursday	SEAPORT	GRAND HALL A	GRAND HALL B	GRAND HALL C
7:00 AM				
7:30 AM				
8:00 AM	SYMPOSIUM 1 <i>Preventing VAD Complications</i>	SYMPOSIUM 2 <i>Group 3 Pulmonary Hypertension</i>	SYMPOSIUM 3 <i>Ex-Vivo Donor Heart Support</i>	SYMPOSIUM 4 <i>Lung Transplant Candidate Selection</i>
8:30 AM				
9:00 AM				
9:30 AM				
10:00 AM	BREAK	BREAK	BREAK	BREAK
10:15 AM	SYMPOSIUM 7 <i>MCS Anticoagulation</i>	SYMPOSIUM 8 <i>CTEPH – Busting the Clot</i>	SYMPOSIUM 9 <i>Transplant Fungal Infections</i>	SYMPOSIUM 10 <i>Chronic Lung Allograft Dysfunction</i>
11:00 AM				
11:30 AM				
12:00 PM				
12:15 PM	LUNCH BREAK	LUNCH BREAK	LUNCH BREAK	
12:30 PM				PHARM COUNCIL MEETING 12:30-1:30 pm
1:00 PM				
1:30 PM				
2:00 PM	SYMPOSIUM 13 <i>Myocardial Recovery</i>	SYMPOSIUM 14 <i>All Stages of Severe Pulmonary Hypertension</i>	SYMPOSIUM 15 <i>Bad Bugs? Drugs Optimize</i>	SYMPOSIUM 16 <i>Ex-Vivo Lung Perfusion</i>
2:30 PM				
3:00 PM				
3:30 PM				
4:00 PM	BREAK	BREAK	BREAK	BREAK
4:15 PM	SYMPOSIUM 19 <i>Changes in MCS Therapy</i>	SYMPOSIUM 20 <i>Pulmonary Hypertension in Left Heart Disease</i>	SYMPOSIUM 21 <i>Controversies in Heart Failure and Heart Transplant</i>	SYMPOSIUM 22 <i>Global Perspectives on DCD in Lung Transplantation</i>
4:45 PM				
5:15 PM				
5:45 PM				
6:00 PM				
6:15 PM				
6:45 PM				
7:15 PM				

CONCURRENT	CONCURRENT	EXHIBIT HALL	POSTERS	TIME
GRAND HALL D	HARBOR GHI	HARBOR A-F	HARBOR/SEAPORT FOYERS	
				7:00 AM
				7:30 AM
SYMPOSIUM 5 <i>Lung Transplantation: Early Engraftment Events</i>	SYMPOSIUM 6 <i>ISHLT/IPTA Symposium</i>	EXHIBIT HALL BUILD 8 am - Noon	POSTER MOUNT 8 am - 10 am	8:00 AM
				8:30 AM
				9:00 AM
				9:30 AM
				BREAK
SYMPOSIUM 11 <i>Evolution of ABO Heart Incompatible Transplantation</i>	SYMPOSIUM 12 <i>VAD or Heart Transplant?</i>	EXHIBITOR SET-UP Noon - 6 pm	POSTER HALL OPEN 10 am - 7:15 pm	10:00 AM
				10:15 AM
				11:00 AM
				11:30 AM
				NHSAH COUNCIL MEETING 12:30-1:30 pm
SYMPOSIUM 17 <i>Frailty Assessment and Implications</i>	SYMPOSIUM 18 <i>Developing a Pediatric VAD Program</i>			12:00 PM
				12:15 PM
				12:30 PM
				1:00 PM
				1:30 PM
SYMPOSIUM 23 <i>Infectious Disease in Pediatric Thoracic Transplantation</i>	SYMPOSIUM 24 <i>Lung Transplant Immunology 201+</i>			2:00 PM
				2:30 PM
				3:00 PM
				3:30 PM
				BREAK
				4:00 PM
				4:15 PM
				4:45 PM
				5:15 PM
				5:45 PM
		EXHIBIT HALL OPEN OPENING RECEPTION 6:15 - 7:15 pm	MODERATED POSTERS 1 6:15 - 7:15 pm	6:00 PM
				6:15 PM
				6:45 PM
				7:15 PM

APRIL 11	PLENARY	CONCURRENT	CONCURRENT	CONCURRENT	CONCURRENT
Friday	SEAPORT	GRAND HALL A	GRAND HALL B	GRAND HALL C	GRAND HALL D
7:00 AM		SUNRISE 1 <i>MCS Building Future</i>	SUNRISE 2 <i>Challenging PH Cases</i>	SUNRISE 3 <i>Endothelial Dysfunction</i>	SUNRISE 4 <i>Lung Transplantation Controversies</i>
7:30 AM					
8:00 AM	OPENING PLENARY SESSION				
8:30 AM					
9:00 AM					
9:30 AM					
10:00 AM	BREAK	BREAK	BREAK	BREAK	BREAK
10:30 AM	CONCURRENT 1 <i>MCS Complications</i>	CONCURRENT 2 <i>MCS Engineering and Biomechanics</i>	CONCURRENT 3 <i>Immune System in Heart Transplantation</i>	CONCURRENT 4 <i>Ex-Vivo Lung Perfusion</i>	CONCURRENT 5 <i>Pediatric MCS</i>
11:00 AM					
11:30 AM					
12:00 PM	LUNCH BREAK	LUNCH BREAK	LUNCH BREAK	LUNCH BREAK	LUNCH BREAK
12:30 PM					
1:00 PM					
1:30 PM					
2:00 PM	CONCURRENT 7 <i>MCS Stop Bleeding</i>	CONCURRENT 8 <i>Cardiac Allograft Immune Function</i>	CONCURRENT 9 <i>Science of EVLP</i>	CONCURRENT 10 <i>Lung Transplantation Outcomes</i>	CONCURRENT 11 <i>Case Dilemmas in Thoracic Transplantation</i>
2:30 PM					
3:00 PM					
3:30 PM	BREAK	BREAK	BREAK	BREAK	BREAK
4:00 PM	CONCURRENT 13 <i>Optimizing MCS Outcomes</i>	CONCURRENT 14 <i>Future of MCS</i>	CONCURRENT 15 <i>Adult Heart Failure Diagnostics</i>	CONCURRENT 16 <i>CLAD Risk and Phenotypes</i>	CONCURRENT 17 <i>Ped Heart Transplantation Recipient Management</i>
4:30 PM					
5:00 PM					
5:30 PM		MINI ORALS 1 <i>Lung Donation</i>	MINI ORALS 3 <i>Patient Selection for HTx or MCS</i>	MINI ORALS 4 <i>MCS Science</i>	MINI ORALS 5 <i>HTx Candidate Selection/Outcome</i>
6:00 PM					
6:30 PM					
7:00 PM					
7:30 PM					
8:00 PM					
8:30 PM					

CONCURRENT	CONCURRENT	EXHIBIT HALL	POSTERS	TIME
HARBOR GHI	SEAPORT H	HARBOR A-F	HARBOR/SEAPORT FOYERS	
	SUNRISE 5 <i>LISH</i>		POSTER MOUNT 7 am - 10 am	7:00 AM
				7:30 AM
				8:00 AM
				8:30 AM
				9:00 AM
				9:30 AM
BREAK	BREAK	EXHIBIT HALL OPEN 10 am - 4 pm	POSTER HALL OPEN 10 am - 6:30 pm	10:00 AM
SYMPOSIUM 25 <i>Pulmonary Hypertension Lifecycle Journey</i>	CONCURRENT 6 <i>ID for Heart Transplant Clinicians</i>			10:30 AM
				11:00 AM
				11:30 AM
JFT COUNCIL MEETING 12:05 - 1:00 pm	LUNCH BREAK			12:00 PM
AUTHOR WORKSHOP 1:00 - 1:55 pm				12:30 PM
				1:00 PM
				1:30 PM
SYMPOSIUM 26 <i>MCS Device Infections</i>	CONCURRENT 12 <i>Improving Outcomes</i>			2:00 PM
				2:30 PM
				3:00 PM
BREAK	BREAK			3:30 PM
CONCURRENT 18 <i>QOL, Ethics, Policy, Economics</i>	SYMPOSIUM 27 <i>HTx and MCS in Latin America</i>			4:00 PM
				4:30 PM
				5:00 PM
MINI ORALS 6 <i>LTx Monitoring and Immunosuppression</i>	MINI ORALS 2 <i>HF and PH</i>		MODERATED POSTERS 2 5:30 - 6:30 pm	5:30 PM
				6:00 PM
				6:30 PM
				7:00 PM
				7:30 PM
				8:00 PM
				8:30 PM

APRIL 12	PLENARY	CONCURRENT	CONCURRENT	CONCURRENT	CONCURRENT
Saturday	SEAPORT	GRAND HALL A	GRAND HALL B	GRAND HALL C	GRAND HALL D
7:00 AM		SUNRISE 6 <i>Aortic Valve</i>	SUNRISE 7 <i>Prostaglandin Therapy in PAH</i>	SUNRISE 8 <i>Exercise Training in HTX</i>	SUNRISE 9 <i>CMV Infection in LTX Recipients</i>
7:30 AM					
8:00 AM	PLENARY SESSION				
8:30 AM					
9:00 AM					
9:30 AM					
10:00 AM	BIZ MTG	BREAK	BREAK	BREAK	BREAK
10:30 AM	CONCURRENT 19 <i>Optimizing MCS Outcomes II</i>	CONCURRENT 20 <i>Science of VAD Support</i>	CONCURRENT 21 <i>Adult HF: Drugs and Devices</i>	CONCURRENT 22 <i>Pushing Limits of Recipient Selection</i>	CONCURRENT 23 <i>Lung Allograft Dysfunction</i>
11:00 AM					
11:30 AM					
12:00 PM	LUNCH BREAK	MCS COUNCIL MEETING 12:05 - 12:55 pm	PH COUNCIL MEETING 12:05 - 12:55 pm	PED COUNCIL MEETING 12:05 - 12:55 pm	ID COUNCIL MEETING 12:05 - 12:55 pm
12:30 PM					
1:05 PM		HFTXM COUNCIL MEETING 1:00 - 1:55 pm	LUNG COUNCIL MEETING 1:00 - 1:55 pm	PED HF WORK-FORCE MTG 1:00 - 1:55 pm	
1:30 PM					
2:00 PM		CONCURRENT 25 <i>Bad VAD Situations</i>	CONCURRENT 26 <i>Living Better with an LVAD</i>	CONCURRENT 27 <i>Learning from HTX Registries</i>	CONCURRENT 28 <i>PH Diagnosis and Monitoring</i>
2:30 PM					
3:00 PM					
3:30 PM		BREAK	BREAK	BREAK	BREAK
4:00 PM		CONCURRENT 31 <i>MCS Bridge to Transplants</i>	CONCURRENT 32 <i>MCS Costs versus Outcomes</i>	CONCURRENT 33 <i>HTX Outcomes Improvements</i>	CONCURRENT 34 <i>CLAD Mechanisms</i>
4:30 PM					
5:00 PM					
5:30 PM		MINI ORALS 7 <i>Heart Donor</i>	MINI ORALS 10 <i>VADS Gone Bad</i>	MINI ORALS 11 <i>HTX Monitoring and Immunosuppression</i>	
6:00 PM					
6:30 PM					
7:00 PM					
7:30 PM	PRESIDENT'S COCKTAIL RECEPTION <i>Manchester Grand Hyatt Pool Deck</i> 7:30 - 9:00 pm				
8:00 PM					
8:30 PM					

CONCURRENT	CONCURRENT	MISC MTGS	MISC MTGS	EXHIBIT HALL	POSTERS	TIME
HARBOR GHI	SEAPORT H	GASLAMP AB	GASLAMP CD	HARBOR A-F	HARBOR/ SEAPORT FOYERS	
	SUNRISE 10 <i>Cardiac Allograft Rejection</i>				POSTER MOUNT 7:00 - 10 am	7:00 AM
						7:30 AM
						8:00 AM
						8:30 AM
						9:00 AM
						9:30 AM
BREAK	BREAK			EXHIBIT HALL OPEN 10 am - 4 pm	POSTER HALL OPEN 10 am - 6:30 pm	10:00 AM
CONCURRENT 24 <i>Immune Monitoring in HTX</i>	SYMPOSIUM 28 <i>JHLT at ISHLT: Year in Capsule</i>					10:30 AM
						11:00 AM
PATH COUNCIL MEETING 12:05 - 12:55 pm	LUNCH BREAK					11:30 AM
						12:00 PM
						12:30 PM
						1:05 PM
						1:30 PM
SYMPOSIUM 29 <i>Sensitized Heart Transplant Patient</i>	CONCURRENT 29 <i>Lung Donation</i>	CONCURRENT 30 <i>Caves Award Presentations</i>	SYMPOSIUM 30 <i>Controversies in Pediatric Transplantation Listing</i>			2:00 PM
						2:30 PM
						3:00 PM
BREAK	BREAK	BREAK	BREAK			3:30 PM
CONCURRENT 35 <i>Alternative Resources for Organs</i>	CONCURRENT 36 <i>Ped HTX Long Term Outcome</i>	CONCURRENT 37 <i>Heart and Lung TX Pathology</i>	CONCURRENT 38 <i>Pharmacothe- rapeutic Approaches</i>			4:00 PM
						4:30 PM
						5:00 PM
	MINI ORALS 12 <i>LTX Candidate Selection</i>	MINI ORALS 8 <i>Ped HTX Immunology</i>	MINI ORALS 9 <i>QOL, Ethics, Policy, Economics</i>		MODERATED POSTERS 3 5:30 - 6:30 pm	5:30 PM
						6:00 PM
						6:30 PM
						7:00 PM
PRESIDENT'S COCKTAIL RECEPTION <i>Manchester Grand Hyatt Pool Deck</i> 7:30 - 9:00 pm						7:30 PM
						8:00 PM
						8:30 PM

APRIL 13	PLENARY	CONCURRENT	MISC MTGS	MISC MTGS	MISC MTGS
Sunday	SEAPORT	HARBOR GHI	SEAPORT H	GASLAMP AB	GASLAMP CD
7:00 AM		SUNRISE 11 <i>VADS Around the World</i>	SUNRISE 12 <i>Hemodynamics Controversies</i>	SUNRISE 13 <i>Lab Methods 101</i>	SUNRISE 14 <i>Infant Lung Transplantation</i>
7:30 AM					
8:00 AM	STRIKE 8 am - 5 pm	CONCURRENT 39 <i>MCS Bench to Bedside</i>	CONCURRENT 40 <i>Heart Transplant Immunosuppression</i>	CONCURRENT 41 <i>PH Varieties</i>	CONCURRENT 42 <i>Ped Heart Transplant Risk Assessment</i>
8:30 AM					
9:00 AM					
9:15 AM		BREAK	BREAK	BREAK	BREAK
9:30 AM		PLENARY SESSION			
10:00 AM					
10:30 AM					
11:00 AM					
11:30 AM					
11:45 AM		BREAK	BREAK	BREAK	BREAK
12:00 PM		CONCURRENT 44 <i>MCS Care Innovations</i>	CONCURRENT 45 <i>Adult Heart Failure and the Liver</i>	CONCURRENT 46 <i>AMR 2014: HLA and Beyond</i>	CONCURRENT 47 <i>Marginal Heart Donors</i>
12:30 PM					
1:00 PM					
1:15 PM		STRIKE 1:15 - 5 pm	STRIKE 1:15 - 5 pm	STRIKE 1:15 - 5 pm	STRIKE 1:15 - 5 pm
1:30 PM					
2:00 PM					
2:15 PM					
3:00 PM					
3:30 PM					
4:00 PM					
4:30 PM					
5:00 PM					
5:30 PM					
6:00 PM					
6:30 PM					
7:00 PM					

MISC MTGS	EXHIBIT HALL	REGISTRATION	SPKR RDY RM	MISC MTGS	TIME
OLD TOWN AB	HARBOR A-F	PALM FOYER	BALBOA ABC	LA JOLLA AB	
SUNRISE 15 <i>High-Risk Donor</i>	EXHIBIT HALL STRIKE 7 am - 1 pm	OPEN 7 am - Noon	OPEN 7 am - 1:30 pm	BOARD MEETING 7:00 - 9:15 am	7:00 AM
CONCURRENT 43 <i>Infectious Diseases for Lung Transplant Clinicians</i>					7:30 AM
					8:00 AM
BREAK					8:30 AM
					9:00 AM
					9:15 AM
					9:30 AM
					10:00 AM
					10:30 AM
					11:00 AM
					11:30 AM
BREAK					11:45 AM
CONCURRENT 48 <i>Heart Failure Novel Approaches</i>		STRIKE Noon - 5 pm			12:00 PM
					12:30 PM
					1:00 PM
					1:15 PM
STRIKE 1:15 - 5 pm			STRIKE 1:30 - 5 pm		1:30 PM
					2:00 PM
				PULM AMR CONSENSUS MEETING 2:15 - 7 pm	2:15 PM
					3:00 PM
					3:30 PM
					4:00 PM
					4:30 PM
					5:00 PM
					5:30 PM
				6:00 PM	
				6:30 PM	
				7:00 PM	



*The INTERNATIONAL
SOCIETY FOR*

*HEART AND LUNG
TRANSPLANTATION*

*extends its heartfelt
gratitude to the
following companies
for their unrestricted
educational grants in
support of this 34th
Annual Meeting and
Scientific Sessions:*



Actelion
Gilead Sciences

ANNUAL MEETING CONTINUING MEDICAL EDUCATION INFORMATION

ACCME Accreditation Statement

The International Society for Heart and Lung Transplantation is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians and allied health professionals.

CME Credit Designation Statement

ISHLT designates this live activity for a maximum of *30.75 AMA PRA Category 1 Credits™*. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

ABTC Accreditation

Continuing Education Points for Transplant Certification (CEPTC) have been approved by the American Board for Transplant Certification. *30.0 Category 1* for ISHLT 34th Annual Meeting and Scientific Sessions. *8.0 Category 1* for the ISHLT Academy: Core Competencies in Nursing, Health Sciences and Allied Health.

ACPE Accreditation

The CU Skaggs School of Pharmacy and Pharmaceutical Sciences is accredited by the Accreditation Council for Pharmacy Education as a provider of continuing pharmacy education. This program has been accredited for up to 14.5 contact hours. To receive CE credit for this seminar, participants must complete all evaluations for programs attended and provide their NABP eProfile ID number and month and day of their birthdate. CE credit will be uploaded to CPE monitor within 60 days.

Disclosure

Current guidelines state that participants in continuing medical and allied health profession education activities must be made aware of any affiliation or financial interest that may affect the program content or a speaker's presentation. Planners, Faculty and Chairs participating in this meeting are required to disclose to the program audience any real or apparent conflict(s) of interest related to the content of their presentations or service as Chair/Planner. These disclosures will be distributed at the meeting. Additionally, all speakers have been asked to verbally disclose at the start of their presentation any financial interest or affiliations and to indicate if a product they are discussing is not labeled for the use under discussion or is still investigational.

Target Audience

The audience for this program includes physicians, surgeons, scientists, nurses and transplant coordinators engaged in the practice of heart and lung transplantation, the management and treatment of heart and lung transplant recipients, the management and treatment of patients with end-stage heart or lung disease, basic science or clinical research related to these fields or specialties which cause them to become involved in the treatment of transplant recipients or patients with end-stage heart or lung disease.

Educational Goals

The educational goals of this activity are: to enable participants to learn about current practices, emerging technologies and medical advances related to heart and lung transplantation and end-stage heart and lung disease and to provide a forum for participants to engage in discussion, debate and examination regarding the efficacy and applicability of these current practices, emerging technologies and medical advances.


Learning Objectives

- 1. At the conclusion of this meeting, participants will have improved competence and professional performance in the areas of understanding** the latest information and approaches regarding transplant research, surgical techniques, medical therapies, donor management and patient management for the treatment of patients suffering from end-stage heart and lung disease.
- 2. At the conclusion of this meeting, participants will have improved competence and professional performance in the areas of understanding** the state-of-the-art treatment approaches, risk factors, risk management approaches, patient selection criteria, disease prevention strategies outcome implications, and psychosocial management strategies for patients with end-stage heart and lung failure.
- 3. At the conclusion of this meeting, participants will have improved competence and professional performance in the areas of understanding** emerging technologies, medical advances and the clinical applications of basic science models of end-stage heart and lung disease management and prevention.



HIGHLIGHTS OF THE MEETING

LIFETIME ACHIEVEMENT AWARD



SIR TERENCE ENGLISH, KBE, FRCS
OXFORD, UNITED KINGDOM

THE 2014 LIFETIME ACHIEVEMENT AWARD RECIPIENT

The lifetime achievement award is bestowed every other year to an ISHLT member who is recognized for their outstanding achievements and tireless dedication in the field of heart and lung transplantation.

A lecture will be given by Sir Terence English, KBE, FRCS, the 2014 recipient of the Lifetime Achievement Award, in the Opening Plenary Session.



H I G H L I G H T S

BASIC SCIENCE

Basic Science and Translational Research (BSTR) will be showcased like never before at ISHLT 2014. **The ISHLT Academy: Core Competencies in Basic Science** will be held on Wednesday, providing an opportunity for delegates to gain or refresh knowledge in the fundamentals of basic science. On the following day, during the pre-meeting symposia, **Lung Transplant Immunology 201-Plus**, will provide an extension course for Academy attendees and Annual Meeting delegates alike, while a Sunrise Symposium primer for budding researchers, **Lab Methods 101**, will shed light where there is currently only darkness. BSTR will really take to the sky during the pre-meeting symposia on Thursday when the leaders in the field will use a case based discussion format to 'decode' the **early engraftment events that control graft survival** and to expose the role of primary graft dysfunction, TH17 skewing of the immune response, allo- and autoimmunity in the chronic loss of the pulmonary allograft. Finally, in what will surely be two of the highlights of the meeting, Lori West will tell how, on the 'Wings of Science' **the crazy idea of ABO incompatible heart transplantation became a reality** and then, in the closing plenary session, how one might trade the ABO and HLA sensitization hands one is often dealt to improve long-term outcomes.

HEART TRANSPLANTATION

ISHLT 2014 will offer new insights into some of the most intriguing and provocative areas of Heart Failure and Transplant Medicine and Heart Transplantation. There are three Pre-Meeting Symposia, two Sunrise Symposia and a Concurrent Symposium, all of which are guaranteed to keep your interest so that you don't wander to the beach or to Petco Park to watch the Padres play baseball. We believe that you will be enthralled by these programs. The Pre-Meeting Symposia will highlight areas of emerging technologic advances and of controversies. We will explore the use of **ex-vivo support of donor hearts** to expand organ availability and to recondition and optimize donor heart function. Speaking at this Symposium will be experts who are working to make this technology the standard of care. The next Symposium will tackle the issue of **when to transplant and when to VAD**. Current outcomes for each approach to advanced heart failure as well as patient selection will be addressed as will when palliative care is a more appropriate option than aggressive interventions. These two Symposia were developed jointly with the Mechanical Circulatory Support (MCS) Council. The third Symposium will highlight **the "sexiest" controversies in end-stage heart failure and transplantation** and will include both talks and debates by experts in the various fields. This Symposium was developed in concert with enthusiastic input from the MCS and BSTR Councils. The Sunrise Symposia will discuss the somewhat neglected but very important topic of exercise training in heart transplantation as well as endothelial dysfunction in advanced heart failure, MCS and heart transplantation. Finally, a Concurrent Symposium will address the vexing and controversial area of how to approach the sensitized patient awaiting heart transplantation.

INFECTIOUS DISEASES

At ISHLT 2014, join our experts to learn more about the fungus among us in our Pre-Meeting Symposium entitled **Invasive Fungal Infections Among Cardiothoracic Transplant Recipients: Consensus Guidelines and Recommendations From The ISHLT Fungal Expert Panel** as well as the conundrum of multi-drug resistant infections in **Bad Bugs? Optimize the Drugs!** For the coffee-fueled early birds, the meeting itself will feature two Sunrise Symposia on managing donors with high risk of infections (**High-Risk Donor: Extending Our Criteria in Times of Organ Shortage**) and the challenges of navigating modern molecular diagnostics and therapies for infectious complications of cardiothoracic transplant in the cleverly titled **What You Always Wanted To Know About LISH (Laboratory Tests, Infectious Agents, Special Situations, Hidden Infections) But Were Afraid To Ask**. There will continue to be a focus on the infectious complications of mechanical circulatory support with a multidisciplinary cast of characters including everyone from infectious diseases specialists to surgeons in the Concurrent Symposium, **Infections in Mechanical Circulatory Support Devices – Understanding and Conquering the Beast**. Other great infectious diseases highlights will include sessions on infections in pediatrics, lung transplantation, concurrent oral abstract sessions and the final plenary. Catch some infections (knowledge, that is) if you can!

LUNG FAILURE AND LUNG TRANSPLANTATION

At ISHLT 2014, there will be four Pre-Meeting Symposia and two Sunrise Symposia with primary content of interest for any lung transplant healthcare professional, and many of the other symposia taking place at the meeting, such as those addressing infectious disease, basic science, nursing, pharmacy, pediatrics and pulmonary hypertension, will have content of interest to the lung transplant professional. This year we will highlight two exciting areas in our field aimed at increasing the availability of organs for our patients: **DCD donors and EVLP**. The Pre-Meeting Symposium on DCD donors will explore their use across the globe, highlighting challenges and successes and hopefully help all of us learn more and utilize this resource the best possible way. The Pre-Meeting Symposium on EVLP will discuss its history and the ways it has been utilized in different regions (cold vs. warm transport) and where the future might take us. In addition, another Pre-Meeting Symposia will address controversial issues on **patient selection, including frailty, infections and transplant from extra corporeal life support** (a very exciting debate between two past presidents of the Society). Our last Pre-Meeting Symposium will address our perennial nemesis, **chronic lung allograft dysfunction** and its many faces. This session will bring pathologists in and discuss the clinical and pathological issues of restrictive vs. obstructive CLAD. All these sessions will take place on Thursday, April 10th. Our Sunrise Symposia will include a session on **CMV** and what is new from a basic science perspective to **restoration of T-cell immunity** to CMV resistance with talks from experts in the field. We will have a session with **popular debates on controversial issues**, like sizing organs to make them fit, using single vs. double lung transplant and transplant for scleroderma.

NURSING, HEALTH SCIENCE AND ALLIED HEALTH

ISHLT 2014 will showcase clinical care and research initiatives through a diverse program of informative sessions relevant to the nursing, health science and allied health community. **The ISHLT Academy: Core Competencies in Nursing, Health Science and Allied Health**, taking place on the Wednesday immediately prior to the start of the Annual Meeting on Thursday, will offer an invaluable educational resource in the fields of nursing and health sciences for transplant-related core competencies. The Pre-Meeting Symposia will highlight two symposia developed jointly with other Councils and titled, **Here They Come: Preparing Pediatric Patients for Transition to Adult Care** and **Frailty: How Do We Assess this Physiologic Variable and At What Point Does It Represent a Contraindication to Transplant?** Two Sunrise Symposia will draw together speakers and members from various disciplines as they examine **The Effects of Prostaglandin Therapy in PAH: The Seen and Unseen Risk/Benefit Profile** and **VAD Teams Working Across Different Countries: How To Do It**. To finish, a plenary session lecture will explore **The Invisible Team Member: Family Caregivers of Thoracic Transplant and Mechanical Circulatory Support Patients** to emphasize the importance of engaging and supporting these important team members. During these highlighted sessions, participants will gain key information concerning new assessment and interventional strategies to enhance clinical outcomes and quality of life for patients and their caregivers.

MECHANICAL CIRCULATORY SUPPORT

ISHLT 2014's scientific content will highlight some of mechanical circulatory support's most captivating topics. The speakers will tackle the **perioperative management of complex heart failure challenging postoperative VAD complications**. There are also early morning sessions on **building a VAD program** and **shared care** along with **how to run the pump** and **the effect on the aortic valve**. There are many MCS-focused symposia that have been devised with other ISHLT councils to improve multidisciplinary educational content. Topics includes a wonderful symposium developed with the BSTR and JFT Councils reviewing **the impact of mechanical circulatory support on myocardial cellular function**; a concurrent session developed with the ID Council on **device infections, biofilms and medical imaging**; a session developed with the NNSAH Council on **shared care and physician outreach**; a session developed with the PED and JFT Councils on **building a successful pediatric VAD to adult transition program**; and a phenomenal symposium developed with the PHARM Council discussing **diagnosis of VAD thrombosis and pharmacologic interventions** for the prevention and treatment of LVAD-associated thrombosis. The MCS-focused educational content offers input from the experts and the latest in MCS scientific investigation.

PEDIATRICS

For members interested in pediatric topics, ISHLT 2014 promises to be busy and enlightening. In a series of Thursday Pre-Meeting Symposia, you will hear experts discuss **Preparing pediatric patients for transition to adult care**, **The evolution, the biology and the limits of ABO incompatible heart transplantation**, **Developing a pediatric VAD program** and **State of the art update on infectious diseases in pediatric thoracic transplantation**. And if you have ever wondered **Why not infant lung transplantation?**, a Sunrise Symposium during the meeting is planned just for you.



PULMONARY HYPERTENSION

We are very pleased to present an outstanding program at ISHLT 2014 that covers a diverse range of innovations and controversial topics in Pulmonary Hypertension. There are four Pre-Meeting Symposia, three Sunrise Sessions and one Concurrent session that will highlight the latest clinical consensus statements, discuss the emerging sciences and pose questions to the experts and audiences for discussion and feedback. These sessions will be of keen interest to all members of ISHLT engaged in the care of patients with cardiopulmonary disease and right heart failure. To kick off the meeting, Pre-Meeting Symposium 2: **Pulmonary Hypertension... You Can't Ignore It any Longer** will tackle the controversial area of managing patients with lung disease and pulmonary hypertension, WHO Group III, focusing on patients with ILD, COPD and sarcoidosis. Next, what better place to focus on all the latest exciting developments in chronic thromboembolic pulmonary hypertension (CTEPH) than San Diego! Pre-Meeting Symposium 8: **CTEPH: Busting the Clot** features both medical and surgical aspects in managing CTEPH patients with presentations highlighting the emerging new treatment, riociguat, as well as a debate to consider exercise-induced PH as an indication for pulmonary thromboendarterectomy. Pre-Meeting Symposium 14: **Treating All Stages of Severe PH: Are We Doing it Right?** will discuss the emerging basic sciences focusing on mechanisms and management approaches for patients with severe PH and right heart failure, from pulmonary vasodilators to mechanical supports. We are also very excited to present to you the **ISHLT and World Symposium on PH (WSPH) Consensus Initiative on PH and Left Heart Disease** in Pre-Meeting Symposium 20, which will present discussions asking what are the important hemodynamic variables in those with advanced heart failure and PH? There are two excellent and novel Pharmacy Council sessions focusing on PH. Concurrent Symposium 6 will present the **Lifecycle Journey of a patient facing PAH**, focusing on clinical milestones and challenges that face these patients from diagnosis to advanced stages of disease. Sunrise Symposium 7: **The Effects of Prostaglandin Therapy in PAH: The Seen and Unseen Risk/Benefit Profile** explores all

the effects, both seen and unseen, in patients associated with parenteral prostanoid treatments. We are also very pleased to bring you a “How To” session, featuring oft asked questions regarding PA catheters in our Sunrise Symposium 12. You will get to engage in discussions regarding how to do volume loading, when to use vasodilator testing and how to utilize exercise RHC and what the results mean. Finally, don’t miss the Sunrise Symposium 2, **Under Too Much Pressure**, which will feature challenging cases with expert panelists to lead the discussions. The grand finale, during the Closing Plenary session, will feature a debate you don’t want to miss: **Stop Treating Secondary PH Right Now!** See which side you will vote for!

PATHOLOGY

Pathology will provide some very important content again at ISHLT 2014 in a number of symposia. **The Many Faces of Chronic Lung Allograft Dysfunction** will explore the clinical, radiologic and pathologic aspects of obstructive and restrictive allograft disorders that affect transplant recipients. **Approach to the Highly Sensitized Patient Awaiting Heart Transplantation** will examine diagnostic and therapeutic strategies for presensitized patients. The 2013 Working Formulation for Cardiac AMR will be discussed. The topic of mixed acute cellular rejection and antibody mediated rejection in cardiac transplant recipients will be addressed in **Outcomes and Considerations in the Management of Mixed Rejection**. The immunologic, histopathologic and clinical aspects of diagnosis and treatment will be addressed.

PHARMACY AND PHARMACOLOGY

The diverse nature of the Pharmacy and Pharmacology Council continues to allow integration of pharmacy professionals into several areas of Society interest. Pharmacy and Pharmacology professionals as well as the broad membership of the Society will benefit from the many learning opportunities provided by symposia constructed for ISHLT 2014. There will be three symposia, the first, developed with the PH Council, is the **annual lifecycle**


journey, this year focusing on pulmonary hypertension. Continuing the PH theme, second session, developed in conjunction with the NNSA Council, focuses on **The Effects of Prostaglandin Therapy in PAH: The Seen and Unseen Risk/Benefit Profile**. The third session, **Making Bloody Sense of Anticoagulation**, was developed in conjunction with the MCS Council and examines the challenges of anticoagulation and antiplatelet therapy in the MCS population. With our ID Council colleagues, we developed multiple shared sessions: **1) Bad Bugs, Optimize the Drugs** and **2) What You Always Wanted To Know About LISH (Laboratory Tests, Infectious Agents, Special Situations, Hidden Infections) But Were Afraid To Ask**. As well, the ISHLT fungal expert panel will be presenting the consensus guidelines on invasive fungal infections among cardiothoracic transplant recipients, a hot topic for all of our members. Other sessions that will be of interest to the diverse pharmacy and pharmacology professionals include the following: **1) Treating All Stages of Severe Pulmonary Hypertension: Are We Getting It Right?** **2) Infections in Mechanical Circulatory Support Devices – Understanding and Conquering the Beast**, and **3) CMV Infection in Lung Transplant Recipients: Are We Ready for Personalized Medicine?** For the pediatric practitioners the following symposia may be of interest: **1) Here They Come: Preparing Pediatric Patients For Transition To Adult Care**, **2) Crossing Clinical Barriers on the Wings of Science: Evolution of ABO Incompatible Heart Transplantation**, **3) Developing A Pediatric VAD Program**, and **4) State of the Art Update on Infectious Disease Issues in Pediatric Thoracic Transplantation**. And last, **Lab Methods 101: What Everyone Needs to Know to Read Basic Transplant Papers** looks to be a great primer for the interpretation of basic science literature and the symposia entitled **Approach to the Highly Sensitized Patient Awaiting Heart Transplantation** should provide some valuable information on strategies for management of this very difficult population.

JUNIOR FACULTY AND TRAINEES

The Junior Faculty Trainee Council (JFTC) submitted 14 proposals for symposia for ISHLT 2014, most of which were developed jointly with other councils. The JFTC is excited to have had 6 of these symposia selected for ISHLT 2014. Topics include a **review of endothelial dysfunction** and a discussion of the **changes that occur at the cellular level during VAD support**. In Pediatrics, there will be a symposium addressing that complicated **transition of pediatric patients to adult cardiology care**, and a **“challenging clinical case” symposium investigating pulmonary hypertension conundrums**. Finally, the popular **“Clinical Case Dilemmas”** session and the **“JHLT Year in Review”** summarizing the best research presented in the Journal with return to the 2014 meeting. These symposia in San Diego 2014 are not to be missed!








PRESIDENT'S COCKTAIL RECEPTION

The President's Cocktail Reception will be held Saturday evening, April 12, at the Manchester Grand Hyatt pool deck overlooking the bay.

One ticket to this event is included with all the scientific registration fees. Additional tickets may be purchased.

As always, you can expect plenty of food, drink, music and friends.


LOBBY LEVEL MANCHESTER GRAND HYATT



SECOND LEVEL MANCHESTER GRAND HYATT




FOURTH LEVEL




THIRD LEVEL



SECOND LEVEL



LOBBY LEVEL



ACRONYMS

To help you navigate your way through the meeting content and find those sessions most likely of interest to you, we have coded each session according to the primary professional audience it was designed for. These codes are explained as follows:

- | | | | |
|--------------------|---|--------------|---|
| ALL | All ISHLT Members | MCS | Adult Mechanical Circulatory Support |
| BSI or BSTR | Basic Science
Basic Science and Translational Research | NHSAH | Nursing, Allied Health, Social Science |
| DMD | Donor Management/ Organ Allocation | PATH | Pathology |
| HF | Adult Heart Failure | PEDS | Pediatrics |
| HTX | Adult Heart Transplantation | PEEQ | Public Policy, Economics, Ethics, Quality of Life |
| ID | Infectious Diseases | PHARM | Pharmacology |
| LF | Adult Lung Failure | PH | Pulmonary Hypertension |
| LTX | Adult Lung Transplantation | | |

SCHEDULE AT A GLANCE

All meetings and activities will take place at the Manchester Grand Hyatt Hotel in San Diego unless otherwise specified. All papers will be presented in English. Please check the ISHLT website (www.isHLT.org) for updates. This Final Program reflects the latest session schedule and room assignments.

WEDNESDAY, APRIL 9, 2014

6:00 AM – 8:00 PM
SPEAKER READY ROOM OPEN
(Balboa ABC)

8:15 AM – 4:00 PM
ISHLT BOARD OF DIRECTORS
MEETING (Gaslamp A-C)

2:00 PM – 4:00 PM
STANDARDS AND GUIDELINES
COMMITTEE MEETING
(Old Town AB)

4:00 PM – 6:00 PM
TRANSPLANT REGISTRY
STEERING COMMITTEE
MEETING (Gaslamp D)

4:00 PM – 6:00 PM
GRANTS AND AWARDS
COMMITTEE MEETING
(Old Town AB)

5:00 PM – 6:00 PM
NOMINATING COMMITTEE
MEETING (Gaslamp A-C)

5:00 PM – 8:00 PM
REGISTRATION DESK OPEN
(Palm Foyer)

THURSDAY, APRIL 10, 2014

7:00 AM – 6:00 PM
SPEAKER READY ROOM OPEN
(Balboa ABC)

7:00 AM – 6:00 PM
REGISTRATION DESK OPEN
(Palm Foyer)

7:00 AM – 8:00 AM
2015 SYMPOSIUM SELECTION
COMMITTEE MEETING
(Gaslamp AC)

8:00 AM – 6:00 PM
PRESS OFFICE OPEN
(Storage Office 7)

8:00 AM – 10:00 AM
PRE-MEETING SYMPOSIUM 1
Preventing VAD Complications
(Seaport)

(MCS, HF, HTX)

8:00 AM – 10:00 AM
PRE-MEETING SYMPOSIUM 2
*Group 3 Pulmonary Hyper-
tension... You Can't Ignore
It Any Longer* (Grand Hall A)

(PH, LF, LTX)

8:00 AM – 10:00 AM
PRE-MEETING SYMPOSIUM 3
*Ex-Vivo Donor Heart Support:
Expanding Availability and
Optimizing Function*
(Grand Hall B)

(DMD, HF, HTX, MCS)

SCHEDULE AT A GLANCE

8:00 AM – 10:00 AM

PRE-MEETING SYMPOSIUM 4

Lung Transplant Candidate Selection: Have We Pushed The Envelope Too Far?

(Grand Hall C)

(LF, LTX, ID)

10:15 AM – 12:15 PM

PRE-MEETING SYMPOSIUM 10

The Many Faces of Chronic Lung Allograft Dysfunction

(Grand Hall C)

(LF, LTX, PATH)

8:00 AM – 10:00 AM

PRE-MEETING SYMPOSIUM 5

Lung Transplantation: Decoding Early Engraftment Events That Control Survival

(Grand Hall D)

(LF, LTX, BSTR)

10:15 AM – 12:15 PM

PRE-MEETING SYMPOSIUM 11

Crossing Clinical Barriers on the Wings of Science: Evolution of ABO Incompatible Heart Transplantation

(Grand Hall D)

(BSTR, HF, HTX)

8:00 AM – 10:00 AM

PRE-MEETING SYMPOSIUM 6

Joint ISHLT/IPTA Symposium: Here They Come: Preparing Pediatric Patients for Transition To Adult Care

(Harbor GHI)

(PEDS, NHSAH, LF, LTX, HF, HTX)

10:15 AM – 12:15 PM

PRE-MEETING SYMPOSIUM 12

To VAD or to Transplant

(Harbor GHI)

(MCS, HF, HTX)

10:00 AM – 10:15 AM

COFFEE BREAK

(Palm and Grand Foyers)

12:00 PM – 12:45 PM

BOX LUNCH DISTRIBUTION

(Palm Foyer)

12:15 PM – 2:00 PM

LUNCH BREAK

10:00 AM – 7:15 PM

POSTERS OPEN

(Harbor and Seaport Foyers)

VIEW POSTERS

(Harbor and Seaport Foyers)

10:15 AM – 12:15 PM

PRE-MEETING SYMPOSIUM 7

Making Bloody Sense of Anticoagulation (Seaport)

(MCS, PHARM, HF, HTX)

12:30 PM – 1:45 PM

JUNIOR FACULTY MENTOR LUNCH

(Gaslamp A-C)

10:15 AM – 12:15 PM

PRE-MEETING SYMPOSIUM 8

Chronic Thromboembolic Pulmonary Hypertension: Busting the Clot

(Grand Hall A)

(PH, HF, HTX, LF, LTX)

12:30 PM – 1:45 PM

I2C2 COMMITTEE MEETING

(Gaslamp D)

12:30 PM – 1:45 PM

EDUCATION COMMITTEE MEETING

(La Jolla AB)

10:15 AM – 12:15 PM

PRE-MEETING SYMPOSIUM 9

Invasive Fungal Infections Among Cardiothoracic Transplant Recipients: Consensus Guidelines and Recommendations from the ISHLT Fungal Expert Panel

(Grand Hall B)

(ID, PHARM, HR, HTX, LF, LTX)

12:30 PM – 1:45 PM

VAD ID WORKFORCE MEETING

(Seaport H)

12:30 PM – 1:30 PM

PHARMACY AND PHARMACOLOGY COUNCIL MEETING

(Grand Hall C)

12:30 PM – 1:30 PM
**NURSING, HEALTH SCIENCE
AND ALLIED HEALTH COUNCIL
MEETING**

(Grand Hall D)

12:30 PM – 1:30 PM
**BASIC SCIENCE
TRANSLATIONAL RESEARCH
COUNCIL MEETING**

(Harbor GHI)

12:30 PM – 1:30 PM
DCD MINI-REGISTRY MEETING

(Old Town AB)

1:30 PM – 2:00 PM
**REGISTRIES AND DATABASES
COMMITTEE MEETING**

(Old Town AB)

1:30 PM – 2:00 PM
**REGISTRY ADVISORY
COMMITTEE MEETING**

(Old Town AB)

2:00 PM – 4:00 PM
PRE-MEETING SYMPOSIUM 13
*Drilling Down on Myocardial
Recovery – Basics and
Clinical* (Seaport)

(MCS, BSTR, HF, HTX)

2:00 PM – 4:00 PM
PRE-MEETING SYMPOSIUM 14
*Treating All Stages of Severe
Pulmonary Hypertension:
Are We Getting It Right?*

(Grand Hall A)

(PH, HF, HTX, LF, LTX)

2:00 PM – 4:00 PM
PRE-MEETING SYMPOSIUM 15
*Bad Bugs? Optimize the
Drugs!* (Grand Hall B)

(ID, LF, LTX, HF, HTX, PHARM)

2:00 PM – 4:00 PM
PRE-MEETING SYMPOSIUM 16
*Ex-Vivo Lung Perfusion
(EVLV): Evolving Strategy
For Improved Donor Lung
Management* (Grand Hall C)

(DMD, LF, LTX)

2:00 PM – 4:00 PM
PRE-MEETING SYMPOSIUM 17
*Frailty – How Do We Assess
This Physiologic Variable
And At What Point Does It
Represent A Contraindica-
tion To Transplant?*

(Grand Hall D)

(MCS, HF, HTX, LF, LTX, NHSAH)

2:00 PM – 4:00 PM
PRE-MEETING SYMPOSIUM 18
*Developing a Pediatric VAD
Program* (Harbor GHI)

(PEDS, MCS, HF, HTX)

4:00 PM – 4:15 PM
COFFEE BREAK (Palm Foyer)

VIEW POSTERS
(Harbor and Seaport Foyers)

4:15 PM – 6:15 PM
PRE-MEETING SYMPOSIUM 19
*The Times They Are
a-Changing* (Seaport)

(MCS, HF, HTX)

4:15 PM – 6:15 PM
PRE-MEETING SYMPOSIUM 20
*Pulmonary Hypertension in
Left Heart Disease (WHO
Group 2 PH): ISHLT and
World Symposium on
Pulmonary Hypertension
(WSPH) Consensus Initiative*

(Grand Hall A)

(PH, HF, HTX)

4:15 PM – 6:15 PM
PRE-MEETING SYMPOSIUM 21
*The Sexiest Controversies in
End-Stage Heart Failure and
Transplantation* (Grand Hall B)

(HF, HTX, MCS, PHARM, BSTR)

4:15 PM – 6:15 PM
PRE-MEETING SYMPOSIUM 22
*Global Perspectives on
Donation after Circulatory
Determination of Death in
Lung Transplantation*

(Grand Hall C)

(DMD, LF, LTX)

4:15 PM – 6:15 PM
PRE-MEETING SYMPOSIUM 23
*State-of-the-Art Update on
Infectious Disease Issues in
Pediatric Thoracic Transplan-
tation* (Grand Hall D)

(ID, PEDS, LF, LTX, PHARM)

SCHEDULE AT A GLANCE

4:15 PM – 6:15 PM
PRE-MEETING SYMPOSIUM 24
Lung Transplant Immunology 201-Plus: Recent Advances
(Harbor GHI)

(BSTR, LF, LTX)

in Advanced Heart Failure, Mechanical Circulatory Support, and Transplant: It's a Pipe and Pump Issue
(Grand Hall C)

(HF, HTX, MCS, BSTR)

6:15 PM – 7:15 PM
EXHIBIT HALL OPENING RECEPTION
(Harbor A-F)

7:00 AM – 8:00 AM
SUNRISE SYMPOSIUM 4
Controversies in Lung Transplantation (Grand Hall D)

(LF, LTX)

6:15 PM – 7:15 PM
MODERATED POSTER SESSION 1
(Harbor and Seaport Foyers)

(ALL)

7:00 AM – 8:00 AM
SUNRISE SYMPOSIUM 5
What You Always Wanted To Know About LISH (Laboratory Tests, Infectious Agents, Special Situations, Hidden Infections) But Were Afraid To Ask (Seaport H)

(ID, PHARM, LF, LTX, HF, HTX)

6:45 PM – 7:45 PM
CLAD GUIDELINES WORKFORCE MEETING
(Gaslamp D)

8:00 AM – 6:00 PM
PRESS OFFICE OPEN
(Storage Office 7)

7:15 PM – 8:30 PM
IMACS REGISTRY MEETING
(Gaslamp A-C)

8:00 AM – 10:00 AM
OPENING PLENARY SESSION
(Seaport)

(ALL)

FRIDAY, APRIL 11, 2014

7:00 AM – 6:30 PM
REGISTRATION DESK OPEN
(Palm Foyer)

SPEAKER READY ROOM OPEN
(Balboa ABC)

10:00 AM – 10:30 AM
COFFEE BREAK (Harbor A-F)

VISIT EXHIBITS (Harbor A-F)

VIEW POSTERS
(Harbor and Seaport Foyers)

7:00 AM – 8:00 AM
JHLT EDITORIAL BOARD BREAKFAST MEETING
(Gaslamp A-C)

10:00 AM – 4:00 PM
EXHIBIT HALL OPEN (Harbor A-F)

7:00 AM – 8:00 AM
SUNRISE SYMPOSIUM 1
Building for the Future
(Grand Hall A)

(MCS, HF, HTX)

10:00 AM – 6:30 PM
POSTERS OPEN
(Harbor and Seaport Foyers)

7:00 AM – 8:00 AM
SUNRISE SYMPOSIUM 2
Under Too Much Pressure: Challenging Cases in Pulmonary Hypertension Management (Grand Hall B)

(PH, HF, HTX, LF, LTX)

10:30 AM – 12:00 PM
CONCURRENT SESSION 1
How to Attack Mechanical Circulatory Support Complications (Seaport)

(MCS)

7:00 AM – 8:00 AM
SUNRISE SYMPOSIUM 3
Endothelial Dysfunction

10:30 AM – 12:00 PM
CONCURRENT SESSION 2
Mechanical Circulatory Support: Engineering and Biomechanics (Grand Hall A)

(MCS)

10:30 AM – 12:00 PM
CONCURRENT SESSION 3
The Tempest (Controlling the Immune System in Heart Transplantation) (Grand Hall B)
(HF, HTX, BSTR)

10:30 AM – 12:00 PM
CONCURRENT SESSION 4
Ex-Vivo Lung Perfusion: Where Are We Going?
(Grand Hall C)
(DMD, LTX, BSTR)

10:30 AM – 12:00 PM
CONCURRENT SESSION 5
Pediatric Mechanical Support (Grand Hall D)
(PEDS, MCS)

10:30 AM – 12:00 PM
CONCURRENT SYMPOSIUM 25
A Lifecycle Journey in Pulmonary Hypertension
(Harbor GHI)
(PHARM, HF, HTX, LF, LTX, PH)

10:30 AM – 12:00 PM
CONCURRENT SESSION 6
Circulating the Microbes: Infections for the Heart Transplant Clinician
(Seaport H)
(ID, HTX)

NOON – 2:00 PM
LUNCH BREAK
VIEW EXHIBITS (Harbor A-F)

VIEW POSTERS
(Harbor and Seaport Foyers)

NOON – 2:00 PM
COUNCIL, COMMITTEE AND BOARD ORIENTATION MEETING
(Gaslamp A-C)

NOON – 12:45 PM
BOX LUNCH DISTRIBUTION
(Palm Foyer)

12:05 PM – 1:00 PM
JUNIOR FACULTY AND TRAINEE COUNCIL MEETING
(Harbor GHI)

12:15 PM – 1:15 PM
PULMONARY COUNCIL QOL WORKFORCE MEETING
(Gaslamp D)

1:00 PM – 1:55 PM
AN AUTHOR WORKSHOP
(sponsor by Elsevier) (Harbor GHI)

2:00 PM – 3:30 PM
CONCURRENT SESSION 7
Mechanical Circulatory Support: Stop the Bleeding!
(Seaport)
(MCS, PHARM)

2:00 PM – 3:30 PM
CONCURRENT SESSION 8
Measure for Measure: Assessment of Cardiac Allograft and Immune Function (Grand Hall A)
(HTX, BSTR)

2:00 PM – 3:30 PM
CONCURRENT SESSION 9
Ex-Vivo Lung Perfusion Science on the Horizon
(Grand Hall B)
(LTX, BSTR, DMD)

2:00 PM – 3:30 PM
CONCURRENT SESSION 10
Lung Transplant Outcomes: Good, Better, Best: Let Us Never Rest (Grand Hall C)
(LTX, LF)

2:00 PM – 3:30 PM
CONCURRENT SESSION 11
Clinical Case Dilemmas in Thoracic Transplantation: The Best of the Best
(Grand Hall D)
(ALL)

2:00 PM – 3:30 PM
CONCURRENT SYMPOSIUM 26
Infections in Mechanical Circulatory Support Devices – Understanding and Conquering the Beast
(Harbor GHI)
(ID, MCS)

2:00 PM – 3:30 PM
CONCURRENT SESSION 12
Improving Outcomes: Interventions & Strategies
(Seaport H)
(NNSAH)

3:30 PM – 4:00 PM
COFFEE BREAK (Harbor A-F)

VIEW EXHIBITS (Harbor A-F)

VIEW POSTERS
(Harbor and Seaport Foyer) **71**

SCHEDULE AT A GLANCE

4:00 PM – 5:30 PM CONCURRENT SESSION 13

Optimizing Mechanical Circulatory Support Outcomes I (Seaport)

(MCS)

5:30 PM – 6:30 PM MINI ORAL SESSION 3

Choosing the Right Patient for Mechanical Assistance or Transplant (Grand Hall B)

(MCS, HTX, HF)

4:00 PM – 5:30 PM CONCURRENT SESSION 14

The Future of Mechanical Circulatory Support is Now (Grand Hall A)

(MCS)

5:30 PM – 6:30 PM MINI ORAL SESSION 4

Mechanical Circulatory Support Rapid Science Session (Grand Hall C)

(MCS, BSTR)

4:00 PM – 5:30 PM CONCURRENT SESSION 15

Adult Heart Failure: Novel Diagnostics (Grand Hall B)

(HF, BSTR)

5:30 PM – 6:30 PM MINI ORAL SESSION 5

Heart Transplant: Candidate Selection and Improving Outcomes (Grand Hall D)

(HTX)

4:00 PM – 5:30 PM CONCURRENT SESSION 16

Chronic Lung Allograft Dysfunction: Phenotypes and Risk Factors (Grand Hall C)

(LTX)

5:30 PM – 6:30 PM MINI ORAL SESSION 6

Lung Transplant Monitoring and Immunosuppression (Harbor GHI)

(LTX, PHARM)

4:00 PM – 5:30 PM CONCURRENT SESSION 17

Management of the Pediatric Heart Recipient (Grand Hall D)

(HTX, PEDS)

5:30 PM – 6:30 PM MODERATED POSTER SESSION 2

(Harbor and Seaport Foyers)

(ALL)

4:00 PM – 5:30 PM CONCURRENT SESSION 18

Quality of Life, Ethics, Policy and the Economics of MCS and Thoracic Transplantation (Harbor GHI)

(NNSAH, PEEQ)

6:30 PM – 8:00 PM COUNCIL AND COMMITTEE REPORTS TO THE BOARD OF DIRECTORS

(Gaslamp A-C)

4:00 PM – 5:30 PM CONCURRENT SYMPOSIUM 27

Heart Transplantation and Mechanical Circulatory Support in Latin America (Seaport H)

(HF, HTX, MCS)

SATURDAY, APRIL 12, 2014

7:00 AM – 6:30 PM REGISTRATION DESK OPEN

(Palm Foyer)

SPEAKER READY ROOM OPEN

(Balboa A-C)

5:30 PM – 6:30 PM MINI ORAL SESSION 1

Pushing the Boundaries in Lung Donation (Grand Hall A)

(LTX, DMD, BSTR)

7:00 AM – 8:00 AM SUNRISE SYMPOSIUM 6

The Aortic Valve – An Open and Shut Case? (Grand Hall A)

(MCS, HF, HTX)

5:30 PM – 6:30 PM MINI ORAL SESSION 2

Heart Failure and Pulmonary Hypertension: The Tale of Two Ventricles (Seaport H)

(HF, PH, HTX)

7:00 AM – 8:00 AM SUNRISE SYMPOSIUM 7

The Effects of Prostaglandin Therapy in Pulmonary

**Arterial Hypertension: The Seen and Unseen Risk/
Benefit Profile** (Grand Hall B)
(PH, PHARM, HF, LF, LTX, NNSAH)

7:00 AM – 8:00 AM
SUNRISE SYMPOSIUM 8
**Exercise Training in Heart
Transplantation** (Grand Hall C)
(HF, HTX)

7:00 AM – 8:00 AM
SUNRISE SYMPOSIUM 9
**CMV Infection in Lung
Transplant Recipients: Are
We Ready for Personalized
Medicine?** (Grand Hall D)
(ID, LTX, LF, PHARM)

7:00 AM – 8:00 AM
SUNRISE SYMPOSIUM 10
**Exploring Interactions
Between Cellular and
Humoral Immunity in
Cardiac Allograft Rejection**
(Seaport H)
(BSTR, PATH)

8:00 AM – 6:00 PM
PRESS OFFICE OPEN
(Storage Office 7)

8:00 AM – 10:00 AM
PLENARY SESSION
(Seaport)
(ALL)

10:00 AM – 10:30 AM
ANNUAL BUSINESS MEETING
(Seaport)

10:00 AM – 10:30 AM
COFFEE BREAK (Harbor A-F)

VIEW EXHIBITS (Harbor A-F)

VIEW POSTERS
(Harbor and Seaport Foyers)

10:00 AM – 4:00 PM
EXHIBITS OPEN (Harbor A-F)

10:00 AM – 6:30 PM
POSTERS OPEN
(Harbor and Seaport Foyers)

10:30 AM – 12:00 PM
CONCURRENT SESSION 19
**Mechanical Circulatory
Support: Optimizing
Outcomes II** (Seaport)
(MCS)

10:30 AM – 12:00 PM
CONCURRENT SESSION 20
**Mechanical Circulatory
Support: Getting Down to
the Science of VAD Support**
(Grand Hall A)
(MCS, BSTR)

10:30 AM – 12:00 PM
CONCURRENT SESSION 21
**Adult Heart Failure: Drugs
and Devices** (Grand Hall B)
(HF, PHARM, MCS)

10:30 AM – 12:00 PM
CONCURRENT SESSION 22
**Frailty, Body Composition
and Coronary Disease: Push-
ing the Limits of Recipient
Selection** (Grand Hall C)
(LTX, NNSAH)

10:30 AM – 12:00 PM
CONCURRENT SESSION 23
**A Fresh Look at Lung Allo-
graft Dysfunction – What the
Bench Is Telling Us** (Grand
Hall D)
(LTX, BSTR, PATH)

10:30 AM – 12:00 PM
CONCURRENT SESSION 24
**Much Ado About Nothing?
(New Approaches to Immune
Monitoring in Heart Trans-
plantation)** (Harbor GHI)
(HTX, BSTR, PATH)

10:30 AM – 12:00 PM
CONCURRENT SYMPOSIUM 28
**JHLT at ISHLT: The Year in a
Capsule** (Seaport H)
(ALL)

NOON – 2:00 PM
LUNCH BREAK

VIEW EXHIBITS (Harbor A-F)

VIEW POSTERS
(Harbor and Seaport Foyers)

NOON – 12:45 PM
BOX LUNCH DISTRIBUTION
(Palm Foyer)

12:05 PM – 12:55 PM
**MECHANICAL CIRCULATORY
SUPPORT SCIENTIFIC
COUNCIL MEETING**
(Grand Hall A)

SCHEDULE AT A GLANCE

12:05 PM – 12:55 PM PULMONARY HYPERTENSION COUNCIL MEETING

(Grand Hall B)

12:05 PM – 12:55 PM PEDIATRIC TRANSPLANTATION COUNCIL MEETING

(Grand Hall C)

12:05 PM – 12:55 PM INFECTIOUS DISEASES COUNCIL MEETING

(Grand Hall D)

12:05 PM – 12:55 PM PATHOLOGY COUNCIL MEETING

(Harbor GHI)

1:05 PM – 1:55 PM HEART FAILURE AND TRANSPLANT MEDICINE COUNCIL MEETING

(Grand Hall A)

1:05 PM – 1:55 PM PULMONARY TRANSPLANTA- TION COUNCIL MEETING

(Grand Hall B)

1:05 PM – 1:55 PM PEDIATRIC HEART FAILURE WORKFORCE MEETING

(Grand Hall C)

2:00 PM – 3:30 PM CONCURRENT SESSION 25 *Tackling Bad VAD Situations: Penalty or Score?*

(Grand Hall A)

(MCS, HF)

2:00 PM – 3:30 PM CONCURRENT SESSION 26 *How to Live Better with an LVAD*

(Grand Hall B)

(MCS, NSHAH, PEEQ)

2:00 PM – 3:30 PM CONCURRENT SESSION 27 *All's Well That Ends Well? What We Can Learn From Heart Transplant Registries*

(Grand Hall C)

(HTX)

2:00 PM – 3:30 PM CONCURRENT SESSION 28 *Diagnosis and Monitoring of Pulmonary Hypertension*

(Grand Hall D)

(PH, HF)

2:00 PM – 3:30 PM CONCURRENT SYMPOSIUM 29 *Approach to the Highly Sensitized Patient Awaiting Heart Transplantation*

(Harbor GHI)

(HF, HTX, PATH, PHARM)

2:00 PM – 3:30 PM CONCURRENT SESSION 29 *Lung Donation: Take It to the Limits*

(Seaport H)

(LTX, DMD)

2:00 PM – 3:30 PM CONCURRENT SESSION 30 *Philip K. Caves Candidate Presentation Session*

(Gaslamp AB)

(ALL)

2:00 PM – 3:30 PM CONCURRENT SYMPOSIUM 30 *Controversies in Listing Children for Thoracic Organ Transplant*

(Gaslamp CD)

(PED)

3:30 PM – 4:00 PM COFFEE BREAK

(Harbor A-F)

VISIT EXHIBITS (Harbor A-F)

VIEW POSTERS

(Harbor and Seaport Foyers)

4:00 PM – 5:30 PM CONCURRENT SESSION 31 *Building the Bridge to Transplant: Old Challenges, New Solutions*

(Grand Hall A)

(MCS, HTX, HF)

4:00 PM – 5:30 PM CONCURRENT SESSION 32 *Mechanical Circulatory Support: Is the Outcome Worth the Cost?*

(Grand Hall B)

(MCS, NSHAH, PEEQ)

4:00 PM – 5:30 PM CONCURRENT SESSION 33 *A Midsummer Night's Dream (Potential Improvements in Outcomes After Cardiac Transplantation)*

(Grand Hall C)

(HTX, HF)

4:00 PM – 5:30 PM
CONCURRENT SESSION 34
*Chronic Lung Allograft
Dysfunction: Mechanisms*
(Grand Hall D)

(LTX, BSTR)

4:00 PM – 5:30 PM
CONCURRENT SESSION 35
*Alternative Resources for
Organs* (Harbor GHI)

(HTX, DMD, BSTR)

4:00 PM – 5:30 PM
CONCURRENT SESSION 36
*Long-Term Outcomes
in Pediatric Heart
Transplantation* (Seaport H)

(PEDS, HTX, PEEQ)

4:00 PM – 5:30 PM
CONCURRENT SESSION 37
*Heart and Lung Transplant
Pathology* (Gaslamp AB)

(PATH, HTX, LTX)

4:00 PM – 5:30 PM
CONCURRENT SESSION 38
*Innovative Pharmacothera-
peutic Approaches to
Thoracic Transplant and
Mechanically Assisted
Patients* (Gaslamp CD)

(PHARM, HTX, LTX, MCS)

5:30 PM – 6:30 PM
MINI ORAL SESSION 7
Improving the Heart Donor
(Grand Hall A)

(DMD, HTX)

5:30 PM – 6:30 PM
MINI ORAL SESSION 8
*Immunology and the Child
in Heart Transplantation*
(Gaslamp AB)

(PEDS, HTX, PATH)

5:30 PM – 6:30 PM
MINI ORAL SESSION 9
*Quality of Life, Ethics, Policy
and Economics in MCS and
Thoracic Transplant*
(Gaslamp CD)

(PEEQ, NSHAH)

5:30 PM – 6:30 PM
MINI ORAL SESSION 10
*VADs Gone Bad, Complica-
tions after MCS* (Grand Hall B)

(MCS, HF)

5:30 PM – 6:30 PM
MINI ORAL SESSION 11
*Heart Transplant: Monitoring
and Immunosuppression*
(Grand Hall C)

(HTX, PHARM, HF)

5:30 PM – 6:30 PM
MINI ORAL SESSION 12
*Lung Transplant: Candidate
Selection and Genetic
Variation* (Seaport H)

(LTX, BSTR, HTX)

5:30 PM – 6:30 PM
MODERATED POSTER SESSION 3
(Harbor and Seaport Foyers)

(ALL)

7:00 PM – 9:30 PM
PRESIDENT'S GALA RECEPTION
(Pool Deck)

SUNDAY, APRIL 13, 2014

7:00 AM – NOON
REGISTRATION DESK OPEN
(Palm Foyer)

7:00 AM – 1:30 PM
SPEAKER READY ROOM OPEN
(Balboa ABC)

7:00 AM – 9:15 AM
**ISHLT BOARD OF
DIRECTORS MEETING**
(La Jolla AB)

7:00 AM – 8:00 AM
SUNRISE SYMPOSIUM 11
*VAD Teams Working Across
Different Countries: How
To Do It* (Harbor GHI)

(NSHAH, MCS)

7:00 AM – 8:00 AM
SUNRISE SYMPOSIUM 12
*Swan Songs and Controver-
sies in Hemodynamics*
(Seaport H)

(PH, HF, LF)

SCHEDULE AT A GLANCE

7:00 AM – 8:00 AM
SUNRISE SYMPOSIUM 13:
Lab Methods 101: What Everyone Needs to Know to Read Transplant Papers (Gaslamp AB)

(ALL)

8:00 AM – 9:15 AM
CONCURRENT SESSION 43
Breathing the Microbes: Infections for the Lung Transplant Clinician (Old Town AB)

(LTX, ID, BSTR)

7:00 AM – 8:00 AM
SUNRISE SYMPOSIUM 14
Why Not Infant Lung Transplantation? (Gaslamp CD)

(PEDS, LF, LTX)

9:15 AM – 9:30 AM
COFFEE BREAK (Palm Foyer)

9:30 AM – 11:45 AM
PLENARY SESSION
(Harbor GHI)

(ALL)

7:00 AM – 8:00 AM
SUNRISE SYMPOSIUM 15
High-Risk Donor: Extending Our Criteria in Times of Organ Shortage (Old Town AB)

(DMD, ID, LF, LTX, HF, HTX)

11:45 AM – NOON
COFFEE BREAK (Palm Foyer)

12:00 PM – 1:15 PM
CONCURRENT SESSION 44
Innovations in Mechanical Circulatory Support Care (Harbor GHI)

(MCS, HF)

8:00 AM – 9:15 AM
CONCURRENT SESSION 39
Mechanical Circulatory Support: Bench to Bedside (Harbor GHI)

(MCS, BSTR)

12:00 PM – 1:15 PM
CONCURRENT SESSION 45
Adult Heart Failure: Look After Your Liver (Seaport H)

(HF, HTX)

8:00 AM – 9:15 AM
CONCURRENT SESSION 40
As You Like It – Optimization of Heart Transplant Immunosuppression (Seaport H)

(HTX, PHARM, HF)

12:00 PM – 1:15 PM
CONCURRENT SESSION 46
Antibody Mediated Rejection 2014: HLA and Beyond (Gaslamp AB)

(PATH, LTX)

8:00 AM – 9:15 AM
CONCURRENT SESSION 41
Left Heart Failure, the RV and Other Types of Pulmonary Hypertension (Gaslamp AB)

(PH, HF, PHARM)

12:00 PM – 1:15 PM
CONCURRENT SESSION 47
What Becomes of the Marginal Hearted (Gaslamp CD)

(DMD, HTX)

8:00 AM – 9:15 AM
CONCURRENT SESSION 42
Risk Assessment in the Pediatric Heart Candidate (Gaslamp CD)

(PEDS, HTX, PATH)

12:00 PM – 1:15 PM
CONCURRENT SESSION 48
Novel Approaches to Keep the Heart Going (Old Town AB)

(HTX, BSTR)

20 YEARS TOGETHER IN TRANSPLANTATION

My, how time flies. Astellas is entering its 20th year focusing on transplant immunology. Today we remain steadfast in our commitment to advancing the field. Tomorrow we will seek new possibilities for improving the transplant experience. Together, we celebrate the remarkable evolution in transplant history.



*The INTERNATIONAL SOCIETY
FOR HEART AND LUNG
TRANSPLANTATION is most
grateful for the support of the
following companies for the
Society and its endeavors:*

TIER 1

*Actelion
Gilead Sciences
Thoratec*

TIER 2

*Astellas
Bayer
Heartware
Maquet
United Therapeutics*

TIER 3

*ImaCor
XDx*

INTERNATIONAL SOCIETY FOR HEART AND LUNG TRANSPLANTATION

**34th ANNUAL MEETING
and SCIENTIFIC SESSIONS
April 10 – 13, 2014**

**SCIENTIFIC
PROGRAM**

All meetings and activities will take place at the Manchester Grand Hyatt Hotel in San Diego unless otherwise specified. All papers will be presented in English. Please check the ISHLT website (www.isHLT.org) for updates. This Final Program reflects the latest session schedule and room assignments.



SCIENTIFIC PROGRAM

WEDNESDAY, APRIL 9, 2014

6:00 AM – 8:00 PM

SPEAKER READY ROOM OPEN (Balboa ABC)

8:15 AM – 4:00 PM

ISHLT BOARD OF DIRECTORS MEETING (Gaslamp A-C)

2:00 PM – 4:00 PM

STANDARDS AND GUIDELINES COMMITTEE MEETING
(Old Town AB)

4:00 PM – 6:00 PM

TRANSPLANT REGISTRY STEERING COMMITTEE MEETING
(Gaslamp D)

4:00 PM – 6:00 PM

GRANTS AND AWARDS COMMITTEE MEETING (Old Town AB)

5:00 PM – 6:00 PM

NOMINATING COMMITTEE MEETING (Gaslamp A-C)

5:00 PM – 8:00 PM

REGISTRATION DESK OPEN (Palm Foyer)

THURSDAY, APRIL 10, 2014

7:00 AM – 6:00 PM

SPEAKER READY ROOM OPEN (Balboa A-C)

7:00 AM – 6:00 PM

REGISTRATION DESK OPEN (Palm Foyer)

7:00 AM – 8:00 AM

2015 SYMPOSIUM SELECTION COMMITTEE MEETING
(Gaslamp A-C)

8:00 AM – 6:00 PM

PRESS OFFICE OPEN (Show Office 7)

8:00 AM – 10:00 AM

PRE-MEETING SYMPOSIUM 1

Preventing VAD Complications (Seaport)**CHAIRS:** Emma Jane Birks, MBBS, PhD, BSc, FRCP and
Martin Strueber, MD**(MCS, HF, HTX)****SESSION SUMMARY:** Despite the unequivocal benefits of continuous flow devices over preexisting pulsatile technologies, certain clinical scenarios and new complications continue to challenge heart failure clinicians. These vexing problems include pump thrombosis, late onset right heart failure and de novo aortic insufficiency. In addition, the success of surgical repair of congenital cardiac disorders has resulted in a growing population of young adults with failing ventricles and complex anatomies in need of mechanical support as a bridge to transplantation. Lastly, the entity of acute cardiogenic shock in the setting of anterior wall MI continues to challenge clinicians who have a wide armamentarium of options (PCI, CABG, short term support, long term support and even TAH) but no clear algorithm as to how to best approach these difficult cases. Clearly, these guideline-lacking topics represent ideal scenarios for singular and detailed case presentations with stop points during the medical and surgical management that can be used to generate “what do you do next” questions for a panel of experts and for the audience.

- 8:00 AM** *Pump Thrombosis: Diagnosis, Management and Prevention*
Jennifer Cowger, MD, St. Vincent Heart Center,
Indianapolis, IN, USA
- 8:15 AM** *Q & A*
- 8:20 AM** *Mechanical Support in Complex Congenital Disease*
Daniel Zimpfer, MD, Medical University of Vienna, Vienna, Austria
- 8:35 AM** *Q & A*
- 8:40 AM** *Late Onset Right Heart Failure... Now What?*
Edwin C. McGee, MD, Northwestern University, Chicago, IL, USA
- 8:55 AM** *Q & A*
- 9:00 AM** *De Novo Aortic Insufficiency: What Are The Options*
Carmelo A. Milano, MD, Duke University Medical Center,
Durham, NC, USA
- 9:15 AM** *Q & A*
- 9:20 AM** *Anterior Wall MI and Cardiogenic Shock: Stent, Bypass, Support or Replace?*
Michel Morshuis, MD, Heart Center NRW, Bad
Oeynhausen, Germany
- 9:35 AM** *Q & A*
- 9:40 AM** *Case Presentation on de Novo Aortic Insufficiency*
Andrew J. Lenneman, MD, University of Louisville,
Louisville, KY, USA
- 9:45 AM** *Q & A*
- 9:50 AM** *Case Presentation on Anterior Wall MI and Cardiogenic Shock: Stent, Bypass, Support or Replace?*
Jose N. Nativi-Nicolau, MD, University of Utah,
Salt Lake City, UT, USA
- 9:55 AM** *Q & A*

8:00 AM – 10:00 AM

PRE-MEETING SYMPOSIUM 2

Group 3 Pulmonary Hypertension... You Can't Ignore It Any Longer (Grand Hall A)

CHAIRS: Oksana A. Shlobin, MD and Raymond L. Benza, MD

(PH, LF, LTX)

SESSION SUMMARY: Pulmonary hypertension (PH) is a common and important comorbid condition among patients with parenchymal lung disease (WHO group III PH) that worsens survival, so the idea of treating these patients with PH specific therapies has always been attractive to pulmonologists and PH treating cardiologists. However randomized, controlled clinical trials have so far failed to demonstrate efficacy of PH specific therapies in these patients, and these drugs can sometimes worsen ventilation-perfusion mismatching and oxygenation. At ISHLT 2013 in Montreal, data was presented that showed improvements in hemodynamics, right heart function, and functional capacity without worsening oxygenation among patients with pulmonary fibrosis and an advanced PH phenotype who were treated with parenteral treprostinil. Recently in the literature, different phenotypes of heart-lung interactions have been described that could identify patients with more severe PH and RV failure who may benefit from PH specific therapies. Just as it may be important to identify and distinguish phenotypic differences in patients with WHO group III PH, it is also important for clinicians to understand the multiple mechanisms by which patients with scleroderma and sarcoidosis can develop PH that are important to identify and distinguish in order to appropriately guide therapy. This session on PH in lung disease aims to discuss the different phenotypes of heart-lung interactions among patients with parenchymal lung disease, the multiple potential causes of PH in patients with scleroderma and sarcoidosis, and to discuss PH specific therapy in WHO group III PH by way of a pro/con debate. This is a topic of great interest to not only PH specialists, but also transplant pulmonologists, pharmacists, and nursing/allied health members.

- 8:00 AM** *Predictors and Pitfalls of Diagnosing Pulmonary Vascular Disease in Group 3 PH and Role of Exercise Hemodynamics*
Rajan Saggar, MD, UCLA, Los Angeles, CA, USA
- 8:20 AM** Q & A
- 8:25 AM** *How to Define PH Due to COPD and ILD? A Discussion of Different Clinical Phenotypes of WHO Group 3 PH*
Lars C. Huber, MD, University Hospital, Zurich, Switzerland
- 8:45 AM** Q & A
- 8:50 AM** *Sarcoidosis: Understanding Pulmonary Hypertension in Diseases with Multifactorial Causes That Influence Treatment Strategies*
Ioana R. Preston, MD, Tufts Medical Center, Boston, MA, USA
- 9:10 AM** Q & A
- 9:15 AM** *PH in Scleroderma ILD or Scleroderma PAH with ILD: What is the Limiting Factor?*
Steven D. Nathan, MD, Inova Fairfax Hospital, Falls Church, VA, USA
- 9:35 AM** Q & A
- 9:40 AM** *Panel Discussion*

8:00 AM – 10:00 AM

PRE-MEETING SYMPOSIUM 3

Ex-Vivo Donor Heart Support: Expanding Availability and Optimising Function (Grand Hall B)**CHAIRS:** Bartley P. Griffith, MD and Stephan Schueler, MD, PhD, FRCS

(DMD, HF, HTX, MCS)

SESSION SUMMARY: Ex-Vivo organ support devices for donor hearts allow a significant reduction of cold ischaemia and therefore permit an extension of the standard geographical procurement distance. Additionally, they allow for both reconditioning of some marginal organs and also provide an evaluation platform for rejecting donor organs with occult disease, thereby limiting any post-implant morbidity in the recipient. This symposium will provide a timely overview of our current understanding and practice of using these devices. Topics to be discussed include the following: – Establishing a new ex-vivo organ support service – Strategies for evaluating organ function – Potential for pre-transplant and ex-vivo treatment of donor hearts – Reconditioning of extended-criteria organs – Role in facilitating the use of hearts from NHBD for clinical transplantation – Economic evidence supporting Ex-Vivo donor organ management. This symposium will provide a much needed educational update, to multi-disciplinary participants, on a topic in organ transplantation that is evolving very rapidly and will provide the necessary baseline appreciation and acceptance of this technology.

- 8:00 AM** *Establishing an Ex-Vivo Donor Heart Support Service*
Martin Strueber, MD, University Heart Centre, Leipzig, Germany
- 8:15 AM** Q & A
- 8:20 AM** *Update on the International, Randomised PROCEED II Trial Comparing Standard Cold Preservation Against Physiological Perfusion with the TransMedics Cardiac OCS*
Abbas Ardehali, MD, UCLA School of Medicine, Los Angeles, CA, USA
- 8:35 AM** Q & A
- 8:40 AM** *Reconditioning of Extended-Criteria Donor Hearts*
Andre Simon, MD, Harefield Hospital, London, United Kingdom
- 8:55 AM** Q & A
- 9:00 AM** *Functional Evaluation and Pre-Transplant Ex-Vivo Treatment Options*
Darren Freed, MD PhD FRCS, Mazankowski Heart Institute, Edmonton, AB, Canada
- 9:15 AM** Q & A
- 9:20 AM** *Facilitating Cardiac Transplantation From Non Heart-Beating Donors*
Kumud Dhital, MD, St. Vincent's Hospital, Sydney, Australia
- 9:35 AM** Q & A
- 9:40 AM** *The Economic Evidence*
Edward Zavala, MBA, Vanderbilt University Medical Center, Nashville, TN, USA
- 9:55 AM** Q & A

8:00 AM – 10:00 AM

PRE-MEETING SYMPOSIUM 4

Lung Transplant Candidate Selection: Have We Pushed The Envelope Too Far? (Grand Hall C)

CHAIRS: Cynthia J. Gries, MD, MSc and Peter M. Hopkins, FRACP

(LF, LTX, ID)

SESSION SUMMARY: Existing selection criteria aim to discriminate those expected to thrive from those anticipated to do poorly following lung transplantation. The last 5 years has witnessed an explosion in lung transplantation for older and sicker candidates who fall outside of selection guidelines. Since these criteria were developed through consensus expert opinion and established, epidemiological studies have confirmed increased mortality for certain criteria including age above 55, extremes of weight, and, possibly, frailty. The common thread underpinning these observations is body composition derived inflammation. This symposium aims to reevaluate key selection criteria through the lens of body composition and inflammation. It will also explore intervention strategies that may be applicable to all lung transplant candidates.

- 8:00 AM** *Debate: PRO: ECMO Should Be An Absolute Contraindication To Lung Transplantation*
Vivek N. Ahya, MD, Hospital of the University of Pennsylvania, Philadelphia, PA, USA
- 8:10 AM** *Debate: CON: ECMO Should Be An Absolute Contraindication To Lung Transplantation*
Allan R. Glanville, MBBS, MD, FRACP, St. Vincent's Hospital, Sydney, NSW, Australia
- 8:20 AM** *Debate PRO Rebuttal*
Vivek N. Ahya, MD, Hospital of the University of Pennsylvania, Philadelphia, PA, USA
- 8:25 AM** *Debate CON Rebuttal*
Allan R. Glanville, MBBS, MD, FRACP, St. Vincent's Hospital, Sydney, Australia
- 8:30 AM** *Body Composition in Lung Transplantation: Older Age, Frailty, and BMI*
David J. Lederer, MD, MS, Columbia University, New York, NY, USA
- 8:50 AM** *The Candidate with a Viral Infection: Don't Go There!*
Paolo A. Grossi, MD, PhD, University of Insubria, Varese, Italy
- 9:10 AM** *The Candidate with a Non-Viral Infection: Don't Go There!*
Fernanda Silveira, MD, University of Pittsburgh Medical Center, Pittsburgh, PA, USA
- 9:30 AM** *If You Are Going To Do It Again, Do It Right!*
Clemens Aigner, MD, Medical University of Vienna, Vienna, Austria
- 9:50 AM** *Panel Discussion*

8:00 AM – 10:00 AM

PRE-MEETING SYMPOSIUM 5

Lung Transplantation: Decoding Early Engraftment Events That Control Survival (Grand Hall D)**CHAIRS:** Andrew J. Fisher, FRCP, PhD and Howard J. Huang, MD
(LF, LTX, BSTR)**SESSION SUMMARY:** It is becoming clear that many significant risk factors for lung transplant rejection occur within the early engraftment period. Also, it is apparent that the current immunosuppression strategies have not significantly improved patient survival in the last decade. Recent developments in experimental lung transplantation have helped uncover novel mechanisms that link innate and acquired immunity following engraftment. In this symposium we propose to present new insights into ischemia reperfusion injury, T cell activation, and humoral immunity that impact the maintenance of allograft tolerance as well as long-term survival, using a clinical case to guide the presentations. The goal of these presentations is to educate the wider transplant community of potential new therapeutic targets and translational opportunities for the development of novel immunosuppression approaches for lung transplant recipients.**8:00 AM Case Presentation: A Patient Develops PGD**

Ramsey Hachem, MD, Washington University School of Medicine, St. Louis, MO, USA

8:05 AM The Role of Necrotic Cell Injury in Th17 Immune Responses Against Lung Transplants

Andrew E. Gelman, PhD, Washington University School of Medicine, St. Louis, MO, USA

8:20 AM Q & A**8:25 AM Case Update: Graft Dysfunction and Autoantibodies Develop**

Ramsey Hachem, MD, Washington University School of Medicine, St. Louis, MO, USA

8:28 AM Immune Mechanisms Leading to Autoimmunity Following Organ Transplantation

David S. Wilkes, MD, Indiana University School of Medicine, Indianapolis, IN, USA

8:43 AM Q & A**8:48 AM Case Update: Chronic Lung Allograft Dysfunction Develops**

Ramsey Hachem, MD, Washington University School of Medicine, St. Louis, MO, USA

8:51 AM IL17 - A Big Player in Chronic Lung Allograft Dysfunction?

Bart M. Vanaudenaerde, PhD, KU Leuven, Leuven, Belgium

9:06 AM Q & A**9:11 AM The Impact of Early Humoral Responses on Long-Term Survival of Lung Grafts**

Thalachallour Mohanakumar, PhD, Washington University School of Medicine, St. Louis, MO, USA

9:31 AM Q & A**9:36 AM Case Update: Autoantibodies are Identified**

Ramsey Hachem, MD, Washington University School of Medicine, St. Louis, MO, USA

9:39 AM Therapeutic Strategies for Blocking IL17 and IL6 Responses

Tereza Martinu, MD, Duke University, Durham, NC, USA

9:54 AM Q & A

SCIENTIFIC PROGRAM

8:00 AM – 10:00 AM

PRE-MEETING SYMPOSIUM 6

Joint ISHLT/IPTA Symposium: Here They Come: Preparing Pediatric Patients for Transition To Adult Care (Harbor GHI)

CHAIRS: Kathleen L. Grady, PhD, APN, FAAN and Elfriede Pahl, MD

(PEDS, NHSAA, LF, LTX, HF, HTX)

SESSION SUMMARY: Transition is defined as “the process by which adolescents and young adults with chronic childhood illnesses are prepared to take charge of their lives and their health in adulthood.” Effective transition programs have the potential to decrease morbidity and mortality associated with transfer of care and can improve quality of life. This session will discuss issues essential to successful transition of pediatric patients to adult care, including patient and family challenges, as well as potential strategies/interventions to meet these challenges.

8:00 AM *Ready or Not? Assessment of Transition Readiness*

Karen Uzark, PhD, CPNP, University of Michigan,
Ann Arbor, MI, USA

8:15 AM *Developmental /Psychosocial Challenges to Transition*

Diana A. Shellmer, PhD, Children's Hospital, Pittsburgh, PA, USA

8:30 AM *Family Factors that Impact Transition*

Leigh C. Reardon, MD, University of California at Los Angeles,
Los Angeles, CA, USA

8:45 AM *Strategies for Transition Preparation in Adolescent Transplant Recipients*

Samantha Anthony, PhD, MSW, RSW, The Hospital for
Sick Children, Toronto, ON, Canada

9:00 AM *Outcomes in Pediatric Thoracic Transplant Recipients Transitioned to Adult Care*

Christian Benden, MD, University Hospital Zurich,
Zurich, Switzerland

9:15 AM *Case Presentation*

Eugene C. DePasquale, MD, University of California at
Los Angeles, Los Angeles, CA, USA

9:20 AM *Panel Discussion*

9:30 AM *Case Presentation*

Kathleen L. Grady, PhD, APN, FAAN, Northwestern
University, Chicago, IL, USA

9:35 AM *Panel Discussion*

9:45 AM *Final Panel Discussion*

10:00 AM – 10:15 AM

COFFEE BREAK (Palm and Grand Foyers)

VIEW POSTERS (Harbor and Seaport Foyers)

10:00 AM – 7:15 PM

POSTERS OPEN (Harbor and Seaport Foyer)

10:15 AM – 12:15 PM

PRE-MEETING SYMPOSIUM 7

Making Bloody Sense of Anticoagulation (Seaport)**CHAIRS:** Haifa Lyster, BPharm(Hons), MSc and Jeffrey J. Teuteberg, MD**(MCS, PHARM, HF, HTX)**

SESSION SUMMARY: Anticoagulation is common in most practice areas represented by the ISHLT membership. Although most clinicians use anticoagulation therapies, questions often arise around how these medications compare with others within this class, interpretation of labs testing, and the function of new and future medications. The goals of this symposium are to discuss: 1) Where anticoagulation therapy has been, 2) The status of anticoagulation in 2014 and 3) Appropriate interpretation and application of anticoagulation monitoring; and then use this information in discussion of MCS recipients and their thrombotic and bleeding risk after implantation where multiple different regimens, goals and management strategies that employed across centers and between devices.

10:15 AM Anticoagulants and Antiplatelets: A Brief Primer!

Rochelle M. Gellatly, PharmD, Alfred Hospital, Melbourne, Australia

10:35 AM Early Post-op Anticoagulation: Is It Needed and What to Use?

Mark S. Slaughter, MD, University of Louisville, Louisville, KY, USA

10:50 AM Warfarin for VADs – What Goals, At Risk Patients, Warfarin Alternatives?

David S. Feldman, MD, PhD, Minneapolis Heart Institute, Minneapolis, MN, USA

11:05 AM Antiplatelet Therapy – Types, Doses, Platelet Functional Assays/Targets

Robert L. Page, PharmD, MSPH, University of Colorado, Denver, CO, USA

11:20 AM Bad VADs - Anticoagulation Failures

Anna L. Meyer, MD, Leipzig Heart Center, Leipzig, Germany

11:35 AM Case Presentation (Bleeding)

Gautam Ramani, MD, University of Maryland, Baltimore, MD, USA

11:40 AM Panel Discussion**11:55 AM Case Presentation (Thrombosis)**

Lazaros A. Nikolaidis, MD, Temple University Hospital, Philadelphia, PA, USA

12:00 PM Panel Discussion

10:15 AM – 12:15 PM

PRE-MEETING SYMPOSIUM 8

Chronic Thromboembolic Pulmonary Hypertension: Busting the Clot (Grand Hall A)

CHAIRS: Nick H. Kim, MD, Michael M. Madani, MD and
Steven Kawut, MD, MS

(PH, HF, HTX, LF, LTX)

SESSION SUMMARY: Chronic thromboembolic disease is an area that overlaps the pulmonary hypertension, lung transplant, and mechanical support councils. The symposium will cover the diagnostics and therapeutics of the disease while discussing novel therapeutics and use of mechanical support pre and post-operatively.

- 10:15 AM** *Medical Approaches in Non-Surgical CTEPH Candidate*
Victor Tapson, MD, Duke University, Durham, NC, USA
- 10:30 AM** *Q & A*
- 10:35 AM** *Is Right Ventricular Dysfunction a Limiting Factor in the Indication for Pulmonary Endarterectomy?*
Marc De Perrot, MD, University of Toronto, Toronto, ON, Canada
- 10:50 AM** *Q & A*
- 10:55 AM** *How to Approach Patients With Residual PH After Pulmonary Endarterectomy?*
David Jenkins, FRCS, Papworth Hospital, Cambridge, United Kingdom
- 11:10 AM** *Q & A*
- 11:15 AM** *Debate PRO: Exercise Induced PH is the Best Indication for Pulmonary Endarterectomy in Patients with Chronic Thromboembolic Disease*
William Auger, MD, University of California San Diego Medical Center, La Jolla, CA, USA
- 11:30 AM** *Debate CON: Exercise Induced PH is the Best Indication for Pulmonary Endarterectomy in Patients with Chronic Thromboembolic Disease*
Elie Fadel, MD, Hospital Marie Lannelongue, Le Plessis Robinson, France
- 11:45 AM** *Debate PRO Rebuttal*
William Auger, MD, University of California San Diego Medical Center, La Jolla, CA, USA
- 11:50 AM** *Debate CON Rebuttal*
Elie Fadel, MD, Hospital Marie Lannelongue, Le Plessis Robinson, France
- 11:55 AM** *Panel Discussion*

10:15 AM – 12:15 PM

PRE-MEETING SYMPOSIUM 9

Invasive Fungal Infections Among Cardiothoracic Transplant Recipients: Consensus Guidelines and Recommendations from the ISHLT Fungal Expert Panel (Grand Hall B)

CHAIRS: Shahid Husain, MD, MS, Orla Morrissey, MD and Amparo Solé, MD, PhD

(ID, PHARM, HR, HTX, LF, LTX)

SESSION SUMMARY: A consensus and guidelines for invasive fungal infection developed by the ISHLT fungal expert panel will present a review of the literature and recommendations regarding the epidemiology, diagnostics, therapeutics and prophylaxis of fungal infections among cardiothoracic transplant recipients.

10:15 AM *Epidemiology and Risk Factors for Fungal Infections Among Cardiothoracic Transplant Recipients*

Denis Hadjiliadis, MD, MHS, University of Pennsylvania, Philadelphia, PA, USA

10:35 AM *Diagnosis of Fungal Infection Among Lung and Heart Transplant Recipients: An Update on Galactomannan, PCR and Beta-D-Glucan*

Me-Linh Luong, MD, University of Montreal St-Luc Hospital, Montreal, QC, Canada

10:55 AM *Antifungal Prophylaxis: What and When?*

Daniel C. Chambers, MBBS MRCP FRACP MD, The Prince Charles Hospital, Brisbane, Australia

11:15 AM *Treatment of Invasive Fungal Infections: State of the Art*

Aric L. Gregson, MD, David Geffen School of Medicine at UCLA, Los Angeles, CA, USA

11:35 AM *Therapeutic Drug Monitoring: A Consensus*

Eliane M Billaud, PhD, PharmD, Hospital Georges Pompidou, Paris, France

11:55 AM *Case Presentation*

Jose M. Cifrian, MD, Hospital University Marques Valdecilla, Santander, Spain

12:00 PM *Panel Discussion*

10:15 AM – 12:15 PM

PRE-MEETING SYMPOSIUM 10

The Many Faces of Chronic Lung Allograft Dysfunction (Grand Hall C)

CHAIRS: Masaaki Sato, MD and Geert Verleden, MD, PhD

(LFLT.X, PATH)

SESSION SUMMARY: Lung allograft dysfunction occurs in many different ways; these present and progress in differing fashions; treatment, although not well developed, could be different between different types; this session will address these issues.

- 10:15 AM** *Restrictive CLAD: Diagnostic Criteria*
Jamie L. Todd, MD, Duke University, Durham, NC, USA
- 10:30 AM** *Restrictive CLAD: Radiology and Clinical Features*
Miranda Paraskeva, MBBS, Alfred Hospital, Melbourne, Australia
- 10:45 AM** *Pathologic Findings in Restrictive CLAD/RAS*
David Hwang, MD, PhD, FRCPC, University Health Network, Toronto, ON, Canada
- 11:00 AM** *Panel Discussion*
- 11:15 AM** *Obstructive CLAD: Diagnostic Criteria*
Sangeeta Borade, MD, Northwestern Memorial Hospital, Chicago, IL, USA
- 11:30 AM** *Obstructive CLAD: Radiology and Clinical Features*
Robin Vos, MD, PhD, University Hospital Gasthuisberg, Leuven, Belgium
- 11:45 AM** *The Pathology of Obstructive CLAD*
Charles C. Marboe, MD, Columbia University, New York, NY, USA
- 12:00 PM** *Panel Discussion*

10:15 AM – 12:15 PM

PRE-MEETING SYMPOSIUM 1 I

Crossing Clinical Barriers on the Wings of Science: Evolution of ABO Incompatible Heart Transplantation (Grand Hall D)

CHAIRS: Kimberly Gandy, MD, PhD and Simon Urschel, MD

(BSTR, HF, HTX)

SESSION SUMMARY: This symposium has multiple purposes. It is intended to show how scientific concepts are developed for clinical application. It will show the history of ABO incompatible heart transplantation, but from the point of view of the designer of therapy. In so doing, it will delineate some of the technical details in the path of a very significant advance in transplantation from idea to clinical reality. In so doing, we hope that this session will be both informative, and inspirational. We intend for this session to stimulate the thought processes necessary to take other burgeoning ideas from bench to bedside by giving a better understanding of the processes involved in translating science to our patients.

10:15 AM *Neonatal Tolerance: The Biological and Historical Background of Exploiting the Immature Immune System for Transplantation*

Leslie L. Brent, Ph.D., Formerly St. Mary's Hospital Medical School, retired, London, United Kingdom

10:40 AM *The Saga of the First Planned ABO Incompatible Heart Transplant*

Lori J. West, MD, DPhil, University of Alberta, Edmonton, AB, Canada

11:00 AM Q & A

11:05 AM *"I Wish We Knew This Back Then:" New Insights and Technologies in ABO Immunobiology*

Mylvaganam Jeyakanthan, MD, University of Alberta, Edmonton, AB, Canada

11:20 AM Q & A

11:25 AM *Outcomes and Limits of ABO Incompatible Heart Transplantation*

Richard Kirk, MA FRCP FRCPC, Freeman Hospital, Newcastle upon Tyne, United Kingdom

11:40 AM Q & A

11:45 AM *Debate: PRO: O(+) MG... This Young Adult Will Die Waiting. I Am Going To Accept An ABOi Donor*

Asif Hasan, MD, Freeman Hospital, Newcastle upon Tyne, United Kingdom

11:55 AM *Debate: CON: O(+) MG... This Young Adult Will Die Waiting. I Am Going To Accept An ABOi Donor*

Gregory I. Snell, FRACP, MBBS, MD, Alfred Hospital, Melbourne, Australia

12:05 PM *Debate PRO Rebuttal*

Asif Hasan, MD, Freeman Hospital, Newcastle upon Tyne, United Kingdom

12:10 PM *Debate CON Rebuttal*

Gregory I. Snell, FRACP, MBBS, MD, Alfred Hospital, Melbourne, Australia

SCIENTIFIC PROGRAM

10:15 AM – 12:15 PM

PRE-MEETING SYMPOSIUM 12

To VAD or to Transplant (Harbor GHI)

CHAIRS: Jose Tallaj, MD and Goran Dellgren, MD, PhD

(MCS, HF, HTX)

SESSION SUMMARY: Heart Transplantation and Mechanical Circulatory Support are therapies that result in improvement in survival and quality of life in patients with end-stage heart disease. Heart transplantation has a long track-record with current estimated survival of about 60% at 10 years. Mechanical circulatory support, on the other hand, is a relatively young field, but current survival with second generation devices is approaching 80% at two years, similar to transplantation in some instances. As the technology improves, the expected survival with mechanical support should continue to increase and maybe even equate that of transplantation. The purpose of this symposium is to compare transplantation to mechanical support in regards to survival, quality of life and morbidity.

10:15 AM *Survival Post-Transplantation*

Andreas O. Zuckermann, MD, Medical University of Vienna, Vienna, Austria

10:35 AM *Survival Post-Mechanical Circulatory Support*

Francis Pagani, MD, PhD, University of Michigan, Ann Arbor, MI, USA

10:55 AM *Quality of Life after Transplant and Mechanical Circulatory Support*

Kathleen L. Grady, PhD, APN, FAAN, Northwestern University, Chicago, IL, USA

11:15 AM *When the Right Choice is Palliative Care*

Jane MacIver, Rn-Np PhD, University Health Network, Toronto, ON, Canada

11:35 AM *Patient Selection or Patient Preference?*

David O. Taylor, MD, The Cleveland Clinic, Cleveland, OH, USA

11:55 AM *To VAD or to Transplant – That is The Final Question*

James K. Kirklin, MD, University of Alabama at Birmingham, Birmingham, AL, USA

12:00 PM – 12:45 PM

BOX LUNCH DISTRIBUTION (Palm Foyer)

12:15 PM – 2:00 PM

LUNCH BREAK/VIEW POSTERS

12:30 PM – 1:45 PM

JUNIOR FACULTY MENTOR LUNCH (Gaslamp A-C)

I2C2 COMMITTEE MEETING (Gaslamp D)

EDUCATION COMMITTEE MEETING (La Jolla AB)

VAD ID WORKFORCE MEETING (Seaport H)

12:30 PM – 1:30 PM**PHARMACY AND PHARMACOLOGY COUNCIL MEETING (Grand Hall C)****NURSING, HEALTH SCIENCE AND ALLIED
HEALTH COUNCIL MEETING (Grand Hall D)****BASIC SCIENCE TRANSLATIONAL RESEARCH
COUNCIL MEETING (Harbor GHI)****DCD MINI REGISTRY MEETING (Old Town AB)****1:30 PM – 2:00 PM****REGISTRIES AND DATABASES COMMITTEE MEETING (Old Town AB)****REGISTRY ADVISORY COMMITTEE MEETING (Old Town AB)****2:00 PM – 4:00 PM****PRE-MEETING SYMPOSIUM 13****Drilling Down on Myocardial Recovery – Basics and
Clinical (Seaport)****CHAIRS:** Stavros G Drakos, MD, PhD and Palak Shah, MD, MS**(MCS, BSTR, HF, HTX)****SESSION SUMMARY:** Mechanical circulatory support, through the advent of continuous-flow left ventricular assist devices, has dramatically altered our management of patients with advanced heart failure. Despite over a decade of experience with continuous-flow pumps, we only have a basic understanding of the human cellular and molecular response to mechanical support. Gene expression, metabolomics and other translational techniques should provide some key insights into the human response to continuous blood flow and will perhaps lead to strategies to predict and prevent the morbidities of VAD therapy. Finally, the “holy grail” of MCS is myocardial recovery which may indeed involve therapy with stem cells, but only if aided by an integrated analysis of the entire human genome and its downstream transcriptional and translational products. This symposium will review our current understanding of translational research in the setting of MCS with an emphasis on its clinical utility and translation.**2:00 PM *What is Myocardial Recovery?***Douglas L. Mann, MD, Washington University in St. Louis,
St. Louis, MO, USA**2:20 PM *Do Molecular Pathways Give Us Insight
Into How We Can Promote Recovery?***Nicolaas De Jonge, MD, PhD, University Medical Center Utrecht,
Utrecht, Netherlands**2:40 PM *Understanding the Metabolome in
Heart Failure and the Unloaded Heart***

Brian D. Lowes, MD, PhD, University of Nebraska, Omaha, NE, USA

3:00 PM *Stem Cells - Which Patients, Which Methods?*

Doris A. Taylor, PhD, Texas Heart Institute, Houston, TX, USA

**3:20 PM *Bridge to Recovery Clinical Trials:
Challenges and Opportunities***

Emma J. Birks, MD, University of Louisville, Louisville, KY, USA

3:40 PM *Panel Discussion*

SCIENTIFIC PROGRAM

2:00 PM – 4:00 PM

PRE-MEETING SYMPOSIUM 14

Treating All Stages of Severe Pulmonary Hypertension: Are We Getting It Right? (Grand Hall A)

CHAIRS: Steven Kawut, MD, MS and Eulalia Roig, MD, PhD

(PH, HF, HTX, LF, LTX)

SESSION SUMMARY: This session will discuss the approved therapeutics and the new agents on the horizon for pulmonary arterial hypertension, focusing on treatment of advanced pulmonary hypertension. Despite the introduction of various oral and outpatient treatments, the approach to the severely ill patient with pulmonary hypertension is less well understood, constituting the practice gap and educational need.

2:00 PM *Approved Therapies for Pulmonary Arterial Hypertension: Are We Using It to Its Best Potential?*
Anne Keogh, MBBS, MD, St. Vincent's Hospital, Sydney, Australia

2:25 PM Q & A

2:30 PM *Targeting Inflammation, Kinases, and Metabolic Modulation for Pulmonary Arterial Hypertension*
Mark R. Nicolls, MD, Stanford University, Palo Alto, CA, USA

2:55 PM Q & A

3:00 PM *Pulmonary Hypertension in the ICU*
John T. Granton, MD, University Health Network, Toronto, ON, Canada

3:25 PM Q & A

3:30 PM *Percutaneous Support for Advanced Pulmonary Hypertension and Right Heart Failure: Atrial Septostomy and Percutaneous Systems*
Tomas Pulido, MD, Ignacio Chavez National Heart Institute, Mexico City, Mexico

3:55 PM Q & A

2:00 PM – 4:00 PM

PRE-MEETING SYMPOSIUM 15

Bad Bugs? Optimize the Drugs! (Grand Hall B)

CHAIRS: Walter E Uber, PharmD and Fernanda Silveira, MD

(ID, LF, LTX, HF, HTX, PHARM)

SESSION SUMMARY: A symposium combining brief illustrative case presentations followed by state-of-the-art lectures reviewing issues and controversies in antiviral, antibacterial, antifungal and antimycobacterial therapeutic drug monitoring. Although there is a small amount of published information on TDM and azole antifungal agents in heart lung transplantation, the antibacterial and antiviral drugs have been very neglected. Inappropriate dosing may lead to treatment failure, toxicity and the development of resistant organisms, both of which can be catastrophic in the transplant setting.

2:00 PM *Antiviral Agents and Therapeutic Drug Monitoring (TDM)*
Erik A. Verschuuren, MD, PhD, University Medical Centre Groningen, Groningen, Netherlands

- 2:20 PM** ***Antibacterial Agents and Therapeutic Drug Monitoring (TDM)***
Jason A. Roberts, PhD, BPharm(Hons), FSHP, The University of Queensland, Brisbane, Queensland, Australia
- 2:40 PM** ***Antifungal Agents and Therapeutic Drug Monitoring (TDM)***
Deborah Marriott, FRACP, FRCPA, St. Vincent's Hospital, Sydney, Australia
- 3:00 PM** ***Antimycobacterial Agents and Therapeutic Drug Monitoring (TDM)***
Vincent G. Valentine, MD, University of Texas Medical Branch, Galveston, TX, USA
- 3:20 PM** ***Managing Interactions With Antimicrobial Agents and Immunosuppressant Therapies***
Tam Khuu, PharmD, BCPS, University of California at Los Angeles, Los Angeles, CA, USA
- 3:40 PM** ***Panel Discussion***

2:00 PM – 4:00 PM**PRE-MEETING SYMPOSIUM 16****Ex-Vivo Lung Perfusion (EVLV): Evolving Strategy For Improved Donor Lung Management (Grand Hall C)**

CHAIRS: Kumud Dhital, MD, PhD, John Dunning, FRCS and Kenneth R McCurry, MD, FACS

(DMD, LF, LTX)

SESSION SUMMARY: The last 5 years have witnessed an exponential rise in the use of ex-vivo lung perfusion (EVLV) for both basic scientific research and clinical practice. Various ex-vivo devices are now available for supporting donor lungs. This symposium aims to provide a timely update on the following aspects of EVLV: Expanding the donor organ pool; Cold Show with subsequent functional assessment versus primary physiological support; Limiting cold ischaemia; Sanguinous versus asanguinous perfusion; Repair and reconditioning of poor donor organs; Improving functional assessment of donor organs; Supporting lungs from DCD; and Clinical trials. The symposium also aims to meet the significant educational need of fully appreciating the principles and practice of EVLV. An additional benefit from this educational session is to stimulate wider evidence-based clinical adoption of this technology to expand the donor pool, improve donor organ function, and potentially extend graft and recipient survival.

- 2:00 PM** ***EVLV: From Concept to Current Practice***
Stig Steen, MD, University Hospital, Lund, Sweden
- 2:15 PM** ***Q & A***
- 2:20 PM** ***European Experience With Static EVLV***
Goran Dellgren, MD, Sahlgrenska University Hospital, Gothenburg, Sweden
- 2:35 PM** ***Q & A***
- 2:40 PM** ***EVLV: The North American Experience***
Bartley Griffith, MD, University of Maryland, Baltimore, MD, USA
- 2:55 PM** ***Q & A***
- 3:00 PM** ***Physiological Perfusion versus Cold Show: Update on the International INSPIRE Trial***
Gregor Warnecke, MD, Hannover Medical School, Hannover, Germany

SCIENTIFIC PROGRAM

- 3:15 PM** Q & A
- 3:20 PM** *New Frontiers in Ex-Vivo Donor Lung Reconditioning*
Marcelo Cypel, MD, Toronto General Hospital, Toronto, ON, Canada
- 3:35 PM** Q & A
- 3:40 PM** *Defining Marginality and Justifying Costs*
Peter Hopkins, FRACP, Prince Charles Hospital, Brisbane, Australia
- 3:55 PM** Q & A

2:00 PM – 4:00 PM

PRE-MEETING SYMPOSIUM 17

Frailty – How Do We Assess This Physiologic Variable And At What Point Does It Represent A Contraindication To Transplant? (Grand Hall D)

CHAIRS: Nancy P. Blumenthal, CRNP and Christiane Kugler, PhD
(MCS, HF, HTX, LF, LTX, NNSAH)

SESSION SUMMARY: Frailty has been defined as a low level of physiologic reserve and reduced ability to withstand stress to the body. One study estimated that twenty five percent of transplant patients met the criteria for frailty, a figure three times higher than in elderly adults who live at home. Other studies of abdominal transplant recipients classified as frail were nearly twice as likely to have early post-transplant complications, and this increased risk of a poor outcome occurred regardless of the age of the transplant recipient. This symposium will describe clinical assessment tools to identify patients at risk for frailty, will determine if frailty is an indicator of poor outcome in the thoracic transplant patient, and will identify interventions to improve outcomes of frail recipients.

- 2:00 PM** *Introductory Case Presentation*
Ashwin K. Ravichandran, MD, Saint Vincent Medical Group, Indianapolis, IN, USA
- 2:05 PM** *What is Frailty, and How is it Measured?*
Oliver Mauthner, RN PhD, University of Basel, Basel, Switzerland
- 2:20 PM** *What Factors are Important to Consider Surrounding Frailty Within the Pediatric Community?*
Debra Lefkowitz, PsyD, Children's Hospital of Philadelphia, Philadelphia, PA, USA
- 2:35 PM** *Does Transplant or MCS Improve Frailty?*
Peter MacDonald, MD, St. Vincent's Health Network, Sydney, Australia
- 2:50 PM** *Physical Therapy Assessment and Interventions Before and After Transplant/MCS*
Louise M. Fuller, PT, Alfred Hospital, Melbourne, Australia
- 3:05 PM** *Nutritional Assessment and Interventions for Frail Candidates*
David J. Lederer, MD, MS, Columbia University, New York, NY, USA
- 3:20 PM** *Supporting Caregivers After Transplant*
Kevin C. Carney, MSN, CRNP, CCTC, Hospital of the University of Pennsylvania, Philadelphia, PA, USA
- 3:35 PM** *Panel Discussion*

2:00 PM – 4:00 PM**PRE-MEETING SYMPOSIUM 18****Developing a Pediatric VAD Program (Harbor GHI)****CHAIRS:** Elizabeth Blume, MD and Robert Weintraub, FRACP, FACC

(PEDS, MCS, HF, HTX)

SESSION SUMMARY: Objectives: 1) To understand and review what is required to develop a VAD program at a pediatric center. 2) To review the outcomes of children discharged home on implantable VAD support, 3) To understand important pediatric-specific medical and social obstacles impacting home VAD, and 4) To discuss the future of VAD support for children.

- 2:00 PM** *One Size Doesn't Fit All*
Peter D. Wearden, MD, PhD, University of Pittsburgh,
Pittsburgh, PA, USA
- 2:20 PM** *Now We Send Them Home? VAD Education
Requirements Prior to Discharge*
Holger Buchholz, MD, Stollery Children's Hospital,
Edmonton, AB, Canada
- 2:40 PM** *Managing the Device at Home: Unique
Issues to Children and Adolescents*
Jennifer Conway, MD, Stollery Children's Hospital,
Edmonton, AB, Canada
- 3:00 PM** *Pushing the Limits on VAD Support: Ethical
and Social Issues Encountered in Children and
Adolescents with Left Ventricular Assist Devices*
Aileen Lin, NP, Lucile Packard Children's Hospital,
Palo Alto, CA, USA
- 3:20 PM** *Case Presentation: Unique Uses of
Devices in Pediatric Centers*
Martin Schweiger, MD, University Children's
Hospital, Zurich, Switzerland
- 3:40 PM** *Panel Discussion*

4:00 PM – 4:15 PM

COFFEE BREAK (Palm and Grand Foyers)

VIEW POSTERS (Harbor and Seaport Foyers)

4:15 PM – 6:15 PM

PRE-MEETING SYMPOSIUM 19

The Times They Are a-Changing (Seaport)

CHAIRS: Cumara Sivathasan, MBBS, FRCS and Craig H Selzman, MD
(MCS, HF, HTX)

SESSION SUMMARY: This session offers education focused on new applications of current available devices and a review of current and upcoming trends in mechanical circulatory support interventions.

- 4:15 PM** *Minimally Invasive Approaches and Alternative Novel Strategies for LVAD Implantation – Are We There Yet?*
Simon Maltais, MD, PhD, Vanderbilt University Medical Center, Nashville, TN, USA
- 4:30 PM** Q & A
- 4:35 PM** *High-Risk Conventional Interventions vs LVAD Implantation – Trend Toward a Paradigm Shift*
Arnt E. Fiene, MD, Rikshospitalet, Oslo, Norway
- 4:50 PM** Q & A
- 4:55 PM** *Smaller, Easier, Better? What to Expect in the Next LVAD Decade*
Mark S. Slaughter, MD, University of Louisville, Louisville, KY, USA
- 5:05 PM** Q & A
- 5:15 PM** *Is Mitral Intervention Warranted for Patients Undergoing LVAD Implant*
Robert M. Adamson, MD, Sharp Memorial Hospital, San Diego, CA, USA
- 5:30 PM** Q & A
- 5:35 PM** *Debate: PRO: Total Implantability Is Near*
George M. Wieselthaler, MD, University of California at San Francisco, San Francisco, CA, USA
- 5:50 PM** *Debate: CON: Total Implantability Is Near*
Pramod Bonde, MD, Yale University School of Medicine, New Haven, CT, USA
- 6:05 PM** *Debate PRO Rebuttal*
George M. Wieselthaler, MD, PhD, University of California at San Francisco, San Francisco, CA, USA
- 6:10 PM** *Debate CON Rebuttal*
Pramod Bonde, MD, Yale University School of Medicine, New Haven, CT, USA

4:15 PM – 6:15 PM

PRE-MEETING SYMPOSIUM 20

Pulmonary Hypertension in Left Heart Disease (WHO Group 2 PH): ISHLT and World Symposium on Pulmonary Hypertension (WSPH) Consensus Initiative (Grand Hall A)**CHAIRS:** Teresa De Marco, MD, FACC, Jean-Luc E Vachieri, MD and Howard J. Eisen, MD**(PH, HF, HTX)**

SESSION SUMMARY: The definition and nomenclature of pulmonary hypertension (PH) related to left heart disease (LHD) (WHO Group 2 PH) are inconsistent and confusing. As a result, many patients with WHO Group 2 PH are misclassified as having pulmonary arterial hypertension (aka primary pulmonary hypertension) and are mistreated with therapies that are potentially deleterious. Over the past several years, the PH Council of ISHLT has had a keen interest in developing standardized definitions and nomenclature to describe pulmonary hypertension due to LHD, with the aim to create a framework for future study design. A summary statement was published last year on the subject (Fang JC et al. J Heart Lung Transplant 2012;31:913-33). PH and right heart failure is a common theme of importance to the ISHLT and World Pulmonary Hypertension group, and a collaborative consensus initiative has been proposed and discussed at the 5th World Symposium on Pulmonary Hypertension (WSPH) in Nice, France. This session will present the definitions and nomenclature proposed in the ISHLT consensus document and discussed at the 5th WSPH, identify key gaps in knowledge, and discuss research initiatives in the context of heart failure/transplantation and mechanical circulatory support.

4:15 PM Overview of the World Symposium Pulmonary Hypertension in LH Disease

Nazzareno Galie, MD, University of Bologna, Bologna, Italy

4:35 PM Q & A**4:40 PM Pulmonary Hypertension in Left Heart Disease – A Case for Diastolic Pulmonary Gradient in the Definition of Pulmonary Hypertension Related to Left Heart Disease**

Myung H. Park, MD, University of Maryland School of Medicine, Baltimore, MD, USA

5:00 PM Q & A**5:05 PM PH in Left Heart Disease: What is the Most Important Hemodynamic Variable for Patients with Advanced Heart Failure Being Considered for Transplantation or Ventricular Assist Devices?**

James Fang, MD, University of Utah, Salt Lake City, UT, USA

5:25 PM Q & A**5:30 PM Research Initiatives and Therapeutic Recommendations for WHO Group 2 PH**

Robert P. Frantz, MD, Mayo Clinic, Rochester, MN, USA

5:50 PM Q & A**5:55 PM Panel Discussion**

4:15 PM – 6:15 PM

PRE-MEETING SYMPOSIUM 21

The Sexiest Controversies in End Stage Heart Failure and Transplantation (Grand Hall B)

CHAIRS: David S. Feldman, MD, PhD and Michal W Zakliczynski, MD
(HF, HTX, MCS, PHARM, BSTR)

SESSION SUMMARY: The goal of this Symposium is to discuss important and controversial issues in Heart Failure and Transplantation in a way that will keep people awake, alert, attentive and perhaps amused.

- 4:15 PM** *Stem Cells: A Translational Science Primer*
Doris Taylor, PhD, FAHA, FACC, Texas Heart Institute, Houston, TX, USA
- 4:25 PM** *Debate: PRO: Stem Cells are the Future of Advanced Heart Failure Therapy and Always Will Be*
Sharon A. Hunt, MD, Stanford University, Stanford, CA, USA
- 4:35 PM** *Debate: CON: Stem Cells are the Future of Advanced Heart Failure Therapy and Always Will Be*
Sonja Schrepfer, MD, PhD, Stanford University, Stanford, CA, USA
- 4:45 PM** *mTORi are an Advancement Beyond Current Therapy*
Arne Andreassen, MD, Oslo University Hospital, Oslo, Norway
- 4:55 PM** *Debate: PRO: All of Our Patients Should Be on MTORi Subsequent to Transplant*
Howard J. Eisen, MD, Drexel University College of Medicine, Philadelphia, PA, USA
- 5:05 PM** *Debate: CON: All of Our Patients Should Be on MTORi Subsequent to Transplant*
Mandeep R. Mehra, MD, FACC, FACP, Brigham and Women's Hospital, Boston, MA, USA
- 5:15 PM** *Basic Physiology and Biomechanics of ECMO*
Pascal N. Leprince, MD, PhD, La Pitie Salpetriere, Paris, France
- 5:25 PM** *Debate: PRO: Patients Supported by ECMO Should Never Get Transplanted*
Mariell Jessup, MD, University of Pennsylvania, Philadelphia, PA, USA
- 5:35 PM** *Debate: CON: Patients Supported by ECMO Should Never Get Transplanted*
Goran Dellgren, MD, Sahlgrenska University Hospital, Gothenburg, Sweden
- 5:45 PM** *Debate: PRO: MCS Will Kill Transplant*
Lars H. Lund, MD, PhD, Karolinska Institute, Stockholm, Sweden
- 5:55 PM** *Debate: CON: MCS Will Kill Transplant*
Donna M. Mancini, MD, Columbia University, New York, NY, USA
- 6:05 PM** Q & A

4:15 PM – 6:15 PM

PRE-MEETING SYMPOSIUM 22

Global Perspectives on Donation after Circulatory Determination of Death in Lung Transplantation (Grand Hall C)

CHAIRS: Christopher H. Wigfield, MD, FRCS and
Dirk EM Van Raemdonck, MD, PhD

(DMD, LF, LTX)

SESSION SUMMARY: It remains true that most donor lungs offered for transplant are discarded with substantial patient numbers dying on the waiting list. DCD has become widely accepted now in lung transplantation with increased experience. EVLP as a new method of treating and evaluating marginal lungs is being used effectively as well and will be more widely adopted. However, the increased complexity and cost of EVLP is one reality that may limit clinical adoption. What is the best way forward to join these practices and employ EVLP most effectively to quickly impact lungs transplanted? Are these technologies additive, competing, should they be combined international perspective? This symposium will explore these issues.

- 4:15 PM** *DCD Lungs: The Australian Experience*
Bronwyn J. Levvey, RN, Grad Dip Clin Ep, Alfred Hospital, Melbourne, Australia
- 4:27 PM** *Q & A*
- 4:32 PM** *DCD Lungs: The Spanish Experience*
Francisco Javier Moradiellos, MD, Puerta de Hierro University Hospital, Madrid, Spain
- 4:44 PM** *Q & A*
- 4:49 PM** *DCD Lungs: The European Experience*
John Dark, MBBS, FRCS, Freeman Hospital, Newcastle upon Tyne, United Kingdom
- 5:01 PM** *Q & A*
- 5:06 PM** *DCD Lungs: The Canadian Experience*
Marcelo Cypel, MD, PhD, Toronto General Hospital, Toronto, ON, Canada
- 5:18 PM** *Q & A*
- 5:23 PM** *DCD Lungs: The U.S. Experience*
David Mason, MD, The Cleveland Clinic, Cleveland, OH, USA
- 5:35 PM** *Q & A*
- 5:40 PM** *Debate: PRO: We Need EVLP To Do DCD*
Robert B. Love, MD, FACS, FRCS, Medical College of Wisconsin, Milwaukee, WI, USA
- 5:52 PM** *Debate: CON: We Need EVLP To Do DCD*
Gregory I. Snell, FRACP, MBBS, MD, Alfred Hospital, Melbourne, Australia
- 6:05 PM** *Debate PRO Rebuttal*
Robert Love, MD, Medical College of Wisconsin, Milwaukee, WI, USA
- 6:10 PM** *Debate CON Rebuttal*
Gregory I. Snell, FRACP, MBBS, MD, Alfred Hospital, Melbourne, Australia

4:15 PM – 6:15 PM

PRE-MEETING SYMPOSIUM 23

State of the Art Update on Infectious Disease Issues in Pediatric Thoracic Transplantation (**Grand Hall D**)

CHAIRS: Tajinder P Singh, MD, MSc and Antonio Moreno-Galdó, MD, PhD (ID, PEDS, LF, LTX, PHARM)

SESSION SUMMARY: The infectious disease sessions at ISHLT traditionally have focused on adults rather than children. Some of the pediatric responses to infections are quite disparate from those of adults. This session will provide a state of the art update based on the latest data in pediatrics.

- 4:15 PM** *Anticipatory Guidance to Reduce Infection Risk After Pediatric Thoracic Transplantation*
Michele Estabrook, MD, St. Louis Children's Hospital, St. Louis, MO, USA
- 4:35 PM** *Donor to Recipient Infectious Disease Transmission*
Sandra Burchett, MD, MSc, Boston Children's Hospital/ Harvard Medical School, Boston, MA, USA
- 4:55 PM** *Vaccination in Pediatric Thoracic Transplantation: Facts and Controversies*
Marian G. Michaels, MD, MPH, Children's Hospital of Pittsburgh of UPMC, Pittsburgh, PA, USA
- 5:15 PM** *Popular Viruses in Thoracic Transplant: EBV and CMV*
Upton D. Allen, MD, Hospital for Sick Children, Toronto, ON, Canada
- 5:35 PM** *Infectious Considerations in Pediatric Lung Transplantation*
Amparo Sole, MD, PhD, Hospital Universitario la Fe, Valencia, Spain
- 5:55 PM** *Panel Discussion*

4:15 PM – 6:15 PM**PRE-MEETING SYMPOSIUM 24****Lung Transplant Immunology 201-Plus: Recent Advances (Harbor GHI)**

CHAIRS: John A Belperio, MD and
Daniel C Chambers, MBBS, MRCP, FRACP, MD

(BSTR, LF, LTX)

SESSION SUMMARY: This session will be an update on recent basic immunology discoveries in the field of lung transplantation. This is a more advanced level than the Transplant Immunology 101 session and is directed to a basic science audience.

- 4:15 PM** *T cell Phenotypes in Transplantation: The Known and The New*
Rebecca A. Shilling, MD, University of Illinois at Chicago, Chicago, IL, USA
- 4:30 PM** *Q & A*
- 4:35 PM** *Innate Immunity, Rejection, and the Breakdown of Tolerance*
Scott M. Palmer, MD, MHS, Duke University, Durham, NC, USA
- 4:50 PM** *Q & A*
- 4:55 PM** *Role of the Macrophage in Lung Allograft Dysfunction*
Andrew J. Fisher, FRCP PhD, Freeman Hospital, Newcastle upon Tyne, United Kingdom
- 5:10 PM** *Q & A*
- 5:15 PM** *Allo-Antibodies and Lung Transplant*
Glen P. Westall, FRACP, PhD, Alfred Hospital, Melbourne, Australia
- 5:30 PM** *Q & A*
- 5:35 PM** *Autoimmunity and Auto-Antibodies*
Stijn E. Verleden, PhD, KU Leuven, Leuven, Belgium
- 5:50 PM** *Q & A*
- 5:55 PM** *Update on Stem Cells in Transplant: The Good and Bad*
Sonja Schrepfer, MD, PhD, Stanford University, Stanford, CA, USA
- 6:10 PM** *Q & A*

6:15 PM – 7:15 PM**EXHIBIT HALL OPENING RECEPTION (Harbor A-F)****6:15 PM – 7:15 PM****MODERATED POSTER SESSION 1 (Harbor and Seaport Foyers)
(ALL)****6:45 PM – 7:45 PM****CLAD GUIDELINES WORKFORCE MEETING (Gaslamp D)****7:15 PM – 8:30 PM****IMACS REGISTRY MEETING (Gaslamp C)**

FRIDAY, APRIL 11, 2014

7:00 AM – 6:30 PM

REGISTRATION DESK OPEN (Palm Foyer)

SPEAKER READY ROOM OPEN (Balboa ABC)

7:00 AM – 8:00 AM

JHLT EDITORIAL BOARD BREAKFAST MEETING (Gaslamp A-C)

7:00 AM – 8:00 AM

SUNRISE SYMPOSIUM 1

Building for the Future (Grand Hall A)

CHAIRS: Juan C. Mejia, MD and James Long, MD, PhD

(MCS, HF, HTX)

SESSION SUMMARY: This session addresses the key issues involved as the MCS field expands. Firstly how to build a VAD program for new and evolving centers, secondly whether and how shared care should be performed for the large number of ongoing patients together with whether it works for the center and its partner, and thirdly the controversial and important topic of whether or not centers should be allowed to perform DT alone without having heart transplantation.

7:00 AM *Building a VAD Program*

Stephan Schueler, MD, PhD, FRCS, Freeman Hospital, Newcastle upon Tyne, United Kingdom

7:15 AM *Shared Care: a Good Idea or Not?*

Todd F. Dardas, MD, University of Washington, Seattle, WA, USA

7:30 AM *Should Centers Perform DT Alone?*

Michael G. Dickinson, MD, Spectrum Health, Grand Rapids, MI, USA

7:45 AM *Panel Discussion*

7:00 AM – 8:00 AM

SUNRISE SYMPOSIUM 2

Under Too Much Pressure: Challenging Cases in Pulmonary Hypertension Management (Grand Hall B)

CHAIRS: Adaani Frost, MD and Vincent G. Valentine, MD

(PH, HF, HTX, LF, LTX)

SESSION SUMMARY: This is meant to be a multidisciplinary symposium (cardiology, pulmonary, PH) discussing management of challenging patients who have complicating pulmonary hypertension. Three cases will be presented by junior faculty members. The case presentations will include challenges to the discussants (in an open forum) regarding next steps in evaluation, management, etc of pulmonary hypertension. The objectives of the symposium are 1) Evaluation and management of challenging cases in PH, 2) Discussion of controversial techniques in PH evaluation, 3) Pre- and post-transplant evaluation of patients with PH, and 4) Post-transplant pharmaceutical management of cardiac transplant patients with preexisting PH.

- 7:00 AM** *Case #1 – The Fight to Keep the RV Working Despite High Pressures*
Amit Banga, MD, Cleveland Clinic, Cleveland, OH, USA
- 7:10 AM** *Expert Discussant*
Adaani Frost, MD, Baylor College of Medicine, Houston, TX, USA
- 7:15 AM** *Case #2 – Go the Extra Mile: When Resting PA Pressures do not Tell the Whole Story*
Kerri Akaya Smith, MD, University of Pennsylvania, Philadelphia, PA, USA
- 7:25 AM** *Expert Discussant*
Raymond L. Benza, MD, Allegheny General Hospital, Pittsburgh, PA, USA
- 7:30 AM** *Case #3 – Challenges for Optimization of the Liver Transplant Candidates with PH*
Mitesh V. Thakrar, MD, University of Calgary, Calgary, AB, Canada
- 7:40 AM** *Expert Discussant*
Dana P. McGlothlin, MD, Kaiser San Francisco Medical Center, San Francisco, CA, USA
- 7:45 AM** *Panel Discussion*

7:00 AM – 8:00 AM**SUNRISE SYMPOSIUM 3****Endothelial Dysfunction in Advanced Heart Failure, Mechanical Circulatory Support, and Transplant: It's a Pipe and Pump Issue (Grand Hall C)**

CHAIRS: David M. Kaye, MD, PhD and Sameh Hozayen, MD, MS
(HF, HTX, MCS, BSTR)

SESSION SUMMARY: Endothelial function is increasingly recognized as a general barometer of health. There is extensive data that endothelial function is impaired in patients with heart failure, and it may be a marker of development of allograft vasculopathy in transplanted patients. A better understanding of the pathophysiology of endothelial dysfunction in heart failure, VAD and transplanted patients, the methods of endothelial dysfunction assessment, and its relation to outcome following VAD and transplant is crucial for specialists caring for patients undergoing advanced heart failure management. It is also critical for scientists working in the field of vascular physiology and outcomes research to understand the interaction between the different modalities and endothelial function in order to further enhance research in this arena. The first discussions of this symposium will provide a general overview of the pathophysiology of endothelial dysfunction. The subsequent talks will provide in depth analyses of the development, treatment, and morbidity of endothelial dysfunction development, treatment, and morbidity in patients with heart failure, transplant, and MCS.

- 7:00 AM** *Why Cells Become Ornerly: Pathophysiology of Endothelial Dysfunction*
David M. Kaye, MD, PhD, The Alfred Hospital, Melbourne, Australia
- 7:15 AM** *Endothelial Dysfunction, Morbidity, and Mortality in Patients with Heart Failure*
W. H. Wilson Tang, MD, Cleveland Clinic Foundation, Cleveland, OH, USA
- 7:30 AM** *Endothelial Dysfunction in Heart Transplantation. Is It a Mediator of Adverse Outcomes?*
Karl B. Lemstrom, MD, PhD, Helsinki University, Helsinki, Finland

SCIENTIFIC PROGRAM

- 7:45 AM** *Deleterious Effect of Changing Nature: Response of the Endothelium to Continuous Flow LVAD Support*
Peter M. Eckman, MD, University of Minnesota, Minneapolis, MN, USA

7:00 AM – 8:00 AM

SUNRISE SYMPOSIUM 4

Controversies in Lung Transplantation (Grand Hall D)

CHAIRS: Marie Budev, DO, MPH and John Dark, MB, FRCS

(LF, LTX)

SESSION SUMMARY: This symposium will address some controversial areas in lung transplantation in the form of Pro and Con debates. This is a very popular format and stimulates great discussions.

- 7:00 AM** *Debate: PRO: Single Lung Transplantation Should Be the Preferred Procedure for COPD and ILD*
Gabriel Thabut, MD, Hopital Bichat, Paris, France
- 7:08 AM** *Debate: CON: Single Lung Transplantation Should Be the Preferred Procedure for COPD and ILD*
Jens Gottlieb, MD, Hannover Medical School, Hannover, Germany
- 7:16 AM** *Debate: PRO: Scleroderma Should Be a Contraindication to Lung Transplantation*
Oksana Shlobin, MD, Inova Fairfax Hospital, Falls Church, VA, USA
- 7:24 AM** *Debate: CON: Scleroderma Should Be a Contraindication to Lung Transplantation*
Jonathan P. Singer, MD MS, University of California at San Francisco, San Francisco, CA, USA
- 7:32 AM** *Debate: PRO: Donor Lungs Should Be Sized to Fit the Highest Priority Recipient*
Tobias Deuse, MD, University Heart Center, Hamburg, Germany
- 7:40 AM** *Debate: CON: Donor Lungs Should Be Sized to Fit the Highest Priority Recipient*
Michael Eberlein, MD PhD, University of Iowa Hospitals and Clinics, Iowa City, IA, USA
- 7:48 AM** *Panel Discussion*

7:00 AM – 8:00 AM

SUNRISE SYMPOSIUM 5

**What You Always Wanted To Know About LISH
(Laboratory Tests, Infectious Agents, Special Situations,
Hidden Infections) But Were Afraid To Ask (Seaport H)**

CHAIRS: Christopher R Ensor, PharmD, BCPS-CV and
Amparo Sole, MD, PhD

(ID, PHARM, LF, LTX, HF, HTX)

SESSION SUMMARY: In the field of infectious diseases there are many accepted standards for treatment and diagnoses. However we do not always know the real explanation for them nor do we question them. This symposium will attempt to clarify several main topics in ID from laboratory to therapy.

7:00 AM *How to Diagnose Infections in Cardiothoracic Transplants (CT)?*

Kate Gould, FRCPath, Freeman Hospital, Newcastle upon Tyne, United Kingdom

7:12 AM *Q & A*

7:15 AM *What are We Interested in Diagnosing?*

Me-Linh Luong, MD, University of Montreal St-Luc Hospital, Montreal, QC, Canada

7:27 AM *Q & A*

7:30 AM *How to Treat Special Situations*

Patricia Munoz, MD, PhD, Hospital General Universitario Gregorio Maranon, Madrid, Spain

7:42 AM *Q & A*

7:45 AM *New Routes for Antibiotic Therapy*

Kyle L. Dawson, PharmD, The Methodist Hospital, Houston, TX, USA

7:57 AM *Q & A*

8:00 AM – 6:00 PM

PRESS OFFICE OPEN (Show Office 7)

SCIENTIFIC PROGRAM

8:00 AM – 10:00 AM

OPENING PLENARY SESSION

(Seaport)

CHAIRS: Jason D. Christie, MD and Allan R. Glanville, MBBS, MD, FRACP
(ALL)

8:00 AM *Welcome/Program Chair Report*
Jason D. Christie, MD, University of Pennsylvania, Philadelphia, PA, USA

8:05 AM *President's Report/
Distinguished Educator Award Presentation*
Allan R. Glanville, MBBS, MD, FRACP, St. Vincent's
Hospital, Sydney, NSW, Australia

8:15 AM *Thoracic Registry Report*
Josef Stehlik, MD, MPH, University of Utah, Salt Lake City, UT, USA

8:30 AM *MCS D Registry Reports*
James K. Kirklin, MD, University of Alabama at
Birmingham, Birmingham, AL, USA

8:40 AM **(1) FEATURED ABSTRACT: The Scientific
Impact of the Annual Meeting of the Interna-
tional Society for Heart & Lung Transplantation;**
*D. Schibilsky¹, C. Haller¹, B. Woernle¹, T. Krueger¹, A. Glanville²,
H. Reichenspurner³, D. Taylor⁴, M. Mehra⁵, T. Walker¹, U. Eriksson⁶,
C. M. Matter⁷, F. Ruschitzka⁷, T. Lüscher⁷, C. Schlensak¹, S. Winnik⁷.*
¹Department of Thoracic and Cardiovascular Surgery, University
Medical Center, Tuebingen, Germany, ²Department of Thoracic
Medicine, St Vincent's Hospital, Sydney, Australia, ³Department of
Cardiovascular Surgery, University Heart Center, Hamburg, Ger-
many, ⁴Cardiovascular Medicine, Cleveland Clinic, Cleveland, OH,
⁵Collaborative Center for Advanced Heart Disease, Brigham and
Womens Hospital, Boston, MA, ⁶Division of Cardiology and Depart-
ment of Medicine, GZO-Zurich Regional Health Centre, Wetzikon,
Switzerland, ⁷Department of Cardiology, University Heart Center,
Zurich, Switzerland.

8:55 AM *INVITED LECTURE: How Digitizing Humans
Changes the Future of Medicine*
Eric J. Topol, M.D., Scripps Translational Science Institute, La Jolla,
CA, USA

9:15 AM **(2) FEATURED ABSTRACT: Concomitant
Aortic Valve Procedures in Patients Undergoing
Implantation of Continuous-Flow LVADs: An
INTERMACS Database Analysis;**
*J. O. Robertson¹, S. L. Meyers², J. K. Kirklin², G. D. Mertz², S. Prasad¹,
A. Itoh¹, S. C. Silvestry¹.* ¹Division of Cardiothoracic Surgery, Wash-
ington University, St. Louis, MO, ²University of Alabama at Birming-
ham, Birmingham, AL.

The abstract presenter is the recipient of the 2014 Branislav
Radovancevic Memorial Best MCS Abstract Award. This award is
supported by a grant from Thoratec.

9:30 AM *Lifetime Achievement Award Recipient Lecture:
"Follow Your Star"*
Sir Terence English, KBE, FRCS, Past President ISHLT, Oxford,
United Kingdom

10:00 AM – 10:30 AM

COFFEE BREAK/VISIT EXHIBITS (Harbor A-F)

VIEW POSTERS (Harbor and Seaport Foyers)

10:00 AM – 4:00 PM

EXHIBIT HALL OPEN (Harbor)

10:00 AM – 6:30 PM

POSTERS OPEN (Harbor and Seaport Foyer)

10:30 AM – 12:00 PM**CONCURRENT SESSION 1****How to Attack Mechanical Circulatory Support Complications (Seaport)****CHAIRS:** Michel Morshuis, MD and Ulrich P. Jorde, MD
(MCS)**10:30 AM (3) Over 400% Increase in LVAD Thrombosis Reported to the FDA's Manufacturer and User Facility Device Experience (MAUDE) Database from 2010 to 2012;**J. X. Wang¹, E. H. Lee¹, P. Bonde². ¹Bonde Artificial Heart Lab, Yale University School of Medicine, New Haven, CT, ²Cardiovascular Surgery, Yale University School of Medicine, New Haven, CT.**10:45 AM (4) Impact of Device Design and Patient Management on the Incidence of Neurologic Events after HVAD Left Ventricular Assist Device;**J. J. Teuteberg¹, M. S. Slaughter², J. Rogers³, E. McGee⁴, F. D. Pagani⁵, R. Gordon⁴, J. E. Rame⁶, M. Acker⁷, R. Kormos⁸, C. T. Salerno⁹, T. P. Schleeter⁹, D. J. Goldstein¹⁰, J. Shin¹⁰, R. C. Starling¹¹, T. Wozniak¹², A. S. Malik¹², S. C. Silvestry¹³, G. Ewald¹³, E. J. Birks², K. B. Najarian¹⁴, D. R. Hathaway¹⁴, K. D. Aaronson⁵. ¹Cardiology, UPMC, Heart and Vascular Institute, Pittsburgh, PA, ²University of Louisville, Louisville, KY, ³Duke University, Durham, NC, ⁴Northwestern University, Chicago, IL, ⁵University of Michigan, Ann Arbor, MI, ⁶University of Pennsylvania, Philadelphia, PA, ⁷University of Pennsylvania, Pittsburgh, PA, ⁸UPMC, Heart and Vascular Institute, Pittsburgh, PA, ⁹St. Vincent Heart Center of Indiana, Indianapolis, IN, ¹⁰Montefiore Medical Center, Bronx, NY, ¹¹Cleveland Clinic, Cleveland, OH, ¹²IU Health Methodist Hospital, Indianapolis, IN, ¹³Barnes Jewish Hospital Washington University, St. Louis, MO, ¹⁴HeartWare Inc, Framingham, MA.**11:00 AM (5) Can Persistent Bleeding in HeartMate II Patients Be Safely Managed with Reduced Anti-thrombotic Regimens? Preliminary Results from the US-TRACE Study;**J. N. Katz¹, R. Adamson², R. John³, A. Tatoes⁴, K. Sundareswaran⁵, F. Kallel⁵, D. J. Farrar⁵, U. Jorde⁶. ¹University of North Carolina, Chapel Hill, NC, ²Sharp Memorial Hospital, San Diego, CA, ³University of Minnesota, Minneapolis, MN, ⁴Advocate Christ Medical Center, Oaklawn, IL, ⁵Thoratec Corporation, Pleasanton, CA, ⁶Columbia University, New York, NY.

- 11:15 AM (6) Minimal Adverse Events in HeartMate II Patients with No Antiplatelet Therapy: Preliminary Results from the European TRACE Study:** I. Netuka¹, P. Y. Litzler², M. Berchtold-Herz³, E. Flecher⁴, D. Zimpfer⁵, L. Damme⁶, K. S. Sundareswaran⁷, D. J. Farrar⁷, J. D. Schmitto⁸. ¹Department of Cardiac Surgery, Institute for Clinical and Experimental Medicine, Prague, Czech Republic, ²Department of Thoracic and Cardiovascular Surgery, Rouen University Hospital Charles Nicolle, Rouen, France, ³Department of Cardiovascular Surgery, Heart Center, University of Freiburg, Freiburg, Germany, ⁴Department of Thoracic and Cardiovascular Surgery, CHU Pontchaillou, Rennes, France, ⁵Department of Cardiothoracic Surgery, University of Vienna, Vienna, Austria, ⁶Thoratec Europe Limited, London, United Kingdom, ⁷Research and Scientific Affairs, Thoratec Corporation, Pleasanton, CA, ⁸Department of Cardiac, Thoracic, Transplantation and Vascular Surgery, Hannover Medical School, Hannover, Germany.
- 11:30 AM (7) Reduction in Driveline Infection Rates: Results from the HeartMate II Multicenter Silicone-Skin-Interface (SSI) Registry:** D. Dean¹, G. A. Ewald², A. Tatoes³, B. C. Sheridan⁴, R. J. Brewer⁵, C. Caldeira⁶, F. Kallel⁷, D. J. Farrar⁷, S. A. Akhter⁸. ¹Piedmont Healthcare, Atlanta, GA, ²Washington University School of Medicine, St Louis, MO, ³Advocate Christ Medical Center, Oaklawn, IL, ⁴University of North Carolina, Chapel Hill, NC, ⁵Henry Ford Hospital, Detroit, MI, ⁶Tampa General Hospital, Tampa, FL, ⁷Thoratec Corporation, Pleasanton, CA, ⁸University of Chicago, Chicago, IL.
- 11:45 AM (8) Right Ventricular Dysfunction Is Associated with Gastrointestinal Bleeding in Patients Supported with Continuous-Flow LVADs:** C. T. Sparrow, M. E. Nassif, D. S. Raymer, E. Novak, S. J. LaRue, J. D. Schilling. Washington University School of Medicine, St. Louis, MO.

10:30 AM – 12:00 PM

CONCURRENT SESSION 2

Mechanical Circulatory Support: Engineering and Biomechanics (Grand Hall A)**CHAIRS:** Francesco Moscato, PhD and Daniel J. Goldstein, MD (MCS)

- 10:30 AM (9) Continuous Left Atrial Pressure Monitoring Improves Outcomes in Heartmate II Patients;**
I. Gosev, R. C. Neely, M. Leacche, S. McGurk, Q. Javed, L. Cohn, G. S. Couper. Cardiac Surgery, Brigham and Women's Hospital, Jamaica Plain, MA.
- 10:45 AM (10) Relationship Between Speed and Left Ventricular Size in HVAD Patients: Lessons from the HVAD Ramp Test Study;**
N. Uriel, A. P. Levin, K. P. Mody, M. Dionizovik-Dimanovski, A. R. Garan, M. Yuzepolskaya, H. Takayama, P. C. Colombo, Y. Naka, U. P. Jorde. Medicine, Columbia University, New York, NY.
- 11:00 AM (11) First Implantation in Human of a Wireless Miniaturized Intracardiac Pressure Sensor in a Patient with a HeartMate II;TM**
L. Hubbert, J. Baranowski, B. Delshad, H. Ahn. The Heart Center at the University Hospital, Division of Cardiovascular Medicine, Department of Medicine and Health, Faculty of Health Sciences, Linköping University, Linköping, Sweden.
- 11:15 AM (12) Increasing Pump Speed During Exercise Improves Peak Oxygen Consumption in Heart Failure Patients Supported With Continuous-Flow Left Ventricular Assist Devices – A Double-Blind Randomized Study;**
M. H. Jung¹, P. B. Hansen¹, K. Sander¹, P. S. Olsen¹, K. Rossing¹, S. D. Russell², S. Boesgaard¹, F. Gustafsson¹. ¹The Heart Center, University Hospital Rigshospitalet, Copenhagen, Denmark, ²Department of Cardiology, Johns Hopkins University Hospital, Baltimore, MD.
- 11:30 AM (13) Interaction of Pulse Perception, Blood Pressure Measurements (By Doppler and Standard Cuff Techniques) and Visual Assessment of Aortic Valve Opening in Continuous Flow LVAD Patients in the Outpatient Setting;**
A. Bhimaraj, R. V. Bellera, D. Martinez, A. M. Cordero-Reyes, B. Elias, B. H. Trachtenberg, G. Ashrith, G. Torre-Amione, M. Loebe, J. D. Estep. Cardiology, Houston Methodist Hospital, Houston, TX.
- 11:45 AM (14) Pressure-Volume Relations in Patients Supported With Continuous-Flow Left Ventricular Assist Devices: A Comparative Descriptive Study of Invasive Hemodynamics Versus Echocardiography;**
M. H. Jung¹, C. Hassager¹, S. D. Russell², L. Balling¹, K. Rossing¹, S. Boesgaard¹, F. Gustafsson¹. ¹Department of Cardiology, The Heart Center, University Hospital Rigshospitalet, Copenhagen, Denmark, ²Department of Cardiology, Johns Hopkins University Hospital, Baltimore, MD.

10:30 AM – 12:00 PM

CONCURRENT SESSION 3

The Tempest (Controlling the Immune System in Heart Transplantation) (Grand Hall B)

CHAIRS: Tuvia Ben Gal, MD and Malgorzata Sobieszczanska-Malek, MD (HF, HTX, BSTR)

10:30 AM (15) Increased Plasma Levels of Graft-Derived Cell-Free DNA Correlate with Rejection in Heart Transplant Recipients;

J. Kobashigawa¹, M. Grskovic², R. Dedrick², K. Gundel², R. Woodward², J. Vanhaecke³, M. G. Crespo-Leiro⁴, J. Stypmann⁵, M. C. Deng⁶, R. Starling⁷. ¹Cedars-Sinai Heart Institute, Los Angeles, CA, ²XDx, Brisbane, CA, ³Cardiovascular Diseases, University Hospitals Leuven, & Department of Cardiovascular Sciences, KU Leuven, Belgium, ⁴Unidad de Insuficiencia Cardiaca Avanzada y Trasplante Cardiaco, Hospital Universitario A Coruña, La Coruña, Spain, ⁵Department of Cardiovascular Medicine, Division of Cardiology, University Hospital Münster, Münster, Germany, ⁶Department of Medicine-Division of Cardiology, UCLA Medical Center, Los Angeles, CA, ⁷Department of Cardiovascular Medicine, Cleveland Clinic, Cleveland, OH.

10:45 AM (16) A Randomized Trial of Everolimus Initiation and Calcineurin Inhibitor (CNI) Elimination in Stable Heart Transplant Recipients With Impaired Renal Function;

J. Vanhaecke¹, D. Derthoo¹, O. Van Caenegem², M. De Pauw³, E. Nellesen⁴, N. Duerinckx¹, A. Ciarka¹, W. Droogne¹, J. Van Cleemput¹, A. Belmans¹, B. Meyns¹. ¹Department of Cardiology, University Hospital Gasthuisberg, Leuven, Belgium, ²Department of Cardiology, CHU St.-Luc, Brussels, Belgium, ³Department of Cardiology, Ghent University Hospital, Ghent, Belgium, ⁴Department of Cardiology, CHU Sart Tilman, Liège, Belgium.

11:00 AM (17) De-Novo Low TAC/Low SIR Immunosuppression after HTx – 10 Year Results of a Prospective Trial;

K. Stroeh¹, S. Guethoff¹, C. Grininger¹, B. Meiser², C. Hagl¹, I. Kaczmarek¹. ¹Cardiothoracic Surgery, University of Munich, Germany, Munich, Germany, ²Transplantationszentrum, University of Munich, Germany, Munich, Germany.

11:15 AM (18) Does the Calcineurin Inhibitor Have Influence on Cytomegalovirus Infection in Heart Transplantation?;

I. Sanchez-Lazaro¹, M. Rodriguez-Serrano¹, L. Almenar-Bonet¹, L. Martinez Dolz¹, R. Lopez-Vilella¹, M. Portoles-Sanz², M. Rivera-Otero², A. Salvador-Sanz¹. ¹Cardiology Department, Heart Failure and Transplantation Unit, Hospital Universitari i Politècnic La Fe, Valencia, Spain, ²Research Center, Hospital Universitari i Politècnic La Fe, Valencia, Spain.

11:30 AM (19) Gender and Race Association with Tacrolimus (CYP3A5) and Simvastatin (SLOCO1B1) Polymorphisms in an Adult Heart Transplant Population;

N. A. Haglund, J. Gray, K. Birdwell, I. Feurer, M. Keebler, S. Maltais, M. Wigger. Vanderbilt University Medical Center, Nashville, TN.

11:45 AM (20) Proliferation Signal Inhibitors for Cardiac Allograft Vasculopathy in Heart Transplant Recipients: A Systematic Review and Meta-Analysis of Randomized Clinical Trials;

D. Greig¹, C. Alba², F. Foroutan³, D. S. Lee², H. J. Ross². ¹Cardiovascular Diseases, P. Universidad Católica de Chile, Santiago, Chile, ²University Health Network, Toronto, ON, Canada, ³University of Toronto, Toronto, ON, Canada.

10:30 AM – 12:00 PM

CONCURRENT SESSION 4

Ex-Vivo Lung Perfusion: Where Are We Going?
(Grand Hall C)**CHAIRS:** Michael J. Weyant, MD and Marcelo Cypel, MD, PhD
(DMD, LTX, BSTR)**10:30 AM (21) Comparison Between Cellular and Acellular Perfusates Used During Ex-Vivo Lung Perfusion in a Porcine Model:**M. Roman, J. Parmar, S. Nair, S. Colah, J. Dunning, S. Tsui. Cardiothoracic Transplantation, Papworth Hospital NHS Foundation Trust, Papworth Everard, United Kingdom.**10:45 AM (22) Circulating Adhesion Molecule in Ex-Vivo Lung Perfusion Predicts Primary Graft Dysfunction:**K. Hashimoto, H. Kim, M. Hsin, T. N. Machuca, R. Zamel, M. Chen, S. Azad, T. K. Waddell, M. Cypel, M. Liu, S. Keshavjee. Latner Thoracic Surgery Research Laboratories, University of Toronto, Toronto, ON, Canada.**11:00 AM (23) Endothelial Glycocalyx Integrity Is Critical To Organ Function During Human Ex-Vivo Lung Perfusion:**D. C. Chambers¹, W. Hunt², I. J. Smith², L. Samson¹, T. M. Sladden³, S. Yerkovich¹, R. Naidoo⁴, D. Wall⁴, P. M. Hopkins¹. ¹Queensland Lung Transplant Service, The Prince Charles Hospital, Brisbane, Australia, ²Department of Anaesthesia, The Prince Charles Hospital, Brisbane, Australia, ³School of Medicine, The University of Queensland, Brisbane, Australia, ⁴Department of Cardiothoracic Surgery, The Prince Charles Hospital, Brisbane, Australia.**11:15 AM (24) Preliminary Results of a Phase II Trial Comparing Outcomes of Patients Transplanted with Lungs from Uncontrolled Donation After Cardiac Death Donors (uDCDDs) Assessed with Ex-Vivo Lung Perfusion (EVLP) to Lungs from Conventional Brain-Dead Donors:**T. Egan¹, B. Haithcock¹, J. Long¹, P. Noone¹, J. Blackwell¹, L. Forrest¹, S. Gazda¹, S. Reddy², R. Davis², K. Birchard³, P. Stewart⁴. ¹Surgery, University of North Carolina School of Medicine, Chapel Hill, NC, ²Surgery, Duke University Medical Center, Durham, NC, ³Radiology, University of North Carolina School of Medicine, Chapel Hill, NC, ⁴Biostatistics, Gillings School of Global Public Health, University of North Carolina School of Medicine, Chapel Hill, NC.**11:30 AM (25) Modulation of Immune-Mediators From Donor Lungs Using the Organ Care System® – A Potential Mechanism for Improved Outcome;**B. Wiegmann¹, C. Falk², B. Müller², C. Neudörf², A. Akhdar², C. Kühn¹, I. Tudorache¹, M. Avsar¹, A. Haverich¹, G. Warnecke¹. ¹Dpt. For Cardiothoracic, Transplantation and Vascular Surgery, Hannover Medical School, Hannover, Germany, ²Institute of Transplant Immunology, Integrated Research and Treatment Center Transplantation, Hannover, Germany.**11:45 AM (26) The EXPAND Lung International Trial to Evaluate the Safety and Effectiveness of the Portable Organ Care System (OCS™) Lung for Recruiting, Preserving and Assessing Expanded Criteria Donor Lungs for Transplantation:**D. Van Raemdonck¹, G. Warnecke², J. Kukreja³, M. Smith⁴, G. Loo⁵, J. Garcia⁶, M. Hertz⁷, J. Madsen⁸, A. Haverich², A. Ardehali⁹. ¹Thoracic Surgery, University Hospitals Leuven, Leuven, Belgium, ²Thoracic and Cardiovascular Surgery, Hannover Medical School,

Hannover, Germany, ³Thoracic Surgery, UCSF Medical Center, San Francisco, CA, ⁴Thoracic Surgery, St. Joseph's Medical Center, Phoenix, AZ, ⁵Cardiothoracic Surgery, University of Minnesota Medical Center, Minneapolis, MN, ⁶Cardiothoracic Surgery, Massachusetts General Hospital, Boston, MA, ⁷Pulmonary Medicine, University of Minnesota Medical Center, Minneapolis, MN, ⁸Cardiothoracic Surgery, Massachusetts General Hospital, Boston, MA, ⁹Cardiothoracic Surgery, UCLA Medical Center, Los Angeles, CA.

10:30 AM – 12:00 PM

CONCURRENT SESSION 5

Pediatric Mechanical Support (Grand Hall D)

CHAIRS: Angela Lorts, MD and David N. Rosenthal, MD
(PEDI, MCS)

10:30 AM (27) Pediatric Heart Transplant Waitlist Mortality in the Era of Ventricular Assist Devices;

F. Zafar¹, M. S. Khan¹, R. Bryant III¹, C. Castleberry², A. Lorts², I. Wilmot², J. L. Jefferies², C. Chin², D. L. Morales¹. ¹Cardiothoracic Surgery, Cincinnati Children's Hospital, Cincinnati, OH, ²Cardiology, Cincinnati Children's Hospital, Cincinnati, OH.

10:45 AM (28) Wait List Outcomes of Pediatric Patients Bridged to Heart Transplantation on Continuous Flow Left Ventricular Assist Devices;

R. K. Singh¹, A. P. Levin², J. Fried², M. E. Richmond², A. R. Garan², W. A. Zuckerman², H. Takayama², K. P. Mody², M. Dionizovik-Dimanovski², Y. Naka², M. Yuzefpolskaya², P. C. Colombo², L. J. Addonizio², U. P. Jorde², N. Uriel². ¹Pediatric Cardiology, Columbia University, New York, NY, ²Medicine, Columbia University, New York, NY.

11:00 AM (29) Outpatient Experience with Heartware® Ventricular Assist Device System in Children: A Multicenter Experience;

M. Schweiger¹, M. Huebler¹, A. Jeewa², I. Adachi², T. Boschert³, M. Mehegan³, P. Jansz⁴, P. E. Parrino⁵, C. Vanderpluym⁶, O. Miera⁷, D. Zimpfer⁸. ¹University Children's Hospital, Congenital Cardiovascular Pediatric Surgery, Zurich, Switzerland, ²Texas Children's Hospital, Houston, TX, ³St. Louis Children's Hospital, St. Louis, MO, ⁴St Vincent's Hospital, Sydney, Australia, ⁵Ochsner Medical Center, Section of Thoracic and Cardiovascular Surgery, New Orleans, LA, ⁶Boston Children's Hospital, Boston, MA, ⁷German Heart Institute Berlin, Berlin, Germany, ⁸Medical University Vienna, Department for Cardiothoracic Surgery, Vienna, Austria.

11:15 AM (30) Centrifugal Ventricular Assist Device Flow Rates <3L/min Is Predictive of Thrombotic Complications in Pediatric Patients;

S. M. Holzer¹, R. K. Singh¹, W. A. Zuckerman¹, L. J. Addonizio¹, J. M. Chen², L. A. Gilmore¹, K. Beddows¹, M. E. Richmond¹. ¹Division of Pediatric Cardiology, Columbia University Medical Center, New York, NY, ²Division of Pediatric Cardiothoracic Surgery, Seattle Children's Hospital, Seattle, WA.

11:30 AM (31) Size Matters: Impact of Pump Size of Berlin Heart EXCOR Pediatric Device on Clinical Outcome in Children;

O. Miera¹, K. R. Schmitt¹, E. M. Delmo-Walter², S. Ovroutzki¹, F. Berger¹, H. Roland². ¹Congenital Heart Disease and Pediatric Cardiology, Deutsches Herzzentrum Berlin, Berlin, Germany, ²Cardiothoracic and Vascular Surgery, Deutsches Herzzentrum Berlin, Berlin, Germany.

11:45 AM (32) Thirty-Day Cardiopulmonary Support with a Novel Portable Pediatric Artificial Pump-Lung;

Y. Liu, P. G. Sanchez, A. Narain, X. Wei, A. C. Watkins, Z. J. Wu, B. Griffith. Department of Surgery, University of Maryland School of Medicine, Baltimore, MD.

10:30 AM – 12:00 PM

CONCURRENT SYMPOSIUM 25

**A Lifecycle Journey in Pulmonary Hypertension
(Harbor GHI)**

CHAIRS: James C. Coons, PharmD and Carmine Dario Vizza, MD

(PHARM, HF, HTX, LF, LTX, PH)

SESSION SUMMARY: After the successful symposium “A lifecycle Journey in Cystic Fibrosis and Lung Transplantation” at ISHLT 2013, we propose to continue this innovative session for the 2014 meeting. Traditional symposia are presented either in pure didactic tracks or cases with panel discussions. This series is a practical hybrid depicting an enduring case interspersed with a best practice based discussion at predefined key “journey intervals.” The symposium will be rounded off by a panel assisted and audience supported anchoring discussion. The lifecycle of pulmonary arterial hypertension will include special emphasis on 4 “journey points:” 1) Appropriate evaluation and diagnosis, 2) Management of acute decompensated PAH, 3) Long term management, and 4) Invasive options for bridging and palliation. The focus of this series will be on therapeutics that uniquely involves emerging or established knowledge in the pharmacology and pharmacy aspects of the interval disease states or situations.

10:30 AM Case Presentation

James C. Coons, PharmD, University of Pittsburgh, Pittsburgh, PA, USA

10:35 AM Beyond the ECHO, Evaluation and Diagnosis of PAH

Jean Luc E Vachieri, MD, Erasme University Hospital, Brussels, Belgium

10:50 AM Case Presentation Update

James C. Coons, PharmD, University of Pittsburgh, Pittsburgh, PA, USA

10:55 AM PAH in Crisis: Pharmacologic Management of Decompensated PAH and RV failure

Patricia Ging, PharmD, Mater Misericordiae University Hospital, Dublin, Ireland

11:10 AM Case Presentation Update

James C. Coons, PharmD, University of Pittsburgh, Pittsburgh, PA, USA

11:15 AM Progression of PAH: Where Do We Go From Here

Patricia Uber, PharmD, University of Hawaii, Hilo, HI, USA

11:30 AM Case Presentation Update

James C. Coons, PharmD, University of Pittsburgh, Pittsburgh, PA, USA

SCIENTIFIC PROGRAM

11:35 AM *When Medical Therapy is Not Enough: Options for Bridging to Lung Transplantation or Palliation*
Robert Kormos, MD, University of Pittsburgh, Pittsburgh, PA, USA

11:50 AM *Panel Discussion*

10:30 AM – 12:00 PM

CONCURRENT SESSION 6

Circulating the Microbes: Infections for the Heart Transplant Clinician (Seaport H)

CHAIRS: Stanley I. Martin, MD and Patricia Munoz, MD
(ID, HTX)

10:30 AM (33) Humoral Immunity Profiles to Identify CMV-seropositive Heart Recipients at Risk of CMV Disease: A Prospective Multicenter Study:

E. Sarmiento¹, M. Jaramillo¹, J. Navarro¹, J. Rodriguez-Molina¹, J. Fernandez-Yañez², J. Palomo², M. Gomez-Sanchez³, M. Crespo-Leiro⁴, M. Paniagua⁴, L. Almenar⁵, M. Cebrian⁵, J. Segovia⁶, M. Gomez⁶, G. Rabago⁷, B. Levy⁷, S. Mirabet⁸, J. Lopez⁹, L. Garcia-Guereta¹⁰, J. Carbone¹. ¹Clinical Immunology, Hospital General Universitario Gregorio Marañón, Madrid, Spain, ²Cardiology, Hospital General Universitario Gregorio Marañón, Madrid, Spain, ³Cardiology, Hospital Universitario Doce de Octubre, Madrid, Spain, ⁴Cardiology, Complejo Hospitalario Universitario A Coruña, La Coruña, Spain, ⁵Cardiology, Hospital Universitario La Fe, Valencia, Spain, ⁶Cardiology, Hospital Universitario Puerta de Hierro, Madrid, Spain, ⁷Cardiac Surgery, Clínica Universitaria de Navarra, Pamplona, Spain, ⁸Cardiology, Hospital de la Santa Creu i Sant Pau, Barcelona, Spain, ⁹Cardiology, Hospital Clínico Universitario, Valladolid, Spain, ¹⁰Cardiology, Hospital Universitario La Paz, Madrid, Spain.

10:45 AM (34) Late Cytomegalovirus (CMV) Infections in Heart Transplantation (HT):

I. A. Echenique¹, M. P. Angarone², R. A. Gordon², J. Rich², A. S. Anderson², E. C. McGee³, T. O. Abicht², G. Ferguson⁴, V. Stosor¹. ¹Medicine and Surgery, Northwestern University Feinberg School of Medicine, Chicago, IL, ²Medicine, Northwestern University Feinberg School of Medicine, Chicago, IL, ³Surgery, Northwestern University Feinberg School of Medicine, Chicago, IL, ⁴Northwestern Memorial Hospital, Chicago, IL.

11:00 AM (35) CMV-Seronegative Heart Recipients Disclose a Lower Immunocompetence Status Before Transplantation in Comparison With Seropositive Patients:

J. Carbone¹, J. Rodriguez-Molina¹, J. Navarro¹, J. Fernandez-Yañez², J. Palomo², R. Alonso³, E. Sarmiento¹. ¹Clinical Immunology, Hospital General Universitario Gregorio Marañón, Madrid, Spain, ²Cardiology, Hospital General Universitario Gregorio Marañón, Madrid, Spain, ³Microbiology, Hospital General Universitario Gregorio Marañón, Madrid, Spain.

11:15 AM (36) Heart Recipients With a Lower Response To the 23-Valent Pneumococcal Polysaccharide Vaccine Are at Significant Risk of Bacterial Infection After Transplantation:

E. Sarmiento¹, J. Rodriguez-Molina¹, J. Navarro¹, J. Palomo², J. Fernandez-Yañez², J. Carbone¹. ¹Clinical Immunology, Hospital General

Universitario Gregorio Marañón, Madrid, Spain, ²Cardiology, Hospital General Universitario Gregorio Marañón, Madrid, Spain.

11:30 AM (37) Persistent Blood Stream Infections Are Associated with Cerebrovascular Accidents in Patients with Continuous Flow LVADs;
 B. H. Trachtenberg¹, M. Aldeiri², A. M. Cordero-Reyes¹, P. Alvarez¹, A. Bhimaraj¹, B. Elias¹, E. E. Suarez¹, B. A. Bruckner¹, M. Loebe¹, R. L. Harris³, Y. J. Zhang⁴, G. Torre-Amione¹, J. D. Estep¹. ¹Cardiology, Houston Methodist Hospital, Houston, TX, ²Cardiology, University of Texas Medical Branch, Galveston, TX, ³Infectious Disease, Houston Methodist Hospital, Houston, TX, ⁴Neurosurgery, Houston Methodist Hospital, Houston, TX.

11:45 AM (38) Spectrum and Etiologies of Ventricular Assist Device Infections: A Single Center Study;
 V. Stosor¹, K. Meehan², T. Abicht³, R. Gordon⁴, J. Rich⁴, A. Anderson⁴, E. McGee³. ¹Medicine and Surgery, Northwestern University Feinberg School of Medicine, Chicago, IL, ²Surgery, Northwestern Memorial Hospital, Chicago, IL, ³Surgery, Northwestern University Feinberg School of Medicine, Chicago, IL, ⁴Medicine, Northwestern University Feinberg School of Medicine, Chicago, IL.

NOON – 2:00 PM

LUNCH BREAK/VIEW POSTERS

COUNCIL, COMMITTEE AND BOARD ORIENTATION (Gaslamp A-C)

NOON – 12:45 PM

BOX LUNCH DISTRIBUTION (Palm Foyer)

12:05 PM – 1:00 PM

JUNIOR FACULTY AND TRAINEE COUNCIL MEETING (Harbor GHI)

12:15 PM – 1:15 PM

PULMONARY COUNCIL QOL WORKFORCE MEETING (Gaslamp D)

1:00 PM – 1:55 PM

AN AUTHOR WORKSHOP (Harbor GHI)

with *Elizabeth Perill*, Executive Publisher, Surgery, Elsevier

Knowing the best way to structure your research paper, identify the most appropriate journal and understand the peer review process is critical to getting your work published.

Attend this workshop and learn from the world's leading publisher of Science, Technology and Health and Medical journals: steps to take before writing a paper; how to develop and submit a manuscript; what editors and publishers are looking for. Sensitive areas such as publishing ethics, plagiarism and duplicate publishing will also be addressed.

2:00 PM – 3:30 PM

CONCURRENT SESSION 7

Mechanical Circulatory Support: Stop the Bleeding! (Seaport)

CHAIRS: Evgenij V. Potapov, MD, PhD and George M. Wieselthaler, MD
(MCS, PHARM)

- 2:00 PM** **(39) A Novel Model to Predict the Risk of Non-Surgical Bleeding Among Patients Receiving Continuous Flow Left Ventricular Assist Devices;**
J. Wever-Pinzon, O. Wever-Pinzon, S. Mckellar, C. Badger, J. Fang, S. Drakos, E. Gilbert, M. Everitt, R. Alharethi, D. Budge, J. Stehlik, A. Kfoury, C. Selzman, J. Nativi-Nicolau. UTAH Cardiac Transplant Program, Salt Lake City, UT.
- 2:15 PM** **(40) Improvement in Acquired Von Willebrand Syndrome with Aortic Valve Opening in Patients with Centrifugal Continuous Flow Left Ventricular Assist Devices;**
K. Muthiah¹, D. Connor², K. Ly², D. Robson¹, P. Macdonald¹, J. Joseph², C. S. Hayward¹. ¹Cardiac Failure and Transplant Unit, St. Vincent's Hospital, Sydney, Australia, ²Department of Haematology, St. Vincent's Center for Applied Medical Research, Sydney, Australia.
- 2:30 PM** **(41) Can We Define a Device-specific Profile for Acquired Von Willebrand Syndrome in Continuous Flow Left Ventricular Assist Device Recipients?;**
N. M. Tricarico, M. E. Davis, M. E. Keebler, S. Maltais, N. A. Haglund, D. J. Lenihan. Vanderbilt University Medical Center, Nashville, TN.
- 2:45 PM** **(42) von Willebrand Factor Degradation with an LVAD Occurs via Two Distinct Mechanisms: Mechanical Demolition and Enzymatic Cleavage;**
C. R. Bartoli, D. J. Restle, J. Woo, M. A. Acker, P. Atluri. University of Pennsylvania, Philadelphia, PA, PA.
- 3:00 PM** **(43) Anti-factor Xa Levels Versus Activated Partial Thromboplastin Time for Monitoring Unfractionated Heparin in Patients with Continuous Flow Left Ventricular Assist Devices;**
H. Yarmohammadi, C. Holley, T. Thennapin, S. Duval, M. Pritzker, R. Cogswell, R. John, M. Colvin-Adams, P. Eckman, S. Adaty. University of Minnesota, Minneapolis, MN.
- 3:15 PM** **(44) Intracranial Hemorrhage Is Associated with a Higher Doppler Blood Pressure during Continuous Flow Left Ventricular Assist Device Support;**
O. Saeed¹, R. Jermyn¹, S. Mannem¹, C. Nucci¹, D. Casazza¹, S. Farooqui², M. Bloom², A. McLarty³, R. Zolty¹, J. Shin¹, D. D'Alessandro⁴, D. J. Goldstein⁴, S. Patel¹. ¹Medicine, Montefiore Medical Center, Albert Einstein College of Medicine, Bronx, NY, ²Medicine, Stony Brook University, Long Island, NY, ³Surgery, Stony Brook University, Long Island, NY, ⁴Cardiothoracic and Vascular Surgery, Montefiore Medical Center, Albert Einstein College of Medicine, Bronx, NY.

2:00 PM – 3:30 PM

CONCURRENT SESSION 8

Measure for Measure: Assessment of Cardiac Allograft and Immune Function (Grand Hall A)

CHAIRS: Kristjan Karason, MD and Lori J. West, MD, DPhil
(HTX, BSTR)

- 2:00 PM (45) Early Immune Monitoring After Cardiac Transplantation Predicts Progression of Maximal Intimal Thickness by Intravascular Ultrasound;**
R. Cheng, B. Azarbal, J. Patel, M. Kittleson, J. Kobashigawa.
Cedars-Sinai Heart Institute, Los Angeles, CA.
- 2:15 PM (46) Incidence and Importance of Donor-Specific HLA Antibody in Heart Transplant Recipients;**
Q. Zhang¹, J. McNamara¹, M. Cadeiras², T. Khuu², A. Baas², E. C. Depasquale², N. Halnon², G. Perens², J. A. Carlos², A. Nsair², R. Shemin³, K. Murray³, A. Ardehali³, M. Deng², E. F. Reed¹.
¹Department of Pathology, UCLA Immunogenetics Center, David Geffen School of Medicine at UCLA, Los Angeles, CA, ²Department of Medicine, David Geffen School of Medicine at UCLA, Los Angeles, CA, ³Department of Surgery, David Geffen School of Medicine at UCLA, Los Angeles, CA.
- 2:30 PM (47) Increased Sensitization To HLA and To Cardiac Self-Antigens (Myosin and Vimentin) in Patients Waiting for Cardiac Transplantation With Left Ventricular Assisting Device (LVAD);**
B. Banan¹, D. Phelan¹, M. Askar², G. Ewald³, T. Mohanakumar¹.
¹Surgery, Washington University School of Medicine, St. Louis, MO, ²Transplantation Center, Cleveland Clinic, Cleveland, OH, ³Cardiology, Washington University School of Medicine, St. Louis, MO.
- 2:45 PM (48) Plasma Protein Biosignatures for Detection of Cardiac Allograft Vasculopathy;**
M. Toma¹, Z. Hollander², J. E. Wilson-McManus², D. Lin¹, K. K. Lam², D. L. Dai², G. Cohen Freue¹, S. J. Tebbutt¹, R. Balshaw³, C. Borchers⁴, R. A. Davies⁵, D. Delgado⁶, H. Haddad⁵, A. Ignaszewski¹, D. L. Isaac⁷, D. H. Kim⁸, M. Rajda⁹, H. Ross⁶, L. J. West¹⁰, M. White¹¹, S. Zieroth¹², J. G. Mancini¹, R. W. McMaster¹, P. A. Keown¹, R. T. Ng², B. M. McManus². ¹University of British Columbia, Vancouver, BC, Canada, ²PROOF Centre of Excellence, Vancouver, BC, Canada, ³BC Centre for Disease Control, Vancouver, BC, Canada, ⁴UVic Genome BC Proteomics Centre, Victoria, BC, Canada, ⁵University of Ottawa Heart Institute, Ottawa, ON, Canada, ⁶Toronto General Hospital, Toronto, ON, Canada, ⁷University of Calgary, Calgary, AB, Canada, ⁸University of Alberta & Mazankowski Alberta Heart Institute, Edmonton, AB, Canada, ⁹Dalhousie University, Halifax, NS, Canada, ¹⁰University of Alberta, Edmonton, AB, Canada, ¹¹Montreal Heart Institute, Montreal, QC, Canada, ¹²University of Manitoba, Winnipeg, MB, Canada.
- 3:00 PM (49) Changes in Longitudinal Myocardial Function During Acute Cardiac Rejection: The Clinical Role of 2D Speckle Tracking Echocardiography;**
T. S. Clemmensen, B. B. Løgstrup, H. Eiskjær, S. H. Poulsen.
Department of Cardiology, Aarhus University Hospital, Skejby, Denmark.

3:15 PM (50) Blood Test to Monitor for the Absence of Acute Cardiac Rejection: From Discovery to Clinical Implementation;

Z. Hollander¹, K. K. Lam¹, J. E. Wilson-McManus¹, S. Assadian¹, D. L. Dai¹, C. Shannon¹, V. Chen¹, S. J. Tebbutt¹, R. Balshaw², C. Borchers³, R. A. Davies⁴, D. Delgado⁵, H. Haddad⁴, A. Ignaszewski⁶, D. L. Isaac⁷, D. H. Kim⁸, A. Mui⁶, M. Rajda⁹, H. Ross⁵, L. J. West¹⁰, M. White¹¹, S. Zieroth¹², R. W. McMaster⁶, P. A. Keown⁶, R. T. Ng¹, B. M. McManus¹. ¹PROOF Centre of Excellence, Vancouver, BC, Canada, ²BC Centre for Disease Control, Vancouver, BC, Canada, ³UVic Genome BC Proteomics Centre, Victoria, BC, Canada, ⁴University of Ottawa Heart Institute, Ottawa, ON, Canada, ⁵Toronto General Hospital, Toronto, ON, Canada, ⁶University of British Columbia, Vancouver, BC, Canada, ⁷University of Calgary, Calgary, AB, Canada, ⁸University of Alberta & Mazankowski Alberta Heart Institute, Edmonton, AB, Canada, ⁹Dalhousie University, Halifax, NS, Canada, ¹⁰University of Alberta, Edmonton, AB, Canada, ¹¹Montreal Heart Institute, Montreal, QC, Canada, ¹²University of Manitoba, Winnipeg, MB, Canada.

2:00 PM – 3:30 PM

CONCURRENT SESSION 9

**Ex-Vivo Lung Perfusion Science on the Horizon
(Grand Hall B)****CHAIRS:** Daniel Kreisel, MD, PhD and Stig Steen, MD, PhD
(LTX, BSTR, DMD)

2:00 PM (51) Pharmacological Inhibition of Peroxynitrite and Poly (ADP-ribose) Polymerase during Ex-Vivo Lung Perfusion (EVLV) Markedly Reduces Ischemia-reperfusion Injury in the Explant Donor Lung; X. Wang¹, E. Abdelnour¹, Y. Wang², R. Parapanov¹, F. Gronchi³, J. Perentes¹, M. Gonzalez¹, H. Ris¹, L. Liaudet⁴, T. Krueger¹. ¹Division of Thoracic Surgery, University Hospital of Lausanne, Lausanne, Switzerland, ²Division of Cardiovascular Surgery, West China Hospital, Lausanne, China, ³Division of Anesthesiology, University Hospital of Lausanne, Lausanne, Switzerland, ⁴Division of Intensive Care Medicine, University Hospital of Lausanne, Lausanne, Switzerland.

2:15 PM (52) Dual Ex-Vivo Lung Perfusion Techniques Ameliorate Airway Hypoxia in Lung Grafts in Rats; Y. Tanaka¹, N. Shigemura¹, K. Noda¹, Y. Saito¹, Y. Maniwa², J. K. Bhama³, J. D'Cunha¹, J. M. Pilewski³, J. D. Luketich¹, C. A. Bermudez¹. ¹Department of Cardiothoracic Surgery, University of Pittsburgh Medical Center, Pittsburgh, PA, ²Department of Thoracic Surgery, Kobe University Graduate School of Medicine, Kobe, Japan, ³Medicine, University of Pittsburgh Medical Center, Pittsburgh, PA.

2:30 PM (53) Preconditioning Lung Grafts with Inhaled Hydrogen during Ex-Vivo Lung Perfusion Improves Post-transplant Lung Grafts Function; K. Noda, N. Shigemura, Y. Tanaka, Y. Saito, J. K. Bhama, J. D'Cunha, J. M. Pilewski, J. D. Luketich, C. A. Bermudez. Department of Cardiothoracic Surgery, University of Pittsburgh Medical Center, Pittsburgh, PA.

2:45 PM (54) A Positive Left Atrial Pressure Is Important During Ex-Vivo Lung Perfusion; V. Linacre, M. Cypel, T. Machuca, D. Nakajima, K. Hashimoto, R. Zamel, M. Chen, I. Iskender, P. R. dos Santos, T. Waddell, M. Liu, S. Keshavjee. Latner Thoracic Surgery Research Laboratories, University Health Network, University of Toronto, Toronto, ON, Canada.

3:00 PM (55) Expanded Thymic CD25+FOXP3+ Regulatory T Cells (Tregs) Maintain Stable Function and Phenotype Under Inflammatory Conditions – Potential for Cellular Therapy?; E. Dijke¹, A. McMurchy², T. Ellis¹, K. Boer³, I. Larsen¹, I. Rebecka¹, D. Ross¹, C. Baan³, M. Levings², L. West¹. ¹University of Alberta, Edmonton, AB, Canada, ²University of British Columbia, Vancouver, BC, Canada, ³Erasmus MC Medical Center, Rotterdam, Netherlands.

3:15 PM (56) Ex-Vivo Perfusion Treatment of Infection in Human Donor Lungs; D. Nakajima¹, M. Cypel¹, R. Bonato¹, T. N. Machuca¹, K. Hashimoto¹, V. Linacre¹, I. Iskender¹, M. Chen¹, T. K. Waddell¹, M. Liu¹, D. M. Hwang¹, S. Husain², S. Keshavjee¹. ¹Latner Thoracic Surgery Research Laboratories, Toronto General Research Institute, University Health Network, Toronto, ON, Canada, ²Transplant Infectious Disease Unit, University Health Network, Toronto, ON, Canada.

2:00 PM – 3:30 PM

CONCURRENT SESSION 10

Lung Transplant Outcomes: Good, Better, Best: Let Us Never Rest (Grand Hall C)

CHAIRS: Joshua M. Diamond, MD and Gregory I. Snell, FRACP, MBBS, MD (LTX, LF)

- 2:00 PM** **(57) Lung Transplantation in Scleroderma?:**
E. C. DePasquale¹, D. Ross², A. Ardehali³. ¹Division of Cardiology, UCLA, Los Angeles, CA, ²Division of Pulmonology, UCLA, Los Angeles, CA, ³Division of Cardiothoracic Surgery, UCLA, Los Angeles, CA.
- 2:15 PM** **(58) Outcomes and Survival Benefit of Lung Transplantation for Cystic Fibrosis: Single-Center Experience of 309 Consecutive Cases:**
T. N. Machuca¹, M. Solomon², C. Chaparro³, A. Stephenson³, E. Tullis³, M. Cypel¹, T. Saito¹, S. Azad¹, H. Grasemann², M. Binnie³, C. Chow¹, A. Pierre¹, K. Yasufuku¹, M. de Perrot¹, T. K. Waddell¹, L. G. Singer³, S. Keshavjee¹. ¹Thoracic Surgery, University of Toronto, Toronto, ON, Canada, ²Respiratory Medicine, Hospital for Sick Children, Toronto, ON, Canada, ³Respirology, University of Toronto, Toronto, ON, Canada.
- 2:30 PM** **(59) Contemporary Outcomes of Lung Transplantation in Patients with Preoperative Extracorporeal Membrane Oxygenation: A Propensity-Match Analysis:**
C. Bermudez¹, T. Richards¹, N. Shigemura¹, J. Bhama¹, P. Sappington², M. Crespo³, M. Morell⁴, J. Pilewski⁴, J. D'Cunha¹. ¹Cardiothoracic Surgery, UPMC, Pittsburgh, PA, ²Critical care Medicine, UPMC, Pittsburgh, PA, ³Department of Medicine, UPMC, Pittsburgh, PA, ⁴Medicine, UPMC, Pittsburgh, PA.
- 2:45 PM** **(60) Outcomes of Intraoperative ECMO Versus Cardiopulmonary Bypass for Lung Transplantation:**
T. N. Machuca¹, S. Collaud¹, O. Mercier¹, V. Linacre¹, T. Krueger¹, S. Azad¹, L. Singer², K. Yasufuku¹, M. de Perrot¹, A. Pierre¹, T. K. Waddell¹, S. Keshavjee¹, M. Cypel¹. ¹Thoracic Surgery, University of Toronto, Toronto, ON, Canada, ²Respirology, University of Toronto, Toronto, ON, Canada.
- 3:00 PM** **(61) Genetic Variation in Immunoglobulin G Receptor Affects Survival After Lung Transplantation:**
D. Ruttens¹, S. E. Verleden¹, P. C. Goeminne¹, E. Vandermeulen¹, E. Wauters², R. Vos¹, D. E. Van Raemdonck¹, D. Lambrechts², B. M. Vanaudenaerde¹, G. M. Verleden¹. ¹Lung Transplant Unit, KULeuven, Leuven, Belgium, ²Vesalius Research Centrum, VIB, Leuven, Belgium.
- 3:15 PM** **(62) Is a Priori Staging of Bilateral Lung Transplant the Optimal Surgical Approach for High-risk Patients With Interstitial Lung Disease?:**
A. M. Ganapathi¹, M. G. Hartwig¹, A. A. Osho¹, B. R. Englum¹, P. J. Speicher¹, S. M. Palmer², R. Davis¹. ¹Department of Surgery, Duke University Medical Center, Durham, NC, ²Department of Medicine, Duke University Medical Center, Durham, NC.

2:00 PM – 3:30 PM

CONCURRENT SESSION 11

**Clinical Case Dilemmas in Thoracic Transplantation:
The Best of the Best (Grand Hall D)****CHAIRS:** Pali D. Shah, MD and Cynthia J. Gries, MD, MSc
(ALL)**EXPERT PANEL:***David O. Taylor, MD, Cleveland Clinic
Foundation, Cleveland, OH, USA (HEART)**Tam Khuu, PharmD, BCPS, University of
California at Los Angeles, Los Angeles, CA,
USA (PHARM)**Nancy L. Reinsmoen, PhD D Abhi, Cedars-Sinai
Health System, Los Angeles, CA, USA (PATH)**Scott M. Palmer, MD, MHS, Duke University,
Durham, NC, USA (LUNG)**Andreas Zuckermann, MD, Medical University of
Vienna, Vienna, Austria (MCS)**Stanley I. Martin, MD, The Ohio State University
Medical Center, Columbus, OH, USA (ID)***2:00 PM (63) Carfilzomib for Refractory Antibody
Mediated Rejection and Allosensitization in
Heart Transplantation;***L. Sacha¹, J. J. Teuteberg², A. Zeevi³, C. Bermudez², R. Kormos²,
C. Ensor¹, J. McDyer⁴, M. A. Shullo¹. ¹Pharmacy and Therapeu-
tics, University of Pittsburgh, Pittsburgh, PA, ²Heart and Vascul-
lar Institute, UPMC, Pittsburgh, PA, ³Histopathology, University
of Pittsburgh, Pittsburgh, PA, ⁴Medicine, University of Pitts-
burgh, Pittsburgh, PA.***2:22 PM (64) Belatacept as Primary Immunosuppression
in a Lung Transplant Recipient;***P. Ong¹, L. Mudambi¹, A. Fuentes², K. Dawson², N. Sinha³, B.
Mankidy³, S. Scheinin¹, T. Kaleekal³, S. Jyothula³. ¹Pulmonary
and Critical Care Medicine, Baylor College of Medicine, Houston,
TX, ²Department of Pharmacy, Houston Methodist Hospital,
Houston, TX, ³JC Walter Jr Transplant Center, Houston Methodist
Hospital, Houston, TX.***2:44 PM (65) Successful Use of Cidofovir and
Leflunomide in Lung Transplant Recipient
with BK Polyomavirus Encephalitis;***P. Ong¹, A. Fuentes², K. Dawson², N. Sinha³, B. Mankidy³, M.
Loebe³, T. Kaleekal³, S. Jyothula³. ¹Pulmonary and Critical Care
Medicine, Baylor College of Medicine, Houston, TX, ²Department
of Pharmacy, Houston Methodist Hospital, Houston, TX, ³JC Walter
Jr Transplant Center, Houston Methodist Hospital, Houston, TX.***3:06 PM (66) Ultrasound-accelerated, Catheter-directed
Thrombolysis in the Treatment of LVAD Thrombosis;***R. T. Cole, E. C. Clermont, D. Gupta, M. Jokhadar, M. Millard, K.
McTeague, V. Babaliaros. Cardiology, Emory University, Atlanta, GA.*

2:00 PM – 3:30 PM

CONCURRENT SYMPOSIUM 26

Infections in Mechanical Circulatory Support Devices – Understanding and Conquering the Beast (Harbor GHI)

CHAIRS: Martha Mooney, MD, FACP and Guy MacGowan, MD

(ID, MCS)

SESSION SUMMARY: This symposium will focus on pathogenesis, recent guidelines on diagnosis, as well as medical and surgical approaches for the management and prevention of Mechanical Circulatory Support Device-associated infections.

2:00 PM *Case Presentation*

Pavan Atluri, M.D., University of Pennsylvania, Philadelphia, PA, USA

2:05 PM *Biofilm Basics: Understanding The Beast*

Robert F. Padera, MD, PhD, Brigham and Women's Hospital, Boston, MA, USA

2:20 PM *Diagnosis and Classification of MCS D Infection*

Margaret M. Hannan, MD, Mater Misericordiae University Hospital, Dublin, Ireland

2:35 PM *Driveline Infection, the Role of Nurse/VAD Coordinator*

Linda L. Staley, RN, MSN NP, Mayo Clinic Hospital, Phoenix, AZ, USA

2:50 PM *Surgical Approach to the Management of MCS D Infections*

Benjamin Medalion, MD, Rabin Medical Center Beilinson Campus, Petach Tiqva, Israel

3:05 PM *Imaging The Infected MCS Patient*

Matthew Romano, MD, University of Michigan, Ann Arbor, MI, USA

3:20 PM *Panel Discussion*

2:00 PM – 3:30 PM

CONCURRENT SESSION 12

Improving Outcomes: Interventions & Strategies (Seaport H)

CHAIRS: Masina Scavuzzo, RN and Emily Stimpson, RN, BSN, CCT
(NNSAH)

- 2:00 PM** **(67) Teen Pocket PATH: A Randomized Pilot of a Mobile Health Application To Improve Adherence Among Adolescent Solid Organ Transplant Recipients;**
D. A. Shellmer¹, A. DeVito Dabbs², M. Dew³, G. Mazariegos¹.
¹Hillman Center for Pediatric Transplantation, University of Pittsburgh/Children's Hospital of Pittsburgh, Pittsburgh, PA, ²Nursing, University of Pittsburgh, Pittsburgh, PA, ³Epidemiology, Psychiatry, University of Pittsburgh, Pittsburgh, PA.
- 2:15 PM** **(68) Longer Versus a Shorter Duration Exercise Rehabilitation Program Following Lung Transplant: A Randomised Controlled Trial;**
L. M. Fuller¹, B. Button¹, B. Tarrant¹, R. Steward¹, G. Snell², A. Holland³. ¹Physiotherapy, The Alfred Hospital, Melbourne, Australia, ²Lung Transplant AIRMED, The Alfred Hospital, Melbourne, Australia, ³Physiotherapy La Trobe University, The Alfred Hospital, Melbourne, Australia.
- 2:30 PM** **(69) Perceived Control: A Target for Improving Psychosocial Outcomes Early After Heart Transplant;**
L. Doering¹, K. Hickey², B. Chen¹, F. Idemundia¹, E. Carter³, D. Pickham³, C. Castillo², D. Mancini⁴, M. Deng⁵, J. Kobashigawa⁶, B. Drew³. ¹School of Nursing, UCLA, Los Angeles, CA, ²School of Nursing, Columbia University, New York, NY, ³School of Nursing, UCSF, San Francisco, CA, ⁴Columbia University Medical Center, New York, NY, ⁵UCLA Ronald Reagan Medical Center, Los Angeles, CA, ⁶Cedars-Sinai Heart Institute, Cedars-Sinai Medical Center, Los Angeles, CA.
- 2:45 PM** **(70) A Longitudinal Examination of Quality of Life and Survival Long-term after Heart Transplantation;**
C. White-Williams¹, P. Fazeli¹, B. Rybarczyk², K. Grady³. ¹UAB, Birmingham, AL, ²VCU, Richmond, VA, ³Northwestern University, Chicago, IL.
- 3:00 PM** **(71) A Patient-Centric Conceptual Framework for Health-related Quality of Life in Mechanical Circulatory Support;**
K. L. Grady¹, S. Magasi², E. A. Hahn³, E. C. McGee Jr.¹, C. Yancy⁴.
¹Surgery/Division of Cardiac Surgery, Northwestern University, Chicago, IL, ²Occupational Therapy, University of Illinois at Chicago, Chicago, IL, ³Medical Social Sciences, Northwestern University, Chicago, IL, ⁴Medicine/Division of Cardiology, Northwestern University, Chicago, IL.
- 3:15 PM** **(72) Higher Quality of Caregiver Support Is Associated with Post-Transplant Adherence at 6 Months;**
J. M. Rowan¹, C. J. Gries¹, A. J. Devito Dabbs². ¹PACCM, UPMC - Pittsburgh, PA, Pittsburgh, PA, ²University of Pittsburgh School of Nursing, UPMC - Pittsburgh, PA, Pittsburgh, PA.

SCIENTIFIC PROGRAM

3:30 PM – 4:00 PM

COFFEE BREAK/VISIT EXHIBITS (Harbor A-F)

VIEW POSTERS (Harbor and Seaport Foyers)

4:00 PM – 5:30 PM

CONCURRENT SESSION 13

Optimizing Mechanical Circulatory Support Outcomes I (Seaport)

CHAIRS: Marian Zembala, MD, PhD and Douglas A. Horstmannshof, MD (MCS)

4:00 PM **(73)** *Outcome and Survival Following Cardiogenic Shock Supported By IABP Versus Mechanical Circulatory Support Devices in a National Cohort;* R. J. Stretch¹, P. Bonde². ¹Bonde Artificial Heart Lab, Yale School of Medicine, New Haven, CT, ²Section of Cardiac Surgery, Yale School of Medicine, New Haven, CT.

4:15 PM **(74)** *Does Preoperative Mitral Regurgitation Influence Outcomes After Continuous-Flow Left Ventricular Assist Device Implantation?;* S. Maltais¹, V. Tchanchaleishvili², N. A. Haglund¹, J. Cowger¹, M. E. Davis¹, M. Keebler¹, L. D. Joyce¹, R. C. Daly¹, S. J. Park³, K. D. Aaronson¹, F. D. Pagani³, J. M. Stulak³. ¹Vanderbilt University Medical Center, Nashville, TN, ²University of Rochester Medical Center, Rochester, NY, ³Mayo Clinic, Rochester, MN.

4:30 PM **(75)** *Does Metabolic Syndrome Affect Outcomes After Left Ventricular Assist Device Implantation?;* S. Maltais¹, N. A. Haglund¹, J. Cowger¹, M. E. Davis¹, L. D. Joyce¹, R. C. Daly¹, S. J. Park¹, K. Aaronson¹, F. Pagani¹, J. M. Stulak². ¹Vanderbilt University Medical Center, Nashville, TN, ²Mayo Clinic, Rochester, MN.

4:45 PM **(76)** *The Impact of LVAD Program Volume and Transplant Status on Cost, Quality, and Survival in the UHC Database 2010-2012;* S. C. Silvestry, A. Itoh, T. Kazui, S. M. Prasad. Surgery/Cardiac Surgery, Washington University School of Medicine, Saint Louis, MO.

5:00 PM **(77)** *Frailty Is Associated With Increased Time on Ventilator in Patients Undergoing Left Ventricular Assist Device Implantation: A Prospective Study;* J. Manghelli¹, J. Vader¹, T. Keeney², S. Martinez¹, J. Patel¹, E. Novak¹, S. Nagabandi¹, M. Rich¹, S. Silvestry³, S. M. Joseph¹. ¹Cardiovascular Division, Washington University School of Medicine, St Louis, MO, ²Rehabilitation Division, Barnes Jewish Hospital, St Louis, MO, ³Division of Cardiothoracic Surgery, Washington University School of Medicine, St Louis, MO.

5:15 PM **(78)** *Comparison of Total Artificial Heart and Biventricular Assist Device Support as Bridge-to-Transplantation;* A. Cheng¹, J. R. Trivedi¹, K. McCants², E. J. Birks², A. J. Lenneman², R. Singh¹, M. L. Williams¹, M. S. Slaughter¹. ¹Thoracic and Cardiovascular Surgery, University of Louisville, Louisville, KY, ²Cardiology – Heart Failure, University of Louisville, Louisville, KY.

4:00 PM – 5:30 PM

CONCURRENT SESSION 14

**The Future of Mechanical Circulatory Support is Now
(Grand Hall A)****CHAIRS:** Fernando A. Figueira, MD and Eugene Christopher DePasquale, MD
(MCS)

- 4:00 PM (79) First Report of the PAS INTERMACs Registry of the HVAD in Commercial Use:**
S. Maltais¹, M. E. Keebler¹, K. H. Schlendorf¹, S. W. Boyce², S. S. Najjar², F. D. Pagani³, K. D. Aaronson³, V. Jeevanandam⁴, C. A. Milano⁵, J. Rogers⁵, R. Love⁶, C. Mahr⁷, D. Thin Pham⁸, M. Kiernan⁸, R. L. Kormos⁹, J. J. Teuteberg⁹, S. C. Silvestry¹⁰, G. Ewald¹⁰, E. C. McGee¹¹, R. Gordon¹¹, H. R. Mallidi¹², O. H. Frazier¹². ¹Vanderbilt Heart and Vascular Institute, Nashville, TN, ²MedStar Heart Institute, Washington, DC, ³University of Michigan, Ann Arbor, MI, ⁴University of Chicago, Chicago, IL, ⁵Duke University Medical Center, Durham, NC, ⁶Froedtert Hospital/Medical College of Wisconsin, Milwaukee, WI, ⁷Froedtert Hospital/Medical College, Milwaukee, WI, ⁸Tufts Medical Center, Boston, MA, ⁹University of Pittsburgh Medical Center, Pittsburgh, PA, ¹⁰Barnes Jewish Hospital, St. Louis, MO, ¹¹Northwestern University, Chicago, IL, ¹²Texas Heart Institute, Houston, TX.
- 4:15 PM (80) Totally Implantable LVAD: Progress on Portable Wireless Power Delivery System and Results of In-vivo Testing:**
B. Waters¹, J. Smith², P. Bonde³. ¹Department of Electrical Engineering, University of Washington, Seattle, WA, ²Department of Computer Science and Engineering, University of Washington, Seattle, WA, ³Center for Advanced Heart Failure and Transplantation, Yale University School of Medicine, New Haven, CT.
- 4:30 PM (81) Contemporary Outcome of Mechanical Circulatory Support Therapy: Analysis of Multicenter Registry, RESCUE:**
H. Takayama¹, M. Kai², M. Camacho³, B. Kalesan¹, U. Jorde¹, L. Truby¹, A. Gass⁴, D. Spielvogel⁵, D. Baran⁶, M. Zucker⁶, B. Sun⁷. ¹Columbia University College of Physicians and Surgeons, New York, NY, ²Westchester Medical Center, Valhalla, NY, ³Newark Beth Israel Medical Center, Newark, NJ, ⁴Cardiology, Westchester Medical Center, Valhalla, NY, ⁵Cardiothoracic Surgery, Westchester Medical Center, Valhalla, NY, ⁶Newark Beth Israel Medical Center, Newark, NJ, ⁷Minneapolis Heart Institute, Minneapolis, MN.
- 4:45 PM (82) Utility of Tricuspid Valve Repair at the Time of Left Ventricular Assist Device Implantation:**
H. K. Song¹, J. O. Mudd¹, J. M. Gelow¹, C. V. Chien¹, F. A. Tibayan¹, K. A. Hollifield², D. C. Naftel², J. K. Kirklin². ¹Oregon Health & Science University, Portland, OR, ²University of Alabama at Birmingham, Birmingham, AL.
- 5:00 PM (83) HeartWare Ventricular Assist Device Implantation: Are In-Hospital Outcomes Using a Minimally Invasive Thoracotomy Approach Comparable to Conventional Sternotomy?:**
N. Haglund, M. E. Davis, H. Nian, J. Kennedy, J. Stulak, K. Schlendorf, M. Keebler, S. Maltais. Vanderbilt University Medical Center, Nashville, TN.
- 5:15 PM (84) The Columbia Experience of 163 Patients with Venoarterial Extracorporeal Membranous Oxygenation for Refractory Cardiogenic Shock:**
L. Truby¹, L. Mundy¹, T. Hongo¹, A. Kirtane¹, L. Mongero², E. Landes¹, M. Yuzefpolskaya¹, N. Uriel¹, P. C. Colombo¹, U. P. Jorde¹, K. Takeda¹, Y. Naka¹, H. Takayama¹. ¹Columbia University College of Physicians and Surgeons, New York, NY, ²New York Presbyterian Hospital, New York, NY.

4:00 PM – 5:30 PM

CONCURRENT SESSION 15

Adult Heart Failure: Novel Diagnostics (Grand Hall B)

CHAIRS: Nicola E. Hiemann, MD and Barry M. Cabuay, MD
(HF, BSTR)

- 4:00 PM** **(85) *The Prognostic Role of Cardiac Power Indices in Advanced Chronic Heart Failure:***
J. L. Grodin¹, M. Dupont², W. Mullens², D. O. Taylor¹, R. C. Starling¹, W. Tang¹. ¹Cardiovascular Medicine, Cleveland Clinic Foundation, Cleveland, OH, ²Cardiology, Ziekenhuis Oost-Limburg, Genk, Belgium.
- 4:15 PM** **(86) *NGS PBMC Transcriptome Analysis Identifies More Pronounced Activation of the Inflammatory Response in Advanced INTERMACS Class Before MCS/DCD Implantation:***
G. Bondar¹, M. Cadeiras¹, N. Wisniewski¹, E. Chang¹, M. Bakir¹, J. Chittoor¹, J. Maque¹, K. Dong¹, C. Y. Chan², Y. D. Korin³, P. Ping², E. F. Reed², M. Deng¹. ¹Medicine/Cardiology, UCLA, Los Angeles, CA, ²Physiology and Medicine/Cardiology, Proteomics Center, David Geffen School of Medicine at UCLA, Los Angeles, CA, ³Pathology and Laboratory Medicine/Immunogenetic Center, David Geffen School of Medicine at UCLA, Los Angeles, CA.
- 4:30 PM** **(87) *A Combined-biomarker Approach To Phenotyping Renal Dysfunction in Heart Failure:***
S. J. Cheng¹, B. D. McCauley², M. A. Brisco³, O. Laur¹, A. J. Kula¹, J. M. Testani¹. ¹Yale University School of Medicine, New Haven, CT, ²University of Pennsylvania School of Medicine, Philadelphia, PA, ³Medical University of South Carolina, Charleston, SC.
- 4:45 PM** **(88) *Cardiac Metabolism Gene Expression Differences in Patients With Advanced Ischemic Versus Non-Ischemic Cardiomyopathy:***
C. Yen, N. Diakos, C. H. Selzman, B. Reid, J. Stehlik, A. Koufry, X. Guo, S. Navankasattusas, W. T. Caine, S. McKellar, E. Gilbert, J. Fang, D. Budge, D. Y. Li, S. G. Drakos. U.T.A.H. Cardiac Transplant, University of Utah, Salt Lake City, UT.
- 5:00 PM** **(89) *The Diastolic Pulmonary Gradient as a Predictor of Adverse Outcomes in Patients With Acute Decompensated Heart Failure:***
V. N. Selby¹, J. Vachieny², J. C. Fang³, M. Janmohamed¹, L. Klein¹, M. H. Park⁴, R. L. Benza⁵, R. P. Frantz⁶, N. Galie⁷, T. De Marco¹. ¹Division of Cardiology, University of California, San Francisco, San Francisco, CA, ²Cliniques Universitaires de Bruxelles – Hôpital Erasme, Brussels, Belgium, ³Division of Cardiology, University of Utah, Salt Lake City, UT, ⁴Division of Cardiology, University of Maryland School of Medicine, Baltimore, MD, ⁵Department of Medicine, Allegheny General Hospital, Pittsburgh, PA, ⁶Division of Cardiovascular Diseases, Mayo Clinic, Rochester, MN, ⁷Department of Experimental, Diagnostic and Specialty Medicine, Bologna University Hospital, Bologna, Italy.
- 5:15 PM** **(90) *Left Ventricular vs. Bi-Ventricular Assist Device Implantation: Improvement of Preoperative Decision Making by Assessing Right Ventricular Adaptation to Loading Conditions:***
M. Dandel, E. Potapov, T. Krabatsch, C. Knosalla, R. Hetzer. Cardiothoracic and Vascular Surgery, Deutsches Herzzentrum Berlin, Berlin, Germany.

4:00 PM – 5:30 PM

CONCURRENT SESSION 16

Chronic Lung Allograft Dysfunction: Phenotypes and Risk Factors (Grand Hall C)**CHAIRS:** Robin Vos, MD, PhD and Scott M. Palmer, MD, MHS (LTX)

- 4:00 PM (91) Developing a Score of Early Postoperative Regulatory T Cell Frequency To Predict Bronchiolitis Obliterans Syndrome-Free Survival at Two Years After Lung Transplantation:**
*J. Salman*¹, A. Knoefel¹, W. Sommer¹, D. Boethig¹, C. Kuehn¹, I. Tudorache¹, M. Avsar¹, F. Ius¹, K. Jansson¹, J. Gottlieb², T. Welte², A. Haverich¹, G. Warnecke¹. ¹Department for Cardiothoracic, Transplant and Vascular Surgery, Hannover Medical School, Hannover, Germany, ²Department of Pneumology, Hannover Medical School, Hannover, Germany.
- 4:15 PM (92) RESULT (Reflux Surgery in Lung Transplantation) To Determine If Prevention of GERD Related Aspiration By Surgical Fundoplication Improves Lung Allograft Function. Sponsor: National Heart, Lung, and Blood Institute (NHLBI):**
*D. Davis*¹, C. Green², S. Keshavjee³, S. Azad³, L. Singer⁴, K. McCurry⁵, M. Budev⁶, S. Palmer⁷. ¹Surgery, Duke University, Durham, NC, ²DCRI, Duke University, Durham, NC, ³Surgery, Toronto, Toronto, ON, Canada, ⁴Medicine, Toronto, Toronto, ON, Canada, ⁵Surgery, CCF, Cleveland, OH, ⁶Medicine, CCF, Cleveland, OH, ⁷Medicine, Duke University, Durham, NC.
- 4:30 PM (93) Bile Acid, Not pH Probe or Gastrin Predicts Allograft Function at One Year, From the Prospective RESULT (Reflux Surgery in Lung Transplantation):**
*D. Davis*¹, S. Azad², W. Parker¹, C. Green³, S. Keshavjee², K. McCurry⁴, L. Singer⁵, M. Budev⁶, S. Palmer⁷. ¹Surgery, Duke University, Durham, NC, ²Surgery, Toronto, Toronto, ON, Canada, ³DCRI, Duke University, Durham, NC, ⁴Surgery, CCF, Cleveland, OH, ⁵Medicine, Toronto, Toronto, ON, Canada, ⁶Medicine, CCF, Cleveland, OH, ⁷Medicine, Duke University, Durham, NC.
- 4:45 PM (94) The Impact of Air Pollution on Outcome After Lung Transplantation in Europe:**
*S. E. Verleden*¹, D. Ruttens¹, E. Bijmens², E. Winckelmans², F. Meloni³, M. Morosini³, J. Gottlieb⁴, G. Warnecke⁴, E. Verschuuren⁵, W. Van Der Bij⁵, G. Weinreich⁶, M. Kamler⁶, U. Sommerwerck⁶, B. Hoffmann⁷, A. Roman⁸, S. Gomez Olles⁸, C. Benden⁹, T. Reichsteiner⁹, B. Luijck¹⁰, E. Oudijk¹⁰, D. Van Kessel¹⁰, J. Kwakkel-Van Erp¹⁰, M. Iversen¹¹, H. Schultz¹¹, P. Jaksch¹², W. Klepetko¹², J. Lordan¹³, P. Corris¹³, A. Fisher¹³, A. Holm¹⁴, E. Vandermeulen¹, R. Vos¹, N. Kneidinger¹⁵, C. Neurohr¹⁵, R. Beelen¹⁰, D. Vienneau¹⁶, G. Hoek¹⁰, K. De Hoogh¹⁷, B. Nemery¹, G. M. Verleden¹, T. S. Nawrot², B. Vanaudenaerde¹. ¹KULeuven, Leuven, Belgium, ²UHasselt, Hasselt, Belgium, ³Università di Pavia, Pavia, Italy, ⁴Hannover Medical School, Hannover, Germany, ⁵Rijksuniversiteit Groningen, Groningen, Netherlands, ⁶Pneumology, Ruhrlandklinik West German Lung Center, University Hospital Essen, University Duisburg-Essen, Essen, Germany, ⁷IUF Leibniz Research Institute for Environmental Medicine at the University of Dusseldorf, Dusseldorf, Germany, ⁸University Hospital Vall d'Hebron, Barcelona, Spain, ⁹University Hospital Zurich, Zurich, Switzerland, ¹⁰University Medical Centre Utrecht/St. Antonius Hospital Nieuwegein, Utrecht/Nieuwegein, Netherlands, ¹¹Copenhagen University Hospital Rigshospitalet, Copenhagen, Denmark, ¹²University of Vienna, Vienna, Austria, ¹³Newcastle University,

Newcastle, United Kingdom, ¹⁴University of Oslo, Oslo, Norway, ¹⁵Klinikum Großhadern der LMU, Munich, Germany, ¹⁶University of Basel, Basel, Switzerland, ¹⁷Imperial College, London, United Kingdom.

5:00 PM **(95) *Post Mortem Confirmation of Chronic Lung Allograft Dysfunction;***

M. A. Malouf, A. P. Havryk, M. Plit, A. L. Rigby, A. R. Glanville.
Lung Transplant Unit, St Vincents Hospital Sydney, Darlinghurst, Australia.

5:15 PM **(96) *Defining Clinically Relevant CLAD Phenotypes in Bilateral and Single Lung Transplant Recipients;***

A. DerHovanesian, N. Li, M. Shino, D. M. Sayah, A. L. Gregson, J. P. Lynch III, R. Saggari, A. Ardehali, D. J. Ross, R. M. Elashoff, S. Weigt. David Geffen School of Medicine at UCLA, Los Angeles, CA.

4:00 PM – 5:30 PM

CONCURRENT SESSION 17

Management of the Pediatric Heart Recipient (Grand Hall D)

CHAIRS: Melanie D. Everitt, MD and Tajinder P. Singh, MD, MSc
(HTX, PEDS)

- 4:00 PM (97) Does Duration of Donor Cardiopulmonary Resuscitation Impact Pediatric Cardiac Graft Survival?:**
M. S. Khan¹, K. B. Karani¹, F. Zafar¹, C. D. Castleberry², R. Bryant III¹, C. Villa², A. Lorts², D. L. Morales¹. ¹Cardiothoracic Surgery, Cincinnati Children's Hospital Medical Center, Cincinnati, OH, ²Cardiology, Cincinnati Children's Hospital Medical Center, Cincinnati, OH.
- 4:15 PM (98) Induction Therapy in African American Infant Heart Transplants: Is There a Benefit?:**
B. Coleman, A. Phillips, J. Mirocha, J. Patel, F. Arabia, J. Kobashigawa. Cedars- Sinai Heart Institute, Los Angeles, CA.
- 4:30 PM (99) mTOR Inhibitors in Pediatric Heart Transplantation: Do the Potential Benefits Outweigh the Risks, Clues from the ISHLT Registry:**
C. Castleberry¹, A. Dipchand², B. Taylor¹, L. Edwards³, Z. Gao⁴, E. King⁴, C. Chin¹. ¹Pediatric Cardiology, Cincinnati Children's Hospital Medical Center, Cincinnati, OH, ²Pediatric Cardiology, Sick Kids Hospital, Toronto, ON, Canada, ³United Network for Organ Sharing, Richmond, VA, ⁴Biostatistics and Epidemiology, Cincinnati Children's Hospital Medical Center, Cincinnati, OH.
- 4:45 PM (100) Global Left Ventricular Relaxation: A Novel Tissue Doppler Index of Acute Rejection in Pediatric Heart Transplantation:**
L. E. Hernandez¹, C. W. Shepard¹, L. Valdes-Cruz², R. K. Ameduri¹. ¹Pediatrics, University of Minnesota, Amplatz Children Hospital, Minneapolis, MN, ²Pediatrics, JoeDiMaggio Children's Hospital, Hollywood, FL.
- 5:00 PM (101) Risk Factor Analysis for Individual Causes of Death Following Pediatric Heart Transplant: An Analysis of the ISHLT Registry:**
R. D. Vanderlaan¹, C. Manlhiot², L. Edwards³, B. McCrindle², A. I. Dipchand². ¹Cardiac Surgery, University of Toronto, Toronto, ON, Canada, ²Pediatrics, Labatt Family Heart Center, Hospital for Sick Children, Toronto, ON, Canada, ³ISHLT Transplant Registry, Dallas, TX.
- 5:15 PM (102) Does the Indication for Retransplantation Following Primary Heart Transplant in Childhood Impact Outcomes? An Analysis from the International Society of Heart and Lung Transplantation Registry:**
J. Conway¹, C. Manlhiot², R. Kirk³, B. W. McCrindle², L. B. Edwards⁴, A. I. Dipchand². ¹Stollery Children's Hospital, Edmonton, AB, Canada, ²The Labatt Family Heart Center, The Hospital for Sick Children, Toronto, ON, Canada, ³Institute of Transplant, Freeman Hospital, Newcastle upon Tyne, United Kingdom, ⁴International Society of Heart and Lung Transplant, Addison, TX.

4:00 PM – 5:30 PM

CONCURRENT SESSION 18

Quality of Life, Ethics, Policy and the Economics of MCS and Thoracic Transplantation (Harbor GHI)

CHAIRS: Lianne G. Singer MD, FRCPC and Fabienne Dobbels, MSc, PhD (NNSAH, PEEQ)

- 4:00 PM** **(103) *The Impact of Primary Caregivers on Long-term Outcomes after Lung Transplantation;***
N. M. Mollberg, F. Farjah, E. Howell, J. Ortiz, L. Backhus, M. S. Mulligan. University of Washington, Seattle, WA.
- 4:15 PM** **(104) *Cost Effectiveness of Routine Surveillance Endomyocardial Biopsy Beyond 12 Months Post Heart Transplantation;***
B. C. Lampert¹, J. J. Teuteberg², M. A. Shullo², J. Holtz², K. Smith³.
¹Division of Cardiovascular Medicine, The Ohio State University Wexner Medical Center, Columbus, OH, ²Heart and Vascular Institute, University of Pittsburgh, Pittsburgh, PA, ³Division of General Internal Medicine, University of Pittsburgh, Pittsburgh, PA.
- 4:30 PM** **(105) *Single Lung Transplantation in the United States: What Happens To the Other Lung?;***
P. J. Speicher, A. Ganapathi, B. Englum, B. C. Gulack, S. S. Lin, S. M. Palmer, L. D. Snyder, M. Daneshmand, R. D. Davis, M. G. Hartwig. Duke University Medical Center, Durham, NC.
- 4:45 PM** **(106) *Development and Validation of a Lung Transplant-Specific Disability Questionnaire;***
J. P. Singer, P. D. Blanc, M. Dean, S. Hays, J. Golden, J. Kukreja, L. Leard, P. Katz. UCSF, San Francisco, CA.
- 5:00 PM** **(107) *Resource and Cost Evaluation of a Destination Therapy Ventricular Assist Device Program;***
A. Barbone, A. Cappelleri, L. Ardino, A. Cappai, A. Basciu, B. Borriello, E. Vanni, M. Lettino, D. Ornaghi, D. Pini. Cardiovascular, Humanitas Research and Clinical Center, Rozzano, Italy.
- 5:15 PM** **(108) *Enhancing National Organ Donations by Prioritizing Registered Donors During Organ Allocation;***
J. Lavee¹, T. Ashkenazi², A. Stoler³. ¹Leviev Heart Center, Sheba Medical Center, Ramat Gan, Israel, ²Israel National Transplant Center, Israel Ministry of Health, Tel Aviv, Israel, ³Department of Economics, DePaul University, Chicago, IL.

4:00 PM – 5:30 PM

CONCURRENT SYMPOSIUM 27

Heart Transplantation and Mechanical Circulatory Support in Latin America (Seaport H)

CHAIRS: Bernarda Antonieta Cedano Ramirez, MD,
Heather J. Ross, MD, MHSc, FRCPC,
Josef Stehlik, MD, MPH and Adriana Torres Navas, MD

(HF, HTX, MCS)

SESSION SUMMARY: This session will review the present state, achievements, challenges and opportunities of heart transplant and MCS programs across Latin America.

- 4:00 PM** *Opening Remarks*
Lori J. West, MD, DPhil, University of Alberta,
Edmonton, AB, Canada
- 4:05 PM** *Heart Transplant in Latin America: Challenges to Overcome (Brazil / Peru)*
Juan C. Mejia, MD, Hospital De Messejana, Fortaleza, Brazil
- 4:15 PM** *Heart Transplant in Cardiomyopathy Due to Chagas Disease*
Fernando Bacal, MD, PhD, University of Sao Paulo,
Sao Paulo, Brazil
- 4:25 PM** *Heart Procurement, Measures to Optimize Results*
Oscar Alejandro Ortega Duran, MD, Centro Medico
Zambrano-Hellion, San Pedro Garza Garcia, Mexico
- 4:35 PM** *Management of Recipients in Cardiogenic Shock*
Mauricio Villavicencio, MD, Instituto Nacional del Torax,
Santiago, Chile
- 4:45 PM** *Long Term Results After Heart Transplant*
Roberto R. Favaloro, MD, Favaloro Foundation
University Hospital, Buenos Aires, Argentina
- 4:55 PM** *MCS as BTT in Latin America*
Alexandre S. Colafranceschi, MD, Procardiaco Hospital,
Rio de Janeiro, Brazil
- 5:05 PM** *Panel Discussion*

5:30 PM – 6:30 PM

MINI ORAL SESSION 1

Pushing the Boundaries in Lung Donation (Grand Hall A)

CHAIRS: David P. Mason, MD and Peter MacDonald, MD, PhD
(LTX, DMD, BSTR)

- 5:30 PM** **(109) *If I Had a Million Lungs: Impact of Uncontrolled Donation After Cardiac Death Donors (uDCDDs) on the Number of Potential Lung Donors in the U.S.:***
T. M. Egan¹, S. Gazda¹, P. Stewart². ¹Surgery, University of North Carolina School of Medicine, Chapel Hill, NC, ²Biostatistics, Gillings School of Public Health, University of North Carolina, Chapel Hill, NC.
- 5:35 PM** **(110) *Evaluation of Human Lungs from Uncontrolled Donation After Cardiac Death Donors (uDCDDs) with Ex-Vivo Lung Perfusion (EVLP):***
T. M. Egan¹, J. Blackwell¹, L. Forrest¹, S. Gazda¹, J. J. Requard III², B. Haithcock¹, K. Birchard³, P. Stewart⁴, S. Randell⁵, A. Venkataraman¹, S. Beamer¹, S. Reddy⁶, B. Myers⁷, M. Bachman⁷, N. Casey⁸, D. Niedfeldt⁸. ¹Surgery, University of North Carolina School of Medicine, Chapel Hill, NC, ²Lung Banks of America, Chapel Hill, NC, ³Radiology, University of North Carolina School of Medicine, Chapel Hill, NC, ⁴Biostatistics, University of North Carolina Gillings School of Global Public Health, Chapel Hill, NC, ⁵Medicine and UNC CF Center, University of North Carolina School of Medicine, Chapel Hill, NC, ⁶Surgery, Duke University Medical Center, Durham, NC, ⁷Wake County Emergency Medical Services, Raleigh, NC, ⁸Carolina Donor Services, Durham, NC.
- 5:40 PM** **(111) *Primary Graft Dysfunction Is Related To Extravascular Lung Water During Ex-Vivo Lung Perfusion:***
G. Trebbia¹, E. Sage², M. Leguen³, E. Waltersperger², A. Chapelier², F. Parquin², M. Stern⁴, M. Fischler³, T. Pham⁵, C. Cerf¹. ¹Intensive Care, Hôpital FOCH, Suresnes, France, ²Thoracic Surgery, Hôpital FOCH, Suresnes, France, ³Anesthesiology, Hôpital FOCH, Suresnes, France, ⁴Pulmonary Medicine, Hôpital FOCH, Suresnes, France, ⁵Statistical Analysis Unit, Hôpital FOCH, Suresnes, France.
- 5:45 PM** **(112) *An Extended Cold Ischemic Period After Normothermic Ex-Vivo Lung Perfusion Does Not Impair Lung Function in a Pig Lung Transplant Model:***
M. K. Hsin, I. Iskander, D. Nakajima, M. Chen, H. Kim, P. Dossantos, J. Sakamoto, J. Lee, T. K. Waddell, M. Liu, S. Keshavjee, M. Cypel. Thoracic Surgery, University of Toronto, Toronto, ON, Canada.
- 5:50 PM** **(113) *Optimal Oxygenation in Lung Graft Circulation during Ex-Vivo Lung Perfusion:***
K. Noda, N. Shigemura, Y. Tanaka, Y. Saito, J. K. Bhama, J. D' Cunha, C. A. Bermudez. Department of Cardiothoracic Surgery, University of Pittsburgh Medical Center, Pittsburgh, PA.
- 5:55 PM** **(114) *Protective Effect of -2 Adrenoreceptor Agonist Inhalation During Ex-Vivo Lung Perfusion:***
T. Kondo, F. Chen, M. Takahashi, K. Ohata, H. Motoyama, K. Hijiya, A. Ohsumi, T. Yamada, M. Sato, A. Aoyama, T. Bando, H. Date. Thoracic Surgery, Kyoto University, Kyoto, Japan.

- 6:00 PM** **(115) *The Effects of Hydrogen Inhalation on Non-Beating Heart Donor Lung During Ex-Vivo Lung Perfusion;***
S. Haam¹, H. Paik², M. Park², J. Song². ¹Yonsei University, Gangnam Severance Hospital, Seoul, Korea, Republic of, ²Yonsei University, Severance Hospital, Seoul, Korea, Republic of.
- 6:05 PM** **(116) *The Role of the Complement System in Pulmonary Dysfunction Among Traumatic Brain Injured Donors;***
 D. J. Weber¹, A. S. Gracon¹, M. S. Ripsch², P. H. Pandya³, Y. Wang⁴, G. E. Sandusky⁵, F. A. White², D. S. Wilkes³. ¹Surgery, Indiana University, Indianapolis, IN, ²Anesthesia, Indiana University, Indianapolis, IN, ³Medicine, Indiana University, Indianapolis, IN, ⁴Alexion Pharmaceuticals, Cheshire, CT, ⁵Pathology, Indiana University, Indianapolis, IN.
- 6:10 PM** **(117) *Medical Gas (Carbon Monoxide, Hydrogen Sulfide) Therapy Prolongs Survival of the Fully MHC-Disparate Lung Graft From Brain-Dead Donors in Miniature Swine;***
H. Sahara, K. Miura, S. Waki, A. Kawai, A. Shimizu, K. Yamada. Division of Organ Replacement of Xenotransplantation Surgery, Kagoshima University, Kagoshima, Japan.
- 6:15 PM** **(118) *Prolonged Ischemia Does Not Affect Survival Following Lung Transplantation;***
J. C. Grimm¹, V. Valero, III¹, A. Kilic¹, J. V. Conte¹, P. D. Shah², C. A. Merlo², A. Shah¹. ¹Surgery, The Johns Hopkins Medical Institution, Baltimore, MD, ²Medicine, The Johns Hopkins Medical Institution, Baltimore, MD.
- 6:20 PM** **(119) *Outcomes of Lung Transplant Recipients of Hepatitis B core Antibody Positive Donors;***
H. K. Rokadia, C. Koval, S. Mistak, O. Akindipe, P. Garcha, C. Lane, W. Tsuang, M. Budev. Cleveland Clinic, Cleveland, OH.
- 6:25 PM** **(120) *Donor Diabetes and Lung Transplant: Does It Matter?;***
J. C. Haney, A. M. Ganapathi, B. R. Englum, P. J. Speicher, B. C. Gulack, A. A. Osho, A. W. Castleberry, R. D. Davis, M. G. Hartwig. Division of Cardiothoracic Surgery, Department of Surgery, Duke University Medical Center, Durham, NC.

5:30 PM – 6:30 PM**MINI ORAL SESSION 2****Heart Failure and Pulmonary Hypertension:
The Tale of Two Ventricles (Seaport H)****CHAIRS:** Sharon Hunt, MD and David Brad Dyke, MD
(HF, PH, HTX)

- 5:30 PM** **(121) *Low Cardiac Output Stimulates Vaso-pressin Release in Patients with Stage D Heart Failure - Its Relevance to Poor Prognosis and Reversal by Surgical Treatment;***
T. Imamura¹, K. Kinugawa², M. Hatano¹, H. Muraoka¹, T. Fujino¹, T. Inaba¹, H. Maki¹, O. Kinoshita³, K. Nawata³, S. Kyo², M. Ono³.
¹Department of Cardiology, Graduate School of Medicine, University of Tokyo, Tokyo, Japan, ²Department of Therapeutic Strategy for Heart Failure, Graduate School of Medicine, University of Tokyo, Tokyo, Japan, ³Department of Thoracic Surgery, Graduate School of Medicine, University of Tokyo, Tokyo, Japan.

- 5:35 PM** **(122) *The Risk Associated With Renal Dysfunction in Chronic Heart Failure Is Restricted Primarily To Patients With Neurohormonal Activation;***
S. J. Cheng¹, M. A. Brisco², A. J. Kula¹, O. Laur¹, W. H. Wilson Tang³, J. M. Testani¹. ¹Yale University School of Medicine, New Haven, CT, ²Medicine, Medical University of South Carolina, Charleston, SC, ³Cardiovascular Medicine, Cleveland Clinic, Cleveland, OH.
- 5:40 PM** **(123) *Outcomes After Heart Transplantation for Amyloid Cardiomyopathy in the Modern Era;***
M. Davis¹, P. Kale², R. M. Witteles¹. ¹Cardiovascular Medicine, Stanford University School of Medicine, Stanford, CA, ²Heart Transplant, Kaiser Permanente Northern California, Santa Clara, CA.
- 5:45 PM** **(124) *Pre-transplant Chemotherapy Does Not Affect Cardiac Transplant Survival in Light-Chain Amyloid Patients;***
N. Sarswat¹, E. Niehaus¹, S. R. Tabtabai¹, J. R. Stone², L. Gilstrap³, M. Mauer⁴, R. Witteles⁵, J. D. Estep⁶, D. Baran⁷, M. J. Zucker⁸, F. Guisepppe⁹, D. C. Seldin¹⁰, M. J. Semigran¹. ¹Cardiology, Massachusetts General Hospital, Boston, MA, ²Pathology, Massachusetts General Hospital, Boston, MA, ³Cardiology, Brigham and Womens Hospital, Boston, MA, ⁴Cardiology, Columbia University Medical Center, NYC, NY, ⁵Cardiology, Stanford Hospital, Stanford, CA, ⁶Cardiology, Houston Methodist Hospital, Houston, TX, ⁷Cardiology, Newark Beth Israel Medical Center, Newark, NJ, ⁸Cardiology, Newark Beth Israel Medical Center, Newark, CA, ⁹Cardiology, University of Padua, Padua, Italy, ¹⁰Hematology, Boston University Medical Center, Boston, MA.
- 5:50 PM** **(125) *Reduced Survival in Lambda Predominant Cardiac AL Amyloidosis Patients Awaiting Heart Transplant;***
S. Tabtabai¹, E. Niehaus¹, N. Sarswat¹, J. R. Stone¹, L. Gilstrap², M. Maurer³, R. Witteles⁴, J. D. Estep⁵, D. Baran⁶, M. J. Zucker⁶, G. Feltrin⁷, D. Seldin⁸, M. J. Semigran¹. ¹Cardiology, Massachusetts General Hospital, Boston, MA, ²Cardiology, Brigham and Women's Hospital, Boston, MA, ³Cardiology, Columbia University Medical Center, New York City, NY, ⁴Cardiology, Stanford University Medical Center, Stanford, CA, ⁵Cardiology, Houston Methodist Hospital, Houston, TX, ⁶Cardiology, Newark Beth Israel Medical Center, Newark, NJ, ⁷Cardiology, University of Padova, Padova, Italy, ⁸Cardiology, Boston University Medical Center, Boston, MA.
- 5:55 PM** **(126) *Predicting Survival in Heart Failure Patients With an Implantable Cardioverter Defibrillator: The Heart Failure Meta-Score;***
A. C. Alba¹, S. Walter², G. Guyatt², H. Ross¹. ¹University Health Network, Toronto, ON, Canada, ²McMaster University, Hamilton, ON, Canada.
- 6:00 PM** **(127) *Brachial Vein Right Heart Access: A Comparative Analysis of >1100 Cases;***
N. Harwani¹, M. Alvarez¹, E. Chukwu¹, V. Thohan². ¹Medicine/ Cardiology, Wake Forest University School of Medicine, Winston Salem, NC, ²Cardiovascular Services/ Advanced Cardiac Care/ Transplant/ VAD Programs, Aurora St Luke Medical Center, Milwaukee, WI.
- 6:05 PM** **(128) *Adverse Effects of Interstitial Pulmonary Edema on Pulmonary Hemodynamics and Right Heart Function in Heart Failure;***
V. Melenovsky¹, S. Hwang², B. A. Borlaug². ¹Department of Cardiology, Institute of Clinical and Experimental Medicine – IKEM, Prague, Czech Republic, ²Department of Cardiovascular Diseases, Mayo Clinic, Rochester, MN.

- 6:10 PM (129) Non-invasive Functional Differentiation of PAH vs. PVH: Resting Hemodynamics vs. Exercise Gas Exchange Evaluation;**
A. Pelaez, D. MacCarter, E. Wallace, N. Raval, B. Czerska, A. Chaudhry, H. B. Bittner. Transplant, Florida Hospital, Orlando, FL.
- 6:15 PM (130) Long-term Outcome in Acute Vasodilator Responsive Connective Tissue Disease-Associated Pulmonary Arterial Hypertension;**
E. Brittain,¹ S. Halliday,² M. Pugh,² A. Hemnes,² I. Robbins.²
¹Cardiovascular Medicine, Vanderbilt University Medical Center, Nashville, TN, ²Vanderbilt University Medical Center, Nashville, TN.
- 6:20 PM (131) Complete Pulmonary Artery Occlusion from Chronic Thromboembolic Disease: Outcomes Following Pulmonary Thromboendarterectomy Surgery;**
A. Kitcher, V. Pretorius, K. Kerr, P. Fedullo, N. H. Kim, D. Poch, M. Madani, S. Jamieson, W. Auger. Pulmonary and Critical Care Medicine, UCSD, La Jolla, CA.
- 6:25 PM (132) Muscularization of Pulmonary Arteries Is Reduced in Female Athymic Rats Exposed to Vascular Endothelial Growth Factor Receptor (VEGF-R) Blockade;**
J. Guihaire¹, E. Fadel², F. Haddad³, T. Deuse¹, H. Reichenspurner¹, R. C. Robbins³, S. Schrepfer¹. ¹Transplant and Stem Cell Immunobiology Lab, University Heart Center Hamburg, Hamburg, Germany, ²Thoracic and Vascular Surgery and Heart-Lung Transplantation, Marie Lannelongue Hospital, University of Paris Sud, Le Plessis Robinson, France, ³Cardiothoracic Surgery, Stanford University, Palo Alto, CA.

5:30 PM – 6:30 PM

MINI ORAL SESSION 3

Choosing the Right Patient for Mechanical Assistance or Transplant (Grand Hall B)

CHAIRS: Stephen H. McKellar, MD and Stavros G. Drakos, MD, PhD
(MCS, HTX, HF)

- 5:30 PM (133) Comparison of Heart Replacement Therapy in Patients Over 65 Years Old;**
R. Sorabella¹, H. Takayama¹, S. DeRoo¹, H. Yerebakan¹, S. Ikeda¹, E. Weiss¹, J. Yang¹, K. Takeda¹, I. George¹, M. Yuzefpolskaya², N. Uriel², P. Colombo², U. Jorde², D. Mancini², Y. Naka¹. ¹Cardiothoracic Surgery, Columbia University College of Physicians and Surgeons, New York, NY, ²Cardiology, Columbia University College of Physicians and Surgeons, New York, NY.
- 5:35 PM (134) Reduced Long-term Outcomes after Orthotopic Heart Transplantation in Septuagenarians;**
H. Yerebakan¹, R. Sorabella¹, M. Najjar¹, E. Castillero¹, V. Choi¹, U. P. Jorde², M. A. Farr², D. M. Mancini², Y. Naka¹, M. S. Maurer², P. Schulze², H. Takayama¹, I. George¹. ¹Department of Surgery, Columbia University Medical Center, New York, NY, ²Department of Medicine, Columbia University Medical Center, New York, NY.

SCIENTIFIC PROGRAM

- 5:40 PM** **(135) Limited Efficacy of Milrinone as a Bridge to Cardiac Transplantation in the Current Era;**
A. Kumar, N. Haglund, M. Wigger, M. Keebler, K. Schlendorf, S. Maltais, T. Di Salvo. Vanderbilt, Nashville, TN.
- 5:45 PM** **(136) Comparison of Early Versus Delayed Left Ventricular Assist Device Implantation in Patients Bridged to Heart Transplantation;**
P. Schulze, S. Kitada, Z. Jin, K. Clerkin, S. Homma, D. M. Mancini. Department of Medicine, Division of Cardiology, Columbia University Medical Center, New York, NY.
- 5:50 PM** **(137) Preoperative Risk Factors for Early Mortality in Patients Bridged to Transplant with a Continuous Flow Left Ventricular Assist Device;**
A. H. Healy¹, J. Stehlik², L. B. Edwards³, S. H. McKellar¹, S. G. Drakos², C. H. Selzman¹. ¹Surgery, University of Utah, Salt Lake City, UT, ²Medicine, University of Utah, Salt Lake City, UT, ³United Network for Organ Sharing, Richmond, VA.
- 5:55 PM** **(138) Favorable Outcomes of Left Ventricular Assist Device as Bridge to Simultaneous Heart Kidney Transplantation;**
G. Murtaza¹, F. X. Downey², J. Crouch², N. Z. Sulemanjee³, O. M. Cheema³, T. Hastings³, D. L. Zwicke³, C. Cho³, V. Thohan³. ¹Medical College of Wisconsin, Milwaukee, WI, ²Aurora Medical Group-Cardiovascular and Thoracic Surgery, Aurora St. Luke's Medical Center, Milwaukee, WI, ³Aurora Cardiovascular Services, Aurora Sinai/Aurora St. Luke's Medical Centers, University of Wisconsin School of Medicine and Public Health, Milwaukee, WI.
- 6:00 PM** **(139) Comparison of Survival between Pediatric and Adult Patients after Biventricular Assist Device Implantation: Analysis of the UNOS Registry;**
E. C. DePasquale, R. P. Vivo, A. Nsair, M. Cadeiras, D. Cruz, R. Ardehali, A. S. Baas, M. C. Deng, G. C. Fonarow, L. C. Reardon, A. Ardehali. Cardiology, University of California Los Angeles, Los Angeles, CA.
- 6:05 PM** **(140) Outcomes of Patients Referred for a Left Ventricular Assist Device But Were Declined: The Recent-Era Forgotten Ones;**
A. K. Johnson, S. P. McCandless, R. Alharethi, W. T. Caine, D. Budge, G. A. Wright, A. Rauf, S. Stoker, B. B. Reid, B. Y. Rasmusson, A. G. Kfoury. Artificial Heart Program, Intermountain Medical Center, Murray, UT.
- 6:10 PM** **(141) Predicting Peri-operative Right Heart Failure, Post-implant Survival and Timing of Mechanical Ventricular Assistance;**
M. Harb¹, R. Lui¹, D. Robson², A. Jabbour², E. Kotlyar², A. Keogh², E. Granger², P. Spratt², P. S. Macdonald², P. Jansz², C. S. Hayward², K. Dhital². ¹St Vincent's Hospital Clinical School, University of New South Wales, Sydney, Australia, ²Heart & Lung Transplant Unit, St Vincent's Health Network, Sydney, Australia.
- 6:15 PM** **(142) Can a Minimally Invasive OFF-pump Implantation Strategy be Considered Safe for Selected Patients Undergoing HeartWare Ventricular Assist Device Implantation?;**
B. Sileshi, M. E. Davis, N. A. Haglund, H. Nian, J. Kennedy, R. Deegan, J. Stulak, K. Schelndorf, M. E. Keebler, S. Maltais. Vanderbilt University Medical Center, Nashville, TN.
- 6:20 PM** **(143) Mechanical Circulatory Support for Failing Systemic Right Ventricle Using Left Ventricular Assist Device – An Option To Decide and Bridge?;**
E. Peng¹, M. Griselli¹, J. O'Sullivan¹, D. Crossland¹, M. Chaudhari¹, N. Wrightson¹, T. Butt¹, C. Roysam², G. Parry¹, G. A. MacGowan¹, S. Schueler¹, A. Hasan¹. ¹Cardiopulmonary Transplant, Freeman

Hospital, Newcastle Upon Tyne, United Kingdom, ²Cardiothoracic Anaesthesia, Freeman Hospital, Newcastle Upon Tyne, United Kingdom.

- 6:25 PM** **(144) First Mid-Term Results Following Minimally Invasive LVAD Implantation:**
S. V. Rojas, J. S. Hanke, Y. Li, P. Ahrens, O. Deutschmann, C. Bara, D. Malehsa, A. Haverich, M. Avsar, J. D. Schmitto. Department of Cardiothoracic-, Transplantation- and Vascular Surgery, Hannover Medical School, Hannover, Germany.

5:30 PM – 6:30 PM

MINI ORAL SESSION 4

Mechanical Circulatory Support Rapid Science Session (Grand Hall C)

CHAIRS: Francis D. Pagani, MD, PhD and Stephen C. Clark, MD (MCS, BSTR)

- 5:30 PM** **(145) Exercise Capacity in Continuous Flow Ventricular Assist Devices Patients: Changes Within the First Two Years of Pump Support:**
F. Moscato¹, E. Xhelili¹, J. Riebandt², D. Zimpfer², H. Schima³, C. Marko⁴. ¹Center for Med. Physics and Biomed. Engineering – Ludwig Boltzmann Cluster for Cardiovasc. Research, Medical University of Vienna, Vienna, Austria, ²Department of Cardiac Surgery, Medical University of Vienna, Vienna, Austria, ³Center for Med. Phys. & Biomed. Eng. – L. B. Cluster for Cardiovasc. Res. – Dept of Cardiac Surgery, Medical University of Vienna, Vienna, Austria, ⁴Rehabilitation Clinic Felbring, Muthmannsdorf, Austria.
- 5:35 PM** **(146) Angiotensin-Converting Enzyme Inhibitors (ACEIs) or Angiotensin- Receptor Blockers (ARBs) during CF-LVAD Support Are Associated with Sustained Improvement in Renal Function:**
O. Saeed¹, R. Jermy¹, S. Patel¹, J. Shin¹, D. D'Alessandro², D. J. Goldstein², R. Zolty¹. ¹Medicine, Montefiore Medical Center, Albert Einstein College of Medicine, Bronx, NY, ²Cardiothoracic and Vascular Surgery, Montefiore Medical Center, Albert Einstein College of Medicine, Bronx, NY.
- 5:40 PM** **(147) The Utility of Pulmonary Function Tests in Predicting Pulmonary Outcomes Following Destination Therapy Left Ventricular Assist Device Placement:**
M. A. Schechter¹, A. W. Castleberry¹, M. Kuchibhatla², C. B. Patel³, L. J. Blue¹, J. G. Rogers³, M. F. Berry¹, J. N. Schroder¹, C. A. Milano¹. ¹Surgery, Duke University Medical Center, Durham, NC, ²Biostatistics & Bioinformatics, Duke University Medical Center, Durham, NC, ³Medicine, Duke University Medical Center, Durham, NC.
- 5:45 PM** **(148) Validation of Peripheral Arterial Tonometry Technique as Surrogate for Central Aortic Pressures:**
A. Singal¹, A. Hamel¹, M. Oura², S. Hozayen³, R. John¹, P. Eckman¹. ¹Cardiovascular Division, University of Minnesota, Minneapolis, MN, ²Medical Devices Center, University of Minnesota, Minneapolis, MN, ³Cardiovascular Division, St Vincent's Medical Center, Bridgeport, CT.

- 5:50 PM** **(149) Second Report of Japanese registry for Mechanically Assisted Circulatory Support (J-MACS);**
T. Nakatani¹, K. Sase², H. Oshiyama³. ¹Transplantation, National Cerebral and Cardiovascular Center, Osaka, Japan, ²Clinical Pharmacology, Juntendo University, Tokyo, Japan, ³Japan Medical Devices Manufacturers Association, Tokyo, Japan,
- 5:55 PM** **(150) Infusion of Nesiritide after Implantation of the Total Artificial Heart Is Associated with Decreased Need for Kidney Transplantation;**
K. B. Shah¹, A. V. Kalya², M. T. Hassanein¹, D. G. Tang¹, F. A. Arabia³, V. Kasirajan¹. ¹Virginia Commonwealth University, Richmond, VA, ²Mayo Clinic, Scottsdale, AZ, ³Cedars-Sinai, Los Angeles, CA.
- 6:00 PM** **(151) Impella 5.0 through an Axillary Access Is a Promising Approach to Improve Outcomes in Decompensated Heart Failure Patients to Receive Long-term Mechanical Circulatory Assistance;**
K. M. Doersch¹, C. W. Tong², B. Sareyyupoglu¹. ¹Surgery, Scott&White Temple Clinic, Temple, TX, ²Cardiology, Scott&White Temple Clinic, Temple, TX.
- 6:05 PM** **(152) Low-Density Lipoprotein, High-Density Lipoprotein and Triglyceride Levels all Increase During Continuous-Flow Left Ventricular Assist Device Support;**
A. R. Vest, S. M. Mistak, M. M. Mountis, J. B. Young. Heart and Vascular Institute, Cleveland Clinic, Cleveland, OH.
- 6:10 PM** **(153) Persistent Hyperbilirubinemia Following LVAD Implantation Predicts Postoperative Multisystem Organ Failure and Mortality;**
K. J. Lavine¹, J. Vader¹, S. Larue¹, M. Nassif¹, D. Raymer¹, A. Tibrewala¹, S. Prasad², S. Silvestry². ¹Cardiology, Washington University School of Medicine, St Louis, MO, ²Cardiac Surgery, Washington University School of Medicine, St Louis, MO.
- 6:15 PM** **(154) Systemic Inflammation in End-Stage Heart Failure Patients Undergoing Different Axial-Flow Left Ventricular Assist Devices;**
L. Botta, R. Caruso, A. Cannata, G. Bruschi, F. Milazzo, S. Nonini, J. Campolo, M. Lanfranconi, C. F. Russo, P. Marraccini, M. Frigerio, O. Parodi, L. Martinelli. Niguarda Hospital, Milano, Italy.
- 6:20 PM** **(155) Stabilin-1: A Possible Functional Biomarker for Pro-Fibrotic Alternative Macrophage Activation in Dilatative Cardiomyopathy Patients With Left Ventricular Assist Device Implantation;**
K. Wassilew^{*1}, E. Potapov^{*2}, C. Schmuttermaier³, A. Gratchev³, R. Hetzer², J. Kzhyshkowska³. ¹Cardiac Pathology, Deutsches Herzzentrum Berlin, Berlin, Germany, ²Cardiothoracic and Vascular Surgery, Deutsches Herzzentrum Berlin, Berlin, Germany, ³Innate Immunity and Tolerance, Institute of Transfusion Medicine and Immunology, Medical Faculty Mannheim, Heidelberg University, Mannheim, Germany.
- 6:25 PM** **(156) Interstitial Fibrosis of the Lungs and the Heart in the Goat Following Prolonged VA-ECMO;**
T. Mizuno, T. Tsukiya, Y. Takewa, E. Tatsumi. Dept. of Artificial Organs, National Cerebral and Cardiovascular Center Institute, Suita, Japan.

5:30 PM – 6:30 PM

MINI ORAL SESSION 5

Heart Transplant: Candidate Selection and Improving Outcomes (Grand Hall D)**CHAIRS:** Elina Minami, MD and Manfred Hummel, MD, PhD
(HTX)

- 5:30 PM (157) *The Role of Donor Age and Gender on Survival after Heart Transplantation;***
D. J. Weber¹, P. Didolkar¹, A. Gracon¹, Y. Hellman², M. A. Hadi², A. Malik², M. Caccamo², I. Gradus-Pizlo², T. Wozniak¹, I. Wang¹, Z. A. Hashmi¹. ¹Cardiothoracic Surgery, Indiana University Health, Indianapolis, IN, ²Cardiology, Indiana University Health, Indianapolis, IN.
- 5:35 PM (158) *Survival Results in Patients Aged of 60 Years and Older in France;***
C. Cantrelle¹, C. Legeai¹, O. Huot¹, N. Strang¹, P. Leprince², E. Flecher³, A. Sirinelli⁴, R. Dorent¹, French Transplant Teams¹. ¹Medical & Scientific, Agence de la Biomedecine, La Plaine Saint Denis, France, ²Service de Chirurgie Thoracique et Cardiovasculaire, Groupe Hospitalier Pitié Salpêtrière, Paris, France, ³Service de Chirurgie Thoracique, Cardiaque et Vasculaire, CHU Pontchaillou, Rennes, France, ⁴Service de Chirurgie Thoracique, Cardiaque et Vasculaire, CHU Tours, Tours, France.
- 5:40 PM (159) *Comparable Mortality and Morbidity of Orthotopic Heart Transplantation for Patients Younger and Older Than 70 Years;***
M. Awad, L. S. Czer, K. R. Rihbany, M. Sasevich, A. Ruzza, M. Rafiei, J. Mirocha, M. De Robertis, R. Kass, F. Arabia, A. Trento, F. Esmailian, D. Ramzy. Cedars Sinai Heart Institute, Cedars Sinai Medical Center, Los Angeles, CA.
- 5:45 PM (160) *Outcomes of Patients Designated Bridge to Candidacy (BTC) at Time of LVAD With and Without Psychosocial Risks Factors: Implications for CMS Coverage;***
V. B. Cruz¹, R. Steffen², K. Hoercher³, M. Mountis⁴, S. Lee⁴, E. Soltesz⁵, R. C. Starling⁶, N. Moazami⁷. ¹Lerner College of Medicine, Cleveland Clinic, Cleveland, OH, ²Heart and Vascular Institute, Cleveland Clinic, Cleveland, OH, ³Center for Heart Failure, Heart and Vascular Institute, Cleveland Clinic, Cleveland, OH, ⁴Section of Heart Failure and Cardiac Transplantation, Department of Cardiovascular Medicine, Cleveland Clinic, Cleveland, OH, ⁵Department of Thoracic and Cardiovascular Surgery, Cleveland Clinic, Cleveland, OH, ⁶Medical Director, Center for Heart Failure, Heart & Vascular Institute, Cleveland Clinic, Cleveland, OH, ⁷Surgical Director, Center for Heart Failure, Cardiac Transplantation and MCS, Cleveland Clinic, Cleveland, OH.
- 5:50 PM (161) *Heart Transplantation for Myocarditis: Outcomes and Survival in a National Cohort;***
O. K. Jawitz¹, P. Bonde². ¹Yale School of Medicine, New Haven, CT, ²Section of Cardiac Surgery, Yale School of Medicine, New Haven, CT.
- 5:55 PM (162) *Low Dose Prothrombin Complex Concentrate in Addition to Vitamin K for Warfarin Reversal Prior to Heart Transplantation;***
J. Fink¹, M. Militello¹, M. Wanek¹, A. Kantorovich¹, B. Silver², S. Sale³, N. Moazami⁴. ¹Pharmacy, Cleveland Clinic, Cleveland, OH, ²Hematology, Cleveland Clinic, Cleveland, OH, ³Cardiothoracic Anesthesia, Cleveland Clinic, Cleveland, OH, ⁴Cardiothoracic Surgery, Cleveland Clinic, Cleveland, OH.

- 6:00 PM** **(163) Heart (HT) Versus Heart-Kidney Transplantation (H+K) in Chronic Kidney Disease (CKD) – Should Our Decisions Be Better Informed? ISHLT Registry Analysis;**
E. C. DePasquale¹, L. Lund², L. Edwards³, M. C. Deng¹, J. Stehlik⁴.
¹Division of Cardiology, UCLA, Los Angeles, CA, ²Karolinska University Hospital, Stockholm, Sweden, ³ISHLT Transplant Registry, Richmond, VA, ⁴University of Utah, Salt Lake City, UT.
- 6:05 PM** **(164) Renal Allograft Outcome after Simultaneous Heart and Kidney Transplantation;**
A. Grupper, A. Grupper, M. A. Hathcock, F. G. Cosio, B. S. Edwards, S. S. Kushwaha. Transplantation Center, Mayo Clinic, Rochester, MN.
- 6:10 PM** **(165) Cardiac Retransplantation: How Far Have We Come?;**
E. C. DePasquale¹, R. K. Cheng², A. Nsair¹, A. Baas¹, M. Cadeiras¹, D. Cruz¹, T. Khuu¹, M. Deng¹, H. Laks¹, A. Ardehali¹. ¹UCLA, Los Angeles, CA, ²University of Washington, Seattle, Seattle, WA.
- 6:15 PM** **(166) Restrictive Cardiomyopathy and Risk of Mortality on Waiting List for Heart Transplantation;**
E. M. Hsich¹, R. C. Starling¹, E. Blackstone¹, J. Rogers², D. O. Taylor¹, J. D. Schold¹. ¹Cleveland Clinic, Cleveland, OH, ²Duke University School of Medicine and the Duke Clinical Research Institute, Durham, NC.
- 6:20 PM** **(167) Preconditioning of Naïve and Activated Endothelial Cells With Induction Agents Modulates Endothelial Cell Function: Non-Depleting Vs. Depleting Agents;**
I. Werner, N. V. Bogert, U. A. Stock, A. Moritz, A. Beiras-Fernandez. Department of Thoracic and Cardiovascular Surgery, University Hospital Frankfurt, Goethe University, Frankfurt am Main, Germany.
- 6:25 PM** **(168) Acute Rejection and Graft Failure Drive Worse Outcomes Among Peripartum Cardiomyopathy (PPCM) Patients Undergoing Heart Transplant (HT) in the US: A UNOS Analysis;**
D. Jacoby¹, O. Jawitz², L. Bellumkonda¹, P. Bonde³. ¹Internal Medicine, Yale School of Medicine, New Haven, CT, ²Yale School of Medicine, New Haven, CT, ³Surgery, Yale School of Medicine, New Haven, CT.

5:30 PM – 6:30 PM

MINI ORAL SESSION 6

**Lung Transplant Monitoring and Immunosuppression
(Harbor GHI)****CHAIRS:** David Weill, MD and Denis Hadjiliadis, MD

(LTX, PHARM)

- 5:30 PM (169) Switch From Twice-Daily Tacrolimus (Prograf) To Once-Daily Prolonged-Release Tacrolimus (Advagraf) in Lung Transplantation;** P. Jaksch, R. Stromberger, G. Murakoezy, C. Lambers, W. Klepetko. Thoracic Surgery, Medical University Vienna, Vienna, Austria.
- 5:35 PM (170) Erratic Tacrolimus Blood Levels are Associated with Bronchiolitis Obliterans Syndrome (BOS) and Death after Lung Transplantation;** H. M. Gallagher¹, G. Sarwar¹, T. Tse¹, T. J. Sladden², S. T. Yerkovich¹, P. M. Hopkins¹, D. C. Chambers¹. ¹Queensland Lung Transplant Service, The Prince Charles Hospital, Brisbane, Australia, ²School of Medicine, The University of Queensland, Brisbane, Australia.
- 5:40 PM (171) Rapid and Combined Measurement of Cyclosporin A, Tacrolimus, Sirolimus and Everolimus in Whole Blood and Dried Blood Spot With LC-MSMS;** A. C. Egas¹, E. M. van Maarseveen¹, J. M. Kwakkel-van Erp², M. J. Wessels-Bakker², M. E. Janssen², B. Luijk², E. A. van de Graaf³. ¹Clinical Pharmacy, University Medical Center Utrecht, Utrecht, Netherlands, ²Respiratory Medicine, University Medical Center Utrecht, Utrecht, Netherlands, ³Division of Heart and Lung, University Medical Center Utrecht, Utrecht, Netherlands.
- 5:45 PM (172) A Randomized, Double-Blind, Placebo-Controlled, Multicenter, Study of Rabbit ATG in the Prophylaxis of Acute Rejection in Lung Transplantation;** G. I. Snell¹, G. P. Westall¹, B. J. Levvey¹, P. Jaksch², S. Keshavjee³, C. W. Hoopes⁴, V. Ahya⁵, A. Mehta⁶, E. P. Trulock⁷. ¹Lung Transplant Service, Allergy, Immunology and Respiratory Medicine, Alfred Hospital, Melbourne, Australia, ²University Hospital, Vienna, Austria, ³Toronto General Hospital, Toronto, ON, Canada, ⁴University of California, San Francisco, CA, ⁵Hospital of the University of Pennsylvania, Philadelphia, PA, ⁶Cleveland Clinic, Cleveland, OH, ⁷Washington University, St Louis, MO.
- 5:50 PM (173) Supplementation of Hypogammaglobulinemia in Lung Transplant Recipients Leads to Favorable Outcomes;** W. M. Tsuang¹, A. Finlen-Copeland², M. Budev¹, C. Pieper², J. Reynolds², S. M. Palmer². ¹Cleveland Clinic, Cleveland, OH, ²Duke University Medical Center, Durham, NC.
- 5:55 PM (174) Level and Kinetics of Plasma Torque Teno Virus DNA After Lung Transplantation as a Marker To Guide Immunosuppressive Therapy;** I. Görzer¹, P. Jaksch², M. Haloschan³, R. Strassl³, W. Klepetko², E. Puchhammer Stöckl³. ¹Dept Virology, Medical University Vienna, Vienna, Austria, ²Dept Thoracic Surgery, Medical University Vienna, Vienna, Austria, ³Dept of Virology, Medical University Vienna, Vienna, Austria.

SCIENTIFIC PROGRAM

- 6:00 PM** **(175) A Novel Diagnostic Assay for Pulmonary Antibody Mediated Rejection – Detection of Circulating Donor Tissue-Specific B Cells;**
*S. Yerkovich*¹, M. Tan¹, C. Smith², L. Samson¹, A. Fiene¹, H. Gallagher¹, P. Hopkins¹, D. Chambers¹. ¹Qld Lung Transplant Service, The Prince Charles Hospital, Brisbane, Australia, ²Tumour Immunology Laboratory, QIMR Berghofer Medical Research Institute, Brisbane, Australia.
- 6:05 PM** **(176) Probe-based Confocal Laser Endomicroscopy (pCLE) Can Identify Perivascular Cellular Infiltration in Patients with Acute Cellular Rejection;**
C. A. Keller, K. E. Hurst, K. D. Petrine, H. A. David-Robinson. Transplant Department, Mayo Clinic, Jacksonville, FL.
- 6:10 PM** **(177) Phenotypes of Chronic Lung Allograft Dysfunction (CLAD): A Multilevel Diagnostic Approach;**
*A. Koutsokera*¹, J. D. Aubert², C. Benden³, P. M. Soccia⁴, C. Pison⁵, L. P. Nicod⁶. ¹Respiratory Medicine Department, Centre Hospitalier Universitaire Vaudois, CHUV, Lausanne, Switzerland, ²Respiratory Medicine Department, Centre Hospitalier Universitaire Vaudois, CHUV and Swiss Transplant Cohort Study (STCS), Lausanne, Switzerland, ³Division of Pulmonary Medicine, University Hospital Zurich, Zurich, Switzerland, ⁴Respiratory Medicine Department, University Hospital of Geneva, Geneva, Switzerland, ⁵Clinique Universitaire de Pneumologie, Université Joseph Fourier and French Cohort of Lung Transplantation (COLT), Grenoble, France, ⁶Respiratory Medicine Department, Centre Hospitalier Universitaire Vaudois, CHUV and SysCLAD (Systems Prediction of Chronic Lung Allograft Dysfunction: A European Union-funded Study, Grant Agreement No FP7:305457-2), Lausanne, Switzerland.
- 6:15 PM** **(178) Chronic Lung Allograft Dysfunction – A Disease of Accelerated Epithelial Ageing?;**
S. Yerkovich, L. Samson, M. Tan, H. Gallagher, A. Fiene, P. Hopkins, D. Chambers. Qld Lung Transplant Service, The Prince Charles Hospital, Brisbane, Australia.
- 6:20 PM** **(179) Restrictive Allograft Syndrome (RAS) in Lung Transplant Recipients Carries Uncertain Additional Prognostic Significance as Compared To BOS;**
*H. L. Schultz*¹, C. B. Andersen², D. A. Steinbrüchel³, N. H. Bjar-nason¹, M. Perch¹, J. Carlsen¹, M. Iversen¹. ¹Department of Cardiology, Section of Lung Transplantation, Rigshospitalet, Copenhagen, Denmark, ²Department of Pathology, Rigshospitalet, Copenhagen, Denmark, ³Department of Thoracic Surgery, Rigshospitalet, Copenhagen, Denmark.
- 6:25 PM** **(180) Extended Preservation of Lungs at Subnormothermia with a Novel Organ Storage Solution “Somah:” Salvage, Reconditioning and Functional Evaluation;**
*A. V. Louis*¹, C. Hemphill¹, D. Schipper¹, N. Qu¹, K. Stavoe¹, K. Penick¹, A. Ferng¹, B. Smith¹, H. Thatte², Z. Khalpey¹. ¹Cardiothoracic Surgery, University of Arizona Medical Center, Tucson, AZ, ²Surgery, Veterans Affairs Boston Healthcare System, Harvard, West Roxbury, MA.

6:30 PM – 8:00 PM
COUNCIL / COMMITTEE REPORTS TO THE BOARD OF DIRECTORS
(Gaslamp A-C)

SATURDAY, APRIL 12, 2014

7:00 AM – 6:30 PM

REGISTRATION DESK OPEN (Palm Foyer)

SPEAKER READY ROOM OPEN (Balboa A-C)

7:00 AM – 8:00 AM

SUNRISE SYMPOSIUM 6

The Aortic Valve – An Open and Shut Case? (Grand Hall A)

CHAIRS: Randall Starling, MD, MPH and Ruchan Akar, MD, FRCS CTh

(MCS, HF, HTX)

SESSION SUMMARY: This session will address how to run the pump – the advantages of running the pump full speed, giving maximal flow and off-loading, versus running the pump slower, letting the valve open and maintaining some pulsatility. The advantages and disadvantages of just sewing the valve over will then be discussed. This session will also touch on providing full versus partial support.

7:00 AM *Full Speed Ahead – Advantages of Keeping the Aortic Valve Closed*

Ivan Netuka, MD, PhD, Institute for Clinical and Experimental Medicine, Prague, Czech Republic

7:15 AM *Taking It Slowly – Advantages of Letting the Aortic Valve Open*

Ulrich P. Jorde, MD, Columbia University, New York, NY, USA

7:30 AM *Sewing the Aortic Valve Over – Problems Solved??*

Walter P. Dembitsky, MD, Sharp Memorial Hospital, San Diego, CA, USA

7:45 AM *Panel Discussion*

7:00 AM – 8:00 AM

SUNRISE SYMPOSIUM 7

The Effects of Prostaglandin Therapy in Pulmonary Arterial Hypertension: The Seen and Unseen Risk/Benefit Profile (Grand Hall B)

CHAIRS: Patricia Ging, BPharm MSc, Andrew J. Fisher, FRCP, PhD and Josef Stehlik, MD, MPH

(PH, PHARM, HF, LF, LTX, NHSAH)

SESSION SUMMARY: Although treatments have improved symptoms, exercise tolerance, and quality of life for patients with pulmonary arterial hypertension, PAH remains a progressive, life limiting disease. The purposes of this symposium are to raise awareness of the physical (seen) and psychological (unseen) effects of IV prostaglandin, the current mainstay for treatment for PAH, culminating in a case presentation/panel discussion.

SCIENTIFIC PROGRAM

- 7:00 AM** *IV Prostaglandin Therapy: Indications and Mechanism of Action for PAH*
James C Coons, PharmD, University of Pittsburgh,
Pittsburgh, PA, USA
- 7:10 AM** **Q & A**
- 7:15 AM** *Physical Effects of PAH and IV Therapy: The "Seen" Effects*
Mardi Gomberg-Maitland, MD, MSc, University of
Chicago Medical Center, Chicago, IL, USA
- 7:25 AM** **Q & A**
- 7:30 AM** *Effects of PAH and IV Therapy: The "Unseen" Effects*
Rachel M Crackett, MSc, Freeman Hospital, Newcastle upon Tyne,
United Kingdom
- 7:40 AM** **Q & A**
- 7:45 AM** *Case Presentation*
Corey E. Ventetuolo, MD, Rhode Island Hospital,
Providence, RI, USA
- 7:50 AM** *Panel Discussion*

7:00 AM – 8:00 AM

SUNRISE SYMPOSIUM 8

Exercise Training in Heart Transplantation (Grand Hall C)

CHAIRS: Michelle M Kittleson, MD, PhD and Nicolas Manito, MD

(HF, HTX)

SESSION SUMMARY: This symposium will examine the role of structured exercise training in the post heart transplant population, including physiology and potential benefits, with a view toward providing transplant physicians with new information on the impact of exercise training on outcomes.

- 7:00 AM** *Exercise Physiology in the Denervated Heart*
Heather J Ross, MD, MHSc, FRCPC, Toronto General Hospital,
Toronto, ON, Canada
- 7:15 AM** **Q & A**
- 7:20 AM** *Immunomodulation and Metabolic Benefits of Exercise Training in Heart Transplantation*
Finn Gustafsson, MD, PhD, DMSci, Rigshospitalet,
Copenhagen, Denmark
- 7:35 AM** **Q & A**
- 7:40 AM** *Benefits of Exercise Training after Heart Transplantation*
Brian Jaski, MD, Sharp Memorial Hospital, San Diego, CA, USA
- 7:55 AM** **Q & A**

7:00 AM – 8:00 AM

SUNRISE SYMPOSIUM 9

CMV Infection in Lung Transplant Recipients: Are We Ready for Personalized Medicine? (Grand Hall D)**CHAIRS:** Marc Schechter, MD and Martin R. Zamora, MD**(ID, LTX, LF, PHARM)**

SESSION SUMMARY: CMV infection continues to be a clinical challenge in select lung transplant recipients (LTRs) despite advancements in prevention and treatment strategies. Identifying LTRs at risk for recurrent viral replication and/or allograft injury is essential for adjusting antiviral therapies and improving long-term outcomes. In this session, the latest in translational bench-to-bedside approaches used to evaluate those at risk for active CMV infection and its sequelae will be discussed. By the completion of this session, attendees will be familiar with measurements of CMV-specific immunity to monitor and predict CMV outcomes in higher-risk LTRs, promising new therapies to treat emerging CMV resistance, and pro/con viewpoints for correlating CMV replication in the lung allograft and the risk of BOS.

- 7:00 AM** *T cell Function and CMV Immune Control in High-Risk Lung Transplant Recipients*
John McDyer, MD, University of Pittsburgh Medical Center, Pittsburgh, PA, USA
- 7:15 AM** *Predicting CMV Reactivation Risk in CMV Positive Lung Transplant Recipients*
Glen P Westall, MD, FRACP, Alfred Hospital, Melbourne, Australia
- 7:30 AM** *When Resistance Strikes: Promising New Therapies*
Fernanda Silveira, MD, University of Pittsburgh Medical Center, Pittsburgh, PA, USA
- 7:45 AM** *Panel Discussion*

7:00 AM – 8:00 AM

SUNRISE SYMPOSIUM 10

Exploring Interactions Between Cellular and Humoral Immunity in Cardiac Allograft Rejection (Seaport H)**CHAIRS:** Patrick Bruneval, MD and Dylan Miller, MD**(BSTR, PATH)**

SESSION SUMMARY: Events and mechanisms in T-cell mediated immunity are distinct from those of B-cell mediated immunity, but the two are not mutually exclusive. This session deals with interactions between the two arms of the immune system at the basic science level (using NK cells and innate immunity as one possible contributor) and reviews what is available with respect to “mixed rejection” in terms of outcomes and management.

- 7:00 AM** *Innate Immunity and its Influence on Cellular and Antibody Mediated Rejection*
Esme Dijke, PhD, University of Alberta, Edmonton, AB, Canada
- 7:15 AM** *Q & A*
- 7:20 AM** *The Gray Zone: Overlapping Histologic Features Between Cellular and Antibody Mediated Rejection*
Annalisa Angelini, MD, University of Padua, Padua, Italy

SCIENTIFIC PROGRAM

7:35 AM Q & A

7:40 AM *Outcomes and Considerations in the Management of Mixed Rejection*

A.G. Kfoury, MD, Intermountain Heart Institute (UTAH Cardiac Transplant Program), Salt Lake City, UT, USA

7:55 AM Q & A

8:00 AM – 6:00 PM

PRESS OFFICE OPEN (Show Office 7)

8:00 AM – 10:00 AM

PLENARY SESSION

(Seaport)

CHAIRS: Stuart Jamieson, MD, FRCS, FACS and
Mandeep R. Mehra, MD, FACC, FACP

(ALL)

8:00 AM *INVITED LECTURE: Trimming Heart Transplantation In The VAD Era*

Lynne W. Stevenson, MD, Brigham & Women's Hospital, Boston, MA, USA

8:20 AM **(308) FEATURED ABSTRACT: The Proceed II International Heart Transplant Trial with the Organ Care System (OCS™) Technology**

A. Ardehali¹, F. Esmailian², M. Deng³, E. Soltesz⁴, E. Hsich⁵, Y. Naka⁶, D. Mancini⁷, M. Camacho⁸, D. Baran⁹, M. Zucker¹⁰, P. Leprince¹¹, J. Madsen¹², S. Tsui¹³, A. Simon¹⁴, U. Livi¹⁵, G. Guzzi¹⁵, J. Kobashigawa¹⁶. ¹Division of Cardiothoracic Surgery, UCLA Medical Center, Los Angeles, CA, ²Heart Transplantation, Cedars-Sinai Heart Institute, Los Angeles, CA, ³Advanced Heart Failure, Heart Transplant Program, UCLA Medical Center, Los Angeles, CA, ⁴Division of Cardiothoracic Surgery, Cleveland Clinic Foundation, Cleveland, OH, ⁵Heart Transplantation, Cleveland Clinic Foundation, Cleveland, OH, ⁶Department of Cardiac Surgery, Columbia University, New York, NY, ⁷Heart Failure, Heart Transplant Program, Columbia University, New York, NY, ⁸Cardiac Transplantation and Mechanical Device Program, Barnabas Health Heart Center at Newark Beth Israel Medical Center, Newark, NJ, ⁹Heart Failure and Transplant Research, Barnabas Health Heart Center at Newark Beth Israel Medical Center, Newark, NJ, ¹⁰Heart Failure Treatment and Transplant, Barnabas Health Heart Center at Newark Beth Israel Medical Center, Newark, NJ, ¹¹Chirurgie Thoracique et Cardiovasculaire, hospitalier Pitié-Salpêtrière, Paris, France, ¹²Division of Cardiothoracic Surgery, Massachusetts General Hospital, Boston, MA, ¹³Division of Cardiothoracic Surgery, Papworth Hospital, Cambridge, United Kingdom, ¹⁴Thoracic Transplantation and Mechanical Support, Harefield Hospital, Harefield, United Kingdom, ¹⁵Cardiac Surgery and Transplantation Unit, "Santa Maria della Misericordia" University Hospital, Udine, Italy, ¹⁶Advanced Heart Disease Section, Heart Transplant Program, Cedars-Sinai Medical Center, Los Angeles, CA

8:35 AM *INVITED LECTURE: Frontiers of DCD in Thoracic Transplantation*

Thomas M. Egan, MD, MSC, University of North Carolina School of Medicine, Chapel Hill, NC, USA

8:55 AM (181) FEATURED ABSTRACT: The NOVEL Lung Trial One-Year Outcomes:
 P. G. Sanchez¹, R. D. Davis², F. D'Ovidio³, E. Cantu⁴, M. Weyant⁵, P. Camp⁶, B. P. Griffith¹. ¹Cardiac Surgery, University of Maryland, Baltimore, MD, ²Cardiac Surgery, Duke University, Durham, NC, ³Thoracic Surgery, Columbia University, New York, NY, ⁴Cardiac Surgery, University of Pennsylvania, Philadelphia, PA, ⁵Cardiothoracic Surgery, University of Colorado, Aurora, CO, ⁶Thoracic Surgery, Brigham and Women's Hospital, Boston, MA.

9:10 AM (182) FEATURED ABSTRACT: The INSPIRE Lung International Trial Evaluating the Impact of Portable Ex-Vivo Perfusion Using the Organ Care System (OCS™) Lung Technology on Routine Lung Transplant Outcomes;

G. Warnecke¹, D. Van Raemdonck², G. Massard³, F. Rea⁴, M. Smith⁵, J. Kukreja⁶, F. De Robertis⁷, K. Dhital⁸, J. Nagendran⁹, J. Moradiellos¹⁰, C. Bermudez¹¹, S. Tsui¹², G. Leseche¹³, C. Knosalla¹⁴, K. McCurry¹⁵, P. Thomas¹⁶, G. Loo¹⁷, J. Garcia¹⁸, I. Wang¹⁹, M. Avsar¹, I. Tudorache¹, C. Kühn¹, B. Wiegmann¹, W. Sommer¹, N. Santelmo³, P. Falcoz³, A. Olland³, M. Schiavon⁴, G. Marulli⁴, G. Di Gregorio⁴, A. Simon⁷, R. Hetzer¹⁴, A. Varela¹⁰, J. Madsen¹⁸, M. Hertz²⁰, A. Haverich¹, A. Ardehali²¹. ¹Thoracic and Cardiovascular Surgery, Hannover Medical School, Hannover, Germany, ²Thoracic Surgery, University Hospitals Leuven, Leuven, Belgium, ³Thoracic Surgery, Strasbourg University Hospital, Strasbourg, France, ⁴Thoracic Surgery, Hospital of University of Padova, Padova, Italy, ⁵Thoracic Surgery, St. Joseph's Medical Center, Phoenix, AZ, ⁶Thoracic Surgery, UCSF Medical Center, San Francisco, CA, ⁷Thoracic and Cardiovascular Surgery, Harefield Hospital, London, United Kingdom, ⁸Thoracic and Cardiovascular Surgery, St. Vincent's Hospital, Sydney, Australia, ⁹Cardiothoracic Surgery, University of Alberta Medical Center, Edmonton, AB, Canada, ¹⁰Thoracic Surgery, University Hospital Puerta de Hierro, Madrid, Spain, ¹¹Thoracic and Cardiovascular Surgery, UPMC Medical Center, Pittsburgh, PA, ¹²Cardiothoracic Surgery, Papworth Hospital, Cambridge, United Kingdom, ¹³Thoracic and Vascular Surgery, Bichat Hospital, Paris, France, ¹⁴Cardiothoracic Surgery, German Heart Institute, Berlin, Germany, ¹⁵Thoracic and Cardiovascular Surgery, Cleveland Clinic Foundation, Cleveland, OH, ¹⁶Thoracic Surgery, Hospital of University of Marseille, Marseille, France, ¹⁷Cardiothoracic Surgery, University of Minnesota, Minneapolis, MN, ¹⁸Cardiothoracic Surgery, Massachusetts General Hospital, Boston, MA, ¹⁹Cardiothoracic Surgery, Indiana University Medical Center, Indianapolis, IN, ²⁰Medicine, University of Minnesota, Minneapolis, MN, ²¹Cardiothoracic Surgery, UCLA Medical Center, Los Angeles, CA.

9:25 AM INVITED LECTURE: Organ Allocation Policy and the Decision to Donate
 Alvin Roth, Professor of Economics, Stanford University, Stanford, CA, USA

10:00 AM – 10:30 AM
ANNUAL BUSINESS MEETING (Seaport)

COFFEE BREAK/VIEW EXHIBITS (Harbor A-F)

VIEW POSTERS (Harbor and Seaport Foyers)

10:00 AM – 4:00 PM
 EXHIBITS OPEN (Harbor A-F)

10:00 AM – 6:30 PM
 POSTERS OPEN (Harbor and Seaport Foyers)

10:30 AM – 12:00 PM

CONCURRENT SESSION 19

Mechanical Circulatory Support: Optimizing Outcomes II (Seaport)

CHAIRS: Bojan Vrtovec, MD, PhD and Peter M. Eckman, MD (MCS)

- 10:30 AM (183) *Prior Hematological Disorders Carry a High Morbidity and Mortality in Patients Supported with Continuous Flow Left Ventricular Assist Devices;***
J. Fried, A. P. Levin, M. Dionizovik-Dimanovski, P. Colombo, M. Yuzefpolskaya, K. P. Mody, A. R. Garan, H. Takayama, Y. Naka, U. P. Jorde, N. Uriel. Medicine, Columbia University, New York, NY.
- 10:45 AM (184) *Regional Differences in Utilization and Outcomes of Left Ventricular Assist Devices: Insights from the INTERMACS Registry;***
S. R. Krim¹, R. P. Vivo², P. T. Campbell¹, D. C. Nattel³, J. D. Estep⁴, G. C. Fonarow², H. O. Ventura¹. ¹Cardiology, Ochsner Heart and Vascular Institute, New Orleans, LA, ²Cardiology, UCLA Medical Center, Los Angeles, CA, ³University of Alabama at Birmingham, Birmingham, AL, ⁴Cardiology, The Methodist DeBakey Heart and Vascular Center, The Methodist Hospital, Houston, TX.
- 11:00 AM (185) *The Impact of Recurrent Readmissions on the Cost of LVAD Therapy;***
K. Lietz, A. Branch, M. McGrath, J. Herre. Division of Advanced Heart Failure, Sentara Norfolk General Hospital, Norfolk, VA.
- 11:15 AM (186) *Long Term Analysis of RV Function in Patients After Continuous Flow Heartware® LVAD Implantation Without the Need for Peri-Operative Mechanical RV Support – Honeymoon Period or Sustainable Success?;***
C. J. Bhagra¹, S. K. Bhagra¹, M. Taylor², G. Parry¹, G. MacGowan¹, S. Schueler³. ¹Cardiology, The Newcastle upon Tyne Hospitals NHS Foundation Trust, Newcastle upon Tyne, United Kingdom, ²Respiratory, The Newcastle upon Tyne Hospitals NHS Foundation Trust, Newcastle upon Tyne, United Kingdom, ³Cardiothoracic Surgery, The Newcastle upon Tyne Hospitals NHS Foundation Trust, Newcastle upon Tyne, United Kingdom.
- 11:30 AM (187) *Development of a Novel Predictive Model for Mortality Post Continuous Flow LVAD Implant using Bayesian Networks (BN);***
N. A. Loghmanpour¹, M. K. Kanwar², S. H. Bailey³, R. L. Benza², J. F. Antaki¹, S. Murali². ¹Department of Biomedical Engineering, Carnegie Mellon University, Pittsburgh, PA, ²Department of Cardiology, Allegheny General Hospital, Pittsburgh, PA, ³Department of Surgery, Allegheny General Hospital, Pittsburgh, PA.
- 11:45 AM (188) *Initial Post Approval Performance of the Heartware LVAD as Bridge to Transplantation: An Analysis of the UNOS Database;***
N. Uriel¹, A. P. Levin¹, M. Yuzefpolskaya¹, A. R. Garan¹, K. P. Mody¹, P. C. Colombo¹, H. Takayama¹, Y. Naka², U. P. Jorde¹. ¹Medicine, Columbia University, New York, NY, ²Surgery, Columbia University, New York, NY.

10:30 AM – 12:00 PM

CONCURRENT SESSION 20

Mechanical Circulatory Support: Getting Down to the Science of VAD Support (Grand Hall A)**CHAIRS:** Daniel Zimpfer, MD and Nader Moazami, MD
(MCS, BSTR)

- 10:30 AM (189) Creation of a Surgical Fontan Animal Model and the Use of a Ventricular Assist Device to Restore Cardiac Output;**
G. R. Derk¹, H. Laks², R. Biniwale², S. Patel², K. DeLaCruz³, E. Mazar⁴, R. Williams¹, J. Valdivinos⁵, D. Levi⁶, J. Aboulhosn¹.
¹Ahmanson/UCLA Adult Congenital Heart Disease Center, UCLA, Los Angeles, CA, ²Cardiothoracic Surgery, UCLA, Los Angeles, CA, ³Cardiac Perfusion Services, UCLA, Los Angeles, CA, ⁴Anesthesiology Department, UCLA, Los Angeles, CA, ⁵Bioengineering Department, UCLA, Los Angeles, CA, ⁶Pediatric Cardiology, UCLA, Los Angeles, CA.
- 10:45 AM (190) Peripheral Pulse Wave Analysis Technique to Detect Aortic Valve State in Continuous-flow LVADs;**
A. Singal, A. Hamel, M. Larson, H. Kelner, M. Almekkawy, R. John, P. Eckman. Cardiovascular Division, University of Minnesota, Minneapolis, MN.
- 11:00 AM (191) Renal Injury Persists Following LVAD Despite Significant Improvement in Glomerular Filtration Rate: Preliminary Insights From Urinary Injury Biomarkers;**
M. A. Brisco¹, V. S. Rao², J. Koyner³, S. Chen², O. Laur², A. Kula², S. E. Fedson³, V. Jeevanandam³, A. A. Mangi², W. Tang⁴, S. Coca², J. M. Testani². ¹Medicine-Cardiology, Medical University of South Carolina, Charleston, SC, ²Internal Medicine and Program of Applied Translational Research, Yale University School of Medicine, New Haven, CT, ³Internal Medicine, University of Chicago, Chicago, IL, ⁴Cardiology, The Cleveland Clinic, Cleveland, OH.
- 11:15 AM (192) Continuous-Flow Left Ventricular Assist Device Support is Associated with Aortic Valve Interstitial Cell Activation;**
J. W. van Rijswijk¹, J. R. Martina¹, N. de Jonge², R. A. de Weger³, A. Vink³, J. Kluin¹. ¹Cardiothoracic Surgery, Utrecht University Medical Center, Utrecht, Netherlands, ²Cardiology, Utrecht University Medical Center, Utrecht, Netherlands, ³Pathology, Utrecht University Medical Center, Utrecht, Netherlands.
- 11:30 AM (193) Targeted Myocardial Gene Expression Profiling By RNA Sequencing;**
K. Dhar¹, A. M. Moulton¹, E. Rome¹, F. Qiu², J. Eudy³, E. Raichlin¹, J. Um⁴, M. Moulton⁴, B. D. Lowes¹. ¹Internal Medicine, University of Nebraska, Omaha, NE, ²Biostatistics, University of Nebraska, Omaha, NE, ³Genetics and Cellular Biology, University of Nebraska, Omaha, NE, ⁴Cardiothoracic Surgery, University of Nebraska, Omaha, NE.
- 11:45 AM (194) Chronic Inflammation in Heart Failure Patients with Mechanical Circulatory Support;**
L. Grosman-Rimon¹, L. C. Tumiaty¹, M. A. McDonald¹, I. Jacobs², S. Pollock Bar-Ziv², A. Chruscinski³, A. Ghashghai¹, D. Z. Chermey⁴, V. Rao¹. ¹Cardiovascular Surgery, Toronto General Hospital, Toronto, ON, Canada, ²Faculty of Kinesiology and Physical Education, University of Toronto, Toronto, ON, Canada, ³Cardiology, Toronto General Hospital, Toronto, ON, Canada, ⁴Medicine, Toronto General Hospital, Toronto, ON, Canada.

10:30 AM – 12:00 PM

CONCURRENT SESSION 21

Adult Heart Failure: Drugs and Devices (Grand Hall B)

CHAIRS: Maryl R. Johnson, MD and Juliane K. Vierecke, MD
(HF, PHARM, MCS)

10:30 AM (195) Chronic Intravenous Milrinone as a Bridge to Cardiac Transplantation Does Not Improve Pulmonary Arterial Compliance;

A. Kumar, M. Wigger, K. Schlendorf, M. Keebler, N. Haglund, S. Maltais, T. Di Salvo. Vanderbilt, Nashville, TN.

10:45 AM (196) Inhaled Milrinone Plasma Level Implications in Patients with RV Dysfunction Receiving Heartmate II LVAD;

I. Dumitru¹, A. Burdorf², T. Turner³, J. Um³, T. Ryan⁴, N. Haglund⁵.
¹Cardiology, Memorial Regional Hospital, Hollywood, FL, ²Cardiology, UNMC, Omaha, NE, ³Cardiothoracic Surgery, UNMC, Omaha, NE, ⁴Cardiothoracic Surgery, UNMC, UNMC, NE, ⁵Cardiology, Vanderbilt University, Memphis, TN.

11:00 AM (197) Outcomes of Heart Transplant (HT) Recipients Bridged with BIVAD (BiVentricular Assist Device);

A. Nsair, L. Reardon, M. Deng, A. Ardehali, E. C. DePasquale. UCLA, Los Angeles, CA.

11:15 AM (198) Percutaneous Implantation of a Novel Interatrial Shunt Device in Patients with Heart Failure and Preserved or Mildly Reduced Ejection Fraction: Initial Results of a Pilot Trial;

F. Gustafsson¹, F. Malek², P. Neuzil³, V. Reddy³, L. Sondergaard⁴, A. Walton⁵, D. Kaye⁶. ¹Department of Cardiology, Rigshospitalet, Copenhagen, Denmark, ²Na Holmoce Hospital, Prague, Czech Republic, ³Mount Sinai School of Medicine, New York, NY, ⁴Rigshospitalet, Copenhagen, Denmark, ⁵Alfred Hospital, Melbourne, Australia, ⁶Baker IDI Heart and Diabetes Institute, Melbourne, Australia.

11:30 AM (199) Extracorporeal Membrane Oxygenation as a Bridge to Recovery, Bridge to Ventricular Assist Device and Bridge to Heart Transplantation: A Retrospective Review of Data From a Single Tertiary Care Institution;

S. Balasubramanya¹, F. Arabia², A. Trento², D. Ramzy², D. Chang³, M. Kittleton³, L. Czer³, J. Moriguchi³, J. Kobashigawa³, F. Esmailian⁴.
¹Cardiac Surgery, Yale University School of Medicine, New Haven, CT, ²Cardiac Surgery, Cedars Sinai Medical Center, Los Angeles, CA, ³Cardiology, Cedars Sinai Medical Center, Los Angeles, CA, ⁴Cardiac Surgery, Cedars Sinai Medical Center, Los Angeles, CA.

11:45 AM (200) Immunoabsorption: A Treatment Alternative for Older Patients with I-Autoantibody Positive Dilated Cardiomyopathy Who Are at Higher Risk for Transplantation;

M. Dandel¹, G. Wallukat², A. Englert¹, C. Knosalla¹, R. Hetzer¹. ¹Cardiothoracic and Vascular Surgery, Deutsches Herzzentrum Berlin, Berlin, Germany, ²Max-Delbrück-Centrum Berlin, Berlin, Germany.

10:30 AM – 12:00 PM

CONCURRENT SESSION 22

**Frailty, Body Composition and Coronary Disease:
Pushing the Limits of Recipient Selection (Grand Hall C)****CHAIRS:** Jonathan P. Singer, MD, MS and Christiane Knoop, MD
(LTX, NNSAH)

- 10:30 AM (201) *The Impact of Pre-Operative Underweight on 1-Year Mortality After Lung Transplantation;***
*J. P. Singer*¹, E. R. Peterson², J. Golden¹, M. E. Snyder², B. Lim²,
A. Desai², J. R. Sonett², J. Kukreja¹, S. M. Arcasoy², P. P. Katz¹,
F. D'Ovidio², S. Hays¹, D. J. Lederer². ¹UCSF, San Francisco, CA,
²Columbia University, New York, NY.
- 10:45 AM (202) *Evolution of the Association Between Obesity and Survival after Adult Lung Transplantation in the Lung Allocation Score Era;***
*M. E. Snyder*¹, E. R. Peterson¹, J. Singer², R. Shah³, J. Golden², J.
Shin¹, N. Wickersham⁴, S. M. Kawut³, A. Desai¹, P. Katz², S. Hays²,
J. Kukreja², J. R. Sonett⁵, S. M. Arcasoy¹, F. D'Ovidio⁵, L. B. Ware⁴,
J. D. Christie³, D. J. Lederer¹. ¹Medicine, Columbia University
Medical Center, New York, NY, ²Medicine, UCSF, San Francisco,
CA, ³Medicine, University of Pennsylvania, Philadelphia, PA,
⁴Medicine, Vanderbilt University Medical Center, Nashville, TN,
⁵Surgery, Columbia University Medical Center, New York, NY.
- 11:00 AM (203) *Frailty in the Lung Transplant Candidate;***
*D. Rozenberg*¹, L. Wickerson², S. Mathur², S. Keshavjee³, L. G.
Singer¹. ¹Respirology, Toronto General Hospital, Toronto, ON,
Canada, ²Physical Therapy, University of Toronto, Toronto, ON,
Canada, ³Division of Thoracic Surgery, Toronto General Hospital,
Toronto, ON, Canada.
- 11:15 AM (204) *Performance Status Impacts Mortality Following Lung Transplantation;***
*J. C. Grimm*¹, V. Valero, III¹, A. Kilic¹, J. V. Conte¹, C. A. Merlo², P. D.
Shah², A. Shah¹. ¹Surgery, The Johns Hopkins Medical Institution,
Baltimore, MD, ²Medicine, The Johns Hopkins Medical Institution,
Baltimore, MD.
- 11:30 AM (205) *The Impact of Coronary Artery Disease on Lung Transplantation Outcomes;***
M. O. Jones, S. M. Patel, L. T. Tefera, J. D. Borrebach, C. Bermudez,
J. Bhama, R. Kormos, N. Shigemura, J. D'Cunha, S. Mulukutla, O.
Marroquin, S. Khandhar. University of Pittsburgh Medical Center,
Pittsburgh, PA.
- 11:45 AM (206) *Lung Transplant for COPD in the Elderly: It Is Still Indicated?;***
C. Brown, D. Mason, D. Johnston, M. Budev, G. Pettersson,
S. Murthy. Thoracic and Cardiovascular Surgery, Cleveland Clinic,
Cleveland, OH.

10:30 AM – 12:00 PM

CONCURRENT SESSION 23

A Fresh Look at Lung Allograft Dysfunction – What the Bench Is Telling Us (Grand Hall D)

CHAIRS: Stephan M. Ensminger, MD, DPhil and Tereza Martinu, MD (LTX, BSTR, PATH)

- 10:30 AM (207) Humoral Allo and Auto Immunity in Human Lung Transplant Recipients;**
O. Gjorgijmajkoska¹, B. Fischer², C. J. Taylor³, E. M. Bolton¹, A. Bradley¹, J. Parmar⁴, G. J. Pettigrew¹. ¹Department of Surgery, University of Cambridge, Cambridge, United Kingdom, ²Cambridge Systems Biology Centre, Cambridge, United Kingdom, ³Tissue Typing Laboratory, Addenbrooke's Hospital, Cambridge, United Kingdom, ⁴Papworth Hospital, Papworth, United Kingdom.
- 10:45 AM (208) Novel Two-Hit Hypothesis for the Development of De Novo Autoimmunity Following Lung Transplantation;**
A. Bharat¹, V. Subramaniam², D. Kreisel³, M. Decamp¹, T. Mohanakumar³. ¹Thoracic Surgery, Northwestern University, Chicago, IL, ²General Surgery, University of Mississippi, Jackson, MS, ³Surgery, Washington University, St Louis, MO.
- 11:00 AM (209) IL-6 Blockage by Anti-Interleukin-6 Receptor Antibody Suppresses Plasma Cells during Development of Alloantibody Responses;**
G. Wu, I. Kim, N. Chai, S. Jordan, A. Klein. Comprehensive Transplant Center, Cedars-Sinai Medical Center, Los Angeles, CA,
- 11:15 AM (210) Regulatory T Cells Attenuate Chronic Rejection by Suppressing T Helper 17 Cells Differentiation after Murine Lung Transplantation;**
W. Zhou¹, X. Zhou², Q. Meng³, J. Liu¹, Z. Zhan³, J. Li³, H. Cao¹, Z. Liu², H. Fan². ¹Department of Cardiac Surgery, Shanghai East Hospital, Tongji University School of Medicine, Shanghai, China, ²Department of Cardiac Surgery, Institute of Heart Failure, Shanghai East Hospital, Tongji University School of Medicine, Shanghai, China, ³Institute of Heart Failure, Shanghai East Hospital, Tongji University School of Medicine, Shanghai, China.
- 11:30 AM (211) Early Downregulation of Innate NK Cell Responses By Post-Transplant Blocking of VEGF Receptors Attenuates Experimental Obliterative Airway Disease in Mice;**
R. Krebs, J. M. Tikkanen, A. Raissadati, M. Hollmen, J. O. Ropponen, M. A. Keränen, K. B. Lemström. Transplantation Laboratory, University of Helsinki, Helsinki, Finland.
- 11:45 AM (212) Protein Kinase C delta-Mediated Unfolded Protein Response and Necrotic Cell Death Contributes to Ischemia-Reperfusion Induced Injury in Lung Transplantation;**
H. Kim, J. Zhao, D. Lee, X. Bai, M. Cypel, S. Keshavjee, M. Liu. Latner Thoracic Surgery Research Laboratories, University Health Network, Toronto, ON, Canada.

10:30 AM – 12:00 PM

CONCURRENT SESSION 24

Much Ado About Nothing? (New Approaches to Immune Monitoring in Heart Transplantation) (Harbor GHI)**CHAIRS:** Jose Luis Lambert, MD, PhD and Deborah E. Meyers, MD
(HTX, BSTR, PATH)

- 10:30 AM (213) Does the Ability for Donor Specific Antibodies to Bind Complement Always Result in C4d Staining in the Endomyocardial Biopsy After Heart Transplant?;**
 N. Lipson-Altman¹, N. Reinsmoen¹, M. Kittleson¹, D. Luthringer², J. Patel¹, F. Liou¹, Z. Yu¹, B. Kearny¹, L. Czer¹, D. H. Chang¹, D. Ramzy¹, J. Kobashigawa¹. ¹Cedars-Sinai Heart Institute, Los Angeles, CA, ²Cedars-Sinai Medical Center, Los Angeles, CA.
- 10:45 AM (214) Static Versus Dynamic Angiographic CAV Evaluation: Prognostic Stratification Beyond ISHLT Grading;**
 M. Masetti¹, A. Aliabadi², M. Sabatino¹, G. Delle-Karth³, P. Prestinzi¹, S. Rödler², K. Uyanik Uenal², J. Gökler², G. Laufer², C. Rapezzi¹, F. Grigioni¹, A. Zuckermann², L. Potena¹. ¹DIMES, S. Orsola Hospital, University of Bologna, Bologna, Italy, ²Heart Transplantation, Cardiac Surgery Department, Vienna General Hospital, Vienna, Austria, ³Cardiology, Vienna General Hospital, Vienna, Austria.
- 11:00 AM (215) Clinical Importance of Flow Cytometry Crossmatch in the Context of Complement-Dependent Cytotoxicity Crossmatch Results Following Heart Transplantation;**
 B. C. Keeshan¹, M. J. O'Connor¹, K. Y. Lin¹, D. S. Monos², C. T. Lind², C. E. Mascio³, T. L. Spray³, R. E. Shaddy¹, J. W. Rossano¹. ¹Division of Cardiology, Children's Hospital of Philadelphia, Philadelphia, PA, ²Immunogenetics Laboratory, Children's Hospital of Philadelphia, Philadelphia, PA, ³Division of Cardiothoracic Surgery, Children's Hospital of Philadelphia, Philadelphia, PA.
- 11:15 AM (216) Defining Prognostic Markers in Heart and Lung Transplant Recipients with PTLN;**
 G. Kumarasinghe¹, O. Lavee², I. Nivison-Smith², A. Parker³, M. Malouf¹, A. Keogh¹, S. Milliken², A. Dodds², M. Plit¹, C. Hayward¹, D. Ma², K. Fay², J. Joseph², E. Kotlyar¹, A. Havryk¹, A. Jabbour¹, A. Glanville¹, P. Macdonald¹, J. Moore¹. ¹Heart and Lung Transplant Unit, St. Vincent's Hospital, Darlinghurst, Australia, ²Dept of Haematology, St. Vincent's Hospital, Darlinghurst, Australia, ³Dept of Anatomical Pathology, St. Vincent's Hospital, Darlinghurst, Australia.
- 11:30 AM (217) Circulating Cell-Free DNA Is a Non-Invasive Marker of Heart Transplant Rejection;**
 I. De Vlaminc¹, H. A. Valantine², H. Luikart², D. Weisshaar³, D. Bernstein⁴, S. R. Quake¹, K. K. Khush². ¹Bioengineering, Stanford University, Palo Alto, CA, ²Cardiovascular Medicine, Stanford University, Palo Alto, CA, ³Heart Transplant Services, Kaiser Permanente Northern California, Santa Clara, CA, ⁴Pediatric Cardiology, Stanford University, Palo Alto, CA.
- 11:45 AM (218) Identification of MicroRNA 628-5p as a Novel Biomarker for Cardiac Allograft Vasculopathy (CAV);**
 A. Neumann¹, J. Kleeberger², N. Benecke¹, A. Holzmann², A. Haverich¹, T. Thum², C. Bara¹. ¹Department of Cardiothoracic, Transplantation and Vascular Surgery, Medizinische Hochschule Hannover, Hannover, Germany, ²Institute of Molecular and Translational Therapeutic Strategies, Medizinische Hochschule Hannover, Hannover, Germany.

SCIENTIFIC PROGRAM

10:30 AM – 12:00 PM

CONCURRENT SYMPOSIUM 28

JHLT at ISHLT: The Year in a Capsule (Seaport H)

CHAIRS: Stephan Schueler, MD, PhD, FRCS and Pali D. Shah, MD
(ALL)

10:30 AM *Highlights of Heart Transplantation and Mechanical Circulatory Support*

Martin Schweiger, MD, University Children's Hospital, Zurich, Switzerland

10:45 AM *Invited Discussant*

Heather J. Ross, MD, University Hospital, Toronto, ON, Canada

10:50 AM *Highlights of Lung Transplantation and Pulmonary Hypertension*

Laveena Chhatwani, MD, MSc, Stanford University, Stanford, CA, USA

11:05 AM *Invited Discussant*

Geert M. Verleden, MD, PhD, University Hospital Gasthuisberg, Leuven, Belgium

11:10 AM *Highlights of End Stage Cardiothoracic Disease in Children*

Steven J. Kindel, MD, Children's Hospital & Medical Center, Omaha, NE, USA

11:25 AM *Invited Discussant*

Richard Kirk, MA, FRCP, FRCPC, Freeman Hospital, Newcastle upon Tyne, United Kingdom

11:30 AM *Highlights of Transplant Infectious Diseases*

Me-linh Luong, M.D., University of Montreal St-Luc Hospital, Montreal, QC, Canada

11:45 AM *Invited Discussant*

Shahid Husain, MD, MS, Toronto General Hospital, Toronto, ON, Canada

11:50 AM *Panel Discussion*

NOON – 2:00 PM

LUNCH BREAK/VIEW POSTERS/VIEW EXHIBITS

NOON – 12:45 PM

BOX LUNCH DISTRIBUTION (Palm Foyer)

12:05 PM – 12:55 PM

MECHANICAL CIRCULATORY SUPPORT COUNCIL MEETING

(Grand Hall A)

PULMONARY HYPERTENSION COUNCIL MEETING (Grand Hall B)

PEDIATRIC TRANSPLANTATION COUNCIL MEETING (Grand Hall C)

INFECTIOUS DISEASES COUNCIL MEETING (Grand Hall D)

PATHOLOGY COUNCIL MEETING (Harbor GHI)

1:05 PM – 1:55 PM**HEART FAILURE AND TRANSPLANT MEDICINE COUNCIL MEETING**
(Grand Hall A)**PULMONARY TRANSPLANTATION COUNCIL MEETING** (Grand Hall B)**PEDIATRIC HEART FAILURE WORKFORCE MEETING** (Grand Hall C)**2:00 PM – 3:30 PM****CONCURRENT SESSION 25****Tackling Bad VAD Situations: Penalty or Score?**

(Grand Hall A)

CHAIRS: Arnt E. Fiene, MD and Mathias Loebe, MD, PhD
(MCS, HF)**2:00 PM (219) Role of VAD Therapy for Patients with Restrictive Cardiomyopathy: Improving Outcomes for a Lethal Disease;**A. Grupper¹, L. D. Joyce², J. M. Stulak², S. D. Schettler¹, Y. Gerber¹, Y. Topilsky¹, N. L. Pereira¹, B. S. Edwards¹, R. C. Daly², S. J. Park², S. S. Kushwaha¹. ¹Division of Cardiovascular Diseases, Mayo Clinic, Rochester, MN, ²Division of Cardiovascular Surgery, Mayo Clinic, Rochester, MN.**2:15 PM (220) Impact of Left Ventricular Assist Device Support on Bridging to Transplantation in Adults with Restrictive Cardiomyopathy;**A. H. Healy¹, B. C. Baird¹, S. G. Drakos², J. N. Nativi², S. H. McKellar¹, J. Stehlik², C. H. Selzman¹. ¹Surgery, University of Utah, Salt Lake City, UT, ²Medicine, University of Utah, Salt Lake City, UT.**2:30 PM (221) Hemodynamic Effects of Partial Right Ventricular Support in the Acute Vs the Chronic Pressure Overloaded Right Ventricle;**T. Verbelen¹, M. Martin², M. Goda¹, K. Kasama¹, I. Van Tichelen¹, D. Burkhoff³, M. Delcroix⁴, F. Rega¹, B. Meyns¹. ¹Experimental Cardiac Surgery, University of Leuven, Leuven, Belgium, ²CircuLite Inc., Hackensack, NJ, ³Cardiology, Columbia University College of Physicians and Surgeons, New York, NY, ⁴Clinical and Experimental Medicine, University of Leuven, Leuven, Belgium.**2:45 PM (222) Pulmonary Artery Pulsatility Index Predicts Right Ventricular Failure After LVAD Implantation;**G. Kang¹, D. Banerjee². ¹Department of Medicine, Stanford University Medical Center, Stanford, CA, ²Department of Medicine, Division of Cardiology, Stanford University Medical Center, Stanford, CA.**3:00 PM (223) Association of Systemic Vascular Resistance and Right Ventricular Failure Following Left Ventricular Assist Device Implantation;**H. Keshmiri, A. J. Tatoes, P. Pappas, G. Bhat, G. T. Sayer. Advocate Christ Medical Center, Oak Lawn, IL.**3:15 PM (224) Impact of vWF Activity in the Long-term Management of Centrifugal Type Continuous-flow LVAD Patients;**Y. Ichihara, T. Nishinaka, Y. Yamada, R. Hoki, C. Kashiwamura, M. Komagamine, H. Tsukui, S. Saito, M. Nagashima, K. Yamazaki. Cardiovascular Surgery, Tokyo Women's Medical University, Tokyo, Japan.

2:00 PM – 3:30 PM

CONCURRENT SESSION 26

How to Live Better with an LVAD (Grand Hall B)

CHAIRS: Jennifer A. Cowger, MD, MS and Yuriy Pya, MD
(MCS, NHAHA, PEEQ)

2:00 PM (225) *How Do Readmissions Impact Survival Among Patients with Continuous-Flow Left Ventricular Assist Devices? Findings from INTERMACS;*

R. P. Vivo¹, S. R. Krim², J. D. Estep³, W. I. Khalife⁴, G. C. Fonarow¹, R. L. Kormos⁵, S. L. Myers⁶, M. C. Deng¹. ¹Cardiology, University of California Los Angeles, Los Angeles, CA, ²Cardiology, John Ochsner Heart and Vascular Institute, New Orleans, LA, ³Cardiology, Methodist DeBakey Heart and Vascular Center, Houston, TX, ⁴Cardiology, University of Texas Medical Branch, Galveston, TX, ⁵Cardiology, University of Pittsburgh Medical Center, Pittsburgh, PA, ⁶Cardiology, University of Alabama at Birmingham, Birmingham, AL.

2:15 PM (226) *Mechanical Circulatory Support Improves Diabetic Control in Patients With Advanced Heart Failure;*

S. K. Sundararajan¹, A. Krikorian², G. Sayer¹, G. Bhat¹. ¹Center for Heart Transplant and Assist Devices, Advocate Christ Medical Center, Oak Lawn, IL, ²Department of Internal Medicine, Advocate Christ Medical Center, Oak Lawn, IL.

2:30 PM (227) *Incidence and Predictors of Myocardial Recovery on Heartmate II Left Ventricular Assist Device Support: Results From the United Network Organ Sharing Database;*

V. K. Topkara. Cardiology, Columbia University, New York, NY.

2:45 PM (228) *The Heart Mate Risk Score Correlates with Mortality in an Unselected Mixed Cohort of Heart Mate II and Heart Ware LVAD from a Single Large Volume Center;*

L. Adamo, M. Nassif, A. Tibrewala, J. Vader, G. Ewald, D. L. Mann, S. LaRue. Cardiology, Washington University in St Louis, St Louis, MO.

3:00 PM (229) *Change in Health-related Quality of Life from Before to After Destination Therapy Mechanical Circulatory Support is Similar for Older and Younger Patients: Analyses from INTERMACS;*

K. L. Grady¹, D. C. Naftel², S. L. Myers², M. Dew³, G. Weidner⁴, K. A. Idrissi⁵, H. B. Lee⁶, E. C. McGee, Jr.⁷, J. K. Kirklin². ¹Northwestern University, Chicago, IL, ²University of Alabama at Birmingham, Birmingham, AL, ³University of Pittsburgh, Pittsburgh, PA, ⁴San Francisco State University, Romberg Center, Tiburon, CA, ⁵Columbia University, New York, NY, ⁶Yale University School of Medicine, New Haven, CT, ⁷Northwestern Memorial Hospital, Chicago, IL.

3:15 PM (230) *Psychosocial Factors Do Not Influence Survival or the Development of Complications After Left Ventricular Assist Device Implantation;*

H. Golwala¹, W. F. Rawasia², K. Vessels³, K. McCants³, M. S. Slaughter⁴, A. Lenneman³, E. J. Birks³. ¹Cardiovascular Medicine, University of Louisville, Rudd Heart and Lung Institute, Louisville, KY, ²Internal Medicine, University of Louisville, Rudd Heart and Lung Institute, Louisville, KY, ³Heart Failure and Mechanical Support, University of Louisville, Rudd Heart and Lung Institute, Louisville, KY, ⁴Cardiothoracic surgery, University of Louisville, Rudd Heart and Lung Institute, Louisville, KY.

2:00 PM – 3:30 PM

CONCURRENT SESSION 27

All's Well That Ends Well? What We Can Learn From Heart Transplant Registries (Grand Hall C)**CHAIRS:** John WC Entwistle, III, MD, PhD and Mirta Diez, MD (HTX)

- 2:00 PM (231) ABO-Incompatible Adult Heart Transplantation. A Registry Study:**
H. Bergenfeldt¹, B. Andersson², J. Nilsson¹. ¹Dept. of Cardiothoracic surgery, Lund University and Skane University Hospital, Lund, Sweden, ²Dept. of Surgery, Lund University and Skane University Hospital, Lund, Sweden.
- 2:15 PM (232) Retransplantation Versus Medical Therapy for Cardiac Allograft Vasculopathy (CAV): Analysis of the International Society for Heart and Lung Transplantation (ISHLT) Registry:**
L. Goldraich¹, J. Stehlik¹, A. Y. Kucheryavaya³, L. B. Edwards³, H. J. Ross⁴. ¹Cardiac Transplant Program, Peter Munk Cardiac Center, University of Toronto, Toronto, ON, Canada, ²University of Utah School of Medicine, Salt Lake City, UT, ³International Society for Heart and Lung Transplantation and United Network for Organ Sharing, Richmond, VA, ⁴Cardiac Transplant Program, University of Toronto, Toronto, ON, Canada.
- 2:30 PM (233) Race/Ethnic Differences in the Epidemiology of Graft Failure in a Contemporary Cohort:**
A. A. Morris¹, A. Kalogeropoulos¹, E. Kransdorf², M. Owen³, R. T. Cole¹, J. Brown¹, D. Gupta¹, S. R. Laskar¹, A. Smith¹, J. Butler¹. ¹Emory University School of Medicine, Atlanta, GA, ²Mayo Clinic Arizona, Scottsdale, AZ, ³Emory University School of Nursing, Atlanta, GA.
- 2:45 PM (234) The Role of Recipient BMI and Age on Survival after Heart Transplantation:**
D. J. Weber¹, P. Didolkar¹, A. Gracon¹, Y. Hellman², M. A. Hadi², A. Malik², M. Caccamo², I. Gradus-Pizlo², T. Wozniak¹, Z. A. Hashmi¹, I. Wang¹. ¹Cardiothoracic Surgery, Indiana University Health, Indianapolis, IN, ²Cardiology, Indiana University Health, Indianapolis, IN.
- 3:00 PM (235) Effect of Match for Ethnicity on Immuno-logic Events After Heart Transplantation: An Analysis of the UNOS/OPTN Database:**
T. Carvajal¹, E. P. Kransdorf², M. Cheng³, D. E. Steidley², R. L. Scott², A. Bordner⁴, V. Balan⁵, O. E. Pajaro⁶. ¹Department of Surgery, Mayo Clinic Arizona, Phoenix, AZ, ²Division of Cardiovascular Diseases, Mayo Clinic Arizona, Scottsdale, AZ, ³Division of Health Sciences Research, Section of Biostatistics, Mayo Clinic Arizona, Phoenix, AZ, ⁴Center for Regenerative Medicine, Mayo Clinic Arizona, Phoenix, AZ, ⁵Division of Gastroenterology and Hepatology, Mayo Clinic Arizona, Phoenix, AZ, ⁶Division of Cardiothoracic Surgery and Center for Regenerative Medicine, Mayo Clinic Arizona, Phoenix, AZ.
- 3:15 PM (236) Need for Renal Replacement Therapy after Cardiac Transplantation in Patients with AL Amyloidosis Is Associated with Poor Survival:**
E. D. Niehaus¹, S. R. Tabatabai¹, N. Sarawat¹, J. R. Stone², L. Gilstrap³, M. Maurer⁴, R. Witteles⁵, J. D. Estep⁶, D. Baran⁷, M. J. Zucker⁷, G. Feltrin⁸, D. C. Seldin⁹, M. J. Semigran¹. ¹Cardiology, Massachusetts General Hospital, Boston, MA, ²Pathology, Massachusetts General Hospital, Boston, MA, ³Cardiology, Brigham and Women's Hospital, Boston, MA, ⁴Cardiology, Columbia University Medical Center, New York City, NY, ⁵Cardiology, Stanford University Medical Center, Stanford, CA, ⁶Cardiology, Houston Methodist Hos-

pital, Houston, TX, ⁷Cardiology, Newark Beth Israel Medical Center, Newark, NJ, ⁸Cardiology, University of Padua, Padua, Italy, ⁹Hematology-Oncology, Boston University Medical Center, Boston, MA.

2:00 PM – 3:30 PM

CONCURRENT SESSION 28

Diagnosis and Monitoring of Pulmonary Hypertension (Grand Hall D)

CHAIRS: Randall C. Starling, MD, MPH and Ioana R. Preston, MD
(PH, HF)

2:00 PM **(237) *Limitations of Right Heart Catheterization in the Diagnosis and Risk Stratification of Patients with Pulmonary Hypertension: Insights from the CHAMPION Trial;***

A. Raina¹, R. C. Bourge², W. Abraham³, P. Adamson⁴, J. Bauman⁵, J. Yadav⁵, R. L. Benza¹. ¹Cardiovascular Institute, Allegheny General Hospital, Pittsburgh, PA, ²Division of Cardiology, University of Alabama at Birmingham, Birmingham, AL, ³Division of Cardiology, Ohio State University, Columbus, OH, ⁴Heart Failure Institute, Oklahoma Heart Hospital, Oklahoma City, OK, ⁵Cardiomems, Inc, Atlanta, GA.

2:15 PM **(238) *Use of a Wireless Implantable Hemodynamic Monitor Leads to Reductions in Heart Failure Hospitalizations Among WHO Group II Pulmonary Hypertension Patients;***

A. Raina¹, R. C. Bourge², W. Abraham³, P. B. Adamson⁴, J. Bauman⁵, J. Yadav⁵, R. L. Benza¹. ¹Cardiovascular Institute, Allegheny General Hospital, Pittsburgh, PA, ²Division of Cardiology, University of Alabama at Birmingham, Birmingham, AL, ³Division of Cardiology, Ohio State University, Columbus, OH, ⁴The Heart Failure Institute, Oklahoma Heart Hospital, Oklahoma City, OK, ⁵Cardiomems, Inc, Atlanta, GA.

2:30 PM **(239) *Demographics and Outcomes from a Binational Australian and New Zealand Registry for Adults with Congenital Heart Disease and Pulmonary Arterial Hypertension;***

M. L. Rose¹, G. Strange², L. Grigg³, F. Kermeen⁴, C. O'Donnell⁵, I. King¹, D. Celermajer⁶, R. Weintraub¹. ¹The Murdoch Children's Research Institute, Parkville, Australia, ²Notre Dame University, Perth, Australia, ³Royal Melbourne Hospital, Parkville, Australia, ⁴Queensland Service, Brisbane, Australia, ⁵The Starship Children's Hospital, Auckland, Australia, ⁶The Royal Prince Alfred Hospital, Sydney, Australia.

2:45 PM **(240) *Echocardiographic Features and Utility of Baseline Echo in the Assessment of Pulmonary Hypertension in Patients with Atrial Septal Defect;***

A. Abernethy¹, K. Stackhouse¹, M. Halane¹, W. ElMallah², A. Qureshi¹, R. Krasuski¹. ¹The Cleveland Clinic, Cleveland, OH, ²The University of Kentucky, Lexington, KY.

- 3:00 PM** **(241) Balloon Atrial Septostomy in Pulmonary Arterial Hypertension: Effect on Survival and Associated Outcomes;**
 J. S. Chiu, W. A. Zuckerman, M. E. Turner, M. E. Richmond, D. Kerstein, U. Krishnan, A. Torres, J. A. Vincent, E. B. Rosenzweig. Division of Pediatric Cardiology, Columbia University Medical Center, New York, NY.
- 3:15 PM** **(242) Assessment of Right Ventricular Adaptability to Loading Conditions Can Improve the Timing of Listing to Transplantation in Patients with Pulmonary Arterial Hypertension;**
 M. Dandel, C. Knosalla, D. Kemper, R. Hetzer. Cardiothoracic and Vascular Surgery, Deutsches Herzzentrum Berlin, Berlin, Germany.

2:00 PM – 3:30 PM**CONCURRENT SYMPOSIUM 29****Approach to the Highly Sensitized Patient Awaiting Heart Transplantation (Harbor GHI)**

CHAIRS: Howard J Eisen, MD and Maria G. Crespo-Leiro, MD, PhD
 (HF, HTX, PATH, PHARM)

SESSION SUMMARY: Sensitization (circulating HLA-antibodies) in patients awaiting heart transplantation may lead to prolonged waiting times and possibly increased complications/death while on the waiting list. This session is designed to provide attendees with practical information and strategies to manage sensitized patients awaiting heart transplantation. Recent research publications and program experience will inform this session.

- 2:00 PM** **Clinical Risk of Circulating Antibodies in Patients Awaiting Heart Transplantation**
 Luciano Potena, MD, PhD, University of Bologna, Bologna, Italy
- 2:20 PM** **Desensitization Therapy vs. Virtual Crossmatch: Does It Make Sense to Desensitize**
 Monica M. Colvin-Adams, MD, University of Minnesota, Minneapolis, MN, USA
- 2:40 PM** **Treatment Strategies for Desensitization**
 A. G. Kfoury, MD, FACC, Intermountain Heart Institute (UTAH Cardiac Transplant Program), Murray, UT, USA
- 3:00 PM** **Sensitized VAD Patients Awaiting Heart Transplantation: Are They Different?**
 Jon Kobashigawa, MD, Cedars-Sinai Heart Institute, Los Angeles, CA, USA
- 3:20 PM** **2013 Final ISHLT Antibody Mediated Rejection Classification**
 Gerald J. Berry, MD, Stanford University, Stanford, CA, USA

2:00 PM – 3:30 PM

CONCURRENT SESSION 29

Lung Donation: Take It to the Limits (Seaport H)

CHAIRS: Michael S. Mulligan, MD and Dirk E. Van Raemdonck, MD, PhD (LTX, DMD)

2:00 PM **(243)** *Impact of Extended Cold Ischemic Times on the Outcome of Clinical Lung Transplantation Using Ex-Vivo Lung Perfusion (EVLV):*

T. Krueger¹, T. Machuca², V. Linacre², M. Chen², L. Singer³, K. Yasufuku², M. De Perrot², A. Pierre², T. Waddell², S. Keshavjee², M. Cype^{1,2}. ¹Division of Thoracic Surgery, University Hospital of Lausanne, Lausanne, Switzerland, ²Division of Thoracic Surgery, Toronto General Hospital, Toronto, ON, Canada, ³Toronto Lung Transplant Program, Toronto General Hospital, Toronto, ON, Canada.

2:15 PM **(244)** *The Effect of Cold and Warm Ischemia Time on Survival After Lung Transplantation in a Large National Cohort:*

J. D. Lannon¹, A. Ball², R. B.C³, N. Yonan², S. Clark³, J. Mascaro⁴, P. Catarino⁵, A. Simon⁶, J. H. Dark³. ¹Statistics and Clinical Studies, NHS Blood and Transplant, Bristol, United Kingdom, ²Wythenshawe Hospital, Manchester, United Kingdom, ³Freeman Hospital, Newcastle upon Tyne, United Kingdom, ⁴Queen Elizabeth Hospital, Birmingham, United Kingdom, ⁵Papworth Hospital, Cambridge, United Kingdom, ⁶Harefield Hospital, Middlesex, United Kingdom.

2:30 PM **(245)** *DCD Lung Transplantation for Pulmonary Arterial Hypertension: Passing the Toughest Test:*

B. Levvey¹, H. Whitford¹, T. Williams¹, T. Miller^{2,3,4}, C. Manterfield², G. Westall¹, M. Paraskeva¹, J. Gooi¹, A. Zimmet¹, A. Pick¹, J. Negri¹, S. Marasco¹, D. McGiffen², G. Snell¹. ¹Lung Transplant Service, The Alfred Hospital, Melbourne, Australia, ²The Alfred Hospital, Melbourne, Australia, ³Allergy, Immunology & Respiratory Medicine, The Alfred, Melbourne, Australia, ⁴The Alfred, Melbourne, Australia.

2:45 PM **(246)** *Length of the Agonal Phase in Donors After Cardiac Death Influences Donor Lung Function After Reperfusion in a Rat Model:*

K. Hijjiya, F. Chen, M. Takahashi, K. Ohata, T. Kondo, H. Motoyama, A. Ohsumi, D. Nakajima, J. Sakamoto, T. Yamada, M. Satoh, A. Aoyama, T. Bando, H. Date. Thoracic Surgery, Kyoto University Graduate School of Medicine, Kyoto, Japan.

3:00 PM **(247)** *Lung Transplant Waitlist Mortality: Height as a Predictor of Poor Outcomes:*

B. C. Keeshan¹, J. W. Rossano¹, N. A. Beck², R. Hammond³, J. L. Kreindler⁴, T. L. Spray⁵, S. Fuller⁵, S. B. Goldfarb⁴. ¹Division of Cardiology, Children's Hospital of Philadelphia, Philadelphia, PA, ²University of California Berkeley, Berkeley, CA, ³Center for Biomedical Informatics, Children's Hospital of Philadelphia, Philadelphia, PA, ⁴Division of Pulmonary Medicine, Children's Hospital of Philadelphia, Philadelphia, PA, ⁵Division of Cardiothoracic Surgery, Children's Hospital of Philadelphia, Philadelphia, PA.

3:15 PM **(248)** *First Lung Transplants Using Controlled and Uncontrolled DCD Lungs Evaluated With OCS-Lung Portable Exvivo Perfusion System:*

F. Moradiellos¹, M. Córdoba¹, P. Merlo², R. Irazzo², G. Díaz³, C. García-Gallo³, A. Varela¹. ¹Thoracic Surgery Department, Hospital Universitario Puerta de Hierro, Madrid, Spain, ²Anesthesiology Department, Hospital Universitario Puerta de Hierro, Madrid, Spain, ³Pneumology Department, Hospital Universitario Puerta de Hierro, Madrid, Spain.

2:00 PM – 3:30 PM

CONCURRENT SESSION 30

Philip K. Caves Award Candidate Presentations

(Gaslamp AB)

CHAIRS: David O. Taylor, MD and Stuart C. Sweet, MD, PhD

(ALL)

- 2:00 PM** **(249) Metabolic Profiling of Perfusate from Clinical Ex-Vivo Lung Perfusion Yields Potential Biomarkers of Early Lung Transplant Outcomes;** M. K. Hsin¹, R. Zamel¹, M. Cypel¹, K. Hashimoto¹, M. Chen¹, T. Machuca¹, D. Wishart², B. Han², T. K. Waddell¹, M. Liu¹, S. Keshavjee¹. ¹Thoracic Surgery, University of Toronto, Toronto, ON, Canada, ²University of Alberta, Edmonton, AB, Canada.
- 2:15 PM** **(250) Ligation of Transgenic MHC Class I Molecule Expressed Only in the Lungs By Its Specific Antibodies Induces Epithelial Injury, Autoimmunity and Obliterative Airway Disease (OAD): A Novel Transgenic Mouse Model of OAD;** N. J. Sarma, V. Tiriveedhi, T. Mohanakumar. Surgery, Washington University School of Medicine, St. Louis, MO.
- 2:30 PM** **(251) Development of Recipient-Matched Engineered Heart Tissue Using 3D Printing;** Y. Yildirim¹, S. Pecha¹, H. Naito², B. Karikkineth², W. Zimmermann³, H. Reichenspurner¹, T. Eschenhagen⁴. ¹Cardiac Surgery, University Heart Center Hamburg, Hamburg, Germany, ²Department of Experimental Pharmacology and Toxicology, University Medical Center Hamburg-Eppendorf, Hamburg, Germany, ³Pharmacology, University Medical Center Göttingen, Göttingen, Germany, ⁴Department of Experimental Pharmacology and Toxicology, University Medical Center Hamburg-Eppendorf, Hamburg, Germany.
- 2:45 PM** **(252) DAP12 Expression By Lung-Resident Macrophages Mediates Pulmonary Ischemia Reperfusion Injury By Promoting Neutrophil Extravasation;** J. Spahn¹, W. Li¹, A. C. Bribriescio¹, J. Liu¹, B. Zinselmeyer², H. Shen³, S. L. Brody², D. Goldstein³, A. S. Krupnick¹, A. Gelman¹, D. Kreisel¹. ¹Surgery, Washington University St. Louis, St. Louis, MO, ²Medicine, Washington University St. Louis, St. Louis, MO, ³Medicine, Yale University, New Haven, CT.
- 3:00 PM** **(253) Halofuginone Inhibition of Th17 Cell Differentiation Attenuates Obliterative Bronchiolitis in Mouse Orthotopic Lung Transplantation;** H. Oishi¹, M. Sato², Y. Matsuda³, S. Hirayama⁴, Z. Guan¹, T. Saito¹, M. Cypel¹, D. Hwang¹, M. Whitman⁵, M. Liu¹, S. Keshavjee¹. ¹Latner Thoracic Surgery Research Laboratories, University Health Network, University of Toronto, Toronto, ON, Canada, ²Department of Thoracic Surgery, Kyoto University, Kyoto, Japan, ³Department of Thoracic Surgery, Tohoku University, Sendai, Japan, ⁴Department of Surgery, Okayama Rosai Hospital, Okayama, Japan, ⁵Department of Cell Biology, Harvard Medical School, Boston, MA.
- 3:15 PM** **(254) De Novo DQ Donor-Specific Antibodies Are Associated With Chronic Lung Allograft Dysfunction;** J. M. Tikkanen, L. G. Singer, S. Azad, M. Binnie, C. Chaparro, C. Chow, M. Cypel, M. dePerrot, A. Pierre, K. Yasufuku, T. K. Waddell, S. Keshavjee, K. Tinckam. Toronto Lung Transplant Program, Toronto General Hospital, Toronto, ON, Canada,

SCIENTIFIC PROGRAM

2:00 PM – 3:30 PM

CONCURRENT SYMPOSIUM 30

Controversies in Listing Children for Thoracic Organ Transplant (Gaslamp CD)

CHAIRS: Charles E. Canter, MD and Janet N. Scheel, MD
(PED)

- 2:00 PM** *Acceptable Transplant Candidates – Genetic and Adherence Considerations*
Asif Hasan, MD, Freeman Hospital, Newcastle, United Kingdom
- 2:15 PM** *The Patient-Provider Liaison: Do social situations really matter in patient outcomes?*
Samantha J. Anthony, PhD, MSW, Hospital for Sick Children, Toronto, Canada
- 2:30 PM** *Adherence: How much does it really matter in picking transplant candidates?*
Fabienne Dobbels, MSc, PhD, University Hospital, Leuven, Belgium
- 2:45 PM** *Shaky Ground: Can we say no without fear of legal action?*
Daniel Bernstein, MD, Stanford University, Palo Alto, CA, USA
- 3:00 PM** *To List or Not to List: Purism or Pragmatism?*
Elizabeth Blume, MD, Children's Hospital, Boston, MA, USA
- 3:15 PM** *Panel Discussion*

3:30 PM – 4:00 PM

COFFEE BREAK/VISIT EXHIBITS (Harbor A-F)

VIEW POSTERS (Harbor and Seaport Foyers)

4:00 PM – 5:30 PM

CONCURRENT SESSION 31

Building the Bridge to Transplant: Old Challenges, New Solutions (Grand Hall A)**CHAIRS:** Paul J. Mohacsi, MD and Geetha Bhat, MD, PhD
(MCS, HTX, HF)

- 4:00 PM (255) Heart Transplantation Outcomes in Patients with Continuous Flow Left Ventricular Assist Device Related Complications:**
M. Quader, L. G. Wolfe, D. Zhao, V. Kasirajan. Cardio-Thoracic Surgery, Virginia Commonwealth University, Richmond, VA.
- 4:15 PM (256) Safety and Efficacy of Pre Transplant Desensitization of Patients Supported by CF-LVADs:**
K. P. Mody¹, M. Dionizovik-Dimanovski¹, J. Duong¹, A. P. Levin¹, A. R. Garan¹, P. C. Colombo¹, H. Takayama², M. Yuzefpolskaya¹, S. W. Restaino¹, Y. Naka², D. M. Mancini¹, U. P. Jorde¹, N. Uriel¹.
¹Medicine, Columbia University, New York, NY, ²Surgery, Columbia University, New York, NY.
- 4:30 PM (257) Do Continuous Flow Left Ventricular Assist Devices Really Cause Allosensitization?:**
C. A. Willis¹, J. Stehlik¹, D. Eckels², O. Wever Pinzon², A. Kfoury², S. G. Drakos², R. Alharethi², J. Nativi Nicolau², D. Budge³, J. C. Fang², E. M. Gilbert², C. H. Selzman², J. Stehlik². ¹Cardiology, University of Utah, Salt Lake City, UT, ²Cardiology, U.T.A.H. Cardiac Transplant Program, Salt Lake City, UT, ³Cardiology, U., Salt Lake City, UT.
- 4:45 PM (258) Five -Fold Increase in Antibody-Mediated Rejection (AMR) Post-Heart Transplant in Patients Developing Allosensitization During Left Ventricular Assist Device Support (LVAD):**
K. P. Mody¹, J. Duong¹, M. Dionizovik-Dimanovski¹, A. P. Levin¹, A. R. Garan¹, J. Fried¹, H. Takayama², M. Yuzefpolskaya¹, P. C. Colombo¹, S. W. Restaino¹, Y. Naka², D. M. Mancini¹, U. P. Jorde¹, N. Uriel¹.
¹Medicine, Columbia University, New York, NY, ²Surgery, Columbia University, New York, NY.
- 5:00 PM (259) Increasing Use of Mechanical Circulatory Support as a Bridge to Cardiac Replantation:**
K. J. Clerkin¹, S. S. Thomas¹, J. Haythe¹, P. C. Schulze¹, M. Farr¹, H. Takayama², U. P. Jorde¹, N. Uriel¹, S. W. Restaino¹, Y. Naka², D. M. Mancini¹. ¹Cardiology, Columbia University Medical Center, New York, NY, ²Cardiac Surgery, Columbia University Medical Center, New York, NY.
- 5:15 PM (260) Safety of Mechanical Circulatory Support as a Bridge to Cardiac Replantation:**
S. S. Thomas¹, K. J. Clerkin¹, J. Haythe¹, P. C. Schulze¹, M. Farr¹, H. Takayama², U. P. Jorde¹, N. Uriel¹, S. W. Restaino¹, Y. Naka², D. M. Mancini¹. ¹Cardiology, Columbia University Medical Center, New York, NY, ²Cardiac Surgery, Columbia University Medical Center, New York, NY.

4:00 PM – 5:30 PM

CONCURRENT SESSION 32

Mechanical Circulatory Support: Is the Outcome Worth the Cost? (Grand Hall B)

CHAIRS: Alejandro M. Bertolotti, MD and Joseph G. Rogers, MD
(MCS, NHAHA, PEEQ)

- 4:00 PM** **(261)** *Readmission after Left Ventricular Assist Device Implantation: Differences Observed Between Two Device Types;*
S. Maltais, N. A. Haglund, M. E. Davis, J. Stulak, N. M. Tricarico, T. DiSalvo, M. Wigger, M. Keebler, K. Schlendorf. Vanderbilt University Medical Center, Nashville, TN.
- 4:15 PM** **(262)** *Relationship Between the Cost and Cause of Hospital Readmissions After LVAD Implantation;*
K. Lietz, A. Branch, M. McGrath, J. Herre. Division of Advanced Heart Failure, Sentara Norfolk General Hospital, NORFOLK, VA.
- 4:30 PM** **(263)** *Reduction of Drive Line Infection in Continuous Flow Assist Devices: Use of Standard Kit Including Silver Dressing and Anchoring Device;*
B. Cagliostro¹, A. P. Levin¹, G. Parkis¹, S. Stewart¹, K. P. Mody¹, H. Takayama², Y. Naka², P. C. Colombo¹, M. Yuzepolskaya¹, U. P. Jorde¹, N. Uriel¹. ¹Medicine, Columbia University, New York, NY, ²Surgery, Columbia University, New York, NY.
- 4:45 PM** **(264)** *Moved to Poster Session 2*
- 5:00 PM** **(265)** *Outcomes of Adult Patients with Small Body Size Supported with a Continuous-Flow Left Ventricular Assist Device;*
S. Lee¹, J. N. Katz², F. D. Pagani³, U. P. Jorde⁴, N. Moazami⁵, R. John⁶, K. S. Sundareswaran⁷, D. J. Farrar⁷, O. H. Frazier⁸. ¹Cardiovascular Medicine, Cleveland Clinic Foundation, Cleveland, OH, ²Divisions of Cardiology and Pulmonary/Critical Care Medicine, University of North Carolina-Chapel Hill, Chapel Hill, NC, ³Center for Circulatory Support, University of Michigan Hospital and Health Systems, Ann Arbor, MI, ⁴Division of Cardiology, Columbia University Medical Center, New York, NY, ⁵Department of Thoracic and Cardiovascular Surgery, Cleveland Clinic Foundation, Cleveland, OH, ⁶University of Minnesota, Minneapolis, MN, ⁷Research and Scientific Affairs, Thoratec Corporation, Pleasanton, CA, ⁸Department of Cardiovascular Surgery, Texas Heart Institute, Houston, TX.
- 5:15 PM** **(266)** *Percutaneous Insertion of Venous-Arterial Extracorporeal Membrane Oxygenation Circuit in the Catheterization Laboratory for Refractory Cardiogenic Shock Is Safe and Associated with Excellent Outcomes;*
Y. Sandoval, B. Sun, L. B. Louis, M. Samara, D. Feldman, I. Chavez, B. Cabuay, P. Zimbwa, M. Bennett, K. Hryniewicz. Minneapolis Heart Institute, Abbott Northwestern Hospital, Minneapolis, MN.

4:00 PM – 5:30 PM

CONCURRENT SESSION 33

A Midsummer Night's Dream (Potential Improvements in Outcomes After Cardiac Transplantation) (Grand Hall C)**CHAIRS:** Howard Eisen, MD and Martin Cadeiras, MD
(HTX, HF)

- 4:00 PM (267) Impact of Cardiac Arrest Resuscitated Donors on Heart Recipients Outcome;**
A. Galeone¹, S. Varnous¹, E. Barreda¹, S. Hariri², A. Pavie¹, P. Leprince¹. ¹Department of Thoracic and Cardiovascular Surgery, La Pitié-Salpêtrière Hospital, Paris, France, ²Department of Anesthesiology, La Pitié-Salpêtrière Hospital, Paris, France.
- 4:15 PM (268) Donor and Recipient Renal Dysfunction and Post Cardiac Transplant Graft Survival: Insights Into Reno-Cardiac Interactions;**
O. Laur¹, M. A. Brisco², A. J. Kula¹, S. J. Cheng¹, A. A. Mangi¹, S. G. Coca¹, W. H. Tang³, J. M. Testani¹. ¹School of Medicine, Yale University, New Haven, CT, ²Medical University of South Carolina, Charleston, SC, ³Cleveland Clinic, Cleveland, OH.
- 4:30 PM (269) Assessing Performance of Human Donor Hearts Following Donation After Circulatory Death;**
F. Rosenfeldt, R. Ou, S. Marasco, I. Buttfield, J. Woodard, S. Perera, K. Bhagwat, D. McGiffin. Cardiothoracic Surgery, Alfred Hospital, Melbourne, Victoria, Australia.
- 4:45 PM (270) Varying Time Frame of Primary Graft Failure After Heart Transplantation;**
S. Letzen, S. Ghadyani, P. Bonde. Section of Cardiac Surgery, Yale School of Medicine, New Haven, CT.
- 5:00 PM (271) Amiodarone Treatment Prior to Heart Transplantation Is Associated with Acute Graft Dysfunction and Early Mortality: A Propensity-Matched Comparison;**
H. Yerebakan¹, Y. Naka¹, R. Sorabella¹, S. C. Hill¹, K. Takeda¹, P. Schulze², I. George¹, M. Yuzefpolskaya², M. A. Farr², N. Uriel², P. C. Colombo², U. P. Jorde², D. M. Mancini², H. Takayama¹. ¹Department of Surgery, Columbia University Medical Center, New York, NY, ²Department of Medicine, Columbia University Medical Center, New York, NY.
- 5:15 PM (272) Are There Indirect Effects of Cytomegalovirus Infection? Utility of Valganciclovir. EPICA Study;**
I. Sanchez-Lazaro, L. Almenar-Bonet, L. Martinez-Dolz, E. Sanchez-Lacuesta, L. Andres-Lalaguna, J. Melero-Ferrer, M. Portoles-Sanz, M. Rivera-Otero, A. Salvador-Sanz. Cardiology Department. Heart Failure and Transplantation Unit, Hospital Universitari i Politècnic La Fe, Valencia, Spain.

4:00 PM – 5:30 PM

CONCURRENT SESSION 34

Chronic Lung Allograft Dysfunction: Mechanisms (Grand Hall D)

CHAIRS: Glen P. Westall, FRACP, PhD and Laurie D. Snyder, MD
(LTX, BSTR)

- 4:00 PM** **(273) Airway Alterations in Chronic Lung Allograft Dysfunction:**
S. E. Verleden¹, D. Vasilescu², S. Willems¹, D. Ruttens¹, R. Vos¹, E. Vandermeulen¹, J. McDonough², E. Verbeken¹, J. Verschakelen¹, D. Van Raemdonck¹, B. Rondelet³, C. Knoop³, M. Decramer¹, J. Cooper⁴, J. Hogg², J. Hostens⁵, G. Verleden¹, B. Vanaudenaerde¹. ¹KU Leuven, Leuven, Belgium, ²University of British Columbia, Vancouver, BC, Canada, ³Université Libre de Bruxelles, Brussel, Belgium, ⁴University of Pennsylvania, Pennsylvania, PA, ⁵Skyscan, Kontich, Belgium.
- 4:15 PM** **(274) Epithelial Injury and Dysregulated Repair in Small and Large Airways of Lung Transplant Patients is Ameliorated by Azithromycin:**
A. Kicic¹, M. Lavender², M. M. Musk², J. Wrobel², B. Banerjee¹, K. Ling¹, K. M. Martinovich¹, L. W. Garratt³, T. Iosifidis³, K. Looi³, E. Kicic-Starcevic¹, F. J. Lannigan⁴, P. Hopkins⁵, S. T. Yerkovich⁵, E. N. Sutanto¹, D. C. Chambers⁶, S. M. Stick⁷. ¹Clinical Sciences, Telethon Institution For Child Health Research, Perth, Australia, ²Royal Perth Hospital, Perth, Australia, ³School of Paediatrics and Child Health, University of Western Australia, Perth, Australia, ⁴School of Medicine, Notre Dame University, Perth, Australia, ⁵School of Medicine, University of Queensland, Brisbane, Australia, ⁶School of Medicine, University of Queensland, Brisbane, Australia, ⁷Department of Respiratory Medicine, Princess Margaret Hospital for Children, Perth, Australia.
- 4:30 PM** **(275) Neutrophilic Enzymes in Human Chronic Lung Allograft Dysfunction: Potential Marker for Biologic Subtyping:**
T. Saito¹, M. Liu¹, M. Binnie², M. Sato¹, S. Azad¹, T. Machuca¹, H. Oishi¹, M. Cypel¹, T. K. Waddell¹, S. Keshavjee¹. ¹Latner Thoracic Surgery Research Laboratories, University Health Network, Toronto, ON, Canada, ²Division of Respiriology, University of Toronto, Toronto, ON, Canada.
- 4:45 PM** **(276) Elevated Hyaluronan Is Associated with Bronchiolitis Obliterans Syndrome:**
J. L. Todd¹, V. E. Kennedy¹, E. N. Pavlisko², H. L. Zhang¹, F. L. Kelly¹, S. M. Palmer¹. ¹Department of Medicine, Duke University Medical Center, Durham, NC, ²Department of Pathology, Duke University Medical Center, Durham, NC.
- 5:00 PM** **(277) An Immunohistological Study To Evaluate the Role of Eosinophils in Chronic Lung Allograft Dysfunction:**
E. Vandermeulen, M. Ricciardi, S. E. Verleden, D. Ruttens, D. E. Van Raemdonck, R. Vos, G. M. Verleden, B. M. Vanaudenaerde. Department of Pneumology, KU Leuven, Leuven, Belgium.
- 5:15 PM** **(278) Identification of a High-Risk Group for Development of BOS Using Latent Class Analysis:**
R. Shah¹, S. Bellamy², J. Diamond¹, E. Cantu³, J. Flesch¹, S. Arcasoy⁴, J. Sonnett⁵, D. Lederer⁴, J. D. Christie¹. ¹Division of Pulmonary, Allergy, and Critical Care Medicine, University of Pennsylvania, Philadelphia, PA, ²Center for Clinical Epidemiology and Biostatistics, University of Pennsylvania, Philadelphia, PA, ³Department of Thoracic Surgery, University of Pennsylvania, Philadelphia, PA, ⁴Division of Pulmonary and Critical Care, Columbia University, New York, NY, ⁵Department of Thoracic Surgery, Columbia University, New York, NY.

4:00 PM – 5:30 PM

CONCURRENT SESSION 35:

Alternative Resources for Organs (Harbor GHI)

CHAIRS: Richard N. Pierson, III, MD and Ali Nsair, MD
(HTX, DMD, BSTR)

- 4:00 PM (279) Pig Artery Patch Transplantation (Tx) in Nonhuman Primates (NHPs): A Predictor of Outcome of PIG-To-NHP Heart Tx;**
*H. Iwase*¹, M. B. Ezzelarab¹, H. Hara¹, J. K. Bhama², M. Wijkstrom¹, P. Bajona¹, V. Satyananda¹, B. Ekser¹, C. Phelps³, D. Ayares³, D. K. Cooper¹. ¹Surgery, Thomas E. Starzl Transplantation Institute, University of Pittsburgh, Pittsburgh, PA, ²Surgery, University of Pittsburgh, Pittsburgh, PA, ³Revivacor, Blacksburg, VA.
- 4:15 PM (280) Transgenic Human Thrombomodulin Expression Reduces Xenogeneic Thrombosis: a Promising Means of Reducing Pig Lung Xenograft Thrombotic Injury;**
*D. G. Harris*¹, Z. Gao², E. P. Sievert¹, P. Benipal¹, X. Cheng¹, L. Burdorf¹, D. L. Ayares³, R. N. Pierson, III¹, A. M. Azimzadeh¹. ¹Surgery, University of Maryland School of Medicine, Baltimore, MD, ²Jiangsu Key Laboratory of Xenotransplantation, Nanjing Medical University, Nanjing, China, ³Revivacor, Incorporated, Blacksburg, VA.
- 4:30 PM (281) Human iPS-cell-derived Engineered Heart Tissue for Cardiac Repair;**
*S. Pecha*¹, F. Weinberger², K. Breckwoldt², B. Geertz², J. Starbatty², T. Schulze², A. Hansen², H. Reichenspurner¹, T. Eschenhagen². ¹Cardiovascular Surgery, University Heart Center Hamburg, Hamburg, Germany, ²Department of Experimental Pharmacology and Toxicology, University Medical Center Hamburg-Eppendorf, Hamburg, Germany.
- 4:45 PM (284) Regulation of Host Immunity By Donor B Cells in Neonatal Tolerance To Cardiac Allografts;**
R. A. Bascom, K. Tao, S. L. Tollenaar, *L. J. West*. University of Alberta, Edmonton, AB, Canada.
- 5:00 PM (283) Establishing a Novel Protocol for Heart Bioscaffold Cryopreservation;**
C. Hemphill, A. V. Louis, N. Qu, T. Son, Z. Khalpey. University of Arizona, Tucson, AZ.
- 5:15 PM (282) Impact of Initial Reperfusion Temperature on the Functional Recovery of DCD Hearts;**
*C. W. White*¹, Y. Li², A. Müller², E. Ambrose², J. Thliveris³, T. W. Lee⁴, R. C. Arora¹, G. Tian⁵, J. Nagendran⁶, L. Hryskho², D. H. Freed⁶. ¹Cardiac Surgery, University of Manitoba, Winnipeg, MB, Canada, ²Institute of Cardiovascular Sciences, St. Boniface Research Center, Winnipeg, MB, Canada, ³Human Anatomy and Cell Science, University of Manitoba, Winnipeg, MB, Canada, ⁴Anesthesia and Perioperative Medicine, University of Manitoba, Winnipeg, MB, Canada, ⁵National Research Council Institute for Biodevices, Winnipeg, MB, Canada, ⁶Cardiac Surgery, University of Alberta, Edmonton, AB, Canada.

4:00 PM – 5:30 PM

CONCURRENT SESSION 36

Long-Term Outcomes in Pediatric Heart Transplantation (Seaport H)

CHAIRS: Robert J. Boucek, Jr., MD and Beth D. Kaufman, MD
(PEDS, HTX, PEEQ)

- 4:00 PM** **(285) *Functional Status of US Children After Heart Transplantation:***
D. M. Peng¹, L. B. Smoot², S. Chen¹, L. J. May¹, B. D. Kaufman¹, J. Yeh¹, S. A. Hollander¹, S. L. Siehr¹, C. S. Almond², D. N. Rosenthal¹. ¹Pediatrics, Stanford University, Palo Alto, CA, ²Pediatric Cardiology, Boston Children's Hospital, Boston, MA.
- 4:15 PM** **(286) *Quality of Life and Metrics of Achievement in Long-Term Adult Survivors of Pediatric Heart Transplant:***
S. A. Hollander¹, S. Chen¹, H. Luikart², M. Burge³, D. N. Rosenthal¹, K. Maeda⁴, S. A. Hunt², D. Bernstein¹. ¹Pediatrics (Cardiology), Stanford University, Palo Alto, CA, ²Cardiology, Stanford University, Palo Alto, CA, ³Department of Social Work, Lucile Packard Children's Hospital, Palo Alto, CA, ⁴Cardiothoracic Surgery, Stanford University, Palo Alto, CA.
- 4:30 PM** **(287) *Social Framework of Pediatric Heart Recipients Who Have Survived More Than 15 Post Transplant Years: A Single Center Experience:***
H. Copeland¹, A. Beckham², A. Razzouk¹, R. Chinnock³, N. Hasaniya¹, K. Bahjri⁴, L. Bailey¹. ¹Thoracic and Cardiovascular Surgery, Loma Linda University School of Medicine, Loma Linda, CA, ²Surgery, Loma Linda University School of Medicine, Loma Linda, CA, ³Pediatrics, Loma Linda University School of Medicine, Loma Linda, CA, ⁴Public Health, Loma Linda University School of Public Health, Loma Linda, CA.
- 4:45 PM** **(288) *Predictors of Late Renal Dysfunction after Pediatric Heart Transplantation: A UNOS Database Analysis:***
K. Molina¹, C. Weng², M. Everitt¹. ¹UTAH Cardiac Transplant Program, University of Utah, Salt Lake City, UT, ²University of Utah, Salt Lake City, UT.
- 5:00 PM** **(289) *Coronary Allograft Vasculopathy in Pediatric Heart Transplant: Is Re-transplant a Prudent Option for All?:***
F. Zafar¹, C. Chin², D. L. Morales¹, K. Karani¹, A. Lorts², I. Wilmot², J. L. Jefferies², R. Bryant III¹, T. D. Ryan², J. A. Towbin², C. Castleberry². ¹Cardiothoracic Surgery, Cincinnati Children's Hospital, Cincinnati, OH, ²Cardiology, Cincinnati Children's Hospital, Cincinnati, OH.
- 5:15 PM** **(290) *Pediatric Cardiac Re-transplantation: Waitlist Mortality Stratified by Age and Era:***
M. Bock¹, K. Nguyen², S. Malerba³, K. Harrison¹, E. Bagiella³, B. Gelb¹, S. Pinney⁴, I. Lytrivi¹. ¹Pediatric Cardiology, Icahn School of Medicine at Mount Sinai, New York, NY, ²Pediatric Cardiothoracic Surgery, Icahn School of Medicine at Mount Sinai, New York, NY, ³Dept. of Health Evidence and Policy, Icahn School of Medicine at Mount Sinai, New York, NY, ⁴Cardiology, Icahn School of Medicine at Mount Sinai, New York, NY.

4:00 PM – 5:30 PM

CONCURRENT SESSION 37

Heart and Lung Transplant Pathology (Gaslamp AB)

CHAIRS: Annalisa Angelini, MD and Carmela D. Tan, MD

(PATH, HTX, LTX)

- 4:00 PM (291) Histologic Findings in Allograft Lung Biopsies: Correlation With Serologic Alloimmunity:**
J. A. Collins¹, A. Iacono², C. Drachenberg¹, A. P. Burke¹. ¹Pathology, University of Maryland Medical Center, Baltimore, MD, ²Pulmonary and Critical Care Medicine, University of Maryland Medical Center, Baltimore, MD.
- 4:15 PM (292) Acute Fibrinous and Organizing Pneumonia is a Common Histological Pattern of Acute Lung Injury in Patients Developing Restrictive Allograft Syndrome:**
S. Karimi¹, M. Sato², T. Saito³, H. C. Roberts⁴, C. Chaparro⁵, L. G. Singer⁵, T. K. Waddell³, S. Keshavjee³, D. M. Hwang¹. ¹Pathology, Toronto General Hospital, Toronto, ON, Canada, ²Thoracic Surgery, Kyoto University, Kyoto, Japan, ³Thoracic Surgery, Toronto General Hospital, Toronto, ON, Canada, ⁴Medical Imaging, Toronto General Hospital, Toronto, ON, Canada, ⁵Respirology, Toronto General Hospital, Toronto, ON, Canada.
- 4:30 PM (293) Reproducibility of C4d by Immunofluorescence and Immunohistochemistry in Lung Allograft Biopsies:**
A. C. Roden¹, J. J. Maleszewski¹, E. S. Yi¹, S. M. Jenkins², M. C. Aubry¹. ¹Laboratory Medicine & Pathology, Mayo Clinic Rochester, Rochester, MN, ²Division of Biomedical Statistics & Informatics, Mayo Clinic Rochester, Rochester, MN.
- 4:45 PM (294) Mixed Acute Cellular Rejection and Antibody Mediated Rejection in Heart Transplantation: A Retrospective Study in a Single Transplant Center:**
M. Fedrigo, G. Feltrin, A. Frigo, G. Toscano, F. Tona, C. Castellani, G. Gerosa, M. Valente, G. Thiene, A. Angelini. Department Cardiac Thoracic and Vascular Sciences, University of Padua, Padua, Italy.
- 5:00 PM (295) Mixed Rejection Is a Low Frequency Event and Not Just Cellular Rejection and C4d Deposition in the Cardiac Allograft:**
C. D. Tan¹, M. Askar², E. R. Rodriguez¹. ¹Anatomic Pathology, Cleveland Clinic, Cleveland, OH, ²Transplantation Center, Cleveland Clinic, Cleveland, OH.
- 5:15 PM (296) miRNAs as Biomarkers of Rejection in Heart Transplantation:**
M. Tible¹, A. Loupy², D. Vernerey³, P. Rouvier⁴, S. Varnous⁴, C. Suberbielle⁵, T. Beuscart³, R. Guillemain¹, X. Jouven³, P. Bruneval¹, J. Duong Van Huyen². ¹Hopital Européen Georges Pompidou, Paris, France, ²Hopital Necker, Paris, France, ³PARCC, Paris, France, ⁴Hopital La Pitié Salpêtrière, Paris, France, ⁵Hopital Saint Louis, Paris, France.

4:00 PM – 5:30 PM

CONCURRENT SESSION 38

Innovative Pharmacotherapeutic Approaches to Thoracic Transplant and Mechanically Assisted Patients (Gaslamp CD)

CHAIRS: Rochelle M. Gellatly, PharmD and Tamara E. Claridge, PharmD (PHARM, HTX, LTX, MCS)

- 4:00 PM (297) *First Experience With the Novel Proteasome Inhibitor Carfilzomib for Antibody Mediated Rejection After Lung Transplantation;***
C. R. Ensor¹, A. Zeevi², M. R. Morrell³, S. A. Yousem⁴, J. D'Cunha⁵, J. M. Pilewski³, C. Bermudez⁵, M. A. Shullo¹, J. J. Teuteberg³, J. F. McDyer³. ¹Pharmacy and Therapeutics, University of Pittsburgh, Pittsburgh, PA, ²Histopathology, University of Pittsburgh, Pittsburgh, PA, ³Medicine, University of Pittsburgh, Pittsburgh, PA, ⁴Pathology, University of Pittsburgh, Pittsburgh, PA, ⁵Surgery, University of Pittsburgh, Pittsburgh, PA.
- 4:15 PM (298) *Concurrent Use of Sirolimus and Voriconazole: Assessing Long Term Safety and Dosing Strategies;***
C. V. Dang, A. Feist, L. Awdishu, S. Reed, G. Yung. UC San Diego, San Diego, CA.
- 4:30 PM (299) *Terbutaline for Treatment of Sinus Node Dysfunction Following Heart Transplantation;***
C. T. Doligalski¹, C. Sammons¹, M. W. Weston². ¹Pharmacy, Tampa General Hospital, Tampa, FL, ²Cardiology, Tampa General Medical Group, Tampa, FL.
- 4:45 PM (300) *Tacrolimus Pharmacokinetic Modeling Predicts Dose Requirement in Pediatric Heart Transplant Recipients;***
B. Taylor¹, C. Castleberry², A. Vinks³, I. Wilmot², C. Chin². ¹Heart Institute/Pharmacy, Cincinnati Children's Hospital, Cincinnati, OH, ²Heart Institute, Cincinnati Children's Hospital, Cincinnati, OH, ³Clinical Pharmacology, Cincinnati Children's Hospital, Cincinnati, OH.
- 5:00 PM (301) *Effect of CYP3A4*22 and CYP3A5 Combined Genotypes on Tacrolimus Disposition in Heart Transplantation;***
A. Vu¹, R. L. Page², N. Roscoe¹, J. A. Lindenfeld³, C. L. Aquilante¹. ¹Department of Pharmaceutical Sciences, University of Colorado, Aurora, CO, ²Department of Clinical Pharmacy, University of Colorado, Aurora, CO, ³Department of Medicine, University of Colorado, Aurora, CO.
- 5:15 PM (302) *High Prevalence of Warfarin Genotype Polymorphisms in Patients with Mechanical Circulatory Support;***
M. Awad, L. S. Czer, J. Pinzas, C. Soliman, K. Rihbany, J. Mirocha, D. Chang, J. Moriguchi, D. Ramzy, F. Arabia. Cedars Sinai Heart Institute, Cedars Sinai Medical Center, Los Angeles, CA.

5:30 PM – 6:30 PM

MINI ORAL SESSION 7

Improving the Heart Donor (Grand Hall A)

CHAIRS: Glenn J.R. Whitman, MD and Carla C. Baan, PhD
(DMD, HTX)

- 5:30 PM (303) Thyroid Hormone Therapy in 63,593 Donors: A Retrospective Review of Heart and Lung Procurement;**
*D. Novitzky*¹, Z. Mi², J. F. Collins², D. K. Cooper¹. ¹Starzl Transplantation Institute, University of Pittsburgh, Pittsburgh, PA, ²Cooperative Studies Program Coordinating Center, VA Medical Center, Perry Point, MD.
- 5:35 PM (304) Examining Long-Term Outcomes in Heart Transplantation Using Donors With a History of Past and Present Cocaine Use;**
S. Jayarajan, S. Taghavi, E. Komaroff, A. Shiose, D. Schwartz, E. Hamad, R. Alvarez, G. Wheatley, T. Guy, Y. Toyoda. Temple University School of Medicine, Philadelphia, PA.
- 5:40 PM (305) Heart Transplantation After Ex-Vivo Perfusion of the Donor Hearts: Does it Affect Inotropic Use and Hospital Stay?;**
*A. Ardehali*¹, D. Mancini², Y. Naka², J. Kobashigawa³, F. Esmailian³, E. Hsieh⁴, E. Soltesz⁴, *M. Deng*¹. ¹UCLA School of Medicine, Los Angeles, CA, ²New York Presbyterian Hospital/Columbia Medical Center, New York, NY, ³Cedars-Sinai Heart Institute, Los Angeles, CA, ⁴Cleveland Clinic, Cleveland, OH.
- 5:45 PM (306) Excellent Long-Term Survival with Extended Ischemic Time in Orthotopic Heart Transplantation;**
*J. W. Smith*¹, K. D. O'Brien², T. F. Dardas², D. P. Fishbein², E. D. Verrier¹, A. Stempien-Otero², R. K. Cheng², S. C. Masri¹, C. Buchter², G. S. Aldea¹, W. C. Levy², N. A. Mokadam¹. ¹Cardiothoracic Surgery, University of Washington, Seattle, WA, ²Cardiology, University of Washington, Seattle, WA.
- 5:50 PM (307) Differences in Regional Recipient Waitlist Time and Pre- and Post-Transplant Mortality Following the 2006 UNOS Policy Changes in the Donor Heart Allocation Algorithm;**
*P. Schulze*¹, S. Kitada², K. Clerkin², Z. Jin², D. M. Mancini². ¹Department of Medicine, Division of Cardiology, Columbia University Medical Center, New York, NY, ²Columbia University Medical Center, New York, NY.
- 6:00 PM (309) Heart Transplantation With Organs Procured After Cardio-Circulatory Death and the Organ Care System. Assessment and Reconditioning of Hearts in a Porcine Model;**
*D. García Sáez*¹, A. Elbetanony², P. Lezberg², A. Hassanein², B. Zych¹, A. Sabashnikov¹, P. Mohite¹, N. Patil¹, A. Weymann¹, A. R. Simon¹. ¹Harefield Hospital NHS Trust, Harefield, London, United Kingdom, ²TransMedics, Boston, MA.
- 6:05 PM (310) Initial Experience With the Organ Care System in High Risk Donor/Recipient Combination Orthotopic Heart Transplantation (OCTx);**
D. García Sáez, B. Zych, A. Sabashnikov, P. Mohite, F. De Robertis, T. Pitt, O. Maunz, C. Bowles, R. Hards, T. Bahrami, M. Amrani, N. Banner, A. R. Simon. Harefield Hospital NHS Trust, Harefield, London, United Kingdom.

- 6:10 PM** **(311) Case Report of Cardiac Allografts Retrieved From Human Donation After Circulatory Death (DCD) Donors – Assessment on Ex-Vivo Beating Heart Perfusion Device:**
A. Iyer¹, L. Gao¹, M. Hicks¹, G. Kumarasinghe¹, P. Jansz², A. Jabbour², S. Al-Soufi³, A. Aneman⁴, G. Flynn⁵, A. Rajamani⁶, A. Cheng⁷, R. Raper⁸, D. Goh⁹, M. MacPartlin¹⁰, P. Saul¹¹, K. Dhital², P. Macdonald². ¹Transplantation Lab, Victor Chang Cardiac Research Institute, Darlinghurst, Australia, ²Heart & Lung Transplant Unit, St Vincent's Hospital, Darlinghurst, Australia, ³Intensive Care Unit, St Vincent's Hospital, Darlinghurst, Australia, ⁴Intensive Care Unit, Liverpool Hospital, Sydney, Australia, ⁵Intensive Care Unit, Prince of Wales Hospital, Sydney, Australia, ⁶Intensive Care Unit, Nepean Hospital, Sydney, Australia, ⁷Intensive Care Unit, St George Hospital, Sydney, Australia, ⁸Intensive Care Unit, Royal North Shore Hospital, Sydney, Australia, ⁹Intensive Care Unit, Westmead Hospital, Sydney, Australia, ¹⁰Intensive Care Unit, Wollongong Hospital, Wollongong, Australia, ¹¹Intensive Care Unit, Newcastle Hospital, Newcastle, Australia.
- 6:15 PM** **(312) Assessment of Myocardial Performance During Ex-Vivo Heart Perfusion:**
C. W. White¹, Y. Li², A. Müller², E. Ambrose², B. Hiebert¹, T. W. Lee³, R. C. Arora¹, G. Tian⁴, J. Nagendran⁵, L. Hryskho², D. H. Freed⁵. ¹Cardiac Surgery, University of Manitoba, Winnipeg, MB, Canada, ²Institute of Cardiovascular Sciences, St. Boniface Research Center, Winnipeg, MB, Canada, ³Anesthesia and Perioperative Medicine, University of Manitoba, Winnipeg, MB, Canada, ⁴National Research Council Institute for Biomedical Research, Winnipeg, MB, Canada, ⁵Cardiac Surgery, University of Alberta, Edmonton, AB, Canada.
- 6:20 PM** **(313) Donor Treatment with N-Octanoyl Dopamine in Brain-Dead Rats Improves Both Donor and Graft Left Ventricular Function After Heart Transplantation:**
G. Szabo¹, S. Li¹, S. Korkmaz¹, R. Spindler², T. Radovits³, S. Loganathan¹, P. Hegedüs¹, L. Tao⁴, S. Höger², M. Karck¹, B. Yard². ¹Department of Cardiac Surgery, University of Heidelberg, Heidelberg, Germany, ²Department of Clinical Pharmacology Mannheim, University of Heidelberg, Mannheim, Germany, ³Heart Center, Semmelweis University, Budapest, Hungary, ⁴Department of Cardiac Surgery, Wuhan Asia Heart Hospital, Wuhan, China.
- 6:25 PM** **(314) Functional Resuscitation of Hearts Preserved in Somah at Subnormothermia: A Comparative Study:**
S. K. Lowalekar¹, H. Cao¹, X. Lu¹, P. R. Treanor², H. S. Thattai¹. ¹Surgery, Harvard Medical School, Boston, MA, ²Surgery, VA Boston Healthcare System, Boston, MA.

5:30 PM – 6:30 PM

MINI ORAL SESSION 8

Immunology and the Child in Heart Transplantation (Gaslamp AB)

CHAIRS: Charles E. Canter, MD and Janet N. Scheel, MD
(PEDI, HTX, PATH)

- 5:30 PM** **(315)** *Low Body Mass Index Is Associated with Increased Waitlist Mortality Among Children Listed for Heart Transplantation:*
R. R. Davies, M. A. McCulloch, S. Haldeman, S. S. Gidding, C. Pizarro. Nemours Cardiac Center, Nemours/A.I. duPont Hospital for Children, Wilmington, DE.
- 5:35 PM** **(316)** *Predictors of Long-Term Survival after Pediatric Heart Transplantation Change with Age:*
M. S. Khan¹, T. Alsaied², F. Zafar¹, C. D. Castleberry¹, R. Bryant III¹, I. Wilmot³, J. L. Jefferies³, D. L. Morales¹. ¹Cardiothoracic Surgery, Cincinnati Children's Hospital Medical Center, Cincinnati, OH, ²Pediatrics, Cincinnati Children's Hospital Medical Center, Cincinnati, OH, ³Cardiology, Cincinnati Children's Hospital Medical Center, Cincinnati, OH.
- 5:40 PM** **(317)** *1-Year Mortality in Adult Congenital Heart Disease Heart Transplant Recipients: Can a Risk Score Be Used To Identify Those at Highest Risk?:*
L. J. Burchill¹, L. B. Edwards², J. Stehlik³, A. I. Dipchand⁴, H. J. Ross⁵. ¹Adult Congenital Heart Disease, Oregon Health Sciences University, Portland, OR, ²International Society of Heart and Lung Transplant Registry, Addison, TX, ³University of Utah, Salt Lake City, UT, ⁴Hospital for Sick Children, Toronto, ON, Canada, ⁵Cardiac Transplant Program, Toronto General Hospital, Toronto, ON, Canada.
- 5:45 PM** **(318)** *Evaluating Pediatric Heart Re-transplant Candidates: Using a Risk Prediction Model to Estimate Early Mortality after Re-Transplant:*
S. L. Siehr¹, S. A. Hollander¹, K. Gauvreau², D. N. Rosenthal¹, T. P. Singh², B. Kaufman¹, J. Yeh¹, C. S. Almond². ¹Pediatric Cardiology, Stanford University School of Medicine, Palo Alto, CA, ²Pediatric Cardiology, Harvard Medical School, Boston, MA.
- 5:50 PM** **(319)** *Prevalence of BK Polyomavirus Infection and Association with Renal Function in Pediatric Heart Transplant Recipients:*
A. L. Ducharme-Smith¹, A. E. Bobrowski², B. Z. Katz³, C. L. Backer⁴, E. Pahl⁵. ¹Northwestern Feinberg School of Medicine, Chicago, IL, ²Nephrology, Ann & Robert H. Lurie Children's Hospital, Chicago, IL, ³Infectious Disease, Ann & Robert H. Lurie Children's Hospital, Chicago, IL, ⁴Cardiovascular-Thoracic Surgery, Ann & Robert H. Lurie Children's Hospital, Chicago, IL, ⁵Medical Director, Heart Transplant Program, Ann & Robert H. Lurie Children's Hospital, Chicago, IL.
- 5:55 PM** **(320)** *Risk Factors for Sudden Death in Children with Cardiac Allograft Vasculopathy:*
B. J. Hong¹, K. Sexson Tejtel¹, A. Jeewa¹, A. G. Cabrera¹, J. F. Price¹, J. S. Heinle², W. J. Dreyer¹, S. W. Denfield¹. ¹Pediatric Cardiology, Baylor College of Medicine/Texas Children's Hospital, Houston, TX, ²Pediatric Cardiothoracic Surgery, Baylor College of Medicine/Texas Children's Hospital, Houston, TX.

SCIENTIFIC PROGRAM

- 6:00 PM** **(321) *Antithymocyte Globulin But Not Basiliximab Is Beneficial After Infant Heart Transplantation – Analysis of the UNOS Database;***
B. Coleman, A. Phillips, J. Mirocha, J. Patel, F. Arabia, J. Kobashigawa. Cedars- Sinai Heart Institute, Los Angeles, CA.
- 6:05 PM** **(322) *C1q Testing in Pediatric Heart Transplant Recipients at Risk for Antibody Mediated Rejection;***
*E. Albers*¹, R. Boucek¹, M. Kemna¹, S. Law¹, P. Warner², Y. Law¹.
¹Pediatric Cardiology, Seattle Children's Hospital, Seattle, WA,
²Puget Sound Blood Center, Seattle, WA.
- 6:10 PM** **(323) *How Does Donor Specific Antibody Relate to Biopsy-diagnosed Antibody-mediated Rejection after Pediatric Heart Transplantation?;***
*A. Ware*¹, G. Snow², E. Hammond³, D. V. Miller³, J. Stehlik⁴, A. G. Kfoury³, A. Eckhauser⁴, D. Eckels⁵, M. Everitt⁴. ¹University of Utah, Salt Lake City, UT, ²Intermountain Medical Center, Salt Lake City, UT, ³Intermountain Medical Center/UTAH Cardiac Transplant Program, Salt Lake City, UT, ⁴University of Utah/UTAH Cardiac Transplant Program, Salt Lake City, UT, ⁵Pathology, University of Utah, Salt Lake City, UT.
- 6:15 PM** **(324) *C4d Deposition is a Marker for Pan Cardiac Vasculopathy after Heart Transplantation;***
N. E. Hiemann, R. Meyer, R. Hetzer, E. Wellnhofer. Cardiothoracic and Vascular Surgery, Deutsches Herzzentrum Berlin, Berlin, Germany.
- 6:20 PM** **(325) *Relative Importance of Antibodies Against Class I and Class II Human Leukocyte Antigens on Graft Survival in Pediatric Heart Transplant Recipients: An Analysis of the United Network for Organ Sharing Database;***
*M. J. O'Connor*¹, B. W. Keeshan¹, K. Y. Lin¹, D. Monos², C. Lind², S. M. Paridon¹, C. E. Mascio³, R. E. Shaddy¹, J. W. Rossano¹.
¹Division of Cardiology, The Children's Hospital of Philadelphia, Philadelphia, PA, ²Department of Pathology and Laboratory Medicine, The Children's Hospital of Philadelphia, Philadelphia, PA, ³Department of Cardiothoracic Surgery, The Children's Hospital of Philadelphia, Philadelphia, PA.
- 6:25 PM** **(326) *Is MFI Value a Solid Ground to Listing Unacceptable HLA Antigens;***
*A. Nikaein*¹, J. Hunt², M. Lerman³. ¹Transplant Immunology, Texas Medical Specialty, Inc., Dallas, TX, ²Transplant Center, Medical City Dallas Hospital, Dallas, TX, ³Transplant Department, Medical City Dallas Hospital, Dallas, TX.

5:30 PM – 6:30 PM

MINI ORAL SESSION 9

Quality of Life, Ethics, Policy and Economics in MCS and Thoracic Transplant (Gaslamp CD)**CHAIRS:** Annette J. Devito Dabbs, PhD, RN and Oliver Mauthner, PhD (PEEQ, NHSAH)

- 5:30 PM (327) Heart Failure Symptom Clusters and Functional Status;**
J. Salyer¹, M. P. Flattery², J. K. Herr³. ¹Department of Adult Health, Virginia Commonwealth University School of Nursing, Richmond, VA, ²Pauley Heart Center, Virginia Commonwealth University Health System, Richmond, VA, ³Quality & Compliance Department, Johnston-Willis Hospital, Richmond, VA.
- 5:35 PM (328) Physical Outcomes Post Paediatric Lung Transplant – Implications of Extra-Corporeal Membrane Oxygenation (ECMO);**
B. J. Tarrant¹, R. S. Martin², R. Steward¹, G. I. Snell², G. P. Westall². ¹Physiotherapy, Alfred Health, Prahran, Australia, ²AIRmed, Alfred Health, Prahran, Australia.
- 5:40 PM (329) The Prevalence of the Frailty Syndrome in Advanced Heart and Lung Failure;**
 D. Carter¹, M. Hannu², E. Montgomery³, M. Harkess³, S. Shaw³, N. De Tullio³, K. Cooper⁴, K. Wilhelm⁴, A. Havryk³, P. S. Macdonald³. ¹Faculty of Medicine, Notre Dame University, Sydney, Australia, ²Occupational Therapy, St. Vincent's Health Network, Sydney, Australia, ³Heart & Lung Transplant Unit, St. Vincent's Health Network, Sydney, Australia, ⁴Liaison Psychiatry, St. Vincent's Health Network, Sydney, Australia.
- 5:45 PM (330) Depression and Social Isolation at Time of Wait Listing Reduce Survival Up to 5 Years After Heart Transplantation – Results from the Waiting for a New Heart Study;**
H. Spaderna¹, S. Hellwig¹, T. Schäfer², F. M. Wagner², J. M. Smits³, G. Weidner⁴. ¹Psychology, University of Wuppertal, Wuppertal, Germany, ²Klinik und Poliklinik für Herz- und Gefäßchirurgie, Universitäres Herzzentrum Hamburg, Hamburg, Germany, ³Eurotransplant International Foundation, Leiden, Netherlands, ⁴Biology, San Francisco State University, San Francisco, CA.
- 5:50 PM (331) Relationship Between Candidate Psychosocial Risk Profile, Post-Implant Medical Compliance and Clinical Outcomes of LVAD Therapy;**
K. Lietz, K. Woodhouse, A. Branch, J. Spruill, L. Lewis-McGowan, M. McGrath, J. Herre. Division of Advanced Heart Failure, Sentara Norfolk General Hospital, Norfolk, VA.
- 5:55 PM (332) Impact of Donor and Recipient Socio-economic Status (SES) on Outcomes in Adult Heart Transplantation: Does It Really Matter?;**
 J. L. Nixon, R. O. McCubrey, D. Budge, E. M. Gilbert, R. A. Alharethi, B. Reid, S. G. Drakos, M. D. Everitt, J. Stehlik, K. M. Molina, J. Fang, J. Doty, A. G. Kfoury. UTAH Cardiac Transplant Program, Salt Lake City, UT.
- 6:00 PM (333) Socio-Economic Classification Is a Predictor of Long Term Survival in Patients With Left Ventricular Assist Device;**
 N. Robinson Smith, N. Wrightson, A. Woods, G. MacGowan, S. Schueler. Mechanical Circulatory Support Team, The Newcastle upon Tyne NHS Trust, Newcastle upon Tyne, United Kingdom.

- 6:05 PM** **(334) Success of Left Ventricular Assist Device Therapy in Uninsured Patients;**
N. Rajagopalan, K. Million, T. A. Tribble, D. R. Dennis, R. Yanagida, C. W. Hoopes. University of Kentucky, Lexington, KY.
- 6:10 PM** **(335) A Zero 90-Day Mortality After Lung Transplantation – What Is the Price?;**
M. Zemtsovski¹, P. F. Jensen¹, M. Østergaard¹, M. Perch², D. Steinbrüchel³, M. Iversen². ¹Department of Cardiothoracic Anaesthesia, Copenhagen University Hospital, Rigshospitalet, Copenhagen, Denmark, ²Department of Cardiology – Division of Lung Transplantation, Copenhagen University Hospital, Rigshospitalet, Copenhagen, Denmark, ³Department of Cardiothoracic Surgery, Copenhagen University Hospital, Rigshospitalet, Copenhagen, Denmark.
- 6:15 PM** **(336) Everolimus and Cyclosporine Equally Improve QoL in De Novo Heart Transplanted Patients: The Results of a Randomized Controlled Trial (SCHEDULE Trial);**
A. Relbo¹, I. Grov¹, B. Andersson², F. Gustafsson³, H. Eiskjær⁴, G. Rådegran⁵, E. Gude¹, K. Jansson⁶, D. Solbu⁷, V. Sigurdardottir⁸, S. Arora¹, G. Dellgren⁸, A. K. Andreassen¹, L. Gullestad¹. ¹Department of Cardiology, Oslo University Hospital – Rikshospitalet, Oslo, Norway, ²Department of Cardiology, Sahlgrenska University Hospital, Gothenburg, Sweden, ³Department of Cardiology, Copenhagen University Hospital, Copenhagen, Denmark, ⁴Department of Cardiology, Skejby University Hospital, Aarhus, Denmark, ⁵The Clinic for Heart Failure and Valvular Disease, Skåne University Hospital and Lund University, Lund, Sweden, ⁶Dept of Cardiology County Hospital, Linköping University, Linköping, Sweden, ⁷Novartis Norge AS, Oslo, Norway, ⁸Transplant Institute, Sahlgrenska University Hospital, Gothenburg, Sweden.
- 6:20 PM** **(337) Transplant Pharmacist Evaluation Prior To Heart Transplantation Uncovers Medication Noncompliance as a Common Issue;**
M. Shullo¹, C. Yost², T. Sabatine², R. Ramani², R. Kormos², J. Bhama², R. Zomak², C. Bermudez², M. Mathier², J. Teuteberg². ¹Department of Pharmacy and Therapeutics, University of Pittsburgh, Pittsburgh, PA, ²Heart and Vascular Institute, UPMC, Pittsburgh, PA.
- 6:25 PM** **(338) Cost Effectiveness of Detection of Tamponade After Postcardiac Surgery By Miniaturized Hemodynamic Transesophageal Echocardiogram (hTEE);**
H. Hirose, S. Gupta, J. Miessau, H. Pitcher, Q. Yang, N. Cavarocchi. Surgery, Thomas Jefferson University, Philadelphia, PA.

5:30 PM – 6:30 PM

MINI ORAL SESSION 10

VADs Gone Bad, Complications after MCS (Grand Hall B)

CHAIRS: M. Angela Rajek, MD and Leslie W. Miller, MD
(MCS, HF)

- 5:30 PM (339) Pre-emptive ID Specialist Consultation Reduces MCS Drive Line Infections;**
M. Caccamo¹, Y. Hellman¹, I. Gradus-Pizlo¹, A. Malik¹, J. Pickrell¹, T. Wozniak², Z. Hashmi², I. Wang¹, A. Hadi¹. ¹Indiana University, Indianapolis, IN, ²Indiana University Health, Indianapolis, IN.
- 5:35 PM (340) Development of De-Novo Aortic Valve Incompetence in Patients With the Continuous Flow Heartware® Ventricular Assist Device;**
S. K. Bhagra¹, C. J. Bhagra¹, M. Taylor², I. A. Fazal¹, G. Parry¹, G. MacGowan¹, S. Schueler³. ¹Cardiology, Freeman Hospital, Newcastle Upon Tyne, United Kingdom, ²Respiratory, Freeman Hospital, Newcastle Upon Tyne, United Kingdom, ³Cardiothoracic Surgery, Freeman Hospital, Newcastle Upon Tyne, United Kingdom.
- 5:40 PM (341) Subcostal vs. Sternotomy Device Exchanges: Comparison of Long-Term Mortality and Re-Exchange;**
A. P. Levin¹, N. Uriel¹, T. Ota², M. Dionizovik-Dimanovski¹, K. P. Mody¹, A. R. Garan¹, P. C. Colombo¹, M. Yuzefpolskaya¹, Y. Naka², H. Takayama², U. P. Jorde¹. ¹Medicine, Columbia University, New York, NY, ²Surgery, Columbia University, New York, NY.
- 5:45 PM (342) Intraplatelet Reactive Oxygen Species, Mitochondrial Damage and Platelet Apoptosis Augment Non-Surgical Bleeding in Heart Failure Patients Supported By Continuous-Flow Left Ventricular Assist Device (CF-LVADs);**
N. K. Mondal¹, E. N. Sorensen², N. Hiivala², E. D. Feller³, S. Pham¹, B. P. Griffith¹, Z. J. Wu¹. ¹Department of Surgery, University of Maryland School of Medicine, Baltimore, MD, ²Department of Clinical Engineering, University of Maryland Medical Center, Baltimore, MD, ³Department of Medicine, University of Maryland School of Medicine, Baltimore, MD.
- 5:50 PM (343) Detection of Early Thrombus Formation in LVAD By Acoustic Fast Fourier Transformation Analysis. A Novel Approach for Monitoring;**
P. von Samson, A. Meyer, T. Mueller, J. Zabel, J. Garbade, S. Lehmann, F. Mohr, M. Strueber. Cardiac Surgery, Heart Center Leipzig, Leipzig, Germany.
- 5:55 PM (344) Factors Related to Pump Thrombosis at Select Medium to High Volume Centers;**
C. T. Klodell¹, H. T. Massey², R. Adamson³, D. Dean⁴, D. Horstman-shof⁵, J. Ransom⁶, C. T. Salerno⁷, J. Cowger⁷, J. Aranda⁸, L. Chen², J. W. Long⁵, K. S. Sundareswaran⁹, D. J. Farrar⁹, W. Dembitsky³. ¹Division of Thoracic and Cardiovascular Surgery, University of Florida, Gainesville, FL, ²University of Rochester Medical Center, Rochester, NY, ³Sharp Memorial Hospital, San Diego, CA, ⁴Piedmont Hospital, Atlanta, GA, ⁵INTEGRIS Baptist Medical Center, Oklahoma City, OK, ⁶Baptist Health Heart Institute, Little Rock, AR, ⁷St. Vincent Heart Center of Indiana, Indianapolis, IN, ⁸Division of Cardiology, University of Florida, Gainesville, FL, ⁹Research and Scientific Affairs, Thoratec Corporation, Pleasanton, CA.

SCIENTIFIC PROGRAM

- 6:00 PM** **(345) No Difference in Pump Thrombosis in Heartmate II Patients With Gelatin Sealed and Unsealed Vascular Grafts;**
K. S. Sundareswaran, D. J. Farrar. Research and Scientific Affairs, Thoratec Corporation, Pleasanton, CA.
- 6:05 PM** **(346) LVAD Exchange for Thrombosis Is Associated with Higher Recurrent Rates of Hemolysis, Thrombosis, and Death;**
A. M. Andruska¹, M. Nassif¹, E. Novak¹, G. A. Ewald¹, S. J. LaRue¹, S. C. Silvestry², A. Itoh². ¹Department of Cardiology, Washington University School of Medicine, Saint Louis, MO, ²Department of Cardiothoracic Surgery, Washington University School of Medicine, Saint Louis, MO.
- 6:10 PM** **(347) Efficacy of Intravenous Tissue Plasminogen Activator (tPA) in Treatment of Device Thrombus in Continuous Flow Left Ventricular Assist Devices with Centrifugal Design;**
M. F. Masood, L. Wang, M. Romano, J. W. Haft, R. Hasan, K. Aaronson, F. D. Pagani. Cardiac Surgery, University of Michigan, Ann Arbor, MI.
- 6:15 PM** **(348) Post Cardiopulmonary Bypass Vasoplegic Syndrome in Continuous Flow Left Ventricular Assist Devices Is Associated With Adverse Outcomes;**
M. Chen¹, B. Griffin¹, K. Ashley¹, M. Domanski¹, G. Fischer², A. Anyanwu³, S. Pinney¹. ¹Cardiology, Mount Sinai Hospital, New York, NY, ²Anesthesiology, Mount Sinai Hospital, New York, NY, ³Cardiothoracic Surgery, Mount Sinai Hospital, New York, NY.
- 6:20 PM** **(349) Aggressive Early Control of Blood Pressure May Prevent Development of Significant Aortic Regurgitation Following Continuous-Flow Left Ventricular Assist Device Implantation;**
N. P. Patil¹, P. N. Mohite¹, A. Sabashnikov¹, A. Weymann¹, D. Garcia-Saez¹, B. Zych¹, R. Hards¹, C. Bowles¹, M. Hedger¹, F. De Robertis¹, A. Moza¹, T. Bahrami¹, M. Amrani¹, N. Banner², A. R. Simon¹. ¹Department of Cardiothoracic Transplantation and Mechanical Circulatory Support, Royal Brompton & Harefield NHS Foundation Trust, Harefield Hospital, London, UK., London, United Kingdom, ²Department of Cardiology and Transplant Medicine, Royal Brompton & Harefield NHS Foundation Trust, Harefield Hospital, London, UK., London, United Kingdom.
- 6:25 PM** **(350) Systolic Blood Pressure on Discharge from LVAD Insertion Is Associated with Future Stroke;**
M. E. Nassif, A. Tibrewala, D. S. Raymer, A. M. Andruska, J. M. Vader, G. A. Ewald, S. J. LaRue. Cardiology, Washington University, St. Louis, MO.

5:30 PM – 6:30 PM

MINI ORAL SESSION 11

**Heart Transplant: Monitoring and Immunosuppression
(Grand Hall C)****CHAIRS:** Bruno Reichart, MD and Shelley Hankins, MD
(HTX, PHARM, HF)

- 5:30 PM (359) The Incidence of Solid Tumours After Heart Transplantation Has Not Declined in the Last Decade. Data from the Spanish Post-Heart Transplant Tumor Registry:**
M. G. Crespo-Leiro¹, M. J. Paniagua-Martín¹, L. Almenar Bonet², L. Alonso-Pulpón³, F. González-Vilchez⁴, J. F. Delgado-Jiménez⁵, P. Díez Villanueva⁶, A. López Granados⁷, S. Mirabet Pérez⁸, N. Manito Lorite⁹, E. Lage-Galle¹⁰, B. Díaz-Molina¹¹, G. Rábago Juan-Aracil¹², F. Pérez Villa¹³, T. Blasco-Peiró¹⁴, I. P. Garrido-Bravo¹⁵, L. de la Fuente Galán¹⁶, J. Muñiz-García¹⁷. ¹Heart Transplant Unit, Hospital Universitario A Coruña, La Coruña, Spain, ²Hospital Universitari i Politècnic La Fe, Valencia, Spain, ³Hospital Universitario Puerta de Hierro, Madrid, Spain, ⁴Hospital Universitario Marqués de Valdecilla, Santander, Spain, ⁵Hospital Universitario 12 de Octubre, Madrid, Spain, ⁶Hospital General Universitario Gregorio Marañón, Madrid, Spain, ⁷Hospital Universitario Reina Sofía, Córdoba, Spain, ⁸Hospital Santa Creu i Sant Pau, Barcelona, Spain, ⁹Hospital Universitari de Bellvitge, Barcelona, Spain, ¹⁰Hospital Universitario Virgen del Rocío, Sevilla, Spain, ¹¹Hospital Universitario Central de Asturias, Asturias, Spain, ¹²Clínica Universidad de Navarra, Pamplona, Spain, ¹³Hospital Clínic i Provincial, Barcelona, Spain, ¹⁴Hospital Universitario Miguel Servet, Zaragoza, Spain, ¹⁵Hospital Universitario Virgen de la Arrixaca, Murcia, Spain, ¹⁶Hospital Clínico Universitario de Valladolid, Valladolid, Spain, ¹⁷Instituto Universitario de Ciencias de la Salud. Universidad de A Coruña, La Coruña, Spain.
- 5:35 PM (352) Coronary Vasomotor Dysfunction Indicates Non-stenotic Coronary Angiographic and Biopsy-proven Vasculopathy in Cardiac Transplant Recipients:**
N. E. Hiemann¹, R. Meyer¹, S. Dreysse², C. Klein², P. Breit², R. Hetzer¹, E. Wellnhofer². ¹Cardiothoracic and Vascular Surgery, Deutsches Herzzentrum Berlin, Berlin, Germany, ²Cardiology, Deutsches Herzzentrum Berlin, Berlin, Germany.
- 5:40 PM (353) Struggle for (Graft-) Survival: Long-Term Results Comparing Standard Therapy With Tacrolimus/Mycophenolate Mofetil Versus De-Novo Low-Dose Tacrolimus/Sirolimus Therapy 10 Years After Heart Transplantation:**
S. Guethoff¹, K. Stroeh¹, M. Koenig¹, B. M. Meiser², M. Zaruba³, C. Grinninger², B. Reichart⁴, P. Ueberfuhr¹, C. Hagl¹, I. Kaczmarek¹. ¹Department of Cardiac Surgery, Ludwig-Maximilians University Munich, Germany, Munich, Germany, ²Transplantation Center, Ludwig-Maximilians University Munich, Germany, Munich, Germany, ³Department of Cardiology, Ludwig-Maximilians University Munich, Germany, Munich, Germany, ⁴Walter-Brendel-Centre of Experimental Medicine, Ludwig-Maximilians University Munich, Germany, Munich, Germany.
- 5:45 PM (354) Exercise Capacity in De-Novo Heart Transplant Recipients With Everolimus Vs Conventional CNI Based Immunosuppression. The Results of a Randomized Trial (SCHEDULE):**
E. Gude¹, S. Bartfay², B. Andersson², V. Sigurdardottir², W. Stuefflotten¹, L. Gullestad¹, A. Andreassen¹. ¹Dep. of Cardiology, Oslo University Hospital, Rikshospitalet, Oslo, Norway, ²Dep. of Cardiology, Sahlgrenska University Hospital, Gothenburg, Sweden.

- 5:50 PM** **(355) Long-term Outcome of Sirolimus (SRL) Based Immunosuppression (IS) in Heart Transplant Patients;**
*S. Wallner*¹, A. Aliabadi¹, D. Dunkler², K. Uyanik-Uenal¹, S. Mahr¹, J. Goekler¹, G. Laufer¹, A. Zuckermann¹. ¹Department of Cardiac Surgery, Medical University of Vienna, Vienna, Austria, ²Department of Medical Statistics, Medical University of Vienna, Vienna, Austria.
- 5:55 PM** **(356) Predictive Value of PAPP-A, sCD40L, Anti-HLA Antibodies Detected By ELISA and Luminex in Heart Transplant Recipients;**
O. P. Shevchenko, T. A. Khalilulin, A. O. Shevchenko, N. V. Apanasenko, E. A. Stakhanova, A. J. Kormer, B. L. Mironkov, A. G. Kupriyanova, S. V. Gautier. Federal V.Shumakov Research Center of Transplantology and Artificial Organs, Moscow, Russian Federation.
- 6:00 PM** **(357) Gene Expression Profile Score Variability Characteristics: Analysis of 49,836 Tests From 12,177 Heart Transplant Patients;**
*A. Kao*¹, P. J. Arnold², D. Hiller². ¹Cardiology, St. Luke's Mid America Heart Institute, Kansas City, MO, ²Expression Diagnostics, Brisbane, CA.
- 6:05 PM** **(358) Venous Thromboembolism in Heart Transplant Patients: Incidence, Recurrence and Predisposing Factors;**
R. J. Alvarez Alvarez, E. Barge Caballero, S. A. Chávez Leal, M. J. Paniagua Martín, R. Marzoa Rivas, I. Blanco Martínez, Z. Grille Cancela, P. Blanco Canosa, J. M. Herrera Noreña, J. J. Cuenca Castillo, A. Castro Beiras, M. G. Crespo Leiro. Advanced Heart Failure and Heart Transplant Unit, Hospital Universitario A Coruña, A Coruña, Spain.
- 6:10 PM** **(351) Prognostic Significance and Long-Term Evolution of Resting Heart Rate After Heart Transplantation;**
E. Barge-Caballero, J. Jimenez-Lopez, S. Chavez-Leal, G. Barge-Caballero, R. Marzoa-Rivas, M. Paniagua-Martin, R. Alvarez-Alvarez, Z. Grille-Cancela, A. Castro-Beiras, M. Crespo-Leiro. Heart Transplant Unit, Hospital Universitario A Coruna, A Coruna, Spain.
- 6:15 PM** **(360) Cardiac MRI of Heart Transplant Recipients With Previous CMV Infection Demonstrates Ventricular Hypertrophy and Dysfunction;**
*C. Butler*¹, J. Preiksaitis², R. Singh¹, M. Toma³, R. Thompson⁴, K. Chow⁴, D. Kim¹, M. Haykowsky⁵, G. Pearson¹, I. Paterson¹. ¹Mazankowski Alberta Heart Institute, Edmonton, AB, Canada, ²Division of Infectious Disease, Edmonton, AB, Canada, ³Division of Cardiology, St. Paul's Hospital, University of British Columbia, Vancouver, BC, Canada, ⁴Biomedical Engineering, University of Alberta, Edmonton, AB, Canada, ⁵Physical Therapy, University of Alberta, Edmonton, AB, Canada.
- 6:20 PM** **(361) Cardiovascular MRI Imaging Independently Predicts Adverse Cardiovascular Events in Heart Transplant Recipients;**
*C. Butler*¹, D. Kim¹, M. Toma², R. Thompson³, K. Chow³, M. Haykowsky⁴, G. Pearson¹, I. Paterson¹. ¹Mazankowski Alberta Heart Institute, Edmonton, AB, Canada, ²Division of Cardiology, St. Paul's Hospital, University of British Columbia, Vancouver, BC, Canada, ³Biomedical Engineering, University of Alberta, Edmonton, AB, Canada, ⁴Physical Therapy, University of Alberta, Edmonton, AB, Canada.

- 6:25 PM** **(362) Invasive Fungal Infections After Heart Transplantation: A Single Center Experience;**
 I. Echenique¹, M. Angarone², R. Gordon², J. Rich², A. Anderson², E. McGee³, T. Abicht³, G. Ferguson⁴, V. Stosor¹. ¹Medicine and Surgery, Northwestern University Feinberg School of Medicine, Chicago, IL, ²Medicine, Northwestern University Feinberg School of Medicine, Chicago, IL, ³Surgery, Northwestern University Feinberg School of Medicine, Chicago, IL, ⁴Northwestern Memorial Hospital, Chicago, IL.

5:30 PM – 6:30 PM

MINI ORAL SESSION 12

Lung Transplant: Candidate Selection and Genetic Variation (Seaport H)

CHAIRS: Miranda Paraskeva, MBBS and David Lederer, MD
 (LTX, BSTR, HTX)

- 5:30 PM** **(363) Lung Transplantation in Recipients >70 Years Old: A Single Center Experience;**
 M. R. Morrell¹, C. Gries¹, M. Crespo¹, B. Johnson¹, A. Hayanga², J. Bhama², N. Shigemura², J. D'Cunha², C. Bermudez², J. Pilewski¹.
¹Division of Pulmonary, Allergy and Critical Care, University of Pittsburgh, Pittsburgh, PA, ²Division of Cardiothoracic Surgery, University of Pittsburgh, Pittsburgh, PA.
- 5:35 PM** **(364) A Contemporary Analysis of Early Outcomes Following Lung Transplantation in the Elderly Using a National Registry: Growing Finer with Time;**
 A. J. Hayanga¹, J. Aboagye², H. E. Kaiser³, J. Yang⁴, N. Shigemura¹, J. D'Cunha¹, M. Morrell⁵, J. K. Bhama¹, C. A. Bermudez¹. ¹Cardiothoracic Surgery, University Of Pittsburgh Medical Center, Pittsburgh, PA, ²Epidemiology, Johns Hopkins School of Public Health, Baltimore, MD, ³Anesthesiology and Critical Care, University Of Pittsburgh Medical Center, Pittsburgh, PA, ⁴Biostatistics and Epidemiology, Johns Hopkins School of Public Health, Baltimore, MD, ⁵Pulmonary Medicine and Critical Care, University Of Pittsburgh Medical Center, Pittsburgh, PA.
- 5:40 PM** **(365) Determining Eligibility for Lung Transplantation: A Nationwide Assessment of Cutoff Glomerular Filtration Rates;**
 A. A. Osho¹, A. W. Castleberry², L. D. Snyder³, A. M. Ganapathi², S. Hirji¹, M. Stafford-Smith⁴, M. A. Daneshmand², S. S. Lin², R. D. Davis², M. G. Hartwig². ¹School of Medicine, Duke University Medical Center, Durham, NC, ²Department of Surgery, Duke University Medical Center, Durham, NC, ³Department of Medicine, Duke University Medical Center, Durham, NC, ⁴Department of Anesthesiology, Duke University Medical Center, Durham, NC.
- 5:45 PM** **(366) Impact of Pre-Transplant Staphylococcus Aureus Colonization on Post-Transplant S. aureus Infection Among Cystic Fibrosis Lung Transplant Recipients;**
 J. St-Pierre¹, C. Poirier², J. Chalaoui³, P. Ferraro⁴, V. Martel-Laferrriere⁵, G. C. Koh⁵, M. Luong⁵. ¹University of Montreal Health Center, Montreal, QC, Canada, ²Respirology, University of Montreal Health Center, Montreal, QC, Canada, ³Radiology, University of Montreal Health Center, Montreal, QC, Canada, ⁴Thoracic

Surgery, University of Montreal Health Center, Montreal, QC, Canada, ⁵Medical Microbiology, University of Montreal Health Center, Montreal, QC, Canada, ⁶Warwick Medical School, University of Warwick, Gibbet Hill, Coventry, United Kingdom.

5:50 PM **(367) A Genetic Polymorphism in IL-23 Receptor Is Protective for Primary Graft Dysfunction;**
J. Somers, D. Ruttens, S. E. Verleden, E. Vandermeulen, E. Wauters, D. Lambrechts, R. Vos, G. M. Verleden, T. S. Nawrot, B. Vanaudenaerde, D. Van Raemdonck. KU Leuven, Leuven, Belgium.

5:55 PM **(368) Donor Surfactant Protein A2 Gene Polymorphisms Are Associated With Early Lung Transplant Survival;**
B. Aramini, C. Kim, E. Peterson, D. J. Lederer, J. Costa, L. Shah, H. Robbins, K. Raza, S. Arcasoy, J. R. Sonett, F. D'Ovidio. Columbia University, New York, NY.

6:00 PM **(369) Candidate Gene Association Study in BOS;**
J. M. Diamond¹, R. Feng², W. Lin², R. Shah¹, E. Cantu², E. Demissie¹, M. Rushefski¹, D. Lederer³, S. Bhorade⁴, M. Crespo⁵, A. Weinacker⁶, J. Belperio⁷, P. Shah⁸, L. Ware¹, D. Wilkes⁹, J. Orens⁸, V. Lama¹⁰, K. Wille¹¹, S. Palmer¹², S. Kawut¹, J. Christie¹. ¹Medicine, University of Pennsylvania, Philadelphia, PA, ²University of Pennsylvania, Philadelphia, PA, ³Medicine, Columbia University, New York, NY, ⁴Medicine, University of Chicago, Chicago, IL, ⁵Medicine, University of Pittsburgh, Pittsburgh, PA, ⁶Medicine, Stanford University, Stanford, CA, ⁷Medicine, UCLA, Los Angeles, CA, ⁸Medicine, Johns Hopkins University, Baltimore, MD, ⁹Medicine, Indiana University, Indianapolis, IN, ¹⁰Medicine, University of Michigan, Ann Arbor, MI, ¹¹Medicine, University of Alabama-Birmingham, Birmingham, AL, ¹²Duke University, Durham, NC.

6:05 PM **(370) Whole Exome Sequencing: A Novel Strategy to Understand Chronic Lung Allograft Dysfunction (CLAD);**
J. L. Todd¹, T. J. Urban¹, C. A. Finlen Copeland¹, F. L. Kelly¹, D. B. Goldstein², S. M. Palmer¹. ¹Department of Medicine, Duke University Medical Center, Durham, NC, ²Department of Molecular Genetics and Microbiology, Duke University Medical Center, Durham, NC.

6:10 PM **(371) What Your Lung Transplant Candidates with Chronic Obstructive Pulmonary Disease (COPD) Want and Expect from Transplant;**
C. J. Gries¹, M. Budev², L. D. Snyder³, J. M. Pilewski¹, M. Dew⁴, A. DeVito-Dabbs⁵, C. Bermudez⁶, S. J. Patterson¹, D. B. White⁷. ¹Pulmonary, Allergy and Critical Care Medicine, University of Pittsburgh Medical Center, Pittsburgh, PA, ²Pulmonary, Allergy and Critical Care Medicine, Cleveland Clinic, Cleveland, OH, ³Medicine-Pulmonary, Duke University, Durham, NC, ⁴Psychiatry, Psychology, Epidemiology, Biostatistics and Clinical and Translational Science, University of Pittsburgh Medical Center, Pittsburgh, PA, ⁵School of Nursing and Center for Bioethics & Health Law, University of Pittsburgh Medical Center, Pittsburgh, PA, ⁶Surgery, University of Pittsburgh Medical Center, Pittsburgh, PA, ⁷Critical Care Medicine, University of Pittsburgh Medical Center, Pittsburgh, PA.

6:15 PM **(372) Extracorporeal Life Support in 'Awake' Patients as a Bridge to Lung Transplantation;**
P. N. Mohite, A. Sabashnikov, B. Zych, D. G. Saez, N. P. Patil, A. Weymann, F. DeRobertis, T. Bahrami, M. Amrani, T. Pitt, L. McBrearty, A. Reed, M. Carby, S. Kaul, A. R. Simon. Department of Cardiothoracic Transplantation & Mechanical Support, Royal Brompton and Harefield NHS, Uxbridge, United Kingdom.

6:20 PM (373) Changes in Left and Right Ventricular Function Before and After Lung Transplantation: Serial Echocardiographic Assessment;

T. S. Kato¹, H. F. Armstrong², P. Schulze¹, M. Lippel¹, M. Farr¹, M. Bacchetta³, M. N. Bartels², M. Di Tullio¹, S. Homma¹, D. Mancini¹. ¹Department of Medicine, Division of Cardiology, Columbia University Medical Center, New York, NY, ²Department of Rehabilitation and Regenerative Medicine, Columbia University Medical Center, New York, NY, ³Division of Cardiothoracic Surgery, Department of Surgery, Columbia University Medical Center, New York, NY.

6:25 PM (374) Abnormal Pulmonary Function Tests Contraindicates Heart Transplant;

A. Kafi, J. Patel, M. Kittleson, Z. Yu, F. Liou, J. Yabuno, T. Kao, L. Czer, D. H. Chang, A. Hage, D. Ramzy, J. Kobashigawa. Cedars-Sinai Heart Institute, Los Angeles, CA.

5:30 PM – 6:30 PM

MODERATED POSTER SESSION 3 (Harbor and Seaport Foyers)

(ALL)

7:00 PM – 9:30 PM

PRESIDENT'S GALA RECEPTION (Pool Deck)

SUNDAY, APRIL 13, 2014

7:00 AM – NOON

REGISTRATION DESK OPEN (Palm Foyer)

7:00 AM – 1:30 PM

SPEAKER READY ROOM OPEN (Balboa ABC)

7:00 AM – 9:15 AM

BOARD OF DIRECTORS MEETING (La Jolla AB)

7:00 AM – 8:00 AM

SUNRISE SYMPOSIUM 1 I

VAD Teams Working Across Different Countries: How To Do It (Harbor GHI)

CHAIRS: Annemarie Kaan, MCN, RN and Tonya I Elliott, RN, MSN
(NNSAH, MCS)

SESSION SUMMARY: At the end of this session, the attendees will be able to discuss the challenges associated with International VAD care. Driveline options, traveling post-MCS, and the care of the VAD patient in the community will be presented with an open panel discussion at the end of the session.

- 7:00 AM** *Driveline Options for Patients Supported with Long Term LVADs: The Newcastle Experience*
Neil W Wrightson, RN, Freeman Hospital, Newcastle upon Tyne, United Kingdom
- 7:15 AM** *On the Road Again: When MCS Patients Travel*
Desiree Robson, RN BSc (Hons), St. Vincent's Hospital, Sydney, Australia
- 7:30 AM** *The VAD Patient in the Community*
Pamela S. Combs, RN, PhD, Seton Hospital, Austin, TX, USA
- 7:45 AM** *Panel Discussion: How We Do It: How Different Nursing Teams Respond to Common Patient Problems, with: Pam Combs, Megan Maltby, Neil Wrightson and Desiree Robson*

7:00 AM – 8:00 AM

SUNRISE SYMPOSIUM 12

**Swan Songs and Controversies in Hemodynamics
(Seaport H)****CHAIRS:** Srinivas Murali, MD and Juan F. Delgado, PhD

(PH, HF, LF)

SESSION SUMMARY: Vasodilator testing, volume loading, and exercise in the cath lab are all areas of great interest and equally great misunderstanding. This session will provide much needed information and discussion on this burgeoning field.**7:00 AM** *Vasodilators in the Cath Lab:
Who, Why, and What?*Ryan J. Tedford, MD, Johns Hopkins School of Medicine,
Baltimore, MD, USA**7:15 AM** *Q & A***7:20 AM** *Volume Loading in the Cath Lab:
Who, Why and How?*

Ivan Robbins, MD, Vanderbilt University, Nashville, TN, USA

7:35 AM *Q & A***7:40 AM** *Exercise Hemodynamics: Nuts and
Bolts of Performance and Interpretation*Susanna Mak, MD, PhD, Mount Sinai Hospital,
University of Toronto, Toronto, ON, Canada**7:55 AM** *Q & A*

7:00 AM – 8:00 AM

SUNRISE SYMPOSIUM 13

**Lab Methods 101: What Everyone Needs to Know to Read
Transplant Papers (Gaslamp AB)****CHAIRS:** Richard Kirk, MA FRCP FRCPCH and Kimberly Gandy, MD, PhD

(ALL)

SESSION SUMMARY: This session offers a clear explanation of select laboratory methods that are used in state-of-the-art research manuscripts these days. This session is designed for professionals who do not perform these assays on a regular basis but would like to have a better understanding in order to make sense of current literature. Each talk will explain the laboratory method or assay and then give 1 or 2 examples of how this is used in transplantation.**7:00 AM** *Making Sense of DNA and RNA Assays:
Snips, Chips and Arrays*Joshua Diamond, MD, University of Pennsylvania,
Philadelphia, PA, USA**7:10 AM** *Q & A***7:15 AM** *Flow Cytometry: It's More than Just a Black Box*Stephanie T. Yerkovich, PhD, The Prince Charles Hospital,
Brisbane, Australia**7:25 AM** *Q & A*

SCIENTIFIC PROGRAM

- 7:30 AM** *Antibody Detection: You, Too, Can Understand It*
Kathryn J. Tinkam, MD, University of Toronto, Toronto, ON, Canada
- 7:40 AM** Q & A
- 7:45 AM** *Measuring Bugs: From One Petri Dish to the Microbiome*
Lara Danziger-Isakov, MD, MPH, Children's Hospital Medical Center, Cincinnati, OH, USA
- 7:55 AM** Q & A

7:00 AM – 8:00 AM

SUNRISE SYMPOSIUM 14

Why Not Infant Lung Transplantation? (Gaslamp CD)

CHAIRS: Christian Benden, MD and Marc G. Schechter, MD

(PEDI, LF, LTX)

SESSION SUMMARY: Less than 100 infant lung transplants have been performed in the world in the last 25 years whereas over 100 infant heart and liver transplants are performed each year. This disconnect suggests that a shortage of organs does not explain this result. Chronic respiratory or cardiopulmonary failure is not rare. A recent report indicates long-term outcome is at least as good for infant lung transplant recipients as for older recipients. This symposium will explore the conundrum.

- 7:00 AM** *The Problem of the Rare Infant Lung Transplant*
David L.S. Morales, MD, Cincinnati Children's Hospital Medical Center, Cincinnati, OH, USA
- 7:12 AM** *Why Infant Lung Transplant is Such a Good Concept!*
George Mallory, MD, Texas Children's Hospital, Houston, TX, USA
- 7:25 AM** *Why Infant Lung Transplant is Not Such a Good Concept*
Samuel B. Goldfarb, MD, Children's Hospital, Philadelphia, PA, USA
- 7:37 AM** *Case Presentation: ABO Incompatible Lung Transplantation in an Infant*
Hartmut Grasmann, MD, PhD, Hospital for Sick Children, Toronto, ON, Canada
- 7:50 AM** *Panel Discussion*

7:00 AM – 8:00 AM

SUNRISE SYMPOSIUM 15

High-Risk Donor: Extending Our Criteria in Times of Organ Shortage (Old Town AB)**CHAIRS:** Martha Mooney, MD, FACP and Orla Morrissey, MD

(DMD, ID, LF, LTX, HF, HTX)

SESSION SUMMARY: Transmission of viral infections through solid organ transplantation can lead to adverse outcomes for recipients. Despite the use of highly sensitive serologic tests for most common infections, the use of organs from high-risk donors remains controversial. Understanding the risk of transplanting the organ of a high-risk donor on the post-transplant outcome is important to judiciously advice candidates on the waiting list and to provide appropriate post-transplant care.

- 7:00 AM** *Limitation of Current Diagnostics Test for HIV, HBV and HCV: What Can We Miss?*
Piedad Ussetti, MD, Hospital Puerta Hierro, Madrid, Spain
- 7:10 AM** **Q & A**
- 7:15 AM** *Donors With Hb-core Antibody: Should We Use Them?*
Valentina Stosor, MD, Northwestern University, Chicago, IL, USA
- 7:25 AM** **Q & A**
- 7:30 AM** *Donors With Hepatitis C*
Paolo A Grossi, MD, PhD, University of Insubria, Varese, Italy
- 7:40 AM** **Q & A**
- 7:45 AM** *Donors With Documented Infection: Can We Safely Use Them?*
Saima Aslam, MD, MS, University of California at San Diego, San Diego, CA, USA
- 7:55 AM** **Q & A**

8:00 AM – 9:15 AM

CONCURRENT SESSION 39

Mechanical Circulatory Support: Bench to Bedside (Harbor GHI)

CHAIRS: Ivan Netuka, MD, PhD and Stuart D. Russell, MD
(MCS, BSTR)

8:00 AM (375) *Weighted Gene Co-expression Network Analysis Reveals Distinct Interaction Patterns in Failing and Recovering Human Myocardium;*
V. K. Topkara. Cardiology, Columbia University, New York, NY.

8:12 AM (376) *Myocardial Regeneration and Recovery with Extracellular Matrix and LVAD Support;*
M. S. Slaughter¹, G. D. Rokosh², R. G. Matheny³, M. A. Sobieski¹, M. Wysoczynski⁴, M. Solanki², G. A. Giridharan¹, K. G. Soucy¹, P. L. Linsky¹, G. Monreal¹, S. C. Koenig¹. ¹Surgery, University of Louisville, Louisville, KY, ²University of Louisville, Louisville, KY, ³CorMatrix, Roswell, GA, ⁴Institute of Molecular Cardiology, University of Louisville, Louisville, KY.

8:24 AM (377) *Change of Myocardial Microvascular Density under Mechanical Circulatory Support in the Failing Heart;*
T. Saito, K. Toda, S. Miyagawa, H. Nishi, Y. Yoshikawa, S. Fukushima, D. Yoshioka, M. Kawamura, M. Ishida, Y. Sawa. Cardiovascular Surgery, Osaka University Graduate School of Medicine, Osaka, Japan.

8:36 AM (378) *Axial Flow LVAD Support Leads to Increases in Effective Arterial Elastance by Ventriculo-Arterial Uncoupling;*
Z. Daniels¹, C. Del Rio², B. Youngblood², R. S. George², Y. Ueyama², M. Cismowski¹, T. West¹, P. I. McConnell³. ¹Research Institute, Nationwide Children's Hospital, Columbus, OH, ²Qtest Labs, Columbus, OH, ³Cardiothoracic Surgery, Nationwide Children's Hospital, Columbus, OH.

8:48 AM (379) *Do Current Anti-Platelet Agents Truly Provide Protection Against Shear-Mediated Platelet Activation in Mechanical Circulatory Support?;*
L. Valerio¹, P. Tran², W. Brengle², M. Hutchinson², J. Sheriff³, D. Bluestein³, M. J. Slepian². ¹Politecnico De Milan, Milan, Italy, ²University of Arizona, Tucson, AZ, ³Stony Brook University, Stony Brook, NY.

9:00 AM (380) *The Effect of Pulsatile and Nonpulsatile Flow on Cerebral Perfusion in Patients with LVADs;*
W. K. Cornwall¹, T. Tarumi², V. Aengevaeren², C. Ayers¹, P. Divanji¹, Q. Fu², D. Palmer², M. Drazner¹, D. Meyer¹, B. Bethea¹, J. Hastings², N. Fujimoto², S. Shibata¹, R. Zhang², D. Markham³, B. Levine². ¹Cardiology, University of Texas Southwestern Medical Center, Dallas, TX, ²Institute of Exercise and Environmental Medicine, Dallas, TX, ³Cardiology, Emory University, Atlanta, GA.

8:00 AM – 9:15 AM

CONCURRENT SESSION 40

As You Like It – Optimization of Heart Transplant Immunosuppression (Seaport H)**CHAIRS:** Bruno Meiser, MD and David S. Feldman, MD, PhD
(HTX, PHARM, HF)

8:00 AM (381) Ten-Year Comparison of Prospective Intervention Trials After Heart Transplantation: Tacrolimus/Mycophenolate Mofetil Versus De-Novo Low-Dose Tacrolimus/Sirolimus;
 S. Guethoff¹, K. Stroeh¹, M. Koenig¹, B. Meiser², M. Zaruba³, C. Grinninger², B. Reichart⁴, P. Ueberfuhr¹, C. Hagl¹, I. Kaczmarek¹.
¹Department of Cardiac Surgery, Ludwig-Maximilians University Munich, Germany, ²Transplantation Center, Ludwig-Maximilians University Munich, Germany, Munich, Germany, ³Department of Cardiology, Ludwig-Maximilians University Munich, Germany, Munich, Germany, ⁴Walter-Brendel-Centre of Experimental Medicine, Ludwig-Maximilians University Munich, Germany, Munich, Germany.

8:12 AM (382) A Novel Allele-Based Measure of HLA Mismatch Predicts Treated Rejection After Heart Transplant;
 E. P. Kransdorf¹, T. Carvajal², M. Cheng³, D. E. Steidley¹, R. L. Scott¹, J. F. Leis⁴, R. H. Adams⁴, A. Bordner⁵, V. Balan⁶, O. E. Pajaro⁷.
¹Division of Cardiovascular Diseases, Mayo Clinic Arizona, Scottsdale, AZ, ²Department of Surgery, Mayo Clinic Arizona, Phoenix, AZ, ³Division of Health Sciences Research, Section of Biostatistics, Mayo Clinic Arizona, Scottsdale, AZ, ⁴Division of Hematology and Oncology, Mayo Clinic Arizona, Scottsdale, AZ, ⁵Center for Regenerative Medicine, Mayo Clinic Arizona, Scottsdale, AZ, ⁶Division of Gastroenterology and Hepatology, Mayo Clinic Arizona, Scottsdale, AZ, ⁷Division of Cardiothoracic Surgery and Center for Regenerative Medicine, Mayo Clinic Arizona, Scottsdale, AZ.

8:24 AM (383) Induction With Anti-Thymocyte Globulin After Heart Transplantation Is Associated with Better Long-term Survival Compared to Basiliximab;
 L. Lund¹, B. Andersson², J. Stehlik³, J. Nilsson⁴. ¹Cardiology, Karolinska University Hospital, Stockholm, Sweden, ²Surgery, Lund University and Skane University Hospital, Lund, Sweden, ³Cardiology, University of Utah School of Medicine, Utah, UT, ⁴Cardiothoracic Surgery, Lund University and Skane University Hospital, Lund, Sweden.

8:36 AM (384) Intravenous Immunoglobulin and Plasmapheresis in Prevention of Antibody Mediated Rejection in Sensitized Recipients in Cardiac Allograft. "Before – After" Treatment Study;
 S. Varnous¹, C. Vidal¹, M. Bories², C. Boissel-Suberbielle³, S. Ouldamar¹, P. Rouvier², P. LePrince¹, J. Amour¹. ¹Institut de Cardiologie, Hôpital Pitié Salpêtrière, Paris, France, ²Laboratoire d'Anatomopathologie, Hôpital Pitié Salpêtrière, Paris, France, ³Laboratoire d'Immunologie, Hôpital Saint Louis, Paris, France.

8:48 AM (385) Single Nucleotide Polymorphisms, SNPs, Associated With the Efficacy and Security of Immunosuppressive Treatment in Heart Transplantation;
 I. Sanchez-Lazaro¹, C. Jordán-de Luna², L. Almenar-Bonet¹, M. Herrero-Cervera², V. Boso-Ribelles², S. Aliño-Pellicer², L. Martinez-Dolz¹, J. Poveda-Andres², A. Salvador-Sanz¹.

¹Cardiology Department, Hert Failure and Transplantation Unit, Hospital Universitari i Politècnic La Fe, Valencia, Spain, ²Pharmacy Department, Hospital Universitari i Politècnic La Fe, Valencia, Spain.

- 9:00 AM** **(386) Long-Term Therapy with Everolimus: Promising Results at Three Years of the CERTIC Registry;**
L. Potena¹, R. Fiocchi², C. Maiello³, A. D'Armini⁴, G. Gerosa⁵, M. Rinaldi⁶, M. Maccherini⁷, U. Livi⁸, M. Frigerio⁹, D. Colombo¹⁰, R. Brusa¹⁰, F. Parisi¹¹. ¹Cardiovascular Department, University of Bologna, Bologna, Italy, ²Papa Giovanni XXIII Hospital, Bergamo, Italy, ³Monaldi Hospital – II Università di Napoli, Napoli, Italy, ⁴San Matteo Hospital, Pavia, Italy, ⁵University Hospital of Padova, Padova, Italy, ⁶San Giovanni Battista Hospital, Torino, Italy, ⁷Policlinico Santa Maria alle Scotte, Siena, Italy, ⁸Santa Maria della Misericordia Hospital, Udine, Italy, ⁹Niguarda – Ca' Granda Hospital, Milano, Italy, ¹⁰Novartis Farma, Origgio (VA), Italy, ¹¹Bambin Gesù Hospital, Roma, Italy,

8:00 AM – 9:15 AM

CONCURRENT SESSION 41

Left Heart Failure, the RV, and Other Types of Pulmonary Hypertension (Gaslamp AB)

CHAIRS: Marc De Perrot, MD and Corey E. Ventetuolo, MD
(PH, HF, PHARM)

- 8:00 AM** **(387) Heart Failure with Preserved Ejection Fraction Induced Reactive Pulmonary Hypertension Lacks Nitric Oxide Vasoreactivity Similar to Pulmonary Arterial Hypertension;**
J. Salamon¹, J. Mazurek², R. Zolty¹. ¹Cardiology, Montefiore Medical Center/Albert Einstein College of Medicine, Bronx, NY, ²Cardiology, Hospital of the University of Pennsylvania, Philadelphia, PA.
- 8:12 AM** **(388) Differentiating Heart Failure with Preserved Ejection Fraction Induced Pulmonary Hypertension from Pulmonary Hypertension Using Demographic Data and Common Blood Measurements;**
J. Salamon¹, J. Mazurek², S. Mannem¹, R. Zolty¹. ¹Cardiology, Montefiore Medical Center/Albert Einstein College of Medicine, Bronx, NY, ²Cardiology, Hospital of the University of Pennsylvania, Philadelphia, PA.
- 8:24 AM** **(389) Right Ventricular Remodeling in Idiopathic Pulmonary Arterial Hypertension: Concentric Versus Eccentric Hypertrophy;**
R. Badagliacca¹, R. Poscia¹, M. Nocioni¹, M. Mezzapesa¹, M. Francone², B. Pezzuto¹, S. Papa¹, C. Gambardella¹, A. Nona¹, S. Sciomer¹, F. Fedele¹, C. D. Vizza¹. ¹Dept. of Cardiovascular and Respiratory Science, Sapienza University of Rome, Rome, Italy, ²Dept. of Radiology, Sapienza University of Rome, Rome, Italy.
- 8:36 AM** **(390) Long Term Partial Right Ventricular Support Induces Reverse Remodelling in the Chronic Pressure Overloaded Right Ventricle;**
T. Verbelen¹, P. Claus², M. Martin³, K. Kasama¹, E. Verbeken⁴, I. Van Tichelen¹, D. Burkhoff⁵, M. Delcroix⁶, F. Rega¹, B. Meyns¹. ¹Experimental Cardiac Surgery, University of Leuven, Leuven,

Belgium, ²Cardiovascular Imaging and Dynamics, University of Leuven, Leuven, Belgium, ³CircuLite Inc., Hackensack, NJ, ⁴Morphology and Molecular Pathology, University of Leuven, Leuven, Belgium, ⁵Cardiology, Columbia University College of Physicians and Surgeons, New York, NY, ⁶Clinical and Experimental Medicine, University of Leuven, Leuven, Belgium.

8:48 AM

(391) SPHERIC-1 (Sildenafil and Pulmonary HypERTension in COPD): Intention-to-Treat (ITT) Analysis of Safety and Efficacy Data;

P. Vitulo¹, A. Callari¹, L. Martino¹, A. Stanzola², T. Oggioni³, F. Meloni⁴, M. Confalonieri⁵, D. Libertucci⁶, P. Rottoli⁷, R. Poscia⁸, R. Badagliacca⁸, D. C. Vizza⁸. ¹Pulmonology Unit, ISMETT-UPMC, Palermo, Italy, ²Respiratory Dept., University of Naples, Naples, Italy, ³Pulmonology Dept., IRCCS foundation S. Matteo, Pavia, Italy, ⁴Dept. Molecular Medicine, University of Pavia, Pavia, Italy, ⁵Pulmonology Unit, Cattinara University Hospital, Trieste, Italy, ⁶Pulmonology Unit, S. Giovanni Battista Hospital, Turin, Italy, ⁷Respiratory Dept., University of Siena, Siena, Italy, ⁸Cardiovasc & Respiratory Dept, Sapienza University of Rome, Rome, Italy.

9:00 AM

(392) The PROSPECT Registry of Pulmonary Arterial Hypertension (PAH): Description of Patients Who Transitioned From Inhaled Prostacyclin to Intravenous Epoprostenol;

H. W. Farber¹, R. P. Frantz², R. J. Schilz³, K. Chin⁴, D. Rosenberg⁵, J. Colvin⁶, B. K. Hartline⁶, D. P. Miller⁷, W. W. Benton⁶, M. Chakinala⁸. ¹Boston University School of Medicine, Boston, MA, ²Mayo Clinic, Rochester, MN, ³University Hospitals of Cleveland, Cleveland, OH, ⁴University of Texas Southwestern, Dallas, TX, ⁵Actelion Pharmaceuticals, Allschwil, Switzerland, ⁶Actelion Pharmaceuticals US, Inc., South San Francisco, CA, ⁷ICON Clinical Research, San Francisco, CA, ⁸Washington University School of Medicine, St. Louis, MO.

8:00 AM – 9:15 AM

CONCURRENT SESSION 42

Risk Assessment in the Pediatric Heart Candidate (Gaslamp CD)

CHAIRS: Yuk M. Law, MD and Debra A. Dodd, MD
(PEDI, HTX, PATH)

- 8:00 AM** **(393)** *Why do Children with Congenital Heart Disease Die on the Waitlist? An Analysis of OPTN Data;*
M. E. Richmond, R. K. Singh, W. A. Zuckerman, T. Lee, L. J. Addonizio. Pediatric Cardiology, Columbia University, New York, NY.
- 8:12 AM** **(394)** *Refusing Donors for HLA Sensitization Reasons Results in Increased Mortality in Pediatric Heart Transplant Candidates;*
M. E. Richmond, R. K. Singh, W. A. Zuckerman, T. M. Lee, L. A. Gilmore, L. J. Addonizio. Pediatric Cardiology, Columbia University, New York, NY.
- 8:24 AM** **(395)** *Comparison of Listing Strategies for Allosensitized Heart Transplant Candidates: A Decision Model Analysis;*
B. Feingold¹, S. A. Webber², C. L. Bryce³, S. Y. Park⁴, H. E. Tomko³, D. M. Comer⁵, W. T. Mahle⁶, K. J. Smith⁷. ¹Pediatric Cardiology, Children's Hospital of Pittsburgh of UPMC, Pittsburgh, PA, ²Pediatrics, Vanderbilt University, Nashville, TN, ³Health Policy Management, University of Pittsburgh School of Public Health, Pittsburgh, PA, ⁴Department of Medicine, Division of General Internal Medicine, University of Pittsburgh, Pittsburgh, PA, ⁵Center for Research on Health Care Data Center, University of Pittsburgh, Pittsburgh, PA, ⁶Pediatrics, Children's Healthcare of Atlanta, Emory University School of Medicine, Atlanta, GA, ⁷Section of Decision Sciences and Clinical Systems Modeling, Department of Medicine, University of Pittsburgh School of Medicine, Pittsburgh, PA.
- 8:36 AM** **(396)** *Effect of HLA-C and DQ Matching on Pediatric Heart Transplant Graft Survival;*
R. Butts¹, A. Atz¹, M. Scheurer¹, M. Kavarana², O. Moussa³, A. Burnette⁴, A. Savage¹. ¹Pediatrics, Medical University of South Carolina, Charleston, SC, ²Surgery, Medical University of South Carolina, Charleston, SC, ³Pathology and Laboratory Medicine, Medical University of South Carolina, Charleston, SC, ⁴Transplant Services, Medical University of South Carolina, Charleston, SC.
- 8:48 AM** **(397)** *Donor-Specific HLA Alloantibodies: Impact on Cardiac Allograft Vasculopathy and Survival After Pediatric Heart Transplantation;*
A. Tran¹, D. Fixler¹, R. Huang², T. Mackling³, A. Barnes¹, B. B. Das¹. ¹Division of Pediatric Cardiology, UT South Western Medical Center, Dallas, TX, ²Dept of Research, Children's Medical Center, Dallas, TX, ³Division of Pediatric Cardiology, Children's Medical Center, Dallas, TX.
- 9:00 AM** **(398)** *Fontan-associated Protein Losing Enteropathy and Heart Transplant: A Pediatric Heart Transplant Study Analysis;*
K. R. Schumacher¹, D. Naftel², E. Pruitt², J. G. Gossett³, M. Carboni⁴, K. Guleserian⁵, D. Dodd⁶, J. Lamour⁷, S. Pophal⁸, M. Zamberlan¹, R. J. Gajarski¹. ¹University of Michigan, Ann Arbor, MI, ²University of Alabama-Birmingham, Birmingham, AL, ³Lurie Children's Hospital, Chicago, IL, ⁴Duke University, Durham, NC, ⁵UT-Southwestern, Dallas, TX, ⁶Vanderbilt University, Nashville, TN, ⁷The Children's Hospital at Montefiore, Bronx, NY, ⁸Phoenix Children's Hospital, Phoenix, AZ.

8:00 AM – 9:15 AM

CONCURRENT SESSION 43

Breathing the Microbes: Infections for the Lung Transplant Clinician (Old Town AB)**CHAIRS:** Piedad Ussetti, MD and Antonio B. Roman, MD, PhD
(LTX, ID, BSTR)

- 8:00 AM (399) Emerging Combination Activity and Resistance Profile for Brincidofovir (CMX001) in CMV Prevention and Treatment;**
S. Foster¹, D. Selleseth¹, M. Prichard², T. Brundage¹, H. Momméja-Marin¹, R. Lanier¹. ¹Chimerix, Inc., Durham, NC, ²University of Alabama, Birmingham, AL.
- 8:12 AM (400) Performance of (1,3)- β -D-Glucan in Bronchoalveolar Lavage of Lung Transplant Recipients (LTRs) for the Diagnosis of Invasive Pulmonary Aspergillosis (IPA);**
A. Bhaskaran¹, L. Singer², T. Mazzulli³, T. Prochnow¹, C. Rotstein¹, S. Husain¹. ¹Transplant Infectious Disease, University of Toronto, Toronto, ON, Canada, ²Multi-organ Transplantation, University of Toronto, Toronto, ON, Canada, ³Department of Microbiology, University of Toronto, Toronto, ON, Canada.
- 8:24 AM (401) Role of Pentaxrin 3 in Differentiating Invasive Aspergillosis (IA) from Aspergillus Colonization (Ac) in Lung Transplant Recipients;**
D. Kabbani, L. Singer, C. Rotstein, T. Pipkin, T. Mazzulli, S. Keshavjee, S. Husain. University Health Network of the University of Toronto, Toronto, ON, Canada.
- 8:36 AM (402) Low IgM Anti-Polysaccharide Antibody Response and Severe Infection in a Cohort of Lung Recipients;**
E. Sarmiento¹, M. Jaramillo¹, J. Navarro¹, J. Rodriguez-Molina¹, J. Cifrian², R. Laporta³, P. Ussetti³, C. Bravo⁴, S. Lopez⁴, A. De Pablos⁵, P. Morales⁶, J. Carbone¹. ¹Clinical Immunology, Hospital General Universitario Gregorio Marañón, Madrid, Spain, ²Pneumology, Hospital Marqués de Valdecilla, Santander, Spain, ³Pneumology, Hospital Universitario Puerta de Hierro, Madrid, Spain, ⁴Pneumology, Hospital Vall de Hebron, Barcelona, Spain, ⁵Pneumology, Hospital Universitario Doce de Octubre, Madrid, Spain, ⁶Pneumology, Hospital Universitario La Fe, Valencia, Spain.
- 8:48 AM (403) Identifying Optimal Treatment Regimens for Lung and Heart Transplant Patients (LTx, HTx pts) Infected With Extreme-Drug Resistant (XDR) Gram-Negative Bacteria;**
C. Clancy, R. Shields, B. Potoski, B. Hao, C. Bermudez, J. Pilewski, M. Crespo, F. Silveira, M. Nguyen. University of Pittsburgh, Pittsburgh, PA.
- 9:00 AM (404) Clinical and Molecular Epidemiologic Characterization of Methicillin-Resistant Staphylococcus aureus (MRSA) Infections Occurring Early After Lung Transplant;**
C. Clancy, M. Shelton, R. Shields, J. Marsh, L. Harrison, C. Bermudez, J. Pilewski, M. Crespo, M. Nguyen. University of Pittsburgh, Pittsburgh, PA.

9:15 AM – 9:30 AM
COFFEE BREAK (Palm Foyer)

9:30 AM – 11:45 AM

PLENARY SESSION

(Harbor GHI)

CHAIRS: Andreas O. Zuckermann, MD and
Hermann C. Reichenspurner, MD, PhD

9:50 AM **CONSENSUS REPORT: Invasive Fungal Infections Among Cardiothoracic Transplant Recipients: Consensus Guidelines and Recommendations From The ISHLT Fungal Expert Panel**

Shahid Husain, MD, MS, Toronto General Hospital,
Toronto, ON, Canada

10:00 AM **CONSENSUS REPORT: Updated Guidelines for Lung Transplant Recipient Selection**
David Weill, MD, Stanford University, Stanford, CA, USA

10:10 AM **(405) FEATURED ABSTRACT: Everolimus Initiation With Calcineurin Inhibitor Withdrawal Reduces Allograft Vasculopathy in De-Novo Heart Transplant Recipients;**

S. Arora¹, B. Andersson², F. Gustafsson³, H. Eiskjær⁴, G. Rådegran⁵, L. Aaberge¹, I. Erikstad¹, E. Gude¹, T. Ueland⁶, P. Aukrust⁶, D. Solbu⁷, G. Dellgren⁸, A. Andreassen¹, L. Gullestad¹. ¹Department of Cardiology, Oslo University Hospital, Rikshospitalet, Oslo, Norway, ²Department of Cardiology, Sahlgrenska University Hospital, Gothenburg, Sweden, ³Department of Cardiology, Copenhagen University Hospital, Copenhagen, Sweden, ⁴Department of Cardiology, Skejby University Hospital, Aarhus, Norway, ⁵The Clinic for Heart Failure and Valvular Disease, Skåne University Hospital and Lund University, Lund, Sweden, ⁶Research Institute of Internal Medicine, Oslo University Hospital, Rikshospitalet, Oslo, Norway, ⁷Department of Cardiology, Novartis Norge AS, Oslo, Norway, ⁸Transplantationscentrum, Sahlgrenska University Hospital, Gothenburg, Sweden.

10:25 AM **INVITED LECTURE: The Invisible Team Member: Family Caregivers of Thoracic Transplant And Mechanical Circulatory Support Patients**

Michael G Petty, PhD, RN, University of Minnesota Medical Center, Minneapolis, MN, USA

10:45 AM **INVITED LECTURE: Trading Risks of Sensitization in Thoracic Transplantation: ABO-Incompatibility to Achieve HLA-Compatibility?**

Lori J West, MD, DPhil, University of Alberta, Edmonton, AB, Canada

11:15 AM **PRESIDENT'S DEBATE: PRO: Stop Treating Secondary PH Right Now!**

Fernando Torres, MD, UT Southwestern Medical Center, Dallas, TX, USA

11:00 AM **(406) FEATURED ABSTRACT: Reconstitution of CMV-Specific Immunity After Heart Transplantation May Guide Customization of Immunosuppressive and Antiviral Strategies: A Prospective Randomized Study;**

L. Potena, G. Bianchi, A. Chierighin, B. Perciaccante, L. Borgese, E. Petrisli, P. Prestinenzi, G. Magnani, T. Lazzarotto, C. Rapezzi, F. Grigioni. University of Bologna, Bologna, Italy.

11:30 AM **PRESIDENT'S DEBATE: CON: Stop Treating Secondary PH Right Now!**

Harrison W Farber, MD, Boston University School of Medicine, Boston, MA, USA

11:45 AM – NOON

COFFEE BREAK (Palm Foyer)

12:00 PM – 1:15 PM**CONCURRENT SESSION 44****Innovations in Mechanical Circulatory Support Care**

(Harbor GHI)

CHAIRS: Murat Sargin, MD and Jack G. Copeland, MD
(MCS, HF)

- 12:00 PM (407) Left Ventricular (LV) Response to Unloading by Continuous-flow Left Ventricular Assist Devices (LVAD): Axial Vs. Centrifugal?;**
A. Rauf, A. K. Johnson, G. A. Wright, S. Stoker, B. B. Reid, W. T. Caine, M. K. Goddard, R. Alharethi, G. E. Thomsen, D. Budge, S. E. Clayson, B. Y. Rasmusson, A. G. Kfoury. Mechanical Circulatory Support, Intermountain Medical Center, Salt Lake City, UT.
- 12:12 PM (408) From Bench To Bedside: Can the Improvements in LVAD Design Mitigate Adverse Events and Increase Survival Rate?;**
V. Tarzia¹, G. Di Giammarco², M. Maccherini³, T. Bottio¹, V. Tursi⁴, M. Maiani⁴, S. Bernazzali³, M. Foschi², S. M. Diso², U. Livi⁴, G. Sani⁵, G. Gerosa¹. ¹Department of Cardiac, Thoracic and Vascular Sciences, Cardiac Surgery, University of Padova, Padova, Italy, ²Cardiac Surgery, University of Chieti, Chieti, Italy, ³Cardiac Surgery, University of Siena, Siena, Italy, ⁴Cardiac Surgery, University of Udine, Udine, Italy, ⁵Cardiac Surgery, University of Florence, Florence, Italy.
- 12:24 PM (409) Left Ventricular Remodeling Following LVAD: Does Pulsatility Matter?;**
M. K. Bennett, W. E. Sweet, S. Baicker-McKee, R. C. Starling, N. Moazami, C. S. Moravec. Department of Cardiovascular Medicine, Cleveland Clinic, Cleveland, OH.
- 12:36 PM (410) Evaluation of Pump Speed Changes with Exercise in Patients with Continuous Flow Ventricular Assist Devices;**
J. V. Lai, K. Muthiah, R. Prichard, R. Walker, D. Robson, C. Lim, L. W. Wang, P. S. Macdonald, P. Jansz, C. S. Hayward. Heart and Lung Transplant Unit, St Vincent's Hospital, Sydney, Australia.
- 12:48 PM (411) TNF as a Predictor of Myocardial Functional Improvement Induced By Left Ventricular Mechanical Unloading;**
N. Diakos¹, C. Yen¹, O. Wever-Pinzon¹, C. Selzman¹, B. Reid², J. Stehlik¹, A. Kfoury², R. Alharethi², J. Nativi¹, A. Catino¹, C. Davis¹, J. Barney¹, S. Wright¹, A. Koliopoulou¹, J. Fang¹, D. Li¹, S. Drakos¹. ¹University of Utah, Salt Lake City, UT, ²Intermountain Medical Center, Salt Lake City, UT.
- 1:00 PM (412) Percutaneous Balloon Occlusion of a Left Ventricular Assist Device Outflow Cannula During Right Heart Catheterization With Pumpstop as Part of the Evaluation of Myocardial Recovery;**
J. Vierecke, M. Hernánedes-Enriquez, M. Dandel, M. Müller, P. Stawowy, S. Dreysse, E. Potapov, T. Krabatsch, R. Hetzer. Deutsches Herzzentrum Berlin, Berlin, Germany.

12:00 PM – 1:15 PM

CONCURRENT SESSION 45

Adult Heart Failure: Look After Your Liver (Seaport H)

CHAIRS: Arezu Z. Aliabadi, MD and Randall H. Vagelos, MD
(HF, HTX)

- 12:00 PM (413) Influence of MELD (Model of End-Stage Liver Disease)_XI (eXcluding INR) on Post-Heart Transplant (HT) Outcomes;**
E. C. DePasquale, A. Nsair, L. Reardon, A. Ardehali, M. Deng. UCLA, Los Angeles, CA.
- 12:12 PM (414) The Combination of Liver Biopsy With MELD-XI Scores for Post-Heart Transplant Outcome Prediction in Patients With Advanced Heart Failure and Suspected Liver Dysfunction;**
M. A. Farr¹, J. Mitchell¹, M. Lippel¹, T. Kato¹, L. Dove¹, S. Murthy¹, U. Jorde¹, H. Takayama², J. Emond², Y. Naka², D. Mancini¹, J. Lefkowitz¹, P. Schulze¹. ¹Medicine, Columbia University Medical Center, New York, NY, ²Surgery, Columbia University Medical Center, New York, NY.
- 12:24 PM (415) Is Pre-Existing Liver Cirrhosis and Fibrosis a Contraindication to Heart Transplantation?;**
M. J. Sasevich, F. Esmailian, K. Rihbany, T. Pouladar, Z. Yu, F. Liou, D. Ramzy, F. Arabia, A. Trento, L. Czer, M. Hamilton, J. Kobashigawa. Cedars- Sinai Heart Institute, Los Angeles, CA.
- 12:36 PM (416) Heart Transplantation Outcomes in Hepatitis C Patients: Influence of New Treatment Options on Post-transplantation Survival;**
M. Quader, L. G. Wolfe, G. Katlaps, V. Kasirajan. Cardio-Thoracic Surgery, Virginia Commonwealth University, Richmond, VA.
- 12:48 PM (417) Outcomes of Heart vs. Heart-Liver Transplantation: UNOS Registry Analysis;**
E. C. DePasquale, A. Nsair, M. Gayheart, L. Reardon, M. Deng, A. Ardehali. UCLA, Los Angeles, CA.
- 1:00 PM (418) Changing Outcomes After Heart Transplantation in Patients with Amyloid Cardiomyopathy;**
M. Davis¹, P. H. Lee², R. M. Witteles¹. ¹Cardiovascular Medicine, Stanford University School of Medicine, Stanford, CA, ²Cardiothoracic Surgery, Stanford University School of Medicine, Stanford, CA.

12:00 PM – 1:15 PM

CONCURRENT SESSION 46

**Antibody Mediated Rejection 2014: HLA and Beyond
(Gaslamp AB)****CHAIRS:** Deborah J. Levine, MD and Tobias Deuse, MD, PhD
(PATH, LTX)**12:00 PM (419) Postoperative Donor Specific Anti-HLA Antibodies in Lung Transplantation: Risk Factors and Impact on Mid-Term Patient and Graft Outcomes;**F. Ius¹, W. Sommer¹, I. Tudorache¹, C. Kühn¹, M. Avsar¹, T. Siemeni¹, J. Salman¹, M. Hallensleben², M. Greer³, J. Gottlieb³, A. Haverich¹, G. Warnecke¹. ¹Department of Cardiothoracic, Transplant and Vascular Surgery, Hannover Medical School, Hannover, Germany, ²Department of Transfusion Medicine, Hannover Medical School, Hannover, Germany, ³Department of Respiratory Medicine, Hannover Medical School, Hannover, Germany.**12:12 PM (420) Identification of Independent Risk Factors for De Novo DSA Development Through Prospective Monitoring;**

A. K. Islam, S. Jyothula, J. Devos, L. Teeter, E. Graviss, L. Moore, N. Sinha, T. Kaleekal, B. Mankidy, S. Scheinin, M. Loebe, B. Bruckner, D. Ren, A. O. Gaber. Houston Methodist, Houston, TX.

12:24 PM (421) The Development of De Novo Donor Specific Antibodies Following Community Acquired Respiratory Virus Infection after Lung Transplantation: A Novel Association;H. W. Ainge-Allen, M. Benzimra, A. P. Havryk, A. L. Rigby, M. A. Malouf, M. Pliit, A. R. Glanville. Lung Transplant Unit, St Vincent's Hospital, Sydney, Australia.**12:36 PM (422) De Novo Development of Donor Specific Antibodies To HLA Is Associated With Dysregulation of microRNA Expression Profile Affecting Immune Responses Resulting in Bronchiolitis Obliterans Syndrome Following Human Lung Transplantation;**Z. Xu¹, S. Ramachandran¹, N. Sarma¹, B. Gautam², A. Aloush¹, R. Hachem², A. Patterson¹, T. Mohanakumar¹. ¹Department of Surgery, Washington University School of Medicine, St. Louis, MO, ²Department of Medicine, Washington University School of Medicine, St. Louis, MO.**12:48 PM (423) Complement-Fixing Donor-Specific Antibody and Lung Transplant Outcomes;**L. Chhatwani¹, J. Mooney¹, R. Balestra¹, R. Lee², C. Lou³, D. Weill¹, D. Tyan³, G. Dhillon¹. ¹Division of Pulmonary and Critical Care Medicine, Stanford University Medical Center, Stanford, CA, ²Department of Pharmacy, Stanford University Medical Center, Stanford, CA, ³Department of Pathology, Stanford University Medical Center, Stanford, CA.**1:00 PM (424) Pre-Emptive Treatment of Donor Specific Anti-HLA Antibodies in Lung Transplantation With Plasmapheresis;**F. Ius¹, W. Sommer¹, I. Tudorache¹, C. Kühn¹, M. Avsar¹, T. Siemeni¹, J. Salman¹, M. Hallensleben², M. Greer³, J. Gottlieb³, A. Haverich¹, G. Warnecke¹. ¹Department of Cardiothoracic, Transplant and Vascular Surgery, Hannover Medical School, Hannover, Germany, ²Department of Transfusion Medicine, Hannover Medical School, Hannover, Germany, ³Department of Respiratory Medicine, Hannover Medical School, Hannover, Germany.

12:00 PM – 1:15 PM

CONCURRENT SESSION 47

What Becomes of the Marginal Hearted (Gaslamp CD)

CHAIRS: Ashish S. Shah, MD and Steven SL Tsui, MD, FRCS
(DMD, HTX)

- 12:00 PM (425) Elderly Heart Transplant Recipient Long-Term Survival Is Not Dependent on Donor Age: A Conditional Survival Analysis;**
Y. Ravi¹, S. Emani², A. Kilic¹, B. Lampert², S. Bansal³, G. Haas², A. K. Hasan², R. Higgins¹, C. B. Sai-Sudhakar¹, B. A. Whitson¹. ¹Cardiac Surgery, The Ohio State University, Columbus, OH, ²Internal Medicine, The Ohio State University, Columbus, OH, ³Cardiac Surgery, University of Pittsburgh, Pittsburgh, PA.
- 12:12 PM (426) Coronary Angiography of Older Donor Hearts During Evaluation for Transplantation;**
M. Davis¹, N. M. Fine², M. Roussos³, R. Khan⁴, T. Malas⁵, S. A. Hunt¹. ¹Cardiovascular Medicine, Stanford University School of Medicine, Stanford, CA, ²University of Calgary, Calgary, AB, Canada, ³Division of Critical Care, Northern Ontario School of Medicine, Thunder Bay, ON, Canada, ⁴Montreal Heart Institute, Montreal, QC, Canada, ⁵Cardiac Surgery, University of Ottawa Heart Institute, Ottawa, ON, Canada.
- 12:24 PM (427) The UK Retrieval Team "Scout" Pilot Programme;**
J. D. Lannon¹, G. Mandersloot², H. L. Thomas¹, A. Vercueil³, R. Venkateswaran⁴, S. Clark⁵, C. Sudarshan⁶, N. Al-Attar⁷, B. Zych⁸, J. Mascaro⁹, P. Murphy², S. Tsui⁶. ¹Statistics and Clinical Studies, NHS Blood and Transplant, Bristol, United Kingdom, ²NHS Blood and Transplant, Bristol, United Kingdom, ³King's College Hospital, London, United Kingdom, ⁴Wythenshawe Hospital, Manchester, United Kingdom, ⁵Freeman Hospital, Newcastle upon Tyne, United Kingdom, ⁶Papworth Hospital, Cambridge, United Kingdom, ⁷Golden Jubilee Hospital, Glasgow, United Kingdom, ⁸Harefield Hospital, Middlesex, United Kingdom, ⁹Queen Elizabeth Hospital, Birmingham, United Kingdom.
- 12:36 PM (428) Marginal Donors: Improvement in Quality of Hearts Transplanted and Mid-Term Survival By Echo-Stress Evaluation;**
S. Bernazzali¹, L. Seri¹, m. Cameli², G. Lisi¹, T. Bombardini³, G. Sani¹, S. Mondillo⁴, M. Maccherini¹. ¹Chirurgia del Cuore e dei Grossi Vasi, Azienda Ospedaliera Universitaria Senese, Siena, Italy, ²Cardiologia Universitaria, Azienda Ospedaliera Universitaria Senese, Siena, Italy, ³Istituto Fisiologia Clinica, Centro Nazionale Ricerche, Pisa, Italy, ⁴Cardiologia Universitaria, Università degli Studi Di Siena, Siena, Italy.
- 12:48 PM (429) Is Bad Donor in Bad Recipient Leading To Bad Outcomes? Potential Utility of Scores To Achieve Optimal Donor-Recipient Match;**
A. Amabile, M. Sabatino, L. Potena, E. Resciniti, V. Manfredini, S. Martin Suarez, G. Magnani, G. Marinelli, F. Grigioni. University of Bologna, Bologna, Italy.
- 1:00 PM (430) Heart Transplant Recipient and Donor Age Mismatching: Should the Older Recipient Be Paired with the Older Donor?;**
B. A. Whitson, Y. Ravi, S. Emani, B. Lampert, A. Kilic, A. Hasan, R. S. Higgins, C. Sai Sudhakar. Department of Surgery, The Ohio State University, Columbus, OH.

12:00 PM – 1:15 PM

CONCURRENT SESSION 48

Novel Approaches to Keep the Heart Going (Old Town AB)

CHAIRS: Daniel R. Goldstein, MD and Zsuzsanna Hollander, MSc
(HTX, BSTR)

- 12:00 PM (431) *Connexins: A New Target for the Prevention of Transplant Vasculopathy?***
J. Porterie¹, B. Marcheix¹, C. Dambrin¹, Y. Glock¹, R. Salvayre², A. Nègre-Salvayre². ¹Cardiovascular Surgery, Rangueil University Hospital, Toulouse, France, ²Inserm UMR 1048 Team ¹⁰, Paul Sabatier University, Toulouse, France.
- 12:12 PM (432) *Discovering Novel Inflammatory Triggers after Heart Transplantation Via Proteomics***
H. Shen¹, E. Heuzey², C. Colangelo³, L. Chung³, C. Bruce³, C. Booth⁴, D. Kreisel⁵, D. R. Goldstein¹. ¹Internal Medicine and Immunobiology, Yale School of Medicine, New Haven, CT, ²Internal Medicine, Yale School of Medicine, CT, ³Keck Facility, Yale School of Medicine, New Haven, CT, ⁴Comparative Medicine, Yale School of Medicine, New Haven, CT, ⁵Surgery and Immunology, Washington University, St Louis, MO.
- 12:24 PM (433) *Myeloperoxidase is Critically Linked to the Development of Diastolic Heart Failure Following Pressure Overload***
F. G. Deuschl¹, A. Klinke², K. Friedrichs², D. Knappe¹, F. Weinberger³, K. Müllerleile¹, D. Westermann¹, H. Reichenspurner⁴, S. Blankenberg¹, S. Baldus². ¹General and Interventional Cardiology, University Heart Center Hamburg, University Hospital Hamburg-Eppendorf, Hamburg, Germany, ²Experimental Cardiology, Clinic for Internal Medicine III, Heart Center University Hospital Cologne, Cologne, Germany, ³Department of Experimental Pharmacology and Toxicology, University Hospital Hamburg-Eppendorf, Hamburg, Germany, ⁴Department for Cardiovascular Surgery, University Heart Center Hamburg, University Hospital Hamburg-Eppendorf, Hamburg, Germany.
- 12:36 PM (434) *Physical Exercise Reduces Transplant Arteriosclerosis in a Fully Allogeneic Mouse Aorta Transplantation Model***
A. K. Knöfel, W. Sommer, N. Madrahimov, K. Jansson, M. Avsar, G. Warnecke, A. Haverich. Medical School Hanover, Hannover, Germany.
- 12:48 PM (435) *Donor Single-dose Treatment with VEGFR-3 Antibody Reduces Acute Alloimmune Response by Targeting Lymphatic Endothelial Cell Activation***
A. Dashkevich¹, S. Syrjälä¹, M. Keränen¹, R. Tuuminen¹, A. Raissadati¹, R. Krebs¹, K. Alitalo², A. Nykänen¹, K. Lemström¹. ¹Transplantation Laboratory, Haartman Institute, University of Helsinki, Helsinki, Finland, ²Wihuri Research Institute, Translational Cancer Biology Program, Biomedicum Helsinki, Helsinki, Finland.
- 1:00 PM (436) *The Ubiquitin Ligase Mule Is Required for the Maintenance of Normal Cardiac Function***
L. Hauck¹, D. Grothe¹, T. W. Mak², F. Billia¹. ¹Toronto General Research Institute, Toronto, ON, Canada, ²Campbell Family Cancer Research Institute, Toronto, ON, Canada.

POSTERS



MODERATED POSTER SESSIONS

THURSDAY, APRIL 10, 2014

POSTER SESSION 1

NOTE: Poster presenters and moderators will be present during the evening poster viewing session from 6:15 PM – 7:15 PM.

BASIC SCIENCE

(BSTR, LTX)

(437) *In Vivo* Evaluation of the Cleveland Clinic

Continuous-Flow Total Artificial Heart in Calves:

J. H. Karimov¹, K. Fukamachi¹, N. Moazami², M. Kobayashi¹, S. Sale³, N. Mielke¹, G. Sunagawa¹, D. Horvath¹, S. Gao¹, L. A. Golding¹. ¹Biomedical Engineering, Lerner Research Institute, The Cleveland Clinic, Cleveland, OH, ²Thoracic and Cardiovascular Surgery, Kaufman Center for Heart Failure, Heart and Vascular Institute, The Cleveland Clinic, Cleveland, OH, ³Cardiothoracic Anesthesiology, Anesthesiology Institute, The Cleveland Clinic, Cleveland, OH.

(438) *Novel Antibody-Engineered Gold Nanoparticles as Targeted Drug Delivery for Primary Mesenchymal Cells Do Not Elicit an Inflammatory Response:*

F. Meloni¹, E. Cova², S. Inghilleri², T. Oggionni³, S. Magni³, M. Morosini³, D. F. Briganti², M. Colombo⁴, M. Agozzino⁵, M. Cusella De Angelis⁶, D. Prosperi⁴. ¹Department of Respiratory Diseases, University of Pavia and IRCCS S. Matteo, Pavia, Italy, ²Molecular Medicine, University of Pavia and IRCCS S. Matteo, Pavia, Italy, ³Molecular Medicine, IRCCS S. Matteo, Pavia, Italy, ⁴Biotechnology and Bioscience, University of Milano Bicocca, Milano, Italy, ⁵Cardiovascular Pathology, IRCCS S. Matteo, Pavia, Italy, ⁶Public Health, University of Pavia, Pavia, Italy.

(439) *Sexual Dimorphism in Lung Inflammatory Process After Brain Death Induction in Rats:*

L. P. Moreira¹, S. G. Ferreira¹, G. K. Kudo¹, C. J. Correia¹, W. Tavares-de-Lima², A. C. Breithaupt-Faloppa¹, P. Sannomiya¹. ¹Cardiovascular Surgery, Heart Institute (Incor), University of Sao Paulo Medical School, Sao Paulo, Brazil, ²Department of Clinical and Toxicological Analyses, Faculty of Pharmaceutical Sciences, University of Sao Paulo, Sao Paulo, Brazil.

(440) *Expression of S100A4 Protein is T Cell-mediated in a Humanized Model of Obliterative Airway Disorder:*

J. Guihaire¹, R. Itagaki¹, X. Hua¹, T. Deuse¹, M. Stubbendorff¹, E. Fadel², P. Dorfmueller³, H. Reichenspurner¹, F. Länger⁴, U. Schumacher⁵, S. Schrepfer¹. ¹Transplant and Stem Cell Immunobiology Lab, University Heart Center Hamburg, Hamburg, Germany, ²Thoracic and Vascular Surgery and Heart-Lung Transplantation, Marie Lannelongue Hospital, University of Paris Sud, Le Plessis Robinson, France, ³Thoracic and Vascular Surgery and Heart-Lung Transplantation, Marie Lannelongue Hospital, University of Paris Sud, Le Plessis Robinson, Germany, ⁴Institute of Pathology, Medizinische Hochschule Hannover, Hannover, Germany, ⁵Department of Anatomy and Experimental Morphology, University Hospital Hamburg-Eppendorf, Hamburg, Germany.

- (441) Gender Specific Influences on Effector T-Cell Function and Proliferation: Hormonal Targeting to Modulate Cellular Rejection in Transplantation;**
J. G. Luc¹, J. Zhao¹, E. D. Michelakis², D. H. Freed¹, J. Nagendran¹.
¹Department of Surgery, University of Alberta, Edmonton, AB, Canada, ²Department of Medicine, University of Alberta, Edmonton, AB, Canada.
- (442) Local Production of Donor Specific Antibodies (DSA) By Intrapulmonary De Novo Lymphoid Tissue Associated With Allograft Airway Rejection;**
H. Motoyama, M. Sato, K. Hijiya, T. Kondo, M. Takahashi, K. Ohata, K. Shikuma, T. Sowa, N. Imamura, T. Yamada, T. Menju, A. Aoyama, F. Chen, T. Bando, H. Date. Thoracic Surgery, Kyoto University Hospital, Kyoto, Japan.
- (443) WITHDRAWN**
- (444) Isolated Transfer of Human Platelets Results in Formation of Transplant Arteriosclerosis in a RAG2^{-/-} α -chain^{-/-} Mouse Aortic Xenograft Model;**
C. Heim¹, S. Müller¹, B. Motsch¹, N. Koch¹, B. Weigmann², M. Ramsperger-Gleixner¹, R. Zimmermann³, M. Weyand¹, S. M. Ensminger⁴. ¹Department of Cardiac Surgery, Erlangen, Germany, ²Department of Medicine ¹, Erlangen, Germany, ³Department of Transfusion Medicine, Erlangen, Germany, ⁴Department of Cardiac Surgery, Bad Oeynhausen, Germany.
- (445) Extravascular Lung Water Measurement During Ex-Vivo Lung Perfusion;**
V. Linacre, M. Cypel, T. Machuca, D. Nakajima, K. Hashimoto, R. Zamel, Y. Chun, T. K. Waddell, M. Liu, S. Keshavjee. Latner Thoracic Surgery Research Laboratories, University Health Network, University of Toronto, Toronto, ON, Canada.
- (446) Tolerance Induction Using Myeloid Progenitor Cells and Autologous HSC;**
J. Domen¹, Y. Li¹, L. Sun¹, P. Simpson², K. Gandy³. ¹Cardiac Surgery, Children's Mercy Hospital and Clinics, Kansas City, MO, ²Dept Pediatrics, Div Quantitative Health Sciences, Medical College of Wisconsin, Milwaukee, WI, ³Biomedical and Health Informatics, University of Missouri-Kansas City, Kansas City, MO.

ADULT HEART FAILURE

(HF. HTX)

- (447) The Predictive Power of Invasive Hemodynamics and MELD Scores in Ambulatory Patients With Advanced Heart Failure;**
T. S. Kato¹, M. S. Kim², C. Wu², M. Farr², D. Mancini², P. Schulze².
¹Heart Center, Department of Cardiothoracic Surgery, Juntendo University School of Medicine, Tokyo, Japan, ²Division of Cardiology, Department of Medicine, Columbia University Medical Center, New York, NY.
- (448) Coronary Artery Bypass Surgery or Heart Transplantation for Treatment of End-stage Ischemic Cardiomyopathy;**
N. E. Hiemann, A. Trogisch, P. Zarubova, M. Bauer, M. Pasic, R. Hetzer. Cardiothoracic and Vascular Surgery, Deutsches Herzzentrum Berlin, Berlin, Germany.
- (449) WITHDRAWN**

(450) Heart Failure Classification Rather Than Ejection Fraction May Be a Major Factor in Considering Patients with Hypertrophic Cardiomyopathy for Heart Transplantation;

K. Hryniewicz¹, K. Anderson¹, K. Harris¹, D. Feldman¹, B. Maron².
¹Minneapolis Heart Institute, Abbott Northwestern Hospital, Minneapolis, MN, ²Minneapolis Heart Institute Foundation, Minneapolis, MN.

(451) Structural Remodeling of the Cardiac Ventricles: When Left Isn't Equally Right;

N. Diakos¹, J. Barney¹, C. Yen¹, J. Stehlik¹, A. Kfoury², C. Selzman¹, B. Reid², O. Wever-Pinzon¹, A. Saidi¹, S. Wright¹, A. Koliopoulou¹, G. Russell³, L. McCreath¹, J. Fang¹, D. Li¹, S. Drakos¹. ¹University of Utah, Salt Lake City, UT, ²Intermountain Medical Center, Salt Lake City, UT, ³Intermountain Donor Service, Salt Lake City, UT.

(452) The Risk of Prior Chest Radiation Therapy in Patients Who Undergo Heart Transplantation;

Z. Yu, J. Patel, M. Kittleson, F. Liou, J. Yabuno, G. Jamero, D. H. Chang, L. Czer, B. Azarbal, A. Trento, F. Esmailian, J. Kobashigawa. Cedars- Sinai Heart Institute, Los Angeles, CA.

(453) Dynamic Changes in Proteinuria Identify a Form of Cardiorenal Dysfunction Associated with Decreased Survival: An Application of the SOLVD Trial Limited Dataset;

M. A. Brisco¹, M. Zile¹, J. Arthur¹, J. M. Testani². ¹Medicine-Cardiology, Medical University of South Carolina, Charleston, SC, ²Internal Medicine and Applied Translational Research, Yale University, New Haven, CT.

(454) Thoracic Organ Transplantation for Autoimmune-Mediated Disease Is Not Associated With Detrimental Clinical Outcomes;

Z. Taimel¹, K. Vakil¹, W. Rawasia², R. Cavallazzi³, D. Nunley⁴, E. Birks², C. Lenneman². ¹Cardiovascular Medicine, University of Minnesota School of Medicine, Minneapolis, MN, ²Cardiovascular Medicine, University of Louisville School of Medicine, Louisville, KY, ³Pulmonary and Critical Care, University of Louisville School of Medicine, Louisville, KY, ⁴Pulmonary and Critical Care Medicine, University of Louisville School of Medicine, Louisville, KY.

(455) Predicting Heart Transplant Outcomes: Do We Have a Reliable Instrument to Assess Psychosocial Risk?;

E. Vandenbergart¹, L. Doering², B. Chen², A. Saltzman³, T. Chaker¹, J. W. Creaser¹, D. Rourke¹, J. Chait¹, N. Livingston¹, R. W. Cheng⁴, G. Fonarow¹, M. Deng¹. ¹Department of Medicine, Division of Cardiology, University of California Los Angeles, Los Angeles, CA, ²UCLA School of Nursing, UCLA, Los Angeles, CA, ³Cardiopulmonary Rehabilitation Center, Ronald Regan UCLA Medical Center, Los Angeles, CA, ⁴Department of Medicine, Division of Cardiology, University of Washington, Seattle, WA.

(456) Role of Serial Measurement of Peak Oxygen Consumption for Prognosis Assessment in Heart Failure;

A. C. Alba, M. Gewarges, M. Bamberger, S. Lalonde, G. Kumar, D. Delgado, M. McDonald, F. Billia, H. Ross. University Health Network, Toronto, ON, Canada.

ADULT HEART TRANSPLANTATION

(HTX, PHARM, HF)

- (457) A Comparison of the Extended-Release and Standard-Release Formulations of Tacrolimus in De Novo Heart Transplant Recipients: A 12-Month Outcome Study;**
 F. Gonzalez-Vilchez¹, J. Lambert², L. Almenar³, E. Lage⁴, J. Vazquez de Prada¹, B. Diaz de Molina², L. Martinez-Dolz³, J. Sobrino-Marquez⁴. ¹University Hospital Marques de Valdecilla, Santander, Spain, ²University Hospital Central de Asturias, Oviedo, Spain, ³University Hospital La Fe, Valencia, Spain, ⁴University Hospital Virgen del Rocío, Sevilla, Spain.
- (458) Safety of Intravascular Ultrasound in Nearly 900 Cases;**
 D. A. Baran¹, A. Jaiswal¹, M. Haseeb¹, A. Adzic¹, J. Pieretti¹, C. Gidea¹, R. Morlend¹, S. Murthy¹, M. T. Camacho¹, M. Feinberg², M. J. Zucker¹. ¹Transplant Center, Newark Beth Israel Medical Center, Newark, NJ, ²Newark Beth Israel Medical Center, Newark, NJ.
- (459) Clinical Observations and Outcome After Ablation of Atrial Arrhythmias in Patients With Orthotopic Heart Transplant;**
 K. L. Weston¹, M. Nellaiyappan², T. Tran², M. Weston¹, B. Herweg³. ¹Tampa General Hospital, Tampa, FL, ²Florida Gulf to Bay Anesthesiology, Tampa, FL, ³Cardiovascular Sciences, University of South Florida, Tampa, FL.
- (460) Epidemiology, Mortality and Risk Factors of Primary and Secondary Graft Failure According with ISHLT Consensus Criteria;**
 G. Vitale¹, M. Sabatino², L. Potena², C. Lonetti², M. Fanizza², M. Luciani², A. Loforte², S. Martin Suarez², G. Marinelli², C. Rapezzi², F. Grigioni². ¹ISMETT, Palermo, Italy, ²University of Bologna, Bologna, Italy.
- (461) Heart Rate After Heart Transplantation – An Independent Predictor of Long Term Survival. Impact of Beta Blockade on Mortality After Heart Transplantation;**
 A. Ciarka, J. Van Cleemput, W. Droogne, G. Voros, B. Meyns, S. Janssens, J. Vanhaecke. Cardiovascular Diseases, Catholic University of Leuven, Leuven, Belgium.
- (462) Maintained Cardiac Reserve in Heart Transplant Patients During Early Calcineurin Inhibitor Avoidance: A Substudy of a Randomised Controlled Trial (SCHEDULE Trial);**
 S. Bartfay¹, L. Gullestad², V. Sigurdardottir³, A. K. Andreassen², E. Gude², B. Andersson¹. ¹Department of Cardiology, Sahlgrenska University Hospital, Gothenburg, Sweden, ²Department of Cardiology, Oslo University Hospital Rikshospitalet, Oslo, Norway, ³Transplant Institute, Sahlgrenska University Hospital, Gothenburg, Sweden.
- (463) Role of Coronary CT in Predicting Cardiovascular Prognosis After Heart Transplantation;**
 M. Masetti¹, A. Aliabadi², C. Löwe³, F. Wolf³, S. Rödler², K. Uyanik Uenal², J. Gökler², G. Laufer², A. Zuckermann². ¹DIMES, S.Orsola Hospital, University of Bologna, Bologna, Italy, ²Heart Transplantation, Cardiac Surgery Department, Vienna General Hospital, Vienna, Austria, ³Cardiovascular and Interventional Radiology, Vienna General Hospital, Vienna, Austria.
- (464) Steroids Withdrawal During the First Year After Heart Transplantation and Its Association With Changes in Renal Function in a Two Year Follow-Up. RESTCO Study;**
 M. G. Crespo-Leiro¹, M. J. Paniagua-Martín¹, M. Gómez Bueno², F. González-Vilchez³, J. L. Lambert-Rodríguez⁴, J. Fernández-Yáñez⁵, V. Brossa Loidi⁶, E. Lage Galle⁷, J. M. Arizón del Prado⁸, L. Almenar

Bonet⁹, T. Blasco Peiró¹⁰, L. de la Fuente Galán¹¹, I. Garrido Bravo¹², J. Muñoz-García¹³, J. F. Delgado Jiménez¹⁴. ¹Heart Transplant Unit, Hospital Universitario A Coruña, La Coruña, Spain, ²Hospital Universitario Puerta de Hierro, Madrid, Spain, ³Hospital Universitario Marqués de Valdecilla, Santander, Spain, ⁴Hospital Universitario Central de Asturias, Asturias, Spain, ⁵Hospital General Universitario Gregorio Marañón, Madrid, Spain, ⁶Hospital Santa Creu i Sant Pau, Barcelona, Spain, ⁷Hospital Universitario Virgen del Rocío, Sevilla, Spain, ⁸Hospital Universitario Reina Sofía, Córdoba, Spain, ⁹Hospital Universitari i Politècnic La Fe, Valencia, Spain, ¹⁰Hospital Universitario Miguel Servet, Zaragoza, Spain, ¹¹Hospital Clínico Universitario de Valladolid, Valladolid, Spain, ¹²Hospital Universitario Virgen de la Arrixaca, Murcia, Spain, ¹³Instituto Universitario de Ciencias de la Salud. Universidad de A Coruña, La Coruña, Spain, ¹⁴Hospital Universitario 12 de Octubre, Madrid, Spain.

(465) Comparative Utility of Gene Expression Profiling Score Variability, Endomyocardial Biopsy, and Echocardiography to Predict Future Clinical Events in Heart Transplant Recipients;

M. Deng¹, A. Kfoury², J. Teuteberg³, B. Elashoff⁴, D. Hiller⁴, J. Yee⁴, H. Valantine⁵. ¹Cardiology, University of California, Los Angeles, CA, ²Intermountain Medical Center and Intermountain Healthcare, Salt Lake City, UT, ³University of Pittsburgh Medical Center, Pittsburgh, PA, ⁴XDx, Brisbane, CA, ⁵Stanford University, Stanford, CA.

(466) Routine Endomyocardial Biopsies Beyond the First Year Have Low Diagnostic Utility in Heart Transplant Recipients;

I. A. Fattah, G. J. Pearson, W. J. Tymchak, J. R. Burton, M. Chan, L. Lalonde, D. H. Kim. Cardiology, University of Alberta, Edmonton, AB, Canada.

(467) Hemodynamic Compromising Antibody Mediated Rejection (HC-AMR) After Heart Transplantation;

A. Z. Aliabadi¹, M. Groemmer¹, K. Uyanik-Uenal¹, J. Gökler¹, S. Wallner¹, M. Masseti¹, K. Aumayr², G. Fischer³, G. Boehmig⁴, G. Laufer¹, A. O. Zuckermann¹. ¹Cardiac Surgery, Medical University of Vienna, Vienna, Austria, ²Pathology, Medical University of Vienna, Vienna, Austria, ³Blood Group Serology and Transfusion Medicine, Medical University of Vienna, Vienna, Austria, ⁴Nephrology, Medical University of Vienna, Vienna, Austria.

(468) Hearts Preserved in Somah at Sub-normothermia Demonstrate Rapid Functional Restoration and Are Less Likely To Develop Heart Failure Upon Transplantation;

S. K. Lowalekar¹, H. Cao¹, X. Lu¹, P. R. Treanor², H. S. Thattai¹. ¹Surgery, Harvard Medical School, Boston, MA, ²Surgery, VA Boston Healthcare System, Boston, MA.

(469) Novel Nomogram of the Immune Response After Heart Transplantation;

M. Bakir¹, T. Khuu², M. Cadeiras¹, N. Wisniewski¹, V. M. Groyberg¹, G. Bondar¹, E. Depasquale¹, J. Fuentes², L. Rangel², J. Zhang³, E. F. Reed³, M. C. Deng¹. ¹Cardiology, UCLA, Los Angeles, CA, ²Heart & Lung Transplant, UCLA, Los Angeles, CA, ³Path & Lab Med-Immunogenetics Cntr, UCLA, Los Angeles, CA.

(470) Presence of C3d Fixing HLA Antibodies Carries Worse Prognosis and Is Associated With Increased Allograft Vasculopathy in Heart Transplant (HT) Patients;

S. Ducreux¹, V. Dubois¹, P. Boissonnat², A. Roussoulières², J. Neidecker², J. Obadia², C. Dubois², L. Sebbag³. ¹Laboratoire Histocompatibilité, EFS Rhone Alpes, Lyon, France, ²Pole de Transplantation Hopital Louis Pradel, Hospices Civils de Lyon, Bron, France, ³Pole de Transplantation Hopital Louis Pradel, Hospices Civils de Lyon, BRON, France.

- (471) *Thirty-Five Years of Heart Transplantation at Papworth Hospital: Factors Influencing Outcomes of 25-Year Survivors;***
A. Prabhu¹, J. Parameshwar², C. J. Lewis². ¹University of Cambridge School of Clinical Medicine, University of Cambridge, Cambridge, United Kingdom, ²Transplant Unit, Papworth Hospital, Cambridge, United Kingdom.
- (472) *Comparison of Heart Transplant Outcomes in Patients Who Received an Axial Versus Centrifugal Flow LVAD as Bridge to Transplant;***
C. M. Rosner, P. Shah, L. Edwards, S. S. Desai, N. A. Burton, A. J. Rongione. Heart Failure and Transplant, Inova Fairfax Hospital, Falls Church, VA.
- (473) *Survival Following Heart Transplantation in Patients with Transthyretin Amyloid Cardiomyopathy;***
V. N. Selby¹, R. Mundayat², M. S. Maurer³, L. Stern⁴, L. Klein¹, M. Janmohamed¹, J. A. Kobashigawa⁵, R. D. Kobes², T. De Marco¹. ¹Division of Cardiology, University of California, San Francisco, San Francisco, CA, ²Pfizer, Inc, New York, NY, ³Division of Cardiology, Columbia University Medical Center, New York, NY, ⁴School of Medicine, University of California, San Francisco, San Francisco, CA, ⁵Cedars-Sinai Heart Institute, Los Angeles, CA.
- (474) *Late Antibody-Mediated Rejection Due To De-Novo Donor-Specific Anti-HLA Antibodies in Heart Transplant Recipients: A Cohort of 20 Consecutive Patients;***
S. Ouldamar¹, G. Coutance¹, P. Rouvier², C. Suberbielle³, S. Saheb⁴, S. Hariri⁵, N. Brechet⁶, G. Lebreton⁷, P. Leprince⁷, S. Varnous¹. ¹Heart Transplantation, Groupe Hospitalier Pitié-Salpêtrière, Paris, France, ²Anatomopathology, Groupe Hospitalier Pitié-Salpêtrière, Paris, France, ³Histocompatibility, Hôpital Saint Louis, Paris, France, ⁴Hemobiotherapy, Groupe Hospitalier Pitié-Salpêtrière, Paris, France, ⁵Anesthesiology, Groupe Hospitalier Pitié-Salpêtrière, Paris, France, ⁶Intensive Care Unit, Groupe Hospitalier Pitié-Salpêtrière, Paris, France, ⁷Cardiac and Thoracic Surgery, Groupe Hospitalier Pitié-Salpêtrière, Paris, France.
- (475) *Relationship Between Anti-HLA Antibodies and Coronary Allograft Vasculopathy after Heart Transplantation;***
S. J. Khandhar¹, M. A. Shullo², A. Zeevi³, C. Toma¹, J. J. Teuteberg¹. ¹Heart and Vascular Institute, University of Pittsburgh Medical Center, Pittsburgh, PA, ²University of Pittsburgh, Pittsburgh, PA, ³Pathology, Surgery, and Immunology, University of Pittsburgh Medical Center, Pittsburgh, PA.
- (476) *Association Between Steroids Withdrawal During the First Year After Heart Transplantation and Changes in Body Mass Index in a Two Year Follow-Up. RESTCO Study;***
M. G. Crespo-Leiro¹, M. J. Paniagua-Martín¹, M. Gómez-Bueno², F. González-Vilchez³, J. L. Lambert-Rodríguez⁴, J. Fernández-Yáñez⁵, V. Brossa Loidi⁶, J. M. Arizón del Prado⁷, T. Blasco Peiró⁸, E. Lage Galle⁹, L. de la Fuente Galán¹⁰, I. Garrido Bravo¹¹, L. Almenar Bonet¹², J. Muñoz-García¹³, J. F. Delgado Jiménez¹⁴. ¹Heart Transplant Unit, Hospital Universitario A Coruña, La Coruña, Spain, ²Hospital Universitario Puerta de Hierro, Madrid, Spain, ³Hospital Universitario Marqués de Valdecilla, Santander, Spain, ⁴Hospital Universitario Central de Asturias, Asturias, Spain, ⁵Hospital General Universitario Gregorio Marañón, Madrid, Spain, ⁶Hospital Santa Creu i Sant Pau, Barcelona, Spain, ⁷Hospital Universitario Reina Sofía, Córdoba, Spain, ⁸Hospital Universitario Miguel Servet, Zaragoza, Spain, ⁹Hospital Universitario Virgen del Rocío, Sevilla, Spain, ¹⁰Hospital Clínico Universitario de Valladolid, Valladolid, Spain, ¹¹Hospital Universitario Virgen de la Arrixaca, Murcia, Spain, ¹²Hospital Universitari i Politècnic La Fe, Valencia, Spain, ¹³Instituto Universitario de Ciencias de la Salud - Universidad de A Coruña, La Coruña, Spain, ¹⁴Hospital Universitario 12 de Octubre, Madrid, Spain,

INFECTIOUS DISEASES

(ID, LTX)

(477) Fighting Flu: A Survey of Seasonal Influenza Vaccination Concordance in Cardiothoracic Transplant Patients in Newcastle (UK);

A. Wort¹, G. Parry², L. Forrest², K. Gould¹. ¹Microbiology, The Newcastle upon Tyne Hospitals NHS Foundation Trust, Newcastle upon Tyne, United Kingdom, ²Institute of Transplantation, The Newcastle upon Tyne Hospitals NHS Foundation Trust, Newcastle upon Tyne, United Kingdom.

(478) Toxoplasma Serology Mismatch with Increased Mortality? Clarifying the Literature;

M. Kittleston¹, A. Chehrazi-Raffle¹, J. Patel¹, Z. Yu¹, F. Liou¹, M. Johnson¹, E. Stimpson¹, A. Hage¹, D. H. Chang¹, L. Czer¹, P. Zakowski², J. A. Kobashigawa¹. ¹Cedars-Sinai Heart Institute, Los Angeles, CA, ²Cedars-Sinai Medical Center, Los Angeles, CA.

(479) Combined Short Term Caspofungin and Nebulized Amphotericin B Prophylaxis May Help To Eradicate Aspergillus Related Complications After Lung Transplantation;

P. T. Hammainen¹, M. Eriksson², M. Halme³, K. Lemstrom¹. ¹Cardiac Surgery, Helsinki Heart and Lung Center, Helsinki, Finland, ²Department of Infectious Diseases, Helsinki University Hospital, Helsinki, Finland, ³Department of Pulmonology, Helsinki Heart and Lung Center, Helsinki, Finland.

(480) Analysis of Incidence and Risk Factors for Polyomavirus Infection after Lung Transplant;

B. Adams¹, A. T. Logan², T. Haddad³. ¹Pharmacy, Tampa General Hospital, Tampa, FL, ²Tampa General Hospital, Tampa, FL, ³New Lung Associates, Tampa, FL.

(481) Cytomegalovirus Infection Following Lung Transplantation – Occurrence, Treatment and Risk of OB;

D. Thomas, A. J. Wilkinson, L. Succony, S. Tsui. Transplant Directorate, Papworth Hospital, Papworth Everard, United Kingdom.

(482) Markedly Reduced Driveline Infection Rates in CF Pumps (HMII) – A Long-term Follow Up;

N. Nair¹, E. Gongora², B. Sareyyupoglu², S. Alvarado², I. X. Collier¹, A. Nazar³, K. J. Zehr². ¹Division of Cardiology, Scott and White Health Care/Texas A&M, Temple, TX, ²Division of Cardiothoracic Surgery, Scott and White Health Care/Texas A&M, Temple, TX, ³Division of Pharmacy, Scott and White Hospital, Temple, TX.

(483) Efficacy and Safety of Sustained Release of Vancomycin Through Fibrin Glue Against Local Prosthesis Infection By Methicillin-resistant Staphylococcus aureus;

S. Ozaki¹, A. Saito¹, H. Nakaminami², J. Shimamura¹, N. Naito¹, M. Ono¹, N. Noguchi², N. Motomura¹. ¹Cardiac Surgery, The University of Tokyo, Tokyo, Japan, ²Microbiology, Tokyo University of Pharmacy and Life Sciences, Hachioji, Japan.

(484) Infectious Complications Following Treatment of Antibody Mediated Rejection in Cardiothoracic Transplant Recipients;

M. A. Moten, C. T. Doligalski, A. T. Logan. Tampa General Hospital, Tampa, FL.

(485) Asymptomatic Cytomegalovirus Viremia Is Associated With Increased Risk of Pneumocystis and Fungal Infections;

G. Poglajen¹, B. Podgoršek², R. Okrajšek¹, M. Šebeštjen¹, S. Frljak¹, G. Zemljič¹, J. Kšela³, I. Kneževič³, F. Haddad⁴, B. Vrtovc¹. ¹Advanced Heart Failure and Transplantation Programme, Dept. of Cardiology, University Medical Center Ljubljana, Ljubljana, Slovenia.

nia, ²Ljubljana Medical Faculty, University of Ljubljana, Ljubljana, Slovenia, ³Dept. of Cardiovascular Surgery, University Medical Center Ljubljana, Ljubljana, Slovenia, ⁴Stanford University School of Medicine, Palo Alto, CA.

(486) Study of Burkholderia Cepacia Complex Strains in Lung Transplant Patients: Analysis of Genomovar and Mortality Impact:

D. S. Carraro¹, S. V. Campos¹, K. A. Oliveira-Braga¹, L. R. Luamoto¹, R. M. Carraro¹, L. C. Oliveira², F. Rossi³, E. C. Sabino⁴, P. M. Pêgo-Fernandes¹. ¹Thoracic Surgery Department, Heart Institute (Incor), Hospital das Clínicas da Faculdade de Medicina da Universidade de São Paulo, São Paulo, Brazil, ²Hospital das Clínicas da Faculdade de Medicina da Universidade de São Paulo, São Paulo, Brazil, ³Patology Department, Hospital das Clínicas da Faculdade de Medicina da Universidade de São Paulo, São Paulo, Brazil, ⁴Department of Infectious Disease, Institute of Tropical Medicine, Faculdade de Medicina da Universidade de São Paulo, São Paulo, Brazil.

ADULT LUNG TRANSPLANTATION

(LTX)

(487) How Donor Graft Lungs Behave in a Recipient Thorax After Living-Donor Lobar Lung Transplantation: 2-Year Follow-up:

F. Chen, K. Ohata, M. Takahashi, M. Takahashi, T. Kondo, H. Motoyoma, K. Hijiya, T. Yamada, M. Sato, A. Aoyama, T. Bando, H. Date. Thoracic Surgery, Kyoto University, Kyoto, Japan.

(488) Donor and Recipient Hepatitis C Status in Lung Transplant:

B. R. Englum¹, A. M. Ganapathi¹, P. J. Speicher¹, B. C. Gulack¹, S. S. Lin¹, S. M. Palmer², L. D. Snyder², M. Daneshmand¹, R. D. Davis¹, M. G. Hartwig¹. ¹Department of Surgery, Duke University Medical Center, Durham, NC, ²Department of Medicine, Duke University Medical Center, Durham, NC.

(489) Clinical Outcome of Bilateral Lung Transplantation for Cystic Fibrosis in the Frame of the European Multicentric COLT Study:

P. Lacoste¹, A. Tissot¹, P. J. Royer², M. Pain², K. Botturi-Cavaillès², A. Magnan and the COLT consortium¹. ¹CHU Nantes, Nantes, France, ²Institut du Thorax, Inserm UMR 1087, Nantes, France.

(490) Microbiome Profiling by Whole Genome Sequencing During Acute and Chronic Lung Transplant Rejection:

B. C. Keller¹, D. E. Byers¹, S. A. Handley², G. Zhao², C. A. Witt¹, R. D. Yussen¹, E. P. Trulock¹, R. R. Hachem¹, D. Wang³, H. W. Virgin². ¹Medicine, Washington University, Saint Louis, MO, ²Pathology & Immunology, Washington University, Saint Louis, MO, ³Molecular Microbiology and Pathology & Immunology, Washington University, Saint Louis, MO.

(491) Community Acquired Respiratory Viral Infection after Lung Transplantation: BOS Risk and Risks of Specific Viruses:

M. Benzimra, H. W. Ainge-Allen, A. L. Rigby, M. A. Malouf, A. P. Havryk, M. Plit, A. R. Glanville. Lung Transplant Unit, St Vincent's Hospital, Sydney, Australia.

(492) Complement-Fixing Donor-Specific Antibodies After Lung Transplantation:

J. A. Iuppa¹, K. B. Bain¹, D. L. Phelan², R. D. Yussen³, D. E. Byers³, C. A. Witt³, E. P. Trulock³, G. A. Patterson⁴, T. Mohanakumar⁵, R.

R. Hachem³. ¹Department of Pharmacy, Barnes-Jewish Hospital, St. Louis, MO, ²Department of Laboratory Medicine, Barnes-Jewish Hospital, St. Louis, MO, ³Division of Pulmonary and Critical Care Medicine, Washington University-School of Medicine, St. Louis, MO, ⁴Division of Cardiothoracic Surgery, Washington University-School of Medicine, St. Louis, MO, ⁵Department of Pathology and Immunology, Washington University-School of Medicine, St. Louis, MO.

(493) Bile Acids in Bronchial Wash: A Biomarker of Aspiration in the Donor and Recipient?;

D. Nakajima, M. Cypel, S. Azad, T. Saito, R. Zamel, T. K. Waddell, M. Liu, L. G. Singer, S. Keshavjee. Toronto Lung Transplant Program, Toronto General Hospital, University Health Network, University of Toronto, Toronto, ON, Canada.

(494) Effect on Survival of Double Versus Single Lung Transplantation in Patients with Primary and Secondary Pulmonary Arterial Hypertension;

T. Madni¹, P. Kilgo², F. G. Fernandez³, A. Pickens³, R. Bag⁴, D. Neujahr⁴, E. Lawrence⁴, S. D. Force³. ¹Surgery, University of Texas Southwestern, Dallas, GA, ²Rollins School of Public Health, Emory University, Atlanta, GA, ³Surgery, Emory University, Atlanta, GA, ⁴Medicine, Emory University, Atlanta, GA.

(495) Underweight Patients with Cystic Fibrosis (CF): A Risk Worth Taking;

S. G. Kapnadak, J. M. Pilewski, C. J. Gries. Pulmonary, Allergy, and Critical Care Medicine, University of Pittsburgh School of Medicine, Pittsburgh, PA.

(496) Endobronchial Therapeutics in Lung Transplant Recipients: A Multi-Center Experience;

H. K. Rokadia¹, M. Machuzak¹, M. Budev¹, A. Mehta¹, L. Yarmus², T. Gildea¹. ¹Cleveland Clinic, Cleveland, OH, ²Johns Hopkins Medical Institutions, Baltimore, MD.

(497) Thrombotic Microangiopathy After Lung Transplantation;

A. Scheed, P. Jaksch, W. Klepetko. Thoracic Surgery, Medical University of Vienna, Vienna, Austria.

(498) Long Term Clinical Outcome of Pulmonary Re-Transplantation for Chronic Lung Allograft Problems;

A. Slama, A. Natmessnig, P. Jaksch, A. Mitterbauer, G. Lang, K. Hoetzenecker, S. Taghavi, W. Klepetko, C. Aigner. Department of Thoracic Surgery, Medical University of Vienna, Vienna, Austria.

(499) Plasma Lipid Peroxidation Products Are Higher in Lung Transplant Recipients with PGD and Are Associated with Donor Smoking;

L. B. Ware¹, L. J. Roberts², J. M. Diamond³, N. Wickersham⁴, S. M. Palmer⁵, D. Lederer⁶, S. Bhorade⁷, M. Crespo⁸, A. Weinacker⁹, V. Lama¹⁰, K. Wille¹¹, S. M. Kawut³, R. Shah³, E. Cantu³, P. Shah¹², D. Wilkes¹³, J. Orens¹², J. Belperio¹⁴, M. Rushefski³, J. D. Christie and the Lung Transplant Outcomes Group³. ¹Departments of Medicine and Pathology, Microbiology and Immunology, Vanderbilt University School of Medicine, Nashville, TN, ²Department of Medicine, Vanderbilt University School of Medicine, Nashville, TN, ³University of Pennsylvania, Philadelphia, PA, ⁴Vanderbilt University School of Medicine, Nashville, TN, ⁵Duke University, Durham, NC, ⁶Columbia University, New York, NY, ⁷University of Chicago, Chicago, IL, ⁸University of Pittsburgh, Pittsburgh, PA, ⁹Stanford University, Palo Alto, CA, ¹⁰University of Michigan, Ann Arbor, MI, ¹¹University of Alabama, Birmingham, AL, ¹²Johns Hopkins University, Baltimore, MD, ¹³Indiana University, Indianapolis, IN, ¹⁴UCLA, Los Angeles, CA.

- (500) *Hypercapnic Ventilatory Response Is Decreased in Long-Term Bilateral Lung Transplant Recipients:***
M. J. Weidmann¹, B. E. Kleibrink¹, T. Rabis¹, G. Weinreich¹, M. Kamler², H. Teschler¹, U. Sommerwerck¹. ¹Department of Pneumology, Ruhrlandklinik, West German Lung Center, University Hospital Essen, University Duisburg-Essen, Essen, Germany, ²Department of Thoracic and Cardiovascular Surgery, West German Heart Center, University Hospital Essen, University Duisburg-Essen, Essen, Germany.
- (501) *Atrial Arrhythmias Following Lung Transplantation: Incidence and Risk Factors in 658 Lung Transplant Recipients:***
J. D'Cunha¹, A. D'Angelo¹, J. A. Hyanga¹, D. Odell¹, J. Pilewski², M. M. Crespo², J. Bhama¹, N. Shigemura¹, T. Richards¹, J. D. Luketich¹, C. Bermudez¹. ¹Cardiothoracic Surgery, University of Pittsburgh, Pittsburgh, PA, ²Pulmonary Medicine, University of Pittsburgh, Pittsburgh, PA.
- (502) *Once-Daily Tacrolimus: A Valuable Option Post Lung Transplantation:***
B. Levvey¹, A. Cunningham², S. Ivulich², L. Mitchell¹, G. Westall¹, M. Paraskeva¹, H. Whitford¹, T. Williams¹, G. Snell¹. ¹Lung Transplant Service, The Alfred Hospital, Melbourne, Australia, ²Pharmacy Department, The Alfred Hospital, Melbourne, Australia.
- (503) *Lung Transplantation Using Allografts From Donation After Cardiac Death Donors:***
J. Costa¹, J. R. Sonett¹, G. Singh¹, M. Bacchetta¹, M. LaVelle¹, D. Lederer², L. Shah³, H. Robbins², K. Raza², S. Arcasoy², F. D'Ovidio¹. ¹Thoracic Surgery, Columbia University Medical Center, New York, NY, ²Pulmonary, Allergy, and Critical Care Medicine, Columbia University Medical Center, New York, NY, ³Pulmonary, Allergy and Critical Care Medicine, Columbia University Medical Center, New York, NY.
- (504) *HLA Mismatches Is an Independent Risk Factor for Worse Patient Survival among Lung Transplant Recipients in the United States:***
M. Askar¹, M. Chan², K. McCurry¹, M. Budev¹, J. Schold¹. ¹Transplant Center, Cleveland Clinic, Cleveland, OH, ²Immunohaematology & Cell Therapy Support Laboratories, Singapore Health Sciences Authority, Singapore, Singapore.
- (505) *Detection of Invasive Pulmonary Aspergillus in Lung Transplant Patients Using a Lateral Flow Device:***
K. Watson, C. Rennison, F. K. Gould, J. Samuel. Microbiology Department, Freeman Hospital, Newcastle upon Tyne NHS Foundation Trust, United Kingdom.
- (506) *The 'Blood Transfusion Effect' in Lung Transplantation – Striking Evidence for an Old Hypothesis in an Unlikely Setting:***
T. Siemeni¹, W. Sommer¹, I. Tudorache¹, C. Kühn¹, M. Avsar¹, F. Ius¹, J. Salman¹, M. Hallensleben², J. Gottlieb³, A. Haverich¹, G. Warnecke¹. ¹Department of Cardiothoracic, Transplant and Vascular Surgery, Hannover Medical School, Hannover, Germany, ²Department of Transfusion Medicine, Hannover Medical School, Hannover, Germany, ³Department of Respiratory Medicine, Hannover Medical School, Hannover, Germany.
- (507) *Predictors of Anxiety and Depression during the First 2 Months after Lung Transplantation:***
M. O. Alrawashdeh, A. DeVito Dabbs. School of Nursing, University of Pittsburgh, Pittsburgh, PA.

- (508) Sirolimus Improves Renal Function and May Prevent BOS Progression After Lung Transplant:**
 M. Mariski Jr¹, A. Feist², G. Yung³, L. Awdishu⁴. ¹Memorial Hermann Texas Medical Center, Houston, TX, ²UC San Diego Health System, San Diego, CA, ³UC San Diego Health System, San Diego, TX, ⁴Skaggs School of Pharmacy and Pharmaceutical Sciences, San Diego, CA.
- (509) Age-Related Decline in Lung Function in Patients Without CLAD After Double Lung Transplantation:**
 H. L. Schultz¹, C. B. Andersen², D. A. Steinbrüchel³, N. H. Bjarnason¹, M. Perch¹, J. Carlsen¹, M. Iversen¹. ¹Department of Cardiology, Section of Lung Transplantation, Rigshospitalet, Copenhagen, Denmark, ²of Pathology, Rigshospitalet, Copenhagen, Denmark, ³Department of Thoracic Surgery, Rigshospitalet, Copenhagen, Denmark.
- (510) Serum KL-6 Levels Are Associated With Long-Term Prognosis in Lung Transplant Recipients:**
 V. Besa¹, S. Ohshimo², G. Weinreich¹, F. Bonella³, U. Costabel³, M. Kamler⁴, H. Teschler¹, U. Sommerwerck¹. ¹Pneumology, Ruhrlandklinik, West German Lung Center, University Hospital Essen, University Duisburg-Essen, Essen, Germany, ²Emergency and Clinical Care Medicine, Graduate School of Biomedical Sciences, Hiroshima University, Hiroshima, Japan, ³Pneumology/Allergology, Ruhrlandklinik, West German Lung Center, University Hospital Essen, University Duisburg-Essen, Essen, Germany, ⁴Thoracic and Cardiovascular Surgery, University Hospital Essen, University Duisburg-Essen, Essen, Germany.
- (511) Evolving Experience of Treating Antibody-Mediated Rejection Following Lung Transplantation:**
 S. Otani¹, A. K. Davis², L. Cantwell³, S. Ivulich⁴, M. A. Paraskeva¹, G. I. Snell¹, G. P. Westall¹. ¹Lung Transplant Service, Allergy, Immunology and Respiratory Medicine, Alfred Hospital, Melbourne, Australia, ²Haematology, Alfred Hospital, Melbourne, Australia, ³National Transplant Services, Australian Red Cross Blood Services, Melbourne, Australia, ⁴Pharmacy, Alfred Hospital, Melbourne, Australia.
- (512) Long-Term Successful Outcomes From Kidney Transplantation Following Lung/Heart-Lung Transplantation:**
 S. Otani¹, B. J. Levvey¹, G. P. Westall¹, M. A. Paraskeva¹, H. M. Whitford¹, T. Williams¹, R. Walker², S. Menahem², G. I. Snell¹. ¹Lung Transplant Service, Allergy, Immunology and Respiratory Medicine, Alfred Hospital, Melbourne, Australia, ²Renal Medicine, Alfred Hospital, Melbourne, Australia.
- (513) Influence of Intraoperative Hemodynamic Factors on the Development of Acute Kidney Injury in Lung Transplantation:**
 R. Romano¹, I. Wong², L. Thakuria², F. De Robertis³, T. Bahrami³, M. Amrani³, S. Kaul³, D. Hall³, A. Reed³, M. Carby³, A. Simon³, N. Marczin¹. ¹Anaesthetics, Imperial College London, London, United Kingdom, ²Imperial College London, London, United Kingdom, ³Royal Brompton and Harefield NHS Foundation Trust, Harefield, United Kingdom.
- (514) Outcome After Transplantation of Lungs Evaluated With Ex-Vivo Lung Perfusion:**
 A. Wallinder¹, S. Ricksten², G. C. Riise³, T. Nilsson⁴, G. Dellgren³. ¹Dep. of Cardiothoracic surgery, Sahlgrenska University Hospital, Gothenburg, Sweden, ²Cardiothoracic Anesthesia and Intensive Care, Sahlgrenska University Hospital, Gothenburg, Sweden, ³Transplant Institute, Sahlgrenska University Hospital, Gothenburg, Sweden, ⁴Cardiothoracic Anaesthesia and Intensive Care, Sahlgrenska University Hospital, Gothenburg, Sweden.

(515) *Is Routine Screening for Community-Acquired Respiratory Virus Infections in Lung Transplant Recipients Worthwhile?:*

M. Greer¹, T. Fühner¹, I. Tudorache², G. Warnecke², A. Haverich², T. Welte¹, J. Gottlieb¹. ¹Respiratory Medicine, Hanover Medical School, Hannover, Germany, ²Cardiac, Thoracic, Transplantation and Vascular Surgery, Hanover Medical School, Hannover, Germany.

(516) *A Peritransplant Strategy in Lung Transplant Recipients with Preformed HLA Donor-Specific Antibodies (pDSA):*

F. Parquin, J. Devaquet, A. Si Larbi, E. Cuquemelle, A. Roux, C. Cerf, C. Picard. Lung Transplant Group, Hopital Foch, Suresnes, France.

MECHANICAL CIRCULATORY SUPPORT

(MCS, HF)

(517) *Impact of Preoperative Atrial Fibrillation on Outcomes Following Continuous Flow LVAD Implantation:*

D. Stern, M. Follis, J. Nguyen, R. Bello, D. D'Alessandro, D. Goldstein. Cardiovascular and Thoracic Surgery, Montefiore-Einstein Center for Heart and Vascular Care, Montefiore Medical Center, Albert Einstein College of Medicine, Bronx, NY.

(518) *The Clinical Impact of Atrial Fibrillation in Patients with the HeartMate II Left Ventricular Assist Device:*

A. D. Enriquez¹, C. Brandon², P. U. Gandhi², A. Nair², A. Anyanwu², S. P. Pinney². ¹Brigham and Women's Hospital, Boston, MA, ²Mount Sinai Medical Center, New York, NY.

(519) *Atrial Fibrillation in Patients Supported by Continuous-Flow Left Ventricular Assist Device:*

A. R. Garan¹, K. P. Mody¹, A. P. Levine¹, J. Fried¹, M. Dionizovik-Dimanovski¹, M. Yuzefpolskaya¹, P. C. Colombo¹, H. Takayama², Y. Naka², S. Restaino¹, D. M. Mancini¹, U. P. Jorde¹, N. Uriel¹. ¹Medicine, Columbia University, New York, NY, ²Surgery, Columbia University, New York, NY.

(520) *Decreased Renal Function Correlates With Severity of Aortic Regurgitation But Not LV EF or RV Function With LVAD Therapy:*

P. Sajgalik, K. Sahakyan, J. M. Stulak, R. C. Daly, S. Kushwaha, B. S. Edwards, L. D. Joyce, J. A. Schirger. Cardiovascular Diseases, Mayo Clinic, Rochester, MN.

(521) *The Impact of Aortic Valve Opening Status on Bleeding and Thrombotic Risk in Patients with CF-LVAD:*

A. P. Levin, J. Fried, K. P. Mody, M. Yuzefpolskaya, M. Dionizovik-Dimankovski, H. Takayama, P. C. Colombo, A. R. Garan, Y. Naka, N. Uriel, U. P. Jorde. Medicine, Columbia University, New York, NY.

(522) *Influence of Aortic Valve Opening in Patients With Aortic Insufficiency After LVAD Implantation:*

J. G. da Rocha e Silva, A. L. Meyer, S. Eifert, J. Garbade, F. W. Mohr, M. Strüber. Heart Center Leipzig, Leipzig, Germany.

(523) *Aortic Valve Pathology in Patients Supported by a Continuous-Flow Left Ventricular Assist Device:*

T. Saito¹, E. Potapov¹, K. Wassilew¹, B. Gorodetski², T. Krabatsch¹, R. Hetzer¹. ¹Cardiothoracic and Vascular Surgery, Deutsches Herzzentrum Berlin, Berlin, Germany, ²Deutsches Herzzentrum Berlin, Berlin, Germany.

- (524) Cardiac CT Parameters as Predictors of Aortic Insufficiency Post LVAD Implantation;**
 K. Kancherla¹, Z. Wang², D. Emerson³, W. G. Weigold², D. Abramov², G. Ruiz², J. M. Steiner⁴, M. Hofmeyer², D. T. Majure², F. H. Sheik², R. D. Bannerman², E. J. Molina⁵, S. W. Boyce⁵, S. S. Najjar², G. Weissman². ¹Medstar Health Research Institute, Washington, DC, ²Cardiology, Medstar Washington Hospital Center, Washington, DC, ³Department of Surgery, Medstar Georgetown University Hospital, Washington, DC, ⁴Medicine, Medstar Georgetown University Hospital, Washington, DC, ⁵Cardiothoracic Surgery, Medstar Washington Hospital Center, Washington, DC.
- (525) Efficacy and Durability of Central Oversewing for Treatment of Aortic Valve Insufficiency in Patients with Continuous Flow Left Ventricular Assist Devices;**
 M. A. Schechter¹, J. T. Joseph¹, J. Finet², A. Krishnamoorthy², A. M. Ganapathi¹, A. J. Lodge¹, C. B. Patel², C. A. Milano¹. ¹Department of Surgery, Duke University Medical Center, Durham, NC, ²Department of Medicine, Duke University Medical Center, Durham, NC.
- (526) Neurologic Complications After Implantation of Total Artificial Heart;**
 I. Tchoukina, M. T. Hassanein, V. Kasirajan, D. G. Tang, K. B. Shah. Virginia Commonwealth University, Richmond, VA.
- (527) Cerebrovascular Accidents and End of Life Admissions Contribute Most to the Cost in Patients With Continuous Flow Left Ventricular Assist Devices;**
 G. Ashrith, F. Kotun, A. M. Cordero-Reyes, A. Bhimaraj, B. H. Trachtenberg, M. Loebe, G. Torre-Amione, J. D. Estep. Cardiology, Houston Methodist Hospital, Houston, TX.
- (528) Effectiveness of Continuous Flow Left Ventricular Assist Device Exchange for Recurrence of Major Drive Line and Pump Pocket Infection;**
 M. F. Masood, M. Romano, J. W. Haft, R. Hasan, K. Aaronson, F. Pagan. Cardiac Surgery, University of Michigan, Ann Arbor, MI.
- (529) Increased BMI Is Associated with Left Ventricular Assist Device-related Infectious Complications;**
 D. S. Raymer¹, J. M. Vader¹, M. E. Nassif¹, C. T. Sparrow¹, S. J. LaRue¹, G. A. Ewald¹, A. Itoh², S. C. Silvestry¹. ¹Cardiovascular Division, Barnes-Jewish Hospital, St. Louis, MO, ²Division of Cardiothoracic Surgery, Barnes-Jewish Hospital, St. Louis, MO.
- (530) Driveline Infection After HeartMate II Is Associated with Lower Rates of Cardiac Transplantation and Longer Transplant Waiting Times in the Bridge to Transplant Population;**
 L. Harvey, C. Holley, R. John, P. Eckman, M. Colvin-Adams, K. Liao, R. Cogswell. University of Minnesota, Minneapolis, MN.
- (531) Utility of PET/CT Imaging for Identifying LVAD Infections;**
 G. Ramani¹, E. Feller¹, N. Hiivala², K. Rajagopal², E. Sorensen². ¹Medicine, University of Maryland, Baltimore, MD, ²Surgery, University of Maryland, Baltimore, MD.
- (532) Hospital Readmissions After Left Ventricular Assist Device Implantation Are Associated With Poor Outcomes: A Single Center Experience;**
 G. Ashrith, A. M. Cordero-Reyes, R. P. Vivo, C. M. Orrego, E. E. Suarez, B. Elias, M. Loebe, B. A. Bruckner, B. H. Trachtenberg, G. Torre-Amione, A. Bhimaraj, J. D. Estep. Cardiology, Houston Methodist Hospital, Houston, TX.
- (533) Reducing 30 Day Hospital Readmissions for Patients with Left Ventricular Support Devices;**
 R. C. Starling¹, T. J. Myers², R. R. Bostic², J. B. O'Connell², N. A. Mokadam³, C. T. Salerno⁴, R. L. Kormos⁵. ¹Cardiovascular Medicine,

Cleveland Clinic, Cleveland, OH, ²Thoratec Corporation, Pleasanton, CA, ³Cardiothoracic Surgery, University of Washington Medical Center, Seattle, WA, ⁴Heart Transplant and Mechanical Assist Device Program, St. Vincent Heart Center of Indiana, Indianapolis, IN, ⁵Cardiothoracic Surgery, University of Pittsburgh Schools of the Health Sciences, Pittsburgh, PA.

(534) Hospital Readmission with LVAD Destination Therapy;

S. Klottz, E. I. Charitos, U. Stierle, H. H. Sievers. Dept. of Cardiac and Thoracic Vascular Surgery, University Hospital Schleswig-Holstein, Campus Luebeck, Luebeck, Germany.

(535) Patterns of Readmission With Contemporary Continuous Flow Circulatory Support;

R. Hernandez¹, S. K. Singh², H. R. Mallidi², D. Hoang³, A. Syed¹, M. Elayda¹, O. Frazier¹, D. Meyers¹. ¹Texas Heart Institute, Houston, TX, ²Baylor College of Medicine; Texas Heart Institute, Houston, TX, ³Cornell University, New York, NY.

(536) Renal Impairment Post VAD Implantation in Patients With Normal Pre-operative Renal Function;

R. Lui¹, M. Harb¹, C. Anthony², D. Robson², J. Sevastos³, E. Granger², C. S. Hayward², A. Jabbour², P. M. Spratt², A. M. Keogh², E. Kotlyar², P. Macdonald², P. Janz², K. Dhital². ¹St Vincent's Hospital Clinical School, University of New South Wales, Sydney, Australia, ²Heart & Lung Transplant Unit, St. Vincent's Health Network, Sydney, Australia, ³Department of Renal Medicine, St. Vincent's Health Network, Sydney, Australia.

(537) The Impact of Baseline Renal Dysfunction on Patient Outcomes after Implantation of Chronic Mechanical Circulatory Support Devices;

C. Anthony¹, R. Lui², J. Sevastos³, K. Dhital¹, E. Granger¹, C. S. Hayward¹, A. Jabbour¹, P. C. Jansz¹, A. M. Keogh¹, E. Kotlyar¹, D. Robson¹, P. S. Macdonald¹, P. M. Spratt¹. ¹Heart & Lung Transplant Unit, St. Vincent's Health Network, Sydney, Australia, ²St Vincent's Hospital Clinical School, University of New South Wales, Sydney, Australia, ³Department of Renal Medicine, St. Vincent's Health Network, Sydney, Australia.

(538) Assessment of the LVAD Inflow Cannula Position by Cardiac CT;

K. Ghafourian¹, W. G. Weigold¹, S. M. Jani¹, D. Abramov¹, G. Ruiz¹, M. Hofmeyer¹, D. T. Majure¹, F. H. Sheikh¹, R. D. Bannerman¹, E. J. Molina², S. W. Boyce², S. S. Najjar¹, G. Weissman¹. ¹Cardiology, Medstar Washington Hospital Center, Washington, DC, ²Surgery, Medstar Washington Hospital Center, Washington, DC.

(539) Heartmate II Inflow Cannula Migration Does Not Predict Late-Term Complications;

K. A. Sell¹, B. Sheridan¹, A. C. Kiser¹, A. Bowen¹, J. N. Katz², W. E. Stansfield¹. ¹Surgery, University of North Carolina, Chapel Hill, NC, ²Medicine, University of North Carolina, Chapel Hill, NC.

(540) Outcomes of Minimally Invasive Approach for Exchange of the HeartMate II (HMII) Left Ventricular Assist Device (LVAD);

B. Soleimani, L. C. Price, E. R. Stephenson, A. El-Banayosy, W. E. Pae. Cardiothoracic Surgery, Penn State Hershey Medical Center, Hershey, PA.

(541) HeartMate II Pump Exchange in the Continuous Flow Pump Era Is Associated with Increased Mortality;

L. Harvey, R. Cogswell, C. Holley, R. John, P. Eckman, K. Liao. University of Minnesota, Minneapolis, MN.

(542) Preliminary Single-center Experience with Left Anterior Mini-thoracotomy for Continuous-flow LVAD Implantation;

M. E. Rodrigo, E. J. Molina, D. T. Majure, F. H. Sheikh, M. R.

Hofmeyer, G. Ruiz, S. S. Najjar, S. W. Boyce. Medstar Heart Institute – Washington Hospital Center, Washington, DC.

(543) Robotic Implantation of Left Ventricular Assist Devices: A New Era in Cardiac Surgery;

Z. Khalpey¹, I. Bin Riaz¹, J. Bilal¹, C. Hsu¹, M. Friedman², R. Smith³, K. Stavoe³, M. J. Slepian², R. Poston¹. ¹Cardiothoracic Surgery, University of Arizona Medical Center, Tucson, AZ, ²Cardiology, University of Arizona Medical Center, Tucson, AZ, ³Surgery, University of Arizona Medical Center, Tucson, AZ.

(544) Can Avoiding Sternotomy Reduce Early Complications of Left Ventricular Assist Device Surgery? Observations from Routine Implantation of Heartmate II Left Ventricular Assist Device without Median Sternotomy;

S. Itagaki¹, S. Pinney², A. C. Anyanwu¹. ¹Cardiothoracic Surgery, Mount Sinai Medical Center, New York, NY, ²Cardiology, Mount Sinai Medical Center, New York, NY.

(545) Surgical LVAD Placement Significantly Reduces Mitral Regurgitation Burden: A Single Center Study;

M. F. Jumean¹, D. Phan², A. R. Patel¹, M. S. Kiernan¹, N. K. Kapur¹, D. DeNofrio¹, K. G. Warner³, D. T. Pham³. ¹Cardiology, Tufts Medical Center, Boston, MA, ²Tufts University, Boston, MA, ³Cardiothoracic Surgery, Tufts Medical Center, Boston, MA.

(546) Influence of Mitral Regurgitation at Time of Implantation on Outcome in Patients With Ventricular Assist Devices;

A. M. Bernhardt¹, F. M. Wagner¹, K. Muellerleile², D. Biermann¹, H. Reichensperner¹, T. Deuse¹. ¹Department of Cardiovascular Surgery, University Heart Center Hamburg, Hamburg, Germany, ²Department of Cardiology, University Heart Center Hamburg, Hamburg, Germany.

(547) Mineralocorticoid Receptor Antagonists Enhance Cardiac Function during Continuous Flow Left Ventricular Assist Device Support;

O. Saeed¹, R. Jermyn¹, S. Gunda¹, S. Patel¹, J. Shin¹, D. D'Alessandro², D. J. Goldstein², R. Zolty¹. ¹Medicine, Montefiore Medical Center, Albert Einstein College of Medicine, Bronx, NY, ²Cardiothoracic and Vascular Surgery, Montefiore Medical Center, Albert Einstein College of Medicine, Bronx, NY.

(548) Global Myocardial Viability by Thallium-201 Redistribution Imaging Can Predict Successful Weaning from Short Term Mechanical Support;

M. Dionizovik-Dimanovski, K. P. Mody, A. P. Levin, A. R. Garan, M. Yuzefpolskaya, P. C. Colombo, H. Takayama, Y. Naka, U. P. Jorde, S. Bokhari, N. Uriel. Medicine, Columbia University, New York, NY.

(549) The Role of Ventricular Reconditioning in Weaning From Continuous-Flow Ventricular Assist Devices;

O. H. Frazier¹, Z. T. Demirozu¹, H. R. Mallidi¹, A. M. Segura¹, R. Hernandez¹, R. Radovancevic¹, H. Taegtmeier², W. E. Cohn¹. ¹Texas Heart Institute, Houston, TX, ²University of Texas Health Science Center School of Medicine, Houston, TX.

(550) Retrospective Analysis of HVAD® Pump Controller Log Data and Its Significance to Physiological Events;

M. C. Brown, J. Carrasquilla, A. Palacios, J. Garcia, N. Voskoboinikov. HeartWare, Inc, Miami Lakes, FL.

(551) Long-Term Mechanical Circulatory Support With EVAHEART Left Ventricular Assist Device;

T. Nishinaka, Y. Ichihara, M. Komagamine, Y. Yamada, K. Yamazaki. Cardiovascular Surgery, Tokyo Women's Medical University, Tokyo, Japan.

- (552) Efficacy and Safety of Paravertebral Block Analgesia Versus General Anaesthesia for Ventricular Assist Device Implantation: A Single-Centre Experience;**
J. Bejko, T. Bottio, G. Bortolussi, M. Carrozzini, V. Tarzia, D. Pittarello, G. Di Gregorio, G. Gerosa. Cardiac Surgery, Padova, Italy.
- (553) Preliminary Results from the C-Pulse® System European Multicenter Study;**
A. Schulz¹, H. Hotz¹, M. Reinartz¹, E. Potapov², M. Seidel³, L. Theres¹, L. Bruch³, J. Schmitto⁴, R. Hetzer², T. Krabatsch². ¹Cardio Centrum Berlin, Berlin, Germany, ²Deutsches Herzzentrum Berlin, Berlin, Germany, ³Unfallkrankenhaus Berlin, Berlin, Germany, ⁴Medizinische Hochschule Hannover, Hannover, Germany.
- (554) Fortuity or Causality: Relation Between Outflow Graft Site of Anastomosis on Aorta and Cerebral Ischemic Events in LVAD Implantation;**
J. Bejko, T. Bottio, G. Bortolussi, V. Tarzia, R. Bianco, G. Rizzoli, G. Gerosa. Cardiac Surgery, University of Padua, Padova, Italy.
- (555) Comparative Study of Left Ventricular Mechanics during Percutaneously-Delivered Circulatory Support in a Preclinical Model of Acute Left Heart Injury;**
V. Paruchuri, N. Shah, S. Dow, H. Salehi, N. Aghili, G. Daly, N. Pandian, R. Karas, D. Pham, N. K. Kapur. Cardiology, Tufts Medical Center, Boston, MA.
- (556) Change in Acoustic Fingerprints at Increased Pump Speed During Echocardiographic Ramp Test;**
P. Sundbom¹, H. Ahn¹, B. Kornhall², M. Loebe³, H. Granfeldt¹, B. Peterze'n¹, L. Hubbert¹. ¹The Heart Center at the University Hospital, Division of Cardiovascular Medicine, Departments of Medicine & Health, Faculty of Health Science, Linköping University, Linköping, Sweden, ²Heart Failure Clinic, Department of Cardiology, Skane University Hospital, Lund, Sweden, ³Division of Transplant and Assist Devices at Methodist DeBakey Heart & Vascular Center, Houston, TX.
- (557) In Vivo Testing of a New Permanent Atrial Connector for Cardiac Assist Devices;**
S. Klotz¹, M. Petersen¹, M. Grossherr², H. H. Sievers¹. ¹Dept. of Cardiac and Thoracic Vascular Surgery, University Hospital Schleswig-Holstein, Campus Luebeck, Luebeck, Germany, ²Dept. of Anesthesiology, University Hospital Schleswig-Holstein, Campus Luebeck, Luebeck, Germany.
- (558) Correlation of Hemodynamics and Function Capacity in 2nd and 3rd Generation LVADs;**
A. Ross¹, M. J. Sheridan², C. Rosner³, C. W. May³. ¹George Washington University Medical Center, Washington, DC, ²INOVA Research Center, Falls Church, VA, ³Heart Failure/Transplant Program, INOVA Fairfax Hospital, Falls Church, VA.
- (559) Reduce Driveline Trauma through Stabilization and Exit Site Management: Results of the RESIST Study;**
M. Stahovich¹, S. Fox², W. Hallinan³, P. Blood⁴, L. Chen³, S. V. Pamboukian⁴, R. Chinn⁵, F. D. Pagani², K. S. Sundareswaran⁶, L. Blue⁷. ¹Mechanical Circulatory Support Department, Sharp Memorial Hospital, San Diego, CA, ²Center for Circulatory Support, University of Michigan Hospital and Health Systems, Ann Arbor, MI, ³University of Rochester Medical Center, Rochester, NY, ⁴University of Alabama at Birmingham, Birmingham, AL, ⁵Sharp Memorial Hospital, San Diego, CA, ⁶Research and Scientific Affairs, Thoratec Corporation, Pleasanton, CA, ⁷Duke University Medical Center, Durham, NC.
- (560) Prevalence of Vitamin D Deficiency Among LVAD Patients;**
D. Knappe¹, M. von Stumm¹, F. Deuschl¹, S. Voss¹, A. Bernhardt¹, B. Silf², F. Wagner¹, T. Deuse¹, S. Blankenberg¹, H. Reichenspurner¹, K. Müllerleile¹. ¹University Heart Center Hamburg, Hamburg, Germany. ²University Heart Center, Hamburg, Germany.

- (561) Durable Improved Diabetic Control Up to 24 Months After Implantation of Left Ventricular Assist Device:**
 J. D. Davis, J. Vader, D. Raymer, J. Schilling, S. M. Joseph, A. K. Ravichandran. Medicine, Washington University in Saint Louis, Saint Louis, MO.
- (562) Does VAD Placement Reduce Weight in Obese Severe Heart Failure Patients?:**
 J. Moriguchi, F. Arabia, J. Patel, M. Kittleston, Z. Yu, F. Liou, J. Yabuno, D. H. Chang, L. Czer, A. Hage, D. Ramzy, J. Kobashigawa. Cedars- Sinai Heart Institute, Los Angeles, CA.
- (563) Outcomes of Mechanical Circulatory Support in HIV Infected Patients from the INTERMACS Registry:**
 S. V. Pamboukian¹, J. W. Baddley¹, J. K. Kirklin¹, R. S. Cantor¹, D. C. Naftel¹, J. D. Miller¹, J. J. Teuteberg². ¹University of Alabama at Birmingham, Birmingham, AL, ²University of Pittsburgh, Pittsburgh, PA.
- (564) Effect of Pre-operative Albumin Level on Patient Outcomes after Implantation of Continuous Flow Left Ventricular Assist Device:**
 T. A. Timek¹, A. T. Davis², T. J. Boeve¹, P. Wilton¹, M. Dickinson¹, D. Langholz¹, A. Khaghani¹. ¹Meijer Heart and Vascular Institute, Grand Rapids, MI, ²Grand Rapids Education Partners, Grand Rapids, MI.
- (565) Mid and Late Outcomes Support Use of Contemporary Continuous Flow Left Ventricular Assist Devices in the Elderly:**
 S. K. Singh¹, R. Hernandez², J. Anand¹, A. C. Baldwin², E. Sandoval Martinez², W. E. Cohn², O. Frazier², H. R. Mallidi¹. ¹Surgery, Baylor College of Medicine, Houston, TX, ²Center for Cardiac Support, Texas Heart Institute, Houston, TX.
- (566) Use of Various Mechanical Circulatory Support Strategies in End Stage Amyloidosis - A Single Center Experience From an Amyloid Heart Transplant Center:**
 A. Bhimaraj, A. M. Cordero-Reyes, B. H. Trachtenberg, G. Ashrith, L. P. Loza, M. Loebe, E. E. Suarez, B. A. Bruckner, G. Torre-Amione, J. D. Estep. Cardiology, Houston Methodist Hospital, Houston, TX.
- (567) A Simplified Scoring System To Predict Post Operative Length of Stay in Mechanical Circulatory Support – A Multi-institutional Analysis:**
 S. Bansal¹, B. A. Whitson¹, S. Moffatt-Bruce¹, A. Joseph², C. Holley³, L. Harvey³, R. S. Higgins¹, R. John³, C. Sai-Sudhakar¹. ¹Surgery, Ohio State Medical Wexner Medical Center, Columbus, OH, ²College of Medicine, Ohio State Medical Wexner Medical Center, Columbus, OH, ³Surgery, Division of Cardiothoracic Surgery, University of Minnesota, Minneapolis, MN.
- (568) Severity of End Organ Damage as a Predictor of Outcomes after Implantation of Continuous Flow Left Ventricular Assist Devices (LVAD) as Bridge to Transplantation (BTT):**
 B. Soleimani, Z. C. Landis, E. R. Stephenson, A. El-Banayoso, W. E. Pae. Cardiothoracic Surgery, Penn State Hershey Medical Center, Hershey, PA.
- (569) Sarcopenia Is Associated with Increased Post Left Ventricular Assist Device Implantation Morbidity:**
 W. D. Xu¹, S. C. Silvestry², A. J. Bierhals³, A. Itoh², E. Novak⁴, S. M. Joseph⁴. ¹Department of Medicine, Washington University in Saint Louis, Saint Louis, MO, ²Division of Cardiothoracic Surgery, Washington University in Saint Louis, Saint Louis, MO, ³Division of Diagnostic Radiology, Washington University in Saint Louis, Saint Louis, MO, ⁴Cardiovascular Division, Washington University in Saint Louis, Saint Louis, MO.

- (570) *Frailty Is Common in Patients Undergoing Left Ventricular Assist Device Implantation Regardless of Age or Transplant Eligibility: Results from a Prospective Trial;***
S. M. Joseph¹, T. Keeney², J. Manghelli¹, S. C. Martinez¹, E. Novak¹, S. Prasad³, M. Rich¹, S. C. Silvestry³. ¹Internal Medicine, Washington University School of Medicine, St. Louis, MO, ²Physical Therapy, Barnes Jewish Hospital, St. Louis, MO, ³Cardiothoracic Surgery, Washington University School of Medicine, St. Louis, MO.
- (571) *Early Ambulation as a Predictor of Length of Stay and Discharge to Home Following LVAD Implantation;***
M. J. Shoemaker¹, J. McLeod², D. H. Karia², M. G. Dickinson², A. Gaskill¹, D. Sefton¹, K. Vandebunte¹, C. Gallagher¹, P. Wilton². ¹Department of Physical Therapy, Grand Valley State University, Grand Rapids, MI, ²Fred and Lena Meijer Heart Center, Spectrum Health, Grand Rapids, MI.
- (572) *Long-Term Outcome of Cardiac Transplant After Continuous-Flow Left Ventricular Assist Device Support;***
K. Takeda¹, H. Takayama¹, N. Uriel², P. C. Colombo², U. P. Jorde², M. Yuzefpolskaya², D. M. Mancini², Y. Naka¹. ¹Cardiothoracic Surgery, Columbia University, NY, NY, ²Cardiology, Columbia University, NY, NY.
- (573) *Recurrent LV Dilation After Initial Decompression with Continuous-flow Left Ventricular Assist Device (CFLVADS): Implications on Long Term Survival;***
T. Yingchoncharoen¹, S. Kumar¹, Z. B. Popovic¹, M. Mountis¹, R. C. Starling¹, S. Lee¹, N. Moazami². ¹Cardiovascular Medicine, Cleveland Clinic, Cleveland, OH, ²Cardiothoracic Surgery, Cleveland Clinic, Cleveland, OH.
- (574) *Epidemiology and Outcomes Associated With Anemia During Long-Term Continuous-Flow Left Ventricular Assist Device Support;***
D. L. Jennings¹, J. L. Wagner², C. W. Nemerovski², J. S. Kalus², J. A. Morgan³, D. E. Lanfear⁴. ¹Pharmacy Practice, Nova Southeastern University, Ft. Lauderdale, FL, ²Pharmacy Services, Henry Ford Hospital, Detroit, MI, ³Cardiac Surgery, Henry Ford Hospital, Detroit, MI, ⁴Cardiovascular Medicine, Henry Ford Hospital, Detroit, MI.
- (575) *A Time-Dependent Model of Survival for Adverse Events in Bridge To Transplant Patients;***
S. Bansal¹, K. R. Jackson², J. K. Bhamra¹, J. Teuterberg¹, M. Simon¹, C. Bermudez¹, M. Shullo¹, L. Huffman¹, J. W. Hayanga¹, K. L. Lockard¹, R. L. Kormos¹. ¹Heart and Vascular Institute, University of Pittsburgh, Pittsburgh, PA, ²College of Medicine, University of Pittsburgh, Pittsburgh, PA.
- (576) *Post-operative Hyperbilirubinemia in Predicting Morbidity and Mortality Associated with Continuous Left Ventricular Assist Implantation;***
S. Kumar¹, T. Yingchoncharoen¹, V. Cruz¹, R. Steffen¹, E. Soltesz², M. Mountis¹, S. Lee¹, R. C. Starling¹, N. Moazami². ¹Heart Failure & Transplantation, Cleveland Clinic Foundation, Cleveland, OH, ²Department of Thoracic And Cardiovascular Surgery, Cleveland Clinic Foundation, Cleveland, OH.
- (577) *Improvement in Left and Right Ventricular Function Measured by 3-D Echocardiography Following Centrifugal Continuous Flow Left Ventricular Assist Device Support;***
K. Muthiah¹, A. Bhat¹, D. Robson¹, F. Ali², A. Dong², P. Macdonald¹, J. McCrohon², C. S. Hayward¹. ¹Cardiac Failure and Transplant Unit, St. Vincent's Hospital, Sydney, Australia, ²Department of Cardiology, St. Vincent's Hospital, Sydney, Australia.

- (578) Safety, Feasibility and Time Requirement of Echocardiography Pump Speed Change Testing in Patients With Continuous-Flow Left Ventricular Assist Devices;**
 J. D. Estep¹, A. M. Cordero-Reyes¹, A. Soliman¹, R. P. Vivo², B. Elias¹, B. H. Trachtenberg¹, G. Ashrith¹, G. Torre-Amione¹, M. Loebe¹, A. Bhimaraj¹. ¹Cardiology, Houston Methodist Hospital, Houston, TX, ²Cardiology, UCLA, Los Angeles, CA.
- (579) Validation of the Echocardiographic RAMP Test to Diagnose Device Obstruction;**
 C. Holley, P. Eckman, R. John, H. Yarmohammedi, M. Colvin-Adams, C. Masri, T. Thennapin, S. Adatya. University of Minnesota, Minneapolis, MN.
- (580) End-organ Dysfunction as a Predictor of Outcomes after Implantation of Continuous Flow Left Ventricular Assist Devices (LVAD);**
 Z. C. Landis, D. A. Brill, E. R. Stephenson, A. El-Banayoso, B. Soleimani, W. E. Pae. Cardiothoracic Surgery, Penn State Hershey Medical Center, Hershey, PA.
- (581) Long-Term Outcomes of Left Ventricular Assist Device Therapy in Scandinavia;**
 L. H. Lund¹, M. Holme-Jung², F. Gustafsson², G. Dellgren³, A. Fiare⁴, K. Lemström⁵, L. Hubbert⁶, L. Hellgren-Johansson⁷, H. Eiskjaer⁸, B. Koul⁹, E. Gude⁴, J. Nilsson⁹. ¹Karolinska University, Stockholm, Sweden, ²Copenhagen University, Copenhagen, Denmark, ³Sahlgrenska Academy, Göteborg, Sweden, ⁴Oslo University, Oslo, Norway, ⁵Helsinki University, Helsinki, Finland, ⁶Linköping University, Linköping, Sweden, ⁷Uppsala University, Uppsala, Sweden, ⁸Århus University, Århus, Denmark, ⁹Lund University, Lund, Sweden.
- (582) Assessment of Blood Pressure Measurements in Patients with Continuous Flow Left Ventricular Assist Devices: Arterial Line vs. Doppler Opening Pressure vs. Double-Cuff Oscillatory Sphygmomanometer;**
 M. F. Masood, K. Knott, J. W. Haft, R. Hasan, M. Romano, K. Aaronson, F. D. Pagani. Cardiac Surgery, University of Michigan, Ann Arbor, MI.
- (583) Blood Pressure Profiles of Patients with Left Ventricular Assist Devices;**
 P. T. Campbell¹, S. Krim¹, S. Desai¹, S. Mandras¹, H. Patel¹, M. R. Mehra², H. Ventura¹. ¹John Ochsner Heart and Vascular Institute, Ochsner Clinic Foundation, New Orleans, LA, ²Cardiology, Brigham and Women's Hospital and Harvard Medical School, Boston, MA.
- (584) Gene Expression Profiling Test (GEP) Scores and Outcomes of Heart Transplant with Prior Mechanical Circulatory Support: Results from IMAGE and CARGO II;**
 N. Uriel¹, J. Teuteberg², S. Pinney³, M. Crespo-Leiro⁴, S. Hall⁵, A. Crumley⁶, M. Deng⁷, J. Vanhaecke⁸, J. Stypmann⁹, D. Hiller¹⁰, P. J. Arnold¹⁰, J. Yee¹⁰, C. Patel¹¹, R. Starling¹², D. Feldman¹³. ¹Medicine, Columbia University, New York, NY, ²Medicine, University of Pittsburgh, Pittsburgh, PA, ³Medicine, Mount Sinai, New York, NY, ⁴Medicine, Unidad de Insuficiencia Cardiaca Avanzada y Trasplante Cardiaco, Hospital Universitario A Coruña, La Coruña, Spain, ⁵Medicine, Baylor Heart Hospital, Dallas, TX, ⁶Medicine, Medical University of South Carolina, Charleston, SC, ⁷Medicine, UCLA Medical Center, Los Angeles, CA, ⁸Cardiovascular Sciences, University Hospitals Leuven, Leuven, Belgium, ⁹Cardiovascular Medicine, University Hospital Münster, Münster, Germany, ¹⁰XDX, Brisbane, CA, ¹¹Medicine, Duke University, Durham, NC, ¹²Cardiovascular Medicine, Cleveland Clinic, Cleveland, OH, ¹³Medicine, Abbott Northwestern Hospital, Minneapolis, MN.

- (585) *Transplanting Patients with VADs Using the Organ Care System Shows Significantly Improved Outcomes: A New Standard of Care?:***
D. García Sáez, B. Zych, P. Mohite, A. Sabashnikov, C. Bowles, R. Hards, M. Hedger, G. Edwards, F. de Robertis, T. Bahrami, M. Amrani, N. Banner, A. R. Simon. Harefield Hospital NHS Trust, Harefield, London, United Kingdom.
- (586) *Extended Bridge To Transplant: 4 Years Outcomes With 3rd Generation LVADs in an Era of Restricted Transplantation:***
T. A. Butt, F. Ozalp, N. Wrightson, N. Robinson Smith, A. Woods, G. Parry, M. Griselli, A. Hasan, S. Schueler, G. MacGowan. Institute of Cardiopulmonary transplantation, Newcastle upon Tyne Hospitals NHS Foundation Trust, Newcastle upon Tyne, United Kingdom.
- (587) *Two-year Survival After Continuous-flow Left Ventricular Assist Device Versus Heart Transplantation: An Italian Single Centre Perspective:***
E. Ammirati, F. Oliva, T. Colombo, C. F. Russo, M. Cipriani, A. Garascia, L. Botta, A. Verde, A. Cannata, R. Paino, L. Martinelli, M. Frigerio. Cardiovascular and Thoracic, AO Ospedale Niguarda Ca' Granda, Milan, Italy.
- (588) *Depression Does Not Affect Outcomes in Patients with Left Ventricular Assist Devices:***
D. S. Raymer, M. E. Nassif, J. M. Vader, E. Novak, G. A. Ewald, S. J. LaRue. Cardiovascular Division, Barnes-Jewish Hospital, St. Louis, MO.
- (589) *Psychosocial Assessment of Candidates for Transplantation Score and Readmissions in HeartMate II Bridge to Transplant Left Ventricular Assist Device Patients:***
S. Schettle, A. Luckhardt, J. Schirger, B. Boilson. Cardiovascular Surgery, Mayo Clinic Rochester, Rochester, MN.
- (590) *Successful LVAD Therapy in Patients Ineligible for Heart Transplantation Due to Psychosocial Considerations:***
N. Rajagopalan, T. A. Tribble, D. R. Dennis, R. Yanagida, C. W. Hoopes. University of Kentucky, Lexington, KY.
- (591) *Clinical Outcomes of Multidisciplinary Team Management in Patients Supported With Left Ventricular Assist Devices:***
M. Pinninti¹, N. Z. Sulemanjee², J. A. Cook¹, C. Cho², O. M. Cheema², T. Hastings², D. L. Zwicke², J. Crouch³, F. X. Downey³, V. Thohan². ¹Aurora St. Luke's Medical Center, Milwaukee, WI, ²Aurora Cardiovascular Services, Aurora Sinai/Aurora St. Luke's Medical Centers, University of Wisconsin School of Medicine and Public Health, Milwaukee, WI, ³Aurora Medical Group-Cardiovascular and Thoracic Surgery, Aurora St. Luke's Medical Center, Milwaukee, WI.
- (592) *Daily Activity in Rotary Blood Pump Recipients:***
F. Moscato, T. Schlöglhofer, H. Ober, J. Riebandt, D. Zimpfer, H. Schima, M. Granegger. Medical University of Vienna, Vienna, Austria.
- (593) *The Necessity of the Caregiver in LVAD Therapy: Time for Introspection and Change?:***
E. H. Lee¹, J. X. Wang¹, P. Bonde². ¹Bonde Artificial Heart Lab, Yale University School of Medicine, New Haven, CT, ²Yale University School of Medicine, New Haven, CT.
- (594) *Emergency Care for Patients with Continuous Flow Left Ventricular Assist Devices:***
K. B. Shah¹, L. F. Cei¹, S. P. Pinney², M. A. Peberdy¹. ¹Virginia Commonwealth University, Richmond, VA, ²Mount Sinai Hospital, New York, NY.

NURSING, ALLIED HEALTH, SOCIAL SCIENCE

(NNSAH)

(595) A New Outpatient Surveillance Program Improves Home Based Care in Long Term LVAD Recipients;

A. Woods, S. Schueler, G. A. MacGowan, N. Wrightson, N. Robinson-Smith. Cardiothoracic, Newcastle upon Tyne NHS Foundations Trust, Newcastle upon Tyne, United Kingdom.

(596) Dried Blood Spot Monitoring After Lung Transplantation: Patients Perspectives;

M. J. Wessels-Bakker¹, E. M. van Maarseveen², M. E. Janssen¹, H. D. Luijk¹, E. A. van de Graaf¹, A. C. Egas², J. M. Kwakkel-van Erp¹. ¹Department of Respiratory Medicine, University Medical Center Utrecht, Utrecht, Netherlands, ²Department of Clinical Pharmacy, University Medical Center Utrecht, Utrecht, Netherlands.

(597) A Descriptive Study Examining Post Lung Transplantation: Patient Employment Status, Restricting Factors for Work, and Support Requirements;

K. Scott, A. Reed. Cardiothoracic Transplantation, Royal Brompton and Harefield NHS Foundation Trust, Harefield, United Kingdom.

(598) The New Normal: A Bourdieusian Examination of Living Into Young Adulthood Being a Paediatric Heart Transplant Recipient;

O. Mauthner¹, J. Angus², D. Gastaldo², H. Ross³. ¹University of Toronto, Toronto, ON, Canada, ²Lawrence S. Bloomberg Faculty of Nursing, University of Toronto, Toronto, ON, Canada, ³Heart Failure and Transplantation, University Health Network, Toronto, ON, Canada.

(599) Running with a VAD;

L. M. Fuller¹, J. M. Van Weel², R. Stornebrink³, A. T. Burge¹, K. Hayes¹, A. Fuller⁴, P. Bergin³. ¹Physiotherapy, The Alfred Hospital, Melbourne, Australia, ²Physiotherapy, Monash University, Melbourne, Australia, ³Heart Transplant Services, The Alfred Hospital, Melbourne, Australia, ⁴Infectious Diseases, The Alfred Hospital, Melbourne, Australia.

(600) Getting Ready and Then Keeping Quiet? Exploring Grief With Pre and Post-Transplant Patients;

J. M. Poole¹, J. Ward², E. De Luca³, M. Shildrick⁴, S. Abbey⁵, O. Mauthner⁶, M. Gewarges⁷, H. J. Ross⁸. ¹School of Social Work, Ryerson University, Toronto, ON, Canada, ²School of Social Work, Laurier University, Waterloo, ON, Canada, ³Department of Cardiology and Transplantation, University Health Network, Toronto, ON, Canada, ⁴The Department of Thematic Studies – Gender Studies, Linköping University, Linköping, Sweden, ⁵Department of Psychiatry, University Health Network, University of Toronto, Toronto, ON, Canada, ⁶Department of Cardiology and Transplantation, University Health Network, Toronto, ON, Canada, ⁷Faculty of Medicine, University of Toronto, Toronto, ON, Canada, ⁸Department of Cardiology and Transplantation, University Health Network, University of Toronto, Toronto, ON, Canada.

(601) Improving the Heart Transplant Decision Making Process: 10-year Experience Using the Heart Transplant Candidate Selection Form;

Q. Young, A. Kaan. Heart Centre, St. Paul's Hospital, Vancouver, BC, Canada.

PEDIATRIC TRANSPLANTATION

(PEDS, LTX, HTX)

- (602) *Non-Adherence Is Associated With Mortality in Adolescent Lung Transplant Recipients;***
M. Paraskeva¹, E. Paul², S. Ivulich³, B. Levvey¹, R. Martin¹, G. Snell¹, G. Westall¹. ¹Lung Transplant Service, Alfred Hospital, Melbourne, Australia, ²Department of Epidemiology and Preventive Medicine, Monash University, Melbourne, Australia, ³Department of Pharmacy, Alfred Hospital, Melbourne, Australia.
- (603) *Outcome of Pediatric Heart Transplantation Has Continued to Improve Over the Last Three Decades: Impact of Mechanical Circulatory Support;***
I. Adachi, F. Guzman-Pruneda, J. S. Heinle, E. D. McKenzie, C. M. Mery, Y. Orr, A. Jeewa, A. G. Cabrera, J. F. Price, S. W. Denfield, W. J. Dreyer, C. D. Fraser Jr. Baylor College of Medicine, Houston, TX.
- (604) *Technique for Pediatric En Bloc Lung Transplantation with Bronchial Artery Revascularization;***
Y. Orr, C. M. Mery, I. Adachi, J. S. Heinle, E. D. McKenzie. Baylor College of Medicine, Houston, TX.
- (605) *Pediatric Lung Transplant Patients with Cystic Fibrosis Need High Voriconazole Dosing to Achieve Therapeutic Drug Levels;***
E. Melicoff¹, M. C. Gazzano¹, S. Kim², M. M. Messinger³, G. B. Mallory¹. ¹Pediatrics, Baylor College of Medicine, Houston, TX, ²Solid Organ Transplant Services, Texas Children's Hospital, Houston, TX, ³Neurology, Texas Children's Hospital, Houston, TX.
- (606) *Reliability of Echocardiographic Measurements of Left Ventricular Function in Potential Pediatric Heart Transplant Donors;***
S. Chen¹, E. Selamet Tierney¹, K. K. Khush², J. Nguyen³, B. Goldstein⁴, L. J. May¹, D. Rosenthal¹. ¹Pediatric Cardiology, Stanford University, Palo Alto, CA, ²Cardiovascular Medicine, Stanford University, Palo Alto, CA, ³California Transplant Donor Network, Oakland, CA, ⁴Medicine, Stanford University, Palo Alto, CA.
- (607) *The Impact of Concomitant Left Ventricular Non-Compaction (LVNC) with Congenital Heart Disease (CHD) on Peri-Operative Outcome;***
P. Ramachandran, H. C. Heydarian, C. Castleberry, I. Wilmot, T. D. Ryan, T. O. Thomas, J. G. Woo, J. L. Jefferies, J. Towbin, A. Lorts. Pediatric Cardiology, Cincinnati Childrens Hospital and Medical Center, Cincinnati, OH.
- (608) *Cumulative Exposure to Medical Sources of Ionizing Radiation in the First Year After Pediatric Heart Transplantation;***
A. McDonnell¹, T. E. Downing¹, X. Zhu², R. Ryan¹, J. Rossano¹, A. C. Glatz¹. ¹Division of Cardiology, Children's Hospital of Philadelphia, Philadelphia, PA, ²Department of Radiology, Children's Hospital of Philadelphia, Philadelphia, PA.
- (609) *CDC "High Risk" Donor Status and Patient Outcome in Pediatric Heart Transplantation;***
R. Sahulee¹, J. J. Savla², I. D. Lytrivi¹, J. W. Rossano². ¹Pediatrics, Icahn School of Medicine at Mount Sinai, New York, NY, ²Pediatrics, The Children's Hospital of Philadelphia, Philadelphia, PA.
- (610) *The Effect of Medication Regimens on Cardiac Allograft Vasculopathy in Pediatric Heart Transplant Recipients;***
B. S. Moffett¹, B. J. Hong², S. W. Denfield², T. J. Humlicek¹, D. M. Orosco¹, A. G. Cabrera², L. Dejesus¹, K. Castrillon¹, J. F. Price², W. J. Dreyer², A. Jeewa². ¹Texas Children's Hospital, Houston, TX, ²Baylor College of Medicine, Houston, TX.

- (611) Influence of MELD (Model of End-Stage Liver Disease) *XI* (eXcluding INR) on Pediatric Post-Heart Transplant (HT) Outcomes;**

E. C. DePasquale, L. Reardon, A. Nsair, M. Deng, J. Alejos.
UCLA, Los Angeles, CA.

**QUALITY OF LIFE, ETHICS POLICY
AND THE ECONOMICS OF THORACIC
TRANSPLANTATION AND MCS**

(PEEQ)

- (612) Impact of Mechanical Support on Quality of Life Measures Over Time – Is There a Differential Response Based Upon Indication?;**

J. J. Teuteberg¹, M. McNulty², J. Holtz¹, N. Kunz¹, K. Lockard¹, E. Dunn¹, C. Bermudez¹, J. K. Bhama¹, M. A. Shullo³, R. Kormos¹, M. Dew². ¹Heart and Vascular Institute, University of Pittsburgh, Pittsburgh, PA, ²Department of Psychiatry, University of Pittsburgh, Pittsburgh, PA, ³Pharmacy and Therapeutics, University of Pittsburgh, Pittsburgh, PA.

- (613) Challenges to Lung Recovery from Sudden Death Victims to Assess Suitability for Transplant, and Strategies to Address These Challenges;**

T. Egan¹, E. Burkner², J. J. Requard III³, P. Noone⁴, G. Murray³. ¹Surgery, University of North Carolina School of Medicine, Chapel Hill, NC, ²Allied Health, University of North Carolina School of Medicine, Chapel Hill, NC, ³Lung Banks of America, Chapel Hill, NC, ⁴Medicine, University of North Carolina School of Medicine, Chapel Hill, NC.

- (614) The Growing Impact of Lung Transplant (LTX) on Survival for Patients with Cystic Fibrosis (CF);**

P. Stewart¹, J. Yankaskas², T. M. Egan³. ¹Biostatistics, Gillings Global School of Public Health University of North Carolina, Chapel Hill, NC, ²Medicine, University of North Carolina School of Medicine, Chapel Hill, NC, ³Surgery, University of North Carolina School of Medicine, Chapel Hill, NC.

PULMONARY HYPERTENSION

(PH, PHARM)

- (615) Macrophages Infiltration Is Associated with Maladaptive Remodeling of the Right Ventricle in an Experimental Model of Pulmonary Hypertension;**

J. Guihaire¹, T. Deuse¹, E. Fadel², H. Reichenspurner¹, R. C. Robbins³, S. Schrepfer¹. ¹Transplant and Stem Cell Immunobiology Lab, University Heart Center Hamburg, Hamburg, Germany, ²Thoracic and Vascular Surgery and Heart-Lung Transplantation, Marie Lannelongue Hospital, University of Paris Sud, Le Plessis Robinson, France, ³Cardiothoracic Surgery, Stanford University, Palo Alto, CA.

- (616) Biomechanics of Right Ventricular Myocardial Remodeling in Response to Pressure Overload;**

M. A. Simon¹, M. Hill², H. C. Champion¹, M. S. Sacks². ¹Vascular Medicine Institute, University of Pittsburgh, Pittsburgh, PA, ²Bio-medical Engineering, The University of Texas at Austin, Austin, TX.

(617) Right Ventricular Dyssynchrony in Idiopathic Pulmonary Arterial Hypertension: Insights From Echocardiographic and Cardiac Magnetic Resonance Imaging;

R. Badagliacca¹, R. Poscia¹, B. Pezzuto¹, S. Papa¹, C. Gambardella¹, M. Francone², M. Mezzapesa¹, M. Nocioni¹, A. Nona¹, R. Rosati², S. Sciomer¹, F. Fedele¹, C. D. Vizza¹. ¹Dept. of Cardiovascular and Respiratory Science, Sapienza University of Rome, Rome, Italy, ²Dept. of Radiology, Sapienza University of Rome, Rome, Italy.

(618) Optical Coherence Tomography in Pulmonary Arteries: A Proof of Concept Study;

E. R. Fenstad, A. Behfar, A. Terzic, M. D. McGoon, G. C. Kane, R. P. Frantz. Cardiovascular Disease, Mayo Clinic, Rochester, MN.

(619) Clinical and Prognostic Significance of Heart Rate Variability in Pulmonary Hypertension;

O. Musayev¹, M. Kayikcioglu², S. Nalbantgil², N. Mogulkoc², O. Vuran², K. Musayev¹, H. Kultursay². ¹Central Clinic, Baku, Azerbaijan, ²Ege University Medical Faculty, Izmir, Turkey.

(620) The Impact of Anemia on Survival in Pulmonary Arterial Hypertension;

G. Raman¹, D. Lam², M. Park¹. ¹Medicine, University of Maryland, Baltimore, MD, ²United Therapeutics Corporation, Durham, NC.

(621) Beta-Blocker Therapy Is Not Associated with Adverse Outcomes in Pulmonary Arterial Hypertension;

T. Thenappan¹, C. Glassner², M. Gomberg-Maitland³. ¹Medicine-Cardiology, University of Minnesota, Edina, MN, ²Medicine-Cardiology, University of Chicago, Chicago, IL, ³Medicine-Cardiology, University of Cardiology, Chicago, IL.

(622) Right Ventriculo-Arterial Coupling in Patients With Pulmonary Arterial Hypertension Undergoing Rapid Dose Escalation of Treprostinil;

F. Rischard¹, H. Champion², R. Vanderpool², A. Waxman³, L. Hansen¹, I. Jenkins⁴. ¹Department of Pulmonary and Critical Care Medicine, University of Arizona, Tucson, AZ, ²Vascular Medicine Research Institute, University of Pittsburgh, Pittsburgh, PA, ³Pulmonary Vascular Disease Program, Brigham and Women's Hospital, Boston, MA, ⁴BIO⁵ Institute, University of Arizona, Tucson, AZ.

(623) Right Ventricular Function and Pulmonary Artery Compliance Improve with Phosphodiesterase type 5A (PDE5A) Inhibitor Therapy in Pulmonary Hypertension;

M. M. Patarroyo Aponte, M. R. Pritzker, K. Weir, A. Sharma, J. Rasmussen, T. Thenappan. Cardiology, University of Minnesota, Minneapolis, MN.

(624) Totally Implantable IV Treprostinil Therapy in Pulmonary Arterial Hypertension: Assessment of the Implantation Procedure;

T. McElderry¹, A. Waxman², M. Gomberg-Maitland³, M. Burke³, E. Ross⁴, M. Bersohn⁵, J. Tarver⁶, D. Zwicke⁷, J. Feldman⁸, M. Chakinala⁹, R. Frantz¹⁰, F. Torres¹¹, P. Li¹², M. Morris¹², L. Peterson¹³, R. Bourge¹. ¹Cardiology, University of Alabama Birmingham, Birmingham, AL, ²Cardiology, Brigham & Women's Hospital, Boston, MA, ³Cardiology, The University of Chicago Medical Center, Chicago, IL, ⁴Anesthesiology, Brigham & Women's Hospital, Boston, MA, ⁵Cardiology, VA Greater Los Angeles Healthcare System, Los Angeles, CA, ⁶Cardiology, Orlando Regional Medical Center Orlando Health, Orlando, FL, ⁷Cardiology, Aurora Cardiovascular Services, Milwaukee, WI, ⁸Cardiology, Arizona Pulmonary Specialists, Ltd., Phoenix, AZ, ⁹Cardiology, Washington University School of Medicine, Saint Louis, MO, ¹⁰Cardiology, Mayo Clinic, Rochester, MN, ¹¹Cardiology, The University of Texas (UT) Southwestern Medical Center, Dallas, TX, ¹²Medtronic, Mounds View, MN, ¹³United Therapeutics Corporation, Research Triangle Park, NC.

MODERATED POSTER SESSIONS

FRIDAY, APRIL 11, 2014

POSTER SESSION 2

NOTE: Poster presenters and moderators will be present during the evening poster viewing session from 5:30 PM – 6:30 PM.

MECHANICAL CIRCULATORY SUPPORT

(MCS, HF, BSTR)

(625) Venous-arterial Shunting Is Tolerated in a Canine Model of Partial Ventricular Assist:

R. Malekan¹, K. Qanud², M. Ochoa², A. Kanevsky¹, T. H. Hintze², S. L. Lansman¹. ¹Cardiothoracic Surgery, Westchester Medical Center, Valhalla, NY, ²Physiology, New York Medical College, Valhalla, NY.

(626) Unloading Characterization of the HeartWare HVAD® Pump in a Healthy and Acute Heart Failure Ovine Model:

K. Chorprenning¹, E. Tuzun², C. Reyes¹, K. Bonugli², S. Reyes-Hadsall¹, D. Tamez¹. ¹Advanced Product Development, HeartWare, Inc, Miami Lakes, FL, ²Texas A&M Institute for Preclinical Studies, College Station, TX.

(627) High Molecular Weight Serum Adiponectin Levels in Advanced Heart Failure Patients Before and After Continuous Flow Left Ventricular Assistance Device:

R. Denadai Benatti¹, S. Khan², D. Thomas², A. Zhang², D. O. Taylor¹, R. C. Starling¹, J. Schold³, M. Askar², W. Baldwin⁴. ¹Department of Cardiovascular Medicine, Cleveland Clinic, Cleveland, OH, ²Allogene Laboratories Transplant Center, Cleveland Clinic, Cleveland, OH, ³Department of Quantitative Health Sciences, Cleveland Clinic, Cleveland, OH, ⁴Immunology, Cleveland Clinic, Cleveland, OH.

(628) Circulating Levels of miR-15b and miR-133b in Patients during Chronic LVAD Unloading:

O. Galenko¹, A. G. Kfoury¹, C. Yen², C. H. Selzman², J. Stehlik², N. Diakos², O. Wever-Pinzon², B. B. Reid¹, H. Peterson¹, S. Knight¹, R. Alharethi¹, D. Budge¹, J. Nativi-Nicolau³, S. McKellar³, D. Y. Li², J. C. Carlquist¹, S. G. Drakos². ¹Intermountain Medical Center, Salt Lake City, UT, ²University of Utah, Salt Lake City, UT, ³UTAH Cardiac Transplant Program, Salt Lake City, UT.

(629) RNAseq Identifies Novel Potential Right Ventricular Biomarkers in Human Heart Failure:

T. Di Salvo¹, A. Hemnes¹, J. Januzzi², S. Maltais¹. ¹Vanderbilt, Nashville, TN, ²Massachusetts General Hospital, Boston, MA,

(630) Patient Risk Stratification by Early Identification of Systemic Inflammatory Response via T cell Immunophenotyping at Time of Mechanical Circulatory Support Device Implantation:

J. M. Schaenman¹, M. Cadeiras², Y. Korin³, G. Bondar², M. H. Kwon⁴, E. F. Reed⁵, M. Deng². ¹Division of Infectious Diseases, Department of Medicine, David Geffen School of Medicine at UCLA, Los Angeles, CA, ²Advanced Heart Failure Program, Division of Cardiology, Department of Medicine, David Geffen School of Medicine at UCLA, Los Angeles, CA, ³UCLA Immunogenetics Center, David Geffen School of Medicine at UCLA, Los Angeles, CA, ⁴Division of Cardiothoracic Surgery, Department of Surgery, David Geffen School of Medicine at UCLA, Los Angeles, CA, ⁵Department of Pathology and Laboratory Medicine, UCLA Immunogenetics Center, David Geffen School of Medicine at UCLA, Los Angeles, CA.

- (631) Does Postoperative Improvement in Brain Natriuretic Peptide Predict Readmission after Left Ventricular Assist Device?:**
N. A. Haglund, M. E. Davis, N. M. Tricarico, H. Nian, K. Schlendorf, S. Maltas, M. E. Keebler. Vanderbilt University Medical Center, Nashville, TN.
- (632) Cellular Ca²⁺ Handling in Cardiac Atrophy and Hypertrophy:**
A. P. Schwoerer¹, D. Biermann², P. Boknik³, A. El-Armouche⁴, T. Eschenhagen⁵, T. Volk⁶, H. Reichenspurner², H. Ehmke¹.
¹Department of Cellular and Integrative Physiology, University Medical Center Hamburg Eppendorf, Hamburg, Germany, ²Department of Cardiovascular Surgery, University Heart Center Hamburg, Hamburg, Germany, ³Department of Pharmacology and Toxicology, University of Muenster, Muenster, Germany, ⁴Department of Pharmacology, University Medical Center Goettingen, Goettingen, Germany, ⁵Institute of Experimental and Clinical Pharmacology and Toxicology, University Medical Center Hamburg Eppendorf, Hamburg, Germany, ⁶Institute of Cellular and Molecular Physiology, Friedrich-Alexander- University Erlangen-Nuremberg, Erlangen, Germany.
- (633) Differential Mitochondrial Gene Expression in Patients Undergoing MCSD Implantation:**
E. Chang, M. Cadeiras, C. Chan, G. Bondar, N. Wisniewski, M. Bakir, J. Chittoor, T. Khuu, M. Deng. Medicine/Cardiology, UCLA, Los Angeles, CA.
- (634) Stromal-Derived Factor-1 (SDF-1) Expression is Downregulated After Chronic Continuous Flow Left Ventricular Assist Device (CF-LVAD) Support:**
A. Godier-Furnemont¹, M. Yuzefpolskaya², A. P. Levin³, M. Dionizovik-Dimanovski², P. C. Colombo², H. Takayama⁴, N. Uriel², Y. Naka², G. Vunjak-Novakovic¹, U. P. Jorde². ¹Stem Cell Engineering, Columbia University, New York, NY, ²Medicine, Columbia University, New York, NY, ³Medicine, Columbia University, New York, NY, ⁴Surgery, Columbia University, New York, NY.
- (635) MicroRNA-1202 Is a Candidate Biomarker To Assist Selection of Patients for Therapy With a Left Ventricular Assist Device:**
A. C. Morley-Smith¹, A. Mills², S. Jacobs³, B. Meyns³, F. Rega³, A. R. Simon¹, J. R. Pepper¹, A. R. Lyon¹, T. Thum⁴. ¹Royal Brompton & Harefield NHS Foundation Trust & Imperial College London, London, United Kingdom, ²Imperial College London, London, United Kingdom, ³University Hospitals Leuven, Leuven, Belgium, ⁴Hannover Medical School, Hannover, Germany; and Imperial College London, London, United Kingdom.
- (636) B-Type Natriuretic Peptide Profiles in the Setting of Chronic Left Ventricular Assist Device Support:**
S. R. Krim¹, P. T. Campbell¹, M. R. Mehra², H. O. Ventura¹.
¹Cardiology, Ochsner Heart and Vascular Institute, New Orleans, LA, ²Cardiology, Brigham and Women's Hospital and Harvard Medical School, Boston, MA.
- (637) Regression of Cellular Hypertrophy Leads to Functional Recovery Following Implantation with Centrifugal Continuous Flow Left Ventricular Assist Devices:**
K. Muthiah¹, D. Humphreys², D. Robson¹, P. Macdonald¹, K. Dhital³, P. Jansz³, C. S. Hayward¹. ¹Cardiac Failure and Transplant Unit, St. Vincent's Hospital, Sydney, Australia, ²Victor Chang Cardiac Research Institute, Sydney, Australia, ³Cardiothoracic Surgery and Transplant Unit, St. Vincent's Hospital, Sydney, Australia.

- (638) Myocardial Microvascular Density Increases After Chronic Continuous Flow Left Ventricular Assist Device (CF-LVAD) Support:**
M. Yuzefpolskaya¹, A. Godier-Furnemont², A. P. Levin¹, M. Dionizovik-Dimanovski¹, H. Takayama³, Y. Naka³, N. Uriel¹, P. C. Colombo¹, G. Vunjak-Novakovic¹, U. P. Jorde¹. ¹Medicine, Columbia University, New York, NY, ²Stem Cell Engineering, Columbia University, New York, NY, ³Surgery, Columbia University, New York, NY.
- (639) Effect of Continuous-Flow LVADs on Pulmonary Arterial Pressure: Comparison Between Axial and Centrifugal Flow Devices:**
M. F. Jumean¹, P. A. Quintero¹, A. R. Patel¹, D. DeNofrio¹, K. G. Warner², D. T. Pham², M. S. Kiernan¹. ¹Cardiology, Tufts Medical Center, Boston, MA, ²Cardiothoracic Surgery, Tufts Medical Center, Boston, MA.
- (640) Can Body Mass Index Identify Patients at Risk for Right Ventricular Failure after LVAD Placement?:**
J. K. Bhamra¹, M. A. Dew², J. J. Teuteberg¹, J. A. Hayanga¹, L. Huffman¹, S. Bansal¹, M. Simon¹, C. A. Bermudez¹, T. Richards¹, R. L. Kormos¹. ¹Heart & Vascular Institute, University of Pittsburgh Medical Center, Pittsburgh, PA, ²Departments of Psychiatry, Epidemiology, & Biostatistic, University of Pittsburgh Medical Center, Pittsburgh, PA.
- (641) Right Ventricular Assist Device Support After Continuous Flow Left Ventricular Assist Device Implantation: Predicting a Poor Predictor:**
S. K. Singh¹, R. Hernandez², J. Anand¹, A. Baldwin², E. Sandoval Martinez², W. E. Cohn², O. H. Frazier², H. R. Mallidi¹. ¹Surgery, Baylor College of Medicine, Houston, TX, ²Centre for Cardiac Support, Texas Heart Institute, Houston, TX.
- (642) Isolated RVAD Implantation - First Results from the EUROMACS Registry:**
A. M. Bernhardt¹, T. M. De By², H. Reichenspurner¹, T. Deuse¹. ¹Department of Cardiovascular Surgery, University Heart Center Hamburg, Hamburg, Germany, ²EUROMACS, Berlin, Germany.
- (643) Banding of Right Ventricular Assist Device (RVAD) of Outflow Conduit: Is It Really Necessary With Current Devices?:**
C. Lo¹, S. Gregory², M. Stevens³, D. Murphy⁴, S. Marasco¹. ¹Sir Charles James Officer Brown Department of Cardiothoracic Surgery, Alfred Hospital, Prahran, Victoria, Australia, ²Innovative Cardiovascular Engineering and Technology Laboratory, The Prince Charles Hospital, Brisbane, Queensland, Australia, ³Innovative Cardiovascular Engineering and Technology Laboratory, The Prince Charles Hospital, Brisbane, Queensland, Australia, ⁴Department of Intensive Care, Alfred Hospital, Prahran, Victoria, Australia.
- (644) RV Fractional Area Change at 6 Months But Not at Pre-Implant Is Associated with Late Indices of Functional Capacity and Renal Function: A Case for the Importance of Late RV Dysfunction in Long Term MCS:**
J. Rame¹, E. Y. Birati¹, V. Ramjee¹, E. Laverty-Wilson¹, T. Plappert¹, J. Donnelly¹, J. Wald¹, P. Atluri², Y. Woo², M. Acker², J. Kirkpatrick¹. ¹Cardiology, Hospital of the University of Pennsylvania, Philadelphia, PA, ²Hospital of the University of Pennsylvania, Philadelphia, PA.

- (645) Dilated Tricuspid Valve Annulus Vs. Tricuspid Regurgitation as a Predictor of Right Ventricular Failure After Left Ventricular Assist Device Implant;**
L. A. Goldraich¹, H. Kawajiri¹, F. Foroutan¹, P. Billia¹, J. Misurka², H. Ross¹, R. Cusimano¹, T. Yau¹, V. Rao¹. ¹Mechanical Circulatory Support Program, Peter Munk Cardiac Center, University of Toronto, Toronto, ON, Canada, ²Echocardiography Laboratory, Peter Munk Cardiac Center, University of Toronto, Toronto, ON, Canada.
- (646) Prevalence of Late Right Ventricular Dysfunction After Left Ventricular Assist Device Implantation;**
E. Roberts¹, N. Z. Sulemanjee¹, L. Lazarov², J. A. Cook², K. A. Schultz², C. Cho¹, O. M. Cheema¹, T. Hastings¹, D. L. Zwickel¹, J. Crouch³, F. X. Downey³, V. Thohan¹. ¹Aurora Cardiovascular Services, Aurora Sinai/Aurora St. Luke's Medical Centers, University of Wisconsin School of Medicine and Public Health, Milwaukee, WI, ²Aurora St. Luke's Medical Center, Milwaukee, WI, ³Aurora Medical Group-Cardiovascular and Thoracic Surgery, Aurora St. Luke's Medical Center, Milwaukee, WI.
- (647) Pulmonary Vasodilators Early and in High Dose Improve Outcomes and Reduce Right Ventricular Failure After Left Ventricular Device Implantation;**
C. H. Critoph, K. Lam, J. A. Baumwol, L. Dembo, A. Shah, H. Hayes, J. Barber, R. Larbalestier, S. Chih. Advanced Heart Failure and Cardiac Transplantation Service, Royal Perth Hospital, Perth, Australia.
- (648) Effect of Left Ventricular Assist Device on Ovine Tricuspid Annular 3D Geometry;**
M. Malinowski¹, P. Wilton², A. Khaghani², M. Brown², D. Karia², D. Langholz², V. Hooker², L. Eberhart², B. Hooker², T. Timek². ¹Department of Cardiac Surgery, Medical University of Silesia, Katowice, Poland, ²Meijer Heart and Vascular Institute at Spectrum Health, Grand Rapids, MI.
- (649) Impact of Preimplantation Tricuspid Regurgitation on Long Term Outcome in Patients Undergoing LVAD Implantation in the Era of Rotary Blood Pumps;**
A. Ghodsizad, M. M. Koerner, B. Soleimani, T. E. Stephenson, A. Haouzi, C. Brehm, W. E. Pae Jr., A. El-Banayosy. Penn State Hershey Medical Center & Heart and Vascular Institute, Hershey, PA.
- (650) Strong Correlation Between Alere Home INR and Core Lab INR in Patients Supported with CF-LVAD;**
M. Dionizovik-Dimanovski, A. P. Levin, K. P. Mody, E. Simonich, A. R. Garan, M. Yuzefpolskaya, H. Takayama, Y. Naka, P. C. Colombo, N. Uriel, U. P. Jorde. Medicine, Columbia University, New York, NY.
- (651) Improving Prothrombin Time International Normalized Ratio (INR) Control in Left Ventricular Assist Device (LVAD) Patients with Computerized Decision Support;**
J. L. Nixon, D. Budge, S. Stoker, W. Caine, R. A. Alharethi, H. Smith, B. Reid, G. Thomsen, S. Clayson, M. Goddard, J. Doty, A. G. Kfoury. Artificial Heart Program at Intermountain Medical Center, Salt Lake City, UT.
- (652) Tolerability and Biological Effects of Long Acting Ocreotide in Patients With Continuous Flow Left Ventricular Assist Devices;**
R. Malhotra¹, C. T. DeWilde¹, M. Smallfield², D. F. Brophy³, K. B. Shah². ¹Internal Medicine/Critical Care Medicine, VCU Health System, Richmond, VA, ²Internal Medicine/Cardiology, VCU Health System, Richmond, VA, ³Pharmacy, VCU Health System, Richmond, VA.

- (653) Early Identification of Impending LVAD Thrombosis Utilizing an Ultra-High Predictive Serum Marker in Lactate Dehydrogenase:**
 C. M. Zalewski, J. E. Cohen, C. E. Hill, S. L. Walsh, J. P. Donnelly, M. L. O'Hara, E. C. VanderMeer, J. L. Howard, E. Lavery-Wilson, P. Atluri, Y. J. Woo. Cardiac Surgery, Hospital of the University of Pennsylvania, Philadelphia, PA.
- (654) Markers of Lower Pump Flow Are Risk Factors for Pump Thrombosis with the Heartmate II Left Ventricular Assist Device:**
 A. Raina, R. Agarwal, C. Morgan, M. Kanwar, G. Sokos, E. Donalson, A. Hopwood, R. J. Moraca, S. H. Bailey, S. Murali, R. L. Benza. Cardiovascular Institute, Allegheny General Hospital, Pittsburgh, PA.
- (655) Continuous Flow Left Ventricular Assist Device Thrombosis: Presentation, Management and Outcomes:**
 D. Zhao, K. B. Shah, L. Wolfe, G. Katlaps, D. Tang, V. Kasirajan, S. Harton, M. Quader. Cardio-Thoracic Surgery, Virginia Commonwealth University, Richmond, VA.
- (656) Prediction of Hemostatic Dysfunction in Patients Implanted with the HeartMate II LVAD:**
 J. M. Walenga¹, E. Coglianesi², V. Escalante³, W. Jeske³, B. Duebner⁴, G. Pems⁴, E. Boyes⁴, J. Bailey⁵, A. Casillian³, E. Pedone⁵, A. Heroux⁴, J. P. Schwartz³, M. Bakhos³. ¹Thoracic-Cardiovascular Surgery, Loyola University Medical Center, Maywood, IL, ²Heart Failure/Heart Transplant, Loyola University Medical Center, Maywood, IL, ³Thoracic-CV Surgery, Loyola University Medical Center, Maywood, IL, ⁴Heart Failure/Heart Transplant Program, Loyola University Medical Center, Maywood, IL, ⁵Stritch School of Medicine, Loyola University Chicago, Maywood, IL.
- (657) Changes in Platelet Count After Heart Mate II Insertion Implications for Rationale Use of Anti Platelet Factor IV Antibodies:**
 P. Alvarez, M. Kassi, A. M. Cordero-Reyes, C. Uribe, P. De hoyos, A. Bhimaraj, B. H. Trachtenberg, G. Ashrith, G. Torre-Amione, L. Rice, J. D. Estep. Cardiology, Houston Methodist Hospital, Houston, TX.
- (658) Nasal Mucosal Changes during Continuous Flow (CF)- LVAD Support:**
 S. Gunda, R. Jermyn, D. Casazza, C. Nucci, J. Shin, P. Loftus, A. Jackman, D. Goldstein. Cardiology, Montefiore Medical Center, Bronx, NY.
- (659) Diagnostic Utility of Capsule Endoscopy in Evaluating GI Bleeding in LVAD Patients:**
 M. Mohammad Alahmad¹, B. Alkhalil¹, S. Sayfo¹, S. Spayd¹, M. Slaughter², E. Birks¹, A. Lenneman¹, K. Mccants¹. ¹Cardiovascular Medicine, University of Louisville, Louisville, KY, ²Cardiovascular Surgery, University of Louisville, Louisville, KY.
- (660) Use of ADP Receptor Inhibitor Prior to LVAD Implantation Does Not Increase Risk of Bleeding:**
 A. Tibrewala, M. Nassif, A. Andruska, J. Vader, E. Novak, J. Shuster, R. Jackups, S. J. LaRue, G. A. Ewald, A. Itoh. Washington University, St. Louis, MO.
- (661) Utility of Octreotide for Treatment of Recurrent Gastrointestinal Bleeding in Continuous-Flow Left Ventricular Assist Device Patients:**
 T. Hashim¹, R. Loyaga-Rendon¹, D. Acharya¹, J. A. Tallaj¹, J. K. Kirklin², W. L. Holman¹, S. V. Pamboukian¹. ¹Division of Cardiovascular Diseases, University of Alabama, Birmingham, AL, ²Division of Cardiothoracic Surgery, University of Alabama, Birmingham, AL.

(662) *Can the Severity of Post-operative Bleeding Events be Predicted from Von Willebrand Factor Dysfunction in Continuous Flow Left Ventricular Assist Device Recipients?*

N. M. Tricarico, M. E. Davis, M. E. Keebler, S. Maltais, N. A. Haglund, D. J. Lenihan. Vanderbilt University Medical Center, Nashville, TN.

(663) *Large Perioperative Red Blood Cell Transfusion Requirements Are Associated with Increased Long Term Mortality After LVAD Implantation:*

C. T. Holley¹, R. J. Cogswell², L. Harvey¹, P. Eckman², M. Colvin-Adams², K. Liao¹, R. John¹. ¹Surgery, University of Minnesota, Minneapolis, MN, ²Cardiology, University of Minnesota, Minneapolis, MN.

(664) *Consequences of Long-Term Anticoagulation and Antiplatelet Cessation in Patients on Bleeding Complications:*

M. Z. Tong¹, Y. A. He¹, V. Cruz¹, E. G. Soltesz¹, N. Smedira¹, S. Lee², N. Moazami¹, M. Mountis³. ¹Thoracic and Cardiovascular Surgery, Cleveland Clinic, Cleveland, OH, ²Cardiovascular Medicine, Cleveland Clinic, Cleveland, OH, ³Cardiovascular Medicine, Cleveland Clinic, Cleveland, OH.

(665) *Epistaxis in Patients with Left Ventricular Assist Devices – Incidence, Risk Factors, and Implications:*

P. Bhat, M. E. Nassif, J. M. Vader, C. T. Sparrow, E. Novak, G. A. Ewald, S. J. LaRue. Division of Cardiology, Department of Medicine, Washington University School of Medicine, St. Louis, MO.

(666) *The Impact of VA ECMO on LV Function:*

M. Dickstein¹, M. Bacchetta². ¹Anesthesiology, Columbia University, New York, N.Y., NY, ²Surgery, Columbia University, New York, N.Y., NY.

(667) *Extracorporeal Membrane Oxygenation (ECMO) Practices for Bridging to Lung Transplantation in North America: A Multi-Center Survey:*

R. Fadal¹, K. McCurry², M. Budev¹, J. J. Yun³. ¹Respiratory Institute, Cleveland Clinic Foundation, Cleveland, OH, ²Heart and Vascular Institute, Cleveland Clinic Foundation, Cleveland, OH, ³Cardiothoracic Surgery, Dartmouth-Hitchcock Medical Center, Lebanon, OH.

(668) *Survival Predictors in Ventricular Assist Device Patients with Prior Extra-Corporeal Life Support: Selecting Appropriate Candidates:*

B. Maxhera¹, A. Albert¹, E. Ansari¹, H. Kamiya¹, R. Westenfeld², U. Boeken¹, E. Godehardt¹, A. Iichtenberg¹, D. Saeed¹. ¹Cardiovascular Surgery, Düsseldorf University Hospital, Düsseldorf, Germany, ²Cardiology, Pneumology and Angiology, Düsseldorf University Hospital, Düsseldorf, Germany.

(669) *Mortality Differences Between Men and Women Following the Use of Extracorporeal Membrane Oxygenation (ECMO) after Myocardial Infarction:*

R. L. Zhang¹, T. J. Richards¹, J. K. Bhamra¹, P. L. Sappington², S. A. Esper³, J. J. Teuteberg⁴, R. Kormos¹, C. A. Bermudez¹. ¹Cardiothoracic Surgery, University of Pittsburgh Medical Center, Pittsburgh, PA, ²Critical Care Medicine, University of Pittsburgh Medical Center, Pittsburgh, PA, ³Anesthesiology, University of Pittsburgh Medical Center, Pittsburgh, PA, ⁴Cardiology, University of Pittsburgh Medical Center, Pittsburgh, PA.

(670) Peripheral Venous-Arterial ECMO as a Bridge To Heart Transplantation: Outcomes From a Single-Centre Experience;

V. N. Poptsov, E. A. Spirina, R. S. Saitgareev, V. M. Zakharevich, O. A. Eremeeva, S. A. Masyutin. Shumakov Centre Heart/Lung Transplant Team, Shumakov Federal Scientific Centre of Transplantology and Artificial Organs, Moscow, Russian Federat, Moscow, Russian Federation.

(671) Extracorporeal Membrane Oxygenator Bridge To Ventricular Assist Device Implantation for Patients in Profound Cardiogenic Shock Achieves Stabilization and Improved Results;

C. Lo¹, D. Murphy², S. Marasco¹. ¹Sir Charles James Officer Brown Department of Cardiothoracic Surgery, Alfred Hospital, Prahran, Victoria, Australia, ²Department of Intensive Care, Alfred Hospital, Prahran, Victoria, Australia.

(672) WITHDRAWN

(673) Extracorporeal Membrane Oxygenation Support in Refractory Cardiogenic Shock: Treatment Strategies and Analysis of Risk Factors;

A. Loforte¹, G. Marinelli¹, F. Musumeci², E. Pilato¹, S. Martin Suarez¹, A. Montalto², G. Folesani¹, S. Castrovinci¹, G. Iafrancesco¹, P. Lilla Della Monica², F. Grigioni¹, L. Potena¹, G. Frascaroli¹, G. Arpesella¹. ¹Cardiovascular Surgery and Transplantation, S. Orsola-Malpighi Hospital, Bologna University, Bologna, Italy, ²Cardiac Surgery and Transplantation, S. Camillo Hospital, Rome, Italy.

(674) Ambulatory Extracorporeal Membrane Oxygenation with Right Atrium to Pulmonary Artery Cannulation Through Hemisternotomy for Long-term Support;

T. H. Song, J. N. Baker, S. I. Melnitchouk, T. M. Sundt, J. P. Garcia. Cardiac Surgery, Massachusetts General Hospital, Boston, MA.

(675) Cardiac Arrest in the Era of Mechanical Circulatory Support: A Single Center Experience with Extracorporeal Cardiopulmonary Resuscitation;

L. Truby¹, T. Hongo¹, L. Mundy¹, A. Kirtane¹, J. Beck², E. Landes¹, M. Yuzefpolskaya¹, N. Uriel¹, P. C. Colombo¹, U. P. Jorde¹, S. Kodali¹, K. Takeda¹, Y. Naka¹, H. Takayama¹. ¹Columbia University College of Physicians and Surgeons, New York, NY, ²New York Presbyterian Hospital, New York, NY.

(676) Thoratec CentriMag® for Temporary Treatment of Refractory Cardiogenic Shock or Severe Cardiopulmonary Insufficiency in Adult and Pediatric Patients: A Systematic Literature Review and Meta-Analysis of Observational Studies;

R. K. Firmin¹, O. Borisenko², J. Payne³, J. Smith⁴, S. Bjessmo², N. Yonan⁵, G. Wyllie⁶. ¹Cardiothoracic Surgery/ECMO, Glenfield Hospital, Leicester, United Kingdom, ²Synergus AB, Danderyd, Sweden, ³Scottish National Advanced Heart Failure Service, Golden Jubilee National Hospital, Glasgow, United Kingdom, ⁴Paediatric and Neonatal ECMO Service, Freeman Hospital, Newcastle, United Kingdom, ⁵Department of Cardiothoracic Transplant, Wythenshawe Hospital, Manchester, United Kingdom, ⁶Yorkhill Children's Hospital, Glasgow, United Kingdom.

(677) Outcome of Extracorporeal Membrane Oxygenation as a Bridge to Lung Transplantation: Institutional Experience;

I. Inci¹, M. Schuurmans², S. Hillinger¹, P. Kestenholz¹, Y. Yamada¹, C. Benden², W. Weder¹. ¹Department of Thoracic Surgery, University Hospital, Zurich, Switzerland, ²Department of Pneumology, University Hospital, Zurich, Switzerland.

- (678) *Partial Flow with 15F Arterial Cannula Provides Sufficient Circulatory Support in Veno-Arterial Extracorporeal Membrane Oxygenation:***
E. L. Landes¹, L. Truby¹, L. Mundy¹, J. Yang¹, A. J. Kirtane², L. Mongero¹, M. Yuzefpolskaya², N. Uriel², P. C. Colombo², U. P. Jorde², K. Takeda¹, S. K. Kodali², Y. Naka¹, H. Takayama¹.
¹Department of Surgery, Columbia University Medical Center, New York, NY, ²Department of Medicine, Columbia University Medical Center, New York, NY.
- (679) *Extracorporeal Membrane Oxygenation as a Bridge to Decision for INTERMACS I Patients:***
J. Moriguchi, F. Arabia, R. Jocson, J. Patel, M. Kittleson, F. Liou, Z. Yu, W. Ernst, M. Hamilton, D. H. Chang, L. Czer, J. Kobashigawa.
Cedars-Sinai Heart Institute, Los Angeles, CA.
- (680) *The Impella Device Offers Superior Survival in Acute Cardiogenic Shock:***
A. Lemaire, L. Y. Lee, A. Ghaly, A. Spotnitz, G. Batsides. Surgery, Robert Wood Johnson University Hospital, New Brunswick, NJ.
- (681) *Early Progression of Pulmonary Edema Predicts Mortality in Patients With Extracorporeal Life Support – A Prospective Study:***
R. Westenfeld¹, D. Saeed², P. Horn¹, K. Esztermann¹, B. Stanske¹, T. Rassaf¹, M. Kelm¹, A. Lichtenberg², A. Albert². ¹Cardiology, Pneumology and Angiology, Düsseldorf University Hospital, Düsseldorf, Germany, ²Cardiovascular Surgery, Düsseldorf University Hospital, Düsseldorf, Germany.
- (682) *Incidence of Hemolysis in Patients With Cardiogenic Shock Treated With Impella Percutaneous Left Ventricular Assist Device:***
G. A. Hernandez, A. Badiye, S. V. Chaparro. Medicine, University of Miami, Miller School of Medicine, Miami, FL.
- (683) *Benefits of an Intra-aortic Cardiorenal Support Pump in Chronic Heart Failure:***
W. Clifton¹, J. Heuring¹, A. Nascimbene², B. Hertzog¹, R. Delgado².
¹Procyon, Houston, TX, ²Texas Heart Institute, Houston, TX.
- (684) *Optimization with Intra-aortic Balloon Counterpulsation Prior to Left Ventricular Assist Device Implantation Results in Improved Postoperative Outcomes:***
M. Gdowski¹, M. Sintek¹, K. Lavine¹, E. Novak¹, S. Nagabandi¹, S. Silvestry², S. Joseph¹. ¹Internal Medicine, Cardiovascular Division, Washington University School of Medicine, St. Louis, MO, ²Surgery, Division of Cardiothoracic Surgery, Washington University School of Medicine, St. Louis, MO.
- (685) *Intra-aortic Balloon Counterpulsation as a Bridge to Left Ventricular Assist Device Implantation in Patients with End-stage Heart Failure and Cardiogenic Shock:***
M. Gdowski¹, M. Sintek¹, K. Lavine¹, E. Novak¹, S. Nagabandi¹, S. Silvestry², S. Joseph¹. ¹Internal Medicine, Cardiovascular Division, Washington University School of Medicine, St. Louis, MO, ²Surgery, Division of Cardiothoracic Surgery, Washington University School of Medicine, St. Louis, MO.
- (264) *Development of a Repair for Traumatic Damage to the Heartware HVAD® Pump Driveline:***
J. D. Graham, N. Voskoboinikov, M. Brown, M. Wagner, S. Schaub, D. Tamez. Heartware Inc., Miami Lakes, FL.

JUNIOR FACULTY CLINICAL

CASE REPORTS

(ALL)

- (876) An Unexpected HeartMateII Driveline Complication:**
 A. K. Johnson, G. A. Wright, A. Rauf, S. Stoker, W. T. Caine, B. B. Reid, R. Alharethi, D. Budge, B. Y. Rasmusson, A. G. Kfoury. Mechanical Circulatory Support, Intermountain Medical Center, Murray, UT.
- (877) Successful Adult Cardiac Transplantation Across Positive Prospective CDC Crossmatch in Highly Sensitized Recipients:**
 A. Shah¹, C. Wood¹, S. J. Fidler², L. Dembo¹, J. Baumwol¹, K. Lam¹, S. Chih¹. ¹Advanced Heart Failure and Cardiac Transplant Unit, Royal Perth Hospital, Perth, Australia, ²Clinical Immunology, Royal Perth Hospital, Perth, Australia.
- (878) Successful Transplantation of Severely Marginal Criteria Lungs After Extended Clinical Normothermic Ex-Vivo Perfusion Performed on a Portable Device for a Duration of 10.5 Hours:**
 J. Nagendran¹, S. J. Bozso². ¹Division of Cardiac Surgery, University of Alberta, Mazankowski Alberta Heart Institute, Edmonton, AB, Canada, ²Faculty of Medicine and Dentistry, University of Alberta, Edmonton, AB, Canada.
- (879) Cardiac Replacement with Two Centrifugal Flow Ventricular Assist Devices:**
 M. A. Daneshmand¹, J. N. Schroder¹, L. J. Blue², C. B. Patel², J. G. Rogers², C. A. Milano¹. ¹Surgery, Duke University, Durham, NC, ²Medicine, Duke University, Durham, NC.
- (880) Cardiac Transplantation in Six Patients With Noonan-Spectrum Disorders: Indications and Outcomes:**
 K. C. Chatfield¹, D. A. Stevenson², M. D. Everitt², M. Pierpont³, R. K. Ameduri³, A. E. Lin⁴, S. D. Miyamoto¹. ¹Pediatrics, University of Colorado Denver, Aurora, CO, ²Pediatrics, University of Utah, Salt Lake City, UT, ³Pediatrics, University of Minnesota, Minneapolis, MN, ⁴Pediatrics, MassGeneral Hospital for Children, Boston, MA.
- (881) Constrictive Pericarditis as a Long Term Complication of Heart Transplantation:**
 A. Adzic, A. Jaiswal, D. A. Baran, M. J. Zucker, J. Pieretti, C. Gidea, R. Morlend, S. Murthy, M. T. Camacho. Transplant Center, Newark Beth Israel Medical Center, Newark, NJ.
- (882) Endovascular Repair of a Continuous Flow Left Ventricular Assist Device:**
 P. Dhesi¹, S. Siddiqi², D. Fusco², D. Wencker², J. Gluck¹, I. Sadiq¹. ¹Cardiology, University of Connecticut/Hartford Hospital, Hartford, CT, ²Cardiology, Hartford Hospital, Hartford, CT.
- (883) An Unusual Case of Isolated Pulmonary Goodpasture Syndrome Requiring 4 Months of Extracorporeal Membrane Oxygenation: Should Lung Transplantation Be Ultimately Considered?:**
 P. Mordant¹, G. Tachon², A. Legras¹, A. Bel³, V. Boussaud³, B. Cholley⁴, F. Le Pimpec-Barthes¹, A. Combes². ¹General Thoracic Surgery, Georges Pompidou European Hospital, Paris, France, ²Medical ICU, Pitié Salpêtrière Hospital, Paris, France, ³Cardiovascular Surgery, Georges Pompidou European Hospital, Paris, France, ⁴Anesthesiology and surgical ICU, Georges Pompidou European Hospital, Paris, France.

- (884) Stenting of Outflow Graft Obstruction Following Implantation of Axial-Flow, Left Ventricular Assist Device: A Case Report;**
D. T. Pham¹, C. Narsule¹, M. Dermody², M. S. Kiernan³, N. Halin⁴, N. K. Kapur³. ¹Cardiothoracic Surgery, Tufts Medical Center, Boston, MA, ²Vascular Surgery, Tufts Medical Center, Boston, MA, ³Cardiology, Tufts Medical Center, Boston, MA, ⁴Interventional Radiology, Tufts Medical Center, Boston, MA.
- (885) Extended Extra-aortic Counterpulsation Support with C-Pulse Device Does Not Alter Aortic Wall Structure;**
A. Cheng, J. R. Trivedi, E. Schumer, M. Ising, M. A. Sobieski, M. S. Slaughter. Thoracic and Cardiovascular Surgery, University of Louisville, Louisville, KY.
- (886) Resolution of Long-segment Aortic Stenosis Following Simultaneous Heart-Liver Transplant for Familial Hypercholesterolemia;**
R. M. Biniwale¹, P. Renella², B. L. Reemtsen¹, J. C. Alejos¹. ¹Cardiothoracic Surgery, University of California at Los Angeles, Los Angeles, CA, ²Pediatric Cardiology, Children's Hospital of Orange County, Orange, CA.
- (887) Deceitful Images: Churg Strauss Vasculitis Masquerading as Posterior Encephalopathy Syndrome;**
A. Jaiswal, D. A. Baran, A. Adzic, M. J. Zucker, M. T. Camacho, J. Pieretti, C. Gidea, R. Morlend, S. Murthy. Transplant Center, Newark Beth Israel Medical Center, Newark, NJ.
- (888) Severe Malnutrition in Cystic Fibrosis (CF): Successful Outcomes Can Be Achieved;**
S. G. Kapnadak, J. M. Pilewski, J. K. Bhama, C. A. Bermudez, N. Shigemura, C. J. Gries. Pulmonary, Allergy, and Critical Care Medicine, University of Pittsburgh Medical Center, Pittsburgh, PA.
- (889) Replacement of Biventricular Paracorporeal Devices With Bi-Ventricular HeartWare Ventricular Assist System: Case Report and Surgical Technique;**
D. T. Pham¹, C. Narsule¹, C. Vassallo¹, M. S. Kiernan², N. K. Kapur², D. DeNofrio², K. G. Warner¹. ¹Cardiothoracic Surgery, Tufts Medical Center, Boston, MA, ²Cardiology, Tufts Medical Center, Boston, MA.
- (890) Ventricular Assist Device Use in Single Ventricle Physiology;**
S. C. West¹, A. Lal¹, S. A. Miller¹, V. Morrell², P. Wearden², B. D. Feingold¹. ¹Cardiology, Children's Hospital of Pittsburgh, Pittsburgh, PA, ²Cardiothoracic Surgery, Children's Hospital of Pittsburgh, Pittsburgh, PA.
- (891) Cutaneous Legionella feeleii Infection in a Patient Following Heart Transplantation;**
K. Watson¹, A. Perry¹, S. Meggitt¹, K. Brennan¹, G. Parry¹, J. Samuel¹, S. Cattell², T. Butt³, F. K. Gould¹. ¹Freeman Hospital, Newcastle upon Tyne, United Kingdom, ²Microbiology, Freeman Hospital, Newcastle upon Tyne, United Kingdom, ³Cardiothoracic Surgery, Freeman Hospital, Newcastle upon Tyne, United Kingdom.
- (892) Utilization of Extended Criteria Lung on a Lobe-By-Lobe Basis Through Ex-Vivo Lung Perfusion Reassessment;**
K. Miyoshi, T. Oto, Y. Konishi, Y. Hirano, M. Okada, N. Iga, S. Hirayama, S. Sugimoto, M. Yamane, S. Miyoshi. Department of Thoracic Surgery/Organ Transplant Centre, Okayama University Hospital, Okayama, Japan.
- (893) Awake Extracorporeal Membrane Oxygenation as a Bridge to Lung Transplant in a Toddler. A Case Report;**
M. C. Gazzaneo, E. Portillo, G. Mallory, Y. Orr, J. Heinle, E. D. McKenzie, M. Nugent. Pediatric Lung Transplant, Baylor College of Medicine/Texas Children's Hospital, Houston, TX.

(894) HLA Desensitization with Bortezomib in a Highly-Sensitized Pediatric Patient;

L. J. May, K. Maeda, J. Yeh, B. D. Kaufman, D. Bernstein, D. N. Rosenthal, S. A. Hollander. Stanford University, Palo Alto, CA.

(895) Successful Heart Transplantation in a Pediatric Patient with Loeys-Dietz Syndrome;

A. Jeewa¹, W. J. Dreyer¹, I. Adachi², S. A. Morris¹, A. G. Cabrera¹, J. F. Price¹, J. S. Heinle², C. M. Gates³, S. Denfield¹, E. D. McKenzie². ¹Pediatric Cardiology, Baylor College of Medicine, Houston, TX, ²Congenital Heart Surgery, Baylor College of Medicine, Houston, TX, ³Texas Children's Hospital, Houston, TX.

(896) Successful Treatment of Burkholderia Cepacia Complex Chest Wall Infection Following Lung Transplantation With Using Hyperbaric Oxygen Therapy;

S. V. Golovinskiy¹, N. A. Karchevskaya², D. H. Tsurova¹, E. A. Tarabrin¹, M. V. Romasenko³, S. N. Avdeev², M. M. Abakumov¹, A. G. Chuchalin⁴, M. S. Hubutiy⁵. ¹Department of Thoraco-abdominal Surgery, Lung Transplantation Group, N.V. Sklifosovskiy Research Institute of Emergency Medicine, Moscow, Russian Federation, ²Department of Pulmonology, Lung Transplantation Group, Research Institute of Pulmonology FMBA of Russia, Moscow, Russian Federation, ³Department of Hyperbaric Oxygen Therapy, N.V. Sklifosovskiy Research Institute of Emergency Medicine, Moscow, Russian Federation, ⁴Research Institute of Pulmonology FMBA of Russia, Moscow, Russian Federation, ⁵N.V. Sklifosovskiy Research Institute of Emergency Medicine, Moscow, Russian Federation.

(897) Usefulness of ECMO Using Double Roller Pumps Instead of a Centrifugal Pump in a Low-Body Weight New-Born: A Novel Strategy of Mechanical Circulatory Support in a Infant;

K. Nakanishi¹, T. Kato¹, S. Kawasaki¹, Y. Wakamatsu², A. Amano¹. ¹Cardiovascular Surgery, Juntendo University School of Medicine, Tokyo, Japan, ²Clinical Engineering, Juntendo University School of Medicine, Tokyo, Japan.

(898) Remission of Kaposi's Sarcoma After Conversion From Calcineurin Inhibitor To Proliferation Signal Inhibitor in Cardiac Transplant;

J. Youn¹, H. Shin², S. Lee², H. Park², S. Kang¹. ¹Severance Cardiovascular Hospital, Yonsei University College of Medicine, Seoul, Korea, Republic of, ²Division of Cardiovascular Surgery, Severance Cardiovascular Hospital, Yonsei University College of Medicine, Seoul, Korea, Republic of.

(899) Bilateral Lung Transplantation From a Donor With Thermal Airway Injury;

R. Yanagida, H. Seethamraju, C. W. Hoopes. Division of Cardiothoracic Surgery, University of Kentucky, Lexington, KY,

(900) Use of Bortezomib To Treat Antibody Mediated Rejection in a Patient Requiring Mechanical Circulatory Support After Heart Transplantation;

J. J. Parent, T. Ryan, C. Castleberry, J. L. Jefferies, A. Lorts, C. Chin. Pediatric Cardiology, Cincinnati Childrens Hospital Medical Center, Cincinnati, OH.

(901) Peri-Operative Cast Prevention for Pediatric Patients With Plastic Bronchitis Undergoing Heart Transplantation;

J. J. Parent¹, R. K. Darragh², T. Ryan¹, A. Lorts¹, J. L. Jefferies¹, J. A. Towbin¹, C. Chin¹. ¹Pediatric Cardiology, Cincinnati Childrens Hospital Medical Center, Cincinnati, OH, ²Pediatric Cardiology, Indiana University School of Medicine, Indianapolis, IN.

- (902) Back Table Outflow Graft Anastomosis Technique for HeartWare HVAD Implantation:**
S. Basher¹, J. S. Bick², S. Maltais³. ¹Cardiology, Vanderbilt University Medical Center, Nashville, TN, ²Cardiothoracic Anesthesiology, Vanderbilt University Medical Center, Nashville, TN, ³Cardiovascular Surgery, Vanderbilt University Medical Center, Nashville, TN.
- (903) Intracardiac Echocardiographic and Intravascular Ultrasound Assessment of a Continuous Flow Left Ventricular Assist Device:**
P. Dhesi¹, N. Krishna², D. Ramu¹, R. Margey², I. Sadiq¹, J. Radojevic¹, D. Wencker², J. Gluck¹. ¹University of Connecticut/Hartford Hospital, Hartford, CT, ²Hartford Hospital, Hartford, CT.
- (904) A Life-Saving Staged ABO-Incompatible Renal Transplant in a Lung Transplant Recipient:**
M. Sharma¹, G. Westall¹, M. Paraskeva¹, H. Whitford¹, T. Williams¹, B. Levvey¹, R. Walker², S. Menahem², G. I. Snell¹. ¹Lung Transplant Service, Alfred Hospital and Monash University, Melbourne, Australia, ²Department of Renal Medicine, Alfred Hospital, Melbourne, Australia.
- (905) Treatment of Left Ventricular Assist Device Associated Arteriovenous Malformations with Thalidomide:**
R. Ray¹, P. P. Kale², R. V. Ha³, D. Banerjee¹. ¹Cardiovascular Medicine, Stanford University, Stanford, CA, ²Heart Transplant, Kaiser Permanente- Northern California, Santa Clara, CA, ³Cardiothoracic Surgery, Stanford University, Stanford, CA.
- (906) What a Headache: Tacrolimus-Induced Reversible Cerebral Vasoconstriction Syndrome in a Lung Transplant Recipient:**
E. M. Lowery. Internal Medicine, Loyola University Medical Center, Maywood, IL.
- (907) Successful Use of Catheter Directed Thrombolysis with Human Recombinant-Tissue Plasminogen Activator (hr-tPA) as Salvage for Acute Massive Pulmonary Embolism (PE) in a Patient 10 Days After Right Single Lung Transplantation: A Case Report:**
P. Ong¹, M. Nair¹, D. Guerra¹, L. Simpson², R. Sista¹. ¹Pulmonary and Critical Care Medicine, Baylor College of Medicine, Houston, TX, ²Advanced Heart Failure and Heart Transplantation, Texas Heart Institute, Houston, TX.
- (908) Successful Treatment of Acute LVAD Thrombosis and Cardiogenic Shock with Intraventricular Thrombolysis and a Tandem Heart:**
R. Agarwal, A. Raina, D. M. Lasorda, R. J. Moraca, S. H. Bailey, M. Kanwar, G. Sokos, S. Murali, R. L. Benza. Cardiovascular Institute, Allegheny General Hospital, Allegheny Health Network, Pittsburgh, PA.
- (909) Acromegalic Cardiomyopathy; Another Reversible Form of Heart Failure:**
S. You¹, J. Youn¹, H. Shin², S. Lee², H. Park², S. Kang¹. ¹Division of Cardiology, Severance Cardiovascular Hospital, Yonsei University College of Medicine, Seoul, Korea, Republic of, ²Division of Cardiovascular Surgery, Severance Cardiovascular Hospital, Yonsei University College of Medicine, Seoul, Korea, Republic of.
- (910) Application of Ex-Vivo Lung Perfusion to Offset Logistical Nightmares in Lung Transplantation:**
T. Krueger¹, M. Cypel², M. Chen², T. Machuca², V. Linacre², O. Mercier², T. Waddell², S. Keshavjee². ¹Division of Thoracic Surgery, University Hospital of Lausanne, Lausanne, Switzerland, ²Division of Thoracic Surgery, Toronto General Hospital, Toronto, ON, Canada.

- (911) Intravenous Thyroxine (T4) Is Associated With Improved Hemodynamic Recovery After Cardiac Transplantation;**
 T. P. Theruvath¹, T. P. Whelan², A. B. Van Bakel³, J. S. Ikonomidis¹, J. M. Toole¹. ¹Cardiothoracic Surgery, Medical University of South Carolina, Charleston, SC, ²Pulmonary and Critical Care Medicine, Medical University of South Carolina, Charleston, SC, ³Cardiology, Medical University of South Carolina, Charleston, SC.
- (912) Constrictive Pericarditis in a Lung Transplant Recipient;**
 F. Kamdar, M. I. Hertz, E. D. Missov. University of Minnesota, Minneapolis, MN.
- (913) Living-Donor Lobar Lung Transplantation for Primary Pulmonary Hypertension With Huge Pulmonary Arterial Dilatation;**
 Y. Yokoyama¹, F. Chen¹, K. Minakata², K. Yamazaki², T. Yamada¹, A. Aoyama¹, M. Sato¹, T. Bando¹, H. Date¹. ¹Thoracic Surgery, Kyoto University, Kyoto, Japan, ²Cardiovascular Surgery, Kyoto University, Kyoto, Japan.
- (914) Lung Transplant with Pulmonary Artery Reconstruction;**
 T. Watanabe¹, Y. Okada¹, M. Noda¹, T. Sado¹, Y. Hoshikawa¹, Y. Matsuda¹, H. Niikawa¹, Y. Saiki², T. Kondo¹. ¹Department of Thoracic Surgery, Institute of Development, Aging and Cancer, Tohoku University, Sendai, Japan, ²Department of Cardiovascular Surgery, Tohoku University Graduate School of Medicine, Sendai, Japan, Sendai, Japan.
- (915) Seizure Post Lung Transplantation;**
 L. Paoletti¹, H. Meadows², C. Denlinger³, T. Whelan¹. ¹Division of Pulmonary and Critical Care Medicine, Medical University of South Carolina, Charleston, SC, ²Pharmacy, Medical University of South Carolina, Charleston, SC, ³Division of Cardiothoracic Surgery, Medical University of South Carolina, Charleston, SC.
- (916) Atypical Presentations of Pulmonary Fibrosis in Saudi Arabia: Something in the Air?;**
 E. L. Bush¹, S. Tokman², B. Elicker³, K. D. Jones⁴, S. Hays², C. W. Hoopes⁵, G. A. Al-Dossari¹, M. Brzezinski⁶, J. A. Golden², J. Kukreja¹. ¹Division of Cardiothoracic Surgery, University California San Francisco, San Francisco, CA, ²Division of Pulmonary and Critical Care, University California San Francisco, San Francisco, CA, ³Department of Radiology, University California San Francisco, San Francisco, CA, ⁴Department of Pathology, University California San Francisco, San Francisco, CA, ⁵Division of Cardiothoracic Surgery, University of Kentucky, Lexington, KY, ⁶Department of Anesthesia, University California San Francisco, San Francisco, CA.
- (917) Persistent Left Superior Vena Cava and Coronary Sinus Ostial Atresia in a Donor Heart During Cardiac Transplantation;**
 N. I. Galindez, M. DiMaio, M. Peltz. Cardiothoracic Surgery, University of Texas Southwestern, Dallas, TX.
- (918) Combined LVAD Pump Exchange and Endovascular AAA Repair;**
 N. Goodale¹, J. Goerbig Campbell², R. Nicholson³, M. J. Bates⁴. ¹University of Iowa Hospitals and Clinics, Iowa City, IA, ²Heart and Vascular Center, University of Iowa Hospitals and Clinics, Iowa City, IA, ³Vascular Surgery, University of Iowa Hospitals and Clinics, Iowa City, IA, ⁴Cardiothoracic Surgery, University of Iowa Hospitals and Clinics, Iowa City, IA.
- (919) Fondaparinux as Anticoagulant in Paracorporeal Ventricular Assist Device: A Single Case in a 2 Years Child;**
 F. Gandolfo, G. Brancaccio, S. Filippelli, P. Cogo, A. Amodeo. Pediatric Cardiac Surgery, Bambino Gesù Children's Hospital, Rome, Italy.

- (920) Successful Heart Transplantation in Three Pediatric Patients with Early-Onset Anthracycline-Induced Heart Failure Following Treatment for Osteogenic Sarcoma;**
W. A. Zuckerman¹, M. E. Richmond¹, R. K. Singh¹, T. M. Lee¹, K. D. Beddows¹, L. A. Gilmore¹, K. L. Woldu¹, A. Lee², L. J. Addonizio¹. ¹Division of Pediatric Cardiology, Columbia University Medical Center, New York, NY, ²Division of Pediatric Oncology, Columbia University Medical Center, New York, NY.
- (921) Case Report of a Heart Graft Turned Down for Transplantation after Organ Care System Evaluation;**
D. García Sáez, P. N. Mohite, F. De Robertis, B. Zych, A. Sabashnikov, N. Patil, O. Maunz, G. Edwards, R. Hards, N. Banner, A. R. Simon. Harefield Hospital NHS Trust, Harefield, London, United Kingdom.
- (922) Atypical Hemolytic-Uremic Syndrome Immediately Following Heart Transplantation;**
E. Kransdorf¹, M. Kittleston¹, B. Coleman¹, D. Hoffman², S. Berkman³, D. Ramzy¹, D. E. Steidley⁴, J. Kobashigawa¹. ¹Cedars- Sinai Heart Institute, Los Angeles, CA, ²Tower Hematology Oncology Medical Group, Los Angeles, CA, ³Division of Hematology and Medical Oncology, UCLA Medical Center, Los Angeles, CA, ⁴Division of Cardiovascular Diseases, Mayo Clinic Arizona, Phoenix, AZ.
- (923) Recurrent Influenza Fulminant Myocarditis in a Pediatric Patient Requiring Mechanical Circulatory Support and Eventual Heart Transplantation;**
J. S. Chiu¹, M. E. Richmond¹, W. A. Zuckerman¹, T. M. Lee¹, L. J. Addonizio¹, J. M. Chen², L. A. Gilmore¹, K. Beddows¹, R. K. Singh¹. ¹Division of Pediatric Cardiology, Columbia University Medical Center, New York, NY, ²Division of Pediatric Cardiothoracic Surgery, Seattle Children's Hospital, Seattle, WA.
- (924) Autoimmune Enteropathy and Hepatitis in Pediatric Heart Transplant Recipient;**
R. Butts¹, A. Quioros¹, M. Hudspeth¹, K. Twombly¹, A. Burnette², S. Self³, A. Savage¹. ¹Pediatrics, Medical University of South Carolina, Charleston, SC, ²Transplant Services, Medical University of South Carolina, Charleston, SC, ³Pathology and Laboratory Medicine, Medical University of South Carolina, Charleston, SC.
- (925) Contrast Enhanced Coronary Artery Imaging for Coronary Allograft Vasculopathy (CAV) Diagnosis;**
N. Dedieu¹, T. Hussain², M. Fenton¹, R. Botnar², G. Greil², M. Burch¹. ¹Paediatric Cardiology, Great Ormond Street Hospital, London, United Kingdom, ²Imaging Science, Kings' College London, London, United Kingdom.
- (926) Successful Management of Thrombosis of the Proximal Aorta Following Implantation with a Biventricular Assist Device;**
M. J. Russo, C. Gidea, R. Karanam, C. R. Saunders, D. Baran, M. J. Zucker, M. Camacho. Harvey and Georgina Weinstein National Heart and Lung Transplant Center, Newark, NJ.
- (927) WITHDRAWN**
- (928) Tardive Respiratory Dyskinesia Due to Metoclopramide in a Lung Transplant Recipient Treated Successfully with Olanzapine;**
S. Aryal. Internal Medicine, Duke University, Cary, NC.

- (929) Novel Treatment of Fulminant Mixed Antibody-Mediated and Cellular Rejection Following Heart and Kidney Transplant: A Case Report:**
 H. K. Siu¹, N. Jones¹, R. Gupta², A. Mustafa², P. J. Mather¹.
¹Cardiology, Thomas Jefferson University Hospital, Philadelphia, PA, ²Internal Medicine, Thomas Jefferson University Hospital, Philadelphia, PA.
- (930) The World's Longest Supported Heartware Ventricular Assist Device Patient: 6 Years and Counting on Minimal Anti-Coagulation:**
 C. H. Critoph, S. Chih, L. Dembo, K. Lam, A. Shah, J. Barber, H. Hayes, R. Larbalestier, J. A. Baumwol. Advanced Heart Failure and Cardiac Transplantation Service, Royal Perth Hospital, Perth, Australia.
- (931) Cardiac Allograft Dysfunction Induced By Right Ventricular Pacing and Reversed By Cardiac Resynchronization Therapy:**
 M. Y. Qattan, M. B. Ginwalla, C. A. Elamm, M. N. Osman, R. N. Goldstein, G. H. Oliveira. Advanced Heart Failure and Transplant Center, University Hospitals Case Medical Center, Case Western Reserve University, Cleveland, OH.
- (932) Successful Use of Bortezomib for Desensitization of a Pediatric Heart Transplant Candidate:**
 A. L. Burnette¹, R. J. Butts², O. Moussa³, S. Waslaske³, K. Twombly⁴, M. Kavarana⁵, A. J. Savage². ¹Heart Transplant, MUSC, Charleston, SC, ²Pediatric Cardiology, MUSC, Charleston, SC, ³Immunology, MUSC, Charleston, SC, ⁴Pediatric Nephrology, MUSC, Charleston, SC, ⁵Pediatric Cardiothoracic Surgery, MUSC, Charleston, SC.
- (933) Ventricular Assist Device as Destination Therapy in Failing Fontan:**
 B. P. Frischhertz, P. R. Ermis, W. J. Franklin, L. Simpson, D. R. Parekh. Pediatric Cardiology, Baylor College of Medicine, Houston, TX.
- (934) Toxic Pulmonary Hypertension:**
 E. R. Fenstad¹, B. L. Bick², R. P. Frantz¹. ¹Cardiovascular Diseases, Mayo Clinic, Rochester, MN, ²Internal Medicine, Mayo Clinic, Rochester, MN.
- (935) Normalization of Serum Abnormalities after Lung Transplantation for Multicentric Castleman's Disease:**
 Y. Morimura, F. Chen, T. Ando, T. Yamada, M. Sato, A. Aoyama, T. Bando, H. Date. Thoracic Surgery, Kyoto University, Kyoto, Japan.
- (936) Home Use of Nebulized Tissue Plasminogen Activator in Preventing Hospital Admissions for Plastic Bronchitis:**
 J. E. Ryan, D. A. Davis, M. A. McCulloch, W. S. Moore. Cardiac Center, Nemours/Alfred I duPont Hospital for Children, Wilmington, DE.
- (937) Transformation of Pulmonary Alveolar Proteinosis into Non-Specific Interstitial Pneumonia:**
 S. Mir¹, M. Lavender¹, T. Bowles¹, J. Wrobel¹, E. Gabbay¹, F. Lake², S. Lawrence¹, M. Musk¹. ¹Advanced Lung Disease & Lung Transplant Unit, Royal Perth Hospital, Perth, Australia, ²Respiratory Medicine, Sir Charles Gairdner Hospital, Perth, Australia.
- (938) Stent-in-Stent Insertion To Treat Recurrent Bronchial Re-Stenosis in Lung Transplanted Recipient:**
 V. Doan, I. Wellemans, B. Bondue, G. Vandermoten, B. Rondelet, C. Knoop, D. Leduc. Chest Department, Erasme University Hospital, Brussels, Belgium.

- (939) Heart Transplantation Combined With Pulmonary Vein Reconstruction in Malignant Cardiac Tumor Occurred in the Right Ventricular Outflow Tract Invaded the Pulmonary Vein;**
S. Jung¹, J. Kim². ¹Department of Thoracic and Cardiovascular Surgery, Asan Medical Center, Seoul, Korea, Republic of, ²Department of Cardiology, Asan Medical Center, Seoul, Korea, Republic of.
- (940) Atypical Presentation of CMV Infection in a Lung Transplant Patient;**
K. Patel¹, N. Arora¹, S. Sharma¹, A. K. Patel², K. Guevarra¹, P. Patel¹, C. Migliore¹. ¹Lung Transplant / Pulmonary / Critical Care, Newark Beth Israel Medical Center, Newark, NJ, ²Infectious Disease, Newark Beth Israel Medical Center, Newark, NJ.
- (941) Early Primary Graft Failure after a Pediatric Heart Transplant and Successful Rescue with Plasmapheresis, Immunoglobulins and Alemtuzumab;**
S. Raj¹, T. Bueno¹, A. Panos², E. Rosenkranz², P. Ruiz², S. M. Pham³, P. G. Rusconi¹. ¹Pediatric Cardiology, University of Miami Miller School of Medicine, Miami, FL, ²Surgery, University of Miami Miller School of Medicine, Miami, FL, ³Surgery, University of Maryland School of Medicine, Baltimore, MD.
- (942) Implanting a Left Ventricular Assist Device in a Visually Impaired Patient: A Case Study;**
M. E. Luetje. Heart Specialty Care and Transplant Center, Seton Medical Center – Austin, Austin, TX.
- (943) T-Cell Mediated Inflammation Resulting in Multifocal Inflammatory Bowel Disease in a Pediatric Heart Transplant Patient;**
K. Puri¹, K. Risma², S. Kocoshis³, C. Chin¹, T. Ryan¹, J. Jefferies¹, C. Castleberry¹. ¹Cardiology, Cincinnati Children's Hospital Medical Center, Cincinnati, OH, ²Allergy, Cincinnati Children's Hospital Medical Center, Cincinnati, OH, ³Gastroenterology, Hepatology and Nutrition, Cincinnati Children's Hospital Medical Center, Cincinnati, OH.
- (944) Inverted Takotsubo Cardiomyopathy as a Cause of Acute Graft Failure Following Cardiac Transplantation;**
M. Urban, J. Pirk, O. Szarszoi, I. Netuka. Cardiac Surgery, Institute for Clinical and Experimental Medicine, Prague, Czech Republic.
- (945) Successful Treatment of Postoperative Mediastinitis after Heart Transplantation by Negative Pressure Wound Therapy Followed by Omental Transposition: A Case Report;**
H. Sunami¹, O. Seguchi¹, M. Hieda¹, S. Nakajima¹, T. Watanabe¹, T. Sato¹, Y. Murata¹, M. Yanase¹, H. Hata², T. Fujita², J. Kobayashi², T. Nakatani¹. ¹Department of Transplantation, National Cerebral and Cardiovascular Center, Osaka, Japan, ²Department of Cardiovascular Surgery, National Cerebral and Cardiovascular Center, Osaka, Japan.
- (946) Refractory Gastrointestinal Bleeding: Is It Worth It To Make the Switch From Continuous Flow To Pulsatile Flow Assist Device?;**
R. Tandon¹, J. Goerbig-Campbell¹, K. Light McGroary². ¹University of Iowa, Iowa City, IA, ²Internal Medicine, University of Iowa, Iowa City, IA.
- (947) Challenges in Treating BK Virus-associated Hemorrhagic Cystitis;**
I. Timofte¹, B. Johnson², M. Morrell², J. Pilewski², J. Kim¹, A. Iacono¹, C. Bermudez³, J. Bhama³, J. D'Cunha³, N. Shigemura³, M. Crespo². ¹Pulmonary and Critical Care, UMMC, Baltimore, MD, ²Pulmonary and Critical Care, UPMC, Pittsburgh, PA, ³Surgery, UPMC, Pittsburgh, PA.

- (948) Management of LVAD-Related Aortic Insufficiency by Ramp-Based Invasive Hemodynamics and Transesophageal Echocardiography;**
 S. S. Thomas¹, R. T. Hahn¹, S. Kodali¹, O. Khalique¹, S. Murthy¹, P. C. Colombo¹, H. Takayama², N. Uriel¹, Y. Naka², U. P. Jorde¹.
¹Cardiology, Columbia University Medical Center, New York, NY, ²Cardiac Surgery, Columbia University Medical Center, New York, NY.
- (949) Mechanical Circulatory Support in an Adult with Transposition of the Great Arteries;**
 R. M. Biniwale, G. S. Derk, H. Laks. Cardiothoracic Surgery, University of California at Los Angeles, Los Angeles, CA.
- (950) Successful Ventricular Assist Device Implant after MitraClip®;**
 K. Lam¹, S. Chih¹, C. Merry¹, E. Yemen², J. Baumwol¹, C. Critoph¹, A. Shah¹. ¹Advanced Heart Failure and Cardiac Transplant Unit, Royal Perth Hospital, Perth, Australia, ²Cardiology, Sir Charles Gairdner Hospital, Perth, Australia.
- (951) Mitral Valve Replacement Following Orthotopic Heart Transplantation;**
 M. Awad, L. S. Czer, K. R. Rihbany, M. Sasevich, D. Ramzy. Cedars Sinai Heart Institute, Cedars Sinai Medical Center, Los Angeles, CA.
- (952) Heart Transplantation in the Setting of Heterotaxy, Interrupted IVC and Functional Single Ventricle;**
 M. Si. Cardiac Surgery, University of Michigan, Ann Arbor, MI.
- (953) Young Woman With Breast Cancer and Cardiotoxicity With Severe Heart Failure Treated With HeartmateII for Nearly Six Years Prior To Heart Transplant;**
 P. Sundbom¹, E. Hedayati², B. Peterzén³, H. Granfeldt³, H. Ahn³, L. Hubbert¹. ¹Clinical Department of Cardiology, Heart Centre, University Hospital, Linköping, Sweden, ²Institution of Medicine and Health, Linköping, Sweden, ³Institution of Oncology-Pathology, Karolinska Institutet and University Hospital, Stockholm, Sweden, ³Department of Cardiovascular Surgery and Anesthesia, Heart Centre, University Hospital of Linköping, Institution of Medicine and Health, Linköping, Sweden.
- (954) Desensitization Utilizing Bortezomib and Plasmapheresis on a Patient Supported Via the Syncardia Freedom® Driver;**
 C. R. Villa, I. Wilmot, C. Castleberry, T. D. Ryan, M. Del Corral, J. L. Jefferies, C. Chin, D. L. Morales, A. Lorts. Cincinnati Children's Hospital, Cincinnati, OH.
- (955) Double Kissing Crush Stenting for Unprotected Distal Left Main Bifurcation Lesion in a Patient with Cardiac Allograft Vasculopathy;**
 B. Skoric, D. Lovric, M. Cikes, J. Ljubas, Z. Baricevic, D. Milicic. Department of Cardiovascular Diseases, University of Zagreb School of Medicine, University Hospital, Zagreb, Croatia.
- (956) Abernethy Malformation: a Candidate for Consecutive Lung-Liver Transplantation as an Uncommon Cause of Pulmonary Hypertension;**
 E. Yekeler¹, I. O. Alici², A. Yazicioglu², O. Tufekcioglu³, B. Bostanci⁴, N. Karaoglanoglu². ¹Thoracic Surgery and Lung Transplantation Center, Turkish Yuksek Ihtisas Training and Research Hospital, Ankara, Turkey, ²Thoracic Surgery and Lung Transplantation Center, Turkish Yuksek Ihtisas Training and Resarch Hospital, Ankara, Turkey, ³Cardiology, Turkish Yuksek Ihtisas Training and Resarch Hospital, Ankara, Turkey, ⁴Gastroenterology Surgery and Liver Transplantation Center, Turkish Yuksek Ihtisas Training and Resarch Hospital, Ankara, Turkey.

- (957) *Posterior Reversible Encephalopathy Syndrome in Post-Transplant Lymphoproliferative Disorder;***
A. Jaiswal¹, D. A. Baran¹, M. J. Zucker¹, I. Sabnani², M. T. Camacho¹, A. Adzic¹, J. Pieretti¹, C. Gidea¹, R. Morlend¹, S. Murthy¹. ¹Transplant Center, Newark Beth Israel Medical Center, Newark, NJ, ²Hematology and Oncology Department, Newark Beth Israel Medical Center, Newark, NJ.
- (958) *Device Failures in a Patient Receiving Nebulized Epoprostenol;***
W. S. Moore, J. E. Ryan, D. A. Davis, M. A. McCulloch. Nemours Cardiac Center, A.I.duPont Hospital for Children, Wilmington, DE.
- (959) *A Case of Pulmonary Rhizopus Infection in a Lung Transplant Recipient Treated Successfully with Surgery and Antifungal Therapy;***
S. Aryal, L. D. Snyder. Internal Medicine, Duke University, Durham, NC.
- (960) *V-V ECMO as a Bridge to Contralateral Retransplantation due to Massive Pulmonary Embolism;***
I. Gosev, C. Phillip. Surgery, Brigham and Women's Hospital, Boston, MA.
- (961) WITHDRAWN**
- (962) *Successful Transapical Aortic Valve Replacement in a Patient With Previous Double Lung Transplant – A Good Alternative To Open Aortic Valve Replacement;***
L. Starzyk¹, E. Horlic², M. Osten², C. Feindel³, A. Van Rensburg¹. ¹Department of Anesthesia and Pain Medicine, University Health Network Toronto, Toronto, ON, Canada, ²Department of Interventional Cardiology of the Peter Munk Cardiac Center, University Health Network Toronto, Toronto, ON, Canada, ³Department of Cardiovascular Surgery at the Peter Munk Cardiac Center, University Health Network Toronto, Toronto, ON, Canada.
- (963) *Reversal of RCM Induced Severe PVR Elevation with MCS Independent of Pharmacotherapy;***
M. A. McCulloch, C. Pizarro, S. S. Gidding, S. M. Haldeman, R. R. Davies. Nemours Cardiac Center, Al duPont Hospital for Children, Wilmington, DE.
- (964) *130 Day-Biventricular Assist Device Support with CentriMag Implanted Emergently for HeartMate II Driveline Infection Related to Colon Injury, Followed by Successful Heart Transplant;***
A. Shiose, E. Hamad, R. Alvarez, T. S. Guy, Y. Toyoda. Temple University, Philadelphia, PA.
- (965) *Large Thrombus on the Left Coronary Cusp Causing Broad Myocardial Infarction in a Small-body-sized Patient with a Continuous-flow Ventricular Assist Device;***
S. Nakajima¹, O. Seguchi¹, Y. Murata¹, T. Fujita², H. Hata², M. Hieda¹, T. Watanabe¹, T. Sato¹, H. Sunami¹, M. Yanase¹, J. Kobayashi², T. Nakatani¹. ¹Department of Transplantation, National Cerebral and Cardiovascular Center, Osaka, Japan, ²Department of Adult Cardiac Surgery, National Cerebral and Cardiovascular Center, Osaka, Japan.
- (966) *Development of Bronchiolitis Obliterans Syndrome 23 Years Post Lung Transplantation;***
A. Hirji, L. G. Singer, C. Chaparro. Toronto Lung Transplant Program, University of Toronto, Toronto, ON, Canada.

- (967) Continuous Flow LVAD Support and Immune Suppression:**
 A. R. Garan, A. P. Levin, K. P. Mody, S. Rao, M. Dionizovik-Dimanovski, P. C. Colombo, M. Yuzefpolskaya, H. Takayama, Y. Naka, S. Restaino, D. Mancini, N. Uriel, U. P. Jorde. Medicine, Columbia University, New York, NY.
- (968) Total Artificial Heart Bridge to Transplantation for a Patient with Occult Intracardiac Malignancy:**
 H. Reich¹, M. Sasevich², K. Rihbany², F. Arabia², L. Czer². ¹Department of Surgery, Cedars-Sinai Medical Center, Los Angeles, CA, ²Heart Institute, Cedars-Sinai Medical Center, Los Angeles, CA.
- (969) Minimal Invasive Right Ventricular Assist Device Implantation in a Patient with HeartWare Left Ventricular Assist Device;**
 B. Maxhera, A. Albert, E. Ansari, A. Lichtenberg, D. Saeed. Cardiovascular Surgery, Düsseldorf University Hospital, Düsseldorf, Germany.
- (970) Offering Heart Transplantation to a Young Patient with HIV Infection:**
 A. Mehdiani, U. Boeken, C. Ballazs, P. Akhyari, J. Minol, D. Saeed, H. Kamiya, R. Westenfeld, A. Lichtenberg. Cardiovascular Surgery, University Hospital, Duesseldorf, Germany.
- (971) Persistent Ventricular Fibrillation, Recurrent GI Bleeding, and Ventricular Thrombi in a Patient with HeartWare Biventricular Assist Devices;**
 D. T. Majure, M. R. Hofmeyer, F. H. Sheikh, G. Ruiz, E. J. Molina, S. S. Najjar, S. W. Boyce. MedStar Heart Institute, MedStar Washington Hospital Center, Washington, DC.
- (972) Step-Wise Approach to Myocarditis Complicated by Cardiogenic Shock;**
 K. P. Mody¹, S. Thomas¹, M. Yuzefpolskaya¹, H. Takayama², P. C. Colombo¹, Y. Naka², U. P. Jorde¹, N. Uriel¹. ¹Medicine, Columbia University, New York, NY, ²Surgery, Columbia University, New York, NY.
- (973) Bilateral Sequential Lung Transplantation in Kartagener's Syndrome with Situs Inversus Totalis;**
 L. N. Blau, L. E. Rodriguez, E. E. Suarez, D. Ren, B. A. Bruckner, M. Loebe. Houston Methodist Hospital, Houston, TX.
- (974) Spontaneous Iliac Intramuscular Bleed Following Orthotopic Heart Transplantation;**
 J. Knisley, M. Weaver, B. Whitson, A. Hasan, R. Higgins, G. Haas, A. Kilic. Ohio State University, Columbus, OH.
- (975) Giant Cell Interstitial Pneumonitis; Recurrence of Disease in Transplanted Lungs;**
 J. K. Thachuthara-George¹, N. Sinha², S. Jyothula², B. Mankidy², B. Bruckner³, S. Scheinin³, M. Loebe³, H. Seethamraju², T. Kaleekal². ¹Pulmonary Critical Care and Sleep Medicine, Baylor College of Medicine, Houston, TX, ²Pulmonary Critical Care and Transplant Medicine, The Methodist Hospital, Houston, TX, ³Department of Cardiothoracic Surgery, The Methodist Hospital, Houston, TX.
- (976) BerlinHeart INCOR® LVAD as Bridge to Transplantation (BTT) for Patient with Noncompaction Cardiomyopathy (NCC);**
 D. R. Galantini, S. M. Ayub-Ferreira, M. S. Avila, B. Biselli, L. Hajjar, M. Sundin, F. B. Jatene, P. Pego-Fernandes, R. Kalil-Filho. Heart Transplantation, Sirio-Libanês Hospital, Sao Paulo, Brazil.

(977) Persistent Posterior Reversible Encephalopathy Syndrome in Lung Transplantation;

P. C. Camargo¹, F. E. Arimura¹, A. N. Costa¹, J. E. Afonso Jr¹, R. M. Carraro¹, S. V. Campos¹, M. N. Samano², R. H. Teixeira¹, P. M. Pego-Fernandes². ¹Pneumology, Heart Institute (InCor), Sao Paulo, Brazil, ²Thoracic Surgery, Heart Institute (InCor), Sao Paulo, Brazil.

(978) Outcome of Heart Transplantation for a Patient with Takayasu's Arteritis;

J. Huang¹, Z. N. Lu², Z. K. Liao², S. S. Hu¹. ¹Department of Heart Transplant Center, State Key Laboratory of Cardiovascular Disease, Fuwai Hospital, National Center for Cardiovascular Diseases, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, China, ²Department of Heart Transplant Center, Fuwai Hospital, National Center for Cardiovascular Diseases, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, China.

(979) A Case of Rapidly Progressive AMR Despite Low DSA After Treatment;

N. Afari-Armah¹, S. Geier², H. Parekh², E. Tsai¹, D. Schwartz¹, A. Bove¹, P. Forfia¹, Y. Toyoda³, A. Shiose³, R. Alvarez¹, E. Hamad¹. ¹Advanced Heart Failure, Temple University Hospital, Philadelphia, PA, ²Medical Pathology, Temple University Hospital, Philadelphia, PA, ³Cardiothoracic Surgery, Temple University Hospital, Philadelphia, PA.

(980) Case Report: Diagnosing Tamponade Physiology Following an Orthotropic Heart Transplant Using a Miniaturized TEE Probe;

S. Elapavaluru¹, P. Linden², J. Rossi³, S. Bailey⁴, R. Moraca⁴, W. McGregor⁵, H. Hastings PhD⁶, R. Benza⁷, S. Murali⁸. ¹Intensivist, Division of Cardiothoracic and Vascular Surgery, Department of Internal Medicine, Allegheny General Hospital, Pittsburgh, PA, ²Director, Surgical Intensive Care Unit, Dept of Internal Medicine, Allegheny General Hospital, Pittsburgh, PA, ³System Division Chief, Critical Care Medicine, Dept of Internal Medicine, Allegheny General Hospital, Pittsburgh, PA, ⁴Cardiothoracic and Vascular Surgery, Allegheny General Hospital, Pittsburgh, PA, ⁵Department of Cardiothoracic and Vascular Surgery, Allegheny General Hospital, Pittsburgh, PA, ⁶Dept of Physics, Hofstra University and Imacor, Hempsted/Garden City, NY, ⁷Professor of Medicine, Temple University, Director MCS, Pulmonary Hypertension, Allegheny General Hospital, Pittsburgh, PA, ⁸Chief of Cardiology, Professor of Medicine, Temple University, Medical Director, Cardiovascular Inst, Allegheny General Hospital, Pittsburgh, PA.

(981) Unexpected Encounter: Pump Outflow Graft Puncture in a Patient with HeartMate II Device's Outflow Graft Bend Relief Disconnection;

K. Chua, T. Tan, C. Lim, K. Kerk, C. Sivathasan. Cardiothoracic Surgery, National Heart Centre Singapore, Singapore, Singapore.

(982) Fulminant Myocarditis Rescued by V-A ECMO: The Importance of Echocardiographic Profiling!;

J. A. Hernandez-Montfort, J. Mallidi, G. Valania. Cardiology, Baystate Medical Center, Springfield, MA.

(983) Low Flow with an LVAD: Unusual Finding on Cardiac CT;

S. M. Jani, W. G. Weigold, K. Ghafourian, G. Ruiz, M. Hofmeyer, F. H. Sheikh, D. T. Majure, S. W. Boyce, S. S. Najjar. MedStar Heart Institute, MedStar Washington Hospital Center, Washington, DC.

- (984) Single Coronary Artery Diagnosed During Routine Echocardiography After Heart Transplant;**
 A. J. Thompson¹, P. W. O'Leary², J. N. Johnson³. ¹Pediatric and Adolescent Medicine, Mayo Clinic, Rochester, MN, ²Department of Pediatrics, Division of Pediatric Cardiology, Mayo Clinic, Rochester, MN, ³Department of Pediatrics, Division of Pediatric Cardiology, Mayo Clinic, Rochester, MN.
- (985) Fourth-Time Re-Transplant or LVAD Implantation in a Patient With Severe Coronary Artery Vasculopathy After Third-Time Heart Transplant;**
 K. Hisamoto¹, A. Shiose¹, E. Leotta¹, G. Wheatley¹, T. S. Guy¹, E. A. Hamad², R. J. Alvarez², Y. Toyoda¹. ¹Temple University Hospital, Philadelphia, PA, ²Cardiology, Temple University Hospital, Philadelphia, PA.
- (986) Real World Use of Ramp Studies to Diagnose Pump Thrombosis;**
 S. Emami¹, B. A. Whitson². ¹Division of Cardiology, The Ohio State University, Columbus, OH, ²Division of Cardiothoracic Surgery, The Ohio State University, Columbus, OH.
- (987) Pulmonary Artery Aneurysm in Porto-Pulmonary Hypertension;**
 T. Bowles, S. Mir, C. Jary, M. Musk, E. Gabbay, M. Lavender, J. Wrobel. Advanced Lung Disease Unit, Royal Perth Hospital, Perth, Australia.
- (988) A Case of Successful Treatment for Axial Flow Device-Associated Repeated Pump Thrombosis by Conversion to Fully Magnetic Levitation Centrifugal Device;**
 T. Saito, K. Toda, S. Miyagawa, H. Nishi, Y. Yoshikawa, S. Fukushima, D. Yoshioka, M. Kawamura, M. Ishida, A. Yamamoto, Y. Sawa. Cardiovascular Surgery, Osaka University Graduate School of Medicine, Osaka, Japan.
- (989) Heart Transplantation in Patient With Partial Anomalous Pulmonary Venous Return From the Left Upper Lobe;**
 J. Kšela¹, I. Knežević¹, M. Jelenc¹, N. Danojevi¹, M. Rai¹, S. Frljak², G. Poglajen², B. Vrtovec². ¹Dept. of Cardiovascular Surgery, University Medical Center Ljubljana, Ljubljana, Slovenia, ²Advanced Heart Failure and Transplantation Programme, Dept. of Cardiology, University Medical Center Ljubljana, Ljubljana, Slovenia.
- (990) Repositioning of Avalon Elite Dual Lumen ECMO Cannula Using a Vascular Snare Device Via Femoral Route;**
 A. Nummi¹, K. Lappalainen², R. Suojaranta-Ylinen³, P. Hämmäinen¹. ¹Heart and Lung Center, Helsinki University Hospital, Helsinki, Finland, ²Radiology, Helsinki University Hospital, Helsinki, Finland, ³Anesthesiology, Helsinki University Hospital, Helsinki, Finland.
- (991) Two Cases of Advanced Heart Failure With Secondary Amenorrhea That Resumed After Long-Term Left Ventricular Assist Device Support;**
 E. Hisamatsu¹, O. Seguchi¹, S. Nakajima¹, T. Watanabe¹, M. Hieda², H. Sunami¹, T. Sato¹, Y. Murata¹, M. Yanase¹, H. Hata², T. Fujita², T. Nakatani¹. ¹Department of Transplantation, National Cerebral and Cardiovascular Center, Suita, Japan, ²Department of Adult Cardiac Surgery, National Cerebral and Cardiovascular Center, Suita, Japan.
- (992) Three Years of Support With the Circulite Partial Support System;**
 A. Cappelleri, A. Barbone, L. Ardino, L. Occhi, M. Mangiacavacchi, D. Ornaghi, M. Lettino, D. Pini. Istituto Clinico Humanitas, Milan, Italy.

- (993) Septic-metastasising *Aspergillus*-Encephalitis Mimicing Massive Cerebral Infarction after Heart Transplantation (HTX):**
C. Ballazs¹, U. Boeken¹, A. Mehdiani¹, J. Minol¹, P. Akhyari¹, H. Kamiya¹, D. Saeed¹, R. Westenfeld², A. Lichtenberg¹. ¹Cardiovascular Surgery, University Hospital, Duesseldorf, Germany, ²Cardiology, University Hospital, Duesseldorf, Germany.
- (994) Early Graft Failure in a Patient with History of Giant Cell Myocarditis:**
D. T. Majure, F. H. Sheikh, M. R. Hofmeyer, S. W. Boyce, S. S. Najjar. MedStar Heart Institute, MedStar Washington Hospital Center, Washington, DC.
- (995) Perflutren and Acute Pulmonary Edema in Stable Congestive Heart Failure; a Unique Occurrence;**
M. A. Chaudhry¹, J. T. Heywood². ¹Cardiology/Heart Failure, University of Southern California, Los Angeles, CA, ²Cardiology/Heart Failure, Scripps Green Hospital, La Jolla, CA.

MODERATED POSTER SESSIONS

SATURDAY, APRIL 12, 2014

POSTER SESSION 3

NOTE: Poster presenters and moderators will be present during the evening poster viewing session from 5:30 PM – 6:30 PM.

BASIC SCIENCE

(BSTR)

(686) Combination of mTOR Inhibitor and Calcineurin Inhibitor in EBV-positive and EBV-negative B-lymphocytes:

S. Schubert, S. Wowro, G. Tong, F. Berger, K. Schmitt. Dept. of Congenital Heart Disease/Pediatric Cardiology, German Heart Center Berlin, Berlin, Germany.

(687) The Alteration of MiR-326 and MiR-142-3p Expressions during Immune Activation Is Positively Correlated with Graft-protective Cytokine TGF-beta:

I. S. Dewi¹, O. Gidlöf¹, F. Ivars², J. Öhman¹. ¹Department of Cardiology, Lund University, Lund, Sweden, ²Department of Immunology, Lund University, Lund, Sweden.

(688) Distribution Pattern of Viable Resident C-Kit Positive Cardiac Stem Cells in the Human Ischemic Heart as a Pool for Cardiac Regeneration:

J. Garbade, M. Arsalan, S. Dhein, M. J. Barten, S. Lehmann, M. A. Borger, F. Mohr. Heart Surgery, Heart Center, University of Leipzig, Leipzig, Germany.

(689) Novel Use of a Nanoparticle Delivery System in an Ex-Vivo Model of Lung Transplantation:

J. C. Grimm¹, F. Zhang², C. A. Beaty, Jr¹, M. Mishra³, J. T. Magruder¹, R. M. Kannan⁴, A. Shah¹. ¹Surgery, The Johns Hopkins Medical Institution, Baltimore, MD, ²Material Sciences and Engineering, The Johns Hopkins Medical Institution, Baltimore, MD, ³Ophthalmology, The Johns Hopkins Medical Institution, Baltimore, MD, ⁴Nanomedicine, The Johns Hopkins Medical Institution, Baltimore, MD.

(690) The Duration of Donor CD4 T Cell Chimerism Following Human Lung Transplantation Is Not Affected By Human Leukocyte Antigen and Natural Killer Cell Alloreactivity:

O. Gjorgjijajkoska¹, D. Mallon¹, J. Jayaraman², J. Traherne², J. Trowsdale², A. Mulder³, F. H. Claas³, C. J. Taylor⁴, E. M. Bolton¹, A. Bradley¹, C. Lewis⁵, J. Parmar⁵, G. J. Pettigrew¹. ¹Department of Surgery, University of Cambridge, Cambridge, United Kingdom, ²Cambridge Institute for Medical Research, University of Cambridge, Cambridge, United Kingdom, ³Dept Immunohaematology and Bloodtransfusion, Leiden University Medical Center, Leiden, Netherlands, ⁴Tissue Typing Laboratory, Addenbrooke's Hospital, Cambridge, United Kingdom, ⁵Papworth Hospital, Papworth, United Kingdom.

(691) Clopidogrel Preserves Microvascular Integrity in Orthotopic Tracheal Transplants affected by Obliterative Bronchiolitis:

C. Heim¹, M. A. Khan², B. Motsch¹, S. Müller¹, M. Ramsperger-Gleixner¹, T. Stamminger³, M. R. Nicolls², M. Weyand¹, S. Ensminger⁴. ¹Department of Cardiac Surgery, Erlangen, Germany, ²Veterans Affairs Palo Alto Health Care

System, Stanford University School of Medicine, CA,
³Department of Virology, Erlangen, Germany, ⁴Department of
Cardiac Surgery, Bad Oeynhausen, Germany.

- (692) Correlation of Physiological Data at Ex-Vivo Lung Perfusion and Reperfusion in a Rat Ischemia-Reperfusion Model Using Plasmin;**
H. Motoyama, F. Chen, K. Hijiya, M. Takahashi, K. Ohata,
T. Yamada, M. Sato, A. Aoyama, T. Bando, H. Date. Thoracic
Surgery, Kyoto University Hospital, Kyoto, Japan.
- (693) Apoptosis and Expression of Inducible Nitric Oxide Synthase in Normothermic Lung Perfused With Organ Care System (OCS) Compared To Standard Cold Show Donor Lungs;**
F. Calabrese, M. Schiavon, N. Nannini, F. Lunardi, G. Marulli,
G. Di Gregorio, A. Rebusso, E. Balestro, M. Loy, F. Rea.
University of Padova, Padova, Italy.
- (694) Image Guided Evaluation of Cellular Retention and Survival After Intramyocardial Transcatheter Based Mesenchymal Stem Cell Transplantation Into the Infarcted Pig Heart;**
M. Y. Emmert¹, P. Wolint¹, J. Pavicevic¹, V. Falk¹, M. Gyöngyösi²,
S. P. Hoerstrup¹. ¹Cardiac Surgery, University Hospital Zurich,
Zurich, Switzerland, ²Cardiology, University Hospital Vienna,
Vienna, Austria.
- (695) The Importance of Airway and Vascular Parameters in Cellular Ex-Vivo Lung Perfusion Assessment of the Donor Lung;**
T. Okamoto¹, D. M. Wheeler², K. R. McCurry³. ¹Transplant
Center, Cleveland Clinic, Cleveland, OH, ²Cardiothoracic
Anesthesia, Cleveland Clinic, Cleveland, OH, ³Cardiovascular
Surgery, Cleveland Clinic, Cleveland, OH.
- (696) Alloantigen Specific Immunosuppression by Induced Regulatory T Cells in Humans;**
K. Boer, A. M. Peeters, R. Kraaijeveld, W. Verschoor, N. H.
Litjens, M. G. Betjes, W. Weimar, C. C. Baan. Internal Medicine –
Nephrology and Transplantation, Erasmus University Medical
Center, Rotterdam, Netherlands.
- (697) Regenerative Stem Cell Transplantation: Biological and Immunogenic Differences Between Infant and Aged Cells;**
M. Stubbendorff¹, E. Neofytou², T. Deuse³, D. Mattutat¹,
C. Lange⁴, H. Reichenspurner³, R. Robbins⁵, H. Volk⁶, R. Beygui⁵,
S. Schrepfer¹. ¹TSI-Lab, Hamburg, Germany, ²CT Surgery,
Stanford University School of Medicine, Stanford, CA,
³CT Surgery, University Heart Center, Hamburg, Germany,
⁴Bone Marrow Transplant, University Hospital Hamburg,
Hamburg, Germany, ⁵CT Surgery, Stanford University
School of Medicine, Hamburg, CA, ⁶Immunology, Charite
Berlin, Berlin, Germany.
- (698) Combined Thromboxane Synthase Inhibition and H2-Receptor Blockade Prevents PVR Elevation During GalTKO.hCD46.hCD55 Pig Lung Perfusion With Human Blood;**
L. Burdorf¹, E. Rybak¹, T. Zhang¹, D. Harris¹, S. Dahi¹, F. Ali¹,
D. Parsell¹, G. Braileanu¹, X. Cheng¹, E. Sievert¹, C. Phelps²,
D. Ayares², A. M. Azimzadeh¹, R. N. Pierson 3rd¹. ¹Surgery,
University of Maryland, Baltimore, MD, ²Revivicor, Inc.,
Blacksburg, VA.

- (699) A Mouse Model for ABO-Incompatible Transplantation (ABOi Tx): Study of Antibody-Mediated Rejection (AMR);**
 B. Motyka¹, F. H. Rahman¹, A. Kratochvil¹, K. Tao¹, J. Pearcey¹, T. Marshall¹, B. Sis², M. Mengel², A. J. d'Apice³, P. J. Cowan³, L. J. West¹. ¹Pediatrics, University of Alberta, Edmonton, AB, Canada, ²Laboratory Medicine and Pathology, University of Alberta, Edmonton, AB, Canada, ³St Vincent's Hospital, Melbourne, Australia.
- (700) Fate of Bronchial Artery Circulation after Lung Transplantation: A Revisit Using Micro CTA Techniques in Rats;**
 K. Noda¹, N. Shigemura¹, K. Tobita², Y. Tanaka¹, Y. Saito¹, J. K. Bhamra¹, J. D'Cunha¹, C. A. Bermudez¹. ¹Department of Cardiothoracic Surgery, University of Pittsburgh Medical Center, Pittsburgh, PA, ²Department of Developmental Biology, University of Pittsburgh, Pittsburgh, PA.
- (701) Real-Time Imaging With the O-Arm of Lung Parenchyma During Ex-Vivo Lung Reconditioning;**
 E. Sage¹, P. Puyo¹, N. Salley¹, N. Liu², G. Trebbia³, P. Bonnette¹, A. Roux⁴, A. Chapelier¹. ¹Department of Thoracic Surgery and Lung Transplantation, Foch Hospital, Suresnes, France, ²Department of Anaesthesiology, Foch Hospital, Suresnes, France, ³Department of Intensive Care, Foch Hospital, Suresnes, France, ⁴Department of Pneumology, Foch Hospital, Suresnes, France.
- (702) Thioredoxin-1 Priming: A Novel Strategy to Induce Tolerance in a Rat Model of Lung Transplantation;**
 H. Hu¹, J. M. Patel². ¹Department of Medicine, University of Florida, Gainesville, FL, ²Department of Medicine, University of Florida, Research Service, North Florida/South Georgia Veterans Health System, Gainesville, FL.
- (703) Influence of Oxidative and Anaplerotic Substrates on Myocardial Metabolism During Hypothermic Machine Perfusion;**
 S. M. Brant, C. Holmes, L. West, M. Cobert, M. E. Jessen, M. Peltz. Cardiovascular and Thoracic Surgery, UT Southwestern, Dallas, TX,

DEVELOPING NATIONS

(ALL)

- (704) FGF23 and Klotho as Cardiovascular Risk Factors in Heart Transplant Recipients;**
 P. Przybylowski¹, L. Janik¹, G. Wasilewski¹, E. Nowak¹, E. Koc-Żórawska, J. Małyszko², J. Małyszko². ¹Cardiac Surgery and Transplantology, Cardiology Institute Jagiellonian University Medical College, Krakow, Poland, ²Nephrology and Transplantology, Medical University, Białystok, Poland.
- (705) Post Heart Transplantation Outcomes of Heart Mate II Bridged Patients Requiring Concomitant Temporary Right Ventricular Mechanical Support;**
 M. Urban, J. Pirk, J. Besik, I. Netuka. Cardiac Surgery, Institute for Clinical and Experimental Medicine, Prague, Czech Republic.

- (706) Device Malfunction in Long Term Mechanical Circulatory Support Devices – A Single Centre Experience;**
K. Kerk¹, C. Sivathanan¹, C. Lim¹, D. Sim², T. Tan¹. ¹Cardiothoracic Surgery, National Heart Centre Singapore, Singapore, Singapore, ²Cardiothoracic, National Heart Centre Singapore, Singapore, Singapore.
- (707) Effect of CYP2C9 and VKORC1 Gene Variants in Determining the Maintenance of Warfarin Dose and Complications in Patients With Left Ventricular Assist Device;**
S. Ertugay¹, B. Durmaz², Ç. Engin¹, H. Onay², S. Nalbantgil³, T. Ya di¹, F. Özkinay², M. Özbaran¹. ¹Cardiovascular Surgery Dept., Ege University Medical School Hospital, Izmir, Turkey, ²Medical Genetics, Ege University Medical School Hospital, Izmir, Turkey, ³Cardiology, Ege University Medical School Hospital, Izmir, Turkey.
- (708) Association Between Plasma Level of Soluble Receptor for Advanced Glycation End Products and Biomarkers of Cardiac Allograft Vasculopathy in Heart Recipients;**
O. P. Shevchenko, N. V. Kuncovich, A. O. Shevchenko, R. M. Kurabekova, T. A. Khalilulin, I. I. Muminov, S. V. Gautier. Federal V.Shumakov Research Center of Transplantation and Artificial Organs, Moscow, Russian Federation.
- (709) The Feasibility of Extracorporeal Membrane Oxygenation Support for Inter-Hospital Transport and Bridge To Lung Transplantation;**
D. Kim¹, B. Son¹, W. Cho². ¹Thoracic and Cardiovascular Surgery, Pusan National University Yangsan Hospital, Yangsan, Korea, Republic of, ²Internal Medicine, Pusan National University Yangsan Hospital, Yangsan, Korea, Republic of.
- (710) Lung Transplantation for Silicosis, Report of 16 Patients;**
D. Rosengarten, V. Rusanov, O. Fruchter, N. Abdel-Rahman, Y. Raviv, M. R. Kramer. Institute of Pulmonology, Rabin Medical Center, Beilinson Campus, Petah Tiqwa, Sackler Faculty of Medicine, Tel Aviv University, Tel Aviv, Israel, Petah Tiqwa, Israel.
- (711) New-onset Diabetes Mellitus Can Confer an Adverse Risk To Long-Term Survival After Heart Transplantation in Asian Patients;**
H. Kim¹, S. Jung¹, J. Kim², J. Kim¹, S. Choo¹, T. Yun³, C. Chung¹, J. Lee¹. ¹Department of Thoracic and Cardiovascular Surgery, Asan Medical Center, Seoul, Korea, Republic of, ²Division of Cardiology, Asan Medical Center, Seoul, Korea, Republic of, ³Division of Pediatric Cardiac Surgery, Asan Medical Center, Seoul, Korea, Republic of.
- (712) Tacrolimus in Heart Transplant Recipients With Chagas Disease. Initial Experience;**
R. R. Favaloro, M. A. Peradejordi Lastras, L. E. Favaloro, L. Favaloro, M. M. López Rosetti, D. O. Absi, A. M. Bertolotti. Intrathoracic Transplantation and Heart Failure Division, University Hospital Favaloro Foundation, Buenos Aires, Argentina.
- (713) Factors Influencing Waiting Time on the Heart Transplant Waiting List in Australia and New Zealand;**
P. Ruygrok¹, R. Pettersson², A. Keogh², P. Bergin³, R. Weintraub⁴, L. Dembo⁵, G. Javorsky⁶. ¹Auckland City Hospital, Auckland, New Zealand, ²St Vincents Hospital, Sydney, Australia, ³The Alfred Hospital, Melbourne, Australia, ⁴Royal Childrens Hospital, Melbourne, Australia, ⁵Royal Perth Hospital, Perth, Australia, ⁶Prince Charles Hospital, Brisbane, Australia.

(714) Evolution of Donor Lung Utilization after Initiation of New Lung Transplant Program;

T. Laisaar¹, M. Savisaar², A. Küüsvek³, J. Milk³, A. Rehme³, J. Kuus³. ¹Thoracic Surgery, Tartu University Hospital, Tartu, Estonia, ²Pneumology, Tartu University Hospital, Tartu, Estonia, ³Transplant Center, Tartu University Hospital, Tartu, Estonia.

(715) Cardiac Retransplantation: A Case Report in a Patient With Acute Reactivation of Chagas Disease;

D. L. Ferraz¹, F. A. Figueira², M. M. Varejao¹, J. T. Rodrigues¹, I. T. Silva¹, C. B. Cunha¹, A. H. Baiao², J. B. Carvalho Junior², R. M. Carneiro², F. R. Moraes Neto¹, V. S. Monteiro². ¹Instituto do Coracao de Pernambuco, Recife, Brazil, ²Instituto de Medicina Integral Prof. Fernando Figueira, Recife, Brazil.

(716) The Change in Pulmonary Vascular Resistance After LVAD Implantation - Can It Aid in Predicting Postimplantation Survival?;

M. Cikes¹, B. Skoric¹, M. Pasalic¹, H. Gasparovic¹, T. Caleta², J. Forgac², T. Grgic², Z. Baricevic¹, D. Lovric¹, V. Ivancan¹, B. Biocina¹, D. Milicic¹. ¹University of Zagreb School of Medicine, Uni. Hosp. Centre Zagreb, Zagreb, Croatia, ²University of Zagreb School of Medicine, Zagreb, Croatia.

(717) Lung Transplantation in Russian Federation;

S. V. Golovinskiy¹, N. A. Karchevskaya², O. A. Kurilova³, D. H. Tsurova¹, A. M. Gasanov⁴, E. A. Tarabrin¹, E. I. Pervakova³, A. A. Romanov³, S. N. Avdeev², M. M. Abakumov¹, A. G. Chuchalin⁵, M. S. Hubutiy⁶. ¹Department of Thoracoabdominal Surgery, Lung Transplantation Group, N.V. Sklifosovskiy Research Institute of Emergency Medicine, Moscow, Russian Federation, ²Department of Pulmonology, Lung Transplantation Group, Research Institute of Pulmonology FMBA of Russia, Moscow, Russian Federation, ³Department of Anesthesiology and Intensive Care, N.V. Sklifosovskiy Research Institute of Emergency Medicine, Moscow, Russian Federation, ⁴Endoscopy Department, N.V. Sklifosovskiy Research Institute of Emergency Medicine, Moscow, Russian Federation, ⁵Research Institute of Pulmonology FMBA of Russia, Moscow, Russian Federation, ⁶N.V. Sklifosovskiy Research Institute of Emergency Medicine, Moscow, Russian Federation.

(718) Profile of Heart Transplant Recipients in a Brazilian Center: Comparison With International Registry;

L. F. Seguro, F. G. Marcondes Braga, M. S. Avila, S. Mangini, B. Biselli, G. P. Franco, C. G. Lima, R. H. Santos, D. D. Lourenço Filho, F. A. Gaiotto, F. Bacal. Heart Institute (InCor), São Paulo, Brazil.

(719) Infection Incidence and Types of Pathogens After Heart Transplantation: Institutional Experience;

M. Sargin¹, S. B. Erdogan¹, M. Tasdemir Mete¹, S. Akansel¹, A. Sensoy², A. Ekmekci³, G. Orhan¹, M. Eren³, S. Aykut Aka¹. ¹Cardiovascular Surgery, Siyami Ersek Cardiovascular Surgery Center, Istanbul, Turkey, ²Department of Infection, Siyami Ersek Cardiovascular Surgery Center, Istanbul, Turkey, ³Cardiology, Siyami Ersek Cardiovascular Surgery Center, Istanbul, Turkey.

(720) Current Status of Heart Transplantation in the Kingdom of Saudi Arabia;

N. Selimovic, Z. Alhalees, U. Kjellman, A. Alsanei, A. Eyjolfsson, W. Alhabeeb, J. Alburaiqi, F. Khouqeer, E. Saad, F. Khaliel. Heart Centre, King Faisal Specialist Hospital & Research Centre, Riyadh, Saudi Arabia.

(721) The Lung Transplant Program in Saudi Arabia. Unique Differences and Challenges;

I. Nizami, B. Khan. Organ Transplant Center, King Faisal Specialist Hospital and Research Center, Riyadh, Saudi Arabia.

(722) A 2-Year Experience of Donor Evaluation for Lung Transplantation in Moscow (Russian Federation);

S. V. Golovinskiy¹, D. H. Turova¹, V. L. Vinogradov², M. G. Minina³, E. A. Tarabrin¹, M. M. Abakumov⁴, M. S. Hubutiy⁴.

¹Department of Thoracoabdominal Surgery, Lung Transplantation Group, N.V. Sklifosovskiy Research Institute of Emergency Medicine, Moscow, Russian Federation, ²Department of General Intensive Care, Donor Coordination Group, N.V. Sklifosovskiy Research Institute of Emergency Medicine, Moscow, Russian Federation, ³Moscow Coordinating Centre of Organ Donation, Moscow, Russian Federation, ⁴N.V. Sklifosovskiy Research Institute of Emergency Medicine, Moscow, Russian Federation.

(723) The Initial Results of Implantable Rotary Blood Pumps from New Center in Istanbul, Turkey;

S. Kucukaksu¹, Z. T. Demirozu¹, E. Pektok¹, N. Arat², B. A. Ertekin³, O. Sogukpinar⁴.

¹Heart Transplantation & Mechanical Circulatory Support, Sisli Florence Nightingale Hospital, Istanbul, Turkey, ²Heart Failure & Cardiology, Sisli Florence Nightingale Hospital, Istanbul, Turkey, ³Adult Psychiatry, Sisli Florence Nightingale Hospital, Istanbul, Turkey, ⁴Pulmonology & Chest Disease, Sisli Florence Nightingale Hospital, Istanbul, Turkey.

(724) Profile of Donor Hearts in Brazil;

J. L. Melo, A. R. Paulo, J. A. Souza, L. A. Ohe, M. B. Barbosa, M. S. Avila, F. G. Marcondes-Braga, L. B. Seguro, S. Mangini, R. H. Santos, D. D. Lourenço Filho, F. A. Gaiotto, L. T. Kawabe, F. Bacal. Department of Heart Transplant, Heart Institute (InCor) – University of Sao Paulo Faculty of Medicine, Sao Paulo, Brazil.

(725) Resurrection of ECMO in India and the Initial Experience in Cardiorespiratory Failure;

K. Krishan¹, R. Kumar², R. Malhotra¹. ¹Cardiovascular Surgery, Max Superspeciality Hospital, New Delhi, India, ²Respiratory Intensive Care, Max Superspeciality Hospital, New Delhi, India.

(726) Beginners Report: Lung Transplantation Program in Szczecin, Poland;

B. Kubisa¹, M. Piotrowska¹, J. Pieróg¹, M. Bielewicz¹, A. Kozak¹, N. Wójcik¹, A. Zygmirska², P. Wasilewski², G. Feledyk², M. Kamiński³, G. Mysiorski³, A. Kubisa⁴, M. Brykczyński⁵, T. Grodzki¹. ¹Department of Thoracic Surgery and Transplantation, Pomeranian Medical University of Szczecin, Szczecin, Poland, ²Intensive Care Unit, Pulmonary A. Sokołowski Hospital, Szczecin, Poland, ³Pulmonary Department, Pulmonary A. Sokołowski Hospital, Szczecin, Poland, ⁴Internal Medicine Department, Pulmonary A. Sokołowski Hospital, Szczecin, Poland, ⁵Cardiac Surgery Department, Pomeranian Medical University of Szczecin, Szczecin, Poland.

DONOR MANAGEMENT

ORGAN PRESERVATION HEART

(DMD, HTX)

- (727) *Has the Survival in Heart Transplant Recipients Older > 65 years Improved Over the Decades?:***
Y. Ravi¹, B. A. Whitson¹, P. G. Boyer², S. Emami³, A. K. Hasan³, V. Franco³, R. Kahwash¹, J. Crestanello¹, G. Haas³, R. Higgins¹, C. B. Sai-Sudhakar¹. ¹Cardiac Surgery, The Ohio State University, Columbus, OH, ²Davis Heart and Lung Research Institute, The Ohio State University, Columbus, OH, ³Internal Medicine, The Ohio State University, Columbus, OH.
- (728) *Towards a Cardiac Allocation Score: Preoperative Stratification Risk and Five Years Survival After Heart Transplantation in a French Cardiac Center:***
T. Noly, A. Anselmi, J. Guihaire, A. Martin, B. Lelong, C. Chabanne, T. Langanay, H. Corbineau, J. Verhoye, A. Leguerrier, E. Flecher. Cardiothoracic Surgery, Rennes University Hospital, Rennes, France.
- (729) *Transplant Activity Around Major US Holidays:***
S. Chen¹, C. P. Chee², S. A. Hollander¹, D. N. Rosenthal¹, K. Maeda³, E. Liu¹, C. S. Almond⁴. ¹Division of Cardiology, Stanford University, Palo Alto, CA, ²Health Economics Resource Center, Department of Veterans Affairs, Menlo Park, CA, ³Cardiothoracic Surgery, Stanford University, Palo Alto, CA, ⁴Department of Cardiology, Boston Children's Hospital, Boston, MA,
- (730) *Donor Hemoglobin Is an Independent Predictor of Long-Term Outcomes in Heart Transplant - A Hypothesis Generating Preliminary Data From a Single Center:***
 A. M. Cordero-Reyes, C. Uribe, B. H. Trachtenberg, G. Ashrith, M. Loebe, P. Alvarez, G. Torre-Amione, J. D. Estep, A. Bhimaraj. Cardiology, Houston Methodist Hospital, Houston, TX.
- (731) *Use of Heavy Drinking Donors in Heart Transplantation is Not Associated With Worse Short- and Medium-Term Mortality:***
S. Taghavi, S. Jayarajan, E. Komaroff, A. Shiose, D. Schwartz, E. Hamad, R. Alvarez, G. Wheatley, T. Guy, Y. Toyoda. Temple University School of Medicine, Philadelphia, PA.
- (732) *Does Sequence Matter? Outcomes of Donors Rejected by Local Centers:***
D. A. Baran, A. Jaiswal, A. Adzic, J. Pieretti, C. Gidea, R. Morlend, S. Murthy, M. T. Camacho, M. J. Zucker. Transplant Center, Newark Beth Israel Medical Center, Newark, NJ.
- (733) *Hepatitis B Vaccination Confers an Increased Rate of Transplant for Patients on the Heart Transplant Waiting List:***
E. Stimpson, D. Dilibero, M. Kittleson, J. Patel, Z. Yu, F. Liou, J. Yabuno, P. Zakowski, L. Czer, A. Trento, F. Esmailian, J. Kobashigawa. Cedars-Sinai Heart Institute, Los Angeles, CA.
- (734) *Predictors of Mortality in Heart Transplant Candidates With or Without Mechanical Circulatory Support: A French National Study:***
C. Cantrelle¹, C. Jasseron¹, C. Legeai¹, N. Al Hawajri¹, L. Sebbag², P. Leprince³, E. Epailly⁴, O. Huot¹, R. Dorent¹. ¹Direction Prélèvement Greffe Organes-Tissus, Agence de la Biomédecine, Saint-Denis La Plaine, France, ²Pôle Médico-chirurgical de Transplantation Cardiaque Adulte, Hôpital Louis Pradel, Bron, France, ³Service de Chirurgie Cardiaque et Thoracique, Hôpital Pitié-Salpêtrière, Paris, France, ⁴Unité de Transplantation Cardiaque et Cardio-pulmonaire, Les Hôpitaux Universitaires de Strasbourg, Strasbourg, France.

DONOR MANAGEMENT

ORGAN PRESERVATION LUNG

(DMD, LTX)

(735) Correlation Between Post-Operative Spirometry and Donor-To Recipient Predicted Total Lung Capacity in Bilateral Lung Transplantation;

R. Rampolla¹, F. Kheir². ¹Multi-Organ Transplant Institute/Pulmonary and Critical Care Medicine, Ochsner Clinic Foundation, New Orleans, LA, ²Pulmonary Diseases, Critical Care and Environmental Medicine, Tulane University Health Sciences Center, New Orleans, LA.

(736) Ex-Vivo Lung Perfusion Does Not Have a Negative Effect on Transplant Rates at Centers without This Technology in a Single Organ Procurement Organization (OPO);

J. L. Tiwari¹, G. Andah¹, C. Borders¹, J. H. Ellis¹, Y. Suzuki¹, J. M. Diamond², S. West³, R. D. Hasz³, S. Bellamy⁴, J. D. Christie², E. Cantu¹. ¹Division of Cardiovascular Surgery, Department of Surgery, University of Pennsylvania, Philadelphia, PA, ²Pulmonary, Allergy, and Critical Care Division, Department of Medicine, University of Pennsylvania, Philadelphia, PA, ³Gift of Life Donor Program, Philadelphia, PA, ⁴Department of Biostatistics and Epidemiology, Center for Clinical Epidemiology and Biostatistics, University of Pennsylvania, Philadelphia, PA.

(737) Effects of Organ Donor Factors on Lung Transplant Recipient Outcome at One-Year Follow-Up;

H. Auråen¹, A. E. Fiare², Ø. Bjørtuft¹, U. Christen³, O. Geiran², J. S. Kongerud¹, A. M. Holm¹. ¹Dept. of Respiratory Medicine, Oslo University Hospital, Oslo, Norway, ²Dept. of Cardiothoracic Surgery, Oslo University Hospital, Oslo, Norway, ³Dept. of Transplantation, Oslo University Hospital, Oslo, Norway.

(738) High Emergency Lung Transplantation: The Experience of a French Centre;

L. Beaumont¹, E. Sage², F. Parquin², D. Grenet¹, S. De Miranda¹, A. Hamid¹, C. Picard¹, M. Fischler³, C. Cerf⁴, M. Stern¹, A. Roux¹. ¹Department of Pneumology, Foch Hospital, Suresnes, France, ²Department of Thoracic Surgery, Foch Hospital, Suresnes, France, ³Department of Anesthesiology, Foch Hospital, Suresnes, France, ⁴Department of Reanimation, Foch Hospital, Suresnes, France.

(739) Process Improvement in Thoracic Organ Donor Retrieval: Implementation of a Donor Assessment Checklist;

G. Loor¹, G. Weide¹, S. Keshavamurthy², S. Hussain², D. Topalidis¹, M. Alsalihi², K. McCurry², C. Koch². ¹University of Minnesota Medical Center, Minneapolis, MN, ²Cleveland Clinic, Cleveland, OH.

(740) A Single Center Experience in the Use of Eurotransplant Donor Scoring on Donor Lung Utilization;

E. Mahoney¹, D. Dilling², J. Schwartz³, E. Lowery². ¹Loyola University Medical Center, Maywood, IL, ²Pulmonary and Critical Care Medicine, Loyola University Medical Center, Maywood, IL, ³Thoracic and Cardiovascular Surgery, Loyola University Medical Center, Maywood, IL.

(741) Impacts of Donor Smoking History and Age on Lung Transplant Survival;

D. Ren, L. N. Blau, T. Motomura, E. E. Suarez, T. Kaleekal, S. Jyothula, M. Loebe, B. A. Bruckner. Houston Methodist Hospital, Houston, TX.

(742) Donor Oxygenation Has No Impact on Postoperative Outcome After Lung Transplantation:

W. Sommer¹, J. Salman¹, I. Tudorache¹, C. Kühn¹, M. Avsar¹, J. Gottlieb², A. Haverich¹, G. Warnecke¹. ¹Cardiothoracic Surgery, Hannover Medical School, Hannover, Germany, ²Department of Respiratory Medicine, Hannover Medical School, Hannover, Germany.

(743) Lung Allocation Score Criteria Adjustment and Impacts on Transplantation: A Retrospective Study:

N. D. Carroll¹, A. Kashem², A. Shiose², G. H. Wheatley 3rd², T. S. Guy², M. Butler-Lebair¹, N. Patel¹, F. Cordova¹, G. J. Criner¹, Y. Toyoda². ¹Temple University, Philadelphia, PA, ²Cardiovascular Surgery, Temple University, Philadelphia, PA.

(744) Outcomes of Lung Transplantation Using Donation after Cardiac Death Donors: Should We Use Ex-Vivo Lung Perfusion?:

T. N. Machuca¹, O. Mercier¹, S. Collaud¹, V. Linacre¹, T. Krueger¹, S. Azad¹, L. Singer², K. Yasufuku¹, M. de Perrot¹, A. Pierre¹, T. K. Waddell¹, S. Keshavjee¹, M. Cypel¹. ¹Thoracic Surgery, University of Toronto, Toronto, ON, Canada, ²Respirology, University of Toronto, Toronto, ON, Canada,

ADULT HEART FAILURE

(HF, BSTR)

(745) Mortality After Readmission Among Heart Failure Patients:

J. G. Benuzillo, K. D. Rasmusson, A. G. Kfoury, J. L. Nixon, D. Budge, R. Alharethi, C. A. Roberts, B. D. Horne, D. L. Lappé. Heart Institute, Intermountain Healthcare, Salt Lake City, UT.

(746) Non-Ischemic Dilated Cardiomyopathy: Biopsy Proved Markers of Disease Sub-Entities:

K. Rucinskas¹, S. Cibiras², E. Zurauskas³, A. Jakubauskas⁴, D. Daunoravicius³, I. Zasytyte⁵, V. Maneikiene⁵, J. Celutkiene⁵, L. Griskevicius⁶, V. Grabauskiene³. ¹Clinic of Cardiovascular Diseases, Centre of Cardiac Surgery, Vilnius University, Medical Faculty, Vilnius, Lithuania, ²Centre of Cardiology and Angiology, Vilnius University Hospital Santariskiu Klinikos, Vilnius, Lithuania, ³Pathology, Forensic Medicine and Pharmacology, Vilnius University, Medical Faculty, Vilnius, Lithuania, ⁴Centre of Hematology, Oncology and Transfusion, Vilnius University Hospital Santariskiu Klinikos, Vilnius, Lithuania, ⁵Clinic of Cardiovascular Diseases, Vilnius University, Medical Faculty, Vilnius, Lithuania, ⁶Centre of Hematology, Oncology and Transfusion, Vilnius University, Medical Faculty, Vilnius, Lithuania.

(747) Fibroblast Growth Factor 23 is a Promising Biomarker of Cardiac Hypertrophy:

V. Polyakova¹, J. Poeling², T. Kubin³, T. Braun³, T. Walther¹, M. H. Richter¹. ¹Cardiac Surgery, Kerckhoff-Clinic, Bad Nauheim, Germany, ²Cardiac Surgery, Schüchtermann-Clinic, Bad Rothenfelde, Germany, ³Heart and Lung Research, Max-Planck-Institute, Bad Nauheim, Germany.

(748) Cardiomyocyte p65 NF- κ B Is Necessary for Compensatory Adaptation To Pressure-Overload:

H. Javan, L. Li, A. Szucsik, C. Schaaf, M. Gao, C. H. Selzman. Cardiothoracic Surgery, University of Utah, Salt Lake City, UT.

- (749) *Is There a Need for Patient Specific Informed Consent in Heart Transplantation?***
N. Yechoor, M. Farneman, B. Whitson, A. Hasan, G. Haas, C. Sai-Sudhakar, R. Higgins, A. Kilic. Ohio State University, Columbus, OH.
- (750) *Improvement of Endothelial Function After Stem Cells Transplantation in Patients With Heart Failure:***
M. Sebestjen, B. Šuligoj, B. Vrtovec, G. Poglajen, R. Okrajšek. Department of Cardiology, UCC Ljubljana, Ljubljana, Slovenia.
- (751) *Left Ventricular Internal Diastolic Diameter as a Predictor of Outcomes in Ischemic Cardiomyopathy:***
J. Shatzkes, J. Salamon, R. Zolty. Cardiology, Montefiore Medical Center/Albert Einstein College of Medicine, Bronx, NY.
- (752) *Higher Serum Galectin-3 Levels Correlate to Lower Cerebral Tissue Oxygenation in Heart Failure Patients:***
L. Rifai¹, C. Pisano², M. Upadhyaya³, M. A. Silver⁴. ¹Department of Cardiology, Advocate Lutheran General Hospital, Park Ridge, IL, ²Heart Failure Institute, Advocate Christ Medical Center, Oak Lawn, IL, ³Department of Medicine, Advocate Christ Medical Center, Oak Lawn, IL, ⁴Department of Medicine, Heart Failure Institute – Advocate Christ Medical Center, Oak Lawn, IL.
- (753) *Myocardial Scar Burden and Response to Stem Cell Therapy in Heart Failure Patients:***
G. Zemljic¹, G. Poglajen¹, U. Mikuz¹, M. Sever², S. Frljak¹, P. Mali³, F. Haddad⁴, J. C. Wu⁴, B. Vrtovec¹. ¹Advanced Heart Failure and Transplantation Programme, Dept. of Cardiology, University Medical Center Ljubljana, Ljubljana, Slovenia, ²Dept. of Hematology, University Medical Center Ljubljana, Ljubljana, Slovenia, ³Blood Transfusion Center of Slovenia, Ljubljana, Slovenia, ⁴Stanford University School of Medicine, Palo Alto, CA.
- (754) *Activation of Copeptin, MRpro-ANP and MRpro-ADM in Heart Failure and Post LVAD and Heart Transplantation:***
S. Zabarovskaja, C. Hage, L. Rydén, L. Mellbin, L. H. Lund. Cardiology, Medicine, Stockholm, Sweden.
- (755) *Independent Prognostic Value of Peak Oxygen Consumption in ICD and Non-ICD Patients:***
A. C. Alba, M. Bamberger, M. Gewarges, S. Lalonde, D. Murninkas, M. McDonald, F. Billia, D. Delgado, H. Ross. University Health Network, Toronto, ON, Canada.
- (756) *Pre-Heart Transplant Recipient Counterpulsation Influences Primary Graft Dysfunction But Not Survival: Analysis of a National Cohort:***
N. G. Jawitz, O. K. Jawitz, P. Bonde. Bonde Artificial Heart Lab, Yale School of Medicine, New Haven, CT.
- (757) *Hemodynamic Correlates and Prognostic Implication of Vasodilator Response in Reactive Pulmonary Hypertension Due To Left Heart Disease (PHLHD):***
S. Lim. University Hospital Birmingham NHS Trust, Birmingham, United Kingdom,

ADULT HEART TRANSPLANTATION

(HF, PHARM)

(758) Proliferative Signal Inhibitor and Deep Vein Thrombosis: Is There a Connection?:

J. Patel, M. Kittleson, Z. Yu, F. Liou, J. Yabuno, C. Aggarwal, B. Kearney, D. H. Chang, L. Czer, F. Esmailian, J. Kobashigawa. Cedars-Sinai Heart Institute, Los Angeles, CA.

(759) Performance of Gene Expression Profiling Variability in Discriminating Heart Transplant Patients at Risk for Future Clinical Events:

M. G. Crespo-Leiro¹, J. Stypmann², H. J. Ross³, P. Mohacsi⁴, J. K. Parameshwar⁵, M. Zakliczyński⁶, M. C. Deng⁷, D. Hiller⁸, B. Elashoff⁸, J. Yee⁸, J. Vanhaecke⁹. ¹Unidad de Insuficiencia Cardiaca Avanzada y Trasplante Cardiaco, Hospital Universitario A Coruña, La Coruña, Spain, ²Department of Cardiovascular Medicine, University Hospital Münster, Muenster, Germany, ³Division of Cardiology and Heart Transplantation, Toronto General Hospital, Toronto, ON, Canada, ⁴Cardiology, University Hospital of Bern, Bern, Switzerland, ⁵Papworth Hospital, Papworth Everard, Cambridge, United Kingdom, ⁶Department of Cardiac Surgery & Transplantation, Silesian Center for Heart Disease, Zabrze, Poland, ⁷Department of Medicine-Division of Cardiology, UCLA Medical Center, Los Angeles, CA, ⁸XDx Inc., Brisbane, CA, ⁹Department of Cardiology, University Hospital of Leuven, Leuven, Belgium.

(760) The Positive Impact of Early Cardiac Rehabilitation on Long Term Survival in Cardiac Transplant Recipients:

A. Rosenbaum, K. Zhuang, W. Kremers, T. Allison, R. Daly, J. Schirger, S. Kushwaha, B. Edwards. The Mayo Clinic, Rochester, MN.

(761) Combined Heart and Abdominal Organ Transplantation: Excellent Outcomes Gained from a Unique Experience:

J. M. Stulak¹, J. A. Schirger², B. Edwards², L. D. Joyce¹, C. Rosen³, J. Heimbach³, M. Prieto³, R. C. Daly¹. ¹Cardiovascular Surgery, Mayo Clinic College of Medicine, Rochester, MN, ²Cardiovascular Diseases, Mayo Clinic College of Medicine, Rochester, MN, ³General Surgery, Mayo Clinic College of Medicine, Rochester, MN.

(762) Efficacy and Safety of Basiliximab as Curative Treatment of Persistent or Complicated Acute Rejection in Cardiac Transplantation:

S. Bouregaa¹, M. Larger¹, P. Boissonnat², A. Roussoulières², J. Neidecker², J. Obadia², L. Sebbag². ¹Département Pharmacie, Groupement Hospitalier Est, Bron, France, ²Pôle de Transplantation, Hôpital Louis Pradel Lyon, Bron, France.

(763) Pre-Transplant Anti-HLA Antibodies and Clinical Events After Heart Transplantation:

T. Gazdic¹, M. Kubanek², E. Svobodova³, A. Slavcev³, I. Netuka¹, J. Pirk¹, I. Málek². ¹Cardiac Surgery, Institute for Clinical and Experimental Medicine, Prague, Czech Republic, ²Cardiology, Institute for Clinical and Experimental Medicine, Prague, Czech Republic, ³Immunogenetics, Institute for Clinical and Experimental Medicine, Prague, Czech Republic.

(764) Long-Term Sildenafil Therapy Improves Right Ventricular Function in Heart Transplant Recipients With Pulmonary Hypertension:

B. Vrtovec¹, G. Poglajen¹, M. Šebešljen¹, R. Okrajšek¹, S. Frljak¹, G. Zemlji¹, J. Kšela², I. Kneževi², F. Haddad³. ¹Advanced Heart Failure and Transplantation Programme, Dept. of Cardiology, University Medical Center Ljubljana, Ljubljana, Slovenia, ²Dept. of Cardiovascular Surgery, University Medical Center Ljubljana, Ljubljana, Slovenia, ³Stanford University School of Medicine, Palo Alto, CA.

- (765) Mechanical Circulatory Support for Primary Graft Dysfunction Following Heart Transplantation: Risk Factors and Clinical Outcome:**
A. A. Ali¹, K. Southerland¹, L. Harling², M. Schechter¹, A. Saeed¹, T. Athanasiou², J. Schroder¹, C. Milano¹. ¹Duke University Medical Center, Durham, NC, ²Imperial College, London, United Kingdom.
- (766) CNI Free Immunosuppression in Heart Transplant Patients Treated With Everolimus: Results of a Multicenter French Registry:**
E. Epailly¹, M. Mattei², L. Sebbag³, N. Kamar⁴, R. Guillemain⁵, M. Noirclerc⁶, B. Lelong⁷, S. Pattier⁸, M. Redonnet⁹, A. Sirinelli¹⁰. ¹Cardiac Surgery, Les Hôpitaux Universitaires de Strasbourg, Strasbourg, France, ²Cardiac Surgery, Les Hôpitaux Universitaires de Nancy, Nancy, France, ³Cardiac Surgery, Les Hôpitaux Universitaires de Lyon, Lyon, France, ⁴Néphrologie, Les Hôpitaux Universitaires de Toulouse, Toulouse, France, ⁵Cardiac Surgery, Hôpital Européen Georges Pompidou, Paris, France, ⁶Cardiac Surgery, Les Hôpitaux Universitaires de Grenoble, Grenoble, France, ⁷Cardiac Surgery, Les Hôpitaux Universitaires de Rennes, Rennes, France, ⁸Cardiac Surgery, Les Hôpitaux Universitaires de Nantes, Nantes, France, ⁹Cardiac Surgery, Les Hôpitaux Universitaires de Rouen, Rouen, France, ¹⁰Cardiac Surgery, Les Hôpitaux Universitaires de Tours, Tours, France.
- (767) Delayed Sternal Closure Following Heart Transplantation: Outcomes and Implications:**
A. A. Ali, K. Southerland, M. Schechter, A. Saeed, J. Schroder, C. Milano. Cardiothoracic Surgery, Duke University Medical Center, Durham, NC.
- (768) YKL-40, a Novel Marker of Cardiovascular Complications, Is Related To Kidney Function in Heart Transplant Recipients:**
P. Przybyłowski¹, G. Wasilewski¹, L. Janik¹, E. Nowak¹, E. Koc-Żórawska², J. Małyszko², J. Małyszko². ¹Cardiac Surgery and Transplantology, Cardiology Institute Jagiellonian University Medical College, Krakow, Poland, ²Nephrology and Transplantology, Medical University, Białystok, Poland.
- (769) Recovery of Myocardial Capillary Bed (Microvascular) Density Persists in Long Term Follow Up of CAV Patients Treated With Sirolimus:**
D. V. Miller¹, M. Revelo¹, J. Wever-Pinzon², J. Nixon², M. H. Hammond¹, J. Stehlik², E. Gilbert², J. C. Fang², M. Everitt³, S. Drakos², R. Alharethi², D. Budge², A. G. Kfoury². ¹Pathology, UTAH Cardiac Transplant Program, Salt Lake City, UT, ²Cardiology, UTAH Cardiac Transplant Program, Salt Lake City, UT, ³Pediatric Cardiology, UTAH Cardiac Transplant Program, Salt Lake City, UT.
- (770) Mycophenolic Acid Area Under the Curve But Not Trough Level or Dose Is Associated With Rejection in Adult Heart Transplant Patients in the First Year Post-Transplantation:**
J. Woillard¹, L. Pouché¹, P. Marquet¹, G. Sinnasse-Raymond², J. Debord¹, C. Knoop³, F. Saint-Marcoux¹. ¹Pharmacology Department, INSERM U850/CHU Limoges, Limoges, France, ²Virology-Nephrology, Roche SAS, Boulogne-Billancourt Cedex, France, ³Unité de transplantation cardiaque et pulmonaire, CHU Erasme, Bruxelles, Belgium.

(771) A CNI-Free, Everolimus Based Regimen in De-Novo Heart Transplant Recipients Increases Albuminuria But Improves Glomerular Filtration Rate Compared With Conventional Immunosuppression;

F. Gustafsson¹, A. Andreassen², S. Arora², B. Andersson³, E. Gude², H. Eiskjær⁴, G. Raadegran⁵, G. Dellgren⁶, L. Gullestad². ¹Department of Cardiology, Rigshospitalet, Copenhagen, Denmark, ²Department of Cardiology, Rikshospitalet, Oslo, Norway, ³Department of Cardiology, Sahlgrenska University Hospital, Gothenburg, Sweden, ⁴Department of Cardiology, Skejby University Hospital, Aarhus, Denmark, ⁵Department of Cardiology, Skaane University Hospital, Lund, Sweden, ⁶Department of Cardiac Surgery, Sahlgrenska University Hospital, Gothenburg, Sweden.

(772) Influence of Junctional-Adhesion-Molecules on Transendothelial Migration Under Hypothermic Conditions: What About the Rewarming During Reperfusion?;

N. V. Bogert, I. Werner, A. Moritz, A. Beiras-Fernandez. Department of Thoracic and Cardiovascular Surgery, University Hospital Frankfurt, Goethe University, Frankfurt am Main, Germany.

(773) High Expression of Plasmacytoid Dendritic Cells in Peripheral Blood Lower the Risk of Acute Cellular Rejection in Heart Transplant Recipients;

M. J. Barten¹, M. Dieterlen¹, J. Garbade¹, S. Dhein¹, F. W. Mohr¹, H. B. Bittner². ¹Cardiac Surgery, University Leipzig, Heart Center, Leipzig, Germany, ²Department of Cardiothoracic Transplantation and Advanced Cardiac Surgery, Florida Hospital Orlando, Orlando, FL.

(774) Usefulness of ECMO for Cardiac Transplanted Patients Suffering From Early Cardiac Dysfunction;

A. Defontaine, T. Le Poivre, M. Treilhaud, P. Bizouarn, S. Pattier, J. Roussel, O. Baron. CHU Nantes, Nantes, France.

(775) Association Between Steroids Withdrawal During the First Year After Heart Transplantation and Changes in Total Cholesterol and Its Fractions in a Two Year Follow-Up. RESTCO Study;

M. G. Crespo-Leiro¹, M. J. Paniagua-Martín¹, M. Gómez-Bueno², J. L. Lambert-Rodríguez³, J. Fernández-Yáñez⁴, J. M. Arizón del Prado⁵, F. González-Vilchez⁶, T. Blasco-Peiró⁷, L. de la Fuente Galán⁸, V. Brossa-Loidí⁹, L. Almenar Bonet¹⁰, I. Garrido-Bravo¹¹, E. Lage-Galle¹², J. Muñoz-García¹³, J. Delgado-Jiménez¹⁴. ¹Heart Transplant Unit, Hospital Universitario A Coruña, La Coruña, Spain, ²Hospital Universitario Puerta de Hierro, Madrid, Spain, ³Hospital Universitario Central de Asturias, Asturias, Spain, ⁴Hospital General Universitario Gregorio Marañón, Madrid, Spain, ⁵Hospital Universitario Reina Sofía, Córdoba, Spain, ⁶Hospital Universitario Marqués de Valdecilla, Santander, Spain, ⁷Hospital Universitario Miguel Servet, Zaragoza, Spain, ⁸Hospital Clínico Universitario de Valladolid, Valladolid, Spain, ⁹Hospital Santa Creu i Sant Pau, Barcelona, Spain, ¹⁰Hospital Universitario i Politècnic La Fe, Valencia, Spain, ¹¹Hospital Universitario Virgen de la Arrixaca, Murcia, Spain, ¹²Hospital Universitario Virgen del Rocío, Sevilla, Spain, ¹³Instituto Universitario de Ciencias de la Salud. Universidad de A Coruña, La Coruña, Spain, ¹⁴Hospital Universitario ¹² de Octubre, Madrid, Spain.

(776) Pioglitazone for the Treatment of Insulin Resistance in Heart Transplant Recipients: Assessment of Efficacy and Safety;

R. Ray¹, M. Shih², N. Constantz¹, B. Kohli¹, H. Luikart¹, K. Khush¹. ¹Cardiovascular Medicine, Stanford University, Stanford, CA, ²Health Research & Policy, Stanford University, Stanford, CA.

(777) Does the Presence of Complement Binding De Novo DSA Distinguish Different Pathology Defined Rejection Patterns in Heart Transplant Recipients?:

N. L. Reinsmoen¹, M. Haas², J. Patel³, C. Lai¹, M. Naim¹, G. Ong¹, Q. Wang¹, J. Mirocha⁴, Z. Yu³, F. Liou³, J. Kobashigawa³. ¹HLA, Cedars-Sinai Health System, Los Angeles, CA, ²Pathology, Cedars-Sinai Health System, Los Angeles, CA, ³CA Heart Foundation, Cedars-Sinai Health System, Los Angeles, CA, ⁴Research Institute, Cedars-Sinai Health System, Los Angeles, CA.

(778) Correlation of Circulating Donor-Specific Anti-HLA Antibodies and Biopsy-Diagnosed Antibody-Mediated Rejection in Endomyocardial Biopsy With Cardiac Allograft Vasculopathy:

T. Sato¹, M. Yanase¹, H. Sunami¹, Y. Murata¹, O. Seguchi¹, K. Ogo², T. Matsuyama², Y. Ikeda², H. Hata³, T. Fujita³, H. Ishibashi-Ueda², T. Nakatani¹. ¹Transplantation, National Cerebral and Cardiovascular Center, Osaka, Japan, ²Pathology, National Cerebral and Cardiovascular Center, Osaka, Japan, ³Cardiovascular surgery, National Cerebral and Cardiovascular Center, Osaka, Japan.

(779) Aging With a New Heart: Long Term Clinical Outcome and Quality of Life After Transplantation in Old Patients:

S. Sponga, C. Travaglini, V. Tursi, S. Enrico, G. Guzzi, C. Nalli, D. Piani, U. Livi. Udine University Hospital, Udine, Italy.

(780) Do Redo Heart Transplant Patients Have an Increased Risk of Antibody Development?:

M. Kittleson, J. Patel, Z. Yu, F. Liou, A. Aquino, A. Velleca, L. Czer, D. H. Chang, M. Hamilton, A. Trento, N. Reinsmoen, J. Kobashigawa. Cedars-Sinai Heart Institute, Los Angeles, CA.

(781) Presence of Coronary Artery Fistulae after Cardiac Transplantation Is Associated with Increased Plaque Progression by Intravascular Ultrasound:

R. Cheng, B. Azarbal, J. Patel, J. Wei, J. Kobashigawa. Cedars-Sinai Heart Institute, Los Angeles, CA.

(782) Novel Lipoprotein Markers Remain Elevated Despite Statin Therapy After Heart Transplant:

S. Christopher¹, M. T. Hassanein², M. P. Flattery¹, M. Smallfield¹, R. H. Cooke¹, K. B. Shah¹. ¹Virginia Commonwealth University Health System, Richmond, VA, ²Virginia Commonwealth University, Richmond, VA.

(783) Mediastinal Re-Entry in Patients Undergoing Ventricular Assist Device Explantation Prior To Heart Transplantation: Role of Peripheral Cannulation for Cardiopulmonary Bypass:

A. A. Ali, K. Southerland, M. Schechter, A. Saeed, J. Schroder, C. Milano. Duke University Medical Center, Durham, NC.

(784) The Utilization of Non-invasive Echocardiographic Indices in Estimating Pulmonary Capillary Wedge Pressure in Heart Transplant Patients:

M. A. Chamsi-Pasha, B. Cookman, S. Saxena, S. Sayyed, E. Raichlin. Cardiovascular Medicine, University of Nebraska Medical Center, Omaha, NE.

(785) Prevalence and Impact of Anti-DP/DP/DQ HLA Antibodies in De Novo Heart Transplantation:

L. Goldraich¹, F. Foroutan¹, S. Chih², H. J. Ross¹, K. Tinckam³. ¹Cardiac Transplant Program, Peter Munk Cardiac Center, University of Toronto, Toronto, ON, Canada, ²Advanced Heart Failure and Cardiac Transplant Service, Royal Perth Hospital, Perth, Australia, ³Histocompatibility Laboratory, University Health Network, University of Toronto, Toronto, ON, Canada.

ADULT LUNG FAILURE

(LF, LTX)

- (786) Mechanical Ventilation of ECMO Patients Is Associated with Decreased Post-Transplant Survival;**
G. J. Bittle, P. G. Sanchez, Z. N. Kon, K. Rajagopal, S. Pham, B. P. Griffith. Cardiac Surgery, University of Maryland, Baltimore, MD.
- (787) Esophageal Motility and Impedence pH in Patients Listed for Lung Transplantation;**
D. Lien¹, J. Weinkauff¹, A. Kapasi¹, D. Helmersen², M. Thakrar², M. Fenton³, J. Wong¹, a. Lazarescu⁴, K. Jackson¹. ¹Lung Transplant Program, University of Alberta, Edmonton, AB, Canada, ²Lung Transplant Program, University of Calgary, Calgary, AB, Canada, ³Lung Transplant Program, University of Saskatchewan, Saskatoon, SK, Canada, ⁴Medicine, University of Alberta, Edmonton, AB, Canada.
- (788) Pulmonary Function and Exercise Tolerance of Lung Transplanted Patients With Initially Rejected Grafts Reconditioned With Ex-Vivo Lung Perfusion: Medium Term Results;**
M. Boffini, D. Ricci, E. Mancuso, R. Bonato, V. Fanelli, M. Ribezzo, M. Attisani, P. Solidoro, M. Ranieri, M. Rinaldi. Surgical Sciences Department, University of Turin, Turin, Italy.
- (789) Acidic Gastroesophageal Reflux and Aspiration Are Not Associated with Earlier Development of Bronchiolitis Obliterans in Pediatric Lung Transplant;**
C. Towe¹, E. Utterson¹, S. Sweet¹, P. Michelson¹, P. Eghtesady², U. Boston², A. Faro¹. ¹Pediatrics, Washington University, St Louis, MO, ²Surgery, Washington University, St Louis, MO.
- (790) A Single Center Experience With Bi-Caval Dual-Lumen Canulation in Venovenous Extracorporeal Life Support;**
V. Cunningham¹, T. N. Machuca², C. Serrick¹, E. Fan³, V. Linacre², K. Yasufuku², A. Pierre², M. de Perrot², T. K. Waddell², S. Keshavjee², M. Cypel². ¹Perfusion Services, Toronto General Hospital, Toronto, ON, Canada, ²Thoracic Surgery, University of Toronto, Toronto, ON, Canada, ³Critical Care Medicine, University of Toronto, Toronto, ON, Canada.
- (791) Evolving Practice: X Linked Agammaglobulinemia and Lung Transplantation;**
G. P. Westall¹, J. Douglass², E. Paul³, F. Hore-Lacy⁴, R. Stitling⁴, B. Levvey¹, G. Snell¹. ¹Lung Transplant Service, Alfred Hospital, Melbourne, Australia, ²Department of Allergy, Royal Melbourne Hospital, Melbourne, Australia, ³Epidemiology and Preventative Medicine, Monash University, Melbourne, Australia, ⁴Allergy, Immunology and Respiratory Medicine, Alfred Hospital, Melbourne, Australia.

ADULT LUNG TRANSPLANTATION

(LTX)

- (792) *The Effect of Donor-Derived Herpes Viruses on Lung Transplant Recipient Survival;***
H. Strah¹, Y. Shindo², T. L. Bricker¹, A. Aloush¹, A. E. Gelman³, J. M. Green¹. ¹Pulmonary and Critical Care Medicine, Washington University School of Medicine, St. Louis, MO, ²Institute for Advanced Research, Nagoya University, Nagoya, Japan, ³Department of Surgery, Washington University School of Medicine, St. Louis, MO.
- (793) *Sildenafil Attenuates Lung Ischemia-Reperfusion Injury in a Rodent Model;***
J. A. Cobb¹, L. Lu², E. Bromberek³, P. Kasinpila³, T. M. Beaver¹. ¹Thoracic and Cardiovascular Surgery, University of Florida, Gainesville, FL, ²Pulmonary Pathology, University of Florida, Gainesville, FL, ³Medicine, University of Florida, Gainesville, FL.
- (794) *Lung Replantation for Early Graft Failure: Trends and Results in 112 Patients Over a 24-Year Period;***
A. Kilic, J. C. Grimm, A. S. Shah, J. V. Conte, C. M. Sciortino. Division of Cardiac Surgery, Johns Hopkins Hospital, Baltimore, MD.
- (795) *Prevalence of Gastroparesis After Lung Transplantation: A Single Center Study;***
H. Jhun¹, K. Chaikriangkrai¹, V. Gudsoorkar¹, N. Sinha², T. Kaleekal², B. Mankidy², S. Scheinin³, M. Loebe³, B. Bruckner³, D. Ren³, S. Jyothula². ¹Internal Medicine, Houston Methodist Hospital, Houston, TX, ²Pulmonary Critical Care, Houston Methodist Hospital, Houston, TX, ³Cardiovascular Surgery, Houston Methodist Hospital, Houston, TX.
- (796) *Serum Hepcidin Antimicrobial Peptide Levels Predict Infection After Lung Transplantation;***
D. J. Ross¹, A. Ardehali¹, J. Belperio¹, A. Derhovanessian¹, S. S. Weigt¹, D. Sayah¹, J. P. Lynch, III¹, R. Sagar¹, M. Shino¹, M. Jacquet¹, B. Kubak², T. Ganz³. ¹Ronald Reagan-UCLA, Lung & Heart-Lung Transplant Program, Los Angeles, CA, ²Division of Infectious Diseases, David Geffen School of Medicine at UCLA, Los Angeles, CA, ³Division of Pulmonary and Critical Care, David Geffen School of Medicine at UCLA, Los Angeles, CA.
- (797) *Impact of Pre-Transplant Pleurodesis in the Outcome After Lung Transplantation for Lymphangiomyomatosis;***
J. Sakamoto, F. Chen, C. Chaparro, W. Karolak, K. Yasufuku, M. de Perrot, A. Pierre, L. G. Singer, M. Hutcheon, T. Waddell, M. Cypel, S. Keshavjee. Toronto Lung Transplant Program, University of Toronto, Toronto, ON, Canada.
- (798) *Bronchial Artery Revascularization and En Bloc Lung Transplant in Children;***
F. Guzman-Pruneda¹, Y. Orr¹, C. M. Mery¹, I. Adachi¹, M. Nugent², J. Maddox², M. G. Schechter³, G. B. Mallory¹, D. L. Morales³, J. S. Heinle¹, E. D. McKenzie¹. ¹Baylor College of Medicine, Houston, TX, ²Texas Children's Hospital, Houston, TX, ³Cincinnati Children's Hospital, Cincinnati, OH.
- (799) *Ex-Vivo Lung Perfusion for Infected Non-Acceptable Donor Lungs: A Pilot Study;***
M. N. Samano, L. G. Abdalla, L. M. Fernandes, N. A. Nepomuceno, K. A. Oliveira Braga, A. E. Azevedo-Pereira, P. M. Pêgo-Fernandes. Thoracic Surgery Department, Heart Institute (Incor), Hospital das Clínicas da Faculdade de Medicina da Universidade de São Paulo, São Paulo, Brazil.

- (800) Cryoanalgesia Complements Thoracic Epidural Use Following Lung Transplantation;**
 M. G. Hartwig¹, A. A. Osho², S. Hirji², A. W. Castleberry¹, A. Ganapathi¹, S. S. Lin¹, D. R. Davis¹. ¹Department of Surgery, Duke University Medical Center, Durham, NC, ²School of Medicine, Duke University Medical Center, Durham, NC.
- (801) Sirolimus Is Associated With Worse Renal Function in a Tacrolimus Based Immunosuppressive Regimen in Lung Transplantation;**
 M. Robinson¹, C. Liao², J. Koyner³, S. Bhorade (on behalf of the AIRSAC investigators)⁴. ¹Internal Medicine, University of Chicago, Chicago, IL, ²Health Studies, University of Chicago, Chicago, IL, ³Nephrology, University of Chicago, Chicago, IL, ⁴Pulmonary and Critical Care, University of Chicago, Chicago, IL.
- (802) Implementation and Medium-Term Outcomes of a Center-Specific High-Urgency Anti-HLA Antibody Policy;**
 A. Stoddart¹, M. I. Hertz², M. David², K. Rosemary², S. Sara², J. Patil². ¹Medicine, University of Vermont, Burlington, VT, ²Medicine, University of Minnesota, Minneapolis, MN.
- (803) Extracorporeal Photoimmune Therapy (ECP) with UVADEX in Conjunction with Standard Therapy Compared to Standard Therapy Alone for the Prevention of Rejection in Lung Transplantation Patients;**
 P. Jaksch¹, G. Murakoezy¹, C. Lambers¹, A. Scheed¹, W. Klepetko¹, R. Knobler². ¹Thoracic Surgery, Medical University Vienna, Vienna, Austria, ²Dept Dermatology, Medical University Vienna, Vienna, Austria.
- (804) Catheter-directed Intrapleural Fibrinolysis for Complicated Pleural Effusion Following Lung Transplantation – A Safe and Effective Strategy;**
 N. Shigemura, J. D'Cunha, A. J. Hayanga, J. K. Bhamra, P. Sappington, J. M. Pilewski, C. A. Bermudez. Cardiothoracic Surgery, University of Pittsburgh, Pittsburgh, PA.
- (805) Comparison of Voriconazole and Posaconazole Use in Lung Transplant Patients;**
 C. Chau¹, S. Yerkovich¹, T. Tse¹, P. Hopkins¹, S. Henning², D. Chambers^{1,3}. ¹Queensland Lung Transplant Service, The Prince Charles Hospital, Brisbane, Australia, ²School of Pharmacy, The University of Queensland, Brisbane, Australia, ³School of Medicine, the University of Queensland, Brisbane, Australia.
- (806) Outcomes Following Pregnancy in Living Lobar Lung Transplantation;**
 C. L. Greene, M. L. Barr, F. A. Schenkel, S. G. Worrell, V. A. Starnes, P. M. McFadden. Surgery, Keck School of Medicine of the University of Southern California, Los Angeles, CA.
- (807) Perioperative Venous Thromboembolism Prophylaxis in Lung Transplant Patients;**
 P. L. McGugan¹, D. Albon², B. Gulack³, S. Hirji⁴, A. Wilk⁵, A. Ganapathi⁶, M. G. Hartwig¹. ¹Cardiothoracic Surgery, Duke University Health Systems, Durham, NC, ²Duke University Health Systems, Durham, NC, ³Surgery, Duke University Health System, Durham, NC, ⁴Duke University, Durham, NC, ⁵Biostatistics and Bioinformatics, Duke University Medical Center, Durham, NC, ⁶Surgery, Duke University Medical Center, Durham, NC.
- (808) Management of Airway Stenoses With Biodegradable Stents After Lung Transplantation. Single Institution Experience;**
 S. Gelvez-Zapata, A. Wilkinson, D. Thomas, M. Pittman, J. Parmar. Transplant Department, Papworth Hospital, Cambridge, United Kingdom.

- (809) Esophageal Motility and Impedance-pH in Lung Transplant Recipients:**
D. Lien¹, J. Weinkauff¹, A. Kapasi¹, M. Fenton², D. Helmersen³, M. Thakrar³, J. Wong¹, A. Lazarescu⁴, K. Jackson¹. ¹Lung Transplant Program, University of Alberta, Edmonton, AB, Canada, ²Lung Transplant Program, University of Saskatchewan, Saskatoon, SK, Canada, ³Lung Transplant Program, University of Calgary, Calgary, AB, Canada, ⁴Medicine, University of Alberta, Edmonton, AB, Canada.
- (810) Halting BOS in Lung Transplant: Is Cyclosporine Conversion the Answer?:**
L. J. Stuckey¹, N. M. Walker², J. Lin³, K. M. Chan², V. N. Lama². ¹Department of Pharmacy Services, University of Michigan Health System, Ann Arbor, MI, ²Department of Internal Medicine, Division of Pulmonary & Critical Care Medicine, University of Michigan Health System, Ann Arbor, MI, ³Section of Thoracic Surgery, University of Michigan Health System, Ann Arbor, MI.
- (811) Prolonged Intensive Care Unit Stay after Bilateral Lung Transplantation – Late Mortality & Functional Outcome?:**
L. P. Ong¹, Z. Tristan², M. Prahbu³, G. Parry⁴, S. C. Clark¹. ¹Cardiothoracic Surgery, Freeman Hospital, Newcastle upon Tyne, United Kingdom, ²Human Anatomy & Clinical Skills, University of Newcastle, Newcastle upon Tyne, United Kingdom, ³Cardiothoracic Anaesthesia and Intensive Care Unit, Freeman Hospital, Newcastle upon Tyne, United Kingdom, ⁴Cardiothoracic Transplantation, Freeman Hospital, Newcastle upon Tyne, United Kingdom.
- (812) Factors Associated With Early Bacterial Infection After Lung Transplantation in Cystic Fibrosis Patients in Two French Centers With Different Antibiotic Prophylaxis Regimen:**
C. Picard¹, V. Boussaud², M. Schmidt¹, R. Guillemin², S. De Miranda¹, C. Amrein², D. Grenet¹, A. Roux¹, M. Stern¹. ¹Respiratory Medicine and Foch Lung Transplantation Group, Foch Hospital, Suresnes, France, ²Lung Transplantation Unit, Cardiac Surgery, Hôpital Européen Georges Pompidou, Paris, France.
- (813) Single Lung Transplantation in Patients with Secondary Pulmonary Hypertension Is Safe and Organ Efficient:**
W. Julliard, G. Levenson, S. Osaki, N. De Oliveira, J. D. Maloney. Department of Surgery, University of Wisconsin, Madison, WI.
- (814) The Impact of Incomplete Pulmonary Fissures of Living Lobar Lung Transplant Donors on Bronchial Stenosis of Lung Recipients:**
S. Sugimoto, T. Oto, M. Okada, K. Miyoshi, A. Nakatani, M. Yamane, S. Miyoshi. Thoracic Surgery, Okayama University Hospital, Okayama, Japan.
- (815) Traffic Density Does Not Affect Lung Function in the First Year After Double Lung Transplant:**
J. Blaikley¹, K. Godri-Pollitt², S. Zhang¹, Y. Guo², K. Sabaliauskas², G. Evans², C. Chaparro¹, S. Keshavjee¹, L. Singer¹, C. Chow¹. ¹Toronto General Hospital, Toronto, ON, Canada, ²University of Toronto, Toronto, ON, Canada.
- (816) Impact of Minimally Invasive Lung Transplantation on Postoperative Renal Outcomes:**
R. Romano¹, I. Wong², L. Thakuria², F. De Robertis³, T. Bahrami³, M. Amrani³, S. Kaul³, D. Hall³, A. Reed³, M. Carby³, A. Simon³, N. Marczin¹. ¹Anaesthetics, Imperial College London, London, United Kingdom, ²Imperial College London, London, United Kingdom, ³Royal Brompton and Harefield NHS Foundation Trust, Harefield, United Kingdom.

- (817) A Simple Risk Score To Predict Long-term Renal Dysfunction Following Lung Transplantation: It's Not Over at 5 Years;**
A. J. Hayanga¹, J. Yang², J. Aboagye³, N. Shigemura¹, H. E. Kaiser⁴, J. K. Bhamra¹, J. D. Luketich¹, J. D'Cunha¹. ¹Cardiothoracic Surgery, University of Pittsburgh Medical Center, Pittsburgh, PA, ²Biostatistics and Epidemiology, Johns Hopkins School of Public Health, Baltimore, MD, ³Epidemiology, Johns Hopkins School of Public Health, Baltimore, MD, ⁴Anesthesiology and Critical Care, Johns Hopkins Medical Institutions, Baltimore, MD.
- (818) Prevalence and Predictors of Diabetes After Lung Transplant – A Prospective, Longitudinal Study;**
K. L. Hackman¹, G. I. Snell², L. A. Bach³. ¹Medicine, Monash University, Melbourne, Australia, ²Lung Transplant Service, The Alfred Hospital, Melbourne, Australia, ³Endocrinology and Diabetes, The Alfred Hospital, Melbourne, Australia.
- (819) Overweight and Obesity Common after Lung Transplantation;**
 J. L. Anderson¹, K. L. Hackman², G. I. Snell³, A. C. Tierney⁴. ¹Nutrition and Dietetics, The Alfred Hospital, Melbourne, Australia, ²Medicine, Monash University, Melbourne, Australia, ³Lung Transplant Service, The Alfred Hospital, Melbourne, Australia, ⁴Nutrition and Dietetics, Monash University, Melbourne, Australia.
- (820) Clinical Outcomes in Lung Retransplantation;**
K. Halloran, S. Keshavjee, C. Chaparro, C. Chow, M. Binnie, T. Waddell, A. Pierre, M. de Perrot, M. Cypel, K. Yasufuku, S. Azad, L. G. Singer. Toronto Lung Transplant program, University of Toronto, Toronto, ON, Canada.
- (821) Donor and Recipient Risk Factors for Early Airway Dehiscence Following Lung Transplantation;**
Z. N. Kon, G. J. Bittle, C. F. Evans, K. Rajagopal, S. M. Pham, B. P. Griffith. University of Maryland School of Medicine, Baltimore, MD.
- (822) Impact of Demographics on Airway Obstruction on Spirometry Among Patients With Lung Transplantation;**
A. Banga, K. McCarthy, M. Budev. Cleveland Clinic Foundation, Cleveland, OH.
- (823) Right Ventricular Recovery Following Lung Transplantation: Does it happen?;**
 K. Addetia, K. Duggan, N. El-Hangouche, A. R. Patel, V. Mor-Avi, R. M. Lang, S. Bhorade. University of Chicago, Chicago, IL.
- (824) Initial Data from a Prospective Observational Study of Hypogammaglobulinemia After Lung Transplantation;**
R. S. Traister, J. Gribowicz, M. Crespo, F. P. Silveira, J. M. Pilewski, A. A. Petrov. Medicine, University of Pittsburgh, Pittsburgh, PA.
- (825) Allosensitization Increases the Risk of Death on the Lung Transplant Waiting List;**
 C. A. Witt¹, D. E. Byers¹, R. D. Yusen¹, J. A. Iuppa², K. B. Bain², G. A. Patterson³, T. Mohanakumar³, E. P. Trulock¹, R. R. Hachem¹. ¹Internal Medicine, Washington University School of Medicine, Saint Louis, MO, ²Pharmacy, Barnes-Jewish Hospital, Saint Louis, MO, ³Surgery, Washington University School of Medicine, Saint Louis, MO.
- (826) Fat Free Mass, Body Mass Index, and Functional Capacity in Patients Awaiting Lung Transplantation;**
J. M. Dolan¹, C. W. Compher², D. J. Lederer³, N. P. Blumenthal⁴, J. Christie⁵, R. J. Shah⁶. ¹Clinical Nutrition Support Service, Hospital of the University of Pennsylvania, Philadelphia, PA, ²School of Nursing, University of Pennsylvania, Philadelphia, PA, ³Division of Pulmonary, Allergy, and Critical Care Medicine, Columbia University Medical Center, New York, NY, ⁴PENN Transplant Institute, Hospital of the University of Pennsylvania,

SCIENTIFIC PROGRAM

Philadelphia, PA, ⁵Division of Pulmonary, Allergy, and Critical Care Medicine, Hospital of the University of Pennsylvania, Philadelphia, PA, ⁶Division Pulmonary, Allergy, and Critical Care Medicine, Hospital of the University of Pennsylvania, Philadelphia, PA.

(827) *Prevalence of Forged Dysfunction in Pulmonary Fibrosis and COPD Patients Undergoing LTx Evaluation:*

N. Hooff, R. Saggar, M. Smith, E. Kuo, J. Huang, R. Walia, R. Bremner. St. Joseph Hospital and Medical Center, Phoenix, AZ.

(828) *CD25+ Regulatory T Cells in Bronchoalveolar Lavage Fluid Are Associated with Lung Allograft Rejection:*

J. R. Greenland¹, C. M. Wong², R. Ahuja², M. Gottschall³, N. N. Trivedi⁴, J. Kukreja², S. R. Hays¹, J. P. Singer¹, J. A. Golden¹, Q. Tang², G. H. Caughey⁴. ¹Medicine, University of California, San Francisco, CA, ²Surgery, University of California, San Francisco, CA, ³Laboratory Medicine, University of California, San Francisco, CA, ⁴Medicine, VAMC, San Francisco, CA.

NURSING, ALLIED HEALTH,

SOCIAL SCIENCE

(NNSAH)

(829) *Multi-Centre Experience of Donor Choice Consent Forms in the United Kingdom:*

K. E. Morley, S. Clark. Institute of Transplantation, Freeman Hospital, Newcastle upon Tyne, United Kingdom.

(830) *Smoking and Mortality in the Waiting for a New Heart Study:*

G. Weidner¹, K. Gali², J. M. Smits³, H. Spaderna⁴. ¹Biology, San Francisco State University, Sausalito, CA, ²Public Health, University of California, Merced, Merced, CA, ³Eurotransplant International Foundation, Leiden, Netherlands, ⁴Psychology, Bergische Universität Wuppertal, Wuppertal, Germany.

(831) *A Quantitative Assessment of Life with a Left Ventricular Assist Device: Questionnaires, Domains and Format:*

K. E. Sandau¹, B. A. Hoglund¹, C. E. Weaver², C. Boisjolie³, D. S. Feldman⁴. ¹Nursing, Bethel University, St. Paul, MN, ²Transplant, Minneapolis Heart Institute/Abbott Northwestern, Minneapolis, MN, ³Cardiology, Minneapolis Heart Institute/Abbott Northwestern Hospital, Minneapolis, MN, ⁴Cardiology, Minneapolis Heart Institute/Morehouse/Georgia Institute of Technology, Minneapolis, MN.

(832) *Safety of Nurse Driven Ambulation for Patients on Venovenous Extracorporeal Membrane Oxygenation:*

D. R. Dennis¹, B. Boling², T. A. Tribble³, N. Rajagopalan⁴, C. W. Hoopes⁵. ¹Cardiothoracic Transplant, University of Kentucky, Lexington, KY, ²Cardiothoracic and Vascular ICU, University of Kentucky, Lexington, KY, ³Mechanical Circulatory Support, University of Kentucky, Lexington, KY, ⁴Division of Cardiology, University of Kentucky, Lexington, KY, ⁵Division of Cardiothoracic Surgery, University of Kentucky, Lexington, KY.

(833) *Evaluation of GI bleeding in LVAD Patients: A Single Center Review:*

K. Miracle¹, V. Cruz², T. Buda¹, C. Gady¹, M. Mountis³, S. Lee⁴, N. Moazami⁵. ¹Mechanical Circulatory Support Team, Cleveland Clinic, Cleveland, OH, ²Lerner College of Medicine of Case West-

ern Reserve, Cleveland Clinic, Cleveland, OH, ³Medical Director, Mechanical Circulatory Support, Cleveland Clinic, Cleveland, OH, ⁴Heart Failure and Cardiac Transplantation, Department of Cardiovascular Medicine, Cleveland Clinic, Cleveland, OH, ⁵Surgical Director, Center for Heart Failure, Cardiac Transplantation and MCS, Cleveland Clinic, Cleveland, OH.

- (834) Patients With Cystic Fibrosis Have a Better Recovery in Exercise Capacity and Quadriceps Muscle Strength Post-Lung Transplant:**
 J. Walsh¹, D. C. Chambers¹, S. T. Yerkovich¹, N. R. Morris², J. Wilson¹, P. M. Hopkins¹. ¹Queensland Lung Transplant Service, Heart Lung Institute, The Prince Charles Hospital, Brisbane, Australia, ²School of Rehabilitation Sciences and Griffith Health Institute, Griffith University, Gold Coast, Australia.
- (835) Predictors of Physical Activity in a Pre-Lung Transplant Population:**
 J. R. Walsh¹, D. C. Chambers¹, S. T. Yerkovich¹, P. M. Hopkins¹, N. R. Morris². ¹Queensland Lung Transplant Service, Heart Lung Institute, The Prince Charles Hospital, Brisbane, Australia, ²School of Rehabilitation Sciences and Griffith Health Institute, Griffith University, Gold Coast, Australia.

PEDIATRIC TRANSPLANTATION

(PEDS, HF, HTX, MCS)

- (836) Risk-Stratification in Children with Advanced Heart Failure Using Hemodynamic Data:**
 P. M. Alexander, E. D. Blume, K. Gauvreau, E. L. Kehoe, T. P. Singh. Cardiology, Boston Children's Hospital, Boston, MA.
- (837) Clinical Significance of Anti-HLA Antibodies Associated With Ventricular Assist Device Use in Pediatric Patients: A United Network for Organ Sharing Database Analysis:**
 H. S. Magdo, S. Yu, J. Donohue, M. Zamberlan, K. Schumacher, R. Gajarski, J. Friedland-Little. Congenital Heart Center, University of Michigan, C.S. Mott Children's Hospital, Ann Arbor, MI.
- (838) Use and Outcomes of Mechanical Circulatory Support for Myocarditis in Pediatric and Adult Patients in the United States:**
 J. W. Rossano¹, K. D. Miller¹, M. J. O'Connor¹, K. Y. Lin¹, C. E. Mascio², J. E. Rame³, J. W. Gaynor², C. Ravishankar¹, R. E. Shaddy¹. ¹Cardiology, Children's Hospital of Philadelphia, Philadelphia, PA, ²Cardiac Surgery, Children's Hospital of Philadelphia, Philadelphia, PA, ³Cardiology, University of Pennsylvania, Philadelphia, PA.
- (839) Allosensitization after Ventricular Assist Device Does Not Impact Post-Transplant Survival:**
 T. O. Thomas, F. Zafar, D. Morales, M. Khan, C. Chin, A. Lorts, J. L. Jefferies, I. Wilmot, C. Castleberry. The Heart Institute, Cincinnati Children's Hospital Medical Center, Cincinnati, OH.
- (840) Bridging Infants <5 kg: Should We Continue To Offer ECMO?:**
 C. R. Villa, F. Zafar, C. Chin, I. Wilmot, C. Castleberry, T. D. Ryan, J. L. Jefferies, D. L. Morales, A. Lorts. Cincinnati Children's Hospital, Cincinnati, OH.

- (841) Cardiac Transplantation in Children with Chromosomal Anomalies: A Multi-Institutional Outcomes Analysis;**
P. Shamszad, C. T. Sower, T. D. Ryan, C. D. Castleberry, A. Lorts, J. L. Jefferies, I. Wilmot, J. A. Towbin, C. Chin. The Heart Institute, Cincinnati Children's Hospital Medical Center, Cincinnati, OH.
- (842) Home Milrinone Therapy in Pediatric Advanced Heart Failure;**
L. Murray, L. Irby, A. Savage, L. Haney, A. Burnette, M. Kavarana, R. Butts. Pediatric Cardiology, Medical University of South Carolina, Charleston, SC.
- (843) Is Doppler Echocardiography Useful for Estimating Ventricular Filling Pressures in Pediatric Heart Transplant Recipients?;**
F. I. Lunze, K. Gauvreau, S. D. Colan, S. Dillis, E. D. Blume, T. P. Singh. Cardiology, Boston Children's Hospital, Boston, MA.
- (844) Impact of Pre-Sensitization and Positive Virtual Cross-Match on Outcomes in Pediatric Heart Transplantation;**
W. A. Zuckerman, M. E. Richmond, R. K. Singh, T. M. Lee, J. M. McAllister, L. J. Addonizio. Division of Pediatric Cardiology, Columbia University Medical Center, New York, NY.
- (845) The Impact of Right Atrial Pressure on Outcomes in Children with Advanced Heart Failure;**
P. M. Alexander, E. D. Blume, K. Gauvreau, H. J. Bastardi, T. P. Singh. Cardiology, Boston Children's Hospital, Boston, MA.
- (846) Sensitized VADs vs. Sensitized Non-VADs: Is There an Immunological Difference?;**
J. Kobashigawa, J. Moriguchi, N. Reinsmoen, M. Kittleson, Z. Yu, F. Liou, A. Ngan, C. Runyan, H. Henry, D. H. Chang, L. Czer, F. Arabia. Cedars-Sinai Heart Institute, Los Angeles, CA.
- (847) Progression of Left Ventricular Dysfunction in Duchenne and Becker Muscular Dystrophies;**
L. Ridall¹, J. Gralla², P. M. Mourani¹, A. Czaja¹, M. Yang³, C. Cunniff⁴, J. A. Donnelly⁵, E. Ciafaloni⁶, J. Oleszek⁷, S. Pandya⁸, E. Price⁴, S. R. Auerbach⁹. ¹Pediatrics, Division of Critical Care, University of Colorado School of Medicine, Aurora, CO, ²Pediatrics, Children's Hospital Research Institute, University of Colorado School of Medicine, Aurora, CO, ³Neurology, University of Colorado School of Medicine, Aurora, CO, ⁴Pediatrics, University of Arizona College of Medicine, Tucson, AZ, ⁵Colorado Department of Public Health and Environment, Denver, CO, ⁶Pediatrics and Neurology, University of Rochester, Rochester, NY, ⁷Physical Medicine and Rehabilitation, University of Colorado School of Medicine, Aurora, CO, ⁸Neurology, University of Rochester, Rochester, NY, ⁹Pediatrics, Division of Cardiology, University of Colorado School of Medicine, Aurora, CO.
- (848) Importance of Genetic Evaluation in Pediatric Restrictive Cardiomyopathy;**
P. T. Thrush¹, S. J. Kindel², K. Gambetta², J. G. Gossett², J. M. Costello², H. M. Russell³, C. L. Backer³, E. Pahl². ¹Cardiology, Nationwide Children's Hospital, Columbus, OH, ²Cardiology, Ann & Robert H. Lurie Children's Hospital, Chicago, IL, ³Cardiovascular Thoracic Surgery, Ann & Robert H. Lurie Children's Hospital, Chicago, IL.
- (849) Post-Transplant Outcomes of Pediatric Patients Bridged with Continuous Flow Left Ventricular Assist Devices;**
A. Levin¹, R. K. Singh¹, J. Fried¹, M. E. Richmond¹, W. A. Zuckerman¹, A. R. Garan¹, K. P. Mody¹, H. Takayama¹, M. Yuzefpolskaya¹, P. C. Colombo¹, M. Dionizovik-Dimanovski¹, Y. Naka², L. J. Addonizio¹, U. P. Jorde¹, N. Uriel¹. ¹Medicine, Columbia University, New York, NY, ²Surgery, Columbia University, New York, NY.

(850) Post Heart Transplant (HT) Survival in Pediatric Patients with Left Ventricular and Biventricular Assist Devices (LVAD/BIVAD): UNOS Registry Analysis;

L. C. Reardon¹, J. C. Alejos², A. A. Nsair³, R. M. Biniwale⁴, M. C. Deng³, B. Reemtsen⁴, A. Ardehali⁴, E. C. Depasquale³. ¹Adult and Pediatric Cardiology, UCLA, Los Angeles, CA, ²Pediatric Cardiology, UCLA, Los Angeles, CA, ³Adult Cardiology, UCLA, Los Angeles, CA, ⁴Cardiothoracic Surgery, UCLA, Los Angeles, CA.

(851) Outcomes of Pediatric Heart Failure Referral;

J. D. Sparks¹, M. Bichanich², K. P. Simpson¹, C. E. Canter¹. ¹Pediatric Cardiology, Washington University in St. Louis, St. Louis, MO, ²School of Medicine, Washington University in St. Louis, St. Louis, MO.

(852) Hospital Charges for Pediatric Heart Failure Related Hospitalizations Admissions in the United States from 2000 to 2009;

D. Nandi¹, K. Y. Lin¹, M. J. O'Connor¹, O. U. Elci², J. J. Kim³, J. A. Decker⁴, J. F. Price³, F. Zafar⁵, D. L. Morales⁵, S. W. Denfield³, W. J. Dreyer³, J. L. Jefferies⁵, J. W. Rossano¹. ¹The Cardiac Center, Children's Hospital of Philadelphia, Philadelphia, PA, ²Westat-CHOP, Rockville, MD, ³Department of Pediatrics, Lillie Frank Abercrombie Section of Pediatric Cardiology, Baylor College of Medicine, Texas Children's Hospital, Houston, TX, ⁴Johns Hopkins All Children's Heart Institute, St Petersburg, FL, ⁵The Heart Institute, Cincinnati Children's Hospital, Cincinnati, OH.

(853) HAVE You Been Fully Evaluated? The Hypertension and Vascular Evaluation Program Detects Nocturnal and Masked Hypertension as Well as Increased Carotid Intima-Media Thickness in Pediatric Heart Transplant Recipients;

C. Bober¹, J. Rossano¹, A. Huante², K. Lin¹, C. Laney³, M. Crane¹, K. Meyers³, S. Natarajan¹. ¹Cardiology, Children's Hospital of Philadelphia, Philadelphia, PA, ²Nephrology, Instituto Nacional de Pediatría, Mexico City, Mexico, ³Nephrology, Children's Hospital of Philadelphia, Philadelphia, PA.

Quality of Life, Ethics, Policy**and the Economics of Thoracic****Transplantation and MCS****(PEEQ)****(854) Impact of Early Major Adverse Events on Quality of Life After Mechanical Circulatory Support;**

J. Holtz, M. A. Dew, M. McNulty, K. Lockard, N. Kunz, E. Dunn, J. Bhama, C. Bermudez, M. Shullo, R. Kormos, J. Teuteberg. Cardiology, University of Pittsburgh Medical Center, Pittsburgh, PA.

(855) Canadian Society of Transplantation (CST) Members' Views on Anonymity in Organ Transplantation;

M. Gewarges¹, J. Poole², E. De Luca¹, M. Shildrick³, S. Abbey⁴, O. Mauthner¹, H. J. Ross¹. ¹Department of Cardiology and Transplantation, Toronto General Hospital, Toronto, ON, Canada, ²School of Social Work, Faculty of Community Services, Ryerson University, Toronto, ON, Canada, ³Department of Thematic Studies – Gender Studies, Linköping University, Linköping, Sweden, ⁴Department of Psychiatry, Toronto General Hospital, Toronto, ON, Canada.

PULMONARY HYPERTENSION

(PH)

(856) Clinical Significance of Gastroesophageal Reflux Disease and Proton Pump Inhibitor Use in Pulmonary Arterial Hypertension:

G. Ramani¹, D. Lam², M. Park³. ¹University of Maryland, Baltimore, MD, ²United Therapeutics Corporation, Durham, MD, ³Medicine, University of Maryland, Baltimore, MD.

(857) Rapid Inpatient Titration of Intravenous Treprostinil for Severe Pulmonary Arterial Hypertension:

L. Hansen, F. Rischard, S. Knoper. Pulmonary, University of Arizona, Tucson, AZ.

(858) S-Nitroso Human Serum Albumin Vs Inhaled Nitric Oxide in Experimental Right Ventricular Failure on Prolonged Overcirculation-Induced Pulmonary Hypertension:

A. Rungatscher¹, S. Hallström², D. Linardi¹, E. Milani¹, K. Gandhi¹, G. Luciani¹, A. Mazzucco¹, G. Faggian¹. ¹University of Verona, Verona, Italy, ²University of Graz, Graz, Austria.

(859) Effects of Acute Volume Loading on the Chronically Pressure Overloaded Right Ventricle:

D. Boulate¹, F. Haddad², D. Chemla³, B. Decante¹, J. Guihaire¹, P. Dartevelle⁴, O. Mercier⁴, E. Fadel⁴. ¹Laboratory of Surgical Research, Marie Lannelongue Surgical Center, Le Plessis Robinson, France, ²Biomarker and Phenotype Core Laboratory, Cardiovascular Institute Stanford University, Stanford, CA, ³Physiology Department, CHU Bicetre - Université Paris XI, Le Kremlin Bicetre, France, ⁴Thoracic and Vascular Surgery and Heart-Lung Transplantation, Marie Lannelongue Surgical Center, Le Plessis Robinson, France.

(860) A Porcine Model of Chronic Right Ventricular Pressure Overload: Pulmonary Hemodynamics Over 16 Weeks, and Effects of Acute Embucrylate Embolization:

D. Boulate¹, E. Fadel², D. Chemla³, F. Haddad⁴, B. Decante¹, J. Guihaire¹, P. G. Dartevelle², O. Mercier¹. ¹Laboratory of Surgical Research, Marie Lannelongue Surgical Center, Le Plessis Robinson, France, ²Thoracic and Vascular Surgery and Heart-lung Transplantation, Marie Lannelongue Surgical Center, Le Plessis Robinson, France, ³Physiology Department, CHU Bicetre – Université Paris XI, Le Kremlin Bicetre, France, ⁴Biomarker and Phenotype Core Laboratory, Cardiovascular Institute Stanford University, Stanford, CA.

(861) Hemodynamics of Pulmonary Hypertension in the Setting of Hereditary Hemorrhagic Telangiectasia:

M. A. Lyle¹, E. R. Fenstad², M. D. McGoon², R. P. Frantz², M. J. Krowka³, G. C. Kane², K. L. Swanson⁴. ¹Division of Internal Medicine, Mayo Clinic, Rochester, MN, ²Division of Cardiovascular Diseases, Mayo Clinic, Rochester, MN, ³Division of Pulmonary and Critical Care Medicine, Mayo Clinic, Rochester, MN, ⁴Division of Pulmonary and Critical Care Medicine, Mayo Clinic, Scottsdale, AZ.

(862) Serum Markers of Vascular Angiogenesis and Inflammation Are Predictive of Functional Capacity and Invasive Hemodynamics in Patients with Pulmonary Arterial Hypertension:

A. Raina¹, L. Zhang², R. L. Benza¹. ¹Cardiovascular Institute, Allegheny General Hospital, Pittsburgh, PA, ²United Therapeutics Corporation, Research Triangle Park, NC.

- (863) Pulmonary Vasodilators Can Reverse Out-of-Proportional Pulmonary Hypertension in Patients with Left Cardiac Disease;**
H. Maki¹, M. Hatano¹, H. Muraoka¹, S. Minatsuki¹, T. Fujino¹, T. Imamura¹, T. Inaba¹, A. Yao², K. Kinugawa³, I. Komuro¹.
¹Cardiovascular Medicine, University of Tokyo, Tokyo, Japan, ²Department of Health Service Promotion, University of Tokyo, Tokyo, Japan, ³Department of Therapeutic Strategy for Heart Failure, University of Tokyo, Tokyo, Japan.
- (864) Endothelin-1 Levels in Patients With Heart Failure With Normal Ejection Fraction and Pulmonary Venous Hypertension;**
A. Moza, A. Ali, G. W. Moukarbel, P. Bhat, J. Tian, S. J. Khouri.
 Cardiovascular Medicine, University of Toledo Medical Center, Toledo, OH.
- (865) Soluble Vascular Endothelial Growth Factor Receptor -1 (sFlt-1) Is Decreased in Patients With Pulmonary Arterial Hypertension;**
N. Selimovic¹, F. Khaliel¹, L. Mattsson Hulten². ¹Heart Centre, King Faisal Specialist Hospital & Research Centre, Riyadh, Saudi Arabia, ²Wallenberg Laboratory, University of Gothenburg, Gothenburg, Sweden.
- (866) Surgical Treatment of Chronic Thromboembolic Pulmonary Hypertension: from Transplantation to Endarterectomy;**
 A. M. D'Armini¹, M. Morsolini¹, G. Mattiucci¹, V. Grazioli¹, M. Pin¹, A. Valentini², C. Goggi¹, R. Dore². ¹Cardiac Surgery, University of Pavia School of Medicine, Foundation I.R.C.C.S. San Matteo Hospital, Pavia, Italy, ²Radiology, University of Pavia School of Medicine, Foundation I.R.C.C.S. San Matteo Hospital, Pavia, Italy.

PHARMACY AND PHARMACOLOGY

(PHARM)

- (867) Antithymocyte Globulin Therapy for Chronic Lung Allograft Dysfunction Following Lung Transplantation;**
 E. George, S. Ivulich, M. Paraskeva, B. Levvey, G. Snell, G. P. Westall. Lung Transplant Service, Alfred Hospital, Melbourne, Australia.
- (868) Assessment of Medication Regimen Complexity Over Time Following Heart Transplantation;**
B. M. Bryant¹, A. M. Libby², K. Metz², R. L. Page², J. A. Lindenfeld³, C. L. Aquilante¹. ¹Department of Pharmaceutical Sciences, University of Colorado, Aurora, CO, ²Department of Clinical Pharmacy, University of Colorado, Aurora, CO, ³Division of Cardiology, University of Colorado, Aurora, CO.
- (869) Safety of Anticoagulation Reversal in Patients Supported With Continuous-Flow Left-Ventricular Assist Devices;**
D. L. Jennings¹, M. Jacob², A. Chopra², C. W. Nemerovski³, J. A. Morgan⁴, D. E. Lanfear⁵. ¹Pharmacy Practice, Nova Southeastern University, Ft. Lauderdale, FL, ²Wayne State University, Detroit, MI, ³Pharmacy Services, Henry Ford Hospital, Detroit, MI, ⁴Cardiac Surgery, Henry Ford Hospital, Detroit, MI, ⁵Cardiovascular Medicine, Henry Ford Hospital, Detroit, MI.

(870) PCC for Warfarin Reversal in High Risk Pediatric Cardiac Transplantation;

A. L. Haney¹, R. J. Butts², A. J. Savage², W. E. Uber¹, M. N. Kavarana³. ¹Department of Pharmacy, Medical University of South Carolina, Charleston, SC, ²Department of Pediatric Cardiology, Medical University of South Carolina, Charleston, SC, ³Department of Pediatric Cardiac Surgery, Medical University of South Carolina, Charleston, SC.

(871) Anticoagulation for the HeartWare HVAD: An International Comparison of Strategies and Outcomes;

D. L. Jennings¹, R. M. Gellatly², E. G. Szandzik³, A. Leet⁴, D. E. Lanfear⁵. ¹Pharmacy Practice, Nova Southeastern University, Ft. Lauderdale, FL, ²Pharmacy, Alfred Hospital, Melbourne, Australia, ³Pharmacy Services, Henry Ford Hospital, Detroit, MI, ⁴Department of Cardiology, Alfred Hospital, Melbourne, Australia, ⁵Cardiovascular Medicine, Henry Ford Hospital, Detroit, MI.

(872) Phenprocoumon in Heartware Ventricular Assist Device Patients – A New Regimen for Early Postoperative Anticoagulation;

Y. Schneeberger¹, M. Kubik², C. Oelschner¹, H. Reichenspurner¹, T. Deuse¹. ¹Department of Cardiac Surgery, University Heart Center Hamburg, Hamburg, Germany, ²Department of Anaesthesiology, University Heart Center Hamburg, Hamburg, Germany.

PATHOLOGY

(PATH)

(873) Characterization of Lymphoid Clusters in the Transplanted Heart; an Effort To Form Tertiary Lymphoid Clusters?;

M. M. Huibers¹, A. Gareau², T. D. Lee², R. Kruit¹, H. Feringa¹, E. Siera-de Koning¹, N. de Jonge³, R. A. de Weger¹. ¹Pathology, University Medical Center Utrecht, Utrecht, Netherlands, ²Department of Microbiology & Immunology, Department of Surgery, Dalhousie University, Halifax, NS, Canada, ³Cardiology, University Medical Center Utrecht, Utrecht, Netherlands.

(874) An International Tutorial for Cardiac Acute Cellular Rejection;

S. Yoshizawa¹, O. Nikolskaia², L. A. Batoroeva³, Y. K. Batoroiev⁴, O. Leone⁵, C. Toquet⁶, J. Duong Van Huyen⁷, P. Bruneval⁷, R. Roberta⁸, J. Majo⁸, S. H. Litovsky⁹, M. K. Halushka². ¹Pathology, Columbia University, New York, NY, ²Pathology, Johns Hopkins University SOM, Baltimore, MD, ³Scientific Center of Reconstructive and Restorative Surgery, Siberian Branch, Russian Academy of Medical Sciences, Irkutsk, Russian Federation, ⁴Irkutsk Institute for Postgraduate Medical Education, Irkutsk Institute for Postgraduate Medical Education, Irkutsk, Russian Federation, ⁵Poloclinico S. Orsola-Malpighi, Bologna, Italy, ⁶University Hospital, Nantes, France, ⁷Université Paris Descartes Médecine, Paris, France, ⁸Royal Victoria Infirmary, Newcastle upon Tyne, United Kingdom, ⁹Pathology, University of Alabama at Birmingham, Birmingham, AL.

(875) Localization of microRNAs in Cardiac Allograft Vasculopathy With In Situ Hybridization; a Role in Immune Regulation and/or Fibrosis?;

M. M. Huibers¹, B. van Holthe tot Echten¹, T. Peeters¹, N. de Jonge², G. Tellides³, R. A. de Weger¹. ¹Pathology, University Medical Center Utrecht, Utrecht, Netherlands, ²Cardiology, University Medical Center Utrecht, Utrecht, Netherlands, ³Surgery, Yale University, New Haven, CT.

EXHIBITORS




Alphabetical Listing of Exhibiting Companies

BOOTH #	EXHIBITING COMPANY
117	Actelion Pharmaceuticals (Commercial)
118	Actelion Pharmaceuticals (Medical)
413	Alere Home Monitoring
205	Bayer Healthcare
323	Berlin Heart
123	Biologic TX
423	Carmat
222	Centurion Medical Products
224	CHI St. Luke's Health
416	CorMatrix CV, Inc.
419	CSL Behring
125	Elsevier
417	Essential Pharmaceuticals
409	Genentech
317	Gilead Sciences, Inc.
311	HeartWare
126	ImaCor, Inc.
324	INTERMACS
420	ISHLT IMACS
422	ISHLT Registry


BOOTH #	EXHIBITING COMPANY
321	Jarvik Heart
221	Maquet Medical Systems
106	Miller Pharmacal Group, Inc
108	One Lambda, Inc. part of Thermo Fisher Scientific
121	Orthodynamics Company, Inc.
104	Scanlan International, Inc.
122	Scholten Surgical Instruments, Inc.
225	Sunshine Heart
320	SynCardia Systems, Inc.
418	Teleresults Corp
102	Thoratec Corp
111	TransMedics, Inc
424	United Network for Organ Sharing
105	United Therapeutic
124	Viracor-IBT Laboratories
421	Vivoline Medical AB
405	XDx
217	XVIVO Perfusion AB

EXHIBIT HALL FLOORPLAN



LIST OF EXIBITORS BY BOOTH NUMBER

- | | | | |
|------------|--|------------|-------------------------------------|
| 102 | Thoratec Corp | 121 | Orthodynamics Company, Inc. |
| 104 | Scanlan International, Inc. | 122 | Scholten Surgical Instruments, Inc. |
| 105 | United Therapeutic | 123 | Biologic TX |
| 106 | Miller Pharmacal Group, Inc | 124 | Viracor-IBT Laboratories |
| 108 | One Lambda, Inc.
part of Thermo Fisher Scientific | 125 | Elsevier |
| 111 | TransMedics, Inc | 126 | ImaCor, Inc. |
| 117 | Actelion Pharmaceuticals
(Commercial) | 205 | Bayer Healthcare |
| 118 | Actelion Pharmaceuticals
(Medical) | 217 | XVIVO Perfusion AB |
| | | 221 | Maquet Medical Systems |
| | | 222 | Centurion Medical Products |



LIST OF EXHIBITORS BY BOOTH NUMBER

- | | | | |
|------------|-------------------------|------------|----------------------------------|
| 224 | CHI St. Luke's Health | 416 | CorMatrix CV, Inc. |
| 225 | Sunshine Heart | 417 | Essential Pharmaceuticals |
| 311 | HeartWare | 418 | Teleresults Corp |
| 317 | Gilead Sciences, Inc. | 419 | CSL Behring |
| 320 | SynCardia Systems, Inc. | 420 | ISHLT IMACS |
| 321 | Jarvik Heart | 421 | Vivoline Medical AB |
| 323 | Berlin Heart | 422 | ISHLT Registry |
| 324 | INTERMACS | 423 | Carmat |
| 405 | XDx | 424 | United Network for Organ Sharing |
| 409 | Genentech | | |
| 413 | Alere Home Monitoring | | |

ACTELION PHARMACEUTICAL**117 · 118**

**5000 Shoreline Ct. South
San Francisco, CA 94080
Web address: www.actelionus.com**

Actelion Ltd. is a leading biopharmaceutical company focused on the discovery, development and commercialization of innovative drugs for diseases with significant unmet medical needs.

Actelion is a leader in the field of pulmonary arterial hypertension (PAH). Our portfolio of PAH treatments covers the spectrum of disease, from WHO Functional Class (FC) II through to FC IV, with oral, inhaled and intravenous medications.

Although not available in all countries, Actelion has treatments approved by health authorities for a number of specialist diseases including Type 1 Gaucher disease, Niemann-Pick type C disease, Digital Ulcers in patients suffering from systemic sclerosis, and mycosis fungoides in patients with cutaneous T-cell lymphoma.

ALERE HOME MONITORING**413**

**30 S. Keller Road, Suite 100 B
Orlando, FL 32810
Web address: www.alere.com/us/en/health-solutions/home-monitoring/vadcare-program.html**

Alere Home Monitoring, through its Alere VAD-Care[®] Program, provides equipment and services for VAD patients and hospital VAD departments. Our newest offering, the Alere VADWatch[®] Tele-monitoring Program allows VAD Coordinators and Physicians to monitor patients after discharge by providing them with alerts when critical patient values are outside of a pre-established acceptable range. The Alere VADWatch[®] Tele-monitoring Program is perfectly designed to help reduce hospital readmissions. In addition, we enable VAD patients to monitor their INR at home using our industry leading home anticoagulation monitoring services.

**100 Bayer Blvd
Whippany, NJ 07901
Web address: www.bayerpharma.com**

Bayer HealthCare is one of the world's leading, innovative companies in the healthcare and medical products industry, and combines the activities of the Animal Health, Consumer Care, Medical Care and Pharmaceuticals divisions. As a specialty pharmaceutical company, Bayer HealthCare provides products for Cardiopulmonary, Hematology, Neurology, Oncology and Women's Healthcare.

**200 Valleywood Rd, Ste A500
The Woodlands, TX 77380
Web Address: www.berlinheart.com**

Berlin Heart, the only company worldwide, that develops, manufactures and distributes VADs for patients of every age and body size. EXCOR® Pediatric provides medium to long-term circulatory support specifically for infants and children awaiting heart transplants. EXCOR Pediatric is approved for use in the USA under HDE regulations by FDA.

**40-D Commerce Way
Totowa, NJ 07512
Web address: www.BiologicTx.com**

BiologicTx® specializes in the administration of intravenous biologic therapies. After the patient has been successfully transplanted, BiologicTx® will provide comprehensive management of their oral immunosuppressive regime, ensure compliance and provide necessary biologic interventions. Our philosophy is to lead, manage and care with the highest level of respect, integrity and dignity.

CARMAT**423**

**36, AVENUE DE L'EUROPE
78941 VELIZY VILLACOUBLAY CEDEX
FRANCE
Web address: www.carmatsa.com**

CARMAT (the contraction of its founders' names, Pr Carpentier and Matra – now part of Airbus Group) develops a bioprosthetic implantable artificial heart, as well as its power supply and remote monitoring systems. The key differentiating features of this project are the use of bovine pericardium for most parts in contact with blood – including the pulsatile internal membrane – and real-time adjustment of flow and rate thanks to embedded sensors and electronics. CARMAT heart is an investigational device only. It started its First-in-Man trial in France in December 2013 and is not approved for clinical use anywhere in the world.

CENTURION MEDICAL PRODUCTS**222**

**100 Centurion Way
Williamston, MI 48895
Web address: www.centurionmp.com**

Centurion Medical Products specializes in creating customized sterile procedural trays (e.g., dressing change trays, line maintenance bundles) designed to meet your special requirements. We also develop and manufacture catheter dressings featuring SorbaView SHIELD, an all-in-one catheter dressing with a built-in stabilization device that prevents catheter movement and dislodgement. In addition to the SHIELD, we offer a full line of unique securement devices, including our Foley Anchor designed to stabilize urinary catheter tubing and LVAD drivelines.

Centurion products help lower the risk of infection, reduce hospital readmissions, increase efficiency, lower costs per procedure and improve outcomes for medical professionals and patients.

Baylor St. Luke's Medical Center
6720 Bertner Ave.
Houston TX 77030
Web address: www.stlukeshouston.com

For over 30 years, Baylor St. Luke's Medical Center (BSLMC) has been recognized as one of the nation's most experienced transplant centers in the world. Performing over 3,500 transplants since 1982, BSLMC is a leader in heart, lung, heart-lung, liver and kidney transplantation. It is also a premier center for the implantation of VADs. BSLMC recently commemorated its 1000th VAD implantation – more than any other program in the country. BSLMC is committed to providing high quality care for the patients we serve. Our transplant programs are consistently recognized for their successful outcomes and innovative approaches to the treatment of organ failure.

1100 Old Ellis Road
Roswell, GA 30076
Web address: www.cormatrix.com

CorMatrix® Cardiovascular markets its ECM® Bioscaffold devices for carotid repair, pericardial repair and reconstruction, and cardiac tissue repair, and is currently conducting preclinical studies to evaluate future applications in other cardio and vascular applications.

CSL BEHRING**419**

1020 First Ave
King of Prussia, PA 19406
Web address: www.cslbehring-us.com

CSL Behring is a global leader in plasma protein therapeutics. The company manufactures safe and effective plasma-derived and recombinant therapies for treating coagulation disorders, primary immune deficiencies, hereditary angioedema and inherited respiratory disease, and neurological disorders in certain markets. The company's products are also used in cardiac surgery, organ transplantation, burn treatment and to prevent hemolytic disease of the newborn. CSL Behring is a subsidiary of CSL Limited (ASX:CSL), a biopharmaceutical company with headquarters in Melbourne, Australia. For more information: www.cslbehring-us.com.

ELSEVIER**125**

1600 JFK Blvd, Suite 1800
Philadelphia, PA 19103
Web address: www.elsevierhealth.com

ELSEVIER is a leading publisher of health science publications, advancing medicine by delivering superior reference information and decision support tools to doctors, nurses, health practitioners and students. With an extensive media spectrum—print, online and handheld, we are able to supply the information you need in the most convenient format.

ESSENTIAL PHARMACEUTICALS**417**

770 Newtown Yardley Road – Suite 212
Newtown PA 18940
Web address: www.essentialpharma.com
www.custodiol.com

Essential Pharmaceuticals is a specialty pharmaceutical company devoted solely to the development and sales of exclusive branded pharmaceutical products including Custodiol® HTK organ preservation solution. Custodiol®

HTK, with its easy handling characteristics, water like viscosity and no need for additives or filters make it a preferred solution for many transplant centers.

GENENTECH

409

**1 DNAWay
South San Francisco, CA 94080
Web address: www.gene.com**

For more than 30 years, we've been following the science, seeking solutions to unmet medical needs. As a proud member of the Roche Group, we make medicines to treat patients with serious medical conditions.

We are headquartered in South San Francisco, California.

GILEAD SCIENCES, INC.

317

**333 Lakeside Dr
Foster City, CA 94404
Web address: www.gilead.com**

Gilead Sciences, Inc. is a research-based biopharmaceutical company that discovers, develops and commercializes innovative medicines in areas of unmet medical need. We strive to transform and simplify care for people with life-threatening illnesses around the world. Gilead's portfolio of products and pipeline of investigational drugs includes treatments for HIV/AIDS, liver diseases, serious respiratory and cardiovascular conditions, cancer and inflammation.

Our portfolio of marketed products includes a number of category firsts, including the first complete treatment regimens for HIV infection available in a once-daily single pill and the first oral antiretroviral pill available to reduce the risk of acquiring HIV infection in certain high-risk adults.

HEARTWARE**311**

205 Newbury Street
Framingham, MA 01701
Web address: www.heartware.com

HeartWare is a global medical device company dedicated to delivering safe, high-performing and transformative therapies that enable patients with heart failure to get back to life. The company's innovative technologies are creating advances in the miniaturization of Ventricular Assist Devices (VADs) leading to less invasive surgical procedures and increasing the patient population who may be suitable for VAD therapy. HeartWare's breakthrough innovations begin with the HVAD® Pump, designed to be implanted next to the heart in the pericardial space avoiding the more invasive surgical procedures required with older LVAD technologies. The HVAD Pump is commercially available around the world.

IMACOR, INC.**126**

839 Stewart Ave
Suite 3
Garden City, NY 11530
Web address: www.imacorinc.com

ImaCor, Inc. is a privately held company headquartered in Garden City, NY. The company designs, manufactures and distributes advanced solutions for hemodynamic management in critical care to improve patient outcomes and healthcare resource utilization. Continuously available direct cardiac visualization with hemodynamic TEE (hTEE™) allows clinicians to optimize cardiac performance in order to assess the effectiveness of therapies and make critical changes in management over time.

ImaCor manufactures the ClariTEE® probe, the only miniaturized, indwelling TEE probe suitable for long-term clinical settings. hTEE™, Zura™, Zura EVO™, Adaptaflex™ and ClariTEE® are trademarks of ImaCor, Inc.

Interagency Registry for Mechanically Assisted Circulatory Support
701 19th Street South, 790 LHRB
Birmingham, AL 35294
Web address: www.intermacs.org

The Interagency Registry for Mechanically Assisted Circulatory Support is a prospective North American registry established in 2005 for patients who are receiving mechanical circulatory support device therapy to treat advanced heart failure.

These activities are supported by the INTERMACS® administrative center, analysis center and the data coordinating center under contract to the National Heart, Lung and Blood Institute (NHLBI). The purpose of the registry is to collect and analyze clinical and laboratory data from patients who are receiving MCSDs for whom discharge from the hospital is feasible. INTERMACS™ provides contemporary data to demonstrate the continued progress of outcomes, with additional insight into appropriate risk stratification and patient selection.

ISHLT Mechanically Assisted Circulatory Support Registry
701 19TH Street South, LHRB 790
Birmingham, AL 35294
Web address: www.isHLT.org/registries/mcsdDatabase.asp

IMACS is an international registry intended to enroll and follow patients who receive durable mechanically assisted circulatory support devices (MCSd) in all countries and hospitals that wish to participate. Durable devices are defined as those devices that are capable of allowing patient discharge with the device in place.

The primary goal of IMACS is to create, implement and analyze a registry that contains high standards for complete enrollment of patients and complete and accurate submission of MCSd data that allows participating centers to engage in important outcomes research about mechanical support devices.

ISHLT REGISTRY**422**

**700 North 4th St
Richmond, Virginia 23219
WEB address: ishlthelp@unos.org**

The ISHLT Transplant Registry was created to collect on-going, current information on the worldwide thoracic organ transplantation experience.

Our registry is the only one of its kind. The data we maintain is utilized for scientific study and contributes to the body of knowledge regarding thoracic transplantation. Our goal is to identify overall and best practices for improving cardio-thoracic patient care.

This year the exhibit will make center-specific information available for review by ISHLT Transplant Registry participants. In addition, data screens can be reviewed and we will provide guidance on enrollment, submission of data and data request services.

JARVIK HEART**321**

**333 West 52nd St.
New York, NY 10019
Web Address: www.jarvikheart.com**

Jarvik Heart, Inc. is a privately held, New York based company that develops and manufactures miniaturized heart assist devices for the treatment of severe heart failure. The Jarvik 2000 is a battery-powered axial-flow left ventricular assist device (LVAD). It is the smallest implantable blood pump available for the long-term treatment of Heart Failure.

45 Barbour Pond Dr.
Wayne NJ 07470
Web address: www.maquet.com/us

MAQUET Medical Systems, USA is a market leader offering a comprehensive portfolio of products utilized in the Hybrid OR, ICU, Cath Lab which are designed to meet the needs of clinical professionals in the areas of: surgery, cardiac intervention, peripheral intervention, dialysis, perfusion, anesthesia and respiratory. MAQUET is focused on improving patient care and quality of life, providing clinicians with future-oriented technology that fits their daily practice and investing in the development of innovative technologies and solutions that will help further advance clinical practice and significantly improve patient outcomes.

350 Randy Rd Ste 2 Carol
Stream, IL 60188
Web address: www.mgplusprotein.com

Miller Pharmacal's magnesium supplement "MG Plus Protein" is used at many transplant centers for the treatment and prevention of the hypomagnesemia caused by CI's, without the GI disturbances common with magnesium oxide.

"MG Plus Protein" is: well-tolerated, effective, inexpensive and easy for patients to swallow.

ONE LAMBDA, INC.**108**

Part of Thermo Fisher Scientific
21001 Kittridge Street
Canoga Park, California 91303
Web address: www.onelambda.com

One Lambda, Inc., part of Thermo Fisher Scientific, has introduced a new standard of care in the transplantation with our line of antibody detection products featuring the LABScreen® Single Antigen Assays for DSA Monitoring. In antibody profiling, the ClqScreen and AT1R assays have transformed the transplant community. Furthermore, in HLA Typing, the new LABType® XR Kit with greater exon coverage and the LABType® CWD kits will allow detection of all common and well documented alleles. Bridging our current technologies in antibody detection and HLA Typing to the next generation platforms is our commitment to the global transplant community. Visit us at www.onelambda.com.

ORTHODYNAMICS COMPANY, INC.**121**

155 Carey Dr.
Noblesville, IN 46060
Web address: www.orthodynamics.com

Since 2004, Orthodynamics has become a leader in the MCS Outpatient Equipment and Supply industry. Focused on patient care and a team approach, our system allows patients to access products and services through manufacturers we represent nationwide. Our strategic alliances with hospitals, clinicians and major insurance carriers, give us the ability to provide a high level of service to patients and healthcare professionals

**One Scanlan Plaza
Saint Paul, Minnesota 55107
Phone: 651-298-0997
Fax: 651-298-0018
Web site: www.scanlaninternational.com
E-mail: info@scanlangroup.com**

Highest quality surgical products designed and manufactured by the Scanlan family since 1921. Over 3,000 titanium and stainless steel instrument designs including needle holders, forceps, scissors, clamps and specialty instruments. Featured instruments include the SCANLAN® LEGACY titanium needle holders and forceps, full line of VATS/MIS Thoracoscopic instruments including the Chitwood Clamp, Knot Pusher, and SUPER CUT™ Suture Cutter; Axial Handle needle holders and forceps, SUPER CUT™ Scissors and Rendina needle holder. Single-use products include: VASCU-STAT™ bull-dog clamps, Aorta/Vein Punch and A/C Locator® graft markers. Also offering custom instrument designs and modifications for your individual needs.

**170 Commerce St., Suite 101
Lodi, CA 95240
Web address: www.bioptome.com**

For more than thirty-five years SSI has manufactured high quality endomyocardial biopsy forceps. The Scholten disposable Bioptome model is called the Novatome™ and, like its predecessors, is specially designed to acquire maximum specimen size for more accurate pathology results. Our device has earned a reputation for its ease of use, heart rhythm feedback and is considered the "gold standard" by many. With our innovative design paired with over three decades of clinical experience makes our device the best choice for safety and performance. With the Novatome™, SSI continues to provide reliability, value and forceps of the highest quality to your industry.

SUNSHINE HEART**225**

12988 Valley View Road
Eden Prairie, MN 55344
Web address: www.Sunshineheart.com

The C-Pulse® Heart Assist System is a balloon counter-pulsation technology used to treat patients with moderate to severe heart failure (Class III/ Ambulatory Class IV). The implantable device is placed outside the bloodstream and gives patients the ability to disconnect from the system. Preliminary results of the C-Pulse System have indicated relief of heart failure symptoms, improved quality of life and cardiac function, and reduced the need for heart failure hospitalization. The C-Pulse implant procedure can be performed minimally invasively. The European Post-Market Study (OPTIONS HF) and the US Investigational Pivotal Trial (COUNTER HF™) are currently underway.

SYNCARDIA SYSTEMS, INC.**320**

1992 E. Silverlake Road
Tucson, Arizona 85713
Web address: www.syncardia.com

The SynCardia temporary Total Artificial Heart (TAH-t) is the world's only FDA, Health Canada and CE approved Total Artificial Heart. The TAH-t is currently approved as a bridge to transplant for patients dying from end-stage biventricular failure. The 13.5 lb Freedom® portable driver has received CE approval in Europe and has completed an IDE clinical study in the U.S. The Freedom driver is designed to provide mobility for stable TAH patients both inside and outside the hospital. Visit our booth for updates on pediatric and other expanding usage and the 50cc TAH clinical study.

**870 Market Street, Suite 556
San Francisco, CA 94102
Web address: www.teleresults.com**

TeleResults Presidio is a proven organ disease and transplant management information system designed to enhance patient care while helping medical centers increase efficiency and meet regulatory compliance. Our thoracic disease modules include comprehensive support for VAD, CHF and PH. The VAD module records and manages all phases of patient care, includes an Equipment Tracking module for managing devices and other equipment, and includes INTERMACS™ registry support by providing report generation for patient registration submission. Presidio interfaces with hospital information systems, labs (internal and external), UNOS UNet for transplant forms, and supports e-prescribing. Online web site access is available for patients, clinicians and prospective living donor applicants."

**6035 Stoneridge Dr.
Pleasanton, CA 94588
Web address: www.thoratec.com**

Thoratec is the world leader in mechanical circulatory support with the broadest product portfolio to treat the full range of clinical needs for patients suffering from advanced heart failure. The company's products include the HeartMate LVAS and Thoratec VAD, with more than 20,000 devices implanted in patients suffering from heart failure. Thoratec also manufactures and markets the CentriMag and PediMag/PediVAS product lines. Thoratec is headquartered in Pleasanton, California. For more information, visit www.thoratec.com

TRANSMEDICS, INC.**111**

**200 Minuteman Road, Suite 302
Andover, MA 01810
Web address: www.transmedics.com**

TransMedics is dedicated to extending the life-saving benefits of transplantation to patients suffering from organ failure. The Organ Care System (OCS™) is a portable, advanced ex-vivo perfusion, monitoring and organ recruitment platform for heart and lung transplantation. The OCS maintains donor organs in a functioning state from donor to recipient and aims to enable more efficient use of potential donor organs and enhance patient outcomes.

The OCS HEART and OCS LUNG systems are CE-marked and in clinical use in leading worldwide transplant centers and in pivotal FDA trials in leading transplant centers.

UNITED NETWORK FOR ORGAN SHARING**424**

**700 North 4th Street
Richmond, VA 23219
Web address: www.unos.com**

United Network for Organ Sharing (UNOS) is the non-profit membership organization that manages the transplant system in the United States, or the Organ Procurement and Transplantation Network (OPTN), under contract with the federal government. UNOS advances organ availability and transplantation by uniting and supporting its communities for the benefit of patients through education, technology and policy development. Tii Informatix, a business unit of UNOS, provides transplant systems consulting, education, technology solutions and assessment services to international governments and healthcare organizations. Tii designs and operates clinical registries including INTERMACS, the ISHLT Global Thoracic Registry and IMACS, as well as, post market surveillance and outcome studies for pharmaceutical and device companies. www.tii-informatix.com

**55 TW Alexander Dr.
Research Triangle Park, NC 27709
Web address: www.unitedtherapeutics.com**

United Therapeutics Corporation is a biotechnology company focused on the development and commercialization of unique products to address the unmet medical needs of patients with chronic and life-threatening conditions.

**1001 NW Technology Drive
Lee's Summit, MO 64086
Web address: www.viracoribt.com**

With over 30 years of expertise in infectious disease, immunology and allergy testing, Viracor-IBT is committed to helping transplant professionals minimize complications with specialized testing. Approximately sixty percent of U.S. transplant programs rely on Viracor-IBT's accelerated turnaround times, broad reportable ranges and extensive specimen types to diagnose faster, when it matters most. Viracor-IBT also offers ImmuKnow® for the detection of cell-mediated immune response in populations undergoing immunosuppression therapy for organ transplant, and cytokines to aid in differential diagnosis. We're passionate about providing timely, actionable information, never losing sight of the patients ultimately served. For more information, visit www.viracoribt.com.

VIVOLINE® MEDICAL AB**421**

Scheelevägen 17
SE-223 70 Lund
SWEDEN
Web address: www.vivoline.se

Vivoline Medical is a Swedish research-based company who develops and manufactures equipment in the field of thoracic transplantation. The first product on the market was Vivoline® LS1, now spread over a large part over the world. Vivoline® LS1 is the world leading system designed for making EVLP in an automatic way, helping medical centers increase efficiency and meet the needs for transplantable organs. The future-oriented company Vivoline Medical will show a brand new product in the booth at ISHLT 2014.

XDX, INC.**405**

3260 Bayshore Blvd.
Brisbane, CA 94005
Web address: www.xdx.com


AlloMap is the only non-invasive gene expression test that helps physicians identify the absence* of heart transplant rejection. It provides quantifiable, objective and reproducible test results. Offers Patient Comfort: Only requires a simple blood draw Widely Adopted: Successfully used in over 50,000 cases to help physicians detect the absence* of heart transplant rejection at the time of testing in 10,000+ heart transplant patients.

Box 53015
SE – 400 14 Göteborg
SWEDEN
Web address: www.xvivoperfusion.com

XVIVO manufactures and markets solutions for transplantation designed to preserve and evaluate organs and tissues prior to transplantation. The XPS™ is a flexible and comprehensive platform for normothermic EVLP empowering the user to remain in control of the entire process. Our principle solutions are Perfadex® for hypothermic flushing and preservation of donor lungs during transport and STEEN Solution™ for normothermic ex-vivo organ evaluation and reconditioning (Approved in US for research purposes only).

XVIVO aims to:

- minimize ischemia-reperfusion injury by improving the solutions used for ex-vivo preservation of organs.
- extend the safe ex-vivo preservation time for organs prior to transplantation.
- increase organ availability and transplantation success rates by introduction of new transplantation concepts and techniques



**See you next
year in Nice!**
à bientôt



**14673 Midway Road, Suite 200
Addison, TX 75001
Phone: 972-490-9495 • Fax: 972-490-9499
www.isHLT.org**



Nice, France 2015

**35th ISHLT Annual Meeting and
Scientific Sessions**

April 14-18, 2015



Washington DC 2016

**36th ISHLT Annual Meeting and
Scientific Sessions**

April 27-30, 2016

APPLICATIONS NOW BEING ACCEPTED

Gilead Sciences Research Scholars Programs



Each program provides financial support to three junior faculty researchers for a 2-year period, with each award funded up to \$130,000.

Cystic Fibrosis

SCIENTIFIC REVIEW COMMITTEE

J. P. Clancy, MD
Committee Chair
Cincinnati Children's Hospital
Medical Center

Christopher H. Goss, MD, MSc
University of Washington

Michael R. Knowles, MD
University of North Carolina
Chapel Hill

Jerry A. Nick, MD
National Jewish Health
Pamela E. Zeitlin, MD, PhD
Johns Hopkins University

Pulmonary Arterial Hypertension

SCIENTIFIC REVIEW COMMITTEE

Paul M. Hassoun, MD
Committee Chair
Johns Hopkins University

Todd M. Bull, MD
University of Colorado

Karen A. Fagan, MD
University of South Alabama
College of Medicine

Nicholas S. Hill, MD
Tufts University
School of Medicine

Steven M. Kawut, MD, MS
University of Pennsylvania
School of Medicine

Bruce R. Pitt, PhD
University of Pittsburgh

For more information and application submission
deadlines, please visit the website below:

<http://researchscholars.gilead.com>



©2014 Gilead Sciences, Inc.
All rights reserved. Gilead and the Gilead logo
are trademarks of Gilead Sciences, Inc.